PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Murata, T; Yamato, I; Igarashi, K; Kakinuma, Y				Murata, T; Yamato, I; Igarashi, K; Kakinuma, Y			Intracellular Na+ regulates transcription of the ntp operon encoding a vacuolar-type Na+ translocating ATPase in Enterococcus hirae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM PROTON ANTIPORTER; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; CYTOPLASMIC PH; ALKALINE PH; GENE; NHAA; AMPLIFICATION; PROTEINS; CLONING	The Gram-positive bacterium Enterococcus hirae has a vacuolar-type Na+-translocating ATPase that is encoded by the ntp operon (ntpFIKECGABDHJ) (Takase, K., Kakinuma, S., Yamato, I., Konishi, K., Igarashi, K., and Kakinuma, Y. (1994) J, Biol, Chem, 269, 11037-11044). Primer extension experiments identified the start site of transcription of this operon upstream of the ntpF gene, In parallel with the increases of both Na+-pumping activity in whole cells and Na+-stimulated ATPase activity in the membranes, the amounts of the two major subunits (A and B) of this enzyme increased remarkably in cells grown on medium containing high concentrations of NaCl but not on medium containing KCl or sorbitol, Chloramphenicol completely abolished the increases of the enzyme activity and the amounts of A and B subunits, suggesting that the Na+-ATPase level increased by de novo synthesis of the enzyme with the stimulation of high concentrations of the external sodium ions. Finally, Western blot and Northern blot experiments revealed that the increase in the Na+-ATPase level with the external Na+ was further accelerated by addition of an ionophore, such as monensin, which rendered the cell membrane permeable to Na+. These results suggest that the transcription of the Na+-ATPase operon is regulated by the intracellular concentration of sodium ions.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; CHIBA UNIV,FAC PHARMACEUT SCI,CHIBA 263,JAPAN	Tokyo University of Science; Chiba University			Murata, Takeshi/J-6181-2017; Murata, Takeshi/F-6114-2011	Murata, Takeshi/0000-0002-5748-4670; Igarashi, Kazuei/0000-0003-3751-3187				ABRAMS A, 1985, ENZYMES BIOL MEMBR, V4, P177; Ausubel FM., 1988, CURRENT PROTOCOLS MO; CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; KAKINUMA Y, 1987, J BACTERIOL, V169, P4403, DOI 10.1128/jb.169.9.4403-4405.1987; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1987, J BACTERIOL, V169, P3886, DOI 10.1128/jb.169.9.3886-3890.1987; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KANE PM, 1995, J BIOL CHEM, V270, P17025; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KINOSHITA N, 1984, J BACTERIOL, V158, P844, DOI 10.1128/JB.158.3.844-848.1984; KOBAYASHI H, 1984, J BACTERIOL, V158, P1157, DOI 10.1128/JB.158.3.1157-1160.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1993, ALKALI CATION TRANSP, P3; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; ROSEN BP, 1986, ANNU REV MICROBIOL, V40, P263, DOI 10.1146/annurev.mi.40.100186.001403; Sambrook J., 2002, MOL CLONING LAB MANU; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P293; SOLIOZ M, 1994, J BIOL CHEM, V269, P9453; STRAUSAK D, 1994, EBEC SHORT REP, V8, P77; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; WASER M, 1992, J BIOL CHEM, V267, P5396; Yamato I., 1993, ALKALI CATION TRANSP, P53	34	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23661	23666		10.1074/jbc.271.39.23661	http://dx.doi.org/10.1074/jbc.271.39.23661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798587	hybrid			2022-12-25	WOS:A1996VJ44200016
J	Swierczynski, SL; Blackshear, PJ				Swierczynski, SL; Blackshear, PJ			Myristoylation-dependent and electrostatic interactions exert independent effects on the membrane association of the myristoylated alanine-rich protein kinase C substrate protein in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; MARCKS-RELATED PROTEIN; PLASMA-MEMBRANE; MOLECULAR-CLONING; CALMODULIN-BINDING; PHOSPHORYLATION; IDENTIFICATION; PEPTIDES; RECEPTOR; 80-KDA	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a widely expressed, prominent substrate for protein kinase C. MARCKS is largely associated with membranes in cells, and hydrophobic interactions involving the amino-terminal myristoyl moiety are thought to play a role in anchoring MARCKS to cellular membranes. In addition, experiments in cell-free systems have suggested that electrostatic interactions between the positively charged phosphorylation site/calmodulin binding domain (PSD) of MARCKS and negatively charged membrane lipids are also involved in this association. Although it has been inferred from phosphorylation experiments, the electrostatic nature of the interaction between the PSD and membranes has not been demonstrated directly in intact cells. We expressed human MARCKS mutated in the myristoylation site and the PSD in REF52 cells; the cells were then fractionated by ultracentrifugation. Both nonmyristoylatable MARCKS and MARCKS in which the four serines in the PSD were mutated to aspartic acids, mimicking phosphorylation, exhibited decreased membrane affinity when compared to the fully myristoylated, wild-type, tetra-Ser protein or a myristoylated, tetra Asn mutant. A double mutant, nonmyristoylatable protein in which the four serines in the PSD were mutated to aspartic acids exhibited negligible membrane association. Similar results were obtained in 293 cells that stably expressed chicken MARCKS mutated in the same domains. The double mutant, nonmyristoylatable tetra-Asp chicken protein exhibited little membrane association as determined by both subcellular fractionation and immunoelectron microscopy. These results indicate that myristoylation and electrostatic interactions involving the PSD exert independent, essentially additive effects on the membrane association of MARCKS in intact cells.	DUKE UNIV, MED CTR,HOWARD HUGHES MED INST, DIV ENDOCRINOL METAB & NUTR,DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SARAH W STEDMAN CTR NUTR STUDIES, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; AMESS B, 1992, FEBS LETT, V297, P285; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1992, GENOMICS, V14, P168, DOI 10.1016/S0888-7543(05)80300-3; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FEDER D, 1991, J BIOL CHEM, V266, P19040; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOSHI R, 1990, J BIOL CHEM, V265, P13130; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; NAKAOKA T, 1995, J BIOL CHEM, V270, P12147, DOI 10.1074/jbc.270.20.12147; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; SWIERCZYNSKI SL, 1996, IN PRESS DEV BIOL; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253	50	65	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23424	23430		10.1074/jbc.271.38.23424	http://dx.doi.org/10.1074/jbc.271.38.23424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798548	hybrid			2022-12-25	WOS:A1996VH76800074
J	Latour, S; Chow, LML; Veillette, A				Latour, S; Chow, LML; Veillette, A			Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; B-CELL DEVELOPMENT; ANTIGEN RECEPTOR; ACTIVATION; PHOSPHORYLATION; BINDING; FAMILY; P56LCK; AUTOPHOSPHORYLATION; SELECTION	Syk and Zap-70 are related protein-tyrosine kinases implicated in antigen and Fc receptor signaling. While Zap-70 is restricted to T-cells and natural killer cells, Syk accumulates in B-cells, mast cells, platelets, and immature T-cells. In addition, we found that an isoform of Syk (SykB), which carries a 23-amino acid deletion in the ''linker'' region, is prominently expressed in bone marrow. To better understand the relative impact of Syk, SykB, and Zap-70 on signal transduction, we compared their intrinsic enzymatic properties in transiently transfected COS-1 cells and in hemopoietic cells. Using modified versions of these enzymes bearing a common Myc epitope at the amino terminus, we determined that the ability of Syk and SykB to undergo autophosphorylation and to phosphorylate erythrocyte band 3 in immune complex kinase reactions was at least 100-fold greater than that of Zap-70. Similarly, Syk and SykB, but not Zap-70, caused prominent tyrosine phosphorylation of p120(c-cbl) in COS-l cells. A similar pattern of activity was also noted for endogenous Syk and Zap-70 from hemopoietic cells. To understand the structural basis for these characteristics, we also created and analyzed a series of chimeras between Syk and Zap-70. These studies indicated that the catalytic domain of Syk and Zap-70, but not their SH2 domains, linker region or carboxyl-terminal tail, was responsible for their respective activity. Taken together, these data demonstrated that the intrinsic enzymatic activity of Syk and SykB is superior to that of Zap-70 and that such a distinction relates to structural variations in the catalytic domain.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University			; Latour, Sylvain/H-3652-2017	Chow, Lionel/0000-0001-8447-063X; Latour, Sylvain/0000-0001-8238-4391				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; COLIGNA JE, 1994, CURRENT PROTOCOLS IM; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KIM KJ, 1979, J IMMUNOL, V122, P549; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Law CL, 1996, MOL CELL BIOL, V16, P1305; LOW PS, 1987, J BIOL CHEM, V262, P4592; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROWLEY RB, 1995, J BIOL CHEM, V270, P12659, DOI 10.1074/jbc.270.21.12659; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TIMSONGAUEN LK, 1994, MOL CELL BIOL, V14, P3729; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; YAGI S, 1994, BIOCHEM BIOPH RES CO, V200, P28, DOI 10.1006/bbrc.1994.1409	43	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22782	22790		10.1074/jbc.271.37.22782	http://dx.doi.org/10.1074/jbc.271.37.22782			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798454	hybrid			2022-12-25	WOS:A1996VG67200073
J	Rowles, J; Scherer, SW; Xi, T; Majer, M; Nickle, DC; Rommens, JM; Popov, KM; Harris, RA; Riebow, NL; Xia, J; Tsui, LC; Bogardus, C; Prochazka, M				Rowles, J; Scherer, SW; Xi, T; Majer, M; Nickle, DC; Rommens, JM; Popov, KM; Harris, RA; Riebow, NL; Xia, J; Tsui, LC; Bogardus, C; Prochazka, M			Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; PIMA-INDIANS; INSULIN-RESISTANCE; MOLECULAR-CLONING; PROTEIN-KINASES; LINKAGE; GENE; EXPRESSION; MARKERS; ASSOCIATION	Different isoenzymes of pyruvate dehydrogenase kinase (PDK) inhibit the mitochondrial pyruvate dehydrogenase complex by phosphorylation of the E1 alpha subunit, thus contributing to the regulation of glucose metabolism. By positional cloning in the 7q21.3-q22.1 region linked with insulin resistance and non-insulin-dependent diabetes mellitus in the Pima Indians, Fee identified a gene encoding an additional human PDR isoform, as evidenced by its amino acid sequence identity (>65%) with other mammalian PDKs, and confirmed by biochemical analyses of the recombinant protein. We performed detailed comparative analyses of the gene, termed PDK4, in insulin-resistant and insulin-sensitive Pima Indians, and detected five DNA variants with comparable frequencies in both subject groups. Using quantitative reverse transcription polymerase chain reaction, we found that the variants identified in the promoter and 5'-untranslated region did not correlate with differences in mRNA level in skeletal muscle and adipose tissue. We conclude that alterations in PDK4 are unlikely to be the molecular basis underlying the observed linkage at 7q21.3-q22.1 in the Pima Indians. Information about the genomic organization and promoter sequences of PDK4 will be useful in studies of other members of this family of mitochondrial protein kinases that are important for the regulation of glucose metabolism.	NIDDK,CLIN DIABET & NUTR SECT,PHOENIX EPIDEMIOL & CLIN RES BRANCH,NIH,PHOENIX,AZ 85016; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Indiana University System; Indiana University-Purdue University Indianapolis			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013; Nickle, David/ABF-2727-2020; Rommens, Johanna/AAT-7465-2021	Scherer, Stephen W./0000-0002-8326-1999; 	NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051262, R01GM051262] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT PH, 1971, LANCET, V2, P125; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; LILLIOJA S, 1986, METABOLISM, V35, P505, DOI 10.1016/0026-0495(86)90006-5; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; Majer M, 1996, DIABETOLOGIA, V39, P314; MCCONLOGUE L, 1988, NUCLEIC ACIDS RES, V16, P9869, DOI 10.1093/nar/16.20.9869; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; POMP D, 1991, BIOTECHNIQUES, V10, P58; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; PROCHAZKA M, 1989, DIABETES, V38, P1446, DOI 10.2337/diabetes.38.11.1446; PROCHAZKA M, 1995, DIABETOLOGIA, V38, P461, DOI 10.1007/s001250050306; PROCHAZKA M, 1993, DIABETES, V42, P514, DOI 10.2337/diabetes.42.4.514; PROCHAZKA M, 1995, DIABETES, V44, pA42; PROCHAZKA M, 1995, CYTOGENET CELL GENET, V71, P30; RANDLE PJ, 1994, J CELL BIOCHEM, V55, P1, DOI 10.1002/jcb.240550002; ROMMENS JM, 1994, IDENTIFICATION OF TRANSCRIBED SEQUENCES, P65; SCHERER SW, 1994, HUM MOL GENET, V3, P1345; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; SCHERER SW, 1995, CYTOGENET CELL GENET, V71, P22; TURNER RC, 1995, DIABETES, V44, P1, DOI 10.2337/diabetes.44.1.1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOUNG AA, 1988, AM J PHYSIOL, V254, pE231, DOI 10.1152/ajpendo.1988.254.2.E231	32	148	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22376	22382		10.1074/jbc.271.37.22376	http://dx.doi.org/10.1074/jbc.271.37.22376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798399	hybrid			2022-12-25	WOS:A1996VG67200018
J	Darmon, AJ; Ley, TJ; Nicholson, DW; Bleackley, RC				Darmon, AJ; Ley, TJ; Nicholson, DW; Bleackley, RC			Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; DEATH GENE CED-3; INTERLEUKIN-1-BETA CONVERTING-ENZYME; IL-1-BETA-CONVERTING ENZYME; SERINE PROTEASES; CYSTEINE PROTEASES; MOLECULAR-CLONING; MAMMALIAN HOMOLOG; RAPID INDUCTION; NATURAL-KILLER	Cytotoxic T lymphocytes (CTLs) are able to recognize and destroy target cells bearing foreign antigen using one of two distinct mechanisms: granule- or Fas-mediated cytotoxicity. The exact mechanisms involved in the induction of apoptotic cell death remain elusive; however, it seems likely that a family of cysteine proteases related to interleukin-1 beta converting enzyme are involved. One family member, CPP32, has been identified as an intracellular substrate for granzyme B, a CTL-specific serine protease responsible for the early induction of target cell DNA fragmentation. Here we use cytolytic cells from granzyme B-deficient mice to confirm that cleavage and activation of CPP32 represents a nonredundant role for granzyme B and that this activation plays a rob in the induction of DNA fragmentation in target cells, a signature event for apoptotic cell death. A peptide inhibitor of CPP32-like proteases confirmed the function of these enzymes in fragmentation. Cr-51 release was not suppressed under these conditions, suggesting that granzyme B cleavage of CPP32 is primarily involved in the induction of DNA fragmentation and not membrane damage during CTL-induced apoptosis.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL, ST LOUIS, MO 63110 USA; MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM & MOL BIOL, POINTE CLAIRE, PQ H9R 4P8, CANADA	University of Alberta; Washington University (WUSTL); Washington University (WUSTL); Merck & Company					NIDDK NIH HHS [DK 49786] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GARNER R, 1994, J IMMUNOL, V153, P5413; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NettFiordalisi M, 1995, J LEUKOCYTE BIOL, V58, P717, DOI 10.1002/jlb.58.6.717; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PODACK ER, 1995, CURR TOP MICROBIOL, V178, P175; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	42	131	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21709	21712		10.1074/jbc.271.36.21709	http://dx.doi.org/10.1074/jbc.271.36.21709			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702964	hybrid			2022-12-25	WOS:A1996VF61200006
J	Creasy, CL; Ambrose, DM; Chernoff, J				Creasy, CL; Ambrose, DM; Chernoff, J			The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; AUTOPHOSPHORYLATION; LOCALIZATION; ACTIVATION; SUBUNITS; ENCODES	The human serine/threonine protein kinases, Mst1 and Mst2, share considerable homology to Ste20 and p21-activated kinase (Pak) throughout their catalytic domains. However, outside the catalytic domains there are no significant homologies to previously described Ste20-like kinases or other proteins. To understand the role of the nonhomologous regions, we performed a structure/function analysis of Mst1. A series of COOH-terminal and internal deletions indicates that there is an element within a central 63-amino acid region of the molecule that inhibits kinase activity. Removal of this domain increases kinase activity approximately 9-fold. Coimmunoprecipitation assays, the yeast two-hybrid procedure, and in vitro cross-linking analysis indicate that Mst1 homodimerizes and that the extreme COOH-terminal 57 amino acids are required for self-association. Size exclusion chromatography indicates that Mst1 is associated with a high molecular weight complex in cells, suggesting that other proteins may also oligomerize with this kinase. While loss of dimerization alone does not affect kinase activity, a molecule lacking both the dimerization and inhibitory domains is not as active as one which lacks only the inhibitory domain. Comparison of Mst1 and Mst2 indicates that both functional domains lie in regions conserved between the two molecules.	FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center			Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [CA-06927, CA-09035, R01 CA58836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA058836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BARTEL PL, 1994, CELLULAR INTERACTION, P153; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DATTA K, 1995, MOL CELL BIOL, V15, P2304; EVAN GL, 1985, MOL CELL BIOL, V8, P551; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HATZ P, 1994, J BIOL CHEM, V269, P16802; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SOBIESZEK A, 1995, BIOCHEMISTRY-US, V34, P11855, DOI 10.1021/bi00037a025; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543	25	172	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21049	21053		10.1074/jbc.271.35.21049	http://dx.doi.org/10.1074/jbc.271.35.21049			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702870	hybrid			2022-12-25	WOS:A1996VE47700016
J	Downey, GP; Butler, JR; Brumell, J; Borregaard, N; Kjeldsen, L; SueAQuan, AK; Grinstein, S				Downey, GP; Butler, JR; Brumell, J; Borregaard, N; Kjeldsen, L; SueAQuan, AK; Grinstein, S			Chemotactic peptide-induced activation of MEK-2, the predominant isoform in human neutrophils - Inhibition by wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; MAP KINASE; SUBSTRATE RECOGNITION; RESPIRATORY BURST; TYROSINE KINASE; GENE-PRODUCT; PHOSPHORYLATION; RECEPTOR	Exposure of neutrophils to a variety of agonists including chemoattractant peptides and cytokines induces degranulation and activation of the oxidative burst which are required for bacterial killing, The signaling pathways regulating these important functions are incompletely characterized, Mitogen-activated protein (MAP) kinases, which include the extracellular signal-regulated kinases (ERKs), are activated rapidly in neutrophils, suggesting that they may regulate cell activation, We found that neutrophils express two isoforms of MAP/ERK kinase (MEK), mixed-function kinases that are responsible for phosphorylation and activation of ERK. Like MEK-1, MEK-2 was found to reside in the cytosol both before and after stimulation, Studies were undertaken to define the relative abundance and functional contribution of MEK-1 and MEK-2 in neutrophils and to characterize the signaling pathways leading to their activation, Although the abundance of the two isoforms was similar, the activity of MEK-2 was at least 3-fold greater than that of MEK-1, A rise in cytosolic [Ca2+] was insufficient for MEK stimulation, and blunting the [Ca2+] change with intracellular chelators failed to prevent receptor-mediated activation of either isoform, implying that cytosolic Ca2+ transients are not necessary. In contrast, both MEK-1 and MEK-2 were activated by exposure of cells to protein kinase C (PKC) agonists. Conversely, PKC antagonists inhibited the chemotactic stimulation of both isoforms, suggesting that PKC was required for their activation, Despite these similarities, clear differences were also found in the pathways leading to activation of the MEK isoforms, In particular, MEK-2 was considerably more sensitive than MEK-1 to the phosphatidylinositol 3-kinase inhibitor wortmannin, Phosphorylation and activation of ERK-1 and ERK-2 were also reduced by this inhibitor, In summary, MEK-2 is stimulated in formyl-methionyl-leucyl-phenylalanine-treated neutrophils, where it appears to be functionally the predominant isoform, The time course and inhibitor sensitivity of MEK-2 activation parallel those of several components of the microbicidal response, suggesting a signaling role of the MEK-ERK pathway.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; RIGSHOSP,GRANULOCYTE RES LAB,DK-2100 COPENHAGEN,DENMARK; HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; Rigshospitalet; University of Copenhagen; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Downey, GP (corresponding author), UNIV TORONTO,DEPT MED,INST MED SCI,RM 6264,MED SCI BLDG,1 KINGS COLL CIRCLE,TORONTO,ON M5S 1A8,CANADA.		Kjeldsen, Lars/AAF-2096-2019	Downey, Gregory P/0000-0003-3253-5862				ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P335; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SMITH RM, 1991, BLOOD, V77, P673; TAUBER AI, 1987, BLOOD, V69, P711; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WOLFF SM, 1972, ANN INTERN MED, V76, P293, DOI 10.7326/0003-4819-76-2-293; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	42	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21005	21011		10.1074/jbc.271.35.21005	http://dx.doi.org/10.1074/jbc.271.35.21005			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702863	hybrid			2022-12-25	WOS:A1996VE47700009
J	Fung, KL; Hilgenberg, L; Wang, NM; Chirico, WJ				Fung, KL; Hilgenberg, L; Wang, NM; Chirico, WJ			Conformations of the nucleotide and polypeptide binding domains of a cytosolic Hsp70 molecular chaperone are coupled	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ATP HYDROLYSIS; PEPTIDE-BINDING; DNAK CHAPERONE; UNCOATING PROTEIN; SUBSTRATE-BINDING; POTASSIUM AFFECTS; REACTION CYCLE; ACTIVE-SITE; HSC70	70-kDa heat shock protein (Hsp70) molecular chaperones are ATPases that participate in protein folding by regulating protein-protein interactions. ATP binds to the highly conserved amino-terminal domain, whereas polypeptides bind to the less conserved carboxyl-terminal domain. These domains are functionally coupled. Polypeptides were previously shown to dissociate from Hsp70s upon ATP binding and to stimulate ATPase activity. We probed the structure of the yeast cytosolic Hsp70 Ssa1p using limited proteolysis to determine whether the conformations of its nucleotide and polypeptide binding domains are also coupled. Ssa1p adopted three distinct conformations, nucleotide-free, ADP-dependent, and ATP-dependent. Complete conformational changes required K+ and Mg2+. Using amino-terminal sequencing, ATP-agarose chromatography, and a carboxyl-terminal-specific antibody, we mapped the locations of the major proteolytic fragments. Nucleotides altered the conformations of both the nucleotide and polypeptide binding domains. Similarly, a polypeptide altered the conformations of both domains. These results indicate that the conformations of the nucleotide and polypeptide binding domains are coupled.	SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Endo T, 1996, J BIOL CHEM, V271, P4161; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, BIOL HEAT SHOCK PROT, P251; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HOHFELD J, 1995, CELL, V83, P589; Horst M, 1996, PROTEIN SCI, V5, P759; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LAIN B, 1994, J BIOL CHEM, V269, P15588; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PARK K, 1993, PROTEIN SCI, V2, P325; Penefsky H S, 1979, Methods Enzymol, V56, P527; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WANG TF, 1993, J BIOL CHEM, V268, P26049; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	47	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21559	21565		10.1074/jbc.271.35.21559	http://dx.doi.org/10.1074/jbc.271.35.21559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702942	hybrid			2022-12-25	WOS:A1996VE47700088
J	Maeda, N; Nishiwaki, T; Shintani, T; Hamanaka, H; Noda, M				Maeda, N; Nishiwaki, T; Shintani, T; Hamanaka, H; Noda, M			6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTP beta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; NERVOUS-SYSTEM; ADULT-RAT; BRAIN; EXPRESSION; NEURONS; CLONING; MIDKINE	A major chondroitin sulfate proteoglycan in the brain, 6B4 proteoglycan/phosphacan, corresponds to the extracellular region of a receptor-like protein-tyrosine phosphatase, PTP zeta/RPTP beta. Here, we purified and characterized 6B4 proteoglycan-binding proteins from rat brain. From the CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid) extract of brain microsomal fractions, 18- 28-, and 40-kDa proteins were specifically isolated using 6B4 proteoglycan-Sepharose. N-terminal amino acid sequencing identified the 18-kDa protein as pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). Scatchard analysis of 6B4 proteoglycan-pleiotrophin binding revealed low (K-d = 3 nM) and high (K-d = 0.25 nM) affinity binding sites. Chondroitinase ABC digestion of the proteoglycan decreased the binding affinities to a single value (K-d = 13 nM) without changing the number of binding sites. This suggested the presence of two subpopulations of the proteoglycan with different chondroitin sulfate structures. Heparin potently inhibited binding of 6B4 proteoglycan to pleiotrophin (IC50 = 3.5 ng/ml). Heparan sulfate and chondroitin sulfate C inhibited moderately (IC50 = 150 and 400 ng/ml, respectively), but, in contrast, chondroitin sulfate A and keratan sulfate were poor inhibitors (IC50 > 100 mu g/ml). Immunofluorescence and immunoblotting analyses indicated that both 6B4 proteoglycan and PTP zeta are located on cortical neurons. Anti-6B4 proteoglycan antibody added to the culture medium suppressed pleiotrophin-induced neurite outgrowth of cortical neurons. These results suggested that interaction between 6B4 proteoglycan and pleiotrophin is required for the action of pleiotrophin, and chondroitin sulfate chains on 6B4 proteoglycan play regulatory roles in its binding.	NATL INST BASIC BIOL,DIV MOL NEUROBIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,DEPT MOL BIOMECH,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X; Shintani, Takafumi/0000-0002-6165-2307				BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; CANNOLL P, 1993, DEV BRAIN RES, V75, P293; GRUMET M, 1994, J BIOL CHEM, V269, P14142; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1996, DEVELOPMENT, V122, P647; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MATSUMOTO K, 1994, DEV BRAIN RES, V79, P229, DOI 10.1016/0165-3806(94)90127-9; MATSUMOTO K, 1994, NEUROSCI LETT, V178, P216, DOI 10.1016/0304-3940(94)90762-5; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; NISBIZUKA M, 1996, NEUROSCI RES, V24, P345; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; RANVALA H, 1994, DEV BRAIN RES, V79, P157; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANAKA A, 1993, DEV BRAIN RES, V72, P133, DOI 10.1016/0165-3806(93)90166-8; WEWETZER K, 1995, BRAIN RES, V693, P31, DOI 10.1016/0006-8993(95)00683-H; WTANABE E, 1996, J NEUROSCI RES, V44, P84	31	254	265	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21446	21452		10.1074/jbc.271.35.21446	http://dx.doi.org/10.1074/jbc.271.35.21446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702927	hybrid			2022-12-25	WOS:A1996VE47700073
J	Francis, SH; Smith, JA; Colbran, JL; Grimes, K; Walsh, KA; Kumar, S; Corbin, JD				Francis, SH; Smith, JA; Colbran, JL; Grimes, K; Walsh, KA; Kumar, S; Corbin, JD			Arginine 75 in the pseudosubstrate sequence of type I beta cGMP-dependent protein kinase is critical for autoinhibition, although autophosphorylated serine 63 is outside this sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOVINE CARDIAC-MUSCLE; LIGHT-CHAIN KINASE; REGULATORY SUBUNIT; MOLECULAR-CLONING; CYCLIC-GMP; INTRASTERIC REGULATION; CDNA STRUCTURE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY	Autoinhibitory domains in many protein kinases include either a phosphorylatable substrate-like sequence or a pseudosubstrate sequence, This study shows that I beta cGMP-dependent protein kinase (cGK) autophosphorylates Ser-63, which is in an atypical cGK substrate sequence (-(59)AQKQSAS-) that is amino-terminal to the pseudosubstrate motif (-(74)KRQAI-), cGMP increases the rate of autophosphorylation (similar to 0,8 phosphate/cGK monomer) similar to 3-fold, Autophosphorylation is an intramolecular process since it is independent of cGK concentration, cGMP activation of cGK enhances proteolysis within and near the pseudosubstrate site; treatment of dimeric cGK with three proteases produces three cGK monomers (similar to 67-70 kDa each), Their amino-terminal sequences are (75)RQAISAEPT-, (76)QAlSAEPTAF-, and (86)DIQDLSXV-, respectively, cGMP stimulates these kinases by 10-, 2.5-, and 1,4-fold, respectively, compared with a 10-fold effect on intact cGK, Increased basaI activity accounts for the diminished stimulation, Thus, the primary autophosphorylation site of I beta cGK is well outside the pseudosubstrate site, but Arg-75 in the pseudosubstrate site is critical for autoinhibition, Autoinhibition also involves elements that are carboxyl-terminal to Arg-75.	UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	Francis, SH (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MOL PHYSIOL & BIOPHYS, 702 LIGHT HALL, NASHVILLE, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BOYER PD, 1986, ENZYMES, V17, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DEJONGE HR, 1977, J BIOL CHEM, V252, P2780; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; ERLICHMAN J, 1974, J BIOL CHEM, V249, P5000; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; GAO ZH, 1995, J BIOL CHEM, V270, P10125, DOI 10.1074/jbc.270.17.10125; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1979, J BIOL CHEM, V254, P9728; GLASS DB, 1983, J BIOL CHEM, V258, P4797; GLASS DB, 1990, PEPTIDES PROTEIN PHO, P210; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HEMMINGS BA, 1986, FEBS LETT, V209, P219, DOI 10.1016/0014-5793(86)81114-0; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1989, CELL SIGNAL, V1, P303, DOI 10.1016/0898-6568(89)90049-1; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LINCOLN TM, 1978, J BIOL CHEM, V253, P6002; LU XY, 1990, J BIOL CHEM, V265, P3293; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; PATTON BL, 1990, J BIOL CHEM, V265, P11204; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SMITH J, 1993, FASEB J, V7, pA1123; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SMITH JA, 1992, FASEB J, V6, pA315; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAKIO K, 1983, J BIOL CHEM, V258, P5531; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; UHLER MD, 1993, J BIOL CHEM, V268, P13586; VINTERMYR OK, 1993, J CELL PHYSIOL, V156, P160, DOI 10.1002/jcp.1041560122; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157	70	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20748	20755		10.1074/jbc.271.34.20748	http://dx.doi.org/10.1074/jbc.271.34.20748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702827	hybrid			2022-12-25	WOS:A1996VD33700079
J	Park, JC; Takeuchi, A; Sharma, S				Park, JC; Takeuchi, A; Sharma, S			Characterization of a new isoform of the NFAT (nuclear factor of activated T cells) gene family member NFATc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; TRANSCRIPTION FACTOR NFATP; HUMAN B-CELL; CYCLOSPORINE-A; IMMUNOSUPPRESSIVE DRUGS; REGULATORY ELEMENTS; EXPRESSION; PROMOTER; INDUCTION; BINDING	The cyclosporin A (CsA)/FK506-sensitive nuclear factor of activated T cells (NFAT) plays a key role in the inducible expression of cytokine genes in T cells. Although NFAT has been recently shown to be inducible in several non-T immune cells, the NFAT gene family members characterized to date have been isolated only from T cells. To further characterize NFAT function in human B cells and to demonstrate cytokine gene specificity of NFAT proteins, we report here the isolation and characterization of a cDNA clone from the Rail B cell line. The cDNA clone encodes a new isoform, NFATc.beta, of the NFAT gene family member NFATc (designated here NFATc.alpha). The amino acid sequence of NFATc.beta differs from that of NFATc.alpha in the first NR(2)-terminal 29 residues and contains an additional region of 142 residues at the COOH terminus. Northern analysis using a probe encompassing a common region of both isoforms showed two mRNA species of 2.7 and 4.5 kilobase pairs, while an NFATc.beta-specific probe detected only the 4.5-kilobase pair mRNA which was preferentially expressed in the spleen. Transient expression of NFATc.beta was capable of activating an interleukin-2 NFAT-driven reporter gene in stimulated Jurkat cells in a CsA-sensitive manner. However, NFATc.beta neither bound to the kappa 3 element (an NFAT-binding site) in the tumor necrosis factor-alpha promoter nor activated the tumor necrosis factor-alpha promoter in cotransfection assays. These data suggest that different members or isoforms of NFAT gene family may regulate inducible expression of different cytokine genes.	BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,EXPT PATHOL SECT,PROVIDENCE,RI 02908	Brown University; Roger Williams Medical Center					NATIONAL CANCER INSTITUTE [R01CA055910] Funding Source: NIH RePORTER; NCI NIH HHS [CA55910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1992, P NATL ACAD SCI USA, V89, P12198, DOI 10.1073/pnas.89.24.12198; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P804; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; KLAUS GGB, 1988, TRANSPLANTATION, V46, pS11; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; Weiss DL, 1996, MOL CELL BIOL, V16, P228; YASEEN NR, 1993, J BIOL CHEM, V268, P14285; YASEEN NR, 1994, MOL CELL BIOL, V14, P6886, DOI 10.1128/MCB.14.10.6886	44	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20914	20921		10.1074/jbc.271.34.20914	http://dx.doi.org/10.1074/jbc.271.34.20914			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702849	hybrid			2022-12-25	WOS:A1996VD33700101
J	Bigoni, R; Negrini, M; Veronese, ML; Cuneo, A; Castoldi, GL; Croce, CM				Bigoni, R; Negrini, M; Veronese, ML; Cuneo, A; Castoldi, GL; Croce, CM			Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization	ONCOGENE			English	Article						bcl-1; chromosome translocation; mantle cell lymphoma	CHRONIC LYMPHOCYTIC-LEUKEMIA; CENTROCYTIC LYMPHOMA; T(11-14)(Q13-Q32) TRANSLOCATION; INTERMEDIATE DIFFERENTIATION; CHROMOSOME-TRANSLOCATION; BREAKPOINT REGION; TUMOR-CELLS; BCL-1 GENE; EXPRESSION; KARYOTYPE	Characterization of chromosome abnormalities in leukemia and lymphoma have contributed to the understanding of the molecular basis of these neoplastic diseases, In addition, specific chromosomal aberrations have acquired diagnostic or prognostic value. The t(11;14)(q13;q32) chromosome translocation has been detected in mantle cell lymphomas, However, possibly due to the limits of conventional cytogenetic analysis and the presence of different breakpoints at the molecular level, it is possible that the true percentage of association is underestimated, In our study, we used a yeast artificial chromosome, spanning the entire area where the rearrangements occur on chromosome 11q13, to detect the presence of translocations by fluorescent in situ hybridization experiments. We detected BCL-1 translocations in eight of eight patients with clinical and immunological features of mantle cell lymphoma, suggesting that the t(11;14) translocation is a critical event in the pathogenesis of MCL and may be a primary element for the diagnosis. Since this translocation is associated with poor prognosis, its detection may help to make a correct diagnosis as well as to evaluate residual disease, which is critical to plan a rational chemotherapy regimen.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC CTR, BLSB, PHILADELPHIA, PA 19107 USA; UNIV FERRARA, DIPARTIMENTO SCI BIOMED & TERAPIE AVANZATE, SEZ EMATOL, FERRARA, ITALY	Jefferson University; University of Ferrara			Negrini, Massimo/J-2377-2016; Cuneo, Antonio/K-7617-2016; Young, Richard A/F-6495-2012	Negrini, Massimo/0000-0002-0007-1920; Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BANKS PM, 1992, AM J SURG PATHOL, V16, P637, DOI 10.1097/00000478-199207000-00001; BERGER R, 1979, HUM GENET, V53, P111, DOI 10.1007/BF00289460; BOSCH F, 1994, BLOOD, V84, P2726; BRITO-BABAPULLE V, 1987, Hematologic Pathology, V1, P27; CASTOLDI GL, 1987, CANCER GENET CYTOGEN, V26, P75, DOI 10.1016/0165-4608(87)90135-X; CHAGANTI RSK, 1987, CYTOGENET CELL GENET, V45, P93, DOI 10.1159/000132436; Coignet LJA, 1996, BLOOD, V87, P1512, DOI 10.1182/blood.V87.4.1512.bloodjournal8741512; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; CUNEO A, 1995, BRIT J HAEMATOL, V90, P409; CUNEO A, 1994, LEUKEMIA LYMPHOMA, V15, P167, DOI 10.3109/10428199409051693; CUNEO A, 1992, BRIT J HAEMATOL, V81, P192, DOI 10.1111/j.1365-2141.1992.tb08206.x; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; GOULD J, 1988, BLOOD, V71, P453; JULIUSSON G, 1991, LEUKEMIA LYMPHOMA, V5, P21, DOI 10.3109/10428199109103374; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; LARDELLI P, 1990, AM J SURG PATHOL, V14, P752, DOI 10.1097/00000478-199008000-00007; LEBEAU MM, 1993, BLOOD, V81, P1979; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MEEKER TC, 1989, BLOOD, V74, P1801; MEEKER TC, 1991, LEUKEMIA, V5, P733; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEWMAN RA, 1993, BLOOD, V82, P1239; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SETO M, 1992, ONCOGENE, V7, P1401; SZEPETOWSKI P, 1995, CYTOGENET CELL GENET, V69, P101, DOI 10.1159/000133948; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDENBERGHE E, 1991, J PATHOL, V163, P13, DOI 10.1002/path.1711630104; VANDENBERGHE E, 1994, BLOOD REV, V8, P79, DOI 10.1016/S0268-960X(05)80011-6; VANDENBERGHE H, 1979, CANCER, V44, P188, DOI 10.1002/1097-0142(197907)44:1<188::AID-CNCR2820440131>3.0.CO;2-F; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WILLIAMS ME, 1990, BLOOD, V76, P1387; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1987, NEW ENGL J MED, V79, P316	43	46	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					797	802						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761301				2022-12-25	WOS:A1996VD43300015
J	Gibson, L; Holmgreen, SP; Huang, DCS; Bernand, O; Copeland, NG; Jenkins, NA; Sutherland, GR; Baker, E; Adams, JM; Cory, S				Gibson, L; Holmgreen, SP; Huang, DCS; Bernand, O; Copeland, NG; Jenkins, NA; Sutherland, GR; Baker, E; Adams, JM; Cory, S			bcl-w, a novel member of the bcl-2 family, promotes cell survival	ONCOGENE			English	Article						bcl-2; bcl-w; apoptosis; survival; oncogene; chromosome 14	CHROMOSOMAL BREAKPOINT; CAENORHABDITIS-ELEGANS; PROTEIN IDENTIFICATION; ENDOPLASMIC-RETICULUM; PROTOONCOGENE BCL-2; SEQUENCE SIMILARITY; CONSERVED DOMAINS; MOLECULAR-CLONING; NUCLEAR-ENVELOPE; HOMOLOG BAK	The prototypic mammalian regulator of cell death is bcl-2, the oncogene implicated in the development of human follicular lymphoma. Several homologues of bcl-2 are now known. Using a PCR-based strategy we cloned a novel member of this gene family, denoted bcl-w. The gene, which is highly conserved between mouse and human, resides near the T-cell antigen receptor a gene within the central portion of mouse chromosome 14 and on human chromosome 14 at band q11. Enforced expression of bcl-w rendered lymphoid and myeloid cells refractory to several (but not all) cytotoxic conditions. Thus, like Bcl-2 and Bcl-x, the Bcl-w protein promotes cell survival, in contrast to other close homologues, Bar and Bak, which facilitate cell death. Comparison of the expected amino acid sequence of Bcl-w with that of these relatives helps to delineate residues likely to convey survival or anti-survival function. While expression of bcl-w was uncommon in B or T lymphoid cell lines, the mRNA was observed in almost all murine myeloid cell lines analysed and in a wide range of tissues. These findings suggest that bcl-w participates in the control of apoptosis in multiple cell types. Its functional similarity to bcl-2 also makes it an attractive candidate proto-oncogene.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; ADELAIDE CHILDRENS HOSP INC, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Gibson, Leonie/AAM-5917-2021; Cory, Suzanne/E-1642-2013; Huang, David C. S./C-7586-2013; Sutherland, Grant Robert/D-2606-2012; Adams, Jerry M/E-1199-2013	Cory, Suzanne/0000-0002-6818-3451; Huang, David C. S./0000-0002-3101-4873; Gibson, Leonie/0000-0002-0904-8145; Adams, Jerry/0000-0002-4360-8628				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; BRAND SF, 1995, GENE, V154, P187, DOI 10.1016/0378-1119(94)00840-O; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOI SS, 1995, ONCOGENE, V11, P1693; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Green EL, 1981, GENETICS PROBABILITY, P77; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HARRIS AW, 1973, J IMMUNOL, V110, P431; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LIN EY, 1993, J IMMUNOL, V151, P1979; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LYNES MA, 1978, J IMMUNOL, V121, P2352; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOORE KJ, 1992, GENOMICS, V12, P388, DOI 10.1016/0888-7543(92)90389-A; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RALPH P, 1975, J IMMUNOL, V114, P898; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Subramanian T, 1995, ONCOGENE, V11, P2403; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1994, APOPTOSIS, V2, P111; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	73	257	276	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					665	675						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761287				2022-12-25	WOS:A1996VD43300001
J	Lee, WC; Lin, KY; Chiu, YT; Lin, JH; Cheng, HC; Huang, HC; Yang, PC; Liu, SK; Mao, SJT				Lee, WC; Lin, KY; Chiu, YT; Lin, JH; Cheng, HC; Huang, HC; Yang, PC; Liu, SK; Mao, SJT			Substantial decrease of heat shock protein 90 in ventricular tissues of two sudden-death pigs with hypertrophic cardiomyopathy	FASEB JOURNAL			English	Article						isoelectrofocusing; tissue homogenization; systolic anterior motion; HSP90; ischemia	GLUCOCORTICOID RECEPTOR; MYOCARDIAL-ISCHEMIA; STEROID-RECEPTORS; ACTIN-FILAMENTS; HSP90; STRESS; EXPRESSION; INDUCTION; BINDING; ASSOCIATION	We recently developed a pig model with naturally occurring hypertrophic cardiomyopathy (HCM). To further characterize the biochemical features of high frequency of sudden death affected by this disease, the protein profiles of ventricular tissues were analyzed on normal, HCM, and HCM with sudden-death pigs. By sodium dodecylsulfate-polyacrylamide gel electrophoresis, a protein corresponding to an apparent molecular mass of 90 kDa (p90) was found to be markedly decreased in the HCM-affected tissues of sudden-death pigs, but not in HCM or normal pigs. Further study showed that the primary decrease of p90 in HCM pigs with sudden death was located mainly in the interventricular septum. As determined by the molecular mass and isoelectric point on 2-dimensional gels and Western immunoblot with a specific 90 kDa heat shock protein (HSP90) monoclonal antibody, the unknown protein was identified as HSP90. Our findings indicate for the first time that substantially decreased heart HSP90 is associated with HCM pigs with sudden death. Although the role that HSP90 may play in protecting pigs with HCM from sudden death is still unclear, the model itself may provide further insight into understanding the role of heat shock proteins in cardiac sudden death.	ANIM MED CTR,NEW YORK,NY									ANDERSON KP, 1994, SUDDEN CARDIAC DEATH, P163; BENJAMIN IJ, 1994, BIOL HEAT SHOCK PROT, P533; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; CURRIE RW, 1993, CIRCULATION, V87, P963, DOI 10.1161/01.CIR.87.3.963; CURRIE RW, 1988, CIRC RES, V63, P543, DOI 10.1161/01.RES.63.3.543; DAI KS, 1995, VET RES COMMUN, V19, P1635; DAI KS, 1995, IN PRESS BR VET J; FACTOR SM, 1991, J AM COLL CARDIOL, V17, P1343, DOI 10.1016/S0735-1097(10)80145-7; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; HADA Y, 1987, AM J CARDIOL, V59, P183, DOI 10.1016/S0002-9149(87)80107-8; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENGSTENBERG C, 1993, CARDIOSCIENCE, V4, P15; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; HUANG SY, 1996, IN PRESS LAB ANIM SC; HUTTER MM, 1994, CIRCULATION, V89, P355, DOI 10.1161/01.CIR.89.1.355; INANOBE A, 1994, J BIOCHEM, V115, P486, DOI 10.1093/oxfordjournals.jbchem.a124363; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; KNOWLTON AA, 1995, J MOL CELL CARDIOL, V27, P121, DOI 10.1016/S0022-2828(08)80012-0; KOGA Y, 1984, AM HEART J, V108, P351, DOI 10.1016/0002-8703(84)90624-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WC, 1991, J CELL PHYSIOL, V149, P66, DOI 10.1002/jcp.1041490110; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIU SK, 1993, AM J CARDIOL, V72, P944, DOI 10.1016/0002-9149(93)91112-U; LIU SK, 1983, VET CLIN N AM-SMALL, V13, P379, DOI 10.1016/S0195-5616(83)50036-3; LIU SK, 1994, CARDIOVASC PATHOL, V3, P261, DOI 10.1016/1054-8807(94)90012-4; LOUIE EK, 1994, PROG CARDIOVASC DIS, V36, P275, DOI 10.1016/S0033-0620(05)80036-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARBER MS, 1993, CIRCULATION, V88, P1263; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1978, AM J CARDIOL, V41, P1133, DOI 10.1016/0002-9149(78)90870-6; MARON BJ, 1986, J AM COLL CARDIOL, V8, P545, DOI 10.1016/S0735-1097(86)80181-4; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MESTRIL R, 1995, J MOL CELL CARDIOL, V27, P45, DOI 10.1016/S0022-2828(08)80006-5; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WALKER DM, 1993, CARDIOVASC RES, V27, P962, DOI 10.1093/cvr/27.6.962; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YELLON DM, 1992, J MOL CELL CARDIOL, V24, P342; 1980, BRIT HEART J, V44, P672	62	39	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1198	1204		10.1096/fasebj.10.10.8751722	http://dx.doi.org/10.1096/fasebj.10.10.8751722			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751722				2022-12-25	WOS:A1996VD42900011
J	Packham, G; Porter, CW; Cleveland, JL				Packham, G; Porter, CW; Cleveland, JL			C-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways	ONCOGENE			English	Article						c-Myc; ODC; apoptosis; cell cycle	ORNITHINE DECARBOXYLASE; SIGNALING PATHWAYS; EXPRESSION; PROTEIN; GENE; TRANSCRIPTION; ARREST; GROWTH; DEATH; BCL-2	Enforced c-Myc expression promotes inappropriate cell cycle progression of growth factor deprived cells and triggers concomitant apoptosis. However, it is not clear what role dysregulation of the cell cycle plays in c-Myc induced apoptosis. Ornithine decarboxylase (ODC) is a transcriptional target of c-Myc and contributes to c-Myc induced apoptosis. Here we have established that high levels of ODC overexpression in interleukin-3 (IL-3)dependent 32D.3 myeloid cells induces apoptosis at rates comparable to those induced by enforced c-Myc expression. However, ODC-induced apoptosis was not accompanied by dysregulation of cell cycle controls, indicating that cell death was not triggered by inappropriate cell cycle progression. Nonetheless, ODC was required downstream of c-Myc for myeloid cell growth. These results suggested that c-Myc-induced pathways leading to cell cycle progression and apoptosis are separable, yet that they share common mediators. In agreement with this concept, treatment of cells overexpressing c-Myc with the inhibitory agent dibutyryl cyclic AMP (Bt(2)cAMP) arrested these cells G(1), without inducing apoptosis. However, c-Myc retained the ability to induce apoptosis of Bt(2)cAMP-arrested cells following removal of IL-3, demonstrating that Bt(2)cAMP selectively inhibits c-Myc-induced pathways promoting cell cycle progression but not apoptosis. These results suggest a 'multiple effecters' model in which c-Myc regulates the expression of mediators which alone are sufficient to induce apoptosis in the absence of survival factors, yet are required in concert to promote cell cycle progression.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ROSWELL PK CANC INST, GRACE CANC DRUG CTR, BUFFALO, NY 14263 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	Imperial College London; Ludwig Institute for Cancer Research; St Jude Children's Research Hospital; Roswell Park Cancer Institute; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [P0 CA 21765, CA 22153] Funding Source: Medline; NIDDK NIH HHS [DK 44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA022153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1994, PEZC S AP, P85; Cleveland John L., 1994, Cancer Bulletin (Houston), V46, P167; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Green D R, 1994, Important Adv Oncol, P37; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HARRINGTON H, 1994, SCIENCE, V265, P2091; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	43	99	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					461	469						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760287				2022-12-25	WOS:A1996VB32800003
J	Mayol, X; Garriga, J; Grana, X				Mayol, X; Garriga, J; Grana, X			G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4	ONCOGENE			English	Article						cell cycle; E2F; pRB; quiescence; TGF-beta	CELL-CYCLE CONTROL; LARGE-T-ANTIGEN; CDC2-RELATED PROTEIN-KINASE; RETINOBLASTOMA GENE FAMILY; TUMOR-SUPPRESSOR PROTEIN; DEPENDENT KINASES; IN-VIVO; INHIBITORS; MEMBER; EXPRESSION	During the transition from G1 to G0, p130 undergoes a specific phosphorylation event - leading to p130-form 2 - that is mediated by a kinase/s other than the known G1, S and G2/M cyclin/CDKs. Changes in the phosphorylation status of p130 during this transition are responsible, at least in part, for the concomitant formation of p130/E2F4 complexes, which are characteristic of GO. These complexes remain abundant during early G1 upon restimulation, but not after mitosis, and are dissociated in mid G1 when p130 is abruptly hyperphosphorylated to form 3. Subsequently, p130 forms 1 and 2 are no longer detected during the remainder of the cell cycle. Consistently, phosphorylation to form 3 and dissociation from E2F-4 complexes is reproduced by a cyclin/CDK holoenzyme in vitro. TGF-beta-induced G1 arrest abrogates cyclin/CDK phosphorylation of p130 but not phosphorylation to form 2. The cell cycle-dependent phosphorylation pattern of p130 is thus shown to comprise two distinct steps that are catalyzed by different kinases. The differential regulation of p130 and pRB phosphorylation during the transition from G1 to G0 may explain the fact that p130 and E2F-4 are the major components of E2F complexes in quiescent cells. Moreover, the newly described phosphorylation of p130 at the transition from G1 to G0 defines a novel mechanism of cell cycle exit regulation.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Mayol, Xavier/C-1391-2012	Grana, Xavier/0000-0001-7134-0473; Mayol, Xavier/0000-0001-7288-195X				BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRANA X, 1994, ONCOGENE, V9, P2097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E., 1988, ANTIBODIES LAB MANUA; HERZINGER T, 1995, ONCOGENE, V10, P2079; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLF DA, 1995, ONCOGENE, V10, P2067; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	43	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					237	246						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710362				2022-12-25	WOS:A1996VA25200002
J	Jaiswal, RK; Weissinger, E; Kolch, W; Landreth, GE				Jaiswal, RK; Weissinger, E; Kolch, W; Landreth, GE			Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; HEAT-SHOCK PROTEIN; PC12 CELLS; IDENTIFICATION; TRANSFORMATION; ASSOCIATION; DROSOPHILA; MEMBRANE; MEK-1; HETEROCOMPLEX	The nerve growth factor (NGF)-mediated activation of the mitogen-activated protein (MAP) kinase cascade is an obligatory step in the morphological differentiation of PC12 cells, Signal transduction through the MAP kinase cascade is dependent upon activation of p21(ras) which binds directly to Raf family protein kinases, mediating their association with the membrane and activation. PC12 cells express two Raf isoforms, c-Raf and B-Raf. The activation of the MAP kinase cascade in response to NGF is due principally to the action of B-Raf. NGF treatment of PC12 cells resulted in the enhanced phosphorylation of B-Raf and c-Raf, and both exhibit reduced electrophoretic mobilities following stimulation of the cells. The NGF-stimulated phosphorylation of B-Raf was correlated with its enzymatic activation as measured by the phosphorylation of its substrate MEK. However, c-Raf does not exhibit significant levels of activity, B-Raf was present as a component of a high molecular mass complex, which included the molecular chaperone, heat shock protein 90 (HSP90). Importantly, c-Raf did not participate in the formation of such complexes, The B-Raf containing HSP90 complexes were normally present in PC12 cells, and their assembly was not dependent upon NGF stimulation, These data suggest that the ability of B-Raf to activate the MAP kinase cascade is due to its association with a large signaling complex, which is likely to impart signaling pathway specificity.	CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMERS RES LAB, DEPT NEUROL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMERS RES LAB, DEPT NEUROSCI, CLEVELAND, OH 44106 USA; GSF MUNICH, INST KLIN MOL BIOL & TUMORGENET, HAEMATOLOGIKUM, D-81377 MUNICH, GERMANY; GSF MUNICH, INST KLIN HAEMATOL, HAEMATOLOGIKUM, D-81377 MUNICH, GERMANY	Case Western Reserve University; Case Western Reserve University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Kolch, Walter/0000-0001-5777-5016	NINDS NIH HHS [NS31987] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031987] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BOHLEN S, 1995, SCIENCE, V268, P1301; BRUGGE J, 1996, CURR TOP MICROBIOL I, V123, P1; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAPIN C, 1995, ONCOGENE, V10, P1647; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P133, DOI 10.1016/0304-419X(93)90002-T; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	45	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23626	23629		10.1074/jbc.271.39.23626	http://dx.doi.org/10.1074/jbc.271.39.23626			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798578	hybrid			2022-12-25	WOS:A1996VJ44200007
J	Adler, V; Pincus, MR; Polotskaya, A; Montano, X; Friedman, FK; Ronai, Z				Adler, V; Pincus, MR; Polotskaya, A; Montano, X; Friedman, FK; Ronai, Z			Activation of c-Jun-NH2-kinase by UV irradiation is dependent on p21(ras)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN KINASE; PROTEIN-KINASE; IONIZING-RADIATION; AP-1 ACTIVITY; CELLS; RAS; EXPRESSION; PHOSPHORYLATION; INDUCTION; PATHWAYS	We have demonstrated previously that Jun-NH2-kinase (JNK) activation in vitro is potentiated by association with the p21(ras) protein. To determine if in vivo activation of JNK also depends on p21(ras), we have used M1311 cells that carry the cDNA for the neutralizing antibody to p21(ras), Y13-259, under a dexamethasone-inducible promoter. The ability of UV to activate JNK gradually decreased over a 4-day period of cell growth in dexamethasone. This decrease coincides with weaker transcriptional activation measured via gel shift and chloramphenicol acetyltransferase assays. Peptides corresponding to amino acids 96-110 on p21(ras), which were shown to block Ras-JNK association, inhibited UV-mediated JNK activation in mouse fibroblast 3T3-4A cells as well as in M1311 cells, further supporting the role of p21(ras) in UV-mediated JNK activation. Overall, the present studies provide in vivo confirmation of the role p21(ras) plays in JNK activation by UV irradiation.	AMER HLTH FDN,MOL CARCINOGENESIS PROGRAM,VALHALLA,NY 10595; VET AFFAIRS MED CTR,DEPT PATHOL & LAB MED,BROOKLYN,NY 11209; SUNY HLTH SCI CTR,BROOKLYN,NY 11203; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; NCI,MOL CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892	American Health Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Cancer Research UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Friedman, Fred K/D-4208-2016; Friedman, Fred/O-6173-2019	Friedman, Fred/0000-0002-0284-7067; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995, CA42500] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042500, R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COFFER PJ, 1995, ONCOGENE, V11, P561; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DYKES DC, 1992, MED SCI RES, V20, P809; FUCHS SY, 1996, ONCOGENE, V13, P1529; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; LIBOI E, 1984, VIROLOGY, V135, P440, DOI 10.1016/0042-6822(84)90199-5; LIWO A, 1994, J PROTEIN CHEM, V13, P237, DOI 10.1007/BF01891982; LOLYED AC, 1989, EMBO J, V8, P1099; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; Monaco R, 1995, J PROTEIN CHEM, V14, P721, DOI 10.1007/BF01886911; MONTANO X, 1995, CELL GROWTH DIFFER, V6, P597; MOODIE SA, 1993, SCIENCE, V260, P1588; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595	30	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23304	23309		10.1074/jbc.271.38.23304	http://dx.doi.org/10.1074/jbc.271.38.23304			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798530	hybrid			2022-12-25	WOS:A1996VH76800056
J	Berger, SA; Rowan, K; Morrison, HD; Ziltener, HJ				Berger, SA; Rowan, K; Morrison, HD; Ziltener, HJ			Identification of a bacterial inhibitor of protein kinases - Mechanism and role in host cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI EPEC; SALMONELLA-TYPHIMURIUM; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; VIRULENCE DETERMINANT; ADENOSINE RELEASE; MAMMALIAN-CELLS; HEP-2 CELLS; MUTANTS	We show that Escherichia coli produce a factor that inhibits the activity of tyrosine and serine/threonine protein kinases. The factor is a protein found in the periplasmic compartment and is also secreted into the culture medium. Using a particle concentration fluorescence immunoassay specific for tyrosine kinase activity and inhibition of the tyrosine kinase p56(lck), we purified this factor to apparent homogeneity. Analysis of trypsin-digested fragments by mass spectrometry identified the inhibitor as the bacterial periplasmic protein UDP-sugar hydrolase, an enzyme with potent and nonspecific 5'-nucleotidase activity. Overexpression of the enzyme in bacteria leads to coordinate increases in both 5'-nucleotidase and p56(lck) inhibitory activity, confirming the identity of the inhibitor. The kinase inhibitory activity appears to be due to the formation of adenosine, which we show is inhibitory for p56(lck), cAMP-dependent protein kinase, and casein kinase. Overexpression of UDP-sugar hydrolase leads to an increase in the recovery of enteropathogenic E. coli following infection of HeLa cell monolayers and corresponding alterations in tyrosine-phosphorylated host proteins. These results suggest that UDP-sugar hydrolase may be an important factor affecting host cell function following intracellular bacterial infection.	UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON M5S 1X8, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 123, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V6T 123, CANADA	University of Toronto; University of British Columbia; University of British Columbia	Berger, SA (corresponding author), WELLESLEY HOSP, RES INST, 160 WELLESLEY ST, TORONTO, ON M4Y 1J3, CANADA.							BABCOOK J, 1991, ANAL BIOCHEM, V196, P245, DOI 10.1016/0003-2697(91)90461-2; BETTS J, 1992, CAN J MICROBIOL, V38, P852, DOI 10.1139/m92-138; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BLISKA JB, 1993, TRENDS GENET, V9, P85, DOI 10.1016/0168-9525(93)90229-B; BURNS DM, 1986, NUCLEIC ACIDS RES, V14, P4325, DOI 10.1093/nar/14.10.4325; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; DONNENBERG MS, 1990, INFECT IMMUN, V58, P1565, DOI 10.1128/IAI.58.6.1565-1571.1990; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Finlay BB, 1990, CURR OPIN CELL BIOL, V2, P815, DOI 10.1016/0955-0674(90)90078-S; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FIRESTEIN GS, 1995, J IMMUNOL, V154, P326; FOUBISTER V, 1994, J EXP MED, V179, P993, DOI 10.1084/jem.179.3.993; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GLASER L, 1967, J BIOL CHEM, V242, P1944; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Gunther G R, 1991, Ann Vasc Surg, V5, P325, DOI 10.1007/BF02015292; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; HSIA RC, 1993, J BACTERIOL, V175, P4817, DOI 10.1128/JB.175.15.4817-4823.1993; KELLY SM, 1992, INFECT IMMUN, V60, P4881, DOI 10.1128/IAI.60.11.4881-4890.1992; KITAKAZE M, 1993, CARDIOVASC RES, V27, P18, DOI 10.1093/cvr/27.1.18; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LEUNG KY, 1991, P NATL ACAD SCI USA, V88, P11470, DOI 10.1073/pnas.88.24.11470; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NEU HC, 1967, J BIOL CHEM, V242, P3896; NNALUE NA, 1990, J MED MICROBIOL, V31, P225, DOI 10.1099/00222615-31-4-225; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; SAITO S, 1994, INFECT IMMUN, V62, P1551, DOI 10.1128/IAI.62.5.1551-1556.1994; SCHWAN WR, 1994, P NATL ACAD SCI USA, V91, P6428, DOI 10.1073/pnas.91.14.6428; SMAIL EH, 1992, J IMMUNOL, V148, P3588; WATTS JD, 1992, J BIOL CHEM, V267, P901; WICK MJ, 1991, CELL, V67, P651; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086	39	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23431	23437		10.1074/jbc.271.38.23431	http://dx.doi.org/10.1074/jbc.271.38.23431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798549	hybrid			2022-12-25	WOS:A1996VH76800075
J	Debinski, W; Miner, R; Leland, P; Obiri, NI; Puri, RK				Debinski, W; Miner, R; Leland, P; Obiri, NI; Puri, RK			Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; SIGNAL-TRANSDUCTION; PROTEIN; AERUGINOSA; TOXIN; IMMUNOTOXIN; EXPRESSION; COMPONENT; THERAPY; MICE	Recently, we have demonstrated that human (h) glioma cell Lines express large number of receptors (R) for interleukin 13 (IL13) (Debinski, W., Obiri, N. I., Powers, S. K., Pastan, L., and Purl, R. K. (1995) Clin. Cancer Res. 1, 1253-1258). These cells are extremely sensitive to a chimeric protein composed of hIL13 and a derivative of Pseudomonas exotoxin (PE), PE38QQR. We have found that the cytotoxicity of hIL13-PE38QQR was blocked by hIL13 but not by hIL4 on the U-251 MG and U-373 MG cells, contrary to what was observed on several adenocarcinoma cell lines. In the present study, we further explored interactions between receptor for IL13 and IL4 on glioma cells. Established human glioma cell lines, such as DBTRG MG, Hs 683, U-87 MG, SNB-19, and A-172, are very susceptible to hIL13-PE38QQR, and the action of the chimeric toxin is not blocked by hIL4 on all these cells either. Also, hIL4 is not a competitor for I-125-hIL13 binding sites on glioma cells. Of interest, a corresponding hIL4-based chimeric toxin, hIL4-PE38QQR, is poorly active or not active on all the tested glioma cell lines. When active, however, hIL4 toxin action was blocked by hIL13. hIL13 is a competitor for I-125-hIL14 binding in a competitive binding assay on glioma cells. hIL13 and hIL4 did not affect the growth of the tested glioma cell lines. Human glioblastoma multiforme explant cells exhibited similar responses to the chimeric toxins and interleukins when compared with that found in established glioma cultures. Our results suggest that the hIL13R on glioma cells is expressed in one predominant form, the form that does not interact with IL4. Thus, this type of hIL13R is apparently different from the one demonstrated previously on several adenocarcinoma cell lines.	US FDA,LAB MOL TUMOR BIOL,DIV CELLULAR & GENE THERAPIES,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	US Food & Drug Administration (FDA)	Debinski, W (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT SURG,DIV NEUROSURG,500 UNIV DR,HERSHEY,PA 17033, USA.							ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; DEBINSKI W, 1993, J BIOL CHEM, V268, P14065; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; Debinski W, 1995, CLIN CANCER RES, V1, P1253; DEBINSKI W, 1994, INT J CANCER, V58, P744, DOI 10.1002/ijc.2910580520; DEBINSKI W, 1994, BIOCONJUGATE CHEM, V5, P40, DOI 10.1021/bc00025a006; DEBRINSKI W, 1995, J BIOL CHEM, V270, P16775; Frankel AE, 1996, CANCER RES, V56, P926; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HARADA N, 1992, J BIOL CHEM, V267, P22752; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; OBIRI NI, 1996, IN PRESS CLIN CANC R; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PHILLIPS PC, 1994, CANCER RES, V54, P1008; PURI RK, 1993, CANCER INVEST, V11, P473, DOI 10.3109/07357909309018879; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; PURI RK, 1994, INT J CANCER, V58, P574, DOI 10.1002/ijc.2910580421; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	28	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22428	22433		10.1074/jbc.271.37.22428	http://dx.doi.org/10.1074/jbc.271.37.22428			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798406	hybrid			2022-12-25	WOS:A1996VG67200025
J	Hou, XH; Dietrich, J; Odum, N; Geisler, C				Hou, XH; Dietrich, J; Odum, N; Geisler, C			The cytoplasmic tail of Fc gamma RIIIA alpha is involved in signaling by the low affinity receptor for immunoglobulin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; NATURAL-KILLER-CELLS; PROTEIN-TYROSINE KINASE; EPSILON-RI-GAMMA; T-CELL; ZETA-CHAIN; PHOSPHATASE CD45; CD3-GAMMA CHAIN; MAST-CELLS; IGG FC	The low affinity receptor for IgG, Fc gamma RIIIA, is a multimeric receptor composed of the ligand binding subunit Fc gamma RIIIA alpha (CD16) in association with the signal-transducing subunits zeta or gamma. Previous studies suggested that the cytoplasmic tail of Fc gamma RIIIA alpha was not required for Fc gamma RIIIA alpha-zeta association or signaling by Fc gamma RIIIA. However, in these studies,the truncated Fc gamma RIIIA alpha chains still expressed the four most membrane-proximal amino acids of the cytoplasmic tail (amino acids 230-233). By successive truncations from the C terminus of Fc gamma RIIIA alpha, we have studied the role played by the membrane-proximal amino acids of the cytoplasmic tail of Fc gamma RIIIA alpha in (i) Fc gamma RIIIA expression, (ii) Fc gamma RIIIA alpha-zeta association, and (iii) signal transduction. We provide evidence that this region is not required for Fc gamma RIIIA expression or Fc gamma RIIIA alpha-zeta association. However, signaling by Fc gamma RIIIA is strictly dependent on the membrane-proximal amino acids in the cytoplasmic tail of Fc gamma RIIIA alpha. Thus, total deletion of the cytoplasmic tail of Fc gamma RIIIA alpha results in a severely impaired tyrosine phosphorylation of phospholipase C-gamma 1, zap, and syk and rise in intracellular free Ca2+ following receptor ligation with specific anti-CD16 monoclonal antibody or Ig-anti-Ig complexes, suggesting that Fc gamma RIIIA alpha-zeta association per se is not sufficient to establish the signal function of Fc gamma RIIIA. In conclusion, the present findings demonstrate that the most membrane-proximal amino acids of the Fc gamma RIIIA alpha cytoplasmic tail play a critical role in ligand-induced signal transduction by the Fc gamma RIIIA alpha-zeta complex.	UNIV COPENHAGEN,PANUM INST,INST MED MICROBIOL & IMMUNOL,DK-2200 COPENHAGEN,DENMARK; NIAID,MOL STRUCT LAB,NIH,ROCKVILLE,MD 20892	University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ALTIN JG, 1994, IMMUNOL CELL BIOL, V72, P87, DOI 10.1038/icb.1994.13; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CASSATELLA MA, 1989, J EXP MED, V169, P549, DOI 10.1084/jem.169.2.549; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DAERON M, 1994, J IMMUNOL, V152, P783; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1988, SCAND J IMMUNOL, V27, P685, DOI 10.1111/j.1365-3083.1988.tb02402.x; GEISLER C, 1992, J IMMUNOL, V148, P3469; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; HOU XH, 1994, EUR J IMMUNOL, V24, P1228, DOI 10.1002/eji.1830240534; HOWARD FD, 1990, P NATL ACAD SCI USA, V87, P7015, DOI 10.1073/pnas.87.18.7015; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JUSTEMENT LB, 1994, IMMUNOL TODAY, V15, P399, DOI 10.1016/0167-5699(94)90268-2; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1991, J IMMUNOL, V146, P1571; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; STAHLS A, 1994, EUR J IMMUNOL, V24, P2491, DOI 10.1002/eji.1830241035; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821; VIVIER E, 1991, J IMMUNOL, V147, P4263; WEGENER AMK, 1995, J BIOL CHEM, V270, P4675, DOI 10.1074/jbc.270.9.4675; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381	51	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22815	22822		10.1074/jbc.271.37.22815	http://dx.doi.org/10.1074/jbc.271.37.22815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798459	hybrid			2022-12-25	WOS:A1996VG67200078
J	Klockner, U; Mikala, G; Schwartz, A; Varadi, G				Klockner, U; Mikala, G; Schwartz, A; Varadi, G			Molecular studies of the asymmetric pore structure of the human cardiac voltage-dependent Ca2+ channel - Conserved residue, GLU-1086, regulates proton-dependent ion permeation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CURRENT FLUCTUATIONS; CALCIUM CHANNELS; MUSCLE-CELLS; SELECTIVITY; DETERMINANTS; ALPHA-1-SUBUNIT; CONDUCTANCE; EXPRESSION; BINDING; SITES	Proton transfer to calcium channels results in rapid fluctuations between two non-zero conductance levels when the current is carried by monovalent cations. A combination of site-directed mutagenesis and single-channel recording techniques were used to identify the unique proton acceptor site as Glu-1086, a conserved glutamate residue located in the S5-S6 linker of motif III of calcium channels. Glu-1086 is part of an array of four glutamate residues in the pore-lining region of the channel conferring the high selectivity of calcium channels. Titration of Glu-1086 yielded a pK(alpha) value of 7.91 which is different from that expected for a free glutamic acid side-chain carboxyl. Proposed electrostatic interactions between charged nearby residues can account only in part for this phenomenon since individual elimination of the other three glutamate residues only slightly decreased the pK(alpha) of Glu-1086. These data, in addition to identifying the proton acceptor site, provide evidence for the influence of the microenvironment in forming the asymmetry of the conducting pathway of calcium channels.	UNIV CINCINNATI,COLL MED,INST MOL PHARMACOL & BIOPHYS,CINCINNATI,OH 45267; UNIV COLOGNE,DEPT PHYSIOL,D-50931 COLOGNE,GERMANY	University of Cincinnati; University of Cologne					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL043231, P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22619-17, HL43231-07] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASH H, 1992, CHEM ACID DERIV 1 SB, V2, P1; Chen X.-H., 1996, Biophysical Journal, V70, pA78; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KLOCKNER U, 1994, J GEN PHYSIOL, V103, P665, DOI 10.1085/jgp.103.4.665; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; MATTHEW JB, 1985, ANNU REV BIOPHYS BIO, V14, P387; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PIETROBON D, 1988, NATURE, V333, P373, DOI 10.1038/333373a0; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; PRODHOM B, 1987, NATURE, V329, P243, DOI 10.1038/329243a0; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; TANG SQ, 1993, J BIOL CHEM, V268, P13026; URRY DW, 1992, J AM CHEM SOC, V114, P8717; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; WENDTGALLITELLI MF, 1989, AM J PHYSIOL, V256, pH574, DOI 10.1152/ajpheart.1989.256.2.H574; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YATANI A, 1994, CIRC RES, V75, P315, DOI 10.1161/01.RES.75.2.315; ZALEWSKI RI, 1992, CHEM FUNCTIONAL G SB, V2, P305	27	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22293	22296						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798385				2022-12-25	WOS:A1996VG67200004
J	Laflamme, L; deGasparo, M; Gallo, JM; Payet, MD; GalloPayet, N				Laflamme, L; deGasparo, M; Gallo, JM; Payet, MD; GalloPayet, N			Angiotensin II induction of neurite outgrowth by AT(2) receptors in NG108-15, cells - Effect counteracted by the AT(1) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; RAT PHEOCHROMOCYTOMA CELLS; GLIOMA HYBRID-CELLS; NERVE GROWTH-FACTOR; PHOSPHATASE INHIBITION; TYPE-2 RECEPTOR; PC12 CELLS; BRAIN; SUBTYPES; TAU	In the present study, 3-day treatment of nondifferentiated NG108-15 cells with 100 nM angiotensin II (Ang II) induces morphological differentiation of neuronal cells characterized by the outgrowth of neurites. These mor morphological changes are correlated with an increase in the level of polymerized tubulin and in the level of the microtubule-associated protein, MAP2c. Mediation by the AT(2) receptor may be inferred since: (a) these cells contain only AT(2) receptors; (b) the effects are mimicked by CGP 42112 (an AT(2) receptor agonist); (c) they are not suppressed by the addition of DUP 753 (an AT(1) receptor antagonist); and (d) are abolished by co-incubation with PD 123319 (an AT(2) receptor antagonist). Application of Ang II in dibutyryl cAMP-differentiated cells (which contain both types of receptors) induces neurite retraction, an effect mediated by the AT(1) receptor. These results indicate that the AT(2) receptor of Ang II induces neuronal differentiation, which is initiated through an increase in the levels of MAP2c associated with tubulin. Moreover, our results demonstrate that the AT(1) receptor inhibit the process of differentiation induced by dibutyryl cAMP, whereas the AT(2) receptors potentiate this effect, illustrating negative cross-talk interaction between the two types of Ang II receptors.	UNIV SHERBROOKE, FAC MED, SERV ENDOCRINOL, SHERBROOKE, PQ J1H 5N4, CANADA; UNIV SHERBROOKE, FAC MED, DEPT PHYSIOL & BIOPHYS, SHERBROOKE, PQ J1H 5N4, CANADA; CIBA GEIGY LTD, DIV PHARMACEUT, DEPT CARDIOVASC RES, BASEL, SWITZERLAND; INST PSYCHIAT, DEPT NEUROL, LONDON SE5 8AF, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON SE5 8AF, ENGLAND	University of Sherbrooke; University of Sherbrooke; Novartis; University of London; King's College London; University of London; King's College London				Gallo, Jean-Marc/0000-0003-0214-4545				BARNES JM, 1993, EUR J PHARMACOL, V230, P251, DOI 10.1016/0014-2999(93)90558-Y; BEAMANHALL CM, 1993, J NEUROBIOL, V24, P1500, DOI 10.1002/neu.480241105; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BRECHLER V, 1994, RECEPTOR CHANNEL, V2, P89; BUISSON B, 1992, FEBS LETT, V309, P161, DOI 10.1016/0014-5793(92)81086-2; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CARRITHERS MD, 1992, NEUROSCI LETT, V135, P45, DOI 10.1016/0304-3940(92)90132-Q; CHIOU JY, 1992, J NEUROCHEM, V59, P1963, DOI 10.1111/j.1471-4159.1992.tb11034.x; DEGASPARO M, 1995, REGUL PEPTIDES, V59, P303, DOI 10.1016/0167-0115(95)00085-P; DOLL T, 1993, J CELL SCI, V106, P633; FERREIRA A, 1991, J NEUROSCI, V11, P392; GEHLERT DR, 1991, NEUROSCIENCE, V44, P501, DOI 10.1016/0306-4522(91)90073-W; GROVE KL, 1993, BIOCHEM PHARMACOL, V46, P1653, DOI 10.1016/0006-2952(93)90335-T; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HAYASHIDA W, 1995, CIRCULATION, V92, P826; HEEMSKERK FMJ, 1993, NEUROREPORT, V4, P103, DOI 10.1097/00001756-199301000-00027; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; KATER SB, 1991, J NEUROSCI, V11, P891; LAFLAMME L, 1994, ANN ENDOCRINOL, V55, P6; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P4567, DOI 10.1073/pnas.85.12.4567-a; LEUNG KH, 1992, EUR J PHARM-MOLEC PH, V227, P63, DOI 10.1016/0922-4106(92)90143-J; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; MATUS A, 1981, P NATL ACAD SCI-BIOL, V78, P3010, DOI 10.1073/pnas.78.5.3010; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; OBERMULLER N, 1991, NEUROSCI LETT, V132, P11, DOI 10.1016/0304-3940(91)90420-X; SHEA TB, 1992, J NEUROSCI RES, V32, P363, DOI 10.1002/jnr.490320308; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; SPETH R C, 1989, Peptide Research, V2, P232; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SWARZENSKI BC, 1994, P NATL ACAD SCI USA, V91, P649, DOI 10.1073/pnas.91.2.649; TAKAHASI K, 1994, BIOCHEM BIOPH RES CO, V198, P60, DOI 10.1006/bbrc.1994.1009; TALLANT EA, 1991, HYPERTENSION, V17, P1135, DOI 10.1161/01.HYP.17.6.1135; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUSUMI K, 1991, ENDOCRINOLOGY, V129, P1075; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; WEBB ML, 1992, PEPTIDES, V13, P499, DOI 10.1016/0196-9781(92)90081-D; WEISSHAAR B, 1992, DEVELOPMENT, V116, P1151; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; XIONG H, 1994, NEUROSCIENCE, V62, P163, DOI 10.1016/0306-4522(94)90322-0; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	54	166	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22729	22735		10.1074/jbc.271.37.22729	http://dx.doi.org/10.1074/jbc.271.37.22729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798447	hybrid			2022-12-25	WOS:A1996VG67200066
J	McConkey, DJ				McConkey, DJ			Calcium-dependent, interleukin 1 beta-converting enzyme inhibitor-insensitive degradation of lamin B-1 and DNA fragmentation in isolated thymocyte nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; FAS-MEDIATED APOPTOSIS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ENDONUCLEASE ACTIVATION; CHROMATIN CONDENSATION; MULTIPLE PROTEASES; ICE/CED-3 PROTEASE; SERINE PROTEASE; LIVER NUCLEI; INDUCTION	Recent work suggests that the proteolytic degradation of the nuclear lamins is a common event in apoptosis, although the nature of the proteases involved is still not clear, Our previous work showed that the degradation of lamin B-1 in glucocorticoid-treated thymocytes occurs via a Ca2+-sensitive mechanism and that exogenous Ca2+ promotes lamin degradation in isolated thymocyte nuclei from untreated cells, Here we demonstrate that peptide-based inhibitors of the interleukin 1 beta-converting enzyme family of cysteine proteases (Tyr-Val-Ala-Asp fluoromethyl ketone) and of the nuclear scaffold multicatalytic proteinase (Ala-Pro-Phe chloromethyl ketone) block the degradation of lamin B-1 to a 21-kDa fragment in thymocytes treated with glucocorticoid, the Ca2+-mobilizing agent thapsigargin, or antibodies to the T cell receptor, However, among a panel of inhibitors specific for several different proteases implicated in apoptosis, only tosylphenylalanyl chloromethyl ketone and the nuclear scaffold protease inhibitor block lamin degradation, histone H1 cleavage, and DNA fragmentation in isolated thymocyte nuclei incubated with Ca2+. Overexpression of human BCL-2 in nuclei by stable transfection resulted in an inhibition of Ca2+-stimulated lamin degradation and DNA fragmentation, suggesting that endogenous nuclear BCL-2 regulates activation of the nuclear scaffold protease, The results demonstrate the existence of an alternative pathway of lamin degradation and DNA fragmentation mediated by a resident Ca2+-stimulated nuclear protease that is not directly dependent upon activation of the interleukin 1 beta-converting enzyme family of cell death regulators.			McConkey, DJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ASHWELL JD, 1987, SCIENCE, V237, P61, DOI 10.1126/science.3037698; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; CLAWSON GA, 1993, CELL GROWTH DIFFER, V4, P589; CLAWSON GA, 1992, CELL GROWTH DIFFER, V3, P827; COHEN GM, 1994, J IMMUNOL, V153, P507; COHEN JJ, 1984, J IMMUNOL, V132, P38; DEJONG D, 1994, CANCER RES, V54, P256; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DOWD DR, 1991, J BIOL CHEM, V266, P18423; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; ENOMOTO K, 1987, CARCINOGENESIS, V8, P1933, DOI 10.1093/carcin/8.12.1933; FEARNHEAD HO, 1995, FEBS LETT, V357, P242, DOI 10.1016/0014-5793(94)01367-A; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; Huang P, 1995, CLIN CANCER RES, V1, P1005; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JONES DP, 1989, J BIOL CHEM, V264, P6398; KANEKO A, 1986, JNCI-J NATL CANCER I, V77, P121; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Khodarev NN, 1996, J IMMUNOL, V156, P922; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MADSEN KR, 1990, EXP CELL RES, V187, P343, DOI 10.1016/0014-4827(90)90103-H; MARTIN MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; STAROSELSKY AH, 1991, CANCER RES, V51, P6292; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; SUN DY, 1994, J EXP MED, V179, P559, DOI 10.1084/jem.179.2.559; SUN XM, 1994, J BIOL CHEM, V269, P14857; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391	60	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22398	22406		10.1074/jbc.271.37.22398	http://dx.doi.org/10.1074/jbc.271.37.22398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798402	hybrid			2022-12-25	WOS:A1996VG67200021
J	Bohm, SK; Khitin, LM; Grady, EF; Aponte, G; Payan, DG; Bunnett, NW				Bohm, SK; Khitin, LM; Grady, EF; Aponte, G; Payan, DG; Bunnett, NW			Mechanisms of desensitization and resensitization of proteinase-activated receptor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL THROMBIN RECEPTOR; SUBSTANCE-P RECEPTOR; KINASE-C; MOLECULAR-CLONING; INDUCED INTERNALIZATION; SELECTIVE INHIBITOR; FEEDBACK-REGULATION; ENDOCYTIC PATHWAY; COUPLED RECEPTOR; NK1 RECEPTOR	Proteinase activated receptor-2 (PAR-2) is a G-protein-coupled receptor that is expressed by intestinal epithelial cells, which are episodically exposed to pancreatic trypsin in the intestinal lumen. Trypsin cleaves PAR-2 to expose a tethered ligand, which irreversibly activates the receptor. Thus, PAR-2 may desensitize and resensitize by novel mechanisms. We examined these mechanisms in kidney epithelial cells, stably expressing human PAR-2, and intestinal epithelial cells, which naturally express PAR-2. Trypsin stimulated a prompt increase in [Ca2+](i), due to mobilization of intracellular Ca2+, followed by a sustained plateau, due to influx of extracellular Ca2+. Repeated application of trypsin caused marked desensitization of this response, which is due in part to (a) irreversible cleavage of the receptor by trypsin and (b) protein kinase C-mediated termination of signaling. Trypsin exposure resulted in internalization of PAR-2 into early endosomes and then lysosomes; but endocytosis was not the mechanism of rapid desensitization. Thus, activated PAR-2 is endocytosed and degraded. The Ca2+ response to trypsin resensitized by 60-90 min. Brefeldin A, which disrupted Golgi stores of PAR-2, and cycloheximide, which inhibited protein synthesis, markedly attenuated resensitization. Thus, PAR-2-mediated Ca2+ mobilization desensitizes by irreversible receptor cleavage, protein kinase C-mediated termination of signaling, and PAR-2 targeting to lysosomes. It resensitizes by mobilization of large Golgi stores and synthesis of new receptors.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT NUTR SCI,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley				Bunnett, Nigel W./0000-0003-3367-0644	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043207, R56DK043207, R01DK039957, R01DK046285, R37DK039957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46285, DK43207, DK39957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALANI B, 1995, CAN J PHYSIOL PHARM, V73, P1203, DOI 10.1139/y95-172; ALI H, 1993, J BIOL CHEM, V268, P24247; APONTE GW, 1991, P NATL ACAD SCI USA, V88, P5282, DOI 10.1073/pnas.88.12.5282; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bohm SK, 1996, BIOCHEM J, V314, P1009; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FUSHIKI T, 1989, FASEB J, V3, P121, DOI 10.1096/fasebj.3.2.2644146; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GODFRAIND T, 1986, PHARMACOL REV, V38, P321; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HALLDEN G, 1994, AM J PHYSIOL-GASTR L, V267, pG730, DOI 10.1152/ajpgi.1994.267.4.G730; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEVINE L, 1994, PROSTAGLANDINS, V47, P437, DOI 10.1016/0090-6980(94)90044-2; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MACFIE HL, 1981, DRUG INTEL CLIN PHAR, V15, P94, DOI 10.1177/106002808101500202; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MUNSHI R, 1993, MOL PHARMACOL, V44, P1185; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RYU SH, 1990, J BIOL CHEM, V265, P17941; SAKAI T, 1992, CELL CALCIUM, V13, P329, DOI 10.1016/0143-4160(92)90068-4; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SOLOMON TE, 1994, PHYSL GASTROINTESTIN, V2, P1499; TANG H, 1995, CIRC RES, V77, P239, DOI 10.1161/01.RES.77.2.239; TEPPERMAN BL, 1994, PHYSL GASTROINTESTIN, V2, P1331; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALSH JH, 1993, J CELL PHYSIOL, V156, P333, DOI 10.1002/jcp.1041560216; XU YP, 1995, J BIOL CHEM, V270, P23887, DOI 10.1074/jbc.270.41.23887; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; YU SS, 1993, J BIOL CHEM, V268, P337; ZACHARIAS U, 1995, EXP CELL RES, V216, P371, DOI 10.1006/excr.1995.1047; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	54	210	213	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22003	22016						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703006				2022-12-25	WOS:A1996VF61200048
J	Goswitz, VC; Matzke, EA; Taylor, MR; JessenMarshall, AE; Brooker, RJ				Goswitz, VC; Matzke, EA; Taylor, MR; JessenMarshall, AE; Brooker, RJ			Structural topology of transmembrane helix 10 in the lactose permease of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; CARRIER PROTEIN; DIRECTED MUTAGENESIS; ENHANCED RECOGNITION; ACTIVE-TRANSPORT; PROTON; MEMBRANE; SYMPORT; MUTANTS; MALTOSE	In the lactose permease of Escherichia coli, transmembrane helix 10 has been shown to be functionally important, The structure of this helix has been examined in greater detail in this study, A total of 46 substitution and 8 insertional mutants were constructed and analyzed along the entire length of transmembrane helix 10, The results identified amino acids that are tolerant of substitutions by a variety of amino acids, Since a number of these amino acids (Thr-320, Val-331, Phe-325, and Ile-317) are clustered in one region in a helical wheel projection of transmembrane helix 10, it seems likely that this face of helix 10 is interacting with the membrane, The channel lining domain is thought to consist of the helical face containing Glu-325, Leu-318, Leu-329, His-322, Val-315, Cys-333, Val-326, and Lys-319 based on the results here and from earlier findings, Deleterious mutations along this face tended to greatly increase the K-m value for lactose transport with only minor effects on the V-max. Analysis of insertional mutants revealed that perturbation of the spatial relationship between amino acids at the periplasmic edge is less deleterious than perturbation in the center of the helix or the cytoplasmic edge. Using all of the above information, a detailed structural topology of transmembrane helix 10 is proposed.	UNIV MINNESOTA,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; CRANE RK, 1962, FED PROC, V21, P891; CRANE RK, 1960, PHYSIOL REV, V40, P784; EDDY AA, 1971, BIOCHEM J, V122, P701, DOI 10.1042/bj1220701; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HOFER M, 1978, BIOCHEM J, V172, P15; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KOMOR E, 1973, FEBS LETT, V38, P16, DOI 10.1016/0014-5793(73)80501-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MALAMY MH, 1966, COLD SPRING HARB SYM, V31, P189, DOI 10.1101/SQB.1966.031.01.027; Mandel M, 1970, J MOL BIOL, V53, P154; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL IH, 1975, ENZYME KINETICS; SLAYMAN CL, 1974, P NATL ACAD SCI USA, V71, P1935, DOI 10.1073/pnas.71.5.1935; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON TH, 1983, CELL MEMBR METH REV, V1, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	42	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21927	21932		10.1074/jbc.271.36.21927	http://dx.doi.org/10.1074/jbc.271.36.21927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702996	hybrid			2022-12-25	WOS:A1996VF61200038
J	Huang, RP; Reusch, RN				Huang, RP; Reusch, RN			Poly(3-hydroxybutyrate) is associated with specific proteins in the cytoplasm and membranes of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-BETA-HYDROXYBUTYRATE; PLASMA-MEMBRANES; COMPLEXES; COMPETENCE; ACID	Poly(3-hydroxybutyrate) (PHB) is well-known as a high molecular weight homopolymer of R-3-hydroxybutyrate which accumulates in storage granules within the cytosols of certain bacteria. Escherichia coli does not amass these granules; however, small amounts of low molecular weight PHB (<0.02% of dry weight) have been found in the plasma membranes in complexes with calcium polyphosphate; the complexes serve as voltage-activated calcium channels. Here we report that polyphosphate-complexed PHB is only a minor fraction of the polyester in E. coli. PRE comprises 0.36 to 0.55% of the dry weight of log-phase cells, depending on culture medium, and this amount increases by 15 to 20% when the cells are made genetically competent. The PHB is widely distributed throughout the cell, wherein it is primarily associated with proteins. The identity of protein-associated PHB was established by antibody reaction, chemical assay, and H-1 NMR spectroscopy. As expected, the physical and chemical properties of protein-associated PHB were found to be considerably different from those of the bulk polymer or granule PHB, e.g. protein-PHB complexes are normally insoluble in chloroform, soluble in water and alkaline hypochlorite, and are converted to crotonic acid more slowly on heating in concentrated sulfuric acid. Our studies indicate that the majority of cellular PHB (over 80%) is located in cytoplasmic proteins, especially proteins of the ribosomal fraction. Western immunoblots, probed with polyclonal anti-PHB IgG, revealed a number of PHB-polypeptides having a wide range of molecular weights in all cell fractions. These results suggest that PHB is a fundamental constituent of cells that may have physiological functions in addition to facilitating ion transmembrane transport or serving as a carbon reserve.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM 33375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; BRANDL H, 1992, FEMS MICROBIOL REV, V103, P441; BRAUNEGG G, 1978, EUR J APPL MICROBIOL, V6, P29, DOI 10.1007/BF00500854; CASTUMA CE, 1995, J BIOL CHEM, V270, P12980, DOI 10.1074/jbc.270.22.12980; Dawes E A, 1973, Adv Microb Physiol, V10, P135, DOI 10.1016/S0065-2911(08)60088-0; HANAHAN D, 1987, ESCHERICHIA COLI SAL, V2, P1177; HOLMES PA, 1987, DEV CRYSTALLINE POLY, V2, P10; HUANG RP, 1995, J BACTERIOL, V177, P486, DOI 10.1128/jb.177.2.486-490.1995; KARR DB, 1983, APPL ENVIRON MICROB, V46, P1339, DOI 10.1128/AEM.46.6.1339-1344.1983; LAW JH, 1961, J BACTERIOL, V82, P33, DOI 10.1128/JB.82.1.33-36.1961; LAW JH, 1961, J BACTERIOL, V82, P37; REUSCH RN, 1992, BIOCHIM BIOPHYS ACTA, V1123, P33, DOI 10.1016/0005-2760(92)90168-U; REUSCH RN, 1989, P SOC EXP BIOL MED, V191, P377; REUSCH RN, 1995, BIOPHYS J, V69, P754, DOI 10.1016/S0006-3495(95)79958-1; REUSCH RN, 1983, J BACTERIOL, V156, P778, DOI 10.1128/JB.156.2.778-788.1983; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; REUSCH RN, 1986, J BACTERIOL, V168, P553, DOI 10.1128/jb.168.2.553-562.1986; REUSCH RN, 1992, FEMS MICROBIOL LETT, V103, P119, DOI 10.1016/0378-1097(92)90301-4; SEEBACH D, 1994, EUR J BIOCHEM, V224, P317, DOI 10.1111/j.1432-1033.1994.00317.x; SYKES J, 1971, METHODS MICROBIOLO B, V5, P55	20	71	74	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22196	22202		10.1074/jbc.271.36.22196	http://dx.doi.org/10.1074/jbc.271.36.22196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703033	hybrid			2022-12-25	WOS:A1996VF61200075
J	Jakobsson, PJ; Mancini, JA; FordHutchinson, AW				Jakobsson, PJ; Mancini, JA; FordHutchinson, AW			Identification and characterization of a novel human microsomal glutathione S-transferase with leukotriene C-4 synthase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C-4 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LUNG; ARACHIDONIC-ACID; BIOSYNTHESIS INHIBITORS; SUBSTRATE-SPECIFICITY; PARTIAL-PURIFICATION; MOLECULAR-CLONING; MEMBRANE-PROTEIN; HUMAN-PLATELETS; EXPRESSION; CELLS	5-Lipoxygenase-activating protein (FLAP) and leukotriene C-4 (LTC(4)) synthase, two proteins involved in leukotriene biosynthesis, have been demonstrated to be 31% identical at the amino acid level. We have recently identified and characterized a novel member of the FLAP/LTC(4) synthase gene family termed microsomal glutathione S-transferase II (microsomal GST-II). The open reading frame encodes a 16.6-kDa protein with a calculated pi of 10.4, Microsomal GST-II has 33% amino acid identity to FLAP, 44% amino acid identity to LTC(4) synthase, and 11% amino acid identity to the previously characterized human microsomal GST (microsomal GST-I). Microsomal GST-II also has a similar hydrophobicity pattern to FLAP, LTC(4) synthase, and microsomal GST-I. Fluorescent in situ hybridization mapped microsomal GST-II to chromosomal localization 4q28-31. Microsomal GST-II has a wide tissue distribution (at the mRNA level) and was specifically expressed in human liver, spleen, skeletal muscle, heart, adrenals, pancreas, prostate, testis, fetal liver, and fetal spleen. In contrast, microsomal GST-II mRNA expression was very low (when present) in lung, brain, placenta, and bone marrow. This differs from FLAP mRNA, which was detected in lung, various organs of the immune system, and peripheral blood leukocytes, and LTC(4) synthase mRNA, which could not be detected in any tissues by Northern blot analysis. Microsomal GST-II and LTC(4) synthase were expressed in a baculovirus insect cell system, and microsomes from Sf9 cells containing microsomal GST-II or LTC(4) synthase were both found to catalyze the production of LTC(4) from LTA(4) and reduced glutathione. Microsomal GST-II also catalyzed the formation of another product, displaying a conjugated triene UV absorption spectra with a maximum at 283 nm, suggesting less catalytic stereospecificity compared with LTC(4) synthase. Also, the apparent K-m for LTA(4) was higher for microsomal GST-II (41 mu M) than LTC(4) synthase (7 mu M). In addition, unlike LTC(4) synthase, microsomal GST-II was able to catalyze the conjugation of 1-chloro-2,4-dinitrobenzene with reduced glutathione. Therefore, it is proposed that this novel membrane protein is a member of the microsomal glutathione S-transferase family, also including LTC(4) synthase, with significant sequence identities to both LTC(4) synthase and FLAP.	MERCK FROSST CTR THERAPEUT RES,KIRKLAND,PQ H9H 3L1,CANADA	Merck & Company			Jakobsson, Per-Johan/ABC-5594-2021					ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; ALI A, 1994, J IMMUNOL, V153, P776; ANDERSON PM, 1994, CLIN PHARMACOKINET, V27, P19, DOI 10.2165/00003088-199427010-00003; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; BOYUM A, 1974, TISSUE ANTIGENS, V4, P269; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; DEJONG JL, 1990, GENOMICS, V6, P379, DOI 10.1016/0888-7543(90)90580-N; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DU JT, 1983, BIOCHIM BIOPHYS ACTA, V753, P159, DOI 10.1016/0005-2760(83)90003-6; EDENIUS C, 1988, EUR J BIOCHEM, V178, P81, DOI 10.1111/j.1432-1033.1988.tb14431.x; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HABIG WH, 1974, J BIOL CHEM, V249, P7130; IZUMI T, 1988, BIOCHIM BIOPHYS ACTA, V959, P305; JAKOBSSON PJ, 1991, BIOCHEM BIOPH RES CO, V178, P302, DOI 10.1016/0006-291X(91)91814-S; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MANCINI JA, 1993, J LIPID MEDIATOR, V8, P145; MANCINI JA, 1994, LIFE SCI, V54, pPL137, DOI 10.1016/0024-3205(94)00872-8; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MANNERVIK B, 1984, FEBS LETT, V175, P289, DOI 10.1016/0014-5793(84)80753-X; MANTLE TJ, 1995, BIOCHEM SOC T, V23, P423, DOI 10.1042/bst0230423; MAYER RJ, 1993, FASEB J, V7, P389; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; METTERS KM, 1994, J BIOL CHEM, V269, P12816; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MORGENSTERN R, 1979, BIOCHEM BIOPH RES CO, V87, P657, DOI 10.1016/0006-291X(79)92009-6; MORGENSTERN R, 1984, BIOCHEM PHARMACOL, V33, P3609, DOI 10.1016/0006-2952(84)90145-X; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MORGENSTERN R, 1988, J BIOL CHEM, V263, P6671; MOSIALOU E, 1995, ARCH BIOCHEM BIOPHYS, V320, P210, DOI 10.1016/0003-9861(95)90002-0; MOSIALOU E, 1993, FEBS LETT, V315, P77, DOI 10.1016/0014-5793(93)81137-O; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; Nugteren D H, 1980, Adv Prostaglandin Thromboxane Res, V6, P129; PACEASCIAK CR, 1986, BIOCHIM BIOPHYS ACTA, V877, P68, DOI 10.1016/0005-2760(86)90119-0; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; PETRIC R, 1995, BBA-LIPID LIPID MET, V1254, P207, DOI 10.1016/0005-2760(94)00185-2; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SODERSTROM M, 1988, BIOCHEM J, V250, P713, DOI 10.1042/bj2500713; SODERSTROM M, 1985, BIOCHEM BIOPH RES CO, V128, P265, DOI 10.1016/0006-291X(85)91673-0; STENKE L, 1987, ACTA ONCOL, V27, P803; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; TSUCHIDA S, 1987, EUR J BIOCHEM, V170, P159, DOI 10.1111/j.1432-1033.1987.tb13681.x; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	61	120	154	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22203	22210		10.1074/jbc.271.36.22203	http://dx.doi.org/10.1074/jbc.271.36.22203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703034	hybrid			2022-12-25	WOS:A1996VF61200076
J	Kimura, Y; Kurzydlowski, K; Tada, M; MacLennan, DH				Kimura, Y; Kurzydlowski, K; Tada, M; MacLennan, DH			Phospholamban regulates the Ca2+-ATPase through intramembrane interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CA-2+ PUMP; FUNCTIONAL ASSOCIATION; CYTOPLASMIC DOMAIN; ATPASE; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; SEQUENCE; ASSAY	There is clear evidence for direct regulatory protein-protein interactions between phospholamban (PLN) and the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) in cytoplasmic domains, but there is less clear evidence for regulatory interactions in the transmembrane domains of the two proteins. We have now coexpressed SERCA isoforms with the transmembrane sequence of PLN and with epitope-tagged transmembrane sequences of PLN to study intramembrane interactions in the absence of cytoplasmic interactions. Coexpression of the transmembrane sequence of phospholamban (Met-PLN(28-52)) with SERCA1a, SERCA2a, and SERCA3 inhibited Ca2+ transport by lowering apparent Ca2+ affinity. Addition of the hemagglutinin (IIA) epitope to the transmembrane sequence of PLN (HA-PLN(28-52)) or deletion of PLN residues 21-29 (PLN(1-20)-PLN(30-52)) ''supershifted'' apparent Ca2+ affinity to values lower than those observed with native PLN without uncoupling Ca2+ transport from ATP hydrolysis. Inhibition by PLN(1-20)-PLN(30-52) or by Flag-PLN(28-52) was reversed by PLN antibody or by Flag antibody, demonstrating that inhibition by these constructs is reversible and that the inhibitory constructs are properly oriented in the membrane. These results suggest that PLN modulates the apparent Ca2+ affinity of SERCA2a through intramembrane interactions, which are disrupted at long range and in concert with disruption of the well characterized cytoplasmic interactions.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; OSAKA UNIV,SCH MED,DEPT MED & PATHOPHYSIOL,SUITA,OSAKA 565,JAPAN	University of Toronto; Osaka University								BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1993, J BIOL CHEM, V268, P11486; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490	25	122	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21726	21731		10.1074/jbc.271.36.21726	http://dx.doi.org/10.1074/jbc.271.36.21726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702967	hybrid			2022-12-25	WOS:A1996VF61200009
J	Larcher, JC; Boucher, D; Lazereg, S; Gros, F; Denoulet, P				Larcher, JC; Boucher, D; Lazereg, S; Gros, F; Denoulet, P			Interaction of kinesin motor domains with alpha- and beta-tubulin subunits at a tau-independent binding site - Regulation by polyglutamylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; MOUSE-BRAIN NEURONS; CYTOPLASMIC DYNEIN; 3-DIMENSIONAL STRUCTURE; AXONAL-TRANSPORT; HEAVY-CHAIN; IN-VITRO; CENP-E; MAP2; PHOSPHORYLATION	interaction of rat kinesin and Drosophila nonclaret disjunctional motor domains with tubulin was studied by a blot overlay assay. Either plus-end or minus-end-directed motor domain binds at the same extent to both alpha- and beta-tubulin subunits, suggesting that kinesin binding is an intrinsic property of each tubulin subunit and that motor directionality cannot be related to a preferential interaction with a given tubulin subunit. Binding features of dimeric versus monomeric rat kinesin heads suggest that dimerization could drive conformational changes to enhance binding to tubulin. Competition experiments have indicated that kinesin interacts with tubulin at a Tau-independent binding site. Complementary experiments have shown that kinesin does not interact with the same efficiency with the different tubulin isoforms. Masking the polyglutamyl chains with a specific monoclonal antibody leads to a complete inhibition of kinesin binding. These results are consistent with a model in which polyglutamylation of tubulin regulates kinesin binding through progressive conformational changes of the whole carboxyl-terminal domain of tubulin as a function of the polyglutamyl chain length, thus modulating the affinity of tubulin for kinesin and Tau as well. These results indicate that microtubules, through tubulin polymorphism, do have the ability to control microtubule-associated protein binding.	UNIV PARIS 06, COLL FRANCE, F-75005 PARIS, FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France; Sorbonne Universite	Larcher, JC (corresponding author), CNRS, UPR 9065, 11 PL MARCELIN BERTHELOT, F-75005 PARIS, FRANCE.							ALLAN V, 1995, J CELL BIOL, V127, P1671; ANDREU JM, 1993, CELL MOTIL CYTOSKEL, V26, P1, DOI 10.1002/cm.970260102; AUDEBERT S, 1993, MOL BIOL CELL, V4, P615, DOI 10.1091/mbc.4.6.615; AUDEBERT S, 1994, J CELL SCI, V107, P2313; BERNSTEIN M, 1994, J CELL BIOL, V125, P1313, DOI 10.1083/jcb.125.6.1313; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; BREITLING F, 1986, J MOL BIOL, V189, P367, DOI 10.1016/0022-2836(86)90517-6; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; GAGNON C, 1996, IN PRESS J CELL SCI; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GOLDSMITH M, 1991, CELL MOTIL CYTOSKEL, V20, P249, DOI 10.1002/cm.970200308; HAGIWARA H, 1994, J BIOL CHEM, V269, P3581; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HEINS S, 1991, J CELL SCI, P121; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOPEZ LA, 1993, CELL MOTIL CYTOSKEL, V24, P1, DOI 10.1002/cm.970240102; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MARYA PK, 1994, J CELL SCI, V107, P339; MASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MILLER RH, 1987, SCIENCE, V235, P220, DOI 10.1126/science.2432661; Murphy DB, 1991, CURR OPIN CELL BIOL, V3, P43, DOI 10.1016/0955-0674(91)90164-T; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; OKADA Y, 1995, J NEUROSCI, V15, P3053; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PONSTINGL H, 1979, NATURE, V282, P423, DOI 10.1038/282423a0; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SAWIN KE, 1992, J CELL SCI, V101, P303; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WOLFF A, 1994, BIOL CELL, V81, P11, DOI 10.1016/0248-4900(94)90049-3; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	58	143	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22117	22124		10.1074/jbc.271.36.22117	http://dx.doi.org/10.1074/jbc.271.36.22117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703022	hybrid			2022-12-25	WOS:A1996VF61200064
J	Okadome, T; Oeda, E; Saitoh, M; Ichijo, H; Moses, HL; Miyazono, K; Kawabata, M				Okadome, T; Oeda, E; Saitoh, M; Ichijo, H; Moses, HL; Miyazono, K; Kawabata, M			Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; PROTEIN; TRANSCRIPTION; CLONING; FAMILY; INHIBITION; SCHNURRI; DOMAINS; ENCODES	The type I transforming growth factor-beta receptor (T beta R-I) is the efferent component of the receptor complex, which presumably phosphorylates intracellular targets. FKBP12, a binding protein for FK506 and rapamycin, is shown to associate with the cytoplasmic region of T beta R-I in vitro. In this report, we investigated the interaction of FKBP12 with T beta R-I in vivo. FKBP12 interacts with T beta R-I in mammalian cells as well as in yeast. Ligand addition does not affect the interaction, and both constitutively active and kinase-negative mutants of T beta R-I bind FKBP12. FKBP12 dissociates from T beta PR-I in the presence of a high concentration of FK506. The juxtamembrane region of T beta R-I, containing the major phosphorylation sites by the type II receptor, is required for the interaction. One of the deletion mutants in this region, which was shown to mediate transcriptional response, does not bind FKBP12, suggesting that FKBP12 is not directly involved in TGF-beta signaling. Furthermore T beta R-I does not phosphorylate FKBP12 in vitro, FKBP12 may not be a direct substrate of T beta R-I but possibly modulates the T beta R-I function through its interaction with the regulatory domain of the kinase.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; VANDERBILT UNIV,CTR CANC,NASHVILLE,TN 37232	Japanese Foundation for Cancer Research; Vanderbilt University				Ichijo, Hidenori/0000-0002-5005-6438				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SEKELSKY JJ, 1995, GENETICS, V139, P1347; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	32	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21687	21690		10.1074/jbc.271.36.21687	http://dx.doi.org/10.1074/jbc.271.36.21687			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702959				2022-12-25	WOS:A1996VF61200001
J	Zhao, ZZ; Tan, ZJ; Diltz, CD; You, M; Fischer, EH				Zhao, ZZ; Tan, ZJ; Diltz, CD; You, M; Fischer, EH			Activation of mitogen-activated protein (MAP) kinase pathway by pervanadate, a potent inhibitor of tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; T-CELL ACTIVATION; RAT ADIPOCYTES; INTACT-CELLS; VANADATE; PHOSPHORYLATION; PHOSPHOTYROSINE; TRANSFORMATION; STIMULATION; 2A	Rapid tyrosine phosphorylation of key cellular pro teins is a crucial event in signal transduction. The regulatory role of protein-tyrosine phosphatases (PTPs) in this process was explored by studying the effects of a powerful PTP inhibitor, pervanadate, on the activation of the mitogen-activated protein (MAP) kinase cascade. Treatment of HeLa cells with pervanadate resulted in a marked inhibition of PTP activity, accompanied by a drastic increase in tyrosine phosphorylation of cellular proteins. The increased tyrosine phosphorylation coincided with the activation of the MAP kinase cascade as indicated by enzymatic activity assays of MEK (MAP kinase/ERK-kinase) and MAP kinase and gel mobility shift analyses of Raf-1 and MAP kinase. The activation was sustained but reversible. Upon removal of pervanadate, both tyrosine phosphorylation and MAP kinase activation declined to basal levels. Therefore, inhibition of PTP activity is sufficient per se to initiate a complete MAP kinase activation program.	VANDERBILT UNIV, DEPT MED, DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; University of Washington; University of Washington Seattle	Zhao, ZZ (corresponding author), VANDERBILT UNIV, DEPT MED, DIV HEMATOL, NASHVILLE, TN 37232 USA.		You, Min/I-4973-2012	You, Min/0000-0003-1977-3479	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007902] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07902] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHEN J, 1994, J BIOL CHEM, V269, P7957; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FANTUS IG, 1994, DIABETES, V43, P375, DOI 10.2337/diabetes.43.3.375; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RIJKSEN G, 1993, J CELL PHYSIOL, V154, P393, DOI 10.1002/jcp.1041540223; ROGERS MV, 1994, NEUROSCIENCE, V60, P479, DOI 10.1016/0306-4522(94)90259-3; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; SHISHEVA A, 1993, ENDOCRINOLOGY, V133, P1562, DOI 10.1210/en.133.4.1562; SWEITZER SM, 1995, J BIOL CHEM, V270, P16510, DOI 10.1074/jbc.270.28.16510; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	30	118	122	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22251	22255		10.1074/jbc.271.36.22251	http://dx.doi.org/10.1074/jbc.271.36.22251			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703041	hybrid			2022-12-25	WOS:A1996VF61200083
J	Braun, JR; Willnow, TE; Ishibashi, S; Ashwell, G; Herz, J				Braun, JR; Willnow, TE; Ishibashi, S; Ashwell, G; Herz, J			The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; MEDIATED ENDOCYTOSIS; LIGAND-BINDING; PROTEIN LRP; LIVER; CELLS; LECTIN; OLIGOSACCHARIDES; SEQUENCE	The mammalian asialoglycoprotein receptor (ASGPR) is located on the sinusoidal membrane of hepatocytes where it binds and endocytoses galactose-terminated glycoproteins (asialoglycoproteins). ASGPR is composed of two highly homologous subunits, termed hepatic lectin 1 and 2. Despite numerous studies the contribution of both subunits to biosynthesis and functional activity of ASGPR in vivo has remained controversial. Mice lacking the murine hepatic lectin (MHL)-2 subunit are viable and fertile without obvious phenotypic abnormalities. In the absence of MHL-2, knockout mice express MHL-1 protein at reduced levels. Here, we examine the intracellular fate and function of this remaining subunit. The results show that MHL-1 reaches the hepatocellular surface in knockout mice but is unable to effectively remove any one of three different radiolabeled ligands within 30 min. A small but detectable residual ligand clearance in knockout mice at 4 h is apparently not mediated by remaining MHL-1. Serum concentrations of galactose-terminating glycoproteins are not elevated in these ASGPR-deficient mice. However, competitive in vitro degradation experiments suggest that other endogenous ASGPR ligands, the nature of which remain to be determined, accumulate in serum of knockout animals.	UNIV TEXAS, SW MED CTR, DEPT MOL GENET, DALLAS, TX 75235 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; NIDDKD, NIH, BETHESDA, MD 20892 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Willnow, Thomas/0000-0001-9515-7921	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH M, 1989, J CELL BIOL, V108, P367, DOI 10.1083/jcb.108.2.367; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BIDER MD, 1995, EUR J BIOCHEM, V230, P207, DOI 10.1111/j.1432-1033.1995.tb20552.x; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; CHIU MH, 1994, J BIOL CHEM, V269, P16195; CLARENBURG R, 1983, AM J PHYSIOL, V244, pG247, DOI 10.1152/ajpgi.1983.244.3.G247; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARDY MR, 1985, BIOCHEMISTRY-US, V24, P22, DOI 10.1021/bi00322a004; HARLOW E, 1988, ANTIBODIES LABORATOR, P354; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HSUEH EC, 1986, J BIOL CHEM, V261, P4940; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KOLBBACHOFEN V, 1982, CELL, V29, P859, DOI 10.1016/0092-8674(82)90447-0; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KURANDA MJ, 1983, ARCH BIOCHEM BIOPHYS, V224, P526, DOI 10.1016/0003-9861(83)90240-0; LEE YC, 1983, J BIOL CHEM, V258, P199; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MONROE RS, 1994, GENE, V148, P237, DOI 10.1016/0378-1119(94)90694-7; MORELL AG, 1968, J BIOL CHEM, V243, P155; OZAKI K, 1992, J BIOL CHEM, V267, P9229; RICE KG, 1990, J BIOL CHEM, V265, P18429; SAWYER JT, 1988, J BIOL CHEM, V263, P10534; SCHAUER R, 1985, CLIN CHIM ACTA, V146, P119, DOI 10.1016/0009-8981(85)90050-6; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WEIGEL PH, 1994, BIOESSAYS, V16, P519, DOI 10.1002/bies.950160713; WEIGEL PH, 1980, J BIOL CHEM, V255, P6111; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P491; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; WONG KL, 1974, CLIN SCI MOL MED, V46, P763, DOI 10.1042/cs0460763	44	62	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21160	21166		10.1074/jbc.271.35.21160	http://dx.doi.org/10.1074/jbc.271.35.21160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702886	hybrid			2022-12-25	WOS:A1996VE47700032
J	Cotten, JF; Ostedgaard, LS; Carson, MR; Welsh, MJ				Cotten, JF; Ostedgaard, LS; Carson, MR; Welsh, MJ			Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CFTR CHLORIDE CHANNELS; P-GLYCOPROTEIN; MULTIDRUG RESISTANCE; SEQUENCE VARIATIONS; MOLECULAR-BASIS; CL CHANNELS; MEMBRANE; IDENTIFICATION; GENE	The cystic fibrosis transmembrane conductance regulator (CFTR) contains multiple membrane spanning sequences that form a Cl- channel pore and cytosolic domains that control the opening and closing of the channel. The fourth intracellular loop (ICL4), which connects the tenth and eleventh transmembrane spans, has a primary sequence that is highly conserved across species, is the site of a preserved sequence motif in the ABC transporter family, and contains a relatively large number of missense mutations associated with cystic fibrosis (CF). To investigate the role of ICL4 in CFTR function and to learn how CF mutations in this region disrupt function, we studied several CF-associated ICL4 mutants. We found that most ICL4 mutants disrupted the biosynthetic processing of CFTR, although not as severely as the most common Delta F508 mutation. The mutations had no discernible effect on the channel's pore properties; but some altered gating behavior, the response to increasing concentrations of ATP, and stimulation in response to pyrophosphate. These effects on activity were similar to those observed with mutations in the nucleotide-binding domains, suggesting that ICL4 might help couple activity of the nucleotide-binding domains to gating of the Cl- channel pore. The data also explain how these mutations cause a loss of CFTR function and suggest that some patients with mutations in ICL4 may have a milder clinical phenotype because they retain partial activity of CFTR at the cell membrane.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL029851, P50HL042385, R01HL029851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42385, HL29851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BOZON D, 1994, HUM MUTAT, V3, P330, DOI 10.1002/humu.1380030329; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Carson MR, 1995, BIOPHYS J, V69, P2443, DOI 10.1016/S0006-3495(95)80113-X; CHAMPIGNY G, 1995, EMBO J, V14, P2417, DOI 10.1002/j.1460-2075.1995.tb07239.x; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DASSA E, 1993, MOL MICROBIOL, V7, P39, DOI 10.1111/j.1365-2958.1993.tb01095.x; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; FEREC C, 1992, NAT GENET, V1, P188, DOI 10.1038/ng0692-188; FEREC C, 1993, HUM MOL GENET, V2, P1557, DOI 10.1093/hmg/2.10.1557; GHANEM N, 1994, GENOMICS, V21, P434, DOI 10.1006/geno.1994.1290; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; MERCIER B, 1993, GENOMICS, V16, P296, DOI 10.1006/geno.1993.1183; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SAVOV A, 1994, HUM MOL GENET, V3, P57; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; XIE JX, 1995, J BIOL CHEM, V270, P28084; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253	46	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21279	21284		10.1074/jbc.271.35.21279	http://dx.doi.org/10.1074/jbc.271.35.21279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702904	hybrid			2022-12-25	WOS:A1996VE47700050
J	Sapirstein, A; Spech, RA; Witzgall, R; Bonventre, JV				Sapirstein, A; Spech, RA; Witzgall, R; Bonventre, JV			Cytosolic phospholipase A(2), (PLA(2)), but not secretory PLA(2), potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INDUCED DNA-DAMAGE; SUPEROXIDE-DISMUTASE; ARACHIDONIC-ACID; LIPID-PEROXIDATION; LLC-PK1 CELLS; ENZYMATIC-ACTIVITY; CALCIUM IONOPHORE; PROXIMAL TUBULES; OXIDATIVE STRESS	Phospholipase A(2) (PLA(2)) and reactive oxygen species have been implicated both individually and synergistically in various forms of cellular injury. The form(s) of PLA(2) important for cell injury and the implications of enhanced activity of the enzyme, however, have not been discerned. Previous studies reveal an increase in PLA(2) activity associated with cell injury, but this association does not establish a causal relationship between the increase in activity and the injury. LLC-PK1 cell lines were created that express either the cytosolic PLA(2) or a group II PLA(2). The susceptibility of these cells to hydrogen peroxide toxicity was determined in order to evaluate the relative importance of these two forms of PLA(2) in oxidant injury. Expression of cytosolic PLA(2) in the LLC-cPLA(2) cell line was associated with a 50-fold increase in PLA(2) activity in the cytosolic fraction, an increase in agonist-stimulated arachidonate release, and immunodetection of the cytosolic PLA(2) protein that was undetectable in control cells. Exposure to hydrogen peroxide or menadione, but not mercuric chloride, resulted in significantly greater lactate dehydrogenase release in LLC-cPLA(2) cells when compared with control cells. Exogenous arachidonic acid (150 mu M) did not enhance hydrogen peroxide-induced injury. The intracellular calcium chelator, 1,2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid/tetra(acetoxymethyl) ester, protected the cells against injury, but the calcium ionophore, A23187, did not increase injury. Glycine conferred no protective effect against hydrogen peroxide toxicity. By contrast to these results with cytosolic PLA(2)-expressing cells, secretory PLA(2) expression to very high levels did not increase susceptibility to hydrogen peroxide. Thus, cytosolic PLA(2) may an be an important mediator of oxidant damage to renal epithelial cells.	MASSACHUSETTS GEN HOSP EAST, MED SERV, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP EAST, ANESTHESIA SERV, CHARLESTOWN, MA 02129 USA; DEPT MED, CHARLESTOWN, MA 02129 USA; DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Witzgall, Ralph/0000-0002-5283-4846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, R01DK039773, R37DK039773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aebi H., 1974, METHOD ENZYMAT AN, P273; BALLMAIER D, 1995, CARCINOGENESIS, V16, P335, DOI 10.1093/carcin/16.2.335; Beutler E., 1975, RED CELL METABOLISM, V2nd, P71; BONVENTRE JV, 1993, J LIPID MEDIATOR, V6, P457; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; BONVENTRE JV, 1995, CONTEMP ISS NEPHROL, P23; BONVENTRE JV, 1996, IN PRESS J LIPID MED; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHIARIELLO M, 1987, J PHARMACOL EXP THER, V241, P560; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Crapo J D, 1978, Methods Enzymol, V53, P382; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOLE VP, 1960, J BIOL CHEM, V235, P2595; ELLIGET KA, 1994, PATHOBIOLOGY, V62, P298, DOI 10.1159/000163923; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOLCONDA MS, 1993, KIDNEY INT, V44, P1228, DOI 10.1038/ki.1993.373; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Griffith O.W., 1985, METHODS ENZYMATIC AN, V7, P521; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LIFSCHITZ MD, 1982, J BIOL CHEM, V257, P2611; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MacEwan DJ, 1996, FEBS LETT, V379, P77, DOI 10.1016/0014-5793(95)01495-0; Malis C D, 1988, Prog Clin Biol Res, V282, P235; MALIS CD, 1990, P NATL ACAD SCI USA, V87, P8845, DOI 10.1073/pnas.87.22.8845; MALIS CD, 1986, J BIOL CHEM, V261, P14201; MATTHYS E, 1984, KIDNEY INT, V26, P153, DOI 10.1038/ki.1984.149; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NAKAMURA H, 1991, J CLIN INVEST, V87, P1810, DOI 10.1172/JCI115202; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; OHNO K, 1990, BIOCHEM BIOPH RES CO, V168, P551, DOI 10.1016/0006-291X(90)92356-5; OTAMIRI T, 1987, GUT, V28, P1445, DOI 10.1136/gut.28.11.1445; PORTILLA D, 1994, J CLIN INVEST, V93, P1609, DOI 10.1172/JCI117141; PROZIALECK WC, 1995, TOXICOL APPL PHARM, V134, P285, DOI 10.1006/taap.1995.1194; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RORDORF G, 1991, J NEUROSCI, V11, P1829; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALGO MG, 1992, BIOCHIM BIOPHYS ACTA, V1127, P131, DOI 10.1016/0005-2760(92)90268-Z; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; SANTOS AA, 1994, ANN SURG, V219, P183, DOI 10.1097/00000658-199402000-00010; SCHNELLMANN RG, 1994, J BIOCHEM TOXICOL, V9, P211, DOI 10.1002/jbt.2570090406; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SHI MM, 1994, J BIOL CHEM, V269, P26512; SierraHonigmann R, 1996, LAB INVEST, V74, P684; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; THOMAS JP, 1990, J BIOL CHEM, V265, P454; THOR H, 1982, J BIOL CHEM, V257, P2419; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; TROYER DA, 1986, KIDNEY INT, V29, P530, DOI 10.1038/ki.1986.31; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; VANDENBERG JJM, 1993, BIOCHEMISTRY-US, V32, P4962, DOI 10.1021/bi00069a035; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; VENKATACHALAM MA, 1995, KIDNEY INT, V48, P118, DOI 10.1038/ki.1995.275; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58; WEINBERG JM, 1991, LAB INVEST, V65, P671; WEINBERG JM, 1987, J CLIN INVEST, V80, P1446, DOI 10.1172/JCI113224; WETZELS JFM, 1993, AM J PHYSIOL, V264, pF94, DOI 10.1152/ajprenal.1993.264.1.F94; Zager RA, 1996, J AM SOC NEPHROL, V7, P64; ZAGER RA, 1993, P NATL ACAD SCI USA, V90, P8297, DOI 10.1073/pnas.90.17.8297	77	125	126	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21505	21513		10.1074/jbc.271.35.21505	http://dx.doi.org/10.1074/jbc.271.35.21505			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702935	hybrid			2022-12-25	WOS:A1996VE47700081
J	Liang, YX; Robinson, DF; Kujoth, GC; Fahl, WE				Liang, YX; Robinson, DF; Kujoth, GC; Fahl, WE			Functional analysis of the SIS proximal element and its activating factors: Regulated transcription of the c-SIS/PDGF-B gene in human erythroleukemia cells	ONCOGENE			English	Article						c-sis/PDGF-B; K562; Sp1; Sp3; TPA	BOX-BINDING-PROTEINS; GROWTH-FACTOR; PROMOTER; EXPRESSION; FAMILY; PDGF; CIS; IDENTIFICATION; MEMBERS; CLONING	The SIS proximal element (SPE) is essential for the basal transcription of the c-sis/PDGF-B gene as well as the lineage-specific, activated transcription of this gene seen in megakaryocytes. In gel mobility shift analyses, the SPE element forms three gel-shift complexes; the t(op) and b(ottom) complexes were detected in nuclear extracts from both untreated and phorbol 12-myristate 13-acetate ('tetradecanoylphorbol acetate', TPA) treated K562 cells, whereas the m(iddle) complex was detected only in nuclear extracts from TPA-treated g562 cells. Site-directed mutagenesis of the SPE revealed CCACCC motif that was essential for promoter activity as well as the formation of all three SPE gel-shift complexes. Nested-deletion analyses showed that the SPE was required for TPA-inducibility of c-sis/PDGF-B transcription. Antibody supershift analyses demonstrated that the t gel-shift complex contained both Sp1 and Sp3, and that the b complex contained only Sp3. In vitvo transcription assays demonstrated that both Sp1 and Sp3 could support c-sis/PDGF-B transcription independent of each other in untreated K562 cells. However, overexpression of Sp1/Sp3 failed to significantly increase the c-sis/PDGF-B transcription in K562 cells.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, R37CA042024, T32CA009681] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA07175, T32-CA09681, R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1991, BAILLIERE CLIN ENDOC, V5, P595, DOI 10.1016/S0950-351X(10)80005-9; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKSRPH, 1995, NUCLEIC ACIDS RES, V23, P1119; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLEMING TP, 1992, ONCOGENE, V7, P1355; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; FRANKLIN GC, 1995, ONCOGENE, V11, P1873; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARTINET Y, 1987, NEW ENGL J MED, V317, P202, DOI 10.1056/NEJM198707233170404; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203	25	8	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					863	871						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761308				2022-12-25	WOS:A1996VD43300022
J	Ueda, Y; Hirai, S; Osada, S; Suzuki, A; Mizuno, K; Ohno, S				Ueda, Y; Hirai, S; Osada, S; Suzuki, A; Mizuno, K; Ohno, S			Protein kinase C delta activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; BETA-GAMMA-SUBUNITS; MAP KINASE; PHORBOL ESTERS; REGULATORY DOMAIN; GROWTH-FACTORS; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; NPKC-EPSILON; IN-VITRO	Although the involvement of protein kinase C (PKC) in the activation of the mitogen-activated protein (MAP) kinase pathway has been implicated through experiments using 12-O-tetradecanoylphorbol-13-acetate (TPA), there has been no direct demonstration that PKC activates the MAP kinase pathway, A Raf-dependent intact cell assay system for monitoring the activation of MAPK/ERK kinase (MEK) and extracellular signal-related kinase (ERK) permitted us to evaluate the role of PRC isotypes in MAP kinase activation. Treatment of cells with TPA or epidermal growth factor resulted in the activation of MEK and ERK. The activation of the MAP kinase pathway triggered by epidermal growth factor was completely inhibited by dominant-negative Ras (RasN17), whereas the activation triggered by TPA was not, consistent with previous observations. The introduction of an activated point mutant of PKC delta, but not PKC alpha or PKC epsilon, resulted in the activation of the MAP kinase pathway. The activation of MEK and ERK by an activated form of PKC delta requires the presence of c-Raf and is independent of RasN17. These results demonstrate that activation of PKC delta is sufficient for the activation of MER and ERK and that the pathway operates in a manner dependent on c-Raf and independent of Ras.	YOKOHAMA CITY UNIV,SCH MED,DEPT MOL BIOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				AHMED S, 1993, J BIOL CHEM, V268, P10709; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; AKITA Y, 1994, J BIOL CHEM, V269, P4653; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GENOT EM, 1995, J BIOL CHEM, V270, P9838; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HATA A, 1993, J BIOL CHEM, V268, P9122; HIRAI S, 1994, EMBO J, V13, P2231; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; INOUE M, 1977, J BIOL CHEM, V252, P7610; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MITRA G, 1993, CELL MOL BIOL RES, V39, P517; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MURAMATSU M, 1992, FEBS LETT, V311, P75, DOI 10.1016/0014-5793(92)81371-R; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SOZERI O, 1992, ONCOGENE, V7, P2259; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	65	498	506	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23512	23519		10.1074/jbc.271.38.23512	http://dx.doi.org/10.1074/jbc.271.38.23512			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798560	hybrid			2022-12-25	WOS:A1996VH76800086
J	Choi, YH; Matsuzaki, R; Suzuki, S; Tanizawa, K				Choi, YH; Matsuzaki, R; Suzuki, S; Tanizawa, K			Role of conserved Asn-Tyr-Asp-Tyr sequence in bacterial copper/2,4,5-trihydroxyphenylalanyl quinone-containing histamine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER AMINE OXIDASE; TOPA QUINONE; ACTIVE-SITE; ARTHROBACTER-GLOBIFORMIS; MONOAMINE-OXIDASE; ESCHERICHIA-COLI; COFACTOR; CLONING; GENERATION; MECHANISM	Copper amine oxidase contains a covalently bound quinonoid cofactor, 2,4,5-trihydroxyphenylalanyl quinone (TPQ), which is synthesized by post-translational modification of a specific tyrosyl residue occurring in the highly conserved sequence, Asn-Tyr-(Asp/Glu)-Tyr. To elucidate the role(s) of the conserved sequence in the biogenesis of TPQ, each of the corresponding residues at positions 401-404 in the recombinant histamine oxidase from Arthrobacter globiformis has been replaced with other amino acids by site-directed mutagenesis. When Asn 401 was changed to Asp or Gln, the rate of TPQ formation by copper-dependent self-processing was 10(3)- to 10(4)-fold slower than in the wild-type enzyme. When Tyr-402 was replaced by Phe, TPQ was not formed at all, showing that Tyr-402 is essential as the precursor to TPQ. In contrast, Asp-403 could be replaced by Glu without changes in the rate of TPQ formation, whereas its replacement by Asn led to a marked decrease. Furthermore, when Tyr-404 was changed to Phe, TPQ was formed swiftly on incubation with copper ions, but the TPQ enzyme exhibited very low activity with altered substrate specificity. These results collectively indicate that a very rigorous structural motif is required for efficient formation of TPQ and for the catalytic activity in the active site of copper amine oxidases.	OSAKA UNIV,INST SCI & IND RES,DIV BIOL SCI,IBARAKI,OSAKA 567,JAPAN; OSAKA UNIV,FAC SCI,DEPT CHEM,TOYONAKA,OSAKA 560,JAPAN	Osaka University; Osaka University								AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; CAI DY, 1994, J BIOL CHEM, V269, P32039; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; COLEMAN AA, 1991, J BIOL CHEM, V266, P6795; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1994, MET IONS BIOL SYST, V30, P361; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MATSUZAKI R, 1995, BIOCHEMISTRY-US, V34, P4524, DOI 10.1021/bi00014a004; McIntire W. S., 1993, COPPER CONTAINING AM, P97; MU D, 1992, J BIOL CHEM, V267, P7979; Nakamura N, 1996, J BIOL CHEM, V271, P4718; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; TANIZAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P1096, DOI 10.1006/bbrc.1994.1343; TIPPING AJ, 1995, J BIOL CHEM, V270, P16939, DOI 10.1074/jbc.270.28.16939; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22598	22603		10.1074/jbc.271.37.22598	http://dx.doi.org/10.1074/jbc.271.37.22598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798429	hybrid			2022-12-25	WOS:A1996VG67200048
J	Hartsough, MT; Frey, RS; Zipfel, PA; Buard, A; Cook, SJ; McCormick, F; Mulder, KM				Hartsough, MT; Frey, RS; Zipfel, PA; Buard, A; Cook, SJ; McCormick, F; Mulder, KM			Altered transforming growth factor beta signaling in epithelial cells when Ras activation is blocked	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; TGF-BETA; CYCLE ARREST; C-MYC; DEPENDENT KINASE; PROTEIN-KINASES; HUMAN KERATINOCYTES; REGULATED KINASE-2; DOWN-REGULATION; MAP KINASE	We have previously demonstrated that growth inhibition of untransformed intestinal epithelial cells by transforming growth factor beta(1) (TGF beta) and TGF beta(2) was associated with a rapid activation of both Ras and extracellular signal-regulated kinase 1 (Erk1) (Mulder, K. M., and Morris, S. L. (1992) J. Biol. Chem. 267, 5029-5031; Hartsough, M. T., and Mulder, K. M. (1995) J. Biol. Chem. 270, 7117-7124). In order to determine whether Ras was required for TGF beta regulation of both Erk1 and down-stream components associated with TGF beta-mediated growth inhibition, the intestinal epithelial cell (IEC) line IEC 4-1 was transfected with a vector containing a dominant-negative mutant of Ras (RasN17) under the control of an inducible metallothionein promoter, Using two different RasN17-transfected clones treated with ZnCl2, we demonstrate here that induction of Ras expression by at least 4-fold completely abrogated the TGF beta-mediated activation of Erk1. Moreover, the RasN17-mediated reversal of the TGF beta effect on Erk1 was dependent upon the level of expression of the dominant-negative protein. ZnCl2 treatment of control cells transfected with the empty vector did not alter Ras expression or the activation of Erk1 by TGF beta. In order to determine whether the activation of Ras by TGF beta was required for the growth inhibitory effect of TGF beta, we examined TGF beta(2) effects on Cdk2-associated histone H1 kinase activity, cyclin A protein expression levels, and DNA synthesis in two intestinal epithelial cell clones transfected with RasN17. In cells expressing RasN17, we observed a 50% reversal of the inhibition of Cdk2 activity, a 78% reversal of the down-regulation of cyclin A protein expression, and a 21% reversal of the inhibition of DNA synthesis by TGF beta. Collectively, these results indicate that Ras activation is obligatory for TGF beta-mediated activation of Erk1, whereas it is partially required for the growth inhibitory effect of TGF beta.	PENN STATE UNIV,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033; ONYX PHARMACEUT,RICHMOND,CA 94806	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [CA68444, CA51452, CA54816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054816, R01CA068444, R29CA051452, R01CA051452] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; BHUSHAN A, 1994, MOL CELL BIOL, V14, P4280, DOI 10.1128/MCB.14.6.4280; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BRONZERT DA, 1990, MOL ENDOCRINOL, V4, P981, DOI 10.1210/mend-4-7-981; Buard A, 1996, INT J CANCER, V67, P539, DOI 10.1002/(SICI)1097-0215(19960807)67:4<539::AID-IJC13>3.0.CO;2-2; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAUTSCH MP, 1995, J CELL BIOCHEM, V58, P517, DOI 10.1002/jcb.240580415; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRUPPUSO PA, 1991, J BIOL CHEM, V266, P3444; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LONGSTREET M, 1992, ONCOGENE, V7, P1549; MASSAGUE J, 1992, CANCER SURV, V12, P81; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1988, CANCER RES, V48, P7120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MULDER KM, 1990, J CELL PHYSIOL, V145, P501, DOI 10.1002/jcp.1041450316; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; ONG G, 1991, ONCOGENE, V6, P761; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; YAN ZF, 1994, J BIOL CHEM, V269, P13231; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; ZIPFEL PA, 1993, CELL GROWTH DIFFER, V4, P637	69	114	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22368	22375		10.1074/jbc.271.37.22368	http://dx.doi.org/10.1074/jbc.271.37.22368			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798398	hybrid			2022-12-25	WOS:A1996VG67200017
J	Wang, HS; Cao, HJ; Winn, VD; Rezanka, LJ; Frobert, Y; Evans, CH; Sciaky, D; Young, DA; Smith, TJ				Wang, HS; Cao, HJ; Winn, VD; Rezanka, LJ; Frobert, Y; Evans, CH; Sciaky, D; Young, DA; Smith, TJ			Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts - An in vitro model for connective tissue inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DERMAL FIBROBLASTS; HUMAN-SKIN FIBROBLASTS; NF-KAPPA-B; CYCLIC ADENOSINE-MONOPHOSPHATE; VESICULAR GLAND MICROSOMES; CULTURED HUMAN-FIBROBLASTS; DENOVO PROTEIN-SYNTHESIS; CELL-DERIVED CYTOKINE; GRAVES OPHTHALMOPATHY; INTERFERON-GAMMA	Several proinflammatory cytokines can increase prostaglandin E(2) (PGE(2)) synthesis in a variety of cell types, constituting an important component of the inflammatory response. We demonstrate here that leukoregulin, a 50-kDa product of activated T lymphocytes, dramatically increases PGE, synthesis in cultured human orbital fibroblasts. This up-regulation is mediated through an induction of prostaglandin-endoperoxide H synthase-2 (PGHS-2), the inflammatory cyclooxygenase. Steady-state levels of PGHS-2 mRNA are increased within 1.5 h of leukoregulin addition and are near maximal. by 6 h, when they are 50-fold or higher above basal levels, The increase in PGHS-2 mRNA levels is partially blocked by cycloheximide, suggesting de novo synthesis of an intermediate protein may be required for a maximal leukoregulin response. Nuclear run-on studies indicate PGHS-2 gene transcription is up-regulated by leukoregulin a-fold after 2 and 6 h. PGHS-2 protein, as assessed by Western blotting and two-dimensional protein gel analysis, is increased dramatically in orbital fibroblasts, This lymphokine-dependent expression of PGHS-2 is blocked by dexamethasone, and the increase in PGE, and cAMP levels following leukoregulin treatment is also blocked by indomethacin and by SC 58125, a newly developed PGHS-2-selective cyclooxygenase inhibitor. The dramatic increase in cAMP levels causes marked alteration in orbital fibroblast morphology. PGHS-2 expression in dermal fibroblasts is also increased by leukoregulin; however, the response is considerably less robust, and these cells do not undergo a change in morphology. Both orbital and dermal fibroblasts express high levels of PGHS-1 mRNA and protein, the other abundant form of cyclooxygenase. In contrast to its effects on PGHS-2 expression, leukoregulin fails to alter PGHS-1 levels in either orbital or dermal fibroblasts, suggesting that PGHS-1 is not involved in cytokine-dependent prostanoid production in human fibroblasts. The increased PGHS-2 expression elicited by leukoregulin in orbital fibroblasts may be a consequence of both transcriptional and post-transcriptional effects. These observations help clarify the pathogenic mechanism relevant to the intense inflammation associated with Graves' ophthalmopathy. Lymphocytes trafficked to orbital tissues have a putative role, through the cytokines they release, in the activation of fibroblasts in this autoimmune disease.	ALBANY MED COLL,DEPT MED,DIV MOL & CELLULAR MED,ALBANY,NY 12208; ALBANY MED COLL,DEPT BIOCHEM & MOL BIOL,ALBANY,NY 12208; SAMUEL S STRATTON VET AFFAIRS MED CTR,ALBANY,NY 12208; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,DIV ENDOCRINOL & METAB,E HENRY KEUTMANN LABS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; NCI,BIOL LAB,BETHESDA,MD 20892; CEA SACLAY,SERV PHARMACOL & IMMUNOL,F-91191 GIF SUR YVETTE,FRANCE	Albany Medical College; Albany Medical College; University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); CEA; UDICE-French Research Universities; Universite Paris Saclay			Smith, Terry/ABG-1360-2020	Winn, Virginia/0000-0003-1136-2907; Smith, Terry/0000-0002-6279-9685	NATIONAL EYE INSTITUTE [R01EY008976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08976] Funding Source: Medline; NIDDK NIH HHS [DK 16177] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT SC, 1988, CLIN EXP IMMUNOL, V73, P505; BARNETT SC, 1986, CANCER RES, V46, P2686; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BENRENSON CS, 1995, J CLIN ENDOCR METAB, V80, P2668; BETZ M, 1991, J IMMUNOL, V146, P108; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; DECARLI M, 1993, J CLIN ENDOCR METAB, V77, P1120, DOI 10.1210/jc.77.5.1120; DIAZ A, 1992, J BIOL CHEM, V267, P10816; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; EHRETSMANN CP, 1995, MOL CELL ENDOCRINOL, V110, P185, DOI 10.1016/0303-7207(95)03531-B; EVANS CH, 1989, ANAL BIOCHEM, V177, P358, DOI 10.1016/0003-2697(89)90066-3; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOX BS, 1993, IMMUNOMETHODS, V2, P255; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GOTO M, 1987, J CLIN INVEST, V80, P786, DOI 10.1172/JCI113135; GRUBECKLOEBENSTEIN B, 1994, J CLIN INVEST, V93, P2738, DOI 10.1172/JCI117289; GRUOL DJ, 1993, MOL ENDOCRINOL, V7, P104, DOI 10.1210/me.7.1.104; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HIGGINS PJ, 1993, BIOCHIM BIOPHYS ACTA, V1181, P23, DOI 10.1016/0925-4439(93)90085-F; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOGG MG, 1995, AM J PHYSIOL-CELL PH, V269, pC359, DOI 10.1152/ajpcell.1995.269.2.C359; HU ZQ, 1995, J IMMUNOL, V155, P2134; HUFNAGEL TJ, 1984, OPHTHALMOLOGY, V91, P1411; JAUME JC, 1994, J CLIN ENDOCR METAB, V78, P348, DOI 10.1210/jc.78.2.348; JONES DA, 1993, J BIOL CHEM, V268, P9049; JUMBLATT MM, 1991, INVEST OPHTH VIS SCI, V32, P360; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEVENSON RM, 1986, ANAL BIOCHEM, V158, P294, DOI 10.1016/0003-2697(86)90553-1; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MAUVIEL A, 1992, J CELL BIOCHEM, V50, P53, DOI 10.1002/jcb.240500110; MAUVIEL A, 1991, J CELL BIOL, V113, P1455, DOI 10.1083/jcb.113.6.1455; MAUVIEL A, 1992, J IMMUNOL, V149, P2969; MAUVIEL A, 1992, J BIOL CHEM, V267, P5644; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; Moore DD, 1995, GLOB MOB SURV; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OHKI S, 1979, J BIOL CHEM, V254, P829; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; RANSOM JH, 1985, CANCER RES, V45, P851; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REGAN JW, 1994, MOL PHARMACOL, V46, P213; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; ROPER RL, 1990, J IMMUNOL, V145, P2644; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366; SMITH TJ, 1995, AM J PHYSIOL-CELL PH, V268, pC382, DOI 10.1152/ajpcell.1995.268.2.C382; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; SMITH TJ, 1992, AM J PHYSIOL, V263, pC24, DOI 10.1152/ajpcell.1992.263.1.C24; SMITH TJ, 1994, P NATL ACAD SCI USA, V91, P5094, DOI 10.1073/pnas.91.11.5094; SMITH TJ, 1993, AM J PHYSIOL, V265, pC138, DOI 10.1152/ajpcell.1993.265.1.C138; SMITH TJ, 1993, J INVEST DERMATOL, V100, P288, DOI 10.1111/1523-1747.ep12469828; SMITH TJ, 1987, J CLIN INVEST, V79, P1493, DOI 10.1172/JCI112979; SMITH TJ, 1995, J CLIN ENDOCR METAB, V80, P2620, DOI 10.1210/jc.80.9.2620; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; SMITH TJ, 1991, J CLIN ENDOCR METAB, V72, P1169, DOI 10.1210/jcem-72-5-1169; SMITH TJ, 1993, BIOCHIM BIOPHYS ACTA, V1181, P300, DOI 10.1016/0925-4439(93)90036-Z; SMITH TJ, 1988, METABOLISM, V37, P179, DOI 10.1016/S0026-0495(98)90015-4; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VORIS BP, 1980, ANAL BIOCHEM, V104, P478, DOI 10.1016/0003-2697(80)90103-7; WANG HS, 1995, J CLIN ENDOCR METAB, V80, P3553, DOI 10.1210/jc.80.12.3553; WINN VD, 1993, J LIPID MEDIATOR, V6, P101; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YANG X, 1995, U20548 GENBANK; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190; [No title captured]	81	88	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22718	22728		10.1074/jbc.271.37.22718	http://dx.doi.org/10.1074/jbc.271.37.22718			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798446	hybrid			2022-12-25	WOS:A1996VG67200065
J	Chou, SJ; Lai, KN; Chung, BC				Chou, SJ; Lai, KN; Chung, BC			Characterization of the upstream sequence of the human CYP11A1 gene for cell type-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; BOX-BINDING-PROTEINS; SIDE-CHAIN CLEAVAGE; STEROID HYDROXYLASE GENES; TRANSCRIPTIONAL ACTIVATION; DNA-REPLICATION; ADRENAL-CORTEX; P450SCC GENE; DEVELOPMENTAL EXPRESSION; SYNERGISTIC ACTIVATION	The CYP11A1 gene encodes the cholesterol side-chain cleavage enzyme P450scc, which catalyzes the synthesis of steroids from cholesterol. This gene is expressed only in steroidogenic organs such as the adrenal, gonad, placenta, and brain. We have characterized an upstream regulatory element of the human CYP11A1 gene, termed AdE, which contributed to its cell type-specific expression. The AdE sequence contains two protein binding regions, AdE1 and AdE2, which bind many proteins including NF1- and Sp1-like proteins as shown by electrophoretic mobility shift assay, footprinting, competition, antibody supershift, and mutagenesis of the binding sites. When cloned in front of the CYP11A1 promoter or the heterologous thymidine kinase promoter, AdE sequences enhanced expression of the reporter gene in steroidogenic cell lines of the adrenal, gonad, and placental origin but not in nonsteroidogenic cell lines such as COS-1 and Rat-1. The function of AdE1 and AdE2 was lower when present individually than together. The combined action of multiple transcription factors binding to the AdE sequence brings about the final activation of the CYP11A1 gene in a tissue-specific manner.	ACAD SINICA,INST MOL BIOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,GRAD SCH ZOOL,TAIPEI,TAIWAN	Academia Sinica - Taiwan; National Taiwan University				Chung, Bon-chu/0000-0002-8612-0219				ALLAN GF, 1991, J BIOL CHEM, V266, P5905; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHANG SF, 1995, MOL ENDOCRINOL, V9, P1330, DOI 10.1210/me.9.10.1330; CHEN CT, 1995, DNA CELL BIOL, V9, P803; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CHUNG BC, 1989, BIOCHEM BIOPH RES CO, V160, P276, DOI 10.1016/0006-291X(89)91652-5; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; ESKILD W, 1994, MOL ENDOCRINOL, V8, P732, DOI 10.1210/me.8.6.732; FISHER RJ, 1991, ONCOGENE, V6, P2449; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAESSMANN A, 1979, J VIROL, V32, P989, DOI 10.1128/JVI.32.3.989-994.1979; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; GUO IC, 1993, DNA CELL BIOL, V12, P849, DOI 10.1089/dna.1993.12.849; GUO IC, 1994, J BIOL CHEM, V269, P6362; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HENNIGHAUSEN L, 1989, NUCLEIC ACIDS RES, V17, P8197, DOI 10.1093/nar/17.20.8197; HONDA S, 1993, J BIOL CHEM, V268, P7494; HUM DW, 1995, DNA CELL BIOL, V14, P451, DOI 10.1089/dna.1995.14.451; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KEENEY DS, 1995, MOL ENDOCRINOL, V9, P1091, DOI 10.1210/me.9.8.1091; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V94, P235, DOI 10.1016/0303-7207(93)90172-G; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MUKAI K, 1995, MOL CELL BIOL, V15, P6003; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAINEY WE, 1994, MOL CELL ENDOCRINOL, V100, P45, DOI 10.1016/0303-7207(94)90277-1; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; ROGLER LE, 1993, MOL ENDOCRINOL, V7, P453, DOI 10.1210/me.7.3.453; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHIMMER BP, 1989, METHOD ENZYMOL, V58, P570; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; ZHANG PL, 1995, MOL ENDOCRINOL, V9, P1571, DOI 10.1210/me.9.11.1571; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340	67	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22125	22129		10.1074/jbc.271.36.22125	http://dx.doi.org/10.1074/jbc.271.36.22125			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703023	hybrid			2022-12-25	WOS:A1996VF61200065
J	LiaudetCoopman, EDE; Wellstein, A				LiaudetCoopman, EDE; Wellstein, A			Regulation of gene expression of a binding protein for fibroblast growth factors by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPEUTIC ANTICANCER AGENTS; SQUAMOUS-CELL DIFFERENTIATION; MESSENGER-RNA EXPRESSION; RESPONSE ELEMENT; HUMAN HEAD; RECEPTOR; STABILITY; ESTROGEN; INHIBITION; CARCINOMA	Retinoids are potent regulators of growth and differentiation and have shown promise as chemotherapeutic agents against selected cancers in particular squamous cell carcinoma (SCC), Earlier studies from our laboratory showed that a secreted binding protein for fibroblast growth factors (BP) is expressed at high levels in SCC cell lines and tissue samples. Here we investigate whether retinoids affect BP gene expression in SCC. In six different human SCC cell lines, we found that all-trans-retinoic acid (tRA) down-regulated BP mRNA by 39-89% within 24 h, From this group of cell lines, we selected the ME-180 cell line for more detailed studies of the mechanisms of this regulation, tRA down-regulated BP mRNA in a time- and dose-dependent manner. The effect of tRA was reversible, and BP mRNA returned to control levels within 24 h after removal of tRA. We also measured BP mRNA half-life and performed nuclear run-on experiments to study if tRA down-regulates BP by destabilizing the mRNA and/or by decreasing the rate of transcription. BP mRNA in ME-180 cells is very stable with a half-life of >16 h, and tRA decreased BP mRNA with a half-time of 5 h, Actinomycin D and cycloheximide blocked the tRA effect, suggesting that transcriptional regulation as well as de novo protein synthesis contribute to this post-transcriptional regulation of BP mRNA levels, In addition, tRA decreased the rate of BP gene transcription by 2- to 3-fold within 1 h, We conclude that retinoids down-regulate BP gene expression by post-transcriptional as well as by transcriptional mechanisms.	GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA	Georgetown University			Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEMAYOR E, 1992, LARYNGOSCOPE, V102, P1133, DOI 10.1288/00005537-199210000-00008; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BERTRAM JS, 1987, CANCER RES, V47, P3012; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BUSAM KJ, 1993, ONCOGENE, V8, P2267; COCHRANE AW, 1988, J MOL BIOL, V203, P555, DOI 10.1016/0022-2836(88)90192-1; CROWE DL, 1993, J CELL SCI, V106, P183; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FROST GH, 1993, J BIOL CHEM, V268, P6748; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; JETTEN AM, 1990, INT J CANCER, V45, P195, DOI 10.1002/ijc.2910450135; LABBAYE C, 1993, BLOOD, V81, P475; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; LIPPMAN SM, 1993, J NATL CANCER I, V85, P499, DOI 10.1093/jnci/85.6.499; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; LOPEZBARAHONA M, 1989, MOL ENDOCRINOL, V3, P805; LOTAN R, 1993, J CELL BIOCHEM, P167; LOTNA R, 1994, CANC RES S7, V54, pS1987; MARODER M, 1990, NUCLEIC ACIDS RES, V18, P1153, DOI 10.1093/nar/18.5.1153; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MOON RC, 1990, CHEM BIOL SYNTHETIC; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PAN CJ, 1992, MOL ENDOCRINOL, V6, P572, DOI 10.1210/me.6.4.572; POLLARD M, 1991, CANCER RES, V51, P3610; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; SCHOENBERG DR, 1989, MOL ENDOCRINOL, V3, P805, DOI 10.1210/mend-3-5-805; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHKLAR G, 1980, ORAL SURG ORAL MED O, V50, P45, DOI 10.1016/0030-4220(80)90330-8; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; WU DQ, 1991, J BIOL CHEM, V266, P16778; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225; ZOU CP, 1994, CANCER RES, V54, P5479	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21303	21308		10.1074/jbc.271.35.21303	http://dx.doi.org/10.1074/jbc.271.35.21303			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702908	hybrid			2022-12-25	WOS:A1996VE47700054
J	Zhu, AH; Kuziora, MA				Zhu, AH; Kuziora, MA			Homeodomain interaction with the beta subunit of the general transcription factor TFIIE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; C-TERMINAL DOMAIN; DNA COMPLEX; HOMEO DOMAIN; DROSOPHILA; SEQUENCE; ACTIVATION; ULTRABITHORAX; EXTRADENTICLE	Homeodomain-containing proteins play a crucial role as transcriptional regulators in the process of cell differentiation, The homeodomain performs a dual function in this regard, acting as a DNA binding domain and participating in protein-protein interactions that enhance DNA binding specificity or regulatory activity, Here we describe a homeodomain class-specific interaction with the beta subunit of the general transcription factor TFIIE. We show that the Antennapedia and Abdominal-B homeodomains bind to TFIIE beta, but the even-skipped homeodomain does not, Using a two-hybrid assay performed in cultured cells, we demonstrate that the homeodomain-TFIIE beta interaction occurs in vivo, The Abdominal-B homeodomain is shown to activate transcription in vitro, and this activation can be blocked with anti-TFIIE beta antibody without affecting basal transcription levels, Together with published data demonstrating an interaction between proteins containing even-skipped class homeodomains and the TATA-binding protein (Um, M., Li, C., and Manley, J. L. (1995) Mol. Cell. Biol. 15, 5007-5016; Zhang, H., Catron, K. M., and Abate-Shen, C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1764-1769), these results suggest various homeodomain containing proteins interact with different general transcription factors, an observation that may have important implications for transcriptional regulation.			Zhu, AH (corresponding author), UNIV PITTSBURGH,DEPT BIOL SCI,A234 LANGLEY HALL,PITTSBURGH,PA 15260, USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lutz B, 1996, GENE DEV, V10, P176, DOI 10.1101/gad.10.2.176; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TONG X, 1995, MOL CELL BIOL, V15, P4735; UM M, 1995, MOL CELL BIOL, V15, P5007; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZAWEL L, 1993, COLD SPRING HARB SYM, V58, P187, DOI 10.1101/SQB.1993.058.01.023; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343; Zhu AH, 1996, DEVELOPMENT, V122, P1577	44	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20993	20996		10.1074/jbc.271.35.20993	http://dx.doi.org/10.1074/jbc.271.35.20993			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702862	hybrid			2022-12-25	WOS:A1996VE47700006
J	Sakano, S; Serizawa, R; Inada, T; Iwama, A; Itoh, A; Kato, C; Shimizu, Y; Shinkai, F; Shimizu, R; Kondo, S; Ohno, M; Suda, T				Sakano, S; Serizawa, R; Inada, T; Iwama, A; Itoh, A; Kato, C; Shimizu, Y; Shinkai, F; Shimizu, R; Kondo, S; Ohno, M; Suda, T			Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature hematopoietic cells	ONCOGENE			English	Article						receptor tyrosine kinase; HTK; HTK ligand; BIAcore; hematopoietic cells	MOLECULAR-CLONING; GROWTH-FACTOR; EPH; FAMILY; GENE; B61; SIGNAL; ALPHA; ELF-1; MEK4	HTK is a receptor tyrosine kinase that belongs to the Eph subfamily. An extensive screening using BIAcore system revealed that a colon cancer cell line, C-l, expressed the ligand for HTK. From the conditioned medium of C-l cells, a soluble form of ligand was purified by receptor affinity chromatography, and the isolation of full-length cDNA revealed that this ligand is identical to the human HTK ligand (HTKL) previously reported. HTK receptor tyrosine phosphorylation was induced by membrane-bound or clustered soluble HTKL but not by unclustered soluble HTKL, indicating that HTKL requires cell-to-cell interaction for receptor activation. Binding analysis demonstrated that HTKL binds to HTK with a much higher affinity (K-d: 1.23 nM) than the other transmembrane-type ligand for Eph family, LERK-2/ELKL (K-d: 135 nM). The expression of HTK in cord blood cells was upregulated after the culture in the presence of stem cell factor. Clustered soluble HTKL stimulated the proliferation of sorted HTK+ cord blood cells and a hematopoietic cell line, UT-7/EPO from which HTK was isolated. These findings suggest the involvement of HTK-HTKL system in the proliferation of HTK+ hematopoietic progenitor cells in the hematopoietic environment.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; ASAHI CHEM IND CO LTD,FUNDAMENTAL RES LAB LIFE SCI,FUJI,SHIZUOKA 416,JAPAN; ASAHI CHEM IND CO LTD,LIFE SCI RES INST,BIOL RES LAB,FUJI,SHIZUOKA 416,JAPAN	Kumamoto University			Shinkai-ouchi, Fumiko/E-3207-2010; Suda, Toshio/H-6761-2013	Shinkai-ouchi, Fumiko/0000-0002-0095-941X; Suda, Toshio/0000-0001-7540-1771				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KOMATSU N, 1993, BLOOD, V82, P456; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKANO S, 1994, ONCOGENE, V9, P1155; SHAO HN, 1994, J BIOL CHEM, V269, P26606; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	29	84	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					813	822						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761303				2022-12-25	WOS:A1996VD43300017
J	LeNaour, F; Prenant, M; Francastel, C; Rubinstein, E; Uzan, G; Boucheix, C				LeNaour, F; Prenant, M; Francastel, C; Rubinstein, E; Uzan, G; Boucheix, C			Transcriptional regulation of the human CD9 gene: Characterization of the 5'-flanking region	ONCOGENE			English	Article						CD9 antigen; tetraspan; promoter; leukemia; platelets	ACUTE LYMPHOBLASTIC-LEUKEMIA; DIPHTHERIA-TOXIN RECEPTOR; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; CELL-LINE; MEMBRANE-PROTEIN; TRANSMEMBRANE-4 SUPERFAMILY; ENCODING METALLOTHIONEIN; IMMUNOGLOBULIN GENES; MOLECULAR-CLONING	The CD9 antigen, initially discovered on B lineage leukemic cells, belongs to the tetraspan superfamily of surface molecules. If no precise function has been assigned to any of these molecules, there are some indications that they could be involved in cell adhesion and cell migration, as well as malignant progression. The CD9 antigen is associated with surface proteins such as VLA integrins or HB-EGF precursor. Transfection of CD9 in melanoma cells reduces tumor growth and metastasis. The heterogenous distribution of the CD9 antigen suggests a complex regulation of its expression. We have previously characterized the CD9 gene and shown that transcription could be initiated at several sites in the TATA-less 5 '-flanking region. We show here, using as a model two human leukemic cell lines with erythromegakaryocytic potential, HEL and K562, that the [-205,-154] region supports a promoter activity when cloned ahead of a CAT reporter gene. Mutagenesis analysis suggested the presence of a positive element located within the [-170,-154] region. Gel shift experiments using HEL extracts were compatible with the binding of the transcriptional factor Spl to the [-237,-205] region and indicated that a non-identified protein binds to the 3 ' end of the [-205,-154] region.	CENG,INSERM,U217,HEMATOL LAB,F-38054 GRENOBLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	LeNaour, F (corresponding author), HOP PAUL BROUSSE,INSERM,U268,F-94807 VILLEJUIF,FRANCE.		Francastel, Claire/AAI-4798-2021; Rubinstein, Eric/B-4650-2019; Uzan, Georges/M-8199-2018	Rubinstein, Eric/0000-0001-7623-9665; Uzan, Georges/0000-0002-0178-5386; Francastel, Claire/0000-0002-6353-4320; Boucheix, Claude/0000-0003-4184-7008				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANTON ES, 1995, J NEUROSCI, V15, P584; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BOUCHEIX C, 1985, LEUKEMIA RES, V9, P597, DOI 10.1016/0145-2126(85)90139-0; BRACH MA, 1992, BLOOD, V79, P728; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HOTTA H, 1988, CANCER RES, V48, P2955; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KADONAGA JT, 1986, TIBS, V11, P21; KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LABBE S, 1993, NUCLEIC ACIDS RES, V21, P1549, DOI 10.1093/nar/21.7.1549; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RIECKMANN P, 1991, J IMMUNOL, V147, P3994; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; RUBINSTEIN E, 1993, GENOMICS, V16, P132, DOI 10.1006/geno.1993.1150; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT AF, 1994, GENOMICS, V20, P227, DOI 10.1006/geno.1994.1157; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SHAW S, 1994, LEUCOCYTE TYPING, V5, P16; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; TROUCHE D, 1991, BLOOD, V77, P55; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; UZAN G, 1991, J BIOL CHEM, V266, P8932; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	66	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					481	486						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760289				2022-12-25	WOS:A1996VB32800005
J	Parekh, AB				Parekh, AB			Nonhydrolyzable analogues of GTP activate a new Na+ current in a rat mast cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; CALCIUM INFLUX; SODIUM-CHANNEL; PROTEINS	Whole cell patch clamp experiments were performed to examine the effects of the nonhydrolyzable GTP analogue, guanosine 5'-3-O-(thio)triphosphate, on membrane currents in rat basophilic leukemia cells, Guanosine 5'-3-O-(thio)triphosphate activated an inward sodium current, This current had a new permeability sequence to monovalent cations and a different pharmacological profile to that of other characterized Na+ channels. Long hyperpolarizing steps revealed that the current declined during the pulse, and the decline was voltage-dependent. Activation of the current required Mg2+ and ATP. The nonhydrolyzable ATP analogues, adenosine 5'-O-(thio)triphosphate and adenosine 5'-(beta,gamma-imino)triphosphate, could not substitute for ATP, Soluble second messengers like cAMP, cGMP, inositol polyphosphates, and Ca2+ did not activate the Na+ current, These results suggest that nonhydrolyzable GTP analogues activate a Na+ current in rat basophilic leukemia cells that is new in terms of its selectivity, pharmacology, and activation mechanism. It may be the prototype for a new family of Na+ channels expressed in certain nonexcitable cells.	MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY	Max Planck Society								Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; EISENMAN G, 1962, Biophys J, V2, P259; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; Hille B., 1992, IONIC CHANNELS EXCIT; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; KAHN RA, 1991, J BIOL CHEM, V266, P15595; LEDERER WJ, 1990, SCIENCE, V248, P376; Mandel G, 1993, Curr Opin Neurobiol, V3, P278, DOI 10.1016/0959-4388(93)90118-I; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	21	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23161	23168		10.1074/jbc.271.38.23161	http://dx.doi.org/10.1074/jbc.271.38.23161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798510	hybrid			2022-12-25	WOS:A1996VH76800036
J	Pio, F; Kodandapani, R; Ni, CZ; Shepard, W; Klemsz, M; McKercher, SR; Maki, RA; Ely, KR				Pio, F; Kodandapani, R; Ni, CZ; Shepard, W; Klemsz, M; McKercher, SR; Maki, RA; Ely, KR			New insights on DNA recognition by ets proteins from the crystal structure of the PU.1 ETS domain DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BINDING DOMAIN; V-ETS; ONCOGENE; MOTIF; RESOLUTION; C-ETS-1; FAMILY; HELIX; ELK-1	Transcription factors belonging to the ets family regulate gene expression and share a conserved ETS DNA-binding domain that binds to the core sequence 5'-(C/ A)GGA(A/T)-3'. The domain is similar to alpha+beta (''winged'') helix-turn-helix DNA-binding proteins. The crystal structure of the PU.1 ETS domain complexed to a 16-base pair oligonucleotide revealed a pattern for DNA recognition from a novel loop-helix-loop architecture (Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R. A., and Ely, K. R. (1996) Nature 380, 456-460). Correlation of this model with mutational analyses and chemical shift data on other ets proteins confirms this complex as a paradigm for ets DNA recognition. The second helix in the helix-turn-helix motif lies deep in the major groove with specific contacts with bases in both strands in the core sequence made by conserved residues in alpha 3. On either side of this helix, two loops contact the phosphate backbone. The DNA is bent (8 degrees) but uniformly curved without distinct kinks. ETS domains bind DNA as a monomer yet make extensive DNA contacts over 30 Angstrom. DNA bending likely results from phosphate neutralization of the phosphate backbone in the minor groove by both loops in the loop-helix-loop motif. Contacts from these loops stabilize DNA bending and may mediate specific base interactions by inducing a bend toward the protein.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037; UNIV PARIS 11,LURE,F-91405 ORSAY,FRANCE; NEUROCRINE BIOSCI,SAN DIEGO,CA 92121	Sanford Burnham Prebys Medical Discovery Institute; UDICE-French Research Universities; Universite Paris Saclay; Neurocrine Biosciences				pio, frederic/0000-0003-2050-847X; Shepard, William/0000-0002-5724-1193	NATIONAL CANCER INSTITUTE [R01CA063489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020194] Funding Source: NIH RePORTER; NCI NIH HHS [CA63489] Funding Source: Medline; NIAID NIH HHS [AI20194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABCOCK MS, 1994, J MOL BIOL, V237, P98, DOI 10.1006/jmbi.1994.1212; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BRENNAN R, 1992, CURR OPIN STRUC BIOL, V2, P100; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CROTHERS DM, 1994, SCIENCE, V266, P18; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1994, MOSFLM USER GUIDE MO; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PIO F, 1995, J BIOL CHEM, V270, P24258, DOI 10.1074/jbc.270.41.24258; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; 1994, ACTA CRYSTALLOGR, V50, P760	48	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23329	23337		10.1074/jbc.271.38.23329	http://dx.doi.org/10.1074/jbc.271.38.23329			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798534	hybrid			2022-12-25	WOS:A1996VH76800060
J	Thaler, CD; Cardullo, RA				Thaler, CD; Cardullo, RA			The initial molecular interaction between mouse sperm and the zona pellucida is a complex binding event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; ACROSOME REACTION; SURFACE GALACTOSYLTRANSFERASE; RECEPTOR ACTIVITY; PLASMA-MEMBRANE; EGG BINDING; GLYCOPROTEIN ZP3; TYROSINE KINASE; FERTILIZATION	Prior to fertilization, mammalian sperm must first bind to the zona pellucida (ZP), a glycoprotein matrix surrounding the egg. Sperm specifically bind to ZP3, an 83-kDa glycoprotein which functions as both an adhesion molecule and as a secretagogue for acrosomal exocytosis (Litscher, E. S., and Wassarman, P. M. (1993) Trends Glycosci. Glycotechnol. 5, 369-388). We used acid solubilized, I-125-labeled ZPs to quantify the initial binding event on mouse spermatozoa. Live sperm could not be used since solubilized ZPs rapidly initiated exocytosis. Instead, acrosome intact mouse sperm were briefly fixed in 1% glutaraldehyde for binding studies using a standard filtration assay. The fixed sperm are suitable for sperm-zona binding assays based on two experiments: 1) incubating either live or fixed sperm in low concentrations of I-125-Zps not sufficient to induce acrosomal exocytosis revealed no differences in binding up to 15 min and 2) solubilized, unlabeled ZPs competed for I-125-ZPs with K-I of approximately 3.78 nM. Sperm-I-125-Zp binding reached equilibrium with a tau(1/2) of similar to 22 min at 37 degrees C. Affinity parameters were calculated using the well substantiated assumption that only ZP3 binds intact mouse sperm. The on-rate constant for association of I-125-Zp binding to the mouse sperm surface was calculated to be 3.2 x 10(6) hr(-1) min(-1). The saturation binding isotherm revealed that there are approximately 30,000 binding sites, ascribed to ZP3, with an EC(50) of 1.29 nM. Further analysis indicated that this binding is complex (Hill coefficient = 1.72), suggesting involvement of multiple receptors on the sperm surface and/or multiple ligand moieties, High and low affinity ZP binding sites on the sperm surface were confirmed by dissociation experiments. I-125-Zp dissociation was clearly biphasic, and kinetic off-rate constants of 0.161 min(-1) and 0.0023 min(-1) were calculated for the low and high affinity sites, respectively. Apparent affinities (K-d values) of 50 nM for the low affinity and 0.72 nM for the high affinity interaction were calculated from the rate constants. These data demonstrate that the initial adhesion event between mouse sperm and the zona pellucida is a high affinity event which is sufficient to tether a sperm to the extracellular matrix prior to the induction of acrosomal exocytosis.	UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside			Cardullo, Richard/GVT-2950-2022		NICHD NIH HHS [HD27244] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027244, R55HD027244] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALTZ JM, 1989, GAMETE RES, V24, P1, DOI 10.1002/mrd.1120240103; BALTZ JM, 1988, BIOPHYS J, V54, P643, DOI 10.1016/S0006-3495(88)83000-5; BENAU DA, 1987, BIOL REPROD, V36, P282, DOI 10.1095/biolreprod36.2.282; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; CARDULLO RA, 1989, BIOCHEMISTRY-US, V28, P1611, DOI 10.1021/bi00430a028; CARDULLO RA, 1995, BIOCHEMISTRY-US, V34, P10027, DOI 10.1021/bi00031a026; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; Chen Q., 1994, Molecular Biology of the Cell, V5, p224A; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P199; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1981, J EXP ZOOL, V216, P159, DOI 10.1002/jez.1402160117; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; GWATKIN RBL, 1977, J REPROD FERTIL, V49, P55, DOI 10.1530/jrf.0.0490055; HULME EC, 1992, RECEPTOR LIGAND INTE, P177; INOUE M, 1975, BIOL REPROD, V13, P340, DOI 10.1095/biolreprod13.3.340; KALAB P, 1994, J BIOL CHEM, V269, P3810; Lauffenburger D, 1993, RECEPTORS MODELS BIN, P9; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; LIPKIN EW, 1986, J BIOL CHEM, V261, P1702; Litscher ES, 1996, BIOCHEMISTRY-US, V35, P3980, DOI 10.1021/bi952722m; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; LITSCHER ES, 1993, TRENDS GLYCOSCI GLYC, V5, P369; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; MATTHEWS JC, 1993, FUNDAMENTALS RECEPTO, P49; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORTILLO S, 1991, DEVELOPMENT, V113, P141; PRUZANSKY JJ, 1986, IMMUNOLOGY, V58, P287; SALING PM, 1979, J EXP ZOOL, V209, P229, DOI 10.1002/jez.1402090205; SALING PM, 1978, DEV BIOL, V65, P515, DOI 10.1016/0012-1606(78)90046-5; SALING PM, 1981, P NATL ACAD SCI-BIOL, V78, P6231, DOI 10.1073/pnas.78.10.6231; SCHRODER H, 1990, BRAIN RES, V514, P249, DOI 10.1016/0006-8993(90)91420-L; SHAGLI R, 1991, MOL REPROD DEV, V29, P365; SHUR BD, 1982, J CELL BIOL, V95, P574, DOI 10.1083/jcb.95.2.574; SHUR BD, 1988, J BIOL CHEM, V263, P17706; SHUR BD, 1982, J CELL BIOL, V95, P567, DOI 10.1083/jcb.95.2.567; Smith K, 1979, MOL BASIS IMMUNE CEL, P223; TANPHAICHITR N, 1993, DEV BIOL, V156, P164, DOI 10.1006/dbio.1993.1067; Thaler C. D., 1994, Molecular Biology of the Cell, V5, p224A; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; TULSIANI DRP, 1989, J CELL BIOL, V109, P1257, DOI 10.1083/jcb.109.3.1257; VANMAURIK P, 1985, EUR J CELL BIOL, V36, P209; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wells J. W., 1992, RECEPTOR LIGAND INTE, P289; WHITTINGHAM DG, 1971, J REPROD FERTIL, V17, P399; ZIDOVETZKI R, 1991, BIOCHEMISTRY-US, V30, P6162, DOI 10.1021/bi00239a012	59	90	93	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23289	23297		10.1074/jbc.271.38.23289	http://dx.doi.org/10.1074/jbc.271.38.23289			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798528	hybrid			2022-12-25	WOS:A1996VH76800054
J	Abramochkin, G; Shrader, TE				Abramochkin, G; Shrader, TE			Aminoacyl-tRNA recognition by the leucyl/phenylalanyl-tRNA-protein transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; BIOSYNTHESIS; CONTAINS; IDENTITY; CLONING	We employ mutant and mischarged aminoacyl-tRNAs to characterize aminoacyl-tRNA recognition by the leucyl/phenylalanyl-tRNA-protein transferase (L/F-transferase). Wild type Met-tRNA(Metm) (CAU anticodon) and mischarged Met-tRNA(Val-1) (CAU anticodon) are substrates for the L/F-transferase during the NH2-terminal aminoacylation of alpha-casein, whereas Val-tRNA(Val-1) (UAC), Val-tRNA(Metm) (UAC), and Arg-tRNA(Metm) (CCG, A20) are not. Mutations in the anticodon and extra arm of tRNA(Leu-1) do not measurably effect its ability to serve as a substrate for the L/F-transferase, and the dissociation constants of the complexes between L/F-transferase and either wild type Leu-tRNA(Leu-4) (UAA) or mutant Leu-tRNA(Leu-4) (CUA) are each 0.4 +/- 0.2 mu M. The dissociation constants for the complexes between the L/F-transferase and uncharged tRNA, leucine methyl ester, and puromycin are all 10-1,000-fold greater than that of the Leu-tRNA L/F-transferase complex. Dissociation of the Leu-tRNA L/F-transferase complex is slow, relative to the rate calculated assuming that association is diffusion controlled, Finally, deoxyoligonucleotide aminoacyl-tRNA hybrids (dO . AA-tRNAs) are employed to characterize the determinants of the Leu-tRNA(Leu-4) acceptor stem recognized by the L/F-transferase. A dO . AA-tRNA completely lacking acceptor stem base pairs remains a substrate for the L/F-transferase, whereas a dO . AA-tRNA containing a a-base pair single-stranded region, at its 3' terminus, does not.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM52440] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052440] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOCHKIN G, 1995, J BIOL CHEM, V270, P20621, DOI 10.1074/jbc.270.35.20621; ASHHARA H, 1993, J MOL BIOL, V231, P219; BILGIN N, 1995, BIOCHEMISTRY-US, V34, P715, DOI 10.1021/bi00003a001; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; FRANCKLYN CS, 1990, CHEM REV, V90, P1327, DOI 10.1021/cr00105a013; HORINISHI H, 1975, BIOCHEM BIOPH RES CO, V67, P1136, DOI 10.1016/0006-291X(75)90792-5; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KAJI A, 1965, J BIOL CHEM, V240, P1185; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; LEIBOWITZ MJ, 1971, J BIOL CHEM, V246, P4431; LIEBOWITZ MJ, 1971, J BIOL CHEM, V246, P5207; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; LOUIE A, 1984, J BIOL CHEM, V259, P5010; Macinga DR, 1996, MOL MICROBIOL, V19, P511, DOI 10.1046/j.1365-2958.1996.385912.x; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; POOLE RK, 1993, MOL MICROBIOL, V10, P421, DOI 10.1111/j.1365-2958.1993.tb02673.x; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; RAO PM, 1974, FEBS LETT, V43, P199, DOI 10.1016/0014-5793(74)80999-3; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCARPULLA RC, 1976, BIOCHEM BIOPH RES CO, V71, P584, DOI 10.1016/0006-291X(76)90827-5; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIEGELE DA, 1993, GENE DEV, V7, P2629, DOI 10.1101/gad.7.12b.2629; SOFFER RL, 1974, ADV ENZYMOL RAMB, V40, P91; SOFFER RL, 1973, J BIOL CHEM, V248, P8424; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006	31	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22901	22907		10.1074/jbc.271.37.22901	http://dx.doi.org/10.1074/jbc.271.37.22901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798470	hybrid			2022-12-25	WOS:A1996VG67200089
J	Beaulieu, M; Levesque, E; Hum, DW; Belanger, A				Beaulieu, M; Levesque, E; Hum, DW; Belanger, A			Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C-19 steroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LNCAP CELL-LINE; HUMAN-LIVER; 3-ALPHA-ANDROSTANEDIOL GLUCURONIDE; ANDROGEN METABOLISM; PROSTATIC-CANCER; EXPRESSION; CLONING; PLASMA; MEN; IDENTIFICATION	To isolate cDNA clones encoding novel UGT2B enzymes, human prostate and LNCaP cell cDNA libraries were screened using a pool of steroid-specific UGT2B cDNA probes, In approximately 10(6) recombinants, we isolated 3 cDNA clones of 2.1 kilobases that encode a novel UGT2B enzyme, UGT2B17 is 95% identical with UGT2B15 and 91% identical with UGT2B8. Primary structure analysis of UGT2B17 based on the nucleotide sequence revealed a putative amino-terminal membrane insertion signal peptide, a carboxyl-terminal membrane-spanning region, and three potential asparagine-linked glycosylation sites. UGT2B17 cloned in the pBK-CMV expression vector was transfected into HK293 cells to obtain a stable clonal cell line expressing a high level of the active 53-kDa UGT2B17 enzyme. Of the over 60 endogenous and exogenous substances tested, 25 compounds revealed reactivity, The major substrates are eugenol > 4-methylumbelliferone > dihydrotestosterone > androstane-3 alpha,17 beta-diol (3 alpha-diol) > testosterone > androsterone (ADT). The apparent K-m values obtained with tritiated steroids in intact cells were 0.4 mu M for ADT, 0.7 mu M for dihydrotestosterone, 1.0 mu M for 3 alpha-diol, and 3.4 mu M for testosterone, Southern blot analysis of reverse transcription-polymerase chain reaction products revealed expression of UGT2B17 mRNA in various tissues including the liver, kidney, testis, uterus, placenta, mammary gland, adrenal gland, skin, and prostate, UGT2B17 is the first human uridine diphosphoglucuronosyltransferase enzyme expressed in extrahepatic tissues to have a specificity for ADT as well as testosterone, dihydrotestosterone, and 3 alpha-diol.	CHU LAVAL, RES CTR, MRC, GRP MOL ENDOCRINOL, QUEBEC CITY, PQ G1V 4G2, CANADA	Laval University								ADAMS JB, 1989, J STEROID BIOCHEM, V33, P1023, DOI 10.1016/0022-4731(89)90256-2; BELANGER A, 1991, J STEROID BIOCHEM, V40, P593, DOI 10.1016/0960-0760(91)90281-9; BELANGER A, 1990, EUR J CANCER, V26, P277, DOI 10.1016/0277-5379(90)90222-F; BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086; BELANGER A, 1990, ANN NY ACAD SCI, V595, P251, DOI 10.1111/j.1749-6632.1990.tb34299.x; BELANGER A, 1986, J CLIN ENDOCR METAB, V62, P812, DOI 10.1210/jcem-62-5-812; BELANGER G, 1995, MOL CELL ENDOCRINOL, V113, P165, DOI 10.1016/0303-7207(95)03627-J; BURCHELL B, 1994, HEPATOLOGY, V20, P1622, DOI 10.1002/hep.1840200636; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; CARMINA E, 1993, J CLIN ENDOCR METAB, V76, P1111, DOI 10.1210/jc.76.5.1111; CHEN F, 1993, BIOCHEMISTRY-US, V32, P10648, DOI 10.1021/bi00091a015; CLARKE DJ, 1994, HDB EXPT PHARM, V112, P3; COFFMAN BL, 1990, ARCH BIOCHEM BIOPHYS, V281, P170, DOI 10.1016/0003-9861(90)90428-2; Dutton G.F., 1980, GLUCURONIDATION DRUG; ELO JP, 1995, HORMONES CANC, P76; FISZERSZAFARZ B, 1981, ANAL BIOCHEM, V110, P165, DOI 10.1016/0003-2697(81)90130-5; GREEN MD, 1994, DRUG METAB DISPOS, V22, P799; Guillemette C, 1995, J STEROID BIOCHEM, V55, P355, DOI 10.1016/0960-0760(95)00183-2; Guillemette C, 1996, ENDOCRINOLOGY, V137, P2872, DOI 10.1210/en.137.7.2872; GUILLEMETTE C, 1995, MOL CELL ENDOCRINOL, V107, P131, DOI 10.1016/0303-7207(94)03434-U; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; JIN CJ, 1993, BIOCHEM BIOPH RES CO, V194, P496, DOI 10.1006/bbrc.1993.1847; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LOBO RA, 1987, J CLIN ENDOCR METAB, V65, P711, DOI 10.1210/jcem-65-4-711; LOOKINGBILL DP, 1988, J CLIN ENDOCR METAB, V67, P986, DOI 10.1210/jcem-67-5-986; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1986, J BIOL CHEM, V261, P14112; MONAGHAN G, 1994, GENOMICS, V23, P496, DOI 10.1006/geno.1994.1531; MULDER GJ, 1992, ANNU REV PHARMACOL, V32, P25; NEGRICESI P, 1994, J STEROID BIOCHEM, V51, P89, DOI 10.1016/0960-0760(94)90119-8; Prevost J, 1987, Gynecol Endocrinol, V1, P331, DOI 10.3109/09513598709082705; RAO PN, 1987, J STEROID BIOCHEM, V28, P565, DOI 10.1016/0022-4731(87)90516-4; RHEAUME E, 1991, NUCLEIC ACIDS RES, V19, P6060, DOI 10.1093/nar/19.21.6060; RITTER JK, 1992, BIOCHEMISTRY-US, V31, P3409, DOI 10.1021/bi00128a015; RITTER JK, 1990, J BIOL CHEM, V265, P7900; RITTMASTER RS, 1993, J CLIN ENDOCR METAB, V76, P977, DOI 10.1210/jc.76.4.977; ROSE JK, 1980, P NATL ACAD SCI-BIOL, V77, P3884, DOI 10.1073/pnas.77.7.3884; SAMBROOK J, 1982, MOL CLONING LAB MANU, pB14; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VIANI A, 1990, HUM EXP TOXICOL, V9, P65, DOI 10.1177/096032719000900201; VISSER TJ, 1993, FEBS LETT, V315, P65, DOI 10.1016/0014-5793(93)81134-L; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145	51	162	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22855	22862		10.1074/jbc.271.37.22855	http://dx.doi.org/10.1074/jbc.271.37.22855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798464	hybrid			2022-12-25	WOS:A1996VG67200083
J	Fanjul, AN; Delia, D; Pierotti, MA; Rideout, D; Qiu, J; Pfahl, M				Fanjul, AN; Delia, D; Pierotti, MA; Rideout, D; Qiu, J; Pfahl, M			4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ACID RECEPTORS; FENRETINIDE 4-HPR; N-(4-HYDROXYPHENYL)RETINAMIDE; APOPTOSIS; PROLIFERATION; AP-1; RAT; TRANSACTIVATION; SUPPRESSION	Retinoids have shown promise as anti cancer and cancer preventative agents. All-trans-N-(4-hydroxyphenyl)retinamide (4HPR) belongs to a new group of retinoids that not only inhibit the proliferation of cancer cells but also can induce apoptosis in certain cancer cells. Because of its increased efficacy against cancer cells and its low toxicity it has been entered into a number of clinical trials. However, its mechanism of action is not known, and it had been assumed that it is not a true retinoid. Here we analyze its ability to function as an activator of nuclear retinoid receptors (RARs and RXRs). We observe that, in transactivation assays, 4HPR is a potent transactivator with RAR gamma and a moderate activator with RAR beta but is not an activator with RAR alpha and RXR alpha. Furthermore, RAR gamma-selective transactivation by 4HPR is enhanced on some response elements and reduced on others when compared to natural retinoids. In contrast to transactivation, 4HPR in transrepression assays functions mostly with RAR alpha, RAR beta, and RXR alpha. Optimal receptor activation is seen at 4HPR concentrations at which it is a potent growth inhibitor and inducer of apoptosis. We conclude that 4HPR is a highly selective activator of retinoid receptors. We propose that this selective activation of the nuclear receptors is likely to be the basis for its specific biological activities and its favorable pharmaceutical properties.	SIDNEY KIMMEL CANC CTR, LA JOLLA, CA 92037 USA; IST NAZL STUDIO & CURA TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan			Pierotti, Marco Alessandro/AAC-4728-2022	Pierotti, Marco Alessandro/0000-0002-7431-8332				BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHIESA F, 1992, ORAL ONCOL, V28B, P97; DECENSI A, 1992, J CELL BIOCHEM, P139; DELIA D, 1993, CANCER RES, V53, P6036; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DEPALO G, 1995, J NATL CANCER I, V87, P146, DOI 10.1093/jnci/87.2.146; DILLEHAY DL, 1991, INT J IMMUNOPHARMACO, V13, P1043, DOI 10.1016/0192-0561(91)90060-K; DOWLATSHAHI K, 1989, CANCER LETT, V47, P187, DOI 10.1016/0304-3835(89)90089-X; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FANJUL AN, 1995, IN PRESS CANC RES; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; KALEMKERIAN G, 1995, P AM ASS CANC RES AA; Kelloff G J, 1994, J Cell Biochem Suppl, V20, P176; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM; MODIANO MR, 1990, INVEST NEW DRUG, V8, P317; MOON RC, 1992, ANTICANCER RES, V12, P1147; MORRISKAY G, 1992, RETINODS NORMAL DEV; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; PIENTA KJ, 1993, CANCER RES, V53, P224; POLLARD M, 1991, CANCER LETT, V59, P159, DOI 10.1016/0304-3835(91)90181-G; PONZONI M, 1995, CANCER RES, V55, P853; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROTMENSZ N, 1991, EUR J CANCER, V27, P1127, DOI 10.1016/0277-5379(91)90309-2; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SANI BP, 1993, RETINOIDS PROGR RES, P237; SCHAEFER H, 1990, NOUV DERMATOL, V9, P3; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAO ZM, 1995, ONCOGENE, V11, P493; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sporn M.B., 1994, RETINOIDS BIOL CHEM; TRADATI N, 1994, CANCER LETT, V76, P109, DOI 10.1016/0304-3835(94)90385-9; VILLA ML, 1993, BRIT J CANCER, V68, P845, DOI 10.1038/bjc.1993.443; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; WILLE JJ, 1986, P AM ASSOC CANC RES, V27, P146; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	49	185	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22441	22446		10.1074/jbc.271.37.22441	http://dx.doi.org/10.1074/jbc.271.37.22441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798408				2022-12-25	WOS:A1996VG67200027
J	Wiech, H; Geier, BM; Paschke, T; Spang, A; Grein, K; Steinkotter, J; Melkonian, M; Schiebel, E				Wiech, H; Geier, BM; Paschke, T; Spang, A; Grein, K; Steinkotter, J; Melkonian, M; Schiebel, E			Characterization of green alga, yeast, and human centrins - Specific subdomain features determine functional diversity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; CA-2+-MODULATED CONTRACTILE PROTEIN; SACCHAROMYCES-CEREVISIAE; CHLAMYDOMONAS-REINHARDTII; FLAGELLAR APPARATUS; MOLECULAR-CLONING; NMR-SPECTROSCOPY; GAMMA-TUBULIN; CALMODULIN; CALCIUM	Centrins are a subfamily within the superfamily of Ca2+-modulated proteins that play a fundamental role in centrosome duplication and contraction of centrin-based fiber systems. We examined the individual molecular properties of yeast, green alga, and human centrins. Circular dichroism spectroscopy revealed a divergent influence of Ca2+ binding on the cu-helical content of these proteins. Ca2+-free centrins were elongated in shape as determined by size exclusion chromatography. The presence of Ca2+ and binding peptide resulted in more spherical shaped centrins. In contrast to yeast calmodulin, centrins formed multimers in the Ca2+-bound state. This oligomerization was significantly reduced in the absence of Ca2+ and in the presence of binding peptide. The Ca2+-dependent polymerization of the green alga Scherffelia dubia centrin (SdCen) resulted in a filamentous network. This molecular property was mainly dependent on the amino-terminal subdomain and the peptide-binding site of SdCen. Finally, we analyzed whether SdCen and Cdc31p-SdCen hybrid proteins functionally substitute for the Saccharomyces cerevisiae centrin Cdc31p. Only hybrid proteins containing the amino-terminal subdomain or the third EF-hand of SdCen and the other subdomains from Cdc31p were functional in vivo.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; UNIV COLOGNE,INST BOT,D-50931 COLOGNE,GERMANY	Max Planck Society; University of Cologne			Spang, Anne/A-7029-2008; Spang, Anne/M-7223-2019	Spang, Anne/0000-0002-2387-6203; Spang, Anne/0000-0002-2387-6203				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BARON AT, 1988, J CELL BIOL, V107, P2669, DOI 10.1083/jcb.107.6.2669; BARON AT, 1995, METHOD CELL BIOL, V47, P341, DOI 10.1016/S0091-679X(08)60828-6; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BHATTACHARYA D, 1993, PLANT MOL BIOL, V23, P1243, DOI 10.1007/BF00042357; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BWARON AT, 1992, CENTROSOME, P167; Byers B, 1981, MOL BIOL YEAST SACCH, P59; BYERS B, 1981, A BENZON S, V16, P119; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P127; ERRABOLU R, 1994, J CELL SCI, V107, P9; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P297; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; LEE VD, 1990, CALCIUM INTRACELLULA, P245; MCFADDEN GI, 1987, J CELL BIOL, V105, P903, DOI 10.1083/jcb.105.2.903; Melkonian M., 1992, P179; MONERIEF ND, 1990, J MOL EVOL, V30, P522; MOSER MJ, 1995, J BIOL CHEM, V270, P20643, DOI 10.1074/jbc.270.35.20643; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SALISBURY JL, 1989, J PHYCOL, V25, P201; SALISBURY JL, 1983, J SUBMICR CYTOL PATH, V15, P105; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SALISBURY JL, 1987, J CELL BIOL, V105, P1799, DOI 10.1083/jcb.105.4.1799; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZE D, 1987, EUR J CELL BIOL, V45, P51; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; SPANG A, 1995, J CELL BIOL, V128, P868; SPANG A, 1996, IN PRESS J CELL SCI; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRAVE G, 1995, EMBO J, V14, P4922, DOI 10.1002/j.1460-2075.1995.tb00175.x; VALLEN EA, 1994, GENETICS, V137, P407; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WEBER C, 1994, J BIOL CHEM, V269, P15795; WRIGHT RL, 1985, J CELL BIOL, V101, P1903, DOI 10.1083/jcb.101.5.1903; ZHU JK, 1992, PLANT PHYSIOL, V99, P1734, DOI 10.1104/pp.99.4.1734	60	79	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22453	22461		10.1074/jbc.271.37.22453	http://dx.doi.org/10.1074/jbc.271.37.22453			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798410	hybrid			2022-12-25	WOS:A1996VG67200029
J	Renshaw, MW; Toksoz, D; Schwartz, MA				Renshaw, MW; Toksoz, D; Schwartz, MA			Involvement of the small GTPase Rho in integrin-mediated activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; CELL-ADHESION; CDC42 GTPASES; MAP KINASE; BINDING; GROWTH; RAC; PATHWAY	Engagement and clustering of integrins triggers a number of intracellular signaling events, including activation of the mitogen-activated protein (MAP) kinases Erk1 and Erk2. To investigate the mechanism by which integrins mediate the activation of MAP kinases upon binding of NIH 3T3 cells to fibronectin, we assessed the effects of both inhibiting and activating the small GTPase Rho. We observed that inhibition of Rho by the Rho-specific inhibitor C3 exoenzyme or by a dominant negative Rho A (RhoN19) inhibited MAP kinase activation. Conversely, activation of Rho by expression of an activated Rho A mutant (RhoQ63L), or the Rho-specific guanine nucleotide exchange factor Ibc, enhanced and partially mimicked activation of Erk2 by plating on fibronectin. These results therefore show that Rho is involved in the integrin-dependent activation of MAP kinase.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02115 USA	Scripps Research Institute; Tufts University				schwartz, martin/0000-0002-2071-1243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07695] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	32	128	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21691	21694		10.1074/jbc.271.36.21691	http://dx.doi.org/10.1074/jbc.271.36.21691			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702960	hybrid			2022-12-25	WOS:A1996VF61200002
J	Clarke, K; Kashiwaya, Y; King, MT; Gates, D; Keon, CA; Cross, HR; Radda, GK; Veech, RL				Clarke, K; Kashiwaya, Y; King, MT; Gates, D; Keon, CA; Cross, HR; Radda, GK; Veech, RL			The beta/alpha peak height ratio of ATP - A measure of free [Mg2+] using P-31 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE EQUILIBRIUM; INTRAVENOUS LOADING TEST; MAGNETIC-RESONANCE; INTRACELLULAR PH; MAGNESIUM-DEFICIENCY; HEART-DISEASE; FREE MG-2+; SPECTROSCOPY; LIVER; MGATP	From P-31 NMR measurements made in vitro at 38 degrees C, I = 0.25, pH 5.75-8.5, and calculated free [Mg2+] from 0 to 5 mm, we show that, within the physiological range of cytosolic free [Mg-2+] from 0.25 to 1.5 mM, the chemical shift difference between the alpha- and beta-ATP resonances, delta(alpha beta), changes by only 0.6 ppm. Consequently, we developed new formalisms from known acid and Mg2+ dissociation constants by which the observed chemical shift of P-i, delta(Pi), and the peak height ratio of the beta- and alpha-ATP resonances, (h) over bar(beta/alpha), could be related to free [Mg2+] by simultaneous solution of: [GRAPHICS] We found that (H) over bar(beta/alpha) changed 2.5-fold as free [Mg2+] varied from 0.25 to 1.5 mM, providing a more sensitive and accurate measure of free cytosolic [Mg2+]. In working rat heart perfused with glucose, free [Mg2+] was 1.0 +/- 0.1 from (h) over bar(beta/alpha) and 1.2 +/- 0.03 from measured [citrate]/ [isocitrate] but 0.51 +/- 0.1 from delta(alpha beta). Addition of ketone bodies to the perfusate decreased free [Mg2+] estimated from (h) over bar(beta/alpha) to 0.61 +/- 0.02 and 0.74 +/- 0.11 by [citrate]/ [isocitrate] but the estimate from delta(alpha beta) was unchanged at 0.46 +/- 0.04 mM. Such differences in estimated free [Mg2+] alter the apparent K-eq of the creatine kinase reaction and hence the estimated cytosolic free [Sigma ADP].	NIAAA, DEPT MEMBRANE BIOCHEM & BIOPHYS, ROCKVILLE, MD 20852 USA; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Oxford								ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; BAILEY IA, 1981, BIOCHEM J, V196, P171, DOI 10.1042/bj1960171; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BOCK JL, 1980, J INORG BIOCHEM, V12, P119, DOI 10.1016/S0162-0134(00)80123-3; BUNN HF, 1971, J BIOL CHEM, V246, P5273; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; COHEN SM, 1983, J BIOL CHEM, V258, P4294; COHN M, 1962, J BIOL CHEM, V237, P176; CORNELL NW, 1979, J BIOL CHEM, V254, P6522; DOBSON GP, 1992, NMR BIOMED, V5, P20, DOI 10.1002/nbm.1940050105; DOWD TL, 1993, J BIOL CHEM, V268, P991; GOLDBERG RN, 1991, BIOPHYS CHEM, V40, P241, DOI 10.1016/0301-4622(91)80024-L; GULLESTAD L, 1992, SCAND J CLIN LAB INV, V52, P245, DOI 10.3109/00365519209088355; GUPTA RK, 1983, BIOCHEM BIOPH RES CO, V117, P210, DOI 10.1016/0006-291X(83)91562-0; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1980, J BIOL CHEM, V255, P3987; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Hille B., IONIC CHANNELS EXCIT; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P1215, DOI 10.1073/pnas.93.3.1215; JONES JE, 1969, ANN NY ACAD SCI, V162, P934, DOI 10.1111/j.1749-6632.1969.tb13022.x; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KOST GJ, 1990, MAGN RESON MED, V14, P496, DOI 10.1002/mrm.1910140307; KWACK H, 1992, METABOLITE METABOLIS, P185; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LAWSON JWR, 1976, GLUCONEOGENESIS ITS, P481; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; LOPRESTI P, 1989, BIOCHIM BIOPHYS ACTA, V998, P317, DOI 10.1016/0167-4838(89)90291-4; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MCLEAN RM, 1994, AM J MED, V96, P63, DOI 10.1016/0002-9343(94)90117-1; MEEMA HE, 1987, KIDNEY INT, V32, P388, DOI 10.1038/ki.1987.222; MOON RB, 1973, J BIOL CHEM, V248, P7276; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; MURPHY E, 1993, MINER ELECTROL METAB, V19, P250; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P128; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; RASMUSSEN HS, 1988, ARCH INTERN MED, V148, P329, DOI 10.1001/archinte.148.2.329; ROBERTS JKM, 1981, BIOCHEMISTRY-US, V20, P5389, DOI 10.1021/bi00522a006; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSE IA, 1968, P NATL ACAD SCI USA, V61, P1079, DOI 10.1073/pnas.61.3.1079; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; SMITH RM, 1956, J AM CHEM SOC, V78, P2376, DOI 10.1021/ja01592a009; TEAGUE WE, 1992, J BIOL CHEM, V267, P14084; VEECH RL, 1994, ALCOHOL CLIN EXP RES, V18, P1040, DOI 10.1111/j.1530-0277.1994.tb00081.x; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WAGMAN DD, 1982, J PHSY CHEM REF D S2, V11, P73; Walser M, 1967, Ergeb Physiol, V59, P185; Weiss Matthias, 1994, Magnesium Research, V7, P135	51	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21142	21150		10.1074/jbc.271.35.21142	http://dx.doi.org/10.1074/jbc.271.35.21142			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702884	hybrid			2022-12-25	WOS:A1996VE47700030
J	Saxena, A; Robertson, JT; Ali, IU				Saxena, A; Robertson, JT; Ali, IU			Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas	ONCOGENE			English	Article						malignant astrocytomas; recurrent tumors; p16; p15; CDK4	EPIDERMAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; DEPENDENT KINASES; FACTOR RECEPTOR; HUMAN CANCERS; GLIAL TUMORS; CYCLIN-D; AMPLIFICATION; EXPRESSION; INHIBITORS	Abnormalities in the p16, p15 and CDK4 genes that regulate transition through the G1 phase of the cell cycle have been implicated in the malignant progression of astrocytomas. The results of the present study demonstrate that dysfunction of these genes also occurs during recurrence of glial tumors that were highly malignant at first presentation. Analysis of 10 matched pairs of high grade malignant astrocytomas and their subsequent recurrences identified three distinct groups. The primary and recurrent tumors in Group A did not show structural alterations in the p16, p15 or CDK4 genes, whereas homozygous codeletion of p16 and p15 was observed in both primary and recurrent tumors in Group B. The primary tumors in Group C had a normal profile of p16, p15 and CDK4 at presentation. Upon recurrence, however, the tumors sustained either deletion of p16 alone or codeletion of both p16 and p15 or amplification of CDK4. Analysis of the molecular differences between primary anaplastic astrocytomas/glioblastomas and their subsequent recurrences, which are clinically indistinguishable, may provide better therapeutic options for treatment.	NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; UNIV TENNESSEE,NINDS,NIH,SURG NEUROL BRANCH,MEMPHIS,TN 38119; UNIV TENNESSEE,DEPT NEUROSURG,MEMPHIS,TN 38119	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center								EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLEMING TP, 1992, CANCER RES, V52, P4550; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; GIANI C, 1994, CANCER RES, V54, P6338; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARBARTH P, 1988, DNA-J MOLEC CELL BIO, V7, P297, DOI 10.1089/dna.1988.7.297; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUKAS J, 1995, CANCER RES, V55, P4818; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; REED JA, 1995, CANCER RES, V55, P2713; SAXENA A, 1992, CANCER RES, V52, P6716; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0	32	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					661	664						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760309				2022-12-25	WOS:A1996VB32800025
J	Shimohigashi, Y; Hatano, R; Fujita, T; Nakashima, R; Nose, T; Sujaku, T; Saigo, A; Shinjo, K; Nagahisa, A				Shimohigashi, Y; Hatano, R; Fujita, T; Nakashima, R; Nose, T; Sujaku, T; Saigo, A; Shinjo, K; Nagahisa, A			Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIATE RECEPTOR; GENE FAMILY; DYNORPHIN; CLONING; MEMBER; LOCALIZATION; LIGANDS; DELTA	Nociceptin or orphanin FQ is a novel neuropeptide that activates an opioid-like G protein-coupled receptor ORL1. This heptadecapeptide FGGFTGARKSARKLANQ resembles kappa-opioid peptide dynorphin A but exhibits an opposite effect to make animals hyperreactive to nociceptive stimulations (Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., Mazarguil, H., Vassart, G., Parmentier, M., and Costentin, J. (1995) Nature 377, 532-535; Reinscheid, R.K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R.A., Bunzow, J.R., Grandy, D.K., Langen, H., Monsma, F.J., Jr., and Civelli, O. (1995) Science 270, 792-794). In the present study, it was found that guinea pig brain contains receptors to which nociceptin binds much more strongly than to ORL1 receptors expressed in human 293 cells. Although the Tyr(1) --> Phe substitution for dynorphin A eliminates almost completely an ability to bind to opioid receptors, the Phe(1) --> Tyr substitution in nociceptin was found to retain almost fully both receptor binding affinity and in vivo hyperalgesic activity in tail-flick assay. Nociceptin was extremely weak to bind to opioid receptors, while Tyr(1)-nociceptin exhibited 10-40 times increased affinity, especially for mu receptors, due to its N-terminal sequential identity to opioid peptides. Shortened analogs of dynorphin A are known to retain receptor binding ability and analgesic activity, whereas the removal of C-terminal hexa- or decapeptide from nociceptin totally abolished the affinity for the ORL1 receptor. These results indicated that the mode of interaction between nociceptin and ORL1 receptor is quite different from that between dynorphin and opioid receptor and that the C-terminal portion of nociceptin is crucial for receptor recognition.	PFIZER PHARMACEUT INC,CENT RES,AICHI 47023,JAPAN	Pfizer	Shimohigashi, Y (corresponding author), KYUSHU UNIV,BIOCHEM LAB,DEPT CHEM,FAC SCI,FUKUOKA 81281,JAPAN.			Nose, Takeru/0000-0001-9771-7267				CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; CORBETT AD, 1982, NATURE, V299, P79, DOI 10.1038/299079a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GOLDSTEIN A, 1981, P NATL ACAD SCI-BIOL, V78, P7219, DOI 10.1073/pnas.78.11.7219; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MOSBERG HI, 1987, MOL PHARMACOL, V31, P599; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; SHIMOHIGASHI Y, 1982, BIOCHEM BIOPH RES CO, V104, P583, DOI 10.1016/0006-291X(82)90677-5; Shimohigashi Y, 1986, NIDA Res Monogr, V69, P65; TACHIBANA S, 1982, NATURE, V295, P339, DOI 10.1038/295339a0; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WEBER E, 1982, NATURE, V299, P77, DOI 10.1038/299077a0; ZHANG SW, 1995, J BIOL CHEM, V270, P22772, DOI 10.1074/jbc.270.39.22772	16	66	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23642	23645		10.1074/jbc.271.39.23642	http://dx.doi.org/10.1074/jbc.271.39.23642			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798582	hybrid			2022-12-25	WOS:A1996VJ44200011
J	Worby, CA; Vega, QC; Zhao, Y; Chao, HHJ; Seasholtz, AF; Dixon, JE				Worby, CA; Vega, QC; Zhao, Y; Chao, HHJ; Seasholtz, AF; Dixon, JE			Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL ACTIVATION; TERMINAL PHOSPHORYLATION; TRANSFORMING GENE; REPORTER GENE; PROTOONCOGENE; MUTATIONS; DISEASE; NEURONS	Glial cell line-derived neurotrophic factor (GDNF), a member of the transforming growth factor-beta family of growth factors, was first identified by its ability to promote the survival of midbrain dopaminergic neurons in culture. We demonstrate that GDNF treatment of several neuroblastoma cell lines leads to dose-dependent tyrosine phosphorylation of the RET receptor and that other transforming growth factor-beta family members are not able to activate the RET receptor. GDNF treatment of neuroblastoma cells also results in increased transcription of an Elk luciferase reporter gene, suggesting that GDNF activates the mitogen-activated protein kinase signal transduction pathway.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					PHS HHS [18849] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LIN LFH, 1994, J NEUROCHEM, V63, P758; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; VEGA QC, 1996, IN PRESS P NATL ACAD; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	34	139	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23619	23622		10.1074/jbc.271.39.23619	http://dx.doi.org/10.1074/jbc.271.39.23619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798576	hybrid			2022-12-25	WOS:A1996VJ44200005
J	McGaughey, KM; Wheeler, LJ; Moore, JT; Maley, GF; Maley, F; Mathews, CK				McGaughey, KM; Wheeler, LJ; Moore, JT; Maley, GF; Maley, F; Mathews, CK			Protein-protein interactions involving T4 phage-coded deoxycytidylate deaminase and thymidylate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIOPHAGE-T4 PROTEINS; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; HYDROXYMETHYLASE; EXPRESSION; SEQUENCE; BINDING; GENE; COMPLEX	The enzymes deoxycytidylate deaminase (EC 3.5.4.12) and thymidylate synthase (EC 2.1.1.45) are functionally associated with one another, since they catalyze sequential reactions, In T4 coliphage infection the two enzymes are found in dNTP synthetase, a multienzyme complex for deoxyribonucleotide biosynthesis, Protein-protein interactions involving the phage-coded forms of these two enzymes have been explored in three experiments that use the respective purified protein as an affinity ligand. First, an extract of radiolabeled T4 proteins was passed through a column of immobilized enzyme (either dTMP synthase or dCMP deaminase), and the specifically bound proteins were identified, Second, two mutant form of dCMP deaminase (H90N and H94N), altered in presumed zinc-binding sites, were analyzed similarly, with the results suggesting that some, but not all, interactions require normal structure near the catalytic site, Third, affinity chromatography using either enzyme as the immobilized ligand, revealed interactions between the two purified enzymes in the absence of other proteins, In these experiments we noted a significant effect of dCTP, an allosteric modifier of dCMP deaminase, upon the interactions.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center	McGaughey, KM (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331, USA.				NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; FINERMOORE JS, 1994, BIOCHEMISTRY-US, V33, P15459, DOI 10.1021/bi00255a028; FLEMING WH, 1965, J BIOL CHEM, V242, P363; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; JI JP, 1991, MOL GEN GENET, V226, P257, DOI 10.1007/BF00273611; MALEY GF, 1982, BIOCHEMISTRY-US, V21, P3780, DOI 10.1021/bi00259a009; MALEY GF, 1988, J BIOL CHEM, V263, P7620; MALEY GF, 1967, J BIOL CHEM, V242, P3517; MALEY GF, 1990, J BIOL CHEM, V265, P47; MALEY GF, 1972, J BIOL CHEM, V247, P940; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; MOORE JT, 1993, J BIOL CHEM, V268, P2288; MOORE JT, 1994, BIOCHEMISTRY-US, V33, P2104, DOI 10.1021/bi00174a017; REIZER J, 1994, PROTEIN SCI, V3, P853; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; WHEELER L, 1992, J BIOL CHEM, V267, P7664; YOUNG JP, 1992, J BIOL CHEM, V267, P10786	26	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23037	23042		10.1074/jbc.271.38.23037	http://dx.doi.org/10.1074/jbc.271.38.23037			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798492	hybrid			2022-12-25	WOS:A1996VH76800018
J	Lewis, AL; Guicherit, OM; Datta, SK; Hanten, GR; Kellems, RE				Lewis, AL; Guicherit, OM; Datta, SK; Hanten, GR; Kellems, RE			Structure and expression of the murine muscle adenylosuccinate synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MOLECULAR-CLONING; BETA-ENOLASE; MOUSE; TRANSCRIPTION; MYOGENESIS; ELEMENTS; PROMOTER; CELLS; DEAMINASE	A muscle-specific isoform of adenylosuccinate synthetase (AdSS1, EC 6.3.4.4) is one of three enzymes that constitute the purine nucleotide cycle, a muscle-specific metabolic cycle. Previously, we showed that the muscle Adss1 gene was highly expressed in both skeletal muscle and heart of the adult mouse. Here we have shown that the Adss1 gene is initially activated early in embryonic development in skeletal muscle and heart precursors and is subsequently up regulated perinatally. The earliest detectable gene expression corresponds with the establishment of the first myogenic and cardiac lineages. To allow identification of the genetic signals controlling this developmental pattern of expression, the Adss1 gene was cloned and its structure determined. Transgenic analysis has shown that 1.9 kilobase pairs of 5' flank can activate expression in skeletal muscle progenitors and direct enhanced expression to adult cardiac muscle. Sequence analysis of the promoter and 5' flanking region revealed the presence of numerous potential muscle-specific cis-regulatory elements.	BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042436] Funding Source: NIH RePORTER; NICHD NIH HHS [2 P30 HD24064] Funding Source: Medline; NIGMS NIH HHS [GM42436] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BUCKINGHAM ME, 1992, CIBA F SYMP, V165, P111; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; GILBERT SF, 1988, DEV BIOL, P214; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; JAVEHERY R, 1994, MOL CELL BIOL, V14, P116; JOH K, 1990, PROG CLIN BIOL RES, V344, P53; KELLER A, 1992, MECH DEVELOP, V38, P41, DOI 10.1016/0925-4773(92)90037-K; LI SSL, 1990, PROG CLIN BIOL RES, V344, P75; LI ZL, 1993, J BIOL CHEM, V268, P10403; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOWENSTEIN JM, 1990, INT J SPORTS MED, V11, pS36; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NAKAZAWA A, 1990, PROG CLIN BIOL RES, V344, P495; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORDAHL C, 1992, CURR TOP DEV BIOL, V26, P146; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; Sambrook J., 2002, MOL CLONING LAB MANU; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SCHWEIGHOFFER F, 1986, J BIOL CHEM, V261, P271; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; VANDENBERGHE G, 1992, PROG NEUROBIOL, V39, P547, DOI 10.1016/0301-0082(92)90006-Z; WASSARMAN PM, 1993, GUIDE TECHNIQUES MOU, P434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P1; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	43	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22647	22656		10.1074/jbc.271.37.22647	http://dx.doi.org/10.1074/jbc.271.37.22647			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798436	hybrid			2022-12-25	WOS:A1996VG67200055
J	Mimnaugh, EG; Chavany, C; Neckers, L				Mimnaugh, EG; Chavany, C; Neckers, L			Polyubiquitination and proteasomal degradation of the p185(c-erbB-2) receptor protein-tyrosine kinase induced by geldanamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT P185; HERBIMYCIN-A; BENZOQUINOID ANSAMYCINS; HETEROPROTEIN COMPLEX; STRESS PROTEINS; UBIQUITIN; PATHWAY; INHIBITION; TRANSFORMATION; AMPLIFICATION	Treatment of SKBr3 human breast carcinoma cells with the benzoquinoid ansamycin, geldanamycin, rapidly depletes p185(c-erbB-2) protein-tyrosine kinase. Loss of p185(c-erbB-2) is initiated by disruption of a heteromeric complex between p185(c-erbB-2) and the 94-kDa glucose-regulated protein, GRP94, to which geldanamycin binds avidly. Here we report that within minutes of exposure to geldanamycin, mature p185(c-erb-2) becomes polyubiquitinated. Treatment of cells with the specific proteasome proteolytic inhibitor, lactacystin, blocked geldanamycin-induced degradation of p185(c-erbB-2) and enhanced the accumulation of polyubiquitinated p185(c-erbB-2). Following geldanamycin and lactacystin treatment, a higher molecular weight form of p185(c-erbB-2), which likely represents ubiquitin-p185(c-erbB-2) conjugates, was detected by anti-p185(c-erbB-2) immunoblotting. Nascent p185(c-erbB-2) synthesized in the presence of geldanamycin is incompletely glycosylated and remains sequestered in the endoplasmic reticulum. While this immature form of the protein is not ubiquitinated in the presence of geldanamycin, its marked, drug-induced instability is nonetheless antagonized by lactacystin. Thus, the rapid depletion of mature p185(c-erbB-2) caused by geldanamycin and the marked, drug-stimulated decrease in half-life of the newly synthesized protein are both mediated by the proteasome, although only the former phenomenon involves polyubiquitination.			Mimnaugh, EG (corresponding author), NCI,CLIN PHARMACOL BRANCH,NIH,BLDG 10,ROOM 12N226,BETHESDA,MD 20892, USA.							BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Chavany C, 1996, J BIOL CHEM, V271, P4974; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1984, J CELL BIOCHEM, V24, P137; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER P, 1994, CANCER RES, V54, P2724; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORI S, 1993, J BIOL CHEM, V268, P577; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	32	397	407	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22796	22801		10.1074/jbc.271.37.22796	http://dx.doi.org/10.1074/jbc.271.37.22796			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798456	hybrid			2022-12-25	WOS:A1996VG67200075
J	Viguera, E; Hernandez, P; Krimer, DB; Boistov, AS; Lurz, R; Alonso, JC; Schvartzman, JB				Viguera, E; Hernandez, P; Krimer, DB; Boistov, AS; Lurz, R; Alonso, JC; Schvartzman, JB			The ColE1 unidirectional origin acts as a polar replication fork pausing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; SV40 DNA-REPLICATION; INTERTWINED CATENATED DIMERS; AGAROSE-GEL ELECTROPHORESIS; PAPILLOMAVIRUS TYPE-1 DNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PLASMID REPLICATION; POTENTIAL ORIGINS; BACILLUS-SUBTILIS	Co-orientation of replication origins is the most common organization found in nature for multimeric plasmids, Streptococcus pyogenes broad-host-range plasmid pSM19035 and Escherichia coli pPI21 are among the exceptions. pPI21, which is a derivative of pSM19035 and pBR322, has two long inverted repeats, each one containing a potentially active ColE1 unidirectional origin. Analysis of pPI21 replication intermediates (RIs) by two-dimensional agarose gel electrophoresis and electron microscopy revealed the accumulation of a specific RI containing a single internal bubble. The data obtained demonstrated that initiation of DNA replication occurred at a single origin in pPI21. Progression of the replicating fork initiated at either of the two potential origins was transiently stalled at the other inversely oriented silent ColE1 origin of the plasmid, The accumulated RIs, containing an internal bubble, occurred as a series of stereoisomers with different numbers of knots in their replicated portion. These observations provide one of the first functional explanations for the disadvantage of head-to-head plasmid multimers with respect to head-to-tail ones.	CSIC, CTR INVEST BIOL, DEPT BIOL CELULAR & DESARROLLO, E-28006 MADRID, SPAIN; ST PETERSBURG STATE TECH UNIV, DEPT BIOPHYS, ST PETERSBURG, RUSSIA; MAX PLANCK INST MOL GENET, D-1000 BERLIN, GERMANY; CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Peter the Great St. Petersburg Polytechnic University; Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Krimer, Dora/J-9176-2014; Alonso, Juan Carlos/D-2595-2009; Mínguez, Enrique Viguera/H-4416-2015; Schvartzman, Jorge B/J-9171-2014	Krimer, Dora/0000-0001-9972-3994; Alonso, Juan Carlos/0000-0002-5178-7179; Mínguez, Enrique Viguera/0000-0001-5475-3807; Pablo, Hernandez/0000-0002-8113-1277				ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BAUER WR, 1980, SCI AM, V243, P118; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CEGLOWSKI P, 1994, GENE, V145, P33, DOI 10.1016/0378-1119(94)90319-0; CEGLOWSKI P, 1993, FEMS MICROBIOL LETT, V109, P145, DOI 10.1016/0378-1097(93)90011-P; CHERNY DI, 1993, J MOL BIOL, V230, P379, DOI 10.1006/jmbi.1993.1154; COLLINS J, 1980, COLD SPRING HARB SYM, V45, P409, DOI 10.1101/SQB.1981.045.01.055; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DEAN FB, 1985, J BIOL CHEM, V260, P4975; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; DROGE P, 1992, METHOD ENZYMOL, V212, P120; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; KUBOTA Y, 1993, GENE, V126, P9; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1995, MOL CELL BIOL, V15, P2893; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; LOPEZESTRANO C, 1996, CHROMOSOMES TODAY, V12, P149; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIZUUCHI K, 1982, J MOL BIOL, V156, P229, DOI 10.1016/0022-2836(82)90325-4; NAKASU S, 1992, P NATL ACAD SCI USA, V89, P10139, DOI 10.1073/pnas.89.21.10139; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; RAO BS, 1994, GENE, V140, P3233; SCHVARTZMAN JB, 1993, NUCLEIC ACIDS RES, V21, P5474, DOI 10.1093/nar/21.23.5474; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; SEUFERT W, 1988, J BIOL CHEM, V263, P2719; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WALDECK W, 1984, EMBO J, V3, P2173, DOI 10.1002/j.1460-2075.1984.tb02109.x; WALMSLEY RM, 1984, MOL GEN GENET, V195, P260, DOI 10.1007/BF00332757; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; WHITE JH, 1987, J MOL BIOL, V197, P585, DOI 10.1016/0022-2836(87)90566-3; WHITE JH, 1984, P NATL ACAD SCI-BIOL, V81, P3322, DOI 10.1073/pnas.81.11.3322; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038	61	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22414	22421		10.1074/jbc.271.37.22414	http://dx.doi.org/10.1074/jbc.271.37.22414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798404	Green Published			2022-12-25	WOS:A1996VG67200023
J	Cavenagh, MM; Whitney, JA; Carroll, K; Zhang, CJ; Boman, AL; Rosenwald, AG; Mellman, I; Kahn, RA				Cavenagh, MM; Whitney, JA; Carroll, K; Zhang, CJ; Boman, AL; Rosenwald, AG; Mellman, I; Kahn, RA			Intracellular distribution of Arf proteins in mammalian cells - Arf6 is uniquely localized to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; GOLGI MEMBRANES; BREFELDIN-A; ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDE; SACCHAROMYCES-CEREVISIAE; COAT PROTEINS; CHOLERA-TOXIN; BETA-COP	Subcellular distributions of the five human Arf proteins were examined, using a set of isoform-specific polyclonal and a pan-Arf monoclonal antibodies. Subcellular fractionation of cultured mammalian cells allowed the demonstration that Arf6 is uniquely localized to the plasma membranes of Chinese hamster ovary cells, The plasma membrane distrubution was unaffected by either GTP gamma S (guanosine 5'-O-(3-thio)triphosphate) or brefeldin A, an activator and inhibitor of Arf activities, respectively. In contrast, Arf proteins 1, 3, 4, and 5 were predominantly cytosolic but could be recruited to a variety of intracellular membranes, but not plasma membranes, upon incubation in the presence of GTP gamma S. The GTP gamma S-promoted binding of the cytosolic Arf proteins to membranes was blocked by brefeldin A. The stable association of Arf6 with plasma membranes and the insensitivity of its localization to either GTP gamma S or brefeldin A revealed a clear distinction between Arf6 and the other Arf isoforms. Localization of Arf6 to the plasma membrane suggests a unique cellular role for this isoform at the plasma membrane, but failure to find endogenous Arf6 on endocytic structures, including clathrin-coated vesicles, appears inconsistent with the proposed role of Arf6 in assembly of coat structures or endosomes in transfected fibroblasts (1, 2).	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Emory University; Yale University			Kahn, Richard/ABD-2666-2020; Mellman, Ira/ABG-5896-2020	Kahn, Richard/0000-0002-0259-0601; 				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Harlow E., 1988, ANTIBODIES LAB MANUA; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9556; RANDAZZO PA, 1994, METHOD ENZYMOL, V250, P394; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1993, J BIOL CHEM, V268, P10820; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITNEY JA, 1995, CELL, V83, P703; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	57	200	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21767	21774		10.1074/jbc.271.36.21767	http://dx.doi.org/10.1074/jbc.271.36.21767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702973	hybrid			2022-12-25	WOS:A1996VF61200015
J	Benito, A; Feliu, JX; Villaverde, A				Benito, A; Feliu, JX; Villaverde, A			beta-galactosidase enzymatic activity as a molecular probe to detect specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE VIRUS; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ALKALINE-PHOSPHATASE; MALATE-DEHYDROGENASE; FUSION PROTEINS; ANTIGENIC SITE; VIRAL PEPTIDE; LACZ-GENE	The main antigenic region of foot-and-mouth disease virus serotype C-1, also called site A, has been inserted in zones of the beta-galactosidase important for the stabilization of the active site, causing important changes in the K-m and the specific activity of the resulting enzymes. The peptide is displayed at the surface of the recombinant proteins and, in all the cases, presents a good antigenicity. Among the recombinant proteins constructed, in proteins M278VP1 and M275SVP1 the peptide is inserted in a large loop of the beta-galactosidase (amino acids 272-288) involved in the formation of the activating interface. In these constructs, the binding of the specific antibodies directed to the foreign peptide causes an increase of the beta-galactosidase activity up to about 200%. This phenomenon has been proved using monoclonal antibodies and also using polyclonal sera generated against the peptide. Different hypothesis of the mechanism of modulation upon antibody binding are discussed. This insertion site seems to be sensitive enough to enzymatic modulation mediated by antibody binding. We propose further exploring this insertion site as a tool for a rapid detection of specific antibodies in a quick and simple homogeneous assay based on the colorimetric determination of beta-galactosidase activity.	UNIV AUTONOMA BARCELONA,INST BIOL FONAMENTAL,BELLATERRA 08193,BARCELONA,SPAIN; UNIV AUTONOMA BARCELONA,DEPT GENET & MICROBIOL,BELLATERRA 08193,BARCELONA,SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona			Villaverde, Antonio/N-3986-2018; Benito, Antoni/D-8537-2011; Wood, David W/B-2992-2012	Villaverde, Antonio/0000-0002-2615-4521; Benito, Antoni/0000-0002-9776-1003; 				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; BENITO A, 1993, J BIOTECHNOL, V29, P299, DOI 10.1016/0168-1656(93)90061-Q; BENITO A, 1994, FEMS MICROBIOL LETT, V123, P107, DOI 10.1016/0378-1097(94)90281-X; BENITO A, 1993, ENZYME MICROB TECH, V15, P66, DOI 10.1016/0141-0229(93)90118-L; BENITO A, 1995, BIO-TECHNOL, V13, P801, DOI 10.1038/nbt0895-801; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; BRENNAN C, 1994, PROTEIN ENG, V7, P509, DOI 10.1093/protein/7.4.509; BRENNAN CA, 1995, P NATL ACAD SCI USA, V92, P5783, DOI 10.1073/pnas.92.13.5783; BREUL A, 1991, EUR J BIOCHEM, V195, P191, DOI 10.1111/j.1432-1033.1991.tb15694.x; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CELADA F, 1972, Q REV BIOPHYS, V5, P395, DOI 10.1017/S0033583500000998; FELIU JX, 1994, BIOTECHNOL TECH, V8, P509, DOI 10.1007/BF00222845; HENDERSON DR, 1986, CLIN CHEM, V32, P1637; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KHANA P, 1991, PRINCIPLES PRACTICE, P326; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; MATEU MG, 1992, EUR J IMMUNOL, V22, P1385, DOI 10.1002/eji.1830220609; MATEU MG, 1990, J GEN VIROL, V71, P629, DOI 10.1099/0022-1317-71-3-629; MATEU MG, 1989, P NATL ACAD SCI USA, V86, P5883, DOI 10.1073/pnas.86.15.5883; Miller JH., 1972, EXPT MOL GENETICS; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; PFAFF E, 1982, EMBO J, V1, P869, DOI 10.1002/j.1460-2075.1982.tb01262.x; ROWLEY GL, 1975, J BIOL CHEM, V250, P3759; ROWLEY GL, 1976, 172 AM CHEM SOC M; RUBENSTEIN KE, 1972, BIOCHEM BIOPH RES CO, V47, P846, DOI 10.1016/0006-291X(72)90570-0; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; STROHMAIER K, 1982, J GEN VIROL, V59, P295, DOI 10.1099/0022-1317-59-2-295; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; ULLMAN EF, 1979, BIOCHIM BIOPHYS ACTA, V567, P66, DOI 10.1016/0005-2744(79)90173-6; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; VILLANUEVA N, 1983, GENE, V23, P185, DOI 10.1016/0378-1119(83)90050-1; Wallenfels K., 1972, ENZYMES, V7, P617; ZABALLOS A, 1987, GENE, V58, P67, DOI 10.1016/0378-1119(87)90030-8	38	46	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21251	21256		10.1074/jbc.271.35.21251	http://dx.doi.org/10.1074/jbc.271.35.21251			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702899	hybrid			2022-12-25	WOS:A1996VE47700045
J	Hajjar, KA; Guevara, CA; Lev, E; Dowling, K; Chacko, J				Hajjar, KA; Guevara, CA; Lev, E; Dowling, K; Chacko, J			Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface - Essential role of endonexin repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; DEPENDENT CA-2+ BINDING; ANTICOAGULANT PROTEIN-I; GROWTH-FACTOR-I; SECRETORY PATHWAY; GLYCOSYL-PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE EXPOSURE; PHOSPHOLIPID BINDING; MEMBRANE-BINDING; SIGNAL SEQUENCE	Endothelial cells express a cell surface co-receptor for plasminogen and tissue plasminogen activator (t-PA) which we recently identified as annexin II (Hajjar, K. A., Jacovina, A. T., and Chacko, J. (1994) J. Biol. Chem., 269, 21191-21197). This protein enhances the catalytic efficiency of t-PA-dependent plasmin generation by 60-fold (Cesarman, G. M., Guevara, C. A., and Hajjar, K. A, (1994) J. Biol. Chem. 269, 21198-21203). Here, we demonstrate that annexin II is constitutively translocated to the endothelial cell surface within 16 h of biosynthesis, and that cell surface annexin II comprises 4.3 +/- 1.0% of the total cellular pool. Exogenous I-125-annexin II bound to EGTA-washed endothelial cells with high affinity (K-d 49 nM) and in a calcium-dependent (I-50 = 3 mu M), phospholipid-sensitive manner. Peptides KASMKGLGTDED and YDSMKGKGTRDK, mimicking the calcium-binding ''endonexin'' motif (KGXGT) of annexin II, blocked its interaction with endothelial cells. Recombinant annexin II, bearing the calcium-binding site substitution D161A of core repeat 2, failed to compete with binding of the wild type protein to the cell surface, while E246A and D321A mutants, corresponding to core repeats 3 and 4, behaved as effective competitors. These data suggest that translocated annexin II interacts with cell surface phospholipid via a high affinity calcium-dependent binding site that includes residues 118-122 (KGLGT) and the coordinating Asp(161) of core repeat 2. Thus, calcium-regulated expression of annexin II on the endothelial cell surface may play a central role in control of plasmin-mediated processes.	CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021	Cornell University	Hajjar, KA (corresponding author), CORNELL UNIV,COLL MED,DEPT PEDIAT,DIV HEMATOL ONCOL,1300 YORK AVE,BOX 45,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL 46403, HL 42493] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042493, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GERKE V, 1992, ANNEXINS, P47; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GOULET F, 1992, BIOCHEM BIOPH RES CO, V188, P554, DOI 10.1016/0006-291X(92)91091-4; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HAJJAR KA, 1995, THROMB HAEMOSTASIS, V74, P294; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUNTER KW, 1986, METHOD ENZYMOL, V121, P541; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOST M, 1992, EUR J BIOCHEM, V207, P923, DOI 10.1111/j.1432-1033.1992.tb17125.x; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAND A, 1991, AM J PATHOL, V139, P629; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MA ASP, 1994, J CELL SCI, V107, P1973; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RAO LVM, 1992, THROMB RES, V67, P517, DOI 10.1016/0049-3848(92)90013-Z; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SMITH PD, 1994, TRENDS GENET, V10, P241, DOI 10.1016/0168-9525(94)90171-6; SORIC J, 1985, SCIENCE, V230, P563, DOI 10.1126/science.2996139; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; VANHEERDE WL, 1994, BIOCHEM J, V302, P305, DOI 10.1042/bj3020305; WENG XW, 1993, PROTEIN SCI, V2, P448; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	54	105	109	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21652	21659		10.1074/jbc.271.35.21652	http://dx.doi.org/10.1074/jbc.271.35.21652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702954	hybrid			2022-12-25	WOS:A1996VE47700100
J	Izard, JW; Rusch, SL; Kendall, DA				Izard, JW; Rusch, SL; Kendall, DA			The amino-terminal charge and core region hydrophobicity interdependently contribute to the function of signal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INNER MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; PEPTIDE HYDROPHOBICITY; POSITIVE CHARGE; SECA; TRANSPORT; RESIDUES; CLEAVAGE; EXPORT	We have constructed a series of signal sequence mutants that contain negatively charged amino termini and simplified core regions of varying hydrophobicity levels. This series provides a means of exploring the relative roles of the amino terminus and the hydrophobic core region during transport. The signal peptides with highly hydrophobic core regions support a rapid rate of transport in the presence of a negatively charged amino terminus. We have found that these negatively charged mutants are secreted in a manner similar to the wild-type signal sequence; sodium azide and carbonyl cyanide 3-chlorophenylhydrazone treatments indicate that the negatively charged mutants depend on SecA and the protonmotive force, respectively. These same mutants also demonstrate reduced competition with co-expressed beta-lactamase, reflecting the lower overall affinity for the transport pathway due to the net negative charge at the amino terminus. In addition, the pronounced effects of introducing three negative charges support the conclusion that the two regions function in a concerted manner.	UNIV CONNECTICUT,DEPT MOL & CELL BIOL,STORRS,CT 06269	University of Connecticut					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; AUSTEN BM, 1979, FEBS LETT, V103, P308, DOI 10.1016/0014-5793(79)81351-4; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHEN M, 1994, J BACTERIOL, V176, P5796, DOI 10.1128/JB.176.18.5796-5801.1994; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; ERNST F, 1994, J BIOL CHEM, V269, P12840; GELLER BL, 1991, MOL MICROBIOL, V5, P2093, DOI 10.1111/j.1365-2958.1991.tb02138.x; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HIKITA C, 1992, J BIOL CHEM, V267, P12375; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; IZARD JW, 1995, BIOCHEMISTRY-US, V34, P9904, DOI 10.1021/bi00031a012; Keller RCA, 1996, BIOCHEMISTRY-US, V35, P3063, DOI 10.1021/bi951870+; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; Miller J.H., 1972, EXPT MOL GENETICS; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7	29	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21579	21582		10.1074/jbc.271.35.21579	http://dx.doi.org/10.1074/jbc.271.35.21579			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702945	hybrid			2022-12-25	WOS:A1996VE47700091
J	Sukhan, A; Hancock, REW				Sukhan, A; Hancock, REW			The role of specific lysine residues in the passage of anions through the Pseudomonas aeruginosa porin OprP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-12 OUTER-MEMBRANE; ESCHERICHIA-COLI; PROTEIN-P; MUTAGENESIS; MALTOPORIN; CHANNELS; PHOE; RESOLUTION; DOMAINS; SITE	When grown under phosphate-limiting conditions Pseudomonas aeruginosa expresses the phosphate-specific porin OprP. In order to determine whether any of the lysine residues located in the amino-terminal half of the protein play a role in the transport of anions through the channels, the first nine amino-terminal lysine residues of OprP were substituted with glutamates. The mutant proteins were purified and the channels they formed were characterized by reconstituting the purified porins in planar lipid membranes. In comparison to the wild-type protein, the Lys(74), Lys(121), and Lys(126) mutants all displayed reduced levels of conductance at KCl concentrations below 1 M, and the Lys(74) and Lys(121) mutants no longer exhibited a saturation of conductance at high anion concentrations. In addition, the ability of phosphate ions to inhibit the conductance of Cl- ions through the channels formed by the Lys(121) mutant was greatly reduced, while their ability to inhibit the Cl- conductance of the Lys(74) mutant was reduced by approximately a fold. To clarify the roles that Lys(74), Lys(121), and Lys(126) play in regulating the channel characteristics of OprP, these amino acids were replaced with either glycine or glutamine residues. Analysis of these mutants suggested that both Lys(74) and Lys(126) may serve to funnel anions toward the binding site, but only the presence of Lys(121) is required for the formation of the inorganic phosphate-specific binding site of OprP.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia			Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				BAUER K, 1989, J BIOL CHEM, V264, P16393; BENZ R, 1983, BIOCHIM BIOPHYS ACTA, V730, P387, DOI 10.1016/0005-2736(83)90356-5; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DARGENT B, 1988, J MOL BIOL, V201, P497, DOI 10.1016/0022-2836(88)90632-8; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; HANCOCK REW, 1982, J BACTERIOL, V150, P730, DOI 10.1128/JB.150.2.730-738.1982; HANCOCK REW, 1986, BIOCHIM BIOPHYS ACTA, V860, P699, DOI 10.1016/0005-2736(86)90569-9; HANCOCK REW, 1983, BIOCHIM BIOPHYS ACTA, V735, P137, DOI 10.1016/0005-2736(83)90269-9; HEINE HG, 1988, J BACTERIOL, V170, P1730, DOI 10.1128/jb.170.4.1730-1738.1988; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SUKHAN A, 1995, J BACTERIOL, V177, P4914, DOI 10.1128/jb.177.17.4914-4920.1995; TOMMASSEN J, 1985, EMBO J, V4, P1583, DOI 10.1002/j.1460-2075.1985.tb03820.x; TOMMASSEN J, 1984, MOL GEN GENET, V197, P503, DOI 10.1007/BF00329950; VANDERLEY P, 1985, EUR J BIOCHEM, V147, P401; WANNER BL, 1980, GENETICS, V96, P353; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; YOUNG M, 1992, ANTIMICROB AGENTS CH, V36, P2365, DOI 10.1128/AAC.36.11.2365	21	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21239	21242		10.1074/jbc.271.35.21239	http://dx.doi.org/10.1074/jbc.271.35.21239			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702897	hybrid			2022-12-25	WOS:A1996VE47700043
J	Voorberg, J; vanStempvoort, G; Bos, JMK; Mertens, K; vanMourik, JA; Donath, MJSH				Voorberg, J; vanStempvoort, G; Bos, JMK; Mertens, K; vanMourik, JA; Donath, MJSH			Enhanced thrombin sensitivity of a factor VIII heparin cofactor II hybrid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; SUBUNIT STRUCTURE; ALPHA-THROMBIN; PROTEIN-C; FACTOR XA; INHIBITION; RECEPTOR; HIRUDIN; ACTIVATION; BINDING	Generation of thrombin at a site of vascular injury is a key event in the arrest of bleeding, In addition to the conversion of fibrinogen into the insoluble fibrin, thrombin can initiate a number of positive and negative feedback mechanisms that either sustain or down-regulate clot formation. We have modulated the thrombin sensitivity of human blood coagulation factor VIII, an essential cofactor in the intrinsic pathway of blood coagulation, We have substituted an acidic region of factor VIII corresponding to amino acid sequence Asp(712)-Ala(736) by amino acid sequence Ile(51)-Leu(80) of the thrombin inhibitor heparin cofactor II. Functional analysis of the resulting factor VIII-heparin cofactor II hybrid, termed des-(868-1562)-factor VIII-HCII, revealed an increase in procoagulant activity as measured in a one-stage clotting assay. Incubation of purified des-(868-1562)-factor VIII-HCII with different amounts of thrombin showed that this protein was more readily activated by thrombin when compared with des-(868-1562)-factor VIII, a control protein lacking amino acid sequence Ile(51)-Leu(80) of heparin cofactor II. This was manifested by an increase in the second order rate constant of activation by thrombin for des-(868-1562) factor VIII-HCII (12.0 +/- 0.48 x 10(6) M(-1) s(-1)) compared with des-(868-1562)-factor VIII (1.77 +/- 0.21 x 10(6) M(-1) s(-1)). Our data suggest that amino acid sequence Ile(51)-Leu(80) of heparin cofactor II endows factor VIII with increased sensitivity towards thrombin which results in accelerated clot formation.			Voorberg, J (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,PLESMANLAAN 125,NL-1066 CX AMSTERDAM,NETHERLANDS.			Voorberg, Jan/0000-0003-4585-2621				BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; Davie EW, 1991, BIOCHEMISTRY-US, V30, P10364; DONATH MJS, 1995, THESIS U AMSTERDAM; DONATH MJSH, 1995, BIOCHEM J, V312, P49, DOI 10.1042/bj3120049; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FAY PJ, 1991, J BIOL CHEM, V266, P8957; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HORTIN GL, 1990, BIOCHEM BIOPH RES CO, V169, P437, DOI 10.1016/0006-291X(90)90350-V; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KANE WH, 1988, BLOOD, V71, P539; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LIU LW, 1991, J BIOL CHEM, V266, P16977; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MERTENS K, 1993, BRIT J HAEMATOL, V85, P133, DOI 10.1111/j.1365-2141.1993.tb08656.x; NEUENSCHWANDER P, 1990, ANAL BIOCHEM, V184, P347, DOI 10.1016/0003-2697(90)90692-3; PITMANN DD, 1988, P NATL ACAD SCI USA, V85, P2429; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SKRZYPCZAKJANKUN E, 1989, J MOL BIOL, V206, P755, DOI 10.1016/0022-2836(89)90582-2; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	30	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20985	20988		10.1074/jbc.271.35.20985	http://dx.doi.org/10.1074/jbc.271.35.20985			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702860	hybrid			2022-12-25	WOS:A1996VE47700004
J	Wolf, A; Lee, KC; Kirsch, JF; Ames, GFL				Wolf, A; Lee, KC; Kirsch, JF; Ames, GFL			Ligand-dependent conformational plasticity of the periplasmic histidine-binding protein HisJ - Involvement in transport specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; MALTOSE-BINDING; RHODOBACTER-CAPSULATUS; MEMBRANE-COMPONENTS; GLUTAMATE RECEPTORS; CRYSTAL-STRUCTURE; ARGININE-BINDING	The periplasmic histidine permease of Salmonella typhimurium is composed of a membrane-bound complex and a soluble histidine-binding protein (the periplasmic receptor), HisJ. Liganded receptor interacts with the membrane-bound complex, inducing ATP hydrolysis and substrate translocation. Preliminary evidence had shown a lack of direct correlation between the affinity of HisJ for a ligand and translocation efficiency, suggesting that the precise form of the receptor is important in determining its interaction with the membrane-bound complex. We have investigated the nature of the conformations assumed by HisJ upon binding a variety of ligands by tryptophan fluorescence enhancement, reaction with a closed form-specific monoclonal antibody, and changes in UV absorption spectra. It is demonstrated that although HisJ binds all the ligands and undergoes a conformational change, it assumes measurably different conformations. We also show that the interaction between HisJ and the membrane-bound complex depends on the nature of the ligand. Transport specificity appears to be defined, at least in part, by the conformation of the bound receptor, manifested either by the effect of a given ligand on the closed structure per se, or by the effect of ligand association on the equilibrium constant relating the open and the closed liganded forms.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIDDK NIH HHS [DK12121] Funding Source: Medline; NIGMS NIH HHS [GM35393] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035393] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1952, J AM CHEM SOC, V74, P252; AMES GFL, 1972, J BIOL CHEM, V247, P4309; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1977, J BACTERIOL, V129, P1289, DOI 10.1128/JB.129.3.1289-1297.1977; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DUNTEN P, 1995, PROTEIN SCI, V4, P2327, DOI 10.1002/pro.5560041110; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FLOCCO MM, 1995, PROTEIN SCI, V4, P2118, DOI 10.1002/pro.5560041017; FRIGUET B, 1990, IMMUNOCHEMICAL ANAL, P287; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; KANG CH, 1991, J BIOL CHEM, V266, P23893; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LEVER JE, 1972, ANAL BIOCHEM, V50, P73, DOI 10.1016/0003-2697(72)90487-3; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MARTINEAU P, 1990, J MOL BIOL, V214, P337, DOI 10.1016/0022-2836(90)90165-I; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Nickitenko AV, 1995, BIOCHEMISTRY-US, V34, P16585, DOI 10.1021/bi00051a006; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OH BH, 1994, J BIOL CHEM, V269, P26323; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PAYNE GM, 1985, MOL GEN GENET, V200, P493, DOI 10.1007/BF00425737; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHIFRIN S, 1966, J BIOL CHEM, V241, P3424; SHUMAN HA, 1993, J BIOENERG BIOMEMBR, V25, P613; SPEISER DM, 1989, THESIS U CALIFORNIA; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; TRAKHANOV SD, 1989, J MOL BIOL, V207, P847, DOI 10.1016/0022-2836(89)90253-2; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549; ZUKIN RS, 1986, BIOPHYS J, V49, P1229, DOI 10.1016/S0006-3495(86)83752-3	65	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21243	21250		10.1074/jbc.271.35.21243	http://dx.doi.org/10.1074/jbc.271.35.21243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702898	hybrid			2022-12-25	WOS:A1996VE47700044
J	Xu, M; Chakraborti, PK; Garabedian, MJ; Yamamoto, KR; Simons, SS				Xu, M; Chakraborti, PK; Garabedian, MJ; Yamamoto, KR; Simons, SS			Modular structure of glucocorticoid receptor domains is not equivalent to functional independence - Stability and activity of the steroid binding domain are controlled by sequences in separate domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HEAT-SHOCK PROTEIN-90; DNA-BINDING; NUCLEAR RECEPTOR; TRANSCRIPTIONAL REGULATION; TYROSINE AMINOTRANSFERASE; CRYSTAL-STRUCTURE; FUSION PROTEINS; GENE-REGULATION; HSP90 BINDING	A long-standing conundrum of glucocorticoid receptors has been why the steroid binding domain is active in hybrid proteins but not in isolation, For this reason, the precise boundaries of the steroid binding domain have not been de fined. These questions have How been systematically examined with a variety of receptor deletion constructs, Plasmids encoding amino acids 537-673 and 537-795 of the rat receptor did not yield stable proteins, while the fusion of receptor or non-receptor sequences upstream of 537-673 afforded stable proteins that did not bind steroid, Wild type steroid binding affinity could be obtained, however, when proteins such as beta-galactosidase or dihydrofolate reductase were fused upstream of receptor amino acids 531-795, Studies of a series of dhfr/receptor constructs with deletions at the amino- and carboxyl-terminal ends of the receptor sequence localized the boundaries of the steroid binding domain to 550-795, The absence of steroid binding upon deletion of sequences in the carboxyl-terminal half of this domain was consistent with improperly folded receptor sequences. This conclusion was supported by analyses of the proteolysis and thermal stability of the mutant receptors, Thus, three independent regions appear to be required for the generation of the steroid binding form of receptors: 1) a protein sequence upstream of the steroid binding domain, which conveys stability to the steroid binding domain, 2) sequences of the carboxyl-terminal amino acids (674-795), which are required far the correct folding of the steroid binding domain, and 3) amino-terminal sequences (550-673), which may be sufficient for steroid binding after the entire steroid binding domain is properly folded. These results establish that the steroid binding domain of glucocorticoid receptors is not independently functional and illustrate the importance of both protein stability and protein folding when constructing mutant proteins.	NIDDK,STEROID HORMONES SECT,LMCB,NATL INST HLTH,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco				xu, ming/0000-0002-3920-8947				ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BANIAHMAD C, 1991, J MOL BIOL, V222, P155, DOI 10.1016/0022-2836(91)90202-H; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EYLES SJ, 1994, BIOCHEMISTRY-US, V33, P13038, DOI 10.1021/bi00248a013; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1989, CANCER RES, V49, pS2292; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; ISRAEL DI, 1993, P NATL ACAD SCI USA, V90, P4290, DOI 10.1073/pnas.90.9.4290; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KIPPEN AD, 1995, BIOCHEMISTRY-US, V34, P1464, DOI 10.1021/bi00004a042; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIYASHITA Y, 1993, J STEROID BIOCHEM, V46, P309, DOI 10.1016/0960-0760(93)90220-Q; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; OHARANEMOTO Y, 1990, J STEROID BIOCHEM, V37, P481, DOI 10.1016/0960-0760(90)90391-W; OPOKU J, 1994, J BIOL CHEM, V269, P503; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1994, VITAM HORM, V49, P49; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; STELLWAGEN RH, 1992, J BIOL CHEM, V267, P23713; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; THOLE HH, 1994, BIOCHEM BIOPH RES CO, V199, P826, DOI 10.1006/bbrc.1994.1303; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WRANGE O, 1978, J BIOL CHEM, V253, P856; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	79	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21430	21438		10.1074/jbc.271.35.21430	http://dx.doi.org/10.1074/jbc.271.35.21430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702925	hybrid			2022-12-25	WOS:A1996VE47700071
J	Sugahara, T; Pixley, MR; Fares, F; Boime, I				Sugahara, T; Pixley, MR; Fares, F; Boime, I			Characterization of the O-glycosylation sites in the chorionic gonadotropin beta subunit in vivo using site-directed mutagenesis and gene transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; ALPHA-D-GALACTOSAMINE; LINKED GLYCOSYLATION; UDP-GALNAC; PEPTIDE; CARBOHYDRATE; SEQUENCES; SECRETION; INVITRO; OLIGOSACCHARIDE	Human chorionic gonadotropin (CG) is a member of a family of glycoprotein hormones which are heterodimers containing two nonidentical subunits: a common alpha and a hormone-specific beta subunit, One of the distinguishing features of the CG beta subunit is the presence of four serine accepters clustered within the last 25 amino acids. We previously demonstrated that this carboxyl terminal region is important for maintaining its biologic half-life, and when the sequence was genetically fused to either the common alpha or follitropin beta subunits, O-glycosylation was observed, Because this carboxyl-terminal sequence is located at the end of the subunit, we considered this region a convenient in vivo model for studying O-linked glycosylation in domains containing multiple serine recognition sites. A CG beta gene was engineered in which the N-linked sites were inactivated to eliminate background from those carbohydrate groups, Using this construct, we made a series of truncation and amino acid substitutions of acceptor serines, and these mutants were transfected into Chinese hamster ovary cells, O-Glycosylation was determined by [H-3]glucosamine incorporation and glycanase sensitivity of the products on SDS-polyacrylamide gels, We show that the O-linked sites comprise independent repetitive regions in which each acceptor serine has a recognition signal bounded by the next carboxy acceptor serine within four to five amino acids, It is also apparent that recognition of one site is not dependent on the glycosylation of another acceptor, Amino acid mutations in the acceptor regions demonstrated the importance of proline as a necessary feature for O-linked recognition in the CG beta sequence.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092922] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD92922] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BIRKEN S, 1977, J BIOL CHEM, V252, P5386; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; COLE LA, 1985, BIOCHEM BIOPH RES CO, V126, P333, DOI 10.1016/0006-291X(85)90610-2; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; GREEN ED, 1985, J BIOL CHEM, V260, P5623; HILL HD, 1977, J BIOL CHEM, V252, P3799; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; KALYAN NK, 1983, J BIOL CHEM, V258, P67; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KEUTMANN HT, 1977, J BIOL CHEM, V252, P5393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG Y, 1992, J BIOL CHEM, V267, P17209; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	33	15	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20797	20804		10.1074/jbc.271.34.20797	http://dx.doi.org/10.1074/jbc.271.34.20797			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702834	hybrid			2022-12-25	WOS:A1996VD33700086
J	Nikiforov, YE; Nikiforova, MN; Gnepp, DR; Fagin, JA				Nikiforov, YE; Nikiforova, MN; Gnepp, DR; Fagin, JA			Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident	ONCOGENE			English	Article						thyroid tumors; radiation; Chernobyl; ras; p53	POINT MUTATIONS; HA-RAS; GENOMIC INSTABILITY; LUNG-CANCER; ONCOGENE; GENE; CARCINOMAS; IRRADIATION; DISASTER; PATTERN	Starting 4 years after the Chernobyl accident, a dramatic increase in incidence of thyroid carcinoma was noticed in children from contaminated areas, The incidence of benign thyroid lesions in the exposed population was also increased, To study the possible role of ras and p53 genes in radiation-induced thyroid tumorigenesis, 33 papillary carcinomas, one follicular carcinoma and 22 benign lesions removed from children aged 5-19 were screened for point mutations of H- K-, and N-ras, as well as of p53 (exons 5-8) using single strand conformation polymorphism (SSCP) analysis, Pas point mutations were detected in 1/1 case of follicular carcinoma (N-ras codon 61 CAA(gln)-->AAA(lys)), and in 3/7 follicular adenomas (N-ras codon 61 CAA(gin)-->CGA(arg) x 2, CAA(gln)-->AAA(lys). None of the cases of papillary thyroid carcinoma was positive for ras oncogene abnormalities, The lack of K-ras mutations was confirmed by allele-specific oligonucleotide hybridization (ASOH), and by sequencing in five cases, Somatic point mutations in p53 were found by SSCP in 2/33 papillary thyroid carcinomas, with one missense mutation (exon 5, codon 160 ATG(met)-->GTG(val)) and another silent mutation (codon 182, TGC(cys)-->TGT(cys)). Immunohistochemically, focally positive p53 staining was found in four papillary carcinomas being primarily confined to solid and poorly-differentiate areas in tumors, These data demonstrate that as opposed to the few reports on tumors arising after therapeutic external irradiation, ras mutations are not primary events in the development of post-Chernobyl thyroid papillary carcinomas, p53 mutations do not appear to be important in the development of these tumors, but may in some cases have a role in progression to a more aggressive phenotype that has not yet fully manifested in these pediatric neoplasms.	UNIV CINCINNATI, COLL MED, DIV ENDOCRINOL & METAB, CINCINNATI, OH 45267 USA; CEDARS SINAI MED CTR, DIV ENDOCRINOL, LOS ANGELES, CA 90048 USA; RHODE ISL HOSP, DEPT PATHOL, PROVIDENCE, RI 02903 USA	University System of Ohio; University of Cincinnati; Cedars Sinai Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital					NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50706] Funding Source: Medline; NIDDK NIH HHS [DK 42792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGDANOVA T, 1995, THYROID S1, V5, pS28; CHALLETON C, 1995, ONCOGENE, V11, P601; CHEN CH, 1993, CANCER RES, V53, P1511; CONARD RA, 1970, J AMER MED ASSOC, V214, P316, DOI 10.1001/jama.214.2.316; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DOBYNS BM, 1992, WORLD J SURG, V16, P126, DOI 10.1007/BF02067128; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; ILYIN LA, 1990, J RADIOL PROTECT, V10, P13; ITO T, 1993, CANCER RES, V53, P2940; KASTAN MB, 1991, CANCER RES, V51, P6304; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRONENBERG A, 1994, INT J RADIAT BIOL, V66, P603, DOI 10.1080/09553009414551691; LEMOINE NR, 1988, ONCOGENE, V3, P541; Lemoine NR, 1989, THYROID TUMOURS, P4; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nikiforov Y, 1996, J CLIN ENDOCR METAB, V81, P9, DOI 10.1210/jc.81.1.9; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; NIKIFOROV YE, 1995, CANCER-AM CANCER SOC, V76, P900, DOI 10.1002/1097-0142(19950901)76:5<900::AID-CNCR2820760527>3.0.CO;2-X; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SAMPSON R J, 1969, Journal of the American Medical Association, V209, P65, DOI 10.1001/jama.209.1.65; SCHNEIDER AB, 1980, CANCER, V46, P1218, DOI 10.1002/1097-0142(19800901)46:5<1218::AID-CNCR2820460523>3.0.CO;2-H; SHORE RE, 1985, J NATL CANCER I, V74, P1177; TAYLOR JA, 1994, LANCET, V343, P86, DOI 10.1016/S0140-6736(94)90818-4; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; Winship T, 1970, CLIN P CHILDRENS HOS, V26, P327; WRIGHT PA, 1991, ONCOGENE, V6, P471; ZHANG PL, 1994, MOL CARCINOGEN, V9, P46, DOI 10.1002/mc.2940090109	38	107	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					687	693						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761289				2022-12-25	WOS:A1996VD43300003
J	Rao, GN				Rao, GN			Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases	ONCOGENE			English	Article						oxidant; receptor tyrosine kinases; signal transduction; vascular smooth muscle cells	EPIDERMAL GROWTH-FACTOR; OXYGEN FREE-RADICALS; SMOOTH-MUSCLE CELLS; I RECEPTOR; C-JUN; PHOSPHORYLATION; SHC; TRANSDUCTION; INSULIN; MOUSE	Protein tyrosine phosphorylation events play determinant roles in cellular processes such as proliferation and differentiation. We have recently reported that hydrogen peroxide, an active oxygen species and a cellular oxidant, stimulates growth response events in vascular smooth muscle cells (VSMC). To understand the mechanisms by which oxidant stress modulates these growth response events, we have studied the effect of hydrogen peroxide on protein tyrosine phosphorylation events in VSMC. Our findings show that hydrogen peroxide stimulates tyrosine phosphorylation of several proteins including epidermal growth factor receptor (EGFR) in VSMC. Hydrogen peroxide-induced tyrosine phosphorylation of EGFR was found to be time dependent; with a threefold increase at 5 min and a 20-fold increase at 30 min of treatment as compared to control levels. Hydrogen peroxide treatment of VSMC also resulted in a time-dependent increase in tyrosine phosphorylation of SHC proteins. In addition, hydrogen peroxide-induced tyrosine-phosphorylated EGFR formed a complex with SHC-Grb2-SOS. These events were followed by activation of Pas and extracellular signal-regulated protein kinases (ERKs) group of mitogen-activated protein kinases (MAPKs). Together these findings demonstrate for the first time that hydrogen peroxide, a cellular oxidant, possess the ability to activate EGFR-mediated signaling events in VSMC. These EGFR-mediated signaling events may be important in oxidant stress-induced cellular responses			Rao, GN (corresponding author), UNIV TEXAS, MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,RT 1064, 301 UNIV BLVD, GALVESTON, TX 77555 USA.							BASU T, 1994, ONCOGENE, V9, P3483; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COFFER PJ, 1995, ONCOGENE, V11, P561; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; DUQUE I, 1993, J PHARMACOL EXP THER, V267, P612; FANTONE JC, 1982, AM J PATHOL, V107, P397; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; XIE YM, 1995, ONCOGENE, V10, P2409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	201	212	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					713	719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761292				2022-12-25	WOS:A1996VD43300006
J	Wahlstrom, GM; Harbers, M; Vennstrom, B				Wahlstrom, GM; Harbers, M; Vennstrom, B			The oncoprotein P75(gag-v-erbA) represses thyroid hormone induced transcription only via response elements containing palindromic half-sites	ONCOGENE			English	Article						v-erbA; homodimers; repression; transcription factor; response elements	AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTORS; DOMINANT NEGATIVE ACTIVITY; V-ERBA; C-ERBA; CELL-TRANSFORMATION; AUXILIARY PROTEINS; LIGAND-BINDING; DOMAIN; GENE	The v-erbA oncoprotein p75(gag-v-erbA), derived from the thyroid hormone receptor alpha (TR alpha), functions as transdominant transcriptional repressor, The mechanism by which P75(gag-v-erbA) acts is however poorly characterized. Here, we show that repression of TR alpha mediated transcription by P75(gag-v-erbA) in transformed erythroblasts is dependent on the structure of the thyroid hormone response element to which it binds. A very efficient repression was seen with hormone response elements having half-sites organized as everted repeats (ER), whereas repression was inefficient with directly repeated half-sites (DR), Promoters containing half-sites organized as an inverted palindrome (IR) gave an intermediate repression, Although P75(gag-v-erbA) failed to associate with the ligand binding domain of retinoid X (RXR) receptor in a two-hybrid test, the oncoprotein in nuclear extracts from transformed cells heterodimerised quantitatively with RXR upon binding to response elements of the DR type, On the other hand, both RXR/P75(gag-v-erb) heterodimers and other types of dimers formed on ER elements, P75(gag-v-erbA) also failed to bind to elements that contained only one half-site in vivo and in vitro, The data demonstrate that P75(gag-v-erbA) represses gene expression efficiently as a dimer, and suggest that thyroid hormone responsive genes that may be targets for the action of the oncoprotein are repressed most efficiently if they contain elements of the ER type.	KAROLINSKA INST,DEV BIOL LAB,DEPT CELLULAR & MOL BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet				Harbers, Matthias/0000-0002-5613-7220				AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P2725; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN DJ, 1995, NATURE, V377, P454; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORREST D, 1990, ONCOGENE, V5, P309; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARBERS H, 1996, NUCLEIC ACIDS RES, V24, P12; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HERMANN T, 1993, ONCOGENE, V8, P55; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; RASCLE A, 1994, ONCOGENE, V9, P2853; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1992, ONCOGENE, V7, P953; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; TRAINOR CD, 1995, MOL ENDOCRINOL, V9, P1135, DOI 10.1210/me.9.9.1135; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	60	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					843	852						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761306				2022-12-25	WOS:A1996VD43300020
J	deBruijn, DRH; Baats, E; Zechner, U; deLeeuw, B; Balemans, M; Weghuis, DO; HirningFolz, U; vanKessel, AG				deBruijn, DRH; Baats, E; Zechner, U; deLeeuw, B; Balemans, M; Weghuis, DO; HirningFolz, U; vanKessel, AG			Isolation and characterization of the mouse homolog of SYT, a gene implicated in the development of human synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; mouse Syt gene SH2-; SH3-binding domains; annexin-like repeats; chromosome 18	KRUPPEL-ASSOCIATED BOX; DICTYOSTELIUM-DISCOIDEUM; BINDING PROTEIN; ANNEXIN-VII; TRANSLOCATION; BREAKPOINT; IDENTIFICATION; CHROMOSOME; CLONING; XP11.2	In a previous study we reported the isolation of the human synovial sarcoma-associated t(X;18) breakpoint. As a result of this translocation, the SYT gene on chromosome 18 fuses to either the SSX1 or the SSX2 gene on the X chromosome, depending on the exact location of the breakpoint within band Xp11.2. As yet, little is known about the modes of action of the SYT and SSX genes and their respective (fusion) products. Here we report the isolation of the mouse homolog of SYT, its full length cDNA sequence, its chromosomal localization, and its spatio-temporal expression patterns in adult and embryonic tissues. The SYT gene was found to be well conserved during evolution and is part of a region of synteny between the human and mouse chromosomes 18. In early embryogenesis, Syt is ubiquitously expressed. In later stages, the expression becomes confined to cartilage tissues, specific neuronal cells and some epithelial derived tissues. In mature testis, expression was specifically observed in primary spermatocytes.	UNIV ULM, DEPT MED GENET, D-7900 ULM, GERMANY	Ulm University	deBruijn, DRH (corresponding author), UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, POB 9101, NL-6500 HB NIJMEGEN, NETHERLANDS.		van Kessel, Ad Geurts/A-2810-2010; Olde Weghuis, Danielle/C-4674-2016; Zechner, Ulrich/G-2116-2010; de Bruijn, D.R.H./L-4233-2015					CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; DELEEUW B, 1993, ONCOGENE, V8, P1457; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; DELEEUW B, 1994, HUM MOL GENET, V3, P745, DOI 10.1093/hmg/3.5.745; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; DELEEUW B, 1993, GENE CHROMOSOME CANC, V6, P182, DOI 10.1002/gcc.2870060309; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GRANT CE, 1990, GENE, V96, P213, DOI 10.1016/0378-1119(90)90255-P; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; OVERHAUSER J, 1995, CYTOGENET CELL GENET, V71, P106; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WEGHUIS DO, 1994, GENE CHROMOSOME CANC, V9, P288; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZHANGKECK ZY, 1993, BIOCHEM J, V289, P735, DOI 10.1042/bj2890735	21	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					643	648						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760306				2022-12-25	WOS:A1996VB32800022
J	Schryver, B; Hinck, L; Papkoff, J				Schryver, B; Hinck, L; Papkoff, J			Properties of Wnt-1 protein that enable cell surface association	ONCOGENE			English	Article						Wnt-1; basic sequence motif; proteoglycan	FIBROBLAST GROWTH-FACTOR; MAMMARY ONCOGENE INT-1; HEPARAN-SULFATE; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; WINGLESS PROTEIN; EXPRESSION; DROSOPHILA; BINDING; TRANSFORMATION	Members of the highly conserved Wnt gene family serve key functions in cellular growth and differentiation. Regulated expression of the murine Wnt-1 protooncogene is essential for normal development of the embryonic nervous system and when misexpressed in the mammary gland leads to hyperplasias and tumorigenic progression. Wnt-1 encodes a cysteine rich glycoprotein that is secreted and tightly associated with the cell surface and/or extracellular matrix. This restricted diffusion of Wnt-1 protein is important for specifying a spatially defined pattern of Wnt-activity necessary for cell to cell signaling in cell growth and differentiation. Since the receptors and cell surface molecules that bind Wnt proteins are as yet unknown we have sought to define the sequences within Wnt-1 protein that enable cell surface association and to define the nature of the cell surface structures with which Wnt-1 protein associates. First, site directed mutagenesis was used to identify a basic amino acid sequence motif within Wnt-1 protein that is required for this protein to accumulate on the cell surface. Second, wild type Wnt-1 protein was expressed in a series of proteoglycan-deficient CHO cell lines to show that, contrary to expectations, cellular glycosaminoglycans are not required for processing, secretion, cell surface association and accumulation of Wnt-1 protein.	STANFORD UNIV,CANC BIOL PROGRAM,STANFORD,CA 94305; SUGEN INC,REDWOOD CITY,CA 94063	Stanford University				Hinck, Lindsay/0000-0002-4009-3913				BAME KJ, 1989, J BIOL CHEM, V264, P8059; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; ESCO JD, 1987, J BIOL CHEM, V262, P12189; ESCO JD, 1986, J BIOL CHEM, V261, P15725; ESCO JD, 1985, P NATL ACAD SCI USA, V82, P3197; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					333	342						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710372				2022-12-25	WOS:A1996VA25200012
J	Welcker, M; Lukas, J; Strauss, M; Bartek, J				Welcker, M; Lukas, J; Strauss, M; Bartek, J			Enhanced protein stability: A novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells	ONCOGENE			English	Article						cell cycle; proto-oncogene; D-cyclin protein stability; retinoblastoma protein; multistep tumorigenesis	HUMAN BREAST-CANCER; G1 PHASE PROGRESSION; D-CDK COMPLEXES; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; GENE-PRODUCT; G(1) CONTROL; EXPRESSION; AMPLIFICATION; LOCALIZATION	The mammalian D-type cyclins promote progression through a G1 checkpoint by phosphorylating the retinoblastoma protein (pRB), and can contribute to oncogenesis via their deregulated expression achieved through gene amplification, chromosomal rearrangement, or retroviral integration. We now report a novel mechanism of tumour-associated D-cyclin over-abundance, resulting from enhanced protein stability. In two human cell lines established from a single uterine sarcoma biopsy, pRB-positive SK-UT-1B and pRB-deficient SK-UT-1, aberrant accumulation of functional cyclins D1, and D2 and D3 occurred in the absence of gene amplification and/or elevated mRNA expression. The abundance of D-cyclin proteins remained elevated throughout the cell cycle, and pulse-chase experiments revealed six to 10-fold prolongation of their protein half-lives as compared with either diploid fibroblasts or control U-2-OS sarcoma cells. These results point to a critical regulatory role of D-type cyclin turnover, and contribute to refinement of current views of the role played by the cyclin D-CDK-p16-pRB pathway in cell cycle control and tumorigenesis.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN O, DENMARK; MAX PLANCK GESELL, D-13122 BERLIN, GERMANY	Danish Cancer Society; Max Planck Society			Bartek, Jiri/G-5870-2014	Welcker, Markus/0000-0001-6723-4790; Lukas, Jiri/0000-0001-9087-506X				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GILLETT C, 1994, CANCER RES, V54, P1812; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETERS G, 1994, J CELL SCI, P89; SCHUURING E, 1992, ONCOGENE, V7, P355; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TAM SW, 1994, ONCOGENE, V9, P2663; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	47	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					419	425						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710382				2022-12-25	WOS:A1996VA25200022
J	Warnock, DE; Hinshaw, JE; Schmid, SL				Warnock, DE; Hinshaw, JE; Schmid, SL			Dynamin self-assembly stimulates its GTPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED-VESICLE FORMATION; TEMPERATURE-SENSITIVE MUTANT; DROSOPHILA-MELANOGASTER; ENDOCYTOSIS; MICROTUBULES; ACTIVATION; BLOCKAGE; DOMAINS	GTP hydrolysis by dynamin is required to drive coated vesicle budding at the plasma membrane, A diverse set of molecules including microtubules, grb2, and acidic phospholipids stimulate dynamin GTPase activity in vitro, although the physiological relevance of these effecters remains to be determined. Dynamin has been shown to assemble around microtubules, the most potent stimulatory molecule, into structures indistinguishable by electron microscopy from collars captured in vivo at the necks of endocytic coated pits. Under low ionic strength conditions purified dynamin self-assembles into rings and helical stacks of rings, Here we show that dynamin self-assembly stimulates its GTPase activity as much as 10-fold. Thus, we identify dynamin, itself, as the first effector of dynamin GTPase activity known to be physiologically relevant. Assembled dynamin's stimulated GTPase activity is not dependent on the direct interaction of high affinity GTP binding sites since a mutant defective in GTP binding and hydrolysis can coassemble with and stimulate GTP hydrolysis by wild-type dynamin. Finally, we find that GTP destabilizes assembled dynamin structures, suggesting that the activated rates of GTP hydrolysis reflect a continuing cycle of assembly, GTP hydrolysis, and disassembly.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Schmid, Sandra/0000-0002-1690-7024	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042455] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42455] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; RAMASWAMI M, 1993, J NEUROGENET, V9, P73, DOI 10.3109/01677069309083451; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TSURUHARA T, 1990, CELL TISSUE RES, V259, P199, DOI 10.1007/BF00318441; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x	20	201	206	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22310	22314		10.1074/jbc.271.37.22310	http://dx.doi.org/10.1074/jbc.271.37.22310			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798389	hybrid			2022-12-25	WOS:A1996VG67200008
J	Parkin, DW				Parkin, DW			Purine-specific nucleoside N-ribohydrolase from Trypanosoma brucei brucei purification, specificity, and kinetic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALYSIS; CRITHIDIA-FASCICULATA; INHIBITOR DESIGN; HYDROLASE; METABOLISM; ENZYMES; CRUZI; CHEMOTHERAPY; SALVAGE; ACID	Trypanosomes have no de novo purine biosynthesis and thus depend upon salvage pathways to obtain purines for their metabolic pathways and for the biosynthesis of nucleic acids. An inosine-adenosine-guanosine preferring nucleoside hydrolase (IAG-nucleoside hydrolase) from the African trypanosome Trypanosoma brucei brucei represents similar to 0.2% of the soluble protein in this organism. The enzyme has been purified over 400-fold to >95% homogeneity from the bloodstream form of this parasite. IAG-nucleoside hydrolase is a dimer of M(r) 36,000 subunits. The k(cat)/K-m for inosine, adenosine, and guanosine are 1.9 x 10(6), 1.2 x 10(6), and 0.83 x 10(6) M(-1) s(-1), respectively. The kinetic mechanism with inosine as substrate is rapid equilibrium with random product release. The turnover rate for inosine at 30 degrees C is 34 s(-1). Pyrimidine nucleosides are poor substrates with k(cat)/K-m values of approximately 10(3) M(-1) s(-1). Deoxynucleosides are also poor substrates with k(cat)/K-m values near 10(2) M(-1) s(-1). AMP is not a detectable substrate and there is no measurable purine nucleoside phosphorylase activity, 3-Deazaadenosine, 7-deazaadenosine (tubercidin), and formycin B are competitive inhibitors with K-is of 1.8, 59, and 13 mu M, respectively. The K-m shows a slight dependence on pH with a pH optimum around 7. The V-max/K-m data indicate there are two ionizable enzymatic groups, pK(a) 8.6, required for the formation of the Michaelis complex. The V-max data indicate three ionizable groups involved in catalysis. Two essential groups exhibit pK(a) values of 8.8, and a third group with a pK(a) of 6.5 increases the V-max an additional 10-fold. All three groups must be protonated for optimum catalytic activity.			Parkin, DW (corresponding author), INT LIVESTOCK RES INST,POB 30709,NAIROBI,KENYA.							ALDHOUS P, 1994, SCIENCE, V264, P1857, DOI 10.1126/science.8009209; BOUTELLIER M, 1994, BIOCHEMISTRY-US, V33, P3994, DOI 10.1021/bi00179a028; Cleland W W, 1979, Methods Enzymol, V63, P103; DAVIES MJ, 1983, PARASITOLOGY, V87, P211, DOI 10.1017/S0031182000052574; ESTUPINAN B, 1994, J BIOL CHEM, V269, P23068; Fersht A., 1985, ENZYME STRUCTURE MEC; FISH WR, 1982, BIOCHIM BIOPHYS ACTA, V719, P223, DOI 10.1016/0304-4165(82)90092-7; GARRETT ER, 1972, J AM CHEM SOC, V94, P8532, DOI 10.1021/ja00779a040; GUTTERIDGE WE, 1981, FEBS LETT, V127, P211, DOI 10.1016/0014-5793(81)80207-4; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; HOUBA V, 1982, ANIMAL HLTH YB; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MARR JJ, 1986, REV INFECT DIS, V8, P884; MAZZELLA LJ, 1996, IN PRESS J AM CHEM S, V6; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MILLER EN, 1981, PARASITOLOGY, V82, P63, DOI 10.1017/S0031182000041871; MILLER RL, 1984, J BIOL CHEM, V259, P5073; MILLER RL, 1986, BIOCHEM PHARMACOL, V36, P553; OGBUNUDE POJ, 1983, MOL BIOCHEM PARASIT, V9, P279, DOI 10.1016/0166-6851(83)90084-1; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; SCHRAMM VL, 1994, J BIOL CHEM, V269, P18259; STEENKAMP DJ, 1991, EUR J BIOCHEM, V197, P431, DOI 10.1111/j.1432-1033.1991.tb15929.x; Tipton K F, 1979, Methods Enzymol, V63, P183; Vickerman K., 1993, Immunology and molecular biology of parasitic infections., P170; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001	28	83	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21713	21719		10.1074/jbc.271.36.21713	http://dx.doi.org/10.1074/jbc.271.36.21713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702965	hybrid			2022-12-25	WOS:A1996VF61200007
J	Salinelli, S; Lo, JY; Mims, MP; Zsigmond, E; Smith, LC; Chan, L				Salinelli, S; Lo, JY; Mims, MP; Zsigmond, E; Smith, LC; Chan, L			Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor - Functional importance of a properly folded surface loop covering the catalytic center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ALPHA(2)-MACROGLOBULIN RECEPTOR; PANCREATIC LIPASE; NONSENSE MUTATION; COMPLEMENTARY-DNA; ENZYME CATALYSIS; APOLIPOPROTEIN-E; TERMINAL DOMAIN; HEPARAN-SULFATE; GENE	We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce I-125-VLDL binding to the hLPL-expressing cells, whereas rabbit beta-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of I-125-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447-->Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/G239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S. Two of the loop mutants (LPL-cH and LPL-cP) and the control double Cys mutant C418S/C438S gave normal enhancement of VLDL binding and catabolism, whereas the third loop mutant, C216S/C239S, was completely inactive. We conclude that although catalytic activity and the actual primary sequence of the loop of LPL are relatively unimportant (wild-type LPL loop and pancreatic lipase loops have little sequence similarity), the intact folding of the loop, flanked by disulfide bonds, must be maintained for LPL to express its bridge function.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	Salinelli, S (corresponding author), BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030, USA.				NHLBI NIH HHS [HL46860, HL27341, HL16512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027341, R01HL046860, R01HL016512, R37HL016512, P60HL027341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIESIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; Cryer A., 1987, LIPOPROTEIN LIPASE, P277; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HENDERSON HE, 1993, J LIPID RES, V34, P1593; HIDE WA, 1992, J LIPID RES, V33, P167; KOBAYASHI J, 1992, BIOCHEM BIOPH RES CO, V182, P70, DOI 10.1016/S0006-291X(05)80113-5; KOZAKI K, 1993, J LIPID RES, V34, P1765; KWAMURA M, 1994, ARTERIOSCLER THROMB, V16, P235; LO JY, 1995, BIOCHEM BIOPH RES CO, V206, P266, DOI 10.1006/bbrc.1995.1037; MATTU RK, 1994, ARTERIOSCLER THROMB, V14, P1090, DOI 10.1161/01.ATV.14.7.1090; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; ROTH RI, 1983, J LIPID RES, V24, P1; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SKARLATOS SI, 1993, J CLIN ENDOCR METAB, V76, P793, DOI 10.1210/jc.76.3.793; Smith L. C., 1992, CURR OPIN STRUC BIOL, V2, P490, DOI DOI 10.1016/0959-440X(92)90076-J; STOCKS J, 1992, J LIPID RES, V33, P853; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WONG H, 1994, J BIOL CHEM, V269, P10319; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757; Zsigmond E, 1996, METHOD ENZYMOL, V263, P327	47	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21906	21913		10.1074/jbc.271.36.21906	http://dx.doi.org/10.1074/jbc.271.36.21906			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702993	hybrid			2022-12-25	WOS:A1996VF61200035
J	Benov, L; Kredich, NM; Fridovich, I				Benov, L; Kredich, NM; Fridovich, I			The mechanism of the auxotrophy for sulfur-containing amino acids imposed upon Escherichia coli by superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; DISMUTASE; DEHYDRATASE; INACTIVATION; CYSTEINE; ENZYME; MUTAGENESIS; CLUSTER; STRESS; GROWTH	Defects in both of the genes coding for the cytosolic superoxide dismutases (SODs) of Escherichia coli impose an oxygen-dependent nutritional requirement for cysteine. This is now seen to be a bradytrophy, rather than an absolute auxotrophy, since lack of Cys merely imposed a growth lag and escape from this growth lag did not involve genetic reversion. This Cys bradytrophy was not seen in the SOD-competent parental strain, and it was relieved by a cell-permeant mimic of SOD activity; hence, it was due to O-2(radical anion). It was also relieved by an osmolyte, such as sucrose; hence, it appears due to leakage from the cell of some component needed for Cys biosynthesis. Medium conditioned by the aerobic growth of the SOD-defective strain relieved the growth lag. Bioassays with Cys mutants suggested that the conditioned medium contained SO33- or its equivalent, and sulfite per se was able to eliminate the growth lag. However, some component of the conditioned medium reacted with added sulfite and interfered with attempts to assay for it colorimetrically. These results suggest that the cell envelope of the SOD-defective strain was weakened, directly or indirectly, by O-2(radical anion) and then leaked sulfite. This prevents cysteine biosynthesis until sulfite accumulates in the medium.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University			Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146				BARRETT EL, 1979, J GEN MICROBIOL, V115, P513, DOI 10.1099/00221287-115-2-513; BECKER MA, 1969, J BIOL CHEM, V244, P2418; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BROWN OR, 1995, ARCH BIOCHEM BIOPHYS, V319, P10, DOI 10.1006/abbi.1995.1262; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CONWAY EJ, 1939, QUANTITATIVE ANAL MI; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FLINT DH, 1993, J BIOL CHEM, V268, P25547; GRANT WM, 1947, ANAL CHEM, V19, P345, DOI 10.1021/ac60005a023; HRYNIEWICZ MM, 1995, J BACTERIOL, V177, P2343, DOI 10.1128/jb.177.9.2343-2353.1995; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1991, MOL GEN GENET, V228, P410, DOI 10.1007/BF00260634; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; KREDICH NM, 1971, J BIOL CHEM, V246, P3474; KUO CF, 1987, J BIOL CHEM, V262, P4724; LEINWEBER FJ, 1965, J BIOL CHEM, V240, P2699; LEINWEBER FJ, 1962, ANAL BIOCHEM, V4, P252, DOI 10.1016/0003-2697(62)90008-8; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H	24	47	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21037	21040		10.1074/jbc.271.35.21037	http://dx.doi.org/10.1074/jbc.271.35.21037			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702868	hybrid			2022-12-25	WOS:A1996VE47700014
J	Matsubara, M; Kusubata, M; Ishiguro, K; Uchida, T; Titani, K; Taniguchi, H				Matsubara, M; Kusubata, M; Ishiguro, K; Uchida, T; Titani, K; Taniguchi, H			Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE STATE; TAU-PROTEIN; BOVINE BRAIN; SUBSTRATE MARCKS; MAJOR SUBSTRATE; C SUBSTRATE; PURIFICATION; MICROTUBULE; PHOSPHOPROTEIN	Posttranslational modifications of synapsin I, a major phosphoprotein in synaptic terminals, were studied by mass spectrometry. In addition to a well known phosphorylation site by calmodulin-dependent protein kinase II (CaM kinase II), a hitherto unrecognized site (Ser(553)) was found phosphorylated in vivo. The phosphorylation site is immediately followed by a proline, suggesting that the protein is an in vivo substrate of so-called proline-directed protein kinase(s). To identify the kinase involved, three proline-directed protein kinases expressed highly in the brain, i.e. mitogen-activated protein (MAP) kinase, Cdk5-p23, and glycogen synthase kinase 3 beta, were tested for the in vitro phosphorylation of synapsin I, Only MAP kinase and Cdk5-p23 phosphorylated synapsin I stoichiometrically. The phosphorylation sites were determined to be Ser(551) and Ser(553) with Cdk5-p23, and Ser(62), Ser(67), and Ser(551) with MAP kinase, Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23. These results raise the possibility that the so-called proline-directed protein kinases together with CaM kinase II and cAMP-dependent protein kinase play an important role in the regulation of synapsin I function.	FUJITA HLTH UNIV, INST COMPREHENS MED SCI, DIV BIOMED POLYMER SCI, TOYOAKE, AICHI 47011, JAPAN; MITSUBISHI KAGAKU INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN	Fujita Health University; Mitsubishi Kagaku Institute of Life Sciences (MITILS)			Taniguchi, Hisaaki/I-9171-2012; Matsubara, Mamoru/AAP-4016-2021	Matsubara, Mamoru/0000-0002-8893-0485				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAINES AJ, 1986, NATURE, V319, P145, DOI 10.1038/319145a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; HUANG CK, 1982, J BIOL CHEM, V257, P6524; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; PETRUCCI TC, 1991, BIOCHEMISTRY-US, V30, P413, DOI 10.1021/bi00216a016; ROMANO C, 1987, J NEUROSCI, V7, P1300; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUDHOF TC, 1986, SCIENCE, V326, P704; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; UEDA T, 1977, J BIOL CHEM, V252, P5155; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	34	203	211	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21108	21113		10.1074/jbc.271.35.21108	http://dx.doi.org/10.1074/jbc.271.35.21108			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702879	hybrid			2022-12-25	WOS:A1996VE47700025
J	Royo, J; Vancanneyt, G; Perez, AG; Sanz, C; Stormann, K; Rosahl, S; SanchezSerrano, JJ				Royo, J; Vancanneyt, G; Perez, AG; Sanz, C; Stormann, K; Rosahl, S; SanchezSerrano, JJ			Characterization of three potato lipoxygenases with distinct enzymatic activities and different organ-specific and wound-regulated expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANUM-TUBEROSUM-L; JASMONIC ACID; ARACHIDONATE 5-LIPOXYGENASE; METHYL JASMONATE; ESCHERICHIA-COLI; GENE-EXPRESSION; ACTIVE ENZYME; HIGH-LEVEL; PURIFICATION; ARABIDOPSIS	Lipoxygenases are ubiquitous enzymes in eukaryotes. In plants, lipoxygenases are involved in the synthesis of the hormone jasmonic acid that regulates plant responses to wounding and, in addition, is an inducer of tuberization in potato. We have isolated potato lipoxygenase cDNA clones, From their deduced amino acid sequences, three distinct classes are defined (Lox1, Lox2, and Lox3), They are encoded in gene families that display organ-specific expression, lox1 being expressed mostly in tubers and roots, lox2 in leaves, and lox3 in leaves and roots. Consistent with their organ-specific expression pattern, Lox1 expressed in bacteria preferentially uses as substrate linoleic acid, abundant in membrane lipids of tubers, whereas linolenic acid, prevalent in leaves, is the preferred substrate for the other two classes of lipoxygenase. Analyses on reaction products of the enzymes expressed in bacteria reveal that Lox1 primarily produces 9-hydroperoxides. In contrast, the jasmonic acid precursor, 13-hydroperoxylinolenic acid, is the major product, of the action of Lox2 and Lox3 on linolenic acid. Upon wounding, the levels of Lox2 and Lox3 transcripts rise markedly in leaves. While Lox3 mRNA accumulation peaks as early as 30 min after wounding, Lox2 shows a steady increase over a 24-h time course, suggesting different roles for these Lipoxygenase isoforms in the synthesis of the plant hormone jasmonic acid.	UNIV AUTONOMA MADRID, CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN; CSIC, INST GRASA, E-41012 SEVILLE, SPAIN; MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG); Max Planck Society			Serrano, Jose J Sanchez/H-6955-2015; Pérez, Ana/GQA-6861-2022; Pérez, Ana G./AAB-4513-2021; Vancanneyt, Guy/P-3809-2015; Sanz, Carlos/K-1743-2014; Pérez, Ana G. G/K-1221-2014; Royo, Joaquin/L-4855-2015	Serrano, Jose J Sanchez/0000-0002-4489-4785; Pérez, Ana G./0000-0002-8096-9190; Vancanneyt, Guy/0000-0003-2557-0723; Sanz, Carlos/0000-0002-7387-3393; Pérez, Ana G. G/0000-0002-8096-9190; Royo, Joaquin/0000-0002-8245-5791				BELL E, 1993, PLANT PHYSIOL, V103, P1133, DOI 10.1104/pp.103.4.1133; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; Blee E, 1996, PLANT PHYSIOL, V110, P445, DOI 10.1104/pp.110.2.445; BOSTOCK RM, 1992, PLANT PHYSIOL, V100, P1448, DOI 10.1104/pp.100.3.1448; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; CASEY R, 1995, PLANT PHYSIOL, V107, P265, DOI 10.1104/pp.107.1.265; CHAPMAN HW, 1958, PHYSIOL PLANTARUM, V11, P215, DOI 10.1111/j.1399-3054.1958.tb08460.x; COHEN JD, 1984, J CHROMATOGR, V303, P193, DOI 10.1016/S0021-9673(01)96061-3; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; DELIEU T, 1972, NEW PHYTOL, V71, P201, DOI 10.1111/j.1469-8137.1972.tb04068.x; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; GALLIARD T, 1971, BIOCHEM J, V124, P431, DOI 10.1042/bj1240431; GALLIARD T, 1980, BIOCH PLANTS COMPREH, V4, P131; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; GREGORY LE, 1956, AM J BOT, V43, P281, DOI 10.2307/2438945; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; JACKSON SD, 1994, PLANTA, V194, P155, DOI 10.1007/BF01101673; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KODA Y, 1991, PHYTOCHEMISTRY, V30, P1435, DOI 10.1016/0031-9422(91)84180-Z; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MELAN MA, 1993, PLANT PHYSIOL, V101, P441, DOI 10.1104/pp.101.2.441; MULLIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V916, P13, DOI 10.1016/0167-4838(87)90205-6; NELSON MJ, 1994, CURR OPIN STRUC BIOL, V4, P878, DOI 10.1016/0959-440X(94)90270-4; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; PELACHO AM, 1991, PLANT PHYSIOL, V97, P1253, DOI 10.1104/pp.97.3.1253; PENACORTES H, 1995, P NATL ACAD SCI USA, V92, P4106, DOI 10.1073/pnas.92.10.4106; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; PENG YL, 1994, J BIOL CHEM, V269, P3755; REDDANNA P, 1990, METHOD ENZYMOL, V187, P268; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; Sambrook J., 1989, IMMUNOLOGY; Saravitz DM, 1996, PLANT PHYSIOL, V110, P287, DOI 10.1104/pp.110.1.287; SHIMIZU T, 1990, METHOD ENZYMOL, V187, P296; SHIRANO Y, 1990, FEBS LETT, V271, P128, DOI 10.1016/0014-5793(90)80388-Y; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAHASHI K, 1995, PLANT SCI, V111, P11, DOI 10.1016/0168-9452(95)04222-G; VICK BA, 1980, LIPIDS, V15, P468, DOI 10.1007/BF02534074; Vick Brady A., 1993, P167; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; YOSHIHARA T, 1989, AGR BIOL CHEM TOKYO, V53, P2835, DOI 10.1080/00021369.1989.10869712	43	178	211	0	39	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21012	21019		10.1074/jbc.271.35.21012	http://dx.doi.org/10.1074/jbc.271.35.21012			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702864	hybrid			2022-12-25	WOS:A1996VE47700010
J	Furukawa, K; Soejima, H; Niikawa, N; Shiku, H; Furukawa, K				Furukawa, K; Soejima, H; Niikawa, N; Shiku, H; Furukawa, K			Genomic organization and chromosomal assignment of the human beta 1,4-N-acetylgalactosaminyltransferase gene - Identification of multiple transcription units	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; TISSUE-SPECIFIC EXPRESSION; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; EUKARYOTIC RIBOSOMES; GD2 GANGLIOSIDE; MESSENGER-RNA; DNA-BINDING; FACTOR AP-2; CELLS; GROWTH	The beta 1,4-N-acetylgalactosaminyltransferase (beta 1,4GalNAc-T) (EC 2.4.1.92) gene is expressed in normal brain tissues and in various malignant transformed cells, such as malignant melanoma, neuroblastoma, and adult T cell leukemia. To analyze the regulatory mechanisms of gene expression, we determined the genomic organization of the beta 1,4GalNAc-T gene. The gene consists of at least 11 exons and spans >8 kilobase pairs, The coding region is located in exons 2-11. To determine the transcription initiation sites, 5'-rapid amplification of cDNA ends analysis and ribonuclease protection assays were performed using RNA obtained from the human melanoma cell line SK-MEL-31. Consequently, we defined three transcription initiation sites and the alternative usage of three exons. Exons 1a and 1b partially overlap; the latter is part (3'-side) of the former and corresponds to the 5'-noncoding region of the cDNA clone previously isolated. The third transcript, exon 1c, corresponds to nucleotides -520 to -412 (position +1 = A of ATG of beta 1,4GalNAc-T cDNA), which are considered to be in intron 1 based on the cloned cDNA sequence. Ribonuclease protection assays revealed the corresponding protection bands in samples of the gene-expressing cell Lines. 5'-Flanking regions of individual initiation sites showed promoter activity when analyzed by chloramphenicol acetyltransferase assay in SK-MEL-31 cells. The multiple transcription initiation sites and their promoters/enhancers identified here might be differentially involved in the cell type-specific expression of the beta 1,4GalNAc-T gene. This gene was assigned to human chromosome 12q13.3 by means of fluorescence in situ hybridization.	NAGASAKI UNIV,SCH MED,DEPT HUMAN GENET,NAGASAKI 852,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 2,TSU,MIE 514,JAPAN	Nagasaki University; Mie University	Furukawa, K (corresponding author), NAGASAKI UNIV,SCH MED,DEPT ONCOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN.			Soejima, Hidenobu/0000-0001-5076-6563				Battey, 1986, BASIC METHODS MOL BI; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEUNG NKV, 1985, CANCER RES, V45, P2642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FURUKAWA K, 1993, P NATL ACAD SCI USA, V90, P1972, DOI 10.1073/pnas.90.5.1972; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAZUKA S, 1994, CURR OPIN STRUT BIOL, V4, P683; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RUAN S, 1992, CANCER RES, V52, P5725; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; THURIN J, 1986, FEBS LETT, V208, P17, DOI 10.1016/0014-5793(86)81522-8; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Yamamoto A, 1996, J NEUROCHEM, V66, P26; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; YAMASHIRO S, 1993, CANCER RES, V53, P5395; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	49	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20836	20844		10.1074/jbc.271.34.20836	http://dx.doi.org/10.1074/jbc.271.34.20836			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702839	hybrid			2022-12-25	WOS:A1996VD33700091
J	Gaidarov, I; Chen, Q; Falck, JR; Reddy, KK; Keen, JH				Gaidarov, I; Chen, Q; Falck, JR; Reddy, KK; Keen, JH			A functional phosphatidylinositol 3,4,5-trisphosphate/phosphoinositide binding domain in the clathrin adaptor AP-2 alpha subunit - Implications for the endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY PROTEIN AP-2; INOSITOL POLYPHOSPHATE RECEPTOR; GROWTH-FACTOR RECEPTOR; PLANAR LIPID BILAYERS; HIGH-AFFINITY BINDING; PLASMA-MEMBRANE; PHOSPHOINOSITIDE-3 KINASE; COATED VESICLES; 3-KINASE; INTERNALIZATION	Clathrin-coated pits are sites of concentration of ligand-bound signaling receptors. Several such receptors are known to recruit, bind, and activate the heterodimeric phosphatidylinositol-3-kinase, resulting in the generation of phosphatidylinositol 3,4,5-trisphosphate. We report here that dioctanoyl-phosphatidylinositol-3,4,5-P-3 binds specifically and saturably to soluble AP-2 and with greater affinity to AP-2 within assembled coat structures. Soluble D-myo-inositol hexakisphosphate shows converse behavior. Binding to bovine brain clathrin-coated vesicles is evident, only after detergent extraction. These observations and evidence for recognition of the diacylglyceryl backbone as well as the inositol phosphate headgroup are consistent with AP-2 interaction with membrane phosphoinositides in coated vesicles and with soluble inositol phosphates in cytoplasm. A discrete binding domain is identified near the N terminus of the AP-2 alpha subunit, and an expressed fusion protein containing this sequence exhibits specific, high affinity binding that is virtually identical to the parent protein. This region of the AP-2 alpha sequence also shows the greatest conservation between a Caenorhabditis elegans homolog and mammalian alpha, consistent with a function in recognition of an evolutionarily unchanging low molecular weight ligand. Binding of phosphatidylinositol 3,4,5-trisphosphate to AP-2 inhibits the protein's clathrin binding and assembly activities. These findings are discussed in the context of the potential roles of phosphoinositides and AP-2 in the internalization and trafficking of cell surface receptors.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235	Jefferson University; Jefferson University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845	NIGMS NIH HHS [GM-49217] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049217] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BECK KA, 1992, J CELL BIOL, V119, P787, DOI 10.1083/jcb.119.4.787; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; FLEISCHER B, 1994, J BIOL CHEM, V269, P71826; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JAUREGUIADELL J, 1975, ANAL BIOCHEM, V69, P468, DOI 10.1016/0003-2697(75)90148-7; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KIJIMA Y, 1993, J BIOL CHEM, V268, P16253; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KISHTA K, 1995, J ORG CHEM, V60, P3385; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Merisko E M, 1986, Pancreas, V1, P95, DOI 10.1097/00006676-198603000-00001; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	71	142	143	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20922	20929		10.1074/jbc.271.34.20922	http://dx.doi.org/10.1074/jbc.271.34.20922			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702850	hybrid			2022-12-25	WOS:A1996VD33700102
J	Jeffers, M; Rong, S; Anver, M; VandeWoude, GF				Jeffers, M; Rong, S; Anver, M; VandeWoude, GF			Autocrine hepatocyte growth factor scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells	ONCOGENE			English	Article						hepatocyte growth factor scatter factor; Met; transformation; invasion; metastasis	FACTOR/SCATTER FACTOR; EPITHELIAL-CELLS; CARCINOMA-CELLS; TYROSINE KINASE; PROTOONCOGENE; RECEPTOR; TUMORIGENICITY; EXPRESSION; INDUCTION; INVASION	Hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic effector of cells expressing the Met tyrosine kinase receptor. C127 is a non-tumorigenic mouse cell line which expresses negligible levels of HGF/SF and Met proteins. In the present report we have generated C127 cells which overexpress HGP/SF and/or Met proteins, and have analysed the effect of HGF/SF-Met signaling in these cells. We show that this signaling pathway stimulates the growth and invasiveness of C127 cells in vitro and that cells overexpressing both HGF/SF and Met proteins (but neither alone) are phenotypically transformed and highly tumorigenic and metastatic in vivo. Our data unequivocally demonstrates the autocrine dependency of HGF/SF-Met-induced transformation and metastasis in this system and supports the theory that the inappropriate expression of HGF/SF and Met proteins could play a role in the development and spread of human tumors. In addition, this system may be useful for identifying metastasis-associated genes that are activated by HGF/SF-Met signaling.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								BELLUSCI S, 1994, ONCOGENE, V9, P1091; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; DVORETZKY I, 1980, VIROLOGY, V103, P309; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GHERARDI E, 1993, SYM SOC EXP BIOL, V47, P163; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Higashio K, 1993, EXS, V65, P351; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JEFFERS M, 1996, UNPUB; KANDA H, 1993, ONCOGENE, V8, P3047; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Matsumoto K, 1993, HEPATOCYTE GROWTH FA, P225; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PORTEOUS DJ, 1986, INT J CANCER, V38, P603, DOI 10.1002/ijc.2910380422; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; ROSEN EM, 1991, CANCER RES, V51, P5315; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SINGHKAW P, 1995, AM J PHYSIOL-LUNG C, V268, pL1012, DOI 10.1152/ajplung.1995.268.6.L1012; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT A, 1995, DEVELOPMENT, V121, P813; SUNITHA I, 1994, CLIN EXP METASTAS, V12, P143, DOI 10.1007/BF01753981; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANG Y, 1995, J CELL BIOL, V131, P1	49	118	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					853	861						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761307				2022-12-25	WOS:A1996VD43300021
J	Li, WQ; Michieli, P; Alimandi, M; Lorenzi, MV; Wu, YM; Wang, LH; Heidaran, MA; Pierce, JH				Li, WQ; Michieli, P; Alimandi, M; Lorenzi, MV; Wu, YM; Wang, LH; Heidaran, MA; Pierce, JH			Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells	ONCOGENE			English	Article						Sis; transformation; PKC-delta	PROTEIN-KINASE-C; SIMIAN SARCOMA-VIRUS; ALPHA-PDGF RECEPTOR; GROWTH-FACTOR; SIGNALING PATHWAYS; 3T3 CELLS; H-RAS; ACTIVATION; LOCALIZATION; SEQUENCE	In an effort to determine the role of protein kinase C-delta (PKC-delta) in cellular transformation mediated by the sis proto-oncogene, we cotransfected expression vectors containing cDNAs that encode for c-sis with an ATP binding mutant of PKC-delta (PKC-delta K376R) or wild type PKC-delta (PKC-delta WT) into NTH3T3 cells, Our results showed that expression of PKC-delta K376R severely impaired Sis-induced focus formation, whereas cotransfection of PKC-delta WT cDNA had no effect on Sis-mediated transformation, Consistent with this result, PKC-delta K376R expression also inhibited PDGF-BB-mediated anchorage-independent colony While cotransfection of a vector containing a dominant negative mutant of uas (N17 ras) cDNA potently inhibited Sis-induced transformation, the expression of PKC-delta K376R did not block transformation mediated by v-H-Ras or v-Raf, In addition, PDGF-BB-induced Raf and mitogen-activated protein kinase activation, which are known to be downstream molecules in the Ras cascade, were not affected by the expression of PKC-delta K376R, indicating that PKC-delta and Ras are segregated in mediating Sis-induced transformation. Interestingly, expression of PKC-delta K376R strongly reduced TPA responsive element (TRE) transactivation induced by PDGF stimulation, suggesting that activation of TRE-containing genes, which may be involved in Sis-mediated transformation, are negatively regulated by expression of PKC-delta K376R.	NIDR,IMMUNOL LAB,BETHESDA,MD 20892; CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Li, WQ (corresponding author), NCI,CELLULAR & MOL BIOL LAB,BLDG 37,ROOM 1E24,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871; Alimandi, Maurizio/0000-0002-1409-6803				BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BECKMANN R, 1994, EUR J BIOCHEM, V222, P335, DOI 10.1111/j.1432-1033.1994.tb18872.x; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALANG CK, 1994, ONCOGENE, V9, P2913; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KROOK A, 1993, MOL CELL BIOL, V13, P1471, DOI 10.1128/MCB.13.3.1471; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; Li W, 1996, CURR TOP MICROBIOL, V211, P55; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHARMA RV, 1993, AM J PHYSIOL, V264, pC71, DOI 10.1152/ajpcell.1993.264.1.C71; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1995, J BIOL CHEM, V270, P7033, DOI 10.1074/jbc.270.13.7033; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	38	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761294				2022-12-25	WOS:A1996VD43300008
J	Paulin, FEM; West, MJ; Sullivan, NF; Whitney, RL; Lyne, L; Willis, AE				Paulin, FEM; West, MJ; Sullivan, NF; Whitney, RL; Lyne, L; Willis, AE			Aberrant translational control of the c-myc gene in multiple myeloma	ONCOGENE			English	Article						c-myc; translational control; multiple myeloma	MESSENGER-RNA TRANSLATION; 5' UNTRANSLATED REGION; PLASMA-CELLS; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; NONCODING REGION; 1ST EXON; P53 GENE; EXPRESSION; ONCOGENE	We demonstrate a 10- to 25-fold increase in the amount of c-myc protein in several independent cell lines derived from patients with multiple myeloma (MM). This is not accompanied by a corresponding increase in the overall level of the c-my mRNA. There is, however, a 3.4-fold increase in the amount of c-myc mRNA associated with the polysomes in these cell Lines without any detectable change in either the polysome size or the rate of translation elongation, thus suggesting that there is an increase in the extent of mobilisation of c-myc mRNA to the polysomes in MM. Analysis of the 5' untranslated region of c-myc has revealed the presence of a mutation, in all of the MM cell lines examined, in a region which has been implicated previously in the translational control of this mRNA species. These data suggest aberrant translational control of the c-myc gene in cell lines derived from patients with MM, which may contribute towards pathogenesis of the disease.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; NUVENTURES LTD,NEWCASTLE TYNE NE2 4HE,TYNE & WEAR,ENGLAND; JESSOP HOSP WOMEN,DEPT OBSTET & GYNAECOL,SHEFFIELD S3 7RE,S YORKSHIRE,ENGLAND	University of Leicester				West, Michelle/0000-0002-9497-9365; Willis, Anne/0000-0002-1470-8531				BARKER HF, 1992, BRIT J HAEMATOL, V81, P331, DOI 10.1111/j.1365-2141.1992.tb08236.x; CORRADINI P, 1993, BLOOD, V81, P2708; CROCE CM, 1985, BLOOD, V65, P1; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Davidson E. H., 1986, GENE ACTIVITY EARLY; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; GREIL R, 1991, BLOOD, V78, P180; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HATA H, 1993, BLOOD, V81, P3357; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JOHANNES G, 1992, J BIOL CHEM, V267, P10108; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LAZARUS P, 1992, ONCOGENE, V7, P1037; Lewis J P, 1984, Hematol Oncol, V2, P307; MAZARS GR, 1992, ONCOGENE, V7, P1015; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1993, BLOOD, V81, P128; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1989, ONCOGENE, V4, P815; PETTERSSON M, 1992, BLOOD, V79, P495; PORTIER M, 1992, ONCOGENE, V7, P2539; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SULLIVAN NF, 1989, ONCOGENE, V4, P1509; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; VANCAMP B, 1990, BLOOD, V76, P377; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; West MJ, 1995, ONCOGENE, V11, P2515	42	51	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					505	513						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760292				2022-12-25	WOS:A1996VB32800008
J	Akagi, T; Ono, H; Shimotohno, K				Akagi, T; Ono, H; Shimotohno, K			Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells	ONCOGENE			English	Article						tyrosine kinase; cell cycle; herbimycin A; cdk6; stability; T-cell	RETINOBLASTOMA SUSCEPTIBILITY GENE; PHOSPHORYLATION; EXPRESSION; PRODUCT; REQUIREMENTS; SPECIFICITY; ACTIVATION; LEUKOCYTES; MUTATIONS; FAMILY	The Cdk6 protein level rapidly decreased after treatment with the tyrosine kinase inhibitor herbimycin A in human T-cell lines. This decrease is fairly specific, because the level of other Cdks such as Cdk2 and Cdk4 and cyclins such as cyclin D2, cyclin E and cyclin A, did not change significantly even after 24 h treatment with herbimycin A. Pulse-chase analysis revealed that the decrease in the Cdk6 protein level results from reduced stability of the protein. Our results suggest that herbimycin A-sensitive protein tyrosine kinase(s) are involved in the regulation of the Cdk6 protein level.	NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan								AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; BATES S, 1994, ONCOGENE, V9, P1633; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GAZDAR AF, 1980, BLOOD, V55, P409; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MODIANO JF, 1994, J BIOL CHEM, V269, P32972; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UMEZAWA K, 1991, METHOD ENZYMOL, V201, P379; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; XU HJ, 1991, ONCOGENE, V6, P1139; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467	35	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					399	405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710379				2022-12-25	WOS:A1996VA25200019
J	Auger, KR; Zhou, SY; Lo, SH; Roberts, TM; Chen, LB				Auger, KR; Zhou, SY; Lo, SH; Roberts, TM; Chen, LB			Platelet-derived growth factor-induced formation of tensin and phosphoinositide 3-kinase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; BINDING-SITE; ASSOCIATION; DOMAINS; ACTIN	Tensin is an SH2 domain-containing cytoskeletal protein that binds to and caps actin filaments. Investigation of signal transduction mechanisms associated with tensin revealed the presence of phosphoinositide 3-kinase (PI 3-kinase) activity in tensin immunoprecipitates from platelet derived growth factor-treated cells. Association of PI 3-kinase activity with tensin was transitory, and the amount of activity was approximately 1% of the total PI 3-kinase activity found in anti-phosphotyrosine (anti-pY) immunoprecipitates. In vitro, PI 3-kinase activity associated with the SH2 domain of tensin in a platelet-derived growth factor-dependent manner. The optimal phosphopeptide binding specificity of the SH2 domain of tensin was determined to be phospho-Y (E or D), N, (I, V, or F). Synthetic phosphopeptides containing the sequence YENI could specifically block the association of PI 3-kinase activity with tensin in a dose dependent manner. These results suggest that PI 3-kinase interacts with the cytoskeleton via the SH2 domain of tensin and may play an important role in platelet-derived growth factor-induced cytoskeletal reorganization that is concomitant with cell migration and proliferation.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Tufts University; Harvard University; Beth Israel Deaconess Medical Center	Auger, KR (corresponding author), DANA FARBER CANC INST, DIV CELL & MOL BIOL, 44 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [CA30002] Funding Source: Medline; NIGMS NIH HHS [GM22427] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030002, R37CA030002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auger K. R., 1990, METHODS INOSITIDE RE, P159; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALDWIN GS, 1993, TRENDS BIOCHEM SCI, V18, P378, DOI 10.1016/0968-0004(93)90093-3; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE M, 1994, BIOCHEM J, V222, P195; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LO SH, 1994, J BIOL CHEM, V269, P22310; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	49	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23452	23457		10.1074/jbc.271.38.23452	http://dx.doi.org/10.1074/jbc.271.38.23452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798552	hybrid			2022-12-25	WOS:A1996VH76800078
J	Brunke, M; Dierks, T; Schlotterhose, P; Escher, A; Schmidt, B; Szalay, AA; Lechte, M; Sandholzer, U; Zimmermann, R				Brunke, M; Dierks, T; Schlotterhose, P; Escher, A; Schmidt, B; Szalay, AA; Lechte, M; Sandholzer, U; Zimmermann, R			Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BACTERIAL LUCIFERASE; CYCLOSPORINE-A; PROTEIN TRANSLOCATION; PRESECRETORY PROTEINS; TRIPLE-HELIX; CYCLOPHILIN; INVIVO; MEMBRANE; LUMEN	The assembly of a heterodimeric luciferase was studied after de novo synthesis of corresponding precursor proteins in reticulocyte lysate and concomitant transport into dog pancreas microsomes. This cytosolic luciferase from a prokaryotic organism (Vibrio harveyi) was specifically used as a model protein to investigate (i) whether the eukaryotic cytosol and the microsomal lumen have similar folding capabilities and (ii) whether the requirements of a polypeptide for certain molecular chaperones and folding catalysts are determined by the polypeptide or the intracellular compartment, The two luciferase subunits were fused to the preprolactin signal peptide, Data indicate that efficient assembly of luciferase occurs in the mammalian microsomes, Furthermore, it was observed that luciferase assembly can be separated in time from synthesis and membrane transport, depends on ATP hydrolysis, is partially sensitive to cyclosporin A and FK506, and in the absence of lumenal proteins is less efficient as compared with the presence of lumenal proteins, Thus, heterodimeric luciferase depends on functionally related molecular chaperones and folding catalysts during its assembly in either the eukaryotic cytosol or the microsomal lumen.	UNIV SAARLAND,D-66421 HOMBURG,GERMANY; UNIV GOTTINGEN,INST BIOCHEM & MOL ZELLBIOL,D-37073 GOTTINGEN,GERMANY; UNIV ALBERTA,DEPT PLANT SCI,PLANT MOL GENET LAB,EDMONTON,AB T6G 2P5,CANADA	Saarland University; University of Gottingen; University of Alberta			Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOSE S, 1994, BIOCHEM J, V300, P871, DOI 10.1042/bj3000871; BOSE S, 1994, BIOCHEM J, V300, P865, DOI 10.1042/bj3000865; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ESCHER A, 1993, MOL GEN GENET, V238, P65, DOI 10.1007/BF00279532; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, TRENDS BIOCHEM SCI, V19, P227; Higuchi R., 1989, PCR TECHNOLOGY, P61; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KRUSE M, 1995, J BIOL CHEM, V270, P2588, DOI 10.1074/jbc.270.6.2588; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OLSSON O, 1988, MOL GEN GENET, V215, P1, DOI 10.1007/BF00331295; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHLENSTEDT G, 1992, J BIOL CHEM, V267, P24328; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760; [No title captured]	40	9	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23487	23494		10.1074/jbc.271.38.23487	http://dx.doi.org/10.1074/jbc.271.38.23487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798557	hybrid			2022-12-25	WOS:A1996VH76800083
J	Charng, MJ; Kinnunen, P; Hawker, J; Brand, T; Schneider, MD				Charng, MJ; Kinnunen, P; Hawker, J; Brand, T; Schneider, MD			FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; MESODERM INDUCTION; COMPLEX; EXPRESSION; CLONING; ACTIVIN; REQUIRES; DOMAINS; CELLS	The FK506-binding protein, FKBP12, is a putative target of type I receptors for transforming growth factor-beta (T beta R-I). As the FK506 motif that competes with T beta R-I for FKBP12 resembles an invariant Leu-Pro dipeptide in T beta R-I, we replaced Leu(193) and Pro(194) with Ala, along with mutations across the Gly/Ser box. L193A, P194A, and L193A/P194A do not alter T beta R-I function; T204D partially activates, independent of ligand; L193A/P194A/T204D was an even more potent constitutive mutation, Association with FKBP12 in a yeast two-hybrid assay was disrupted by P194A, L193A/P194A, and L193A/P194A/T204D, but not L193A or T204D alone. Thus, FKBP12 recognition is dispensable for TGF beta signaling.	BAYLOR COLL MED,MOL CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PHYSIOL & MOL BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Brand, Thomas/AAR-7545-2020	Brand, Thomas/0000-0001-7090-5356	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047567, P01HL049953, R01HL052555] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL47567, P01 HL49953, R01 HL52555] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; BRAND T, 1993, J BIOL CHEM, V268, P11500; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LABONNE C, 1994, DEVELOPMENT, V120, P463; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	26	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22941	22944		10.1074/jbc.271.38.22941	http://dx.doi.org/10.1074/jbc.271.38.22941			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798476				2022-12-25	WOS:A1996VH76800002
J	Orpiszewski, J; Aswad, DW				Orpiszewski, J; Aswad, DW			High mass methyl-accepting protein (HMAP), a highly effective endogenous substrate for protein L-isoaspartyl methyltransferase in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL RESIDUES; CARBOXYL METHYLTRANSFERASE; O-METHYLTRANSFERASE; REPAIR; PEPTIDES; DEAMIDATION; POLYPEPTIDES; ERYTHROCYTE; RECOGNITION; CONVERSION	A previously unidentified endogenous substrate for protein L-isoaspartyl methyltransferase in mammalian brain has been characterized and partially purified. This high mass methyl-accepting protein (HMAP) is concentrated in rat brain cytosol and is not detectable in rat liver, heart, lung, kidney, or skeletal muscle, HMAP is acidic and heterogeneous in size, with an average mass, as judged by size exclusion high performance liquid chromatography, greater than 700 kDa, After partial purification from cow brain by anion-exchange chromatography, ammonium sulfate fractionation, and gel filtration, HMAP could accept 12.1 nmol of methyl groups per mg of protein, suggesting that it contains a level of isoaspartate at least 50 times greater than that of the average protein in brain cytosol. Partially purified HMAP is degraded by trypsin, verifying that it is composed, at least in part, of protein. Additional studies on this unusual macromolecule may shed important new light on mechanisms of isoaspartate formation in cells and the molecular pathology of brain aging.	UNIV CALIF IRVINE,DEPT BIOCHEM & MOL BIOL,IRVINE,CA 92697	University of California System; University of California Irvine					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17269] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRENNAN TV, 1995, DEAMIDATION ISOASPAR, P65; DAVID CL, 1995, PROTEIN EXPRES PURIF, V6, P312, DOI 10.1006/prep.1995.1041; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; FAIRBANKS G, 1972, Journal of Supramolecular Structure, V1, P66, DOI 10.1002/jss.400010110; GALLETTI P, 1995, BIOCHEM J, V306, P313, DOI 10.1042/bj3060313; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; JOHNSON BA, 1991, BIOCHEM INT, V24, P841; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; JONES AJ, 1983, BIOCHEM J, V211, P499, DOI 10.1042/bj2110499; KIM S, 1971, BIOCHIM BIOPHYS ACTA, V252, P526, DOI 10.1016/0304-4165(71)90155-3; LADINO CA, 1992, J CELL PHYSIOL, V153, P297, DOI 10.1002/jcp.1041530209; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072	26	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22965	22968		10.1074/jbc.271.38.22965	http://dx.doi.org/10.1074/jbc.271.38.22965			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798482	hybrid			2022-12-25	WOS:A1996VH76800008
J	Zhu, XR; Lamango, NS; Lindberg, I				Zhu, XR; Lamango, NS; Lindberg, I			Involvement of a polyproline helix-like structure in the interaction of 7B2 with prohormone convertase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDES; SH3 DOMAINS; NEUROENDOCRINE CHAPERONE; TYROSINE KINASE; BINDING; PC2; POLYPEPTIDE; PROTEINS; FAMILY; CELLS	The neuroendocrine protein 7B2 is known to be involved in the biosynthesis and activity of prohormone convertase 2 (PC2). Previous studies have demonstrated that while the carboxyl-terminal portion of 7B2 (residues 155-186) regulates the enzymatic activity of PC2, the amino terminus of the molecule (residues 1-151) is required for maturation of proPC2. In this study we employed four different experimental approaches (co-immunoprecipitation with proPC2, facilitation of proPC2 maturation, acquisition of enzymatic activity, and thermal protection assays) to identify structural elements of 7B2 important for bioactivity. Inspection of the sequence of 7B2 indicated potential involvement of a polyproline helix-like (PPII) structure, with similarities to those present within SH3 domain ligands, in the interaction of 7B2 with proPC2. Site-directed point mutagenesis of this proline-rich region confirmed the involvement of this area. Replacement of prolines in positions critical to helix formation (Pro(90), Pro(91), Pro(93), and Pro(95)) either severely impaired or totally abolished 7B2 bioactivity, as gauged by the four assays described. In addition, constructs longer than residues 1-121 were still functional, whereas those shorter than residues 1-109 were not. Computer-assisted analysis predicts the presence of an alpha-helix structure between residues 107 and 123. We conclude that both the proline-rich region and the alpha-helix contribute to 7B2 activity. Polyproline-containing peptides have been shown to be involved in cytoplasmic protein-protein interactions; our results suggest that the polyproline helix motif may also be used to mediate protein-protein interactions within the secretory pathway.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, NEW ORLEANS, LA 70112 USA	Louisiana State University System			Lindberg, Iris/Q-3825-2019; Lamango, Nazarius/W-8459-2019		NIDA NIH HHS [DA05084, R56 DA005084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BRAKS JAM, 1995, FEBS LETT, V371, P154, DOI 10.1016/0014-5793(95)00915-V; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; CEDERGRENZEPPEZ.ES, 1994, EMBO J, V13, P2341; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SHEN FS, 1993, J BIOL CHEM, V268, P24910; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	30	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23582	23587		10.1074/jbc.271.38.23582	http://dx.doi.org/10.1074/jbc.271.38.23582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798569	hybrid			2022-12-25	WOS:A1996VH76800095
J	Gregoire, CJ; Loret, EP				Gregoire, CJ; Loret, EP			Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 TAT; CIRCULAR-DICHROISM; TRANS-ACTIVATOR; SECONDARY STRUCTURE; RNA RECOGNITION; BINDING; TRANSACTIVATION; INVITRO; COMPLEX; INDUCTION	TAT protein is an essential regulatory protein of the human immunodeficiency virus type 1 (HIV-1). Inhibition of TAT activity blocks the virus cycle, and a drug that blocks TAT is one of the possibilities to cure AIDS. Circular dichroism (CD) was measured for TAT peptides covering the TAT sequence with overlaps. The CD spectrum of each peptide was measured in different solvents to evaluate the ability of each TAT region to form different secondary structures, The most variation or conformational heterogeneity is observed with the two regions adjacent to the TAT basic region. CD data show that the basic region can adopt an extended structure in a full TAT protein, which is not the case for the isolated peptide, TAT sequences from the different HIV-1 isolates were analyzed, and the results showed that the sequences could be gathered into six groups. Molecular modeling was done on the various isolates based on a TAT structure from two-dimensional NMR. After minimization and dynamic steps, the modeled three dimensional structures were compared. The results showed structural variations of the TAT protein as a function of the HIV-1 isolates, These structural variations were mainly in the two regions adjacent to the basic region, confirming the conformational heterogeneity indicated by the CD measurements. Furthermore, Chou-Fasman analysis shows significant changes in propensities for each secondary structure only for regions III and V, This conformational heterogeneity should be essential for TAT activity and points out that regions III and V are a poor potential target to design a TAT ligand. We propose a target involving TAT structurally conserved regions, accessible whatever the size of the TAT C terminus.	CNRS,UPR 9027,LAB INGN & DYNAM SYST MEMBRANAIRES,INST BIOL STRUCT & MICROBIOL,F-13402 MARSEILLE 20,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN JB, 1991, GENE DEV, V5, P210; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CORPET F, 1989, NUCLEIC ACIDS RES, V22, P10881; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; JONES AK, 1994, ANNREV BIOCH, V63, P717; KAMINE J, 1991, VIROLOGY, V182, P570, DOI 10.1016/0042-6822(91)90598-6; KOKEN SEC, 1994, J BIOL CHEM, V269, P8366; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MATHEWS CK, 1990, BIOCHEMISTRY-US, P176; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MUJEEB A, 1994, P NATL ACAD SCI USA, V91, P8248, DOI 10.1073/pnas.91.17.8248; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAPPAPORT J, 1989, New Biologist, V1, P101; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SANGER F, 1963, BIOCHIM BIOPHYS ACTA, V71, P468, DOI 10.1016/0006-3002(63)91108-9; WATERHOUS DV, 1994, BIOCHEMISTRY-US, V33, P2121, DOI 10.1021/bi00174a019; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x	40	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22641	22646		10.1074/jbc.271.37.22641	http://dx.doi.org/10.1074/jbc.271.37.22641			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798435	hybrid			2022-12-25	WOS:A1996VG67200054
J	Hill, JR; Corbett, JA; Kwon, G; Marshall, CA; McDaniel, ML				Hill, JR; Corbett, JA; Kwon, G; Marshall, CA; McDaniel, ML			Nitric oxide regulates interleukin 1 bioactivity released from murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ANTAGONIST; IL-1-BETA; INHIBITION; BINDING; ALPHA; IDENTIFICATION; THIOREDOXIN; IL-1-ALPHA; SUPEROXIDE; APOPTOSIS	The bioactivity of interleukin-1 (IL-1), a major proinflammatory cytokine, can be modulated by a variety of factors including inhibitors of IL-1 production and release and receptor blockade by IL-1 receptor antagonist and by binding to nonsignaling soluble receptors. This study demonstrates that the free radical nitric oxide (NO) is also a regulator of IL-1 bioactivity. Lipopolysaccharide-activated murine macrophage RAW264.7 cells, and lipopolysaccharide plus interferon-gamma-activated murine peritoneal macrophages release IL-1 bioactivity, which is increased 10-fold over control levels by 24 h. N-G-Monomethyl L-arginine (NMMA), a nitric oxide synthase (NOS) inhibitor, almost completely inhibits the release of IL-1 bioactivity from activated macrophages in a time- and concentration-dependent manner with an IC50 of 50 mu M. IL-1 activity was determined by thymocyte proliferation bioassay and by a new spectrophotometric bioassay based on TL-1-specific induction of NOS and NO production by an insulinoma cell Line, RnNm5F. Neither NO nor NOS inhibitors present in the macrophage supernatant interfere with the bioassays. Aminoguanidine and iodonium diphenyl, mechanistically unrelated NOS inhibitors, also prevent the release of IL-1 activity hom RAW 264.7 cells. The addition of the NO donor S-nitrosoacetylpenicillamine reconstituted the release of IL-1 bioactivity inhibited by NMMA in a concentration-dependent manner. NO appears to increase the amount of IL-1 protein released by activated macrophages as determined by enzyme-linked immunosorbent assay, but not by mechanisms involving cell death nor modification of IL-1 precursor processing. A cGMP donor, 8-bromo-cGMP, dose-dependently reverses NMMA inhibition of bioactive IL-1 release, suggesting that NO regulates IL-1 release by a cGMP-dependent mechanism, These observations suggest that NO stimulation of the activity of IL-1, a key mediator of the immune response, may be a potentially important mechanism for control of IL-1 activity in vivo.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; ST LOUIS UNIV,DEPT BIOCHEM,ST LOUIS,MO 63104	Washington University (WUSTL); Saint Louis University					NIDDK NIH HHS [F32 DK-08748, DK-06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008748, R56DK006181, R01DK006181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; AREND WP, 1994, J IMMUNOL, V153, P4766; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BORTH W, 1990, J IMMUNOL, V145, P3747; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DINARELLO CA, 1993, TRENDS PHARMACOL SCI, V14, P155, DOI 10.1016/0165-6147(93)90200-4; ESTRADA C, 1992, BIOCHEM BIOPH RES CO, V186, P475, DOI 10.1016/S0006-291X(05)80832-0; Ferreira S H, 1993, Drugs, V46 Suppl 1, P1; GEARING AJH, 1985, J IMMUNOL METHODS, V83, P1, DOI 10.1016/0022-1759(85)90053-5; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; JESSOP JJ, 1993, LYMPHOKINE CYTOK RES, V12, P51; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LANCASTER JR, 1992, AM SCI, V80, P248; MICHETTIM, 1995, BIOCHEM BIOPH RES CO, V207, P1009; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUEGGE K, 1991, MEASUREMENT SOLUBLE, V1; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; REMVIG L, 1993, DAN MED BULL, V40, P255; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHEFFLER LA, 1995, J IMMUNOL, V155, P886; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TEODORESCU M, 1991, MOL IMMUNOL, V28, P323, DOI 10.1016/0161-5890(91)90144-9; WILLIAMS DLH, 1985, CHEM SOC REV, V14, P171, DOI 10.1039/cs9851400171; ZYCHLINSKY A, 1994, J CLIN INVEST, V94, P1328, DOI 10.1172/JCI117452	39	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22672	22678		10.1074/jbc.271.37.22672	http://dx.doi.org/10.1074/jbc.271.37.22672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798439	hybrid			2022-12-25	WOS:A1996VG67200058
J	Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ				Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ			tau couples the leading- and lagging-strand polymerases at the Escherichia coli DNA replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE HOLOENZYME PARTICLE; OKAZAKI FRAGMENT SIZE; III HOLOENZYME; SLIDING CLAMPS; INITIATION COMPLEX; PRIMER SYNTHESIS; BETA-SUBUNIT; BACTERIOPHAGE-T4; PURIFICATION; PROTEINS	Synthesis of an Okazaki fragment occurs once every 1 or 2 s at the Escherichia coli replication fork. To account for the rapid recycling required of the lagging-strand polymerase, it has been proposed that it is held at the replication fork by protein-protein interactions with the leading-strand polymerase as part of a dimeric polymerase assembly, Solution studies showed that the replicative polymerase, the DNA polymerase III holoenzyme, was indeed a dimer with two catalytic cores held together by the tau subunit. However, the functionality of this arrangement at the replication fork has never been demonstrated, We showed previously that the lagging-strand polymerase acted processively during multiple rounds of Okazaki fragment synthesis, i.e. the same polymerase core assembly synthesized each and every fragment made by the fork. Using extreme dilution of active replication forks and the isolation of protein-DNA complexes capable of supporting coupled leading- and lagging-strand synthesis, we demonstrate here that this coupling of leading- and lagging-strand synthesis is, in fact, mediated by the tau subunit of the holoenzyme acting as a physical bridge between the core assemblies synthesizing the leading and lagging strands.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOL BIOL,DENVER,CO 80262; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Memorial Sloan Kettering Cancer Center	Kim, S (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036255, R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36255, GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1989, J BIOL CHEM, V264, P12220; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LEE MS, 1989, J BIOL CHEM, V264, P14531; MAKI H, 1988, J BIOL CHEM, V263, P6570; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; SELICK HE, 1987, UCLA S MOL CELLULAR, P183; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; WU YH, 1984, J BIOL CHEM, V259, P2117; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	43	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21406	21412		10.1074/jbc.271.35.21406	http://dx.doi.org/10.1074/jbc.271.35.21406			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702922	hybrid			2022-12-25	WOS:A1996VE47700068
J	Terry, MJ; Kendrick, RE				Terry, MJ; Kendrick, RE			The aurea and yellow-green-2 mutants of tomato are deficient in phytochrome chromophore synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG HYPOCOTYL MUTANTS; IMMUNOCHEMICALLY DETECTABLE PHYTOCHROME; SHADE-AVOIDANCE RESPONSES; FAR-RED LIGHT; SIGNAL-TRANSDUCTION; BLUE-LIGHT; BIOSYNTHESIS; ARABIDOPSIS; EXPRESSION; PLANTS	The phytochrome-deficient aurea mutant of tomato has been widely used for the study of both phytochrome function and the role of other photoreceptors in the control of development in higher plants. To date the exact nature of the aurea mutation has remained unknown, though this information is clearly important for the interpretation of these studies. It has been proposed that aurea and yellow-green-2, another mutant of tomato that has a similar phenotype to aurea, could be deficient in phytochrome chromophore synthesis. We have examined this hypothesis by measuring the activity of the enzymes committed to phytochrome chromophore synthesis in these mutants. The approach takes advantage of a recently developed high pressure liquid chromatography-based assay for the synthesis of the free phytochrome chromophore, phytochromobilin from its immediate precursors biliverdin IX alpha and heme. Isolated etioplasts from aurea and yellow-green-2 seedlings were specifically unable to convert biliverdin IX alpha to 3Z-phytochromobilin and heme to biliverdin IX alpha, respectively. In addition, the level of total noncovalently bound heme in the mutants was the same as in wild type seedlings. Together, these results identify both aurea and yellow-green-2 as mutants that are deficient in phytochrome chromophore synthesis.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,LAB PHOTOPERCEPT & SIGNAL TRANSDUCT,WAKO,SAITAMA 35101,JAPAN	RIKEN	Terry, MJ (corresponding author), UNIV SOUTHAMPTON,DEPT BIOL,BASSETT CRESCENT E,BIOMED SCI BLDG,SOUTHAMPTON SO16 7PX,HANTS,ENGLAND.		Terry, Matthew/B-3000-2012; Terry, Matthew/ABE-6419-2020	Terry, Matthew/0000-0001-5002-2708; Terry, Matthew/0000-0001-5002-2708				ADAMSE P, 1988, J PLANT PHYSIOL, V133, P436, DOI 10.1016/S0176-1617(88)80032-4; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; BECKER TW, 1992, PLANTA, V188, P39, DOI 10.1007/BF00198937; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burdick A.B., 1958, TOMATO GENET COOP RE, V8, P9; BUURMEIJER WF, 1987, PROGR PHOTOSYNTHESIS, V2, P383; CASAL JJ, 1993, PLANT CELL ENVIRON, V16, P703, DOI 10.1111/j.1365-3040.1993.tb00489.x; CHERESKIN BM, 1982, PLANT PHYSIOL, V68, P112; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; Darby L. A., 1978, UK, Glasshouse Crops Research Institute: Annual report 1977., P168; ELICH TD, 1989, J BIOL CHEM, V264, P183; ELICH TD, 1987, PLANT PHYSIOL, V84, P304, DOI 10.1104/pp.84.2.304; GEORGHIOU K, 1991, PHYSIOL PLANTARUM, V82, P127, DOI 10.1111/j.1399-3054.1991.tb02912.x; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KENDROR S, 1990, PLANT PHYSIOL, V9, P1004; KERCKHOFFS LHJ, 1992, PHOTOCHEM PHOTOBIOL, V56, P611, DOI 10.1111/j.1751-1097.1992.tb02210.x; KERR EA, 1979, TOMATO GENET COOP RE, V29, P27; KHUSH GS, 1968, CHROMOSOMA, V23, P452, DOI 10.1007/BF00625288; Koornneef M., 1981, Induced mutations -- a tool in plant research. Proceedings of an international symposium. Vienna, 9-13 March 1981, P227; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; KOORNNEEF M, 1985, J PLANT PHYSIOL, V120, P153, DOI 10.1016/S0176-1617(85)80019-5; KRAEPIEL Y, 1994, MOL GEN GENET, V242, P559, DOI 10.1007/BF00285279; LEE HJ, 1991, PLANT PHYSIOL, V96, P910, DOI 10.1104/pp.96.3.910; LESLEY JW, 1956, GENETICS, V41, P575; LOPEZJUEZ E, 1990, J PHOTOCH PHOTOBIO B, V4, P391, DOI 10.1016/1011-1344(90)85018-R; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OELMULLER R, 1989, PLANT MOL BIOL, V13, P223, DOI 10.1007/BF00016140; OELMULLER R, 1991, PLANT MOL BIOL, V16, P293, DOI 10.1007/BF00020560; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; PARKS BM, 1987, PLANT MOL BIOL, V9, P97, DOI 10.1007/BF00015642; PARKS BM, 1989, PLANT MOL BIOL, V12, P425, DOI 10.1007/BF00017582; PETERS JL, 1992, PHOTOCHEM PHOTOBIOL, V56, P75, DOI 10.1111/j.1751-1097.1992.tb09605.x; PRATT LH, 1995, PHOTOCHEM PHOTOBIOL, V61, P10, DOI 10.1111/j.1751-1097.1995.tb09238.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; SHARMA R, 1993, PLANT J, V4, P1035, DOI 10.1046/j.1365-313X.1993.04061035.x; SHARROCK RA, 1988, MOL GEN GENET, V213, P9, DOI 10.1007/BF00333391; SMITH H, 1993, PLANT CELL ENVIRON, V16, P929, DOI 10.1111/j.1365-3040.1993.tb00516.x; SMITH KM, 1975, PORPHYRINS METALLOPO, P872; TERRY MJ, 1995, J BIOL CHEM, V270, P11111, DOI 10.1074/jbc.270.19.11111; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; TERRY MJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P1, DOI 10.1006/abbi.1993.1473; VANTUINEN A, 1995, PLANT PHYSIOL, V108, P939, DOI 10.1104/pp.108.3.939; VANTUINEN A, 1995, MOL GEN GENET, V246, P133, DOI 10.1007/BF00294675; vanTuinen A, 1996, PLANT J, V9, P173, DOI 10.1046/j.1365-313X.1996.09020173.x; Weller JL, 1996, PLANT CELL, V8, P55; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439; WHITELAM GC, 1994, PLANT CELL ENVIRON, V17, P615, DOI 10.1111/j.1365-3040.1994.tb00153.x; WHITELAM GC, 1991, J PLANT PHYSIOL, V139, P119, DOI 10.1016/S0176-1617(11)80176-8	52	81	86	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21681	21686		10.1074/jbc.271.35.21681	http://dx.doi.org/10.1074/jbc.271.35.21681			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702958	hybrid			2022-12-25	WOS:A1996VE47700104
J	Pei, L				Pei, L			Identification of a negative glucocorticoid response element in the rat type 1 vasoactive intestinal polypeptide receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ENHANCER; DNA ELEMENT; HORMONE; LUNG; EXPRESSION; BINDING; INHIBITION; PROMOTER; PEPTIDE; MODULATION	Glucocorticoids play important roles in lung development and function by modulating the expression of a variety of genes. The type 1 vasoactive intestinal polypeptide (VIP) receptor gene is highly expressed in the lung where it mediates VIP physiological functions. In this study, the effect of glucocorticoid on VIP receptor gene expression was examined. Dexamethasone (100 nM) suppresses endogenous VIP receptor mRNA expression in cultured lung cells. Transient transfection of lung cells with fusion constructs containing various portions of the VIP receptor 5'-flanking sequences linked to the luciferase reporter gene shows that 126 base pairs (bp) of the VIP receptor upstream sequences are sufficient to mediate transcriptional repression by glucocorticoid. DNase I footprinting demonstrates that purified glucocorticoid receptor (Gat) binds to the VIP receptor promoter between -21 and -36 bp relative to the transcription start site. Point mutations within this binding site not only abolish GR binding and GR-mediated transcriptional repression of the VIP receptor gene, but basal transcription is also reduced to background levels, Co-transfection of GR expression vector and the VIP receptor GR binding site linked to the thymidine kinase promoter and luciferase shows that this sequence is sufficient to confer glucocorticoid-mediated transcriptional repression to a heterologous promoter. These results indicate that the VIP receptor gene contains a negative glucocorticoid response element between -21 and -36 bp that may act to regulate both basal and glucocorticoid-mediated expressions of the VIP receptor gene in lung cells.	UNIV CALIF LOS ANGELES, CEDARS SINAI RES INST, SCH MED, DIV ENDOCRINOL, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRODY JS, 1992, ANNU REV PHYSIOL, V54, P351, DOI 10.1146/annurev.physiol.54.1.351; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P1409; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHARRON J, 1986, P NATL ACAD SCI USA, V83, P8903, DOI 10.1073/pnas.83.23.8903; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LITWIN D K, 1989, American Review of Respiratory Disease, V139, pA158; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MARIENCHECK W, 1994, AM J RESP CELL MOL, V10, P419, DOI 10.1165/ajrcmb.10.4.8136157; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; OTTAWAY CA, 1987, IMMUNOLOGY, V62, P291; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PEI L, 1995, BIOCHEM J, V308, P719, DOI 10.1042/bj3080719; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SAID SI, 1988, ANN NY ACAD SCI, V527, P450; SAID SI, 1987, AM REV RESPIR DIS S, V136, P525; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SARANTOS P, 1993, METABOLISM, V42, P795, DOI 10.1016/0026-0495(93)90252-J; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P934; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCREEDHARAN SP, 1993, BIOCH BOPHYS RES COM, V193, P546; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; WASCHEK JA, 1995, CANCER LETT, V92, P143, DOI 10.1016/0304-3835(95)03768-R; WRANGE O, 1989, J BIOL CHEM, V264, P5253; WRANGE O, 1986, J BIOL CHEM, V261, P1770; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZITNIK RJ, 1994, AM J RESP CELL MOL, V10, P643, DOI 10.1165/ajrcmb.10.6.7516173	42	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20879	20884						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702844				2022-12-25	WOS:A1996VD33700096
J	Young, P; Andersson, J; Sahlin, M; Sjoberg, BM				Young, P; Andersson, J; Sahlin, M; Sjoberg, BM			Bacteriophage T4 anaerobic ribonucleotide reductase contains a stable glycyl radical at position 580	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; TYROSYL RADICAL-DIIRON(III) COFACTOR; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; MOSSBAUER SPECTROSCOPIES; DIPHOSPHATE REDUCTASE; PHENOTYPIC SELECTION; FE2+ REACTION; PROTEIN; IRON	It has been recently recognized that the class III anaerobic ribonucleotide reductase requires the presence of a second activating gene product, NrdG, me have proposed that the rob for NrdG involves the generation of an oxygen sensitive glycyl free radical within the NrdD enzyme, In this article we present the generation of such a glycyl free radical within the T4 NrdD subunit and its dependence upon the phage NrdG subunit, Initially, an overexpression system was created that allowed the joint production of T4 NrdD and T4 NrdG, With this system and in the presence of T4 NrdG, an oxygen-sensitive cleavage of NrdD was observed that mimicked the cleavage observed in phage infected Escherichia coli extracts, Under anaerobic conditions the presence of T4 NrdD with NrdG revealed a strong doublet EPR signal (g = 2.0039), Isotope labeling of the NrdD with [H-2]glycine and [C-13]glycine, respectively, confirmed the presence of a stabilized glycine radical, The unpaired electron is strongly coupled to C-2 in glycine and the doublet splitting originates from one of the alpha-protons, The glycine residue at position 580 was determined to be the radical containing residue through site-directed mutagenesis studies involving a G580A NrdD mutant, The glycyl radical generation was specific for the T4 NrdG, and the host E. coli NrdG was found to be unable to activate the phage reductase, Finally, anaerobic purification revealed the holoenzyme complex to contain iron, whereas the NrdD polypeptide was found to lack the metal, Our results suggest a tetrameric structure for the T4 anaerobic ribonucleotide reductase containing one homodimer each of NrdD and NrdG, with a single glycyl radical present.	UNIV STOCKHOLM, DEPT MOL BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ALBERTS BM, 1986, AM ZOOL, V26, P781; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BERGLUND O, 1972, J BIOL CHEM, V247, P7270; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; ELIASSON R, 1994, J BIOL CHEM, V269, P26116; ELIASSON R, 1995, BIOCHEM BIOPH RES CO, V214, P28, DOI 10.1006/bbrc.1995.2252; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ERIKSSON S, 1977, J BIOL CHEM, V252, P6132; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FREY M, 1994, J BIOL CHEM, V269, P12432; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARDER J, 1992, J BIOL CHEM, V267, P25548; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LING JS, 1994, J BIOL CHEM, V269, P5595; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P5712, DOI 10.1021/bi00017a002; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAWERS G, 1989, J BACTERIOL, V171, P2485, DOI 10.1128/jb.171.5.2485-2498.1989; SAWERS G, 1988, J BACTERIOL, V170, P5330, DOI 10.1128/jb.170.11.5330-5336.1988; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; STUBBE J, 1994, NATURE, V370, P502, DOI 10.1038/370502a0; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WATSON JD, 1987, MOL BIOL GENE, P1098; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005; YOUNG P, 1994, J BIOL CHEM, V269, P27815; YOUNG P, 1994, J BIOL CHEM, V269, P20229; ZEEH A, 1991, J BACTERIOL, V173, P6980, DOI 10.1128/jb.173.21.6980-6985.1991	44	46	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20770	20775		10.1074/jbc.271.34.20770	http://dx.doi.org/10.1074/jbc.271.34.20770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702830	hybrid			2022-12-25	WOS:A1996VD33700082
J	Gotley, DC; Reeder, JA; Fawcett, J; Walsh, MD; Bates, P; Simmons, DL; Antalis, TM				Gotley, DC; Reeder, JA; Fawcett, J; Walsh, MD; Bates, P; Simmons, DL; Antalis, TM			The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases	ONCOGENE			English	Article						DCC; monoclonal antibodies; colon cancer; Dukes Stage; Western blotting	HUMAN TISSUES; FREQUENT LOSS; CARCINOMAS; CELLS; RNA; DIFFERENTIATION; PROGRESSION; INHIBITION	The DCC (deleted in colorectal cancer) gene was originally identified as a candidate tumour suppressor gene in colon carcinogenesis on the basis of allelic losses in chromosome 18q.21 in 70% of colon cancers, Reverse transcriptase polymerase chain reaction (RT-PCR) of DCC mRNA suggests that DCC expression may also be reduced in colon cancers, We have used monoclonal antibodies generated against the DCC immunoglobulinlike domain to investigate DCC isoforms and DCC protein expression during colon cancer progression, Normal mucosa and colonic tumour specimens representative of the range of colonic tumour progression from benign adenomatous polyps to metastases were compared by Western blot analyses, We show that while M(r) 194 000 DCC is present in normal colonic mucosa and adenomatous polyps, it is also similarly expressed in colorectal carcinomas and colonic metastases in the liver, The presence of DCC protein is consistent with the presence of DCC mRNA transcripts in the same tissue specimens. Notably DCC was not completely lost in any colonic tumour specimens examined, even those that had progressed to metastatic cancers, Quantitation of DCC protein expression in tissue specimens by densitometry demonstrated that both normal and malignant specimens exhibit a wide range of DCC protein levels and there was no significant correlation between diminished DCC protein expression and colon cancer progression, These results demonstrate the pattern of expression of the DCC gene product in colonic tumour progression and show that absence of DCC expression is not associated with colonic tumour progression.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,PRINCESS ALEXANDRA HOSP,DEPT SURG,BRISBANE,QLD 4029,AUSTRALIA; QUEENSLAND CANC FUND EXPT ONCOL UNIT,BRISBANE,QLD 4029,AUSTRALIA; GRIFFITH UNIV,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; GRIFFITH UNIV,FAC SCI & TECHNOL,BRISBANE,QLD 4029,AUSTRALIA; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,CELL ADHES LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,OXFORD OX3 9DU,ENGLAND	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Griffith University; QIMR Berghofer Medical Research Institute; Griffith University; University of Oxford; University of Oxford			Gotley, David/F-5481-2013	Gotley, David/0000-0002-8604-253X				ANTALIS TM, 1992, EUR J BIOCHEM, V205, P203, DOI 10.1111/j.1432-1033.1992.tb16769.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOX SB, 1994, CANCER RES, V54, P4539; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KUAN SF, 1989, J BIOL CHEM, V264, P19271; MIYAKE S, 1994, CANCER RES, V54, P3007; NARAYANAN R, 1992, ONCOGENE, V7, P553; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; REALE MA, 1994, CANCER RES, V54, P4493; SCHECK AC, 1993, CANCER RES, V53, P5605; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TURLEY H, 1995, CANCER RES, V55, P5628; UCHINO S, 1992, CANCER RES, V52, P3099; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	28	36	36	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					787	795						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761300				2022-12-25	WOS:A1996VD43300014
J	Wang, JK; Xu, H; Li, HC; Goldfarb, M				Wang, JK; Xu, H; Li, HC; Goldfarb, M			Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of Ras	ONCOGENE			English	Article						FGFR; SLP; Sos; p13(suc1)	FIBROBLAST GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; CELL-CYCLE CONTROL; PC12 CELLS; SIGNAL-TRANSDUCTION; POINT MUTATION; NEURONAL DIFFERENTIATION; NEUROTROPHIC FACTOR; INSULIN-RECEPTOR	SNT was originally described as a similar to 90 kilodalton protein in neuronal precursor cells which bears affinity for the yeast cell cycle protein p13(sucl) and which undergoes rapid tyrosine phosphorylation following stimulation with growth factors which trigger terminal differentiation, but not by other growth factors which promote proliferation (Rabin et al,, 1993), We show here that similarly sized SNT-like proteins (SLPs) are expressed in fibroblast, myoblast, and lymphoid cell lines, and undergo robust tyrosine phosphorylation in response to several mitogenic ligands, including fibroblast growth factors (FGFs). SLPs are tyrosine phosphorylated within 15 s of FGF stimulation, are predominantly membrane-associated, and are weakly associated with activated FGF receptor-1, suggesting that these proteins may be direct targets of the receptor kinase, Kinetic analysis of SLP phosphorylation and studies with serine/threonine kinase and phosphatase inhibitors suggest that SLPs are no larger than 70 000 kilodaltons, and that serine/threonine phosphorylation follows tyrosine phosphorylation to substantially retard gel electrophoretic mobility, SLPs are associated with the Grb-2 adaptor and are the major tyrosine phosphorylated proteins associated with the Ras guanine nucleotide exchange factor Sos in FGF-stimulated fibroblasts, suggesting that SLP-Grb2-Sos complexes modulate the activity of Ras proteins.	MT SINAI SCH MED, BROOKDALE CTR MOL BIOL, NEW YORK, NY 10029 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI HC, 1981, ARCH BIOCHEM BIOPHYS, V207, P270, DOI 10.1016/0003-9861(81)90034-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RICCI A, 1995, ONCOGENE, V11, P1519; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SALTON SRJ, 1991, MOL CELL BIOL, V11, P2335, DOI 10.1128/MCB.11.5.2335; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TOGARI A, 1985, J NEUROSCI, V5, P307; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; ZHANG B, 1991, J BIOL CHEM, V266, P990	58	90	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					721	729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761293				2022-12-25	WOS:A1996VD43300007
J	Sastry, KJ; Marin, MC; Nehete, PN; McConnell, K; ElNaggar, AK; McDonnell, TJ				Sastry, KJ; Marin, MC; Nehete, PN; McConnell, K; ElNaggar, AK; McDonnell, TJ			Expression of human immunodeficiency virus type 1 tat results in downregulation of bcl-2 and induction of apoptosis in hematopoietic cells	ONCOGENE			English	Article						HIV-1 tat; apoptosis; bcl-2; bax; Fas	PROTEIN INDUCES APOPTOSIS; HIV-1 TAT; T-CELLS; KAPOSIS-SARCOMA; GENE-EXPRESSION; DEATH; INFECTION; AIDS; LYMPHOCYTES; ACTIVATION	Infection by human immunodeficiency virus type 1 (HIV-1) is characterized by progressive loss of various cell types, mainly CD4(+) T lymphocytes. While a passive role for the virus in cell destruction is recognized, it does not account for the vast amount of cell death including those of uninfected 'bystander' cells. Since in the past we and others have demonstrated the capacity of the Tat protein of HIV-1 to modulate the expression of various cellular genes and that Tat secreted by HIV-infected cells can be readily taken up by various cell types, we have investigated the role of Tat on inducing apoptosis. Our results indicate that T lymphocytes transfected to constitutively express HIV-1 tat, when grown under serum-free conditions results in rapid apoptosis characterized by typical ultrastructural features and DNA fragmentation. Additionally, we observed that in several hematopoietic cell types, including T and B lymphoid cells and monocytoid cells, the expression of HIV-1 tat results in down-regulation of bcl-2, an oncogene with known potential for inhibition of apoptosis. The tat-mediated down-regulation of bcl-2 was observed at both the transcriptional and translational levels. Also, tat-transfected cells expressed increased amounts of bax, a bcl-2 family protein known to induce apoptosis. While these results support reports in the literature of an active role for tnt in inducing cell death in HIV-infected individuals, they point to a new mechanism involving Tat-mediated modulation of bcl-2 and bax.	BAYLOR COLL MED,DEPT MOL PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL ANAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	Sastry, KJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT VET SCI,SCI PK,ROUTE 2,BOX 151-B1,BASTROP,TX 78602, USA.		Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X; Sastry, Jagannadha/0000-0002-6987-4422	NCI NIH HHS [CA 09255] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; EMBERTSON J, 1993, NATURE, V362, P359; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; GORZYCA W, 1992, INT J ONCOL, V1, P639; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVY JA, 1994, HIV PATHOGENESIS AID, P77; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NATURE MED, V2, P118; PURVIS SF, 1995, AIDS RES HUM RETROV, V11, P443, DOI 10.1089/aid.1995.11.443; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; STECK KD, 1995, CYTOMETRY, V20, P154, DOI 10.1002/cyto.990200208; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TORNESELLO ML, 1993, INTERVIROLOGY, V36, P57, DOI 10.1159/000150322; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAULI G, 1993, CANCER RES, V53, P4481	37	92	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					487	493						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760290				2022-12-25	WOS:A1996VB32800006
J	Cattaneo, E; DeFraja, C; Conti, L; Reinach, B; Bolis, L; Govoni, S; Liboi, E				Cattaneo, E; DeFraja, C; Conti, L; Reinach, B; Bolis, L; Govoni, S; Liboi, E			Activation of the JAK/STAT pathway leads to proliferation of ST14A central nervous system progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; NEURONAL DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; NEUROTROPHIC FACTOR; INTERLEUKIN-3; EXPRESSION; BRAIN; SIGNALS	We were interested in whether central nervous system progenitor cells possess the signal transduction machinery necessary to mediate cytokine functions and whether this machinery can become activated upon stable expression of a particular cytokine receptor. For this purpose we utilized a previously obtained conditionally immortalized striatum-derived nestin-positive cell. line (ST14A). We found that ST14A cells express Jak2, but not Jak1 or Tyk2. An identical pattern of expression was found in embryonic striatal tissue. To evaluate the susceptibility of these cytokine specific cytoplasmic transducers to activation, ST14A cells were stably transfected with the alpha and beta (AIC2A) chains of the murine interleukin-3 receptor. Four independent lines expressing both the alpha and beta receptor subunits were obtained. We found that cells from each of these lines were induced to proliferate upon exposure to interleukin-3. Dose response curve, antibody blocking experiments and binding studies revealed that the response was mediated by the reconstituted high affinity interleukin-3 receptor. Immunoprecipitation studies on these cells showed that Jak2 and Stat5 were being phosphorylated after stimulation of the reconstituted receptor. These results indicate that members of the JAK/STAT family of proteins are expressed in central nervous system progenitor cells and are susceptible to activation through stimulation of an exogenously expressed cytokine receptor, ultimately leading to cell proliferation.	UNIV VERONA,INST BIOL CHEM,I-37100 VERONA,ITALY; UNIV PAVIA,INST PHARMACOL,I-27100 PAVIA,ITALY	University of Verona; University of Pavia	Cattaneo, E (corresponding author), UNIV MILAN,INST PHARMACOL SCI,VIA BALZARETTI 9,I-20133 MILAN,ITALY.		Govoni, Stefano/K-2965-2015; Conti, Luciano/H-4184-2012	Govoni, Stefano/0000-0002-7243-6837; Conti, Luciano/0000-0002-2050-9846; CATTANEO, ELENA/0000-0002-0755-4917				ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; CATTANEO E, 1994, DEV BRAIN RES, V83, P197, DOI 10.1016/0165-3806(94)00137-5; CATTANEO E, 1993, SOC NEUR ABSTR, V107, P6; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; FARRAR WL, 1989, BLOOD, V73, P137; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KAMEGAI M, 1990, NEURON, V2, P429; KONISHI Y, 1994, NEUROSCI LETT, V182, P271, DOI 10.1016/0304-3940(94)90814-1; KONISHI Y, 1995, J NEUROSCI RES, V41, P572, DOI 10.1002/jnr.490410503; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LIBOI E, 1992, BLOOD, V80, P1183; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LUNDBERG C, 1994, SOC NEUR ABSTR, V205, P2; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NICOLA NA, 1986, J CELL PHYSIOL, V128, P180, DOI 10.1002/jcp.1041280207; POUSSET F, 1994, DEV BRAIN RES, V81, P143, DOI 10.1016/0165-3806(94)90078-7; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; VANDERHEYDEN J, 1991, J IMMUNOL, V147, P3413; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YANG XJ, 1993, J NEUROSCI, V13, P3006; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	31	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23374	23379		10.1074/jbc.271.38.23374	http://dx.doi.org/10.1074/jbc.271.38.23374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798541	Green Published, hybrid			2022-12-25	WOS:A1996VH76800067
J	Dvir, A; Conaway, RC; Conaway, JW				Dvir, A; Conaway, RC; Conaway, JW			Promoter escape by RNA polymerase II - A role for an ATP cofactor in suppression of arrest by polymerase at promoter-proximal sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-DELTA; MAJOR LATE PROMOTER; ABORTIVE INITIATION; ELONGATION COMPLEXES; RUNOFF TRANSCRIPTS; FACTOR-EPSILON; BASAL FACTORS; RAT-LIVER; REQUIREMENT; INVITRO	It is well established that TFIIH-dependent transcription by RNA polymerase II requires a hydrolyzable ATP cofactor for synthesis of the first phosphodiester bond of nascent transcripts. Whether an ATP cofactor is also required after initiation for escape of RNA polymerase II from the promoter has, however, been controversial. We have now addressed this question directly by investigating the ability of RNA polymerase II transcription complexes containing short, similar to 5-8-nucleotide transcripts synthesized in the presence of limiting nucleotides to escape the promoter in the absence of an ATP cofactor in a basal transcription system reconstituted with purified RNA polymerase II and general initiation factors. Depletion of ATP had a profound effect on the ability of initiated complexes to progress into the elongation phase: whereas in the presence of ATP, the majority of transcription complexes could be chased away from the promoter proximal region, most complexes deprived of ATP catalyzed synthesis of only a few phosphodiester bonds and then ceased elongation after synthesizing transcripts less than 10-14 nucleotides in length. A significant fraction of these transcripts could be extended following addition of ATP, indicating that they were contained in arrested, but potentially active elongation complexes. Like the ATP-requiring step in initiation, ATP-dependent suppression of arrest by RNA polymerase II at promoter proximal sites is inhibited by adenosine 5'-O-(thio)triphosphate. Transcription complexes containing transcripts longer than 9-10 nucleotides are insensitive to inhibition by ATP gamma S, indicating that susceptibility to ATP sensitive arrest is a property of very early elongation complexes. Taken together, our findings reveal a novel role for an ATP cofactor in transcription by RNA polymerase II.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CAI H, 1987, J BIOL CHEM, V262, P298; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; ERNST H, 1983, MOL CELL BIOL, V3, P2172, DOI 10.1128/MCB.3.12.2172; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; JIANG Y, 1993, J BIOL CHEM, V268, P6535; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUSE DS, 1987, J BIOL CHEM, V262, P289; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TANTIN D, 1994, J BIOL CHEM, V269, P17397; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361	29	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23352	23356		10.1074/jbc.271.38.23352	http://dx.doi.org/10.1074/jbc.271.38.23352			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798537	hybrid			2022-12-25	WOS:A1996VH76800063
J	GopalSrivastava, R; Cvekl, A; Piatigorsky, J				GopalSrivastava, R; Cvekl, A; Piatigorsky, J			Pax-6 and alpha B-crystallin/small heat shock protein gene regulation in the murine lens - Interaction with the lens-specific regions, LSR1 and LSR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; RETINOIC ACID RECEPTOR; PAIRED DOMAIN; EYELESS GENE; EXPRESSION; IDENTIFICATION; DNA; FAMILY; MUTATIONS; ENHANCER	We have demonstrated previously that a transgene comprising the -164/+44 fragment of the murine alpha B-crystallin gene fused to the bacterial chloramphenicol acetyltransferase (cat) gene is lens-specific in transgenic mice. The -147 to -118 sequence was identified as a lens-specific regulatory region and is called here LSR1 for lens-specific region 1. In the present experiments, a -115/+44-cat transgene was also lens specific in transgenic mice, although the average activity was 30 times lower than that derived from the -164/+44-cat transgene. The -115/+44 alpha B-crystallin fragment contains a highly conserved region (-78 to -46) termed here LSR2. A -68/+44-cat transgene, in which LSR2 is truncated, was inactive in transgenic mice. DNase I footprinting indicated that LSR1 and LSR2 bind partially purified nuclear proteins from either alpha TN4-1 lens cells or the mouse lens as well as the purified paired domain of Pax-6. Site-specific mutation of LSR1 eliminated both Pax-6 binding and promoter activity of the -164/+44-cat transgene in transgenic mice. Finally antibody/electrophoretic mobility shift assays and cotransfection experiments indicated that Pax-6 can activate the alpha B-crystallin promoter via LSR1 and LSR2. Our data strengthen the idea that Pax-6 has had a major role in recruiting genes for high expression in the lens.	NEI, MOL & DEV BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			Cvekl, Ales/B-2427-2013					BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; CVEKL A, 1991, GENE, V103, P253, DOI 10.1016/0378-1119(91)90282-G; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DENNY P, 1992, NUCLEIC ACIDS RES, V20, P2887, DOI 10.1093/nar/20.11.2887; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Earle WR, 1943, J NATL CANCER I, V4, P165; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GLASER T, 1992, NAT GENET, V8, P463; GOPALSRIVASTAVA R, 1994, NUCLEIC ACIDS RES, V22, P1281, DOI 10.1093/nar/22.7.1281; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HALDER G, 1995, CURR OPIN GENET DEV, V5, P602, DOI 10.1016/0959-437X(95)80029-8; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HAYNES JI, 1996, IN PRESS DEV DYNAMIC; HENRY JJ, 1990, DEV BIOL, V141, P149, DOI 10.1016/0012-1606(90)90110-5; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN B, 1986, MANIPULATING MOUSE E, P174; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KEL OV, 1995, NUCLEIC ACIDS RES, V23, P4097, DOI 10.1093/nar/23.20.4097; Maniatis T, 1989, MOL CLONING; MARTHA A, 1994, AM J HUM GENET, V54, P801; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WISTOW G, 1995, BBA-GENE STRUCT EXPR, V1263, P105, DOI 10.1016/0167-4781(95)00087-W; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052	52	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23029	23036		10.1074/jbc.271.38.23029	http://dx.doi.org/10.1074/jbc.271.38.23029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798491	hybrid			2022-12-25	WOS:A1996VH76800017
J	Lengyel, E; Wang, H; Stepp, E; Juarez, J; Wang, Y; Doe, W; Pfarr, CM; Boyd, D				Lengyel, E; Wang, H; Stepp, E; Juarez, J; Wang, Y; Doe, W; Pfarr, CM; Boyd, D			Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN-COLON CARCINOMA; GROWTH-FACTOR; MESSENGER-RNA; C-JUN; TRANSCRIPTIONAL ACTIVATION; LAMININ DEGRADATION; SIGNAL-TRANSDUCTION; FIBROBLAST GROWTH; PROMOTER ACTIVITY	The urokinase-type plasminogen activator receptor (u-PAR) facilitates extracellular matrix proteolysis by accelerating plasmin formation at the cell surface, The present study was undertaken to identify elements in the u-PAR promoter required for the elevated expression of this binding site, Toward this end, we used two cultured colon cancer cell lines; one (RKO) has a transcriptionally activated u-PAR gene, and the other (GEO) overexpresses the receptor only after phorbol ester treatment. A chloramphenicol acetyltransferase (CAT) reporter driven by 398 nucleotides of 5' regulatory sequence of the u-PAR gene was strongly activated in the RKO cells, which displays approximately 3 x 10(5) receptors/cell. A region of this promoter between -197 and -8 was required for optimal expression, as indicated using a CAT reporter driven by 5' deleted fragments. DNase I footprinting revealed three protected regions (I, -190 to -171; II, -148 to -124; and III, -99 to -70) in this part of the promoter, Mutation of an AP-1 binding site at -184 within region I reduced activation of the promoter by 85%. Deletion of either region II or III also reduced promoter activity by over 60%. An oligonucleotide spanning the AP-1 motif at -184 bound, specifically, nuclear factors from RKO cells, and antibodies specific for Jun-D, c-Jun, or Fra-1 proteins supershifted the complex indicating the presence of these proteins. The amount of these factors was reduced in GEO cells in which the u-PAR gene is only weakly transcriptionally activated, Expression of a vector encoding a wild-type Jun-D cDNA increased u-PAR promoter activity in GEO cells, Conversely, transfection of RKO cells with a transactivation domain-lacking Jun-D expression construct resulted in a dose-dependent decrease in u-PAR promoter activity, Treatment of GEO cells with phorbol ester increased u-PAR mRNA and the activity of a CAT reporter driven by the wild-type but not the AP-1 (-184)mutated u-PAR promoter, and this was associated with a strong induction in the amount of Jun-D, c-Jun, and c-Fos. Methylation interference studies using a fragment of the u-PAR promoter (spanning -201 to -150) bound with nuclear extracted proteins from RKO cells, and phorbol 12-myristate 13 acetate-treated and -untreated GEO cells showed that the contact points corresponded 60 the AP-1 binding site at -184, Thus, the elevated expression of u-PAR in RKO cells, which constitutively produces this binding site, as well as in phorbol 12-myristate 13-acetate stimulated GEO cells requires an AP-1 motif located 184 bp upstream of the transcriptional start site.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; TECH UNIV MUNICH,DEPT OBSTET & GYNECOL,D-81675 MUNICH,GERMANY; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MUCOSAL INFLAMMAT & CANC GRP,DIV MOL MED,CANBERRA,ACT 2601,AUSTRALIA; INST PASTEUR,DEPT BIOTECHNOL,UNITE VIRUS ONCOGENES,F-75724 PARIS 15,FRANCE	University of Texas System; UTMD Anderson Cancer Center; Technical University of Munich; Australian National University; John Curtin School of Medical Research; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lengyel, Ernst/D-9220-2014; Pfarr, Curt/HHD-1410-2022	Lengyel, Ernst/0000-0001-8624-1507; 	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGARWAL S, 1995, ONCOGENE, V11, P427; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BOYD D, 1989, CANCER RES, V49, P816; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CASEY JR, 1994, BLOOD, V84, P1151; CHANTRET I, 1988, CANCER RES, V48, P1936; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS V, 1991, J BIOL CHEM, V266, P12752; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HOLLAS W, 1991, CANCER RES, V51, P3690; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KARIKO K, 1993, CANCER RES, V53, P3109; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; LUND LR, 1992, FEBS LETT, V298, P177, DOI 10.1016/0014-5793(92)80050-Q; LUND LR, 1991, EMBO J, V10, P3399, DOI 10.1002/j.1460-2075.1991.tb04904.x; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; Maxam A M, 1980, Methods Enzymol, V65, P499; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; Suzuki T, 1996, J BIOL CHEM, V271, P1626, DOI 10.1074/jbc.271.3.1626; SUZUKI T, 1992, NUCLEIC ACIDS RES, P5537; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731	62	84	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23176	23184		10.1074/jbc.271.38.23176	http://dx.doi.org/10.1074/jbc.271.38.23176			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798512	hybrid			2022-12-25	WOS:A1996VH76800038
J	Ruocco, MR; Chen, XE; Ambrosino, C; Dragonetti, E; Liu, WM; Mallardo, M; DeFalco, G; Palmieri, C; Franzoso, G; Quinto, I; Venuta, S; Scala, G				Ruocco, MR; Chen, XE; Ambrosino, C; Dragonetti, E; Liu, WM; Mallardo, M; DeFalco, G; Palmieri, C; Franzoso, G; Quinto, I; Venuta, S; Scala, G			Regulation of HIV-1 long terminal repeats by interaction of C/EBP(NF-IL6) and NF-kappa B/Rel transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LOOP-HELIX PROTEINS; C/EBP FAMILY; DNA-BINDING; INTERLEUKIN-8 GENE; NUCLEAR FACTOR; P50 SUBUNIT; EXPRESSION; TYPE-1; INFECTION	We report the characterization of a CAAT enhancer-binding protein (C/EBP) (NF-IL6) element encompassing the region from -174 to -166 of the U3 long terminal repeat (LTR) region of HIV-1. This C/EBP cis sequence was found to bind to C/EBP beta and C/EBP delta factors in DNA band shift assay. Transfection of NTera-2 cells with a HIV-1-LTR CAT construct (pC15CAT), together with C/EBP beta or C/EBP delta expression plasmids showed that C/EBP proteins strongly activated the HIV-1 promoter. Deletions encompassing the C/EBP-binding site resulted in the enhancement of the LTR activation mediated by C/EBP proteins, suggesting that other sequences located 3' to -170 were indeed the target for C/EBP factors, This possibility was confirmed by using the pCD54E9CAT plasmid, in which the NF-kappa B enhancer was inserted 5' to the HIV-1 LTR TATA box. A NF-kappa B1(p50) expression plasmid was also utilized to test for functional co-operation between NF-kappa B and C/EBP factors. We observed that p50 . C/EBP beta and p50 . C/EBP delta complexes were generated in tested cells and strongly activated the HIV-1 LTR by binding to the NF-kappa B sequences, The physical association of NF-kappa B1(p50) with C/EBP factors was assayed by direct interaction of in vitro translated p50 proteins with C/EBP beta or C/EBP delta produced as glutathione S-transferase fusion proteins. Moreover, p50 . C/EBP beta complexes were observed in vivo by using DNA affinity studies with biotinylated NF-kappa B oligonucleotides. By using mutant forms of p50 or C/EBP beta proteins we found that the transactivation of HIV-1 LTR by p50 . C/EBP beta complexes required the DNA-binding domain of p50 and the transcription activation domain of C/EBP beta.	UNIV REGGIO CALABRIA,SCH MED,INST CLIN & EXPT MED,I-88100 CATANZARO,ITALY; UNIV NAPLES FEDERICO II,SCH MED,DEPT BIOCHEM & BIOMED TECHNOL,I-80131 NAPLES,ITALY; NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892	Universita Mediterranea di Reggio Calabria; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			SCALA, GIUSEPPE/A-3280-2009; Franzoso, Guido/GRR-8628-2022; Palmieri, Camillo/A-3195-2009	Palmieri, Camillo/0000-0001-6707-4723; QUINTO, Ileana/0000-0001-8212-8515; Franzoso, Guido/0000-0002-0778-988X; MALLARDO, Massimo/0000-0002-4001-3856				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, RES IMMUNOL, V143, P734, DOI 10.1016/0923-2494(92)80012-A; AVITAHL N, 1994, J BIOL CHEM, V269, P23553; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DIFAGAGNA FD, 1995, J VIROL, V69, P2765, DOI 10.1128/JVI.69.5.2765-2775.1995; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KIM JYH, 1993, J VIROL, V67, P1658, DOI 10.1128/JVI.67.3.1658-1662.1993; KUNSCH C, 1994, J IMMUNOL, V153, P153; LAPSIA MF, 1989, CELL, V59, P283; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEVINE AM, 1992, BLOOD, V80, P8; LI XX, 1991, J BIOL CHEM, V266, P15192; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V88, P966; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MULLER CR, 1990, CELL, V61, P279; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P8202; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; Sambrook J., 2002, MOL CLONING LAB MANU; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; WEY X, 1995, NATURE, V373, P117; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG YH, 1995, J CLIN INVEST, V95, P2324, DOI 10.1172/JCI117924	63	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22479	22486		10.1074/jbc.271.37.22479	http://dx.doi.org/10.1074/jbc.271.37.22479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798413	hybrid			2022-12-25	WOS:A1996VG67200032
J	Sibbesen, O; DeVoss, JJ; deMontellano, PRO				Sibbesen, O; DeVoss, JJ; deMontellano, PRO			Putidaredoxin reductase-putidaredoxin-cytochrome P450(cam) triple fusion protein - Construction of a self-sufficient Escherichia coli catalytic system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NADPH-P450 REDUCTASE; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; FUSED ENZYME; PSEUDOMONAS-PUTIDA; NADPH-CYTOCHROME-P450 REDUCTASE; AMINO-ACID; EXPRESSION; P-450CAM	Fusion proteins of cytochrome P450(cam) with putidaredoxin (Pd) and putidaredoxin reductase (PdR), the two proteins required to transfer electrons from NADH to P450(cam), were constructed by fusing cDNAs encoding the three proteins in the expression vector pCWori(+). Several fusion proteins, in which the order of the three protein domains and the linkers between them were varied, were expressed in Escherichia coli, purified, and characterized, The highest activity (k(cat) = 30 min(-1)) was obtained with a PdR-Pd-P450(cam) construct in which the peptides TDGTASS and PLEL were used, respectively, to Link the PdR to the Pd and the Pd to the P450(cam) domains, Oxygen and NADH consumption is tightly coupled to substrate oxidation in the fusion proteins, The rate-limiting step in the catalytic turnover of these fusion proteins is electron transfer from Pd to P450(cam). This is indicated by high rates of electron transfer from the PdR and Pd domains to exogenous electron accepters, by an increase in the activity of the P450(cam) domain upon addition of exogenous Pd, and by the high activity of wild-type P450(cam) when incubated with a PdR-Pd fusion protein. E. cold cells expressing the PdR-Pd-P450(cam) fusion protein efficiently oxidize camphor to 5-exo-hydroxycamphor and 5-oxocamphor. E. coli cells expressing the triple fusion protein thus constitute the first heterologous self-sufficient catalytic system for the oxidation of camphor and other substrates by P450(cam).	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM-25515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BLACK SM, 1994, P NATL ACAD SCI USA, V91, P7247, DOI 10.1073/pnas.91.15.7247; COLLINS JR, 1988, J BIOL CHEM, V263, P3164; CUPPVICKERY JR, 1995, STRUCT BIOL, V2, P144; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; DEVOSS JJ, 1995, J AM CHEM SOC, V117, P4185, DOI 10.1021/ja00119a041; FISHER CW, 1992, P NATL ACAD SCI USA, V89, P10817, DOI 10.1073/pnas.89.22.10817; FRUETEL J, 1994, J AM CHEM SOC, V116, P11643, DOI 10.1021/ja00105a003; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; GELB MH, 1982, BIOCHEM BIOPH RES CO, V104, P853, DOI 10.1016/0006-291X(82)91327-4; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, P1; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JONES JP, 1993, J AM CHEM SOC, V115, P381, DOI 10.1021/ja00055a002; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KOGA H, 1985, BIOCHEM BIOPH RES CO, V130, P412, DOI 10.1016/0006-291X(85)90432-2; KOGA H, 1993, FEBS LETT, V331, P109, DOI 10.1016/0014-5793(93)80307-G; LI SY, 1993, BIOCHEMISTRY-US, V32, P9355, DOI 10.1021/bi00087a014; LOIDA PJ, 1995, J BIOL CHEM, V270, P5326, DOI 10.1074/jbc.270.10.5326; Mueller Ernest J., 1995, P83; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; NAKAMURA K, 1994, BBA-PROTEIN STRUCT M, V1207, P40, DOI 10.1016/0167-4838(94)90049-3; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1982, J BIOL CHEM, V257, P427; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RAAG R, 1993, BIOCHEMISTRY-US, V32, P4571, DOI 10.1021/bi00068a013; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1994, BIOCHEMISTRY-US, V33, P4933, DOI 10.1021/bi00182a023; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; SHET MS, 1995, ARCH BIOCHEM BIOPHYS, V318, P314, DOI 10.1006/abbi.1995.1235; SHET MS, 1994, ARCH BIOCHEM BIOPHYS, V311, P402, DOI 10.1006/abbi.1994.1255; SHIBATA M, 1990, DNA CELL BIOL, V9, P27, DOI 10.1089/dna.1990.9.27; SHIOTA N, 1994, PLANT PHYSIOL, V106, P17, DOI 10.1104/pp.106.1.17; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STAYTON PS, 1991, BIOCHEMISTRY-US, V30, P1845, DOI 10.1021/bi00221a017; TRUDGILL PW, 1966, J BIOL CHEM, V241, P1194; UNGER BP, 1986, J BIOL CHEM, V261, P1158; WADA A, 1991, ARCH BIOCHEM BIOPHYS, V290, P376, DOI 10.1016/0003-9861(91)90554-V; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YAMAZAKI S, 1993, J BIOCHEM-TOKYO, V114, P652, DOI 10.1093/oxfordjournals.jbchem.a124232	51	96	96	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22462	22469		10.1074/jbc.271.37.22462	http://dx.doi.org/10.1074/jbc.271.37.22462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798411	hybrid			2022-12-25	WOS:A1996VG67200030
J	Tobimatsu, T; Azuma, M; Matsubara, H; Takatori, H; Niida, T; Nishimoto, K; Satoh, H; Hayashi, R; Toraya, T				Tobimatsu, T; Azuma, M; Matsubara, H; Takatori, H; Niida, T; Nishimoto, K; Satoh, H; Hayashi, R; Toraya, T			Cloning, sequencing, and high level expression of the genes encoding adenosylcobalamin-dependent glycerol dehydrase of Klebsiella pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOL DEHYDRASE; ESCHERICHIA-COLI; DHA REGULON; COENZYME; PROTEIN; DNA	The gld genes encoding adenosylcobalamin-dependent glycerol dehydrase of Klebsiella pneumoniae were cloned by cross-hybridization with a DNA fragment of Klebsiella oxytoca diol dehydrase genes. Since the Escherichia coli clones isolated did not show appreciable enzyme activity, plasmids for high level expression of cloned genes were constructed. The enzyme expressed in E. coli was indistinguishable from the wild-type glycerol dehydrase of K. pneumoniae by the criteria of polyacrylamide gel electrophoretic, immunochemical, and catalytic properties, It was also shown that the recombinant functional enzyme consists of M(r) 61,000, 22,000, and 16,000 subunits. Sequence analysis of the genes revealed four open reading frames separated by 2-12 bases. The sequential three open reading frames from the first to the third (gldA, gldB, and gldC genes) encoded polypeptides of 555, 194, and 141 amino acid residues with predicted molecular weights of 60,659(alpha), 21,355(beta), and 16,104(gamma), respectively. High level expression of these three genes in E. coli produced more than 14-fold higher level of fully active apoenzyme than that in a pneumoniae. It was thus concluded that these are the genes encoding the subunits of glycerol dehydrase. The deduced amino acid sequences of the three subunits were 71, 58, and 54% identical with those of the alpha, beta, and gamma subunits of diol dehydrase, respectively, but failed to show any apparent homology with other proteins.	OKAYAMA UNIV,FAC ENGN,DEPT BIOSCI & BIOTECHNOL,OKAYAMA 700,JAPAN	Okayama University			TOBIMATSU, Takamasa/B-2646-2011					CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DANIEL R, 1992, FEMS MICROBIOL LETT, V100, P281, DOI 10.1016/0378-1097(92)90222-A; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER Z, 1966, B ACAD POL SCI BIOL, V14, P7; STROINSKI A, 1974, ARCH BIOCHEM BIOPHYS, V162, P321, DOI 10.1016/0003-9861(74)90189-1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; TONG IT, 1991, APPL ENVIRON MICROB, V57, P3541, DOI 10.1128/AEM.57.12.3541-3546.1991; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1980, J BACTERIOL, V141, P1439, DOI 10.1128/JB.141.3.1439-1442.1980; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	27	65	88	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22352	22357		10.1074/jbc.271.37.22352	http://dx.doi.org/10.1074/jbc.271.37.22352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798396	hybrid			2022-12-25	WOS:A1996VG67200015
J	vanderDrift, KMGM; Spaink, HP; Bloemberg, GV; vanBrussel, AAN; Lugtenberg, BJJ; Haverkamp, J; ThomasOates, JE				vanderDrift, KMGM; Spaink, HP; Bloemberg, GV; vanBrussel, AAN; Lugtenberg, BJJ; Haverkamp, J; ThomasOates, JE			Rhizobium leguminosarum bv trifolii produces lipo-chitin oligosaccharides with nodE-dependent highly unsaturated fatty acyl moieties - An electrospray ionization and collision-induced dissociation tandem mass spectrometric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-SPECIFICITY; NODULATION FACTORS; SIGNAL MOLECULES; ACID MOIETY; MELILOTI; BIOSYNTHESIS; GENES	The lipo-chitin oligosaccharides (LCO) or nodulation factors synthesized by Rhizobium leguminosarum bv. trifolii were analyzed using positive mode fast atom bombardment and positive and negative mode electrospray ionization mass spectrometry. From their mass spectrometric behavior it is clearly possible to distinguish between the [M + Na](+) pseudomolecular ion of the nodE-independent molecule IV(C18:1,Ac) and the [M + H](+) pseudomolecular ion of the nodE-dependent molecule IV(C20:4,Ac), although they both have the same mass value. The results unequivocally show that the bacterial strain investigated produces nodE-dependent LCOs with highly unsaturated fatty acyl moieties. We further demonstrate that the interpretation of the mass spectrometric data by Philip-Hollingsworth et al. (Philip-Hollingsworth, S., Orgambide, G. G., Bradford, J. J., Smith, D. K., Hollingsworth, R. I., and Dazzo, F. B. (1995) J. Biol. Chem. 270, 20968) is incorrect and that their data do not contradict our hypothesis that the nodE gene determines the host specificity of R. leguminosarum bv. trifolii.	LEIDEN UNIV,CLUSIUS LAB,INST MOL PLANT SCI,NL-2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	vanderDrift, KMGM (corresponding author), UNIV UTRECHT,DEPT MASS SPECTROMETRY,FAFC WENT GEBOUW,SORBONNELAAN 16,NL-3584 CA UTRECHT,NETHERLANDS.		Spaink, Herman P./S-3586-2017; Bloemberg, Guido/AAC-4914-2020	Spaink, Herman P./0000-0003-4128-9501; 				CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; CARROLL JA, 1995, ANAL CHIM ACTA, V307, P431, DOI 10.1016/0003-2670(94)00514-M; CERNY RL, 1986, ORG MASS SPECTROM, V21, P655, DOI 10.1002/oms.1210211009; DEMONT N, 1993, J BIOL CHEM, V268, P20134; DEMONT N, 1994, EMBO J, V13, P2139, DOI 10.1002/j.1460-2075.1994.tb06490.x; FISHER RF, 1993, J MOL BIOL, V233, P336, DOI 10.1006/jmbi.1993.1515; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; ORLANDO R, 1990, BIOMED ENVIRON MASS, V19, P747, DOI 10.1002/bms.1200191202; PHILIPHOLLINGSWORTH S, 1995, J BIOL CHEM, V270, P20968, DOI 10.1074/jbc.270.36.20968; RELIC B, 1993, MOL PLANT MICROBE IN, V6, P764, DOI 10.1094/MPMI-6-764; Ritsema T, 1996, MOL GEN GENET, V251, P44; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHULTZE M, 1995, INT REV CYTOL, V156, P1; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1995, MOL PLANT MICROBE IN, V8, P155, DOI 10.1094/MPMI-8-0155; SPAINK HP, 1994, PLANT MOL BIOL, V26, P1413, DOI 10.1007/BF00016482; VERDUYN R, 1992, RECL TRAV CHIM PAY B, V111, P367; ZHOU ZR, 1990, J ORG CHEM, V55, P5444, DOI 10.1021/jo00307a011	18	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22563	22569		10.1074/jbc.271.37.22563	http://dx.doi.org/10.1074/jbc.271.37.22563			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798424	Green Published, hybrid			2022-12-25	WOS:A1996VG67200043
J	Anders, RA; Leof, EB				Anders, RA; Leof, EB			Chimeric granulocyte/macrophage colony-stimulating factor transforming growth factor-beta (TGF-beta) receptors define a model system for investigating the role of homomeric and heteromeric receptors in TGF-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTORS; AKR-2B CELLS; MESSENGER-RNA; HETEROOLIGOMERIC COMPLEXES; SERINE/THREONINE KINASES; EXPRESSION CLONING; OVERLAP EXTENSION; GENE-EXPRESSION; CARCINOMA-CELLS; GS DOMAIN	Transforming growth factor-beta (TGF-beta) belongs to a family of ligands that regulate cell growth and differentiation. The most commonly observed receptors are referred to as the type I, type II, and type III (betaglycan) TGF-beta receptors. Two receptor models have been presented to account for the various cellular responses to TGF-beta. The first proposes that all TGF-beta signaling results from the formation of a heteromeric type I/type II complex, while the second suggests that distinct type I or type II TGF-beta receptor combinations mediate aspects of TGF-beta signaling. We have addressed this general question relating to TGF-beta signaling by constructing chimeric receptors consisting of the extracellular domain of the granulocyte/macrophage colony-stimulating factor (GM-CSF) alpha or beta receptor fused to the transmembrane and cytoplasmic domain of the type I or type II TGF-beta receptor. Since high affinity GM-CSF binding requires dimerization of the alpha and beta ligand binding subunits, the response elicited by defined type I and/or type II TGF-beta receptor cytoplasmic domain homomers or heteromers can be examined. We show in mesenchymal AKR-2B cells that while TGF-beta-dependent transient luciferase activity, endogenous gene activity, and longterm biological responses are similarly induced by activating the chimeric heteromeric receptors with GM-CSF as the endogenous TGF-beta receptor, chimeric homomeric type I/type I or type II/type II receptors are signaling-incompetent.	MAYO CLIN & MAYO FDN,THORAC RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054200] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54200] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIJKE PT, 1994, PROG GROWTH FACTOR R, V5, P55; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; EBLEN ST, 1995, CANCER RES, V55, P1994; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FILMUS J, 1992, ONCOGENE, V7, P521; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; GOUSTIN AS, 1987, EXP CELL RES, V172, P293, DOI 10.1016/0014-4827(87)90388-0; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HOWE PH, 1989, CANCER RES, V49, P6024; ICHIJO H, 1990, EXP CELL RES, V187, P263, DOI 10.1016/0014-4827(90)90090-W; KINSLEY DM, 1994, GENE DEV, V8, P133; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEE F, 1985, P NATL ACAD SCI USA, V82, P4360, DOI 10.1073/pnas.82.13.4360; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINASK KK, 1991, EXP CELL RES, V192, P1, DOI 10.1016/0014-4827(91)90149-O; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LUO KX, 1995, P NATL ACAD SCI USA, V92, P11761, DOI 10.1073/pnas.92.25.11761; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OKADOME T, 1994, J BIOL CHEM, V269, P30753; REISS M, 1990, CANCER COMMUN, V2, P363, DOI 10.3727/095535490820874029; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	62	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21758	21766		10.1074/jbc.271.36.21758	http://dx.doi.org/10.1074/jbc.271.36.21758			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702972	hybrid			2022-12-25	WOS:A1996VF61200014
J	Chiaramello, A; Neuman, T; Peavy, DR; Zuber, MX				Chiaramello, A; Neuman, T; Peavy, DR; Zuber, MX			The GAP-43 gene is a direct downstream target of the basic helix-loop-helix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED PROTEIN; C-MYC GENE; DNA-BINDING PROTEINS; NERVOUS-SYSTEM; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; NEGATIVE REGULATOR; HLH PROTEINS; EXPRESSION; PROMOTER	The GAP-43 promoter region contains seven E-boxes (E1 to E7) that are organized in two clusters, a distal cluster (E3 to E7) and a proximal cluster (E1 and E2), Deletion analysis and site-directed mutagenesis of the GAP-43 promoter region showed that only the most proximal E1 E-box significantly modulates GAP-43 promoter activity. This E-box is conserved between the rat and human GAP-43 promoter sequences in terms of flanking sequence, core sequence (CAGTTG), and position. We found that endogenous E-box-binding proteins present in neuronal N18 cells recognize the E1 E-box and activate the GAP-43 promoter. The transcriptional activity of the GAP-43 promoter was repressed not only by the negative regulator Id2 protein, but also by two class A basic helix-loop-helix proteins, E12 and ME1a. In vitro analyses showed that both ME1a and E12 bind to the E1 E-box as homodimers. By Northern analyses, we established an inverse correlation between the level of E12 and ME1a mRNAs and GAP-43 mRNA in various neuronal cell lines as well as in ME1a-overexpressing PC12 cells. Therefore, we have identified a cis-acting element, the E1 E-box, located in the GAP-43 promoter region that modulates either positively or negatively the expression of the GAP-43 gene depending on which E-box-binding proteins occupy this site. Together, these data indicate that basic helix-loop-helix transcription factors regulate the expression of the GAP-43 gene and that the class A ME1a and E12 proteins act as down-regulators of GAP-43 expression.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523; COLORADO STATE UNIV,PROGRAM NEURONAL GROWTH & DEV,FT COLLINS,CO 80523; COLORADO STATE UNIV,DEPT BIOCHEM & MOL BIOL,FT COLLINS,CO 80523	Colorado State University; Colorado State University; Colorado State University			Chiaramello, Anne/AAG-9825-2020	Chiaramello, Anne/0000-0001-8424-0826	NINDS NIH HHS [NS33804] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033804] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIARAMELLO A, 1995, MOL BRAIN RES, V29, P107, DOI 10.1016/0169-328X(94)00236-8; CHIARAMELLO A, 1995, MOL CELL BIOL, V15, P6036; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG MS, 1992, EUR J NEUROSCI, V4, P883, DOI 10.1111/j.1460-9568.1992.tb00115.x; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGGEN BJL, 1994, MOL BRAIN RES, V23, P221, DOI 10.1016/0169-328X(94)90229-1; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRABCZYK E, 1990, EUR J NEUROSCI, V2, P822, DOI 10.1111/j.1460-9568.1990.tb00393.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HELMS JA, 1994, MECH DEVELOP, V48, P93, DOI 10.1016/0925-4773(94)90019-1; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V194, P495; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; ORTOFT E, 1993, MOL CELL NEUROSCI, V4, P549, DOI 10.1006/mcne.1993.1068; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SOMMERVAILLE T, 1991, NEUROSCIENCE, V45, P213, DOI 10.1016/0306-4522(91)90117-7; STARR RG, 1994, BRAIN RES, V638, P211, DOI 10.1016/0006-8993(94)90652-1; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	56	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22035	22043		10.1074/jbc.271.36.22035	http://dx.doi.org/10.1074/jbc.271.36.22035			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703010	hybrid			2022-12-25	WOS:A1996VF61200052
J	Hollnagel, A; Schroder, D; Gross, G				Hollnagel, A; Schroder, D; Gross, G			Domain-specific gene activation by parathyroid hormone in osteoblastic ROS17/2.8 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE RECEPTOR; ORNITHINE DECARBOXYLASE ACTIVITY; MESSENGER-RIBONUCLEIC-ACID; PROTEIN-KINASE-C; ROS 17/2.8; ALKALINE-PHOSPHATASE; TRABECULAR BONE; CYCLIC-AMP; DNA METHYLTRANSFERASE; MOLECULAR-CLONING	Parathyroid hormone (PTH)-mediated gene activation was assessed in the osteoblast-like rat cell line ROS17/2.8 with two PTH fragments harboring distinct activating domains: PTH-(1-34) and PTH-(28-48). The PTH response of genes expressed immediate early in the cell cycle or in the osteoblast developmental sequence was investigated, In addition, subtractive cloning was used to identify genes in ROS17/2.8 cells that are activated by the two PTH domains, PTH-(1-34) immediately increased the transcript levels of c-fos and C-jun at a considerably higher rate than PTH-(28-48), A significant immediate PTH effect on osteoblastic marker genes could not be detected, with the exception of elevated ornithine decarboxylase transcript levels. However, continuous application of PTH-(1-34) increased transcript levels of the osteoblast-specific osteocalcin gene and reduced those of other osteoblastic marker genes including alkaline phosphatase and the PTH/PTH-related peptide receptor, By subtractive cloning, nine cDNAs were isolated corresponding to mRNAs directly up-regulated by PTH-(1-34) or PTH-(28-48). Among these were a cyclic phosphodiesterase, a (cytosine 5)-methyltransferase, an 80-kDa protein kinase C substrate, junB, and a novel GC-binding protein, Three cDNAs are unknown at present, Interestingly, in all cases, the efficiency of gene activation by PTH-(28-48) was substantially lower in comparison with PTH-(1-34), PTH-mediated protein kinase C signaling in ROS17/2.8 cells may therefore constitute a minor pathway in comparison with the dominant cAMP/protein kinase A cascade.	GESELL BIOTECHNOL FORSCH MBH,GENE REGULAT & DIFFERENTIAT,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH								AHOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOONEKAMP PM, 1985, BONE, V6, P37, DOI 10.1016/8756-3282(85)90405-3; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; Collip JB, 1925, J BIOL CHEM, V64, P485; COSMAN F, 1989, J BONE MINER RES, V4, P413; DORSSERS L, 1987, NUCLEIC ACIDS RES, V15, P3629, DOI 10.1093/nar/15.8.3629; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221-8747(84)90026-2; HEFTI E, 1982, CLIN SCI, V62, P389, DOI 10.1042/cs0620389; HOCK JM, 1989, J BONE MINER RES, V4, P449; HORI M, 1988, BONE MINER, V3, P193; JOHNSTON CC, 1962, J BIOL CHEM, V237, P3560; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1989, PEPTIDE HORMONES PRO, P325; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LIU CC, 1990, J BONE MINER RES, V5, P973; LOWIK CWGM, 1986, CALCIFIED TISSUE INT, V38, P21, DOI 10.1007/BF02556590; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MAJESKA RJ, 1985, ENDOCRINOLOGY, V116, P170, DOI 10.1210/endo-116-1-170; MAJESKA RJ, 1981, CALCIFIED TISSUE INT, V33, P36; Mallette Lawrence E., 1994, P171; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MURRAY TM, 1989, ENDOCRINOLOGY, V124, P1097, DOI 10.1210/endo-124-2-1097; NAKAMURA T, 1990, J BIOL CHEM, V265, P22011; NODA M, 1988, J BIOL CHEM, V263, P18574; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PODBESEK R, 1983, ENDOCRINOLOGY, V112, P1000, DOI 10.1210/endo-112-3-1000; RAISZ LG, 1976, HDB PHYSL, V3, P117; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; REID IR, 1987, AM J PHYSIOL, V252, pE45; RODAN SB, 1986, ENDOCRINOLOGY, V118, P2510, DOI 10.1210/endo-118-6-2510; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SOMJEN D, 1990, BIOCHEM J, V272, P781; SOMJEN D, 1991, BIOCHEM J, V277, P863; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; TAKIGAWA M, 1979, J BIOCHEM-TOKYO, V84, P311; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; URENA P, 1994, ENDOCRINOLOGY, V134, P451, DOI 10.1210/en.134.1.451; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	55	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21870	21877		10.1074/jbc.271.36.21870	http://dx.doi.org/10.1074/jbc.271.36.21870			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702988	hybrid			2022-12-25	WOS:A1996VF61200030
J	Graf, R; Harvey, WR; Wieczorek, H				Graf, R; Harvey, WR; Wieczorek, H			Purification and properties of a cytosolic V-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; TOBACCO HORNWORM MIDGUT; VESICLE PROTON PUMP; V-ATPASE; PLASMA-MEMBRANE; NEUROSPORA-CRASSA; 14-KDA SUBUNIT; 40-KDA SUBUNIT; MANDUCA-SEXTA; BOVINE KIDNEY	The native V-1 complex of the tobacco hornworm vacuolar type ATPase (V-ATPase) was purified from cytosolic extracts of molting larval midgut. It consisted of the established V-ATPase subunits A, B, and E along with the 14-kDa subunit F and the novel 13-kDa subunit G, The final amount of purified V-1 complex made up an unexpectedly high 2% of the total cytosolic protein, with a yield of similar to 0.4 mg/g of tissue. An equally high amount of cytosolic V-1 complex was obtained from starving intermolt larvae, By contrast, the cytosolic V-1 pool was reduced drastically in feeding intermolt larvae or in larvae that had been refed after starvation. The activity of the membrane-bound V-ATPase holoenzyme was inversely related to the size of the cytosolic V-1 pool, suggesting that the insect plasma membrane V-ATPase is regulated by reversible disassembly of the V-1 complex as a function of the feeding condition of the larvae. Like F-1-ATPases, the purified V-1 complex exhibited Ca2+-dependent ATPase activity and, in the presence of 25% methanol, exhibited Mg2+-dependent ATPase activity. Therefore, we designate the native V-1 complex, V-1-ATPase. Both enzyme activities were completely inhibited by micromolar-N-ethylmaleimide. In contrast to the Ca2+-dependent V-1-ATPase activity, the Mg2+/methanol-dependent V-1-ATPase activity did not decrease with the incubation time and thus was not inhibited by ADP. Methanol appears to induce a conformational change of the V-1 complex, leading to enzymatic properties of the V-1-ATPase that are similar to those of the membrane-bound V-ATPase holoenzyme. This is the first time that a native and enzymatically active V-1 complex has been purified from the cytosol.	UNIV MUNICH,INST ZOOL,D-80333 MUNICH,GERMANY; TEMPLE UNIV,DEPT BIOL,PHILADELPHIA,PA 19122	University of Munich; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			/AAU-6215-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22444] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; BALDWIN KM, 1991, TISSUE CELL, V23, P411, DOI 10.1016/0040-8166(91)90058-2; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DOW JAT, 1984, AM J PHYSIOL, V246, pR633, DOI 10.1152/ajpregu.1984.246.4.R633; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; FLORES GO, 1982, BIOCHIM BIOPHYS ACTA, V679, P466, DOI 10.1016/0005-2728(82)90168-2; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GLUCK SL, 1992, J EXP BIOL, V172, P219; GOGARTEN JP, 1992, J EXP BIOL, V172, P137; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; GRAF R, 1995, P GER ZOOL SOC, V88, P103; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HARVEY WR, 1992, J EXP BIOL, V172, P1; HARVEY WR, 1983, J EXP BIOL, V106, P91; HARVEY WR, 1992, J EXP BIOL, V172; HICKS DB, 1986, J BIOL CHEM, V261, P2896; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KANE PM, 1995, J BIOL CHEM, V270, P17025; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; MCCARTY RE, 1992, J EXP BIOL, V172, P431; MCCARTY RE, 1968, J BIOL CHEM, V243, P129; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; PENG SB, 1994, J BIOL CHEM, V269, P27778; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PENG SB, 1995, J BIOL CHEM, V270, P16926; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SAKURAI H, 1981, J BIOCHEM, V90, P95, DOI 10.1093/oxfordjournals.jbchem.a133473; SCHUSTER SM, 1979, BIOCHEMISTRY-US, V18, P1162, DOI 10.1021/bi00574a007; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WARD JM, 1992, PLANT PHYSIOL, V99, P170, DOI 10.1104/pp.99.1.170; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1986, BIOCHIM BIOPHYS ACTA, V857, P271, DOI 10.1016/0005-2736(86)90356-1; WIECZOREK H, 1995, PHYSIOL ZOOL, V68, P15, DOI 10.1086/physzool.68.4.30166357; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; XIE XS, 1988, J BIOL CHEM, V263, P9859	54	120	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20908	20913		10.1074/jbc.271.34.20908	http://dx.doi.org/10.1074/jbc.271.34.20908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702848	hybrid			2022-12-25	WOS:A1996VD33700100
J	Ollivier, V; Parry, GCN; Cobb, RR; deProst, D; Mackman, N				Ollivier, V; Parry, GCN; Cobb, RR; deProst, D; Mackman, N			Elevated cyclic AMP inhibits NF-kappa B-mediated transcription in human monocytic cells and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TISSUE FACTOR GENE; FACTOR MESSENGER-RNA; LEUKOCYTE ADHESION MOLECULE-1; FACTOR EXPRESSION; FACTOR-ALPHA; E-SELECTIN; LIPOPOLYSACCHARIDE INDUCTION; MONONUCLEAR PHAGOCYTES; C-REL/P65 HETERODIMERS	The NF-kappa B/Rel family of transcription factors regulates the inducible expression of many genes in activated human monocytes and endothelial cells. In this study, we examined the molecular mechanism by which agents that elevate intracellular cAMP inhibit the expression of the tumor necrosis factor alpha (TNF alpha), tissue factor, endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1 genes. Both forskolin and dibutyryl cAMP, which elevate intracellular cAMP by independent mechanisms, inhibited TNF alpha and tissue factor expression at the level of transcription. Induction of NF-kappa B-dependent gene expression in transiently transfected human monocytic THP-1 cells and human umbilical vein endothelial cells was inhibited by elevated cAMP and by overexpression of the catalytic subunit of protein kinase A (PKA). Elevated cAMP did not prevent nuclear translocation of p50/p65 and c-Rel/p65 heterodimers, decrease nuclear translocation of p65, or significantly modify TNF alpha-induced phosphorylation of p65. Functional studies demonstrated that transcriptional activation of a plasmid containing multimerized kappa B sites by p65 was inhibited by agents that elevate cAMP and by overexpression of the catalytic subunit of PKA. This study indicates that activation of PKA reduces the induction of a distinct set of genes in monocytes and endothelial cells by inhibiting NF-kappa B-mediated transcription.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; TANABE RES LABS, DEPT BIOL, SAN DIEGO, CA 92121 USA; CHU XAVIER BICHAT, INSERM, U294, F-75877 PARIS 18, FRANCE; CHU XAVIER BICHAT, SERV HEMATOL & IMMUNOL BIOL, F-75877 PARIS 18, FRANCE	Scripps Research Institute; Scripps Research Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite			Ollivier, Véronique/AAA-2241-2022	Ollivier, Veronique/0000-0003-1318-1712	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16411, HL48872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BENZAKOUR O, 1995, BIOCHEM J, V309, P385, DOI 10.1042/bj3090385; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CRUTCHLEY DJ, 1991, BLOOD, V78, P382; CRUTCHLEY DJ, 1993, ARTERIOSCLER THROMB, V13, P1082, DOI 10.1161/01.ATV.13.7.1082; CRUTCHLEY DJ, 1992, ARTERIOSCLER THROMB, V12, P664, DOI 10.1161/01.ATV.12.6.664; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DEPROST D, 1990, MOL PHARMACOL, V38, P562; EOTH P, 1995, BLOOD, V86, P4144; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GHERSA P, 1994, J BIOL CHEM, V269, P29129; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; Grilli Mariagrazia, 1993, V143, P1; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; HIROZANE T, 1995, CLIN EXP IMMUNOL, V102, P186; HOHMANN HP, 1991, MOL CELL BIOL, V11, P2315, DOI 10.1128/MCB.11.4.2315; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; LALLI E, 1994, J BIOL CHEM, V269, P17359; LYBERG T, 1983, THROMB HAEMOSTASIS, V50, P804; MACKMAN N, 1994, J BIOL CHEM, V269, P26363; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; Maniatis T., 1982, MOL CLONING; Min W, 1996, MOL CELL BIOL, V16, P359; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOSIALOS G, 1993, ONCOGENE, V8, P721; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OLLIVIER V, 1993, BLOOD, V81, P973; OLLIVIER V, 1993, FEBS LETT, V322, P231, DOI 10.1016/0014-5793(93)81576-L; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; POBER JS, 1993, J IMMUNOL, V150, P5114; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SEMMLER J, 1993, INT J IMMUNOPHARMACO, V15, P409, DOI 10.1016/0192-0561(93)90052-Z; SOMMER N, 1995, NAT MED, V1, P244, DOI 10.1038/nm0395-244; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; TAYLOR R, 1994, J NIH RES, V6, P57; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; TREDE NS, 1995, J IMMUNOL, V155, P902; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	58	306	312	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20828	20835		10.1074/jbc.271.34.20828	http://dx.doi.org/10.1074/jbc.271.34.20828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702838	hybrid			2022-12-25	WOS:A1996VD33700090
J	Martin, DC; Ruther, U; SanchezSweatman, OH; Orr, FW; Khokha, R				Martin, DC; Ruther, U; SanchezSweatman, OH; Orr, FW; Khokha, R			Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice	ONCOGENE			English	Article						TIMP-1; tumor suppression; T antigen; transgenic mice	B16-F10 MELANOMA-CELLS; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; METALLOPROTEINASE INHIBITOR; CANCER METASTASIS; GENE-EXPRESSION; TUMOR INVASION; GROWTH-FACTOR; ANGIOGENESIS; COLLAGENASE	The potential of tissue inhibitors of metalloproteinases (TIMPs) to inhibit neoplastic progression has been postulated from studies of genetically manipulated cells. To investigate whether the TIMP-1 expressed in a host tissue suppresses cancer in vivo and to identify the affected stages, we developed transgenic mice with constitutive overexpression or reduction of TIMP-1 in the liver. In double transgenic experiments, the TIMP-1 lines were crossed with a second transgenic line which expresses the Simian Virus 40 t/T antigen (TAg). This viral oncogene leads to heritable development of hepatocellular carcinomas with a 100% incidence. Effects of TIMP-1 coexpression on the TAg-induced neoplasms were determined at the tissue and cellular level. Here, we report that overexpression of hepatic TIMP-1 blocked the development of TAg-induced hepatocellular carcinomas. High TIMP-1 levels inhibited not only the later stages in tumor development (growth and angiogenesis), but also events associated with tumor initiation (altered hepatocyte cytology and tissue architecture). We further show that an antisense-mediated reduction of TIMP-1 resulted in a more rapid tumor initiation and progression. These data demonstrate that intrinsic TIMP-1 levels contribute to a tissue's susceptibility to viral oncogene-induced tumorigenesis.	UNIV WESTERN ONTARIO,LONDON REG CANC CTR,DEPT ONCOL,LONDON,ON N6A 4L6,CANADA; UNIV WESTERN ONTARIO,LONDON REG CANC CTR,DEPT BIOCHEM,LONDON,ON N6A 4L6,CANADA; HANNOVER MED SCH,INST MOL BIOL,D-30655 HANNOVER,GERMANY; HAMILTON REG CANC CTR,HAMILTON,ON L8V 5C2,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Hannover Medical School; McMaster University								ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BERTAUX B, 1993, CR SOC BIOL, V187, P192; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BISWAS C, 1995, CANCER RES, V55, P434; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BOUJRAD N, 1995, SCIENCE, V268, P1609, DOI 10.1126/science.7777858; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULLEN JM, 1993, VET PATHOL, V30, P111, DOI 10.1177/030098589303000203; DECLERCK YA, 1992, CANCER RES, V52, P701; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HOGAN B, 1986, MANIPULATING MOUSE E, P153; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KOOP S, 1994, CANCER RES, V54, P4791; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIGNATTI P, 1988, MOL CELLULAR BIOL WO, P497; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MULLER E, 1995, ONCOGENE, V10, P1175; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; RUTHER U, 1993, ONCOGENE, V8, P87; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAKIGAWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1264, DOI 10.1016/0006-291X(90)90822-5; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; WATERHOUSE P, 1993, MOL REPROD DEV, V35, P219, DOI 10.1002/mrd.1080350302; WELGUS HG, 1979, J BIOL CHEM, V254, P1938; WERNERT N, 1994, CANCER RES, V54, P5683; WITTY JP, 1995, CANCER RES, V55, P1401	54	79	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					569	576						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760297				2022-12-25	WOS:A1996VB32800014
J	Bajzar, L; Kalafatis, M; Simioni, P; Tracy, PB				Bajzar, L; Kalafatis, M; Simioni, P; Tracy, PB			An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V-Leiden	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; INACTIVATION; FIBRINOLYSIS; RESISTANCE	Factor Va is the essential cofactor in prothrombinase-dependent activation of prothrombin. Resistance of Factor Va(Leiden) to inactivation by activated protein C (APC) contributes to thrombotic tendencies in subjects with the variant due, in part, to the inability to terminate thrombin production which increases both fibrin accretion and the frequency of thrombus formation, A reduced ability to inhibit thrombin generation, however, may lead to the stabilization of a clot through the activation of thrombin activatable fibrinolysis inhibitor (TAFI). This hypothesis was tested by determining the profibrinolytic effect of APC on lysis time using clots formed with plasma from either homozygous normal (n = 4) or homozygous factor V-Leiden (n = 4) subjects, Clots were formed in the presence of tissue-type plasminogen activator, thrombin, phosphatidylcholine/phosphatidylserine vesicles, Ca2+, and various concentrations of APC, Approximately 10-fold more APC was required to reduce lysis time from 140 to 50 min in clots containing factor V-Leiden compared to normal factor V. This effect was specific to the form of factor V present in plasma since identical results were obtained in an appropriately reconstituted purified system, which included both TAFI and either form of factor V purified from pooled plasma, In the absence of TAFI, APC did not affect clot lysis in experiments with either normal factor V or factor V-Leiden. During the various lysis assays performed with purified components, clots were solubilized and the proteolytic alterations in factor V/Va were assessed by Western blotting using a specific factor Va heavy chain monoclonal antibody, The heavy chain of factor Va(Leiden) persisted for as long as 60 min, in the presence of 6.3 nM APC indicating sustained activity of factor Va(Leiden) during the lysis assay, In contrast, no factor Va heavy chain was present after the first 5.0 min in clots formed in the presence of normal factor V and 6.3 nM APC. These combined data indicate that factor Va(Leiden) specifically attenuates the profibrinolytic effect of APC, Thus, an impaired TAFI-dependent profibrinolytic response to APC in APC-resistant individuals appears to be an additional factor contributing to the prothrombotic tendencies in subjects with factor V-Leiden.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV PADUA,IST SEMEIOT MED,I-35100 PADUA,ITALY	University of Vermont; University of Padua			Simioni, Paolo/AAC-5416-2022; SIMIONI, PAOLO/AAC-5438-2022	SIMIONI, PAOLO/0000-0002-6744-383X	NHLBI NIH HHS [HL P01-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; Kalafatis M, 1996, BLOOD, V87, P4695, DOI 10.1182/blood.V87.11.4695.bloodjournal87114695; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; Mann K G, 1981, Ann N Y Acad Sci, V370, P378, DOI 10.1111/j.1749-6632.1981.tb29750.x; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; von dem Borne PA, 1995, BLOOD, V86, P3035	16	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22949	22952		10.1074/jbc.271.38.22949	http://dx.doi.org/10.1074/jbc.271.38.22949			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798478	hybrid			2022-12-25	WOS:A1996VH76800004
J	Voshol, H; vanZuylen, WEM; Orberger, G; Vliegenthart, JFG; Schachner, M				Voshol, H; vanZuylen, WEM; Orberger, G; Vliegenthart, JFG; Schachner, M			Structure of the HNK-1 carbohydrate epitope on bovine peripheral myelin glycoprotein P0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDE STRUCTURES; SULFATED GLUCURONYL GLYCOLIPIDS; MAGNETIC-RESONANCE SPECTROSCOPY; MONOCLONAL-ANTIBODY HNK-1; L2/HNK-1 CARBOHYDRATE; NERVOUS-SYSTEM; CELL-ADHESION; L-SELECTIN; NEUROPATHY; PROTEIN	The HNK-1 carbohydrate epitope, expressed by many neural recognition molecules, is involved in cell interactions that control cell type-specific neurite outgrowth and regeneration, It is also the target for autoimmune IgM antibodies in demyelinating neuropathies of the peripheral nervous system in humans, Despite its acknowledged importance in cell interactions, the HNK-1 carbohydrate-structure, when expressed on glycoproteins, is still unknown, Here, we describe the structure of one of the predominant HNK-1-bearing glycans of bovine P0. The epitope consists of the sulfated trisaccharide SO4-3GlcA beta 1-3Gal beta 1-4GlcNAc, attached to the alpha 1-6 arm of a diantennary core with a bisecting N-acetylglucosamine. It is the first example of a terminal 3-sulfated glucuronic acid on an asparagine-linked carbohydrate, Because the similarity between the glycoprotein derived structure and the glycosphingolipids carrying HNK-1 is restricted to the terminal sulfated trisaccharide, we conclude that this element is sufficient for HNK-1 immunoreactivity. Knowledge of the HNK-1 structure on proteins is an important prerequisite for the elucidation of its functional role in development and disease.	ETH ZURICH,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND; UNIV UTRECHT,BIJVOET CTR BIOMOL RES,DEPT BIOORGAN CHEM,NL-3508 TB UTRECHT,NETHERLANDS	Swiss Federal Institutes of Technology Domain; ETH Zurich; Utrecht University								ABO T, 1981, J IMMUNOL, V127, P1024; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNDEN KR, 1992, J NEUROCHEM, V58, P1659, DOI 10.1111/j.1471-4159.1992.tb10038.x; BURGER D, 1992, J NEUROCHEM, V58, P845, DOI 10.1111/j.1471-4159.1992.tb09334.x; BURGER D, 1992, J NEUROCHEM, V58, P854, DOI 10.1111/j.1471-4159.1992.tb09335.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GREY AA, 1982, CAN J BIOCHEM CELL B, V60, P1123, DOI 10.1139/o82-144; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; HARD K, 1992, EUR J BIOCHEM, V205, P785; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; ILYAS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1225, DOI 10.1073/pnas.81.4.1225; KANDA T, 1995, P NATL ACAD SCI USA, V92, P7897, DOI 10.1073/pnas.92.17.7897; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LOW K, 1994, EUR J NEUROSCI, V6, P1773, DOI 10.1111/j.1460-9568.1994.tb00570.x; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; NEEDHAM LK, 1993, J CELL BIOL, V121, P397, DOI 10.1083/jcb.121.2.397; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; OKA S, 1992, J BIOL CHEM, V267, P22711; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SHY ME, 1986, J NEUROIMMUNOL, V12, P291, DOI 10.1016/0165-5728(86)90035-4; TATUM AH, 1993, ANN NEUROL, V33, P502, DOI 10.1002/ana.410330514; UYEMURA K, 1991, COMP BIOCHEM PHYS C, V98, P63; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1	33	143	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22957	22960		10.1074/jbc.271.38.22957	http://dx.doi.org/10.1074/jbc.271.38.22957			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798480	Green Published, hybrid			2022-12-25	WOS:A1996VH76800006
J	Behrendt, N; Ronne, E; Dano, K				Behrendt, N; Ronne, E; Dano, K			Domain interplay in the urokinase receptor - Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTOR; LINKED-IMMUNOSORBENT-ASSAY; HUMAN TISSUE FACTOR; PLASMINOGEN-ACTIVATOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; EXTRACELLULAR DOMAIN; NH2-TERMINAL DOMAIN; MONOCLONAL-ANTIBODY; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE	The urokinase plasminogen activator receptor (uPAR) is a membrane protein comprised of three extracellular domains. In order to study the importance of this domain organization in the ligand-binding process of the receptor we subjected a recombinant, soluble uPAR (suPAR) to specific proteolytic cleavages leading to liberation of single domains. Treatment of the receptor with pepsin resulted in cleavage between residues 183 and 184, thus separating the third domain (D3) from the rest of the molecule, which was left as an intact fragment (D(1 + 2)), D(1 + 2) proved capable of ligand binding as shown by chemical cross-linking, but quantitative binding/competition studies showed that the apparent ligand affinity was 100- to 1000-fold lower than that of the intact suPAR. This loss of affinity was comparable with the loss found after cleavage between the first domain (D1) and D(2 + 3), using chymotrypsin. This result shows that in addition to D1, which has an established function in ligand binding (Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Dana, K. (1991) J. Biol. Chem. 266, 7842-7847), D3 has an important role in governing a high affinity in the intact receptor. Real-time biomolecular interaction analysis revealed that the decrease in affinity was caused mostly by an increased dissociation rate of the ligand complex of D(1 + 2), Zero length cross-linking, using carbodiimide-induced, direct condensation, was used to identify regions within suPAR engaged in molecular ligand contact. The purified suPAR was cross-linked to the radiolabeled aminoterminal fragment (ATF) of urokinase, followed by cleavage with chymotrypsin, In accordance with the cleavage pattern found for the uncomplexed receptor, this treatment led to cleavage between D1 and D(2 + 3), Analysis of the radiolabeled fragments revealed the expected ligand labeling of D1 but a clear labeling of D(2 + 3) was also found, indicating that this part of the molecule is also situated in close contact with ATF in the receptor-ligand complex, The latter contact site may contribute to the role of molecular regions outside D1 in high affinity binding.			Behrendt, N (corresponding author), RIGSHOSP,FINSEN LAB,STRANDBOULEVARDEN 49,BLDG 72,DK-2100 COPENHAGEN 0,DENMARK.			Behrendt, Niels/0000-0003-1833-3922				APPELLA E, 1987, J BIOL CHEM, V262, P4437; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENDT N, 1993, J BIOL CHEM, V268, P5985; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; ONISHI H, 1992, BIOCHEMISTRY-US, V31, P1201, DOI 10.1021/bi00119a033; *PHARM BIOS, 1995, BIAEV 2 1 SOFTW HDB; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; RONNE E, 1995, BREAST CANCER RES TR, V33, P199, DOI 10.1007/BF00665944; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	43	94	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22885	22894		10.1074/jbc.271.37.22885	http://dx.doi.org/10.1074/jbc.271.37.22885			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798468	hybrid			2022-12-25	WOS:A1996VG67200087
J	Chan, CL; Gill, GN				Chan, CL; Gill, GN			Mutational analysis of the nucleotide binding site of the epidermal growth factor receptor and v-Src protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; PEPTIDE INHIBITOR; DOMAIN; SPECIFICITY; EXPRESSION; ADENOSINE; PHOSPHORYLATION; ANTIBODIES; TRANSIENT	Tyrosine kinases differ from serine/threonine kinases in sequences located at the active site where ATP and substrate bind. In the structure of cyclic AMP-dependent protein kinase, the catalytic loop contains the sequence Lys-Pro-Glu where the Lys residue contacts the gamma-phosphate of ATP and the Glu residue contacts a basic residue located in the peptide substrate. In tyrosine kinases, the analogous sequence is Ala-Ala-Arg in the receptor tyrosine kinase subfamily and Arg-Ala-Ala in the Src tyrosine kinase subfamily. To deduce the role of these residues in tyrosine kinase function, site-directed mutations were prepared in the epidermal growth factor receptor (EGFR) and in v-Src and effects on ATP binding and kinase activity were determined. Changing Arg to either Lys or Ala dramatically reduced activity of both tyrosine kinases and this correlated with loss of ATP binding. Changing the orientation of this sequence impaired activity of EGFR to a greater extent than that of v-Src but did not change substrate specificity of the two enzymes. These results support the hypothesis that Arg functions to coordinate the gamma-phosphate of ATP. Analysis of sequence inversions in the catalytic loop indicate that the active site of v-Src exhibits greater flexibility than that of EGFR.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NIDDK NIH HHS [DK13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BUHROW SA, 1985, METHOD ENZYMOL, V109, P816; CACHIANES G, 1993, BIOTECHNIQUES, V15, P255; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERBST R, 1991, J BIOL CHEM, V266, P19908; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; WEBER W, 1984, J BIOL CHEM, V259, P4631; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	33	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22619	22623		10.1074/jbc.271.37.22619	http://dx.doi.org/10.1074/jbc.271.37.22619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798432	hybrid, Green Published			2022-12-25	WOS:A1996VG67200051
J	Garrow, TA				Garrow, TA			Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE METABOLISM; RAT-LIVER; ASSAY; N,N-DIMETHYLGLYCINE; CHROMATOGRAPHY; COBALAMIN; PROTEINS; SYNTHASE; TISSUES; ACID	Porcine liver betaine-homocysteine methyltransferase (BHMT; EC 2.1.1.5) was purified to homogeneity, and the Michaelis constants for betaine, dimethylacetothetin, and L-homocysteine are 23, 155, and 32 mu M, respectively. The maximum rate of catalysis is 47-fold greater using dimethylacetothetin as a methyl donor compared with betaine. Partial amino acid sequence of porcine BHMT was obtained, and inosine containing redundant oligonucleotide primers were used to amplify an 815-base pair sequence of the porcine cDNA by polymerase chain reaction (PCR). Nondegenerate oligonucleotide primers based on the porcine cDNA were synthesized and used to isolate a 463-base pair fragment of the human cDNA by PCR. The human PCR DNA product was then used to screen a cDNA library by plaque hybridization, and cDNAs encoding human BHMT were isolated. The primary structure of the human cDNA is reported here, and the open reading frame encodes a 406-residue protein of M(r) 44,969. The deduced amino acid sequence of human BHMT shows limited homology to bacterial vitamin B-12-dependent methionine synthases (EC 2.1.1.13). A plasmid containing the human BHMT cDNA fused in frame to the N terminus of beta-galactosidase was transformed into Escherichia coli, and transformants expressed BHMT activity, an activity that is absent from wild type E. coli.	UNIV ILLINOIS,DIV NUTR SCI,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	Garrow, TA (corresponding author), UNIV ILLINOIS,DEPT FOOD SCI & HUMAN NUTR,445 BEVIER HALL,905 S GOODWIN AVE,URBANA,IL 61801, USA.							ALLEN RH, 1993, METABOLISM, V42, P1448, DOI 10.1016/0026-0495(93)90198-W; BARAK AJ, 1979, LIPIDS, V14, P860, DOI 10.1007/BF02534129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; DUBNOFF JW, 1948, J BIOL CHEM, V176, P789; Dudman NPB, 1996, J NUTR, V126, pS1295, DOI 10.1093/jn/126.suppl_4.1295S; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; DURELL J, 1957, BIOCHIM BIOPHYS ACTA, V26, P270, DOI 10.1016/0006-3002(57)90005-7; ERICSON LE, 1960, ACTA CHEM SCAND, V14, P2113, DOI 10.3891/acta.chem.scand.14-2113; ERICSON LE, 1960, ACTA CHEM SCAND, V14, P2127, DOI 10.3891/acta.chem.scand.14-2127; ERICSON LE, 1960, ACTA CHEM SCAND, V14, P2101; FINKELSTEIN JD, 1967, J BIOL CHEM, V242, P873; FINKELSTEIN JD, 1972, ARCH BIOCHEM BIOPHYS, V153, P320, DOI 10.1016/0003-9861(72)90451-1; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FINKELSTEIN JD, 1983, J NUTR, V113, P519, DOI 10.1093/jn/113.3.519; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1974, ARCH BIOCHEM BIOPHYS, V165, P774, DOI 10.1016/0003-9861(74)90306-3; FINKELSTEIN JD, 1982, ARCH BIOCHEM BIOPHYS, V218, P169, DOI 10.1016/0003-9861(82)90332-0; FINKELSTEIN JD, 1982, BIOCHEM BIOPH RES CO, V108, P344, DOI 10.1016/0006-291X(82)91872-1; FROMM HJ, 1959, ARCH BIOCHEM BIOPHYS, V81, P363, DOI 10.1016/0003-9861(59)90214-0; GOEGER DE, 1993, ARCH BIOCHEM BIOPHYS, V302, P222, DOI 10.1006/abbi.1993.1203; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARYEA MD, 1994, CLIN CHIM ACTA, V230, P169, DOI 10.1016/0009-8981(94)90269-0; LEE KH, 1992, ARCH BIOCHEM BIOPHYS, V292, P77, DOI 10.1016/0003-9861(92)90053-Y; MAR MH, 1995, J NUTR BIOCHEM, V6, P392, DOI 10.1016/0955-2863(95)80008-Z; MARTIN JJ, 1981, ANAL BIOCHEM, V111, P72, DOI 10.1016/0003-2697(81)90230-X; MAW GA, 1956, BIOCHEM J, V63, P116, DOI 10.1042/bj0630116; MAW GA, 1959, BIOCHEM J, V72, P602, DOI 10.1042/bj0720602; MAW GA, 1948, J BIOL CHEM, V176, P1037; MAW GA, 1953, BIOCHEM J, V55, P42, DOI 10.1042/bj0550042; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Motulsky AG, 1996, AM J HUM GENET, V58, P17; NELSON LD, 1985, J CHROMATOGR, V324, P203, DOI 10.1016/S0021-9673(01)81320-0; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; ROBERTS DL, 1994, J BACTERIOL, V176, P6127, DOI 10.1128/jb.176.19.6127-6130.1994; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIDRANSKY H, 1960, ARCH BIOCHEM BIOPHYS, V87, P129, DOI 10.1016/0003-9861(60)90133-8; SKIBA WE, 1982, J BIOL CHEM, V257, P4944; SPEED D, 1968, J CHROMATOGR, V35, P497, DOI 10.1016/S0021-9673(01)82415-8; STEELE RD, 1978, J BIOL CHEM, V253, P7844; UELAND PM, 1984, J BIOL CHEM, V259, P2360; UELAND PM, 1992, ATHEROSCLEROTIC CARD; WANG J, 1991, CLIN CHIM ACTA, V204, P239, DOI 10.1016/0009-8981(91)90235-5; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; WHITFIELD CD, 1970, J BIOL CHEM, V245, P390	49	197	204	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22831	22838		10.1074/jbc.271.37.22831	http://dx.doi.org/10.1074/jbc.271.37.22831			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798461	hybrid			2022-12-25	WOS:A1996VG67200080
J	Powell, W; Bartholomew, B; Reines, D				Powell, W; Bartholomew, B; Reines, D			Elongation factor SII contacts the 3'-end of RNA in the RNA polymerase II elongation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; INITIATION FACTOR-ALPHA; ESCHERICHIA-COLI; ACTIVE-SITE; TERNARY COMPLEXES; TFIIS	Elongation factor SII (also known as TFIIS) is an RNA polymerase II binding protein that allows bypass of template arrest sites by activating a nascent RNA cleavage reaction. Here we show that SII contacts the 3'-end of nascent RNA within an RNA polymerase II elongation complex as detected by photoaffinity labeling, Photocross-linking was dependent upon the presence of SII, incorporation of 4-thio-UMP into RNA, and irradiation and was sensitive to treatment by RNase and proteinase. A transcriptionally active mutant of SII lacking the first 130 amino acids was also cross-linked to the nascent RNA, but SII from Saccharomyces cerevisiae, which is inactive in concert with mammalian RNA polymerase II, failed to become photoaffinity labeled, SII-RNA contact was not detected after a labeled oligoribonucleotide was released from the complex by nascent RNA cleavage, demonstrating that this interaction takes place between elongation complex-associated but not free RNA. This shows that the 3'-end of RNA is near the SII binding site on RNA polymerase II and suggests that SII may activate the intrinsic RNA hydrolysis activity by positioning the transcript in the enzyme's active site.	EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOL BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; SO ILLINOIS UNIV,DEPT BIOCHEM MED,CARBONDALE,IL 62901	Emory University; Emory University; Southern Illinois University System; Southern Illinois University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Powell, Wade H./0000-0002-3727-2822	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331, GM46331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CONAWAY RC, 1996, IN PRESS METHODS ENZ, V273; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GU W, 1993, J BIOL CHEM, V268, P18762; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1993, J BIOL CHEM, V268, P25604; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RIVA M, 1990, J BIOL CHEM, V265, P16498; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SHENG NJ, 1993, BIOCHEMISTRY-US, V32, P2248, DOI 10.1021/bi00060a017; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WU J, 1996, IN PRESS P NATL ACAD, V93	27	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22301	22304		10.1074/jbc.271.37.22301	http://dx.doi.org/10.1074/jbc.271.37.22301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798387	Green Accepted, hybrid			2022-12-25	WOS:A1996VG67200006
J	Tezuka, KI; Denhardt, DT; Rodan, GA; Harada, SI				Tezuka, KI; Denhardt, DT; Rodan, GA; Harada, SI			Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; SECRETED PHOSPHOPROTEIN; NEOPLASTIC TRANSFORMATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; DNA-BINDING; 3T3 CELLS; RNA; IDENTIFICATION; REQUIREMENT	Osteopontin is an arginine-glycine-aspartic acid containing cell adhesion protein, which is frequently expressed in transformed cells and is thought to play a role in tumorigenesis. v-Src is a transforming viral oncogene product encoded by Rous sarcoma virus (RSV). We report that v-Src expression in HT1080 fibrosarcoma cells significantly stimulates mouse osteopontin promoter activity. We also determined the v-Src response element in the osteopontin promoter as an inverted CCAAT box located at -53 to -49 from the transcription start site. Mutations of the CCAAT box disrupts protein-DNA interaction and diminishes both v-Src stimulation and basal promoter activity. A CCAAT box-containing fragment corresponding to -155 to -122 of RSV long terminal repeat competed with the -72 to -38 fragment of mouse osteopontin promoter for specific protein binding in the gel shift assay. A polyclonal antibody against CEF, a CCAAT box-binding factor, supershifted in gel shift assays the protein-DNA complex formed by nuclear extract of HT1080 with either the RSV CCAAT box fragment or with the osteopontin -72 to -38 fragment. Moreover, both osteopontin mRNA levels and enhancer activity of CCAAT box-containing -72 to -38 fragment were significantly elevated in v-src-transformed NIH 3T3 cells relative to parental cells. These findings suggest that the elevated osteopontin expression in transformed cells could be due, at least in part, to v-Src stimulation of the osteopontin promoter and that this effect is mediated by a CBF-like factor.	MERCK RES LABS, DEPT BONE BIOL & OSTEOPOROSIS RES, West Point, PA 19486 USA; RUTGERS STATE UNIV, DEPT BIOL SCI, PISCATAWAY, NJ 08855 USA	Merck & Company; Rutgers State University New Brunswick			Tezuka, Ken-ichi/B-3836-2012					APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; Ausbel FM, 1994, CURRENT PROTOCOLS MO; BEHREND EI, 1994, CANCER RES, V54, P832; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chackalaparampil I, 1996, ONCOGENE, V12, P1457; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; FABER M, 1990, J BIOL CHEM, V265, P22243; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GARDNER HAR, 1994, ONCOGENE, V9, P2321; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAITY SN, 1992, J BIOL CHEM, V267, P8286; NODA M, 1988, J BIOL CHEM, V263, P13916; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; SATO H, 1993, J BIOL CHEM, V268, P23460; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STACEY DW, 1991, ONCOGENE, V6, P2297; SU LC, 1995, ONCOGENE, V10, P2163; TAKESHITA S, 1988, GENE, V71, P9, DOI 10.1016/0378-1119(88)90072-8; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TUCK AB, 1991, J NATL CANCER I, V83, P485	46	43	44	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22713	22717		10.1074/jbc.271.37.22713	http://dx.doi.org/10.1074/jbc.271.37.22713			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798445				2022-12-25	WOS:A1996VG67200064
J	Chong, SR; Shao, Y; Paulus, H; Benner, J; Perler, FB; Xu, MQ				Chong, SR; Shao, Y; Paulus, H; Benner, J; Perler, FB; Xu, MQ			Protein splicing involving the Saccharomyces cerevisiae VMA intein - The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHED INTERMEDIATE; INTERVENING SEQUENCE; CHEMICAL LIGATION; GENE-PRODUCT; PEPTIDE-BOND; SUBUNIT; INTRONS; IDENTIFICATION; SELECTION; MECHANISM	Protein splicing involves the excision of an internal protein segment, the intein, from a precursor protein and the concomitant ligation of the flanking N- and C-terminal regions. It occurs in mesophilic bacteria, yeast, and thermophilic archaea. The ability to control protein splicing of a thermophilic intein by temperature and pH in a foreign protein context facilitated the study of the mechanism of protein splicing in thermophiles. On the other hand, no direct studies have been done on the mechanism of protein splicing in mesophiles. We examined the splicing of a chimeric protein containing the intein of the vacuolar ATPase subunit (VMA) of Saccharomyces cerevisiae that involves cysteines rather than serines at the reaction center. The steps in the splicing process were deduced by analyzing intermediates and side products that accumulated as a result of amino acid substitutions and were found to be analogous to those occurring in thermophiles. Moreover, appropriate amino acid replacements allowed us to develop the first mesophilic in vitro protein splicing system as well as strategies for modulating the rate of protein splicing and for converting the splicing reaction to an efficient protein cleavage reaction at either splice junction.	NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915; BOSTON BIOMED RES INST,BOSTON,MA 02114	Boston Biomedical Research Institute				Chong, shaorong/0000-0002-6525-3389				BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUICE TC, 1966, BIOORGANIC MECH, V1, P266; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DAVIS EO, 1991, J BACTERIOL, V173, P5653, DOI 10.1128/jb.173.18.5653-5662.1991; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Gros E., 1967, METHOD ENZYMOL, V11, P238; GU HH, 1993, J BIOL CHEM, V268, P7372; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6253; JENCKS WP, 1960, J BIOL CHEM, V235, P3608; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWONG MY, 1994, PROTEIN SCI, V3, P147; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIU CF, 1994, J AM CHEM SOC, V116, P4149, DOI 10.1021/ja00089a001; MUELLER JE, 1994, NUCLEASES, P111; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SEIFTER S, 1960, J BIOL CHEM, V235, P2613; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; TAM JP, 1995, P NATL ACAD SCI USA, V92, P21485; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; XU MQ, 1996, INPRESS EMBO J	39	212	234	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22159	22168		10.1074/jbc.271.36.22159	http://dx.doi.org/10.1074/jbc.271.36.22159			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703028	hybrid			2022-12-25	WOS:A1996VF61200070
J	Hartley, D; Corvera, S				Hartley, D; Corvera, S			Formation of c-Cbl center dot phosphatidylinositol 3-kinase complexes on lymphocyte membranes by a p56(lck)-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN PRODUCT; TYROSINE KINASE; JURKAT CELLS; P85 SUBUNIT; V-CBL; PROTOONCOGENE; ASSOCIATION; ACTIVATION; PHOSPHORYLATION	The proto-oncogene c-Cbl was originally identified as a cellular homologue of the transforming protein expressed by the murine Cas NS-1 retrovirus. The full-length c-Cbl protein is a predominantly cytoplasmic protein, abundant in lymphoid cells, and potentially involved in signal transduction in several cell types, The specific signal transduction pathways in which c-Cbl participates, and its precise role in these pathways, are unclear. Previous studies from our laboratory have shown that c-Cbl is the predominant tyrosine-phosphorylated protein bound to the p85 subunit of phosphatidylinositol (PI) 3-kinase on T lymphocyte and B lymphocyte activation, To further understand the properties of c-Cbl and the significance of its interactions with PI 3-kinase, we have further studied the cellular biological and biochemical responses of c-Cbl to stimulation in lymphoid cells, We show that stimulation induces the association of a highly tyrosine-phosphorylated pool of c-Cbl with lymphocyte membranes and with a detergent-insoluble particulate fraction, Immunoprecipitation of c-Cbl from subcellular fractions reveals that p85 is predominantly associated with the c-Cbl pool recovered from the membrane fraction, despite the fact that this pool represents a small amount of total cellular c-Cbl. The formation of c-Cbl . PI 3-kinase complexes on lymphocyte membranes did not depend on the catalytic activity of PI 3-kinase since it was unaltered by the treatment of cells with wortmannin prior to stimulation, Interestingly, c-Cbl tyrosine phosphorylation and the formation of c-Cbl PI 3-kinase complexes were also observed in a mutant Jurkat cell line, JCaM1.6, lacking p56(lck) expression. Because p56(lck) is critical for mitogenic signal transduction in response to T cell receptor activation, our results suggest that the activation of c-Cbl and the formation of c-Cbl . PI 3-kinase complexes occur upstream or independently of mitogenic signal transduction pathways in T cells.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOL MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIDDK NIH HHS [DK40330] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040330] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; COLIGAN E, 1991, CURRENT PROTOCOLS IM; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; JANEWAY CA, 1993, CURR OPIN IMMUNOL, V5, P313, DOI 10.1016/0952-7915(93)90048-W; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	18	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21939	21943		10.1074/jbc.271.36.21939	http://dx.doi.org/10.1074/jbc.271.36.21939			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702998	hybrid			2022-12-25	WOS:A1996VF61200040
J	Komalavilas, P; Lincoln, TM				Komalavilas, P; Lincoln, TM			Phosphorylation of the inositol 1,4,5-trisphosphate receptor - Cyclic GMP-dependent protein kinase mediates cAMP and cGMP dependent phosphorylation in the intact rat aorta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; TRISPHOSPHATE RECEPTOR; CA2+ MOBILIZATION; HUMAN PLATELETS; CA-2+ RELEASE; AMP; CELLS; CALCIUM; PURIFICATION; HEPATOCYTES	The effects of cyclic GMP (cGMP) and activation of cGMP-dependent protein kinase (PKG) on the phosphorylation of the inositol 1,4,5-trisphosphate (IP3) receptor were examined in intact rat aorta using the technique of back phosphorylation, Aorta treated with the nitric oxide donors, S-nitroso-N-acetylpenicillamine and sodium nitroprusside, or the selective PKG activator, 8-(4-para-chlorophenylthio)-cGMP (8-CPT-cGMP), demonstrated increased IP3 receptor phosphorylation in situ, which was both time- and concentration-dependent with a stoichiometry of 0.5 mol of phosphate/mol of receptor above control, Treatment of aorta with the adenyl cyclase activator, forskolin, also demonstrated increased phosphorylation of the IP3 receptor on the PKG site, although the selective cAMP-dependent protein kinase activator, 8-(4-para-chlorophenylthio)-cAMP (8-CPT-cAMP), did not increase the phosphorylation of the IP3 receptor, Moreover, the PKG selective inhibitor, KT 5823, inhibited both sodium nitroprusside and forskolin-induced IP3 receptor phosphorylation more potently than the selective cAMP-dependent protein kinase inhibitor, KT 5720, suggesting that PKG mediates the increase in IP3 receptor phosphorylation by both cyclic nucleotides in intact aorta, These results provide further support for the notion that PKG is activated by both cAMP and cGMP in intact vascular smooth muscle and that PKG performs a critical role in cyclic nucleotide-dependent relaxation of blood vessels.			Komalavilas, P (corresponding author), UNIV ALABAMA, DEPT PATHOL, DIV MOL & CELLULAR PATHOL, VOLKER HALL RM G038, 1670 UNIV BLVD, BIRMINGHAM, AL 35294 USA.				NHLBI NIH HHS [HL-34646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALIOUA A, 1995, AM J PHYSIOL-LUNG C, V268, pL1057, DOI 10.1152/ajplung.1995.268.6.L1057; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BUTT E, 1994, J BIOL CHEM, V269, P14509; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FORN J, 1978, P NATL ACAD SCI USA, V75, P5195, DOI 10.1073/pnas.75.10.5195; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GRIDER JR, 1993, AM J PHYSIOL, V264, pG334, DOI 10.1152/ajpgi.1993.264.2.G334; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; JIANG H, 1992, J BIOL CHEM, V267, P1015; JIN JG, 1993, AM J PHYSIOL, V264, pG470, DOI 10.1152/ajpgi.1993.264.3.G470; KARCZEWSKI P, 1992, LIFE SCI, V51, P1205, DOI 10.1016/0024-3205(92)90357-U; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; Lincoln T., 1996, BIOCH SMOOTH MUSCLE, P257; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; MARKS AR, 1990, J BIOL CHEM, V265, P20719; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	41	159	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21933	21938		10.1074/jbc.271.36.21933	http://dx.doi.org/10.1074/jbc.271.36.21933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702997				2022-12-25	WOS:A1996VF61200039
J	Leitman, DC; Costa, CHRM; Graf, H; Baxter, JD; Ribeiro, RCJ				Leitman, DC; Costa, CHRM; Graf, H; Baxter, JD; Ribeiro, RCJ			Thyroid hormone activation of transcription is potentiated by activators of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED TRANSCRIPTION; RETINOID-X RECEPTOR; VITAMIN-D RECEPTOR; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTOR; CO-REPRESSOR; SYNERGISTIC ACTIVATION; GENE-TRANSCRIPTION; ESTROGEN-RECEPTOR; PHOSPHORYLATION	We characterized the cross-talk between activators of protein kinase A (PKA) and thyroid hormone (T-3) in T-3 receptor (TR)-mediated transcription. U937 cells mere cotransfected with a plasmid expressing the TR and a reporter plasmid containing a T-3 response element (TRE) oriented either as a direct repeat or as a palindrome upstream of the thymidine kinase promoter linked to the chloramphenicol acetyltransferase gene. T-3 activated transcription by 10-fold. T-3 response was potentiated 2.5-3-fold by activators of PKA, but an activator of protein kinase C or of guanylate kinase was ineffective. In the absence of T-3, activators of PKA had no effect on transcription. TR heterodimerization with the retinoid X receptor may facilitate T-3/PKA cross-talk because coexpression of the retinoid X receptor potentiated cross-talk. Synergy was not observed in JEG-3, F9, CV-1, HeLa, L929, and HTC cells, indicating that it may require cell-specific factors. Synergy required the DNA- and ligand-binding domains, but not the amino-terminal domain, indicating that T-3- and TRE-induced conformational changes on the TR are essential for cross-talk. PKA phosphorylated the TR in vitro, suggesting that, like other nuclear receptors, the TR is a target for PKA. These results imply that PICA cross-talks with T-3 at the level of the TRE-bound TR, enhancing its transcriptional. activity in a cell-specific manner.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA; UNIV FED PARANA, DEPT ENDOCRINOL, BR-80060900 CURITIBA, PARANA, BRAZIL	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade Federal do Parana					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARWISH HM, 1993, BIOCHIM BIOPHYS ACTA, V1167, P29, DOI 10.1016/0005-2760(93)90213-S; DAY RN, 1989, J BIOL CHEM, V264, P431; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENSPAN FS, 1994, BASIC CLIN ENDOCRINO, V1, P160; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HSIEH JC, 1993, J BIOL CHEM, V268, P15118; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; JONES KE, 1994, ENDOCRINOLOGY, V134, P543, DOI 10.1210/en.134.2.543; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; NORDEEN SK, 1994, BIOCHEM BIOPH RES CO, V198, P1183, DOI 10.1006/bbrc.1994.1167; ONATE SA, 1995, SCIENCE, V270, P1354; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; RIBEIRO RCJ, 1995, ANN NY ACAD SCI, V758, P366, DOI 10.1111/j.1749-6632.1995.tb24843.x; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; STAUBER C, 1992, NEW BIOL, V4, P527; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	51	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21950	21955		10.1074/jbc.271.36.21950	http://dx.doi.org/10.1074/jbc.271.36.21950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703000	hybrid			2022-12-25	WOS:A1996VF61200042
J	Lalo, D; Steffan, JS; Dodd, JA; Nomura, M				Lalo, D; Steffan, JS; Dodd, JA; Nomura, M			RRN11 encodes the third subunit of the complex containing Rrn6p and Rrn7p that is essential for the initiation of rDNA transcription by yeast RNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; BINDING PROTEIN; GENE; DNA; SPECIFICITY; MUTANTS; SL1; TBP	A new gene, RRN11, has been defined by certain rrn mutants of Saccharomyces cerevisiae which are defective specifically in the transcription of 35 S rRNA gene by RNA polymerase I (pol I), We have cloned the gene and found that it encodes a protein of 507 amino acids. We have used a strain with the chromosomal RRN11 deleted and carrying HA1 epitope-tagged RRN11 on a plasmid to isolate a protein complex containing the protein encoded by RRN11, This protein complex complemented rrn6 mutant extracts, which were previously shown to be deficient in the essential pol I transcription factor called Rrn6/7 complex or core factor (CF), The CF complex was previously shown to consist of three proteins, the 102- and 60-kDa subunits encoded by RRN6 and RRN7, respectively, and the 66-kDa subunit. The results of the above complementation experiments combined with mobility of Rrn11p in SDS-polyacrylamide gel electrophoresis analysis relative to Rrn6p and Rrn7p led to the conclusion that RRN11 encodes the 66-kDa subunit of CF. Glutathione S-transferase-Rrn11p fusion protein was found to bind strongly to S-35-labeled Rrn6p and Rrn7p but only weakly to S-35-labeled TATA-binding protein, Similarly, glutathione S-transferase-Rrn7p fusion protein bound strongly to S-3S-labeled Rrn6p and Rrn11p but only weakly to S-35-labeled TATA-binding protein, These results are consistent with the fact that one can purify CF consisting of Rrn6p, Rrn7p, and Rrn11p from yeast: cell extracts, but the purified complex does not contain TATA-binding protein, RRN11 was shown to be an essential gene, and [H-3]uridine pulse experiments demonstrated directly that RRN11 is essential for rDNA transcription by pol I in vivo, Thus all three subunits of CF are essential for rDNA transcription, Because of the resemblance of CF to mammalian essential pol I transcription factor SL1, the amino acid sequences of Rrn11p and the other two subunits of CF were compared with those of the three TATA-binding protein-associated factors (TAFs) in the human SL1, TAF(I)48, TAF(I)63, and TAF(I)110. No significant similarity was detected between two sets of the proteins. Similarity as well as differences between CF and SL1 are discussed.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92697	University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035949] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM35949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P362; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P225; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P7026, DOI 10.1073/pnas.88.16.7026; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; REEDER RH, 1992, TRANSCRIPTIONAL REGU, V2, P315; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	30	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21062	21067		10.1074/jbc.271.35.21062	http://dx.doi.org/10.1074/jbc.271.35.21062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702872	hybrid			2022-12-25	WOS:A1996VE47700018
J	Moffett, S; Adams, L; Bonin, H; Loisel, TP; Bouvier, M; Mouillac, B				Moffett, S; Adams, L; Bonin, H; Loisel, TP; Bouvier, M; Mouillac, B			Palmitoylated cysteine 341 modulates phosphorylation of the beta(2)-adrenergic receptor by the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; CHINESE-HAMSTER FIBROBLASTS; SF9 CELLS; DISTINCT PATHWAYS; ADENYLATE-CYCLASE; CARBOXYL-TERMINUS; BOVINE RHODOPSIN; 2 DOMAINS; DESENSITIZATION	We previously showed that substitution of a glycine residue for the palmitoylated cysteine 341 of the human beta(2)-adrenergic receptor (Gly(341)beta(2)AR), increases the basal level of the receptor phosphorylation and reduces its ability to functionally interact with G(s). In the present study, we show that additional mutation of serines 345 and 346 (Ala(345,346)Gly(341)beta(2)AR) restored normal phosphorylation and receptor-G(s) coupling, thus suggesting that the increased phosphorylation of this site, rather than the lack of palmitoylation per se, is responsible for the poor coupling of the unpalmitoylated receptor. This is supported by the observation that chemical depalmitoylation of purified beta(2)AR did not affect the ability of the receptor to stimulate adenylyl cyclase in reconstitution assays. Furthermore, mutation of Ser(345,346) in a wild type receptor background (Ala(345,346)beta(2)AR) significantly decreased the rate of agonist-promoted desensitization of the receptor-stimulated adenylyl cyclase activity, supporting a role for this phosphorylation site in regulating the functional coupling of the receptor. Since serines 345 and 346 are located in a putative cyclic AMP-dependent protein kinase (PKA) phosphorylation site immediately downstream of the palmitoylated cysteine 341, the hypothesis that the accessibility of this site may be regulated by the receptor palmitoylation state mas further assessed in vitro. In membrane phosphorylation assays, Gly(341)beta(2)AR was found to be a better substrate for PKA than the wild type receptor, thus supporting the notion that palmitoylation restrains access of the phosphorylation site to the enzyme. Taken together, the data demonstrate that palmitoylation of cysteine 341 controls the phosphorylation state of the PKA site located in the carboxyl tail of the beta(2)AR and by doing so modulates the responsiveness of the receptor.	UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, GRP RECH SYST NERVEUX AUTONOME, MONTREAL, PQ H3C 3J7, CANADA; CNRS, INSERM, CTR PHARMACOL ENDOCRINOL, UNITE 401, F-34094 MONTPELLIER 5, FRANCE	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			MOUILLAC, Bernard/M-3896-2014; Bouvier, Michel/H-2758-2014	MOUILLAC, Bernard/0000-0002-3906-8673; Bouvier, Michel/0000-0003-1128-0100				ALALUF S, 1995, J NEUROCHEM, V64, P1548; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DELEAN A, 1982, MOL PHARMACOL, V21, P5; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; JENSEN AA, 1995, J NEUROCHEM, V65, P1325, DOI 10.1046/j.1471-4159.1995.65031325.x; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Post SR, 1996, J BIOL CHEM, V271, P895, DOI 10.1074/jbc.271.2.895; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SHORR RGL, 1981, J BIOL CHEM, V256, P5820; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YUAN NY, 1994, J BIOL CHEM, V269, P23032	48	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21490	21497		10.1074/jbc.271.35.21490	http://dx.doi.org/10.1074/jbc.271.35.21490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702933	hybrid			2022-12-25	WOS:A1996VE47700079
J	Santee, SM; OwenSchaub, LB				Santee, SM; OwenSchaub, LB			Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; T-CELL DEVELOPMENT; NF-KAPPA-B; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; FUNCTIONAL-CHARACTERIZATION; VIRAL-PROTEINS; DNA-SEQUENCES; MESSENGER-RNA; EXPRESSION	Tumor necrosis factor receptor p75 (TNF-R p75) is a 75-kDa type I transmembrane protein expressed predominantly on cells of hematopoietic lineage. TNF-R p75 belongs to the TNF receptor superfamily characterized by cysteine rich extracellular regions composed of three to six disulfide-linked domains. In the present report we have characterized, for the first time, the complete gene structure for human TNF-R p75, which spans approximately 43 kbp. The gene consists of 10 exons (ranging from 34 base pairs to 2.5 kilobase pairs) and nine introns (343 base pairs to 19 kilobase pairs). Consensus elements for transcription factors involved in T cell development and activation were noted in the 5'-flanking region including T cell factor-1, Ikaros, AP-1, CK-2, interleukin-6 receptor E (IL-6RE), ISRE, GAS, NF-kappa B, and Sp1. The unusual (GATA)(n) and (GAA)(GGA) repeats found within intron 1 may prove useful for further genome analysis within the 1p36 chromosomal locus. Characterization of the human TNF-R p75 gene structure will permit further assessment of its involvement in normal hematopoietic cell development and function, autoimmune disease, and nonrandom translocations in hematopoietic malignancies.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE Y, 1995, J LEUKOCYTE BIOL, V57, P462, DOI 10.1002/jlb.57.3.462; AGGARWAL BB, 1993, LYMPHOKINE CYTOK RES, V12, P149; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAKER E, 1991, CYTOGENET CELL GENET, V57, P117, DOI 10.1159/000133127; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BEMELMANS MHA, 1993, J IMMUNOL, V150, P2007; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BIRKELAND ML, 1995, EUR J IMMUNOL, V25, P926, DOI 10.1002/eji.1830250410; BLOOMFIELD CD, 1985, BLOOD, V66, P1409; CAMBRIN GR, 1986, CANCER GENET CYTOGEN, V22, P75, DOI 10.1016/0165-4608(86)90140-8; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DRAKE CG, 1994, P NATL ACAD SCI USA, V91, P4062, DOI 10.1073/pnas.91.9.4062; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EPPLEN JT, 1988, J HERED, V79, P409, DOI 10.1093/oxfordjournals.jhered.a110544; EPPLEN JT, 1992, CLIN CHIM ACTA, V209, pS5, DOI 10.1016/0009-8981(92)90174-O; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1994, J IMMUNOL, V153, P1963; GRIMALDI JC, 1992, J IMMUNOL, V149, P3921; GROSEN EA, 1993, GYNECOL ONCOL, V50, P68, DOI 10.1006/gyno.1993.1166; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; JACOBSEN FW, 1995, J IMMUNOL, V154, P3732; KAUFMAN BA, 1994, HUM GENET, V94, P418; KEMPER O, 1991, HUM GENET, V87, P623; KEMPER O, 1993, GENE, V134, P209, DOI 10.1016/0378-1119(93)90095-K; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRAFT R, 1992, GENOMICS, V12, P555, DOI 10.1016/0888-7543(92)90448-2; KUHNERT P, 1994, GENE, V150, P381, DOI 10.1016/0378-1119(94)90457-X; KWON BS, 1994, J IMMUNOL, V152, P2256; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LINDVALL L, 1993, LYMPHOKINE CYTOK RES, V12, P205; LOENEN WAM, 1992, J IMMUNOL, V149, P3937; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MOIR DJ, 1984, BLOOD, V64, P553; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEUNER P, 1994, CANCER RES, V54, P6001; OWENSCHAUB LB, 1989, J IMMUNOL, V143, P2236; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; PANYUTIN IG, 1992, J BIOL CHEM, V267, P5495; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; REEVES BR, 1980, HUM GENET, V53, P349, DOI 10.1007/BF00287055; RICHARDS ML, 1991, J IMMUNOL, V147, P1067; ROTHE J, 1993, MOL IMMUNOL, V30, P165, DOI 10.1016/0161-5890(93)90088-S; RUDERT F, 1995, DNA CELL BIOL, V14, P931, DOI 10.1089/dna.1995.14.931; Singer M., 1991, GENES GENOMES; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANNENBAUM CS, 1993, J IMMUNOL, V151, P6833; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRENTIN L, 1993, BLOOD, V81, P752; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; WELBORN JL, 1987, CANCER GENET CYTOGEN, V28, P277, DOI 10.1016/0165-4608(87)90214-7; WINZEN R, 1993, J IMMUNOL, V150, P4346; YAMADA K, 1983, CANCER GENET CYTOGEN, V9, P93, DOI 10.1016/0165-4608(83)90029-8; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	71	128	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21151	21159		10.1074/jbc.271.35.21151	http://dx.doi.org/10.1074/jbc.271.35.21151			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702885	hybrid			2022-12-25	WOS:A1996VE47700031
J	Tang, CM; Tomkinson, AE; Lane, WS; Wold, MS; Seto, E				Tang, CM; Tomkinson, AE; Lane, WS; Wold, MS; Seto, E			Replication protein A is a component of a complex that binds the human metallothionein IIA gene transcription start site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; LONG TERMINAL REPEAT; DNA-REPLICATION; T-ANTIGEN; INITIATOR ELEMENTS; MAMMALIAN-CELLS; CAP SITE; TATA-BOX; SACCHAROMYCES-CEREVISIAE	Previous studies revealed that sequences surrounding the initiation sites in many mammalian and viral gene promoters, called initiator (Inr) elements, may be essential for promoter strength and for determining the actual transcription start sites. DNA sequences in the vicinity of the human metallothionein IIA (hMTIIA) gene transcription start site share homology with some of the previously identified Inr elements. However, in the present study we have found by in vitro transcription assays that the hMTIIA promoter does not contain a typical Inr. Electrophoretic mobility shift assays identified several DNA-protein complexes at the hMTIIA gene transcription start site. A partially purified protein fraction containing replication protein A (RPA) binds to the hMTIIA gene transcription start site and represses transcription from the hMTIIA promoter in vitro. In addition, overexpression of the human 70-kDa RPA-1 protein represses transcription of a reporter gene controlled by the hMTIIA promoter in vivo. These findings suggest that hMTIIA transcription initiation is controlled by a mechanism different from most mammalian and viral promoters and that the previously identified RPA may also be involved in transcription regulation.	UNIV S FLORIDA,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOL MED,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	State University System of Florida; University of South Florida; University of Texas System; University of Texas Health San Antonio; Harvard University; University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NATIONAL CANCER INSTITUTE [R01CA061257] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA61257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BEACH LR, 1981, P NATL ACAD SCI-BIOL, V78, P2110, DOI 10.1073/pnas.78.4.2110; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BOYER TG, 1990, J BIOL CHEM, V265, P20524; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CONCINO MF, 1984, NUCLEIC ACIDS RES, V12, P7423, DOI 10.1093/nar/12.19.7423; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FRIEDENREICH H, 1990, NUCLEIC ACIDS RES, V18, P3299, DOI 10.1093/nar/18.11.3299; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KAINA B, 1990, P NATL ACAD SCI USA, V87, P2710, DOI 10.1073/pnas.87.7.2710; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1980, EUR J BIOCHEM, V107, P395; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIEBERMAN MW, 1983, CELL, V35, P207, DOI 10.1016/0092-8674(83)90223-4; MATTHIJS G, 1994, BIOCHEM BIOPH RES CO, V202, P65, DOI 10.1006/bbrc.1994.1894; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MULLER T, 1991, ARCH TOXICOL, V65, P20; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUDD CJ, 1979, TOXICOL APPL PHARM, V47, P273, DOI 10.1016/0041-008X(79)90321-1; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH KK, 1995, P NATL ACAD SCI USA, V92, P4907, DOI 10.1073/pnas.92.11.4907; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TALKINGTON CA, 1982, NATURE, V298, P192, DOI 10.1038/298192a0; TEBB G, 1988, EMBO J, V7, P3785, DOI 10.1002/j.1460-2075.1988.tb03263.x; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; TJIAN R, 1981, CELL, V26, P1, DOI 10.1016/0092-8674(81)90026-X; TOKUNAGA K, 1984, NUCLEIC ACIDS RES, V12, P1543, DOI 10.1093/nar/12.3.1543; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823	88	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21637	21644		10.1074/jbc.271.35.21637	http://dx.doi.org/10.1074/jbc.271.35.21637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702952	hybrid			2022-12-25	WOS:A1996VE47700098
J	Tremblay, JM; Helmkamp, GM; Yarbrough, LR				Tremblay, JM; Helmkamp, GM; Yarbrough, LR			Limited proteolysis of rat phosphatidylinositol transfer protein by trypsin cleaves the C terminus, enhances binding to lipid vesicles, and reduces phospholipid transfer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE RECOMBINANT PROTEINS; ESCHERICHIA-COLI; BOVINE BRAIN; SACCHAROMYCES-CEREVISIAE; CA2+-ACTIVATED SECRETION; RNA-POLYMERASE; CLONED GENES; GROWTH; SEC14; EXCHANGE	Rat phosphatidylinositol transfer protein (PITP) is a 32-kDa protein of 271 amino acids that transfers phosphatidylinositol and phosphatidylcholine between membranes. The alpha isoform of rat PITP was expressed in Escherichia coli and purified in high yields, The purified protein contained 1 mol of phosphatidylglycerol and had a transfer activity for phosphatidylinositol and phosphatidylcholine equal to or greater than that of PITP purified from mammalian brain, Limited protease digestion was used to further define structure, activity, and function relationships in PITP. PITP alone is relatively resistant to digestion by chymotrypsin, trypsin, and Staphylococcus V8 protease but is readily cleaved by subtilisin. Phospholipid vesicles containing phosphatidic acid enhance susceptibility to digestion by all four proteases, In the presence of vesicles, PITP, which migrates as a 36-kDa protein in SDS-polyacrylamide gel electrophoresis, is cleaved rapidly by trypsin to a form that appears to be 2-3 kDa smaller than the native form, The tryptic fragment retains partial phospholipid transfer activity and shows an enhanced affinity for phospholipid vesicles containing phosphatidic acid. Analysis of the tryptic digestion products by immunoblotting, N-terminal sequencing, and electrospray mass spectrometry showed that trypsin cleaves the C terminus of PITP at Arg(253) and Arg(259), Thus, removal of the C terminus enhances the affinity of PITP for vesicles and results in a dimunition of transfer activity, Overall, the data show that PITP undergoes conformation changes and that the C terminus becomes more accessible to trypsin when bound to vesicles. Hence, the C terminus is not an essential component of the membrane binding site and may be located distal to it.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center					NIGMS NIH HHS [GM-24035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DEVRIES KJ, 1995, BIOCHEM J, V310, P648; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DICKESON SK, 1994, GENE, V142, P301, DOI 10.1016/0378-1119(94)90279-8; DICORLETO PE, 1979, J BIOL CHEM, V254, P7795; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Helmkamp G M Jr, 1990, Subcell Biochem, V16, P129; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; KASPER AM, 1981, BIOCHIM BIOPHYS ACTA, V664, P22, DOI 10.1016/0005-2760(81)90025-4; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; LEE SC, 1992, J BIOL CHEM, V267, P2849; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SOMERHARJU P, 1983, BIOCHIM BIOPHYS ACTA, V731, P186, DOI 10.1016/0005-2736(83)90008-1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WYNN RM, 1992, J BIOL CHEM, V267, P12400	37	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21075	21080		10.1074/jbc.271.35.21075	http://dx.doi.org/10.1074/jbc.271.35.21075			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702874	hybrid			2022-12-25	WOS:A1996VE47700020
J	Rabault, B; Roussel, MF; Quang, CT; Ghysdael, J				Rabault, B; Roussel, MF; Quang, CT; Ghysdael, J			Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis	ONCOGENE			English	Article						Ets1; phosphorylation; mitogenesis; mitogen-activated protein kinase	TRANSCRIPTION FACTORS; PROTEIN-KINASE; MAP KINASE; GENE; CELLS; ACTIVATION; EXPRESSION; FAMILY; MYC; IDENTIFICATION	Ets1, the founder member of the Ets transcription factor family, is involved in a variety of developmental and cellular processes, Previous studies have shown that serine phosphorylation of Ets1 inhibits its DNA binding activity, suggesting that phosphorylation is important in the regulation of Ets1 function. To further examine Ets1 phosphorylation, we ectopically expressed Ets1 in fibroblasts and stimulated these cells with serum, Using two-dimensional tryptic phosphopeptide analysis and site-directed mutagenesis, we found that Ets1 was phosphorylated on threonine 38, a residue conserved in several Ets proteins, Substitution of this residue with alanine enhanced CSF-1-dependent colony formation in semi-solid medium of NIH3T3 cells expressing a mitogenically defective CSF-1 receptor [Y809F], Threonine 38 is part of a consensus amino-acid sequence frequently recognized and targeted by members of the MAP kinase family, Moreover, this residue is phosphorylated in vitro by recombinant ERK2, which suggests that the kinase which phosphorylates threonine 38 in vivo is a member of the MAP kinase family, In addition, phosphorylation on threonine 38 seems to negatively regulate Ets1 activity in response to growth-factor stimulation.	CTR UNIV ORSAY, INST CURIE, CNRS UMR 146, LAB ONCOL VIRALE & CELLULAIRE, F-91405 ORSAY, FRANCE; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; St Jude Children's Research Hospital			Roussel, Martine F/F-1469-2016; GHYSDAEL, Jacques/F-3377-2013; QUANG, christine TRAN/G-7508-2016	Roussel, Martine F/0000-0002-1740-8139; 	NCI NIH HHS [CA-56819, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056819, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P995; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Yang BS, 1996, MOL CELL BIOL, V16, P538	26	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					877	881						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761310				2022-12-25	WOS:A1996VD43300024
J	Murthy, KS; Coy, DH; Makhlouf, GM				Murthy, KS; Coy, DH; Makhlouf, GM			Somatostatin receptor-mediated signaling in smooth muscle - Activation of phospholipase C-beta 3 by G(beta gamma) and inhibition of adenylyl cyclase by G(alpha il) G(alpha o)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CA2+ MOBILIZATION; G-PROTEINS; MOLECULAR-BIOLOGY; INTESTINAL MUSCLE; OPIOID RECEPTORS; ALPHA-SUBUNITS; CELLS; RAT; MEMBRANES	In COS-7 cells, all five cloned somatostatin receptors are coupled via inhibitory G proteins to activation of an unidentified phospholipase C-beta (PLC-beta) isozyme and inhibition of adenylyl cyclase. In the present study, intestinal smooth muscle cells (SMC) that express only one receptor type, sstr3, and possess a full complement of G proteins and PLC-beta isozymes were used to identify the PLC beta isozyme and the G proteins coupled to it and to adenylyl cyclase. Somatostatin-14 bound with high affinity to intestinal SMC; stimulated D-myo-inositol-1,4,5-trisphosphate (IP3) formation, Ca2+ release, and contraction; and inhibited forskolin-stimulated cAMP formation in a pertussis toxin-sensitive fashion. Somatostatin also stimulated phosphoinositide hydrolysis in plasma membranes. Only those somatostatin analogs that shared a high affinity for sstr3 receptors elicited muscle contraction. IP3 formation, Ca2+ release, and contraction in permeabilized SMC and phosphoinositide hydrolysis in plasma membranes were inhibited (similar to 80%) by pretreatment with antibodies to PLC-beta 3 but not other PLC-beta isozymes, and by antibodies to G(beta) but not G(alpha). Inhibition of cAMP formation was partially blocked by antibody to G(alpha i1) or G(alpha o) and additively blocked by a combination of both antibodies. Somatostatin-stimulated [S-35]GTP gamma S-G(alpha) complexes in plasma membranes were bound selectively by G(alpha i1) and G(alpha o) antibodies. We conclude that in smooth muscle sstr3 is coupled to G(i1) and G(o); the alpha subunits of both G proteins mediate inhibition of adenylyl cyclase, while the beta gamma subunits mediate activation of PLC-beta 3.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298; TULANE UNIV,MED CTR,PEPTIDE RES LAB,NEW ORLEANS,LA 70112	Virginia Commonwealth University; Virginia Commonwealth University; Tulane University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015564, R37DK015564] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-15564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BITO H, 1994, J BIOL CHEM, V269, P12722; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; GU ZF, 1995, AM J PHYSIOL-GASTR L, V268, pG739, DOI 10.1152/ajpgi.1995.268.5.G739; HADCOCK JR, 1994, MOL PHARMACOL, V45, P410; HOYER D, 1994, N-S ARCH PHARMACOL, V350, P441; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KUBOTA A, 1994, BIOCHEM BIOPH RES CO, V204, P176, DOI 10.1006/bbrc.1994.2442; KUEMMERLE JF, 1992, AM J PHYSIOL, V263, pG269, DOI 10.1152/ajpgi.1992.263.2.G269; KUEMMERLE JF, 1994, AM J PHYSIOL, V266, pC1421, DOI 10.1152/ajpcell.1994.266.5.C1421; LAW SF, 1995, CELL SIGNAL, V7, P1, DOI 10.1016/0898-6568(94)00064-I; LAW SF, 1994, MOL PHARMACOL, V45, P587; LI XJ, 1992, J BIOL CHEM, V267, P21307; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; MURTHY KS, 1991, AM J PHYSIOL, V261, pG945, DOI 10.1152/ajpgi.1991.261.6.G945; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V269, pC969, DOI 10.1152/ajpcell.1995.269.4.C969; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; MURTHY KS, 1995, AM J PHYSIOL-GASTR L, V269, pG93, DOI 10.1152/ajpgi.1995.269.1.G93; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; MURTHY KS, 1996, IN PRESS MOL PHARM; MURTHY KS, 1985, J PHARMACOL EXP THER, V274, P300; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OKAMOTO T, 1992, FEBS LETT, V305, P125, DOI 10.1016/0014-5793(92)80878-K; PARK DG, 1993, J BIOL CHEM, V268, P4573; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROSSOWSKI WJ, 1993, BIOCHEM BIOPH RES CO, V197, P366, DOI 10.1006/bbrc.1993.2488; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SIMS SM, 1991, J PHYSIOL-LONDON, V441, P615, DOI 10.1113/jphysiol.1991.sp018770; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WANG XB, 1993, BIOCHEM BIOPH RES CO, V193, P483, DOI 10.1006/bbrc.1993.1649; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YAJIMA Y, 1993, MOL CELL ENDOCRINOL, V92, P143, DOI 10.1016/0303-7207(93)90001-Z; YASUDA K, 1992, J BIOL CHEM, V267, P20422	44	111	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23458	23463		10.1074/jbc.271.38.23458	http://dx.doi.org/10.1074/jbc.271.38.23458			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798553	hybrid			2022-12-25	WOS:A1996VH76800079
J	Rich, CB; Nugent, MA; Stone, P; Foster, JA				Rich, CB; Nugent, MA; Stone, P; Foster, JA			Elastase release of basic fibroblast growth factor in pulmonary fibroblast cultures results of elastin gene transcription - A role for basic fibroblast growth factor in regulating lung repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-I; FUNCTIONAL PROMOTER; 5'-FLANKING REGION; SKIN FIBROBLASTS; FACTOR-BETA; EXPRESSION; EMPHYSEMA; MODULATION; BINDING	We have reported previously that a factor released by elastase treatment of pulmonary fibroblast cultures is capable of down-regulating elastin gene expression. In the present study we have pursued the identification of the factor released by elastase treatment and the characterization of the level of elastin gene expression at which this factor exerts its effect. We have found by immunologic and biochemical procedures that elastase treatment results in the release of basic fibroblast growth factor (bFGF) that is bound within the matrix. Both purified bFGF and bFGF released by elastase from cell matrices decrease the transcriptional level of the elastin gene by 70-80% within 24 h. Transient transfections of pulmonary fibroblasts with a series of elastin promoter deletion constructs show that the region of the elastin gene responsive to bFGF is located within sequences spanning -900 to -200 base pairs. The biological implications of these findings coupled with our previous report are significant, since they demonstrate that elastase digestion of pulmonary fibroblast matrices not only results in the proteolysis of elastin but also results in the release of a potent regulator of elastin gene transcription whose activity can influence repair mechanisms.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University				Nugent, Matthew/0000-0002-8630-4712	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046100, P01HL046902] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46100, HL 46902] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBIN RJ, 1987, PULMONARY EMPHYSEM 5, P283; BERK JL, 1991, J BIOL CHEM, V266, P3192; BRETTELL LM, 1994, AM J RESP CELL MOL, V10, P306, DOI 10.1165/ajrcmb.10.3.8117449; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; KUHN C, 1976, LAB INVEST, V34, P372; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; SANDHAUS RA, 1987, PULMONARY EMPHYSEMA, P227; SNIDER GL, 1991, ANN NY ACAD SCI, V624, P45, DOI 10.1111/j.1749-6632.1991.tb17005.x; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRINKAUSRANDALL V, 1993, INVEST OPHTH VIS SCI, V34, P3103; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; WU Y, 1992, J BIOL CHEM, V267, P24199	20	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23043	23048		10.1074/jbc.271.38.23043	http://dx.doi.org/10.1074/jbc.271.38.23043			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798493	hybrid			2022-12-25	WOS:A1996VH76800019
J	Watanabe, K; Yamaguchi, Y				Watanabe, K; Yamaguchi, Y			Molecular identification of a putative human hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PYOGENES; GROWTH-FACTOR; PROTEIN; CHITIN; BIOSYNTHESIS; SYNTHETASE; CELLS; GENE; PROTEOGLYCAN; FIBROBLASTS	To identify the putative mammalian hyaluronan synthase, we cloned a human cDNA that is related to the Streptococcus hyaluronan synthase (HasA) and the Xenopus developmental protein DG42 which has been shown to have chitin synthase activity. The cDNA, for which we propose the name Has2, encodes a novel protein with a predicted molecular mass of 63.6 kDa, Has2 shows 55% amino acid identity with Xenopus DG42 and 52% identity with the mouse HAS protein, another putative hyaluronan synthase recently reported by Itano and Kimata (Itano, N., and Kimata, K. (1996) J. Biol. Chem. 271, 9875-9878). The deduced primary structure revealed the presence of several hydrophobic stretches which can form multiple transmembrane domains. It also demonstrated the complete conservation of amino acid residues that are known to be critical for N-acetylglucosaminyltransferase activity of yeast chitin synthase. When the Has2 cDNA was transfected into human 293 and Chinese hamster ovary cells, the production of hyaluronan in the transfected cells increased up to 34- and 9-fold, respectively, Strong expression of Has2 mRNA was observed in exponentially proliferating human IMR-90 fibroblasts but not in growth-arrested IMR-90 cells. These results suggest that the Has2 protein is a crucial component of the human hyaluronan synthase system.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Watanabe, Ken/I-3960-2013	Watanabe, Ken/0000-0003-0664-3915	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032717] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 25938] Funding Source: Medline; NINDS NIH HHS [NS 32717] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; BULAWA CE, 1991, NATURE, V353, P710, DOI 10.1038/353710b0; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; HELDIN P, 1992, BIOCHEM J, V283, P165, DOI 10.1042/bj2830165; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; MATUOKA K, 1987, J CELL BIOL, V104, P1105, DOI 10.1083/jcb.104.4.1105; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1984, BIOCHEM J, V220, P191; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SEMINO CE, 1994, CELL MOL BIOL, V40, P1029; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TAKAYAMA S, 1996, IN PRESS GENOMICS; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0	25	177	193	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22945	22948		10.1074/jbc.271.38.22945	http://dx.doi.org/10.1074/jbc.271.38.22945			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798477	hybrid			2022-12-25	WOS:A1996VH76800003
J	DiStefano, PS; Boulton, TG; Stark, JL; Zhu, YA; Adryan, KM; Ryan, TE; Lindsay, RM				DiStefano, PS; Boulton, TG; Stark, JL; Zhu, YA; Adryan, KM; Ryan, TE; Lindsay, RM			Ciliary neurotrophic factor induces down-regulation of its receptor and desensitization of signal transduction pathways in vivo: Non-equivalence with pharmacological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; RETROGRADE AXONAL-TRANSPORT; TRIPARTITE CNTF RECEPTOR; EPIDERMAL GROWTH-FACTOR; FACTOR-BINDING PROTEIN; CRYSTAL-STRUCTURE; RECOMBINANT HUMAN; ALPHA COMPONENT; CELL-SURFACE; SOLUBLE FORM	Despite the widespread use of polypeptide growth factors as pharmacological agents, little is known about the extent to which these molecules regulate their cognate cell surface receptors and signal transduction pathways in vivo. We have addressed this issue with respect to the neurotrophic molecule ciliary neurotrophic factor (CNTF). Administration of CNTF in vivo resulted in modest decreases in levels of CNTFR alpha mRNA and protein in skeletal muscle, CNTF causes the rapid tyrosine phosphorylation of LIFR beta and gp130 and the induction of the immediate-early gene, tis11; injection of CNTF 3-7 h after an initial exposure failed to re-stimulate these immediate early responses, suggesting a biochemical desensitization to CNTF not accounted for by decreased receptor protein. To determine whether the desensitization of immediate-early responses caused by CNTF resulted in a functional desensitization, we compared the efficacy of multiple daily injections versus a single daily dose of CNTF in preventing the denervation-induced atrophy of skeletal muscle. Surprisingly, injections of CNTF every 6 h, which falls within the putative refractory period for biochemical responses, resulted in efficacy equal to or greater than injections once daily. These results suggest that although much of the CNTF signal transduction machinery is down-regulated with frequent CNTF dosing, biological signals continue to be recognized and interpreted by the cell.			DiStefano, PS (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ALDERSON RF, 1994, IN PRESS J NEUROCHEM; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CEDARBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; Curtis Rory, 1994, Trends in Cell Biology, V4, P383, DOI 10.1016/0962-8924(94)90045-0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; Distefano P. S., 1994, Society for Neuroscience Abstracts, V20, P42; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Frank L, 1996, EUR J NEUROSCI, V8, P1220, DOI 10.1111/j.1460-9568.1996.tb01290.x; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LIPSON KE, 1989, BIOCHEM J, V261, P333, DOI 10.1042/bj2610333; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MACLENNAN AJ, 1994, MOL BRAIN RES, V25, P251, DOI 10.1016/0169-328X(94)90160-0; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; *NIH, 1985, NIH PUBL, V8623; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PORTEU F, 1991, J BIOL CHEM, V266, P18846; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; ZUPAN AA, 1991, J BIOL CHEM, V266, P15384	52	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22839	22846		10.1074/jbc.271.37.22839	http://dx.doi.org/10.1074/jbc.271.37.22839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798462	hybrid			2022-12-25	WOS:A1996VG67200081
J	Schjerling, CK; Hummel, R; Hansen, JR; Borsting, C; Mikkelsen, JM; Kristiansen, K; Knudsen, J				Schjerling, CK; Hummel, R; Hansen, JR; Borsting, C; Mikkelsen, JM; Kristiansen, K; Knudsen, J			Disruption of the gene encoding the acyl-CoA-binding protein (ACB1) perturbs acyl-CoA metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR DBI; MOLECULAR-CLONING; YEAST; HOMOLOG; EXPRESSION; RAT	The ACB1 gene encoding the acyl-CoA-binding protein (ACBP) was disrupted in Saccharomyces cerevisiae. The disruption did not affect the growth rate on glucose but reduced the growth rate on ethanol slightly. Although the growth rate of the acb1-disrupted cells was unaffected or only slightly affected, the acb1-disrupted strain was unable to compete with wild type cells when grown in mixed culture. The acyl-CoA level in the disrupted cells was increased from 1.5- to 2.5-fold during exponential growth. The increase in the acyl-CoA level was caused solely by an increase in de novo synthesized stearoyl-CoA. Experiments with purified yeast fatty acid synthetase show that it will synthesize long chain acyl-CoAs in the absence of acyl-CoA-binding protein. The addition of ACBP to the incubation medium resulted in a dramatic decrease in the chain length of the synthesized acyl-CoA esters. Despite the fact that the stearoyl-CoA concentration was increased 7-fold and the Delta 9-desaturase mRNA level was increased 3-fold, the synthesis of oleic acid was unchanged in the acb1-disrupted strain. The results strongly indicate that ACBP in yeast is involved in the transport of newly synthesized acyl-CoA esters from the fatty acid synthetase to acyl-CoA-consuming processes.	ODENSE UNIV,INST BIOCHEM,DK-5230 ODENSE M,DENMARK; ODENSE UNIV,DEPT MOL BIOL,DK-5230 ODENSE M,DENMARK	University of Southern Denmark; University of Southern Denmark			Kristiansen, Karsten/J-5148-2014	Kristiansen, Karsten/0000-0002-6024-0917; Borsting, Claus/0000-0003-0421-7429				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; BOVOLIN P, 1990, REGUL PEPTIDES, V29, P267, DOI 10.1016/0167-0115(90)90089-F; DAMITYO T, 1976, P NATL ACAD SCI USA, V73, P386; FREINBERG AP, 1983, ANAL BIOCHEM, V132, P6; FYRST H, 1995, BIOCHEM J, V306, P793, DOI 10.1042/bj3060793; HILLS MJ, 1994, PLANT MOL BIOL, V25, P917, DOI 10.1007/BF00028886; KNUDSEN J, 1994, BIOCHEM J, V302, P479, DOI 10.1042/bj3020479; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; KNUDSEN J, 1981, ANAL BIOCHEM, V112, P190, DOI 10.1016/0003-2697(81)90279-7; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MOGENSEN IB, 1987, BIOCHEM J, V241, P189, DOI 10.1042/bj2410189; OSTENSON CG, 1994, EUR J ENDOCRINOL, V131, P201, DOI 10.1530/eje.0.1310201; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1293; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; ROSE TM, 1992, P NATL ACAD SCI USA, V89, P11287, DOI 10.1073/pnas.89.23.11287; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SLABAS AR, 1983, EUR J BIOCHEM, V134, P27, DOI 10.1111/j.1432-1033.1983.tb07526.x; SNYDER MJ, 1993, MOL CELL ENDOCRINOL, V94, pR1, DOI 10.1016/0303-7207(93)90064-Q; SUMPER M, 1969, EUR J BIOCHEM, V10, P377, DOI 10.1111/j.1432-1033.1969.tb00701.x; SUMPER M, 1973, FEBS LETT, V30, P29, DOI 10.1016/0014-5793(73)80612-X	25	96	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22514	22521		10.1074/jbc.271.37.22514	http://dx.doi.org/10.1074/jbc.271.37.22514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798418	hybrid			2022-12-25	WOS:A1996VG67200037
J	Suzuki, Y; Sato, N; Tohyama, M; Wanaka, A; Takagi, T				Suzuki, Y; Sato, N; Tohyama, M; Wanaka, A; Takagi, T			cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain - LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE L1; TRANSMEMBRANE PROTEIN; NEUROTROPHIC FACTOR; GROWTH-FACTOR; NG-CAM; SUPERFAMILY; DROSOPHILA; RECEPTOR; MEMBER; BINDING	A cDNA encoding a protein designated as LIG-1 has been cloned and characterized. A fragment of this cDNA was found previously in a screen for genes up-regulated during neural differentiation in mouse P19 embryonal carcinoma cells. Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids. This protein, therefore, is a new member of both the leucine-rich repeat and the immunoglobulin superfamilies. Furthermore, Northern blot and in situ hybridization analyses showed LIG-1 gene expression to be predominantly in the brain, restricted to a small subset of glial cells such as Bergmann glial. cells of the cerebellum and glial cells in the nerve fiber layer of the olfactory bulb. On the basis of its structural features and expression pattern, we propose that LIG-1 functions as a cell type-specific adhesion molecule or receptor at the glial cell surface, and plays a role in the nervous system in for example neuroglial differentiation, development, and/or maintenance of neural functions where it is expressed.	OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,SUITA,OSAKA 565,JAPAN; TANABE SEIYAKU CO LTD,LEAD GENERAT RES LAB,YODOGAWA KU,OSAKA 532,JAPAN	Osaka University; Mitsubishi Tanabe Pharma Corporation	Suzuki, Y (corresponding author), OSAKA UNIV,SCH MED,DEPT MOL NEUROBIOL TANABE,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Wanaka, Akio/ABE-4671-2020; Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/GPW-8926-2022	Wanaka, Akio/0000-0001-9951-9862; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GRUMET M, 1992, J NEUROSCI RES, V31, P1, DOI 10.1002/jnr.490310102; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; ORTEGA A, 1991, NEUROSCIENCE, V41, P335, DOI 10.1016/0306-4522(91)90331-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SOTELO C, 1994, J NEUROSCI, V14, P124; Suzuki Y, 1996, NUCLEIC ACIDS RES, V24, P797, DOI 10.1093/nar/24.4.797; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	51	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22522	22527		10.1074/jbc.271.37.22522	http://dx.doi.org/10.1074/jbc.271.37.22522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798419	hybrid			2022-12-25	WOS:A1996VG67200038
J	Lavrik, OI; Prasad, R; Beard, WA; Safronov, IV; Dobrikov, MI; Srivastava, DK; Shishkin, GV; Wood, TG; Wilson, SH				Lavrik, OI; Prasad, R; Beard, WA; Safronov, IV; Dobrikov, MI; Srivastava, DK; Shishkin, GV; Wood, TG; Wilson, SH			dNTP binding to HIV-1 reverse transcriptase and mammalian DNA polymerase beta as revealed by affinity labeling with a photoreactive dNTP analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; STEADY-STATE KINETICS; DOUBLE-STRANDED DNA; I KLENOW FRAGMENT; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; CATALYTIC DOMAIN; RNA-POLYMERASES; PRIMER BINDING; MECHANISM	The dNTP binding pocket of human immunodeficiency virus type 1 reverse transcriptase (RT) and DNA polymerase beta (beta-pol) were labeled using a photoreactive analog of dCTP, exo-N-[beta-(p-azidotetrafluorobenzamido)ethyl]-deoxycytidine-5'-triphosphate (FABdCTP), Two approaches of photolabeling were utilized, In one approach, photoreactive FABdCTP and radiolabeled primer-template were UV-irradiated in the presence of each enzyme and resulted in polymerase radiolabeling. In an alternate approach, FABdCTP was first UV-cross linked to enzyme; subsequently, radiolabeled primer-template was added, and the enzyme-linked dCTP analog was incorporated onto the 3'-end of the radiolabeled primer. The results showed strong labeling of the p66 subunit of RT, with only minor labeling of p51. No difference in the intensity of cross linking was observed with either approach, FABdCTP crosslinking was increased in the presence of a dideoxyterminated primer-template with RT, but not with beta-pol, suggesting a significant influence of prior primer-template binding on dNTP binding for RT. Mutagenesis of beta-pol residues observed to interact with the incoming dNTP in the crystal structure of the ternary complex resulted in labeling consistent with kinetic characterization of these mutants and indicated specific labeling of the dNTP binding pocket.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; RUSSIAN ACAD SCI, INST BIOORGAN CHEM, SIBERIAN DIV, NOVOSIBIRSK 630090, RUSSIA	University of Texas System; University of Texas Medical Branch Galveston; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences			Lavrik, Olga I/G-4641-2013; Wilson, Samuel H/E-6644-2019; Wood, Thomas/B-6172-2012; Wood, Thomas/GWZ-2481-2022	Wilson, Samuel H/0000-0002-1702-5293; Wood, Thomas/0000-0001-8962-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06776, ES06492] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; CHENG N, 1993, BIOCHEMISTRY-US, V32, P7630, DOI 10.1021/bi00081a005; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DORONIN SV, 1994, FEBS LETT, V354, P200, DOI 10.1016/0014-5793(94)01110-9; DORONIN SV, 1992, FEBS LETT, V313, P31, DOI 10.1016/0014-5793(92)81177-N; DORONIN SV, 1989, FEBS LETT, V259, P83, DOI 10.1016/0014-5793(89)81500-5; GRACHEV MA, 1982, FEBS LETT, V137, P89, DOI 10.1016/0014-5793(82)80321-9; HUSAIN I, 1995, NUCLEIC ACIDS RES, V23, P1597, DOI 10.1093/nar/23.9.1597; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KNORRE DG, 1988, BIOCHIMIE, V70, P655, DOI 10.1016/0300-9084(88)90250-7; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1993, BIOCHEMISTRY-US, V32, P7466, DOI 10.1021/bi00080a018; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MITINA RL, 1990, FEBS LETT, V272, P181, DOI 10.1016/0014-5793(90)80478-2; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PELLETIER H, 1994, SCIENCE, V266, P2025, DOI 10.1126/science.7801132; PELLETIER H, 1996, IN PRESS BIOCHEMISTR; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sambrook J, 1989, MOL CLONING; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; Srivastava DK, 1996, BIOCHEMISTRY-US, V35, P3728, DOI 10.1021/bi952632h; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003; Zakharova OD, 1995, BIOCHIMIE, V77, P699, DOI 10.1016/0300-9084(96)88184-3	44	34	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21891	21897		10.1074/jbc.271.36.21891	http://dx.doi.org/10.1074/jbc.271.36.21891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702991	hybrid			2022-12-25	WOS:A1996VF61200033
J	Galisteo, ML; Chernoff, J; Su, YC; Skolnik, EY; Schlessinger, J				Galisteo, ML; Chernoff, J; Su, YC; Skolnik, EY; Schlessinger, J			The adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase pak1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR-CLONING; CDC42; SH3; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION; DOMAINS; PLASMID	Nck is an adaptor protein composed of a single SH2 domain and three SH3 domains. Upon growth factor stimulation, Nck is recruited to receptor tyrosine kinases via its SH2 domain, probably initiating one or more signaling cascades, In this report, we show that Nck is bound in living cells to the serine-threonine kinase Pak1. The association between Nck and Pak1 is mediated by the second SH3 domain of Nck and a proline-rich sequence in the amino terminus of Pak1. We also show that Pak1 is recruited by activated epidermal growth factor (EGF) and platelet-derived growth factor receptors, Moreover, Pak1 kinase activity is increased in response to EGF in HeLa cells transfected with human Pak1, and the kinase activity was enhanced when Nck was co-transfected. It is concluded that Nck links receptor tyrosine kinases with Pak1 and is probably involved in targeting and regulation of Pak1 activity.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	New York University; Fox Chase Cancer Center			Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [R01 CA58836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harlow E., 1988, ANTIBODIES LAB MANUA; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCCUNE K, 1993, YEAST, V9, P295; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARK D, 1992, MOL CELL BIOL, V12, P5834; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rose MD., 1990, METHODS YEAST GENETI; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHLESSINGER J, 1993, CURR BIOL, V3, P434; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	36	236	240	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20997	21000		10.1074/jbc.271.35.20997	http://dx.doi.org/10.1074/jbc.271.35.20997			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8798379	hybrid			2022-12-25	WOS:A1996VE47700007
J	Tomic, M; Jobin, RM; Vergara, LA; Stojilkovic, SS				Tomic, M; Jobin, RM; Vergara, LA; Stojilkovic, SS			Expression of purinergic receptor channels and their role in calcium signaling and hormone release in pituitary gonadotrophs - Integration of P-2 channels in plasma membrane- and endoplasmic reticulum-derived calcium oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; CHROMAFFIN CELLS; ATP RECEPTORS; CA2+ RELEASE; EXTRACELLULAR ATP; XENOPUS-OOCYTES; SENSORY NEURONS; ION CHANNELS; AR42J CELLS; ADENOSINE	The role of ATP as a positive feedback element in Ca2+ signaling and secretion was examined in female rat pituitary gonadotrophs. ATP and ADP, but not AMP or adenosine, induced a dose- and extracellular Ca2+-dependent rise in [Ca-2+](i) in identified gonadotrophs in a Mg2+- and suramin-sensitive manner. ATP, adenosine-5'-O-(3-thiotriphosphate), adenosine-5'-O-(1-thiotriphosphate), 2-methylthio-ATP, and 3'-O-(4-benzoyl)benzoyl-ATP. were roughly equipotent in rising [Ca2+](i) in gonadotrophs, while ADP was effective only at submillimolar concentration range, and none of these compounds permeabilized the cells. On the other hand, alpha,beta-methylene-ATP, beta,gamma-methylene-ATP, and UTP were unable to induce any rise in [Ca2+](i). This pharmacological profile is consistent with expression of P2X(2) and/or P2X(5) purinergic receptor channels. Patch-clamp experiments showed that ATP induced an inward depolarizing current in gonadotrophs clamped at -90 mV, associated with an increase in [Ca2+](i). The ATP-induced [Ca2+](i) response was partially inhibited by nifedipine, a blocker of voltage-sensitive Ca2+ channels (VSCC), but was not affected by tetrodotoxin, a blocker of voltage-sensitive Na+ channels. Thus, the P-2-depolarizing current itself drives Ca2+ into the cell, but also activates Ca2+ entry through VSCC. In accord with this, low [ATP] induced plasma membrane-dependent [Ca2+](i) oscillations in quiescent cells, and increased the frequency of spiking in spontaneously active cells. ATP-induced Ca2+ influx also affected agonist-induced and InsP(3)-dependent [Ca2+](i) oscillations by increasing the frequency, base line, and duration of Ca2+ spiking. In addition, ATP stimulated gonadotropin secretion and enhanced agonist-induced gonadotropin release. ATP was found to be secreted by pituitary cells during agonist stimulation and was promptly degraded by ectonucleotidase to adenosine. These observations indicate that ATP represents a paracrine/autocrine factor in the regulation of Ca2+ signaling and secretion in gonadotrophs, and that these actions are mediated by P-2 receptor channels.	NICHHD,ERRB,UCS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Tomic, Melanija/C-3371-2016					ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BENNETT MR, 1995, BIOPHYS J, V68, P925, DOI 10.1016/S0006-3495(95)80268-7; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BOSMA MM, 1992, ENDOCRINOLOGY, V130, P3411, DOI 10.1210/en.130.6.3411; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; CAREW MA, 1994, CELL CALCIUM, V16, P227, DOI 10.1016/0143-4160(94)90025-6; CASTRO E, 1995, J BIOL CHEM, V270, P5098, DOI 10.1074/jbc.270.10.5098; CENA V, 1990, BIOCHIM BIOPHYS ACTA, V1023, P213, DOI 10.1016/0005-2736(90)90416-L; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chen ZP, 1996, ENDOCRINOLOGY, V137, P248, DOI 10.1210/en.137.1.248; CHEN ZP, 1994, ENDOCRINOLOGY, V135, P1280, DOI 10.1210/en.135.3.1280; CHEN ZP, 1995, P NATL ACAD SCI USA, V92, P5219, DOI 10.1073/pnas.92.11.5219; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; Collo G, 1996, J NEUROSCI, V16, P2495; CUSACK NJ, 1993, DRUG DEVELOP RES, V28, P244, DOI 10.1002/ddr.430280310; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DEUSSEN A, 1993, AM J PHYSIOL, V264, pH692, DOI 10.1152/ajpheart.1993.264.3.H692; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; ILLES P, 1993, TRENDS PHARMACOL SCI, V14, P50, DOI 10.1016/0165-6147(93)90030-N; JOBIN RM, 1995, ENDOCRINOLOGY, V136, P3398, DOI 10.1210/en.136.8.3398; KEIZER J, 1995, MOL BIOL CELL, V6, P945, DOI 10.1091/mbc.6.8.945; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; KUKULJAN M, 1994, J BIOL CHEM, V269, P4860; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LI YX, 1995, BIOPHYS J, V69, P785, DOI 10.1016/S0006-3495(95)79952-0; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MARCHETTI C, 1987, AM J PHYSIOL, V252, pE340, DOI 10.1152/ajpendo.1987.252.3.E340; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Pearson J.D., 1985, METHODS PHARM, V6, P83; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROZENGURT E, 1975, BIOCHEM BIOPH RES CO, V67, P1581, DOI 10.1016/0006-291X(75)90207-7; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1994, MOL PHARMACOL, V45, P1013; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; STOJILKOVIC SS, 1990, NEW BIOL, V3, P272; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TSCHOPL M, 1992, EUR J PHARMACOL, V213, P71, DOI 10.1016/0014-2999(92)90234-U; TSE A, 1993, ENDOCRINOLOGY, V132, P1475, DOI 10.1210/en.132.4.1475; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VANDERMERWE PA, 1989, FEBS LETT, V243, P333, DOI 10.1016/0014-5793(89)80156-5; VERGARA LA, 1995, BIOPHYS J, V69, P1606, DOI 10.1016/S0006-3495(95)80033-0; WILEY JS, 1993, ARCH BIOCHEM BIOPHYS, V305, P54, DOI 10.1006/abbi.1993.1392; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHAO H, 1990, J BIOL CHEM, V265, P20856	58	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21200	21208		10.1074/jbc.271.35.21200	http://dx.doi.org/10.1074/jbc.271.35.21200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702891	hybrid			2022-12-25	WOS:A1996VE47700037
J	Moffat, GJ; McLaren, AW; Wolf, CR				Moffat, GJ; McLaren, AW; Wolf, CR			Functional characterization of the transcription silencer element located within the human Pi class glutathione S-transferase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; ANTIOXIDANT RESPONSIVE ELEMENT; DNA-PROTEIN INTERACTION; ESCHERICHIA-COLI K-12; CRP ACTIVATOR COMPLEX; BINDING PROTEIN; CYTR REPRESSOR; RETINOBLASTOMA PROTEIN; REGULATORY ELEMENTS; CONFERS RESISTANCE	We have previously demonstrated enhanced transcriptional activity of the human Pi class glutathione S-transferase (GSTP1) promoter in a multidrug-resistant derivative (VCREMS) of the human mammary carcinoma cell line, MCF7 (Moffat, G, J,, McLaren, A. W., and Wolf, C. R (1994) J. Biol. Chem. 269, 16397-16402), Furthermore, we have identified an essential sequence (C1; -70 to -59) within the GSTP1 promoter that bound a Jun-Fos heterodimer in VCREMS but not in MCF7 cells, These present studies have examined the negative regulatory element (-105 to -86), which acted to suppress GSTP1 transcription in MCF7 cells. Mutational analysis of this silencer element further defined the repressor binding site to be located between nucleotides -97 and -90, In vitro DNA binding assays suggested that the repressor exerted its action by causing displacement of the essential non-AP-1-like MCF7 C1 complex, However, the addition of MCF7 nuclear extract did not disrupt binding of the VCREMS jun-Fos C1 complex to the GSTP1 promoter, Furthermore, upstream insertion of the GSTP1 silencer element failed to inhibit activity of a heterologous promoter in MCF7 cells, These results highlighted the cell and promoter specificity of the GSTP1 transcriptional repressor and implicated a functional requirement for contact between the repressor and C1 complex, In this regard, the introduction of half-helical turns between the silencer and the C1 element abrogated repressor activity, thus leading to the hypothesis that a direct interaction between the repressor and C1 complex was required to suppress GSTP1 transcription, Moreover, these findings suggest that cell-specific differences in the composition of the C1 nuclear complex may dictate repressor activity.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,IMPERIAL CANC RES FUND,MOL PHARMACOL UNIT,BIOMED RES CTR,DUNDEE DD1 9SY,SCOTLAND	University of Dundee								ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BATIST G, 1986, J BIOL CHEM, V261, P5544; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CARMICHAEL J, 1988, CARCINOGENESIS, V9, P1617, DOI 10.1093/carcin/9.9.1617; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FIELDS WR, 1994, CARCINOGENESIS, V15, P1155, DOI 10.1093/carcin/15.6.1155; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GORMAN C, 1986, DNA CLONING PRACTICA, V3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAO XY, 1994, CARCINOGENESIS, V15, P1167, DOI 10.1093/carcin/15.6.1167; HEIBERT SW, 1991, J VIROL, V65, P3547; HOLST B, 1992, EMBO J, V11, P3635, DOI 10.1002/j.1460-2075.1992.tb05448.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KODATE C, 1986, GANN, V77, P226; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PETERS WHM, 1989, CARCINOGENESIS, V10, P2371, DOI 10.1093/carcin/10.12.2371; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOFFOLI G, 1992, EUR J CANCER, V28A, P1441, DOI 10.1016/0959-8049(92)90540-I; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; Whelan R D, 1989, Cancer Commun, V1, P359; WHELAN RDH, 1992, INT J CANCER, V52, P241, DOI 10.1002/ijc.2910520215	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20740	20747		10.1074/jbc.271.34.20740	http://dx.doi.org/10.1074/jbc.271.34.20740			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702826	hybrid			2022-12-25	WOS:A1996VD33700078
J	Rusciano, D; Lorenzoni, P; Burger, MM				Rusciano, D; Lorenzoni, P; Burger, MM			Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; HGF RECEPTOR; MET/HGF RECEPTOR; EXPRESSION; CANCER; PHOSPHORYLATION; OVEREXPRESSION; COLONIZATION; PROGRESSION	Serial selection in vivo for liver colonization of B16 murine melanoma cells consistently resulted in cell lines expressing elevated amounts of the hepatocyte growth factor/scatter factor receptor (c-Met), which is constitutively activated in the absence of its cognate ligand, In this paper we present evidence suggesting that c-Met constitutive activation in liver specific B16 melanoma cells depends on both receptor concentration on the cell surface and a cytosolic tyrosine phosphatase activity. In fact, c-Met constitutive activation is suddenly lost upon detachment of the cells from the substrate and is dramatically decreased in adherent cells plated at low density, The loss of tyrosine phosphorylation of c-Met in suspension appears to depend, at least partly, on an increased cytosolic tyrosine phosphatase activity, Instead, lower activation of c-Met at low density mostly results from a decrease in receptor concentration on the membrane, Moreover, we show that c-Met activation does not occur homogeneously on the surface of adherent cells, In fact, receptor concentration and activation appear to be higher on the ventral surface (adherent to the substrate) than on the apical surface, Upon detachment, compartmentalization is lost, leading to a decrease in average receptor density on the plasma membrane and hence to a lower activation.			Rusciano, D (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Rusciano, Dario/AAP-7450-2020	Rusciano, Dario/0000-0002-9577-2585				BOSSERT NL, 1990, DEV BIOL, V142, P75, DOI 10.1016/0012-1606(90)90152-9; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FERRACINI R, 1995, ONCOGENE, V10, P739; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; LIAO K, 1991, J BIOL CHEM, V266, P6544; LICHTNER RB, 1990, J CELL PHYSIOL, V144, P303, DOI 10.1002/jcp.1041440217; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; MANSBRIDGE JN, 1992, J CELL PHYSIOL, V151, P433, DOI 10.1002/jcp.1041510302; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MAUCHAMP J, 1987, J CELL SCI, P345; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PONZETTO C, 1991, ONCOGENE, V6, P553; Prat M, 1995, ANTIBODY IMMUNOCONJ, V8, P341; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; RUSCIANO D, 1995, ONCOGENE, V11, P1979; RUSCIANO D, 1993, INVAS METAST, V13, P212; Tuck AB, 1996, AM J PATHOL, V148, P225; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	28	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20763	20769		10.1074/jbc.271.34.20763	http://dx.doi.org/10.1074/jbc.271.34.20763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702829	hybrid			2022-12-25	WOS:A1996VD33700081
J	Carbone, M; Rizzo, P; Procopio, A; Giuliano, M; Pass, HI; Gebhardt, MC; Mangham, C; Hansen, M; Malkin, DF; Bushart, G; Pompetti, F; Picci, P; Levine, AS; Bergsagel, JD; Garcea, RL				Carbone, M; Rizzo, P; Procopio, A; Giuliano, M; Pass, HI; Gebhardt, MC; Mangham, C; Hansen, M; Malkin, DF; Bushart, G; Pompetti, F; Picci, P; Levine, AS; Bergsagel, JD; Garcea, RL			SV40-like sequences in human bone tumors	ONCOGENE			English	Article						SV40; human bone tumors	HUMAN-BRAIN-TUMORS; T-DELETION MUTANTS; SIMIAN-VIRUS 40; GROWTH-FACTOR-I; SV40; ANTIGEN; SIMIAN-VIRUS-40; MICE; GENE; TRANSFORMATION	Simian virus 40 (SV40) is a monkey virus that induces ependymomas, choroid plexus tumors, mesotheliomas, osteosarcomas, sarcomas and true histiocytic lymphomas when injected in hamsters. Recently, approximately 60% of human ependymomas, choroid plexus tumors and mesotheliomas were reported to contain and express SV40-like sequences (N. Engl. J. Med., 1992, 36, 988-993; Oncogene, 1994, 9, 1781-1790). In this study the presence of SV40-like sequences was investigated in additional types of human tumors. Initially, 200 tumor and normal tissue DNA samples were analysed by polymerase chain reaction (PCR) with primers that were analysed by with primers that amplify a 574 base pair region of SV40 large T antigen (Tag), which includes the Rb-pocket binding domain and the intron of Tag. PCR amplification and Southern blot hybridization with a probe specific for SV40 Tag revealed that 18/200 samples contained SV40-like sequences and, unexpectedly, 11/18 were from patients with osteosarcomas. Additional DNA samples from bone tumors were then analysed. In 40/126 osteosarcomas, and 14/34 other bone-related tumors, Tag sequences could be amplified. Sequence analysis of the DNA amplified from seven different tumors confirmed that the amplified sequences corresponded to SV40 Tag, with some demonstrating deletions in the intron region but not in the Rb-pocket binding domain. The extent of SV40 genome sequences present in the DNA samples was further analysed in two osteosarcomas. PCR amplification, Southern blot hybridization, and sequence analysis revealed that these samples also contained sequences for the carboxy-terminal domain of Tag, the viral regulatory region, and the VP1 capsid protein. These results indicate that SV40-like sequences are present in human bone tumors.	NIH, SECT DNA REPLICAT REPAIR & MUTAGENESIS, BETHESDA, MD 20892 USA; UNIV G DANNUNZIO, EXPT CTR GENE THERAPY & DIAG, CHIETI, ITALY; NCI, THORAC ONCOL SECT, BETHESDA, MD 20892 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, BOSTON, MA 02115 USA; BOSTON UNIV, BOSTON, MA 02215 USA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV ULM, D-7900 ULM, GERMANY; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; SCOTTISH RITE HOSP, ATLANTA, GA USA; CHILDRENS HOSP, DENVER, CO 80218 USA	National Institutes of Health (NIH) - USA; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Boston Children's Hospital; Harvard Medical School; Boston University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ulm University; IRCCS Istituto Ortopedico Rizzoli; Children's Hospital Colorado	Carbone, M (corresponding author), UNIV CHICAGO, DEPT PATHOL, 5841 S MARYLAND AVE, MC3083, ROOM S-342, CHICAGO, IL 60637 USA.		Bergsagel, Daniel John/I-6464-2019; Malkin, David/AAW-8715-2021; Procopio, Antonio Domenico/AAB-2451-2021; Picci, Piero/J-5979-2016	Procopio, Antonio Domenico/0000-0001-6897-8724; Pass, Harvey/0000-0003-3222-3471; Picci, Piero/0000-0002-8519-4101; rizzo, paola/0000-0001-7174-9674; Giuliano, Mariateresa/0000-0002-7338-9200				ABRAMCZUK J, 1984, J VIROL, V49, P540, DOI 10.1128/JVI.49.2.540-548.1984; AVANTAGGIATI ML, IN PRESS EMBO J; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BRIGHT RK, 1994, J IMMUNOL, V153, P2064; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BUCHMAN AR, 1981, DNA TUMOR VIRUSES 2, P799; BUTEL JS, 1994, ENCY VIROLOGY, V2, P1322; CARBONE M, 1994, ONCOGENE, V9, P1781; CARBONE M, 1989, CANCER RES, V49, P1565; CARBONE M, 1991, MOL BASIS HUMAN CANC, P191; CARBONE M, 1995, DNA TUMOR VIRUSES ON, P75; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DIXON K, 1982, NATURE, V296, P672, DOI 10.1038/296672a0; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GEISSLER E, 1983, HUM GENET, V63, P1, DOI 10.1007/BF00285389; GEISSLER E, 1990, PROG MED VIROL, V37, P211; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; ILYINSKII PO, 1992, J VIROL, V66, P6353, DOI 10.1128/JVI.66.11.6353-6360.1992; JENSEN F, 1964, J NATL CANCER I, V29, P1123; KE Y, 1989, AM J PATHOL, V134, P979; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; KRIEG P, 1984, VIROLOGY, V138, P336, DOI 10.1016/0042-6822(84)90357-X; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEDNICKY JA, 1995, VIRUS RES, V35, P143, DOI 10.1016/0168-1702(94)00093-R; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; MARTIN JD, 1991, VIRUS RES, V19, P163, DOI 10.1016/0168-1702(91)90043-U; MARTINI F, 1995, J NATL CANCER I, V87, P1331, DOI 10.1093/jnci/87.17.1331; MAYOL X, 1993, ONCOGENE, V8, P2561; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; PASS HI, IN PRESS IMPORTANT A; PASS HI, IN PRESS CANC RES; POMPETTI F, IN PRESS J CELL BIOC; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RABSON AS, 1962, J NATL CANCER I, V29, P1123; Ray F.A., 1995, DNA TUMOR VIRUSES ON, P15; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; SAMBROOK S, 1989, MOL CLONING, V2; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SHEIN HM, 1962, P NATL ACAD SCI USA, V48, P1164, DOI 10.1073/pnas.48.7.1164; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TIEMANN F, 1994, ONCOGENE, V9, P1907; TODARO GJ, 1967, P SOC EXP BIOL MED, V124, P1232; VALENTINIS B, 1994, ONCOGENE, V9, P825; WALKER DL, 1986, PAPOVAVIRIDAE, V1, P327; WALSH JW, 1982, NEUROSURGERY, V10, P643, DOI 10.1227/00006123-198205000-00018; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WEINER LP, 1972, NEW ENGL J MED, V305, P1517; WILKIE TM, 1994, ONCOGENE, V9, P2889; YOSHIIKE K, 1986, PAPOVAVIRIDAE, V1, P295	60	178	182	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					527	535						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760294				2022-12-25	WOS:A1996VB32800010
J	Thompson, A; Zhang, Y; Kamen, D; Jackson, CW; Cardiff, RD; Ravid, K				Thompson, A; Zhang, Y; Kamen, D; Jackson, CW; Cardiff, RD; Ravid, K			Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CELL-CYCLE; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; PLATELET PRODUCTION; PROGENITOR CELLS; BONE-MARROW	Platelets, essential for vascular integrity and hemostasis, fragment from polyploid megakaryocytes, characterized by their endomitotic cell cycle. We studied the influence of overexpression of c-myc oncogene on megakaryopoiesis and endomitosis in vivo, using transgenic mice carrying c-myc fused to the estrogen receptor under the control of the platelet factor 4 (PF4) megakaryocyte-specific promoter. The rationale behind this strategy was to obtain controlled overexpression of an active c-Myc, depending on the estrogen level in the mouse circulation. Analysis of these transgenic mice revealed that the bone marrow of female transgenic mice or of estrogen-injected male transgenic mice, but not of age-matched transgenic males nor nontransgenic females, contained frequent immature myeloid cells and an increased number of megakaryocytes. Deregulated expression of c-Myc shifted the normal ploidy profile of megakaryocytes due to a significant increase in proliferating megakaryocytes and a decrease in the fraction of ploidizing cells. These transgenic mice represent a novel in vivo model for a Myc induced myeloproliferative disorder which can be controlled.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02139 USA; ST JUDE CHILDRENS RES HOSP, DIV EXPT HEMATOL, MEMPHIS, TN 38105 USA; UNIV CALIF DAVIS, DEPT MED PATHOL, SACRAMENTO, CA 95817 USA	Boston University; St Jude Children's Research Hospital; University of California System; University of California Davis				Thompson, Alex/0000-0002-9315-5321; Ravid, Katya/0000-0002-9918-3024	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053080] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53080] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARRIAGA M, 1987, BLOOD, V69, P486; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BURSTEIN SA, 1992, EXP HEMATOL, V20, P1170; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DORN GW, 1994, AM J PHYSIOL, V266, pC1231, DOI 10.1152/ajpcell.1994.266.5.C1231; ECKHARDT SG, 1994, P NATL ACAD SCI USA, V91, P6674, DOI 10.1073/pnas.91.14.6674; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GEWIRTZ AM, 1990, EXP HEMATOL, V18, P945; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guy CT, 1996, MOL CELL BIOL, V16, P685; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; JACKSON CW, 1992, BLOOD, V79, P1672; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUTER DJ, 1989, BLOOD, V74, P1952; LEPORE DA, 1984, BRIT J HAEMATOL, V58, P473, DOI 10.1111/j.1365-2141.1984.tb03994.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAZUR EM, 1987, EXP HEMATOL, V15, P340; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MULLERSIEBURG CE, 1991, J EXP MED, V174, P161, DOI 10.1084/jem.174.1.161; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ODELL TT, 1968, EXP CELL RES, V53, P321, DOI 10.1016/0014-4827(68)90302-9; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; RAVID K, 1993, J CELL BIOL, V123, P1545, DOI 10.1083/jcb.123.6.1545; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINCI G, 1984, BRIT J HAEMATOL, V56, P589, DOI 10.1111/j.1365-2141.1984.tb02184.x; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang Y, 1996, J BIOL CHEM, V271, P4266	50	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22976	22982		10.1074/jbc.271.38.22976	http://dx.doi.org/10.1074/jbc.271.38.22976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798484	hybrid			2022-12-25	WOS:A1996VH76800010
J	Walsh, AA; Tullis, K; Rice, RH; Denison, MS				Walsh, AA; Tullis, K; Rice, RH; Denison, MS			Identification of a novel cis-acting negative regulatory element affecting expression of the CYP1A1 gene in rat epidermal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; DIOXIN-RESPONSIVE ENHANCER; NUCLEAR TRANSLOCATOR PROTEIN; AH-RECEPTOR; DNA RECOGNITION; TRANSCRIPTIONAL REGULATION; AROMATIC-HYDROCARBONS; HEPATOMA-CELLS; BINDING; KERATINOCYTES	Polycyclic aromatic hydrocarbons such as 3-methylcholanthrene are toxic to rat epidermal cells in low passages (3 to 6), but cultures of high passage (greater than or equal to 15) are resistant. Since such compounds can be metabolically activated by cytochrome P4501A1, we have examined the regulation of this gene in low and high passage cells, Consistent with this difference, little or no 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible P4501A1 mRNA or enzyme activity was observed in high passage as compared to low passage cultures. Similarly, transfection of a luciferase reporter construct containing -1317 to +256 base pairs of the 5'-flanking region of the murine CYP1A1 gene was TCDD-inducible in low but not high passage cells. Ligand binding and transfection experiments demonstrated the presence of functional Ah receptor complexes in both high and low passage cells. Deletion analysis identified a 26-base pair negative regulatory DNA (NeRD) element contained within the upstream regulatory region of the CYP1A1 gene responsible for this effect. Nuclear extracts from both low and high passage cells contain a protein which specifically binds to NeRD-containing DNA. Thus, the loss of polycyclic aromatic hydrocarbon sensitivity in high passage rat epidermal cells appears to be due to decreased expression of CYP1A1, and this effect may be mediated by an altered NeRD binding factor(s) present in these cells.	UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis			Rice, Robert/AAP-7813-2021	Tullis, Kathryn/0000-0003-2517-4886	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007059] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR27130] Funding Source: Medline; NIEHS NIH HHS [ES05707, ES07059] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; ASMAN DC, 1993, J BIOL CHEM, V268, P12530; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; BNAK PA, 1995, ARCH BIOCHEM BIOPHYS, V317, P439; BOUCHER PD, 1993, J BIOL CHEM, V268, P17384; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIEL V, 1988, NUCLEIC ACIDS RES, V16, P351, DOI 10.1093/nar/16.1.351; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1991, ARCH BIOCHEM BIOPHYS, V284, P158, DOI 10.1016/0003-9861(91)90278-Q; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GRADIN K, 1993, J BIOL CHEM, V268, P4061; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HEIMANN R, 1983, J CELL PHYSIOL, V117, P362, DOI 10.1002/jcp.1041170311; HEIMANN R, 1983, CANCER RES, V43, P4856; HENRY EC, 1993, BIOCHEM J, V294, P95, DOI 10.1042/bj2940095; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JONES CL, 1996, FUND APPL TOXICOL S, V30, P275; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KAWAJIRI K, 1986, EUR J BIOCHEM, V159, P219, DOI 10.1111/j.1432-1033.1986.tb09857.x; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MUHKTAR H, 1989, CLIN DERM, V7, P1; MUMFORD JL, 1987, SCIENCE, V235, P217, DOI 10.1126/science.3798109; NELSON DR, 1991, DNA CELL BIOL, V12, P1; PELKONEN O, 1982, PHARMACOL REV, V34, P189; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; Reiners J. J. Jr., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P155; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; ROBBINS M, 1992, MOL BRAIN RES, V13, P83, DOI 10.1016/0169-328X(92)90047-F; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; Sterling K, 1996, MOL PHARMACOL, V49, P329; STERLING K, 1993, MOL PHARMACOL, V44, P560; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TODOROVIC R, 1991, MOL CARCINOGEN, V4, P308, DOI 10.1002/mc.2940040409; VANCANTFORT J, 1977, BIOCHEM BIOPH RES CO, V79, P505, DOI 10.1016/0006-291X(77)90186-3; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	63	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22746	22753		10.1074/jbc.271.37.22746	http://dx.doi.org/10.1074/jbc.271.37.22746			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798449	hybrid			2022-12-25	WOS:A1996VG67200068
J	Patel, BKR; Wang, LM; Lee, CC; Taylor, WG; Pierce, JH; LaRochelle, WJ				Patel, BKR; Wang, LM; Lee, CC; Taylor, WG; Pierce, JH; LaRochelle, WJ			Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; SIMIAN SARCOMA-VIRUS; PROTEIN-TYROSINE KINASES; RECEPTOR GAMMA-CHAIN; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; CYTOKINE RECEPTORS; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ELEVATED LEVELS	Both platelet-derived growth factor (PDGF) and interleukin-4 (IL-4) play major roles in cell proliferation, differentiation, chemotaxis, and other functional responses, Here, we demonstrate that Stat6, previously shown to be activated by only IL-4 and IL-3, becomes activated after PDGF stimulation of NIH 3T3 fibroblasts, PDGF BB, and to a lesser extent PDGF AA, rapidly induced DNA binding activity from NIH 3T3 cell lysates utilizing the immunoglobulin heavy chain germ line a promoter (I epsilon) that specifically binds to StatG in an electrophoretic mobility shift assay. DNA binding activity could be detected within 5 min and reached maximum levels at approximately 20 min in parental NIH 3T3 cells, An identical mobility shift and time course of PDGF-mediated I epsilon binding activity was more pronounced in lysates of NIH 3T3 transfectants overexpressing human Stat6 (NIH 3T3-Stat6), The observed radiolabeled I epsilon mobility shift was competed by unlabeled I epsilon as well as by the beta-casein gene promoter but not by the interferon-alpha-stimulated response element or the interferon-gamma response region of the guanylate-binding protein gene, A StatG specific polyclonal antisera also supershifted the PDGF-induced I epsilon mobility shift, After PDGF BB treatment, a 100-kDa tyrosine phosphorylated species was detected in anti-Stat6 immunoprecipitates. Cycloheximide had little effect on Stat6 tyrosine phosphorylation, In addition to State, Stat5a, and Stat5b, PDGF BE also induced Jak1 tyrosine phosphorylation suggesting a potential pathway for Stat activation, Strikingly, the concurrent addition of IL-4 enhanced PDGF BE-induced I epsilon binding activity, Jak1 tyrosine phosphorylation, and [H-3]thymidine incorporation. These results provide evidence that State and Jak1 are common elements in PDGF and IL-4 signaling pathways and suggest that IL-4 could play a role in potentiating certain known PDGF-induced biological responses.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1995, TRENDS GENET, V11, P3951; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAPLAN MH, 1996, IMMUNITY, V4, P1; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NARAYANAN AS, 1983, J BIOL CHEM, V258, P1694; NEEDLEMAN BW, 1992, ARTHRITIS RHEUM, V35, P67, DOI 10.1002/art.1780350111; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; PAUL WE, 1991, BLOOD, V77, P1859; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; PERNIS A, 1995, J BIOL CHEM, V270, P14517, DOI 10.1074/jbc.270.24.14517; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	62	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22175	22182		10.1074/jbc.271.36.22175	http://dx.doi.org/10.1074/jbc.271.36.22175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703030	hybrid			2022-12-25	WOS:A1996VF61200072
J	Arrandale, JM; GoreWillse, A; Rocks, S; Ren, JM; Zhu, J; Davis, A; Livingston, JN; Rabin, DU				Arrandale, JM; GoreWillse, A; Rocks, S; Ren, JM; Zhu, J; Davis, A; Livingston, JN; Rabin, DU			Insulin signaling in mice expressing reduced levels of Syp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; RECEPTOR SUBSTRATE-1; RAT ADIPOCYTES; MAP KINASE; SH-PTP2; STIMULATION; ACTIVATION; DEPHOSPHORYLATION; PHOSPHORYLATION	Syp is a protein tyrosine phosphatase implicated in insulin and growth factor signaling. To evaluate the role of syp in insulin's regulation of plasma glucose, we generated knockout mice, Homozygous knockout mice die prior to day 10.5 of embryonic development. Hemizygous mice express half the levels of syp protein compared with their wild type littermates but do not display any gross morphological changes. Total body weight (age 2-10 weeks) and plasma insulin and glucose levels both in fasting and glucose-challenged states were comparable in the wild type and the hemizygous mice. No differences were observed in insulin-induced glucose uptake in soleus muscle and epididymal fat; insulin inhibition of lipolysis was also similar. We injected insulin into the portal vein of the mice to examine upstream events of the insulin signaling cascade. Tyrosine phosphorylation of insulin receptor and insulin receptor substrate-1 (IRS-1) from hemizygous tissue was similar to that of wild type tissue. Association of the p85 subunit of phosphatidylinositol 3-kinase to IRS-1 increased an average of a-fold in both groups, We did not observe an increase of IRS-1/syp association after insulin administration, but we did note a significant basal association in both wild type and hemizygous tissue, Our results do not support a major role for syp in the acute in, vivo meta belie actions of insulin.	BAYER CORP,DIV PHARMACEUT,METAB DISORDERS RES,WEST HAVEN,CT 06516	Bayer AG								AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HOGAN B, 1986, MANIPULATING MOUSE E, P153; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KUHNE MR, 1995, BIOCHEM BIOPH RES CO, V211, P190, DOI 10.1006/bbrc.1995.1795; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LIVINGSTON JN, 1984, ENDOCRINOLOGY, V115, P55, DOI 10.1210/endo-115-1-55; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOSS AM, 1993, BIOCHEM J, V294, P685, DOI 10.1042/bj2940685; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; REN JM, 1993, J BIOL CHEM, V268, P16113; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P19; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOOWARREN H, 1994, BIOCHEM BIOPH RES CO, V205, P347, DOI 10.1006/bbrc.1994.2671	32	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21353	21358		10.1074/jbc.271.35.21353	http://dx.doi.org/10.1074/jbc.271.35.21353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702915	hybrid			2022-12-25	WOS:A1996VE47700061
J	Beck, K; Boswell, BA; Ridgway, CC; Bachinger, HP				Beck, K; Boswell, BA; Ridgway, CC; Bachinger, HP			Triple helix formation of procollagen type I can occur at the rough endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; EMBRYO BLOOD-VESSELS; AIR-WATER-INTERFACE; THERMAL-STABILITY; PEPTIDE-BONDS; COLLAGEN; TENDON; ISOMERIZATION; SECRETION; PROTEINS	One key problem in understanding the biosynthesis of collagens remains the assembly of the three alpha-chains. How and when are the different gene products selected, aligned, and folded into a triple helix? As the spatial arrangement during biosynthesis might be important, we concentrated on whether the rough endoplasmic reticular membrane is involved in this process. Microsomes were prepared from biosynthetically labeled chick tendon fibroblasts. Vesicles were spread as a monomolecular film which was then transferred over several compartments of a filmbalance containing fresh subphase. Fluorograms of the surface film showed that the monolayer contains procollagen chains. When the monolayer was transferred onto a chymotrypsin/trypsin-containing subphase, the gel bands of the pro alpha-chains were shifted into the position of mature alpha-chains, indicating that only the propeptides were digested and the collagenous regions were protected due to triple helix formation. Our results suggest that newly synthesized pro alpha-chains can associate as trimers and fold into a triple helical conformation while they are still associated with the membranes of the rough endoplasmic reticulum. These processes also occur when interchain disulfide linkage is inhibited, indicating that chain selection and registration is not dependent on formation of covalent bonds among the carboxyl propeptides.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University	Beck, K (corresponding author), SHRINERS HOSP CHILDREN, RES UNIT, 3101 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.		Beck, Konrad/AAX-1351-2020	Beck, Konrad/0000-0001-5098-9484				Adam G., 1968, STRUCTURAL CHEM MOL, P198; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3085, DOI 10.1021/bi00308a036; BORNSTEIN P, 1967, BIOCHEMISTRY-US, V6, P3082, DOI 10.1021/bi00862a015; BORNSTEIN P, 1967, J BIOL CHEM, V242, P2572; BROWNELL AG, 1976, J BIOL CHEM, V251, P7137; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1975, P NATL ACAD SCI USA, V72, P3009, DOI 10.1073/pnas.72.8.3009; CHAPMAN D, 1982, TRENDS BIOCHEM SCI, V7, P67, DOI 10.1016/0968-0004(82)90080-9; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; DELPOZO AM, 1988, COLLAGEN REL RES, V8, P133; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Engel J., 1987, ADV MEAT RES, V4, P145; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FESSLER LI, 1981, J BIOL CHEM, V256, P2531; FESSLER LI, 1975, P NATL ACAD SCI USA, V72, P4905, DOI 10.1073/pnas.72.12.4905; FROMHERZ P, 1975, REV SCI INSTRUM, V46, P1380, DOI 10.1063/1.1134025; Gaines GL, 1966, INSOLUBLE MONOLAYERS; GREEN M, 1979, ARCH BIOCHEM BIOPHYS, V195, P368, DOI 10.1016/0003-9861(79)90362-X; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HU G, 1995, J CELL BIOCHEM, V59, P350, DOI 10.1002/jcb.240590307; JIMENEZ S, 1973, BIOCHEM BIOPH RES CO, V52, P106, DOI 10.1016/0006-291X(73)90960-1; JIMENEZ SA, 1978, J BIOL CHEM, V253, P1420; JUVA K, 1966, SCIENCE, V152, P92, DOI 10.1126/science.152.3718.92; KADLER K, 1995, PROTEIN PROFILE, V2, P491; KAO WWY, 1977, J BIOL CHEM, V252, P8391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKENS LN, 1976, J BIOL CHEM, V251, P3530; MARGOLIS RL, 1971, ARCH BIOCHEM BIOPHYS, V147, P612, DOI 10.1016/0003-9861(71)90419-X; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P88, DOI 10.1083/jcb.102.1.88; MORRIS NP, 1979, J BIOL CHEM, V254, P1024; MORRIS NP, 1975, J BIOL CHEM, V250, P5719; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; OLSON BR, 1991, CELL BIOL EXTRACELLU, P177; OZGUNES N, 1988, BIOCHEM MED METAB B, V40, P269, DOI 10.1016/0885-4505(88)90128-4; PEDERSEN BJ, 1994, CLIN CHEM, V40, P811; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; RABINOWI.JL, 1972, ARCH ORAL BIOL, V17, P547, DOI 10.1016/0003-9969(72)90070-2; Ramachandran G. N., 1976, BIOCH COLLAGEN; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SCHINDLER H, 1979, BIOCHIM BIOPHYS ACTA, V555, P316, DOI 10.1016/0005-2736(79)90171-8; SCHOFIELD JD, 1974, BIOCHEMISTRY-US, V13, P1801, DOI 10.1021/bi00706a004; SCHURHOLZ T, 1991, EUR BIOPHYS J BIOPHY, V20, P71; SMABY JM, 1985, BIOPHYS J, V48, P701, DOI 10.1016/S0006-3495(85)83828-5; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; Trurnit H.J., 1960, J COLLOID SCI, V15, P1, DOI [10.1016/0095-8522(60)90002-7, DOI 10.1016/0095-8522(60)90002-7]; TRURNIT HJ, 1945, FORT CHEM ORG NAT, V4, P347; VEIS A, 1989, J BIOL CHEM, V264, P3884; VEIS A, 1985, P NATL ACAD SCI USA, V82, P3693, DOI 10.1073/pnas.82.11.3693; VERGER R, 1976, CHEM PHYS LIPIDS, V16, P285, DOI 10.1016/0009-3084(76)90023-2; White D.A., 1973, FORM FUNCTION PHOSPH	66	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21566	21573		10.1074/jbc.271.35.21566	http://dx.doi.org/10.1074/jbc.271.35.21566			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702943	hybrid, Green Accepted			2022-12-25	WOS:A1996VE47700089
J	Henle, ES; Luo, YZ; Gassmann, W; Linn, S				Henle, ES; Luo, YZ; Gassmann, W; Linn, S			Oxidative damage to DNA constituents by iron-mediated Fenton reactions - The deoxyguanosine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; DEOXYRIBONUCLEIC-ACID; AQUEOUS-SOLUTION; 2'-DEOXYGUANOSINE; MECHANISM; BASES; DEGRADATION; NUCLEOTIDES; TOXICITY; PRODUCT	2'-Deoxyguanosine, 3'-dGMP, 5'-dGMP, d-GpG, or double-stranded DNA were exposed to H2O2 in the presence of Fe2+ under anaerobic conditions or under aerobic conditions in the presence of Fe3+, Fe2+, Fe2+/NADH, or Fe3+/NADH with and without ethanol. The products were enzymatically digested to nucleosides, separated by high performance liquid chromatography (HPLC), quantified, and characterized by HPLC retention time, radiolabeling, UV absorbance spectrometry, NMR, and mass spectrometry. 20 products, constituting 78-81% of the damage, were distinguished from aerobic reactions of Fe2+/H2O2 with dG and dGMP, 16 of which were identified. The product spectra from dG, 3'-dGMP, and 5'-dGMP differ from one another, and the spectrum of the 5' nucleoside of d-GpG differs from that of the 3' nucleoside, 7,8-Dihydro-8-oxo-2'-deoxyguanosine is the most abundant DNA-bound product aside from abasic sites, and its formation was more closely analyzed. Both NADH, which can reduce Fe3+, and ethanol, which can scavenge some free radicals, change the product profiles, Damage enhancement by NADH follows the sequence dG < d-GpG < 3'-dGMP < 5'-dGMP < DNA; the reverse sequence is observed for ethanol quenching, This sequence of susceptibility and the product differences seen for the 3' and 5' phosphate may reflect localization of iron and the damaging radicals upon the substrate.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Gassmann, Walter/0000-0002-7527-0385	NIEHS NIH HHS [T32ES070075] Funding Source: Medline; NIGMS NIH HHS [R29GM19020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM019020] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN SA, 1994, MUTAT RES, V306, P35, DOI 10.1016/0027-5107(94)90165-1; ARUOMA OI, 1989, J BIOL CHEM, V264, P13024; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; BEERS RF, 1952, J BIOL CHEM, V195, P133; BERGER M, 1985, Z NATURFORSCH B, V40, P1519; BUCHKO GW, 1993, INT J RADIAT BIOL, V63, P669, DOI 10.1080/09553009314552061; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; DIZDAROGLU M, 1994, METHOD ENZYMOL, V234, P1; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; GROVES JT, 1976, J AM CHEM SOC, V98, P5290, DOI 10.1021/ja00433a039; GUTMAN M, 1968, BIOCHEMISTRY-US, V7, P2778, DOI 10.1021/bi00848a012; HENNER WD, 1983, J BIOL CHEM, V258, P711; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; LANGFINGER D, 1985, Z NATURFORSCH C, V40, P446; LINN S, 1965, J BIOL CHEM, V240, P1287; LUO HZ, 1994, METHOD ENZYMOL, V234, P51; LUO Y, 1996, J BIOL CHEM, P21167; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MARRIAGI N, 1979, RADIAT RES, V79, P431; MCGALL GH, 1992, J AM CHEM SOC, V114, P4958, DOI 10.1021/ja00039a002; PEZZANO H, 1980, CHEM REV, V80, P365, DOI 10.1021/cr60327a001; RUSH JD, 1990, METHOD ENZYMOL, V186, P148; Sissoeff I, 1976, Prog Biophys Mol Biol, V31, P165; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; SUNDQUIST WI, 1991, NUCLEIC ACIDS MOL BI, V2, P1; Tan Z K, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P383; VANDEVORST A, 1978, EFFECTS IONIZING RAD, P3; VONSOUNTAG C, 1987, CHEM BASIS RAD BIOL; WEINFELD M, 1989, NUCLEIC ACIDS RES, V17, P3735, DOI 10.1093/nar/17.10.3735; WINK DA, 1994, P NATL ACAD SCI USA, V91, P6604, DOI 10.1073/pnas.91.14.6604; YAMAZAKI I, 1990, J BIOL CHEM, V265, P13589	32	117	118	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21177	21186		10.1074/jbc.271.35.21177	http://dx.doi.org/10.1074/jbc.271.35.21177			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702888	hybrid			2022-12-25	WOS:A1996VE47700034
J	Lebendiker, M; Schuldiner, S				Lebendiker, M; Schuldiner, S			Identification of residues in the translocation pathway of EmrE, a multidrug antiporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; PROTEIN; CHANNEL; TRANSPORTER; BACTERIA; PERMEASE; SITE	EmrE is a small, 12-kDa, highly polyspecific antiporter, which exchanges hydrogen ions with aromatic cations such as methyl viologen. EmrE-mediated transport is inhibited by the sulfhydryl-reactive reagent 4-(chloromercuri)benzoic acid (PCMB) but not by a variety of other sulfhydryl reagents. This differential effect is due to the fact that the organic mercurial is a substrate of the transporter and can reach domains otherwise inaccessible to the different reagents. To find out which of the three cysteine residues in EmrE is reacting with PCMB, each was replaced with serine and it was shown that none of them is essential for transport activity, A protein completely devoid of Cys residues (CL) is also capable of substrate accumulation albeit at a slower rate. Mutated proteins in which only one of the native cysteines was left whereas the other changed to serine were also constructed. The use of these proteins demonstrated that two of the three Cys in EmrE, Cys-41 and Cys-95, but not Cys-39, react with PCMB. A related mercurial, 4-(chloromercuri)benzenesulfonic acid (PCMBS), is only a very poor inhibitor, probably because of the negative charge it bears. PCMBS reacts with EmrE in an asymmetric and unique way. It reacts with the mutant bearing a single Cys residue in position 95 (CL-C95) only when the reagent is present in the outside face of the membrane and with the mutant CL-C41 only when allowed to permeate to the cell interior; as expected, it does not react with the mutant protein bearing a single Cys at position 39 (CL-C39). It is concluded that PCMB permeates through the substrate pathway of EmrE and covalently reacts with the two exposed residues, Cys-95 and Cys-41, but not with Cys-39, located on the opposite face of the helix relative to residue 41. In addition, because of the asymmetric reactivity to PCMBS, an inhibitor that does not permeate through the protein, it is concluded that Cys-41 is closer to the cytoplasmic face than Cys-95. The results demonstrate the existence of a domain accessible only to substrates and provide a unique tool for studying the substrate permeation pathway of an ion-coupled transporter.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; CULOTTA E, 1994, SCIENCE, V264, P362, DOI 10.1126/science.8153617; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOX CF, 1965, P NATL ACAD SCI USA, V54, P891, DOI 10.1073/pnas.54.3.891; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Shi LB, 1996, BIOCHEMISTRY-US, V35, P538, DOI 10.1021/bi9520038; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; XU M, 1993, J BIOL CHEM, V268, P21505; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	30	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21193	21199		10.1074/jbc.271.35.21193	http://dx.doi.org/10.1074/jbc.271.35.21193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702890	hybrid			2022-12-25	WOS:A1996VE47700036
J	Linder, M; Salovuori, I; Ruohonen, L; Teeri, TT				Linder, M; Salovuori, I; Ruohonen, L; Teeri, TT			Characterization of a double cellulose-binding domain - Synergistic high affinity binding to crystalline cellulose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REESEI CELLOBIOHYDROLASE-I; NUCLEAR-MAGNETIC-RESONANCE; TRICHODERMA-REESEI; ESCHERICHIA-COLI; ADSORPTION; FIMI	Most cellulose-degrading enzymes have a two-domain structure that consists of a catalytic and a cellulose-binding domain (CBD) connected by a linker region. The linkage and the interactions of the two domains represent one of the key questions for the understanding of the function of these enzymes. The CBDs of fungal cellulases are small peptides folding into a rigid, disulfide-stabilized structure that has a distinct cellulose binding face. Here we describe properties of a recombinant double CBD, constructed by fusing the CBDs of two trichoderma reesei cellobiohydrolases via a linker peptide similar to the natural cellulase linkers. After expression in Escherichia coli, the protein was purified from the culture medium by reversed phase chromatography and the individual domains obtained by trypsin digestion. Binding of the double CBD and its single CBD components was investigated on different types of cellulose substrates as well as chitin. Under saturating conditions, nearly 20 mu mol/g of the double CBD was bound onto microcrystalline cellulose. The double CBD exhibited much higher affinity on cellulose than either of the single CBDs, indicating an interplay between the two components. A two-step model is proposed to explain the binding behavior of the double CBD. A similar interplay between the domains the the native enzyme is suggested for its binding to cellulase.			Linder, M (corresponding author), VTT BIOTECHNOL & FOOD RES, BOX 1500, FIN-02044 ESPOO, FINLAND.		Linder, Markus/N-8043-2019; Teeri, Tuula T/E-7509-2013; Linder, Markus B/E-5879-2011	Linder, Markus/0000-0002-7271-6441; Linder, Markus B/0000-0002-7271-6441				ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; AHO S, 1991, EUR J BIOCHEM, V200, P643, DOI 10.1111/j.1432-1033.1991.tb16227.x; BELSHAW NJ, 1993, EUR J BIOCHEM, V211, P717, DOI 10.1111/j.1432-1033.1993.tb17601.x; BLACKWELL J, 1988, METHOD ENZYMOL, V161, P435; Cantor C.R, 1980, BIOPHYSICAL CHEM 3, P874; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; EK R, 1994, INT J PHARM, V111, P43, DOI 10.1016/0378-5173(94)90400-6; GILKES NR, 1992, J BIOL CHEM, V267, P6743; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JOHANSSON G, 1989, FEBS LETT, V243, P389, DOI 10.1016/0014-5793(89)80168-1; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P25; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; LINDER M, 1995, FEBS LETT, V372, P96, DOI 10.1016/0014-5793(95)00961-8; NEVALAINEN H, 1995, MYCOTA, V2, P303; ONG E, 1993, BIOTECHNOL BIOENG, V42, P401, DOI 10.1002/bit.260420402; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; REINIKAINEN T, 1992, PROTEINS, V14, P475, DOI 10.1002/prot.340140408; REINIKAINEN T, 1995, PROTEINS, V22, P392, DOI 10.1002/prot.340220409; REINIKAINEN T, 1996, IN PRESS ENZYME MICR; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNELLMANN J, 1994, MOL MICROBIOL, V13, P807, DOI 10.1111/j.1365-2958.1994.tb00473.x; SHOEMAKER S, 1983, BIO-TECHNOL, V1, P691, DOI 10.1038/nbt1083-691; SRISODSUK M, 1993, J BIOL CHEM, V268, P20756; STAHLBERG J, 1991, BIO-TECHNOL, V9, P286, DOI 10.1038/nbt0391-286; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; TEERI TT, 1983, BIOTECHNOLOGY, V1, P670; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; TOMME P, 1995, J BACTERIOL, V177, P4356, DOI 10.1128/jb.177.15.4356-4363.1995; VANTILBEURGH H, 1986, FEBS LETT, V204, P223, DOI 10.1016/0014-5793(86)80816-X; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	32	120	122	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21268	21272		10.1074/jbc.271.35.21268	http://dx.doi.org/10.1074/jbc.271.35.21268			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702902	hybrid			2022-12-25	WOS:A1996VE47700048
J	Orth, K; ORourke, K; Salvesen, GS; Dixit, VM				Orth, K; ORourke, K; Salvesen, GS; Dixit, VM			Molecular ordering of apoptotic mammalian CED-S/ICE-like proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; CLEAVAGE; ENZYME	Apoptosis is executed by cysteine proteases belonging to the CED-3/ICE family, which, unlike other mammalian cysteine proteases, cleave their substrates following aspartate residues. Proteases belonging to this family exist in the cytosol as zymogens that require accurate processing at internal aspartate residues to generate the two-chain active enzymes. As such, CED-S/ICE family members are capable of activating each other in a manner analogous to the protease zymogens of the coagulation or complement cascades. At present, it is unknown whether such mutual processing exists in vivo, and if so whether it is sequential, implying an order to the death pathway. Using a cell-free apoptosis system, recombinant ICE proteases and both biochemical and morphological criteria, we demonstrate an ordering of the mammalian ICEs that are most related to the Caenorhabditis elegans death protease CED-3.	UNIV MICHIGAN,DEPT PATHOL,SCH MED,ANN ARBOR,MI 48109; BURNHAM INST,LA JOLLA,CA 92037	University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute			dixit, vishva m/A-4496-2012; Orth, Kim/AAV-4421-2021	dixit, vishva m/0000-0001-6983-0326; Orth, Kim/0000-0002-0678-7620	NCI NIH HHS [CA64803, CA68769] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064803, F32CA068769] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DUAN H, 1996, J BIOL CHEM, V271, P35013; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251	27	184	186	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20977	20980		10.1074/jbc.271.35.20977	http://dx.doi.org/10.1074/jbc.271.35.20977			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702858	hybrid			2022-12-25	WOS:A1996VE47700002
J	Ribeiro, CMP; Putney, JW				Ribeiro, CMP; Putney, JW			Differential effects of protein kinase C activation on calcium storage and capacitative calcium entry in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; PHORBOL ESTER; CA2+ ENTRY; ENDOPLASMIC-RETICULUM; CHEMOTACTIC PEPTIDE; RBL-2H3 CELLS; RECEPTOR; ASSOCIATION; PATHWAY; FIBROBLASTS	In NIH 3T3 cells, treatment with phorbol 12-myristate 13-acetate (PMA) reduced the release of Ca2+ by thapsigargin, but did not activate Ca2+ entry; Ca2+ influx was triggered after the residual pool was emptied by thapsigargin, and this Ca2+ influx was similar to that induced by thapsigargin in control cells. The effect of PMA was clue to decreased Ca2+ storage because 1) Ca2+ release by ionomycin was similarly affected by PMA, and in both control and PMA-treated cells, ionomycin did not release Ca2+ following thapsigargin treatment; 2) PMA reduced Ca-45(2+) accumulation; and 3) studies with Ca2+ indicator compartmentalized into the endoplasmic reticulum indicated that stored Ca2+ was reduced by PMA. Although PMA did not itself activate Ca2+ entry, PMA potentiated Ca2+ entry with low concentrations of cyclopiazonic acid. With a somewhat higher concentration of cyclopiazonic acid, PMA had no effect on calcium entry. Thus, protein kinase C has two apparent actions on calcium signaling in NIH 3T3 cells: 1) reduced intracellular Ca2+ storage capacity and 2) augmented calcium entry with submaximal intracellular Ca2+ pool depletion. These actions indicate a complex and potentially important role for the protein kinase C system in calcium homeostasis in this cell type.			Ribeiro, CMP (corresponding author), NIEHS,NATL INST HLTH,POB 12233,MAIL DROP 7-10,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019; Ribeiro, Carla Maria P/A-6955-2009	Putney, James W/0000-0002-3379-4789; 				BARANSKA J, 1995, CELL CALCIUM, V17, P207, DOI 10.1016/0143-4160(95)90035-7; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDBERG KK, 1994, J CELL PHYSIOL, V158, P337, DOI 10.1002/jcp.1041580216; JAFFE LA, 1993, DEV BIOL, V156, P566, DOI 10.1006/dbio.1993.1103; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDON RE, 1994, AM J PHYSIOL, V266, pC1313, DOI 10.1152/ajpcell.1994.266.5.C1313; LUDOWYKE RI, 1994, CELL MOTIL CYTOSKEL, V29, P354, DOI 10.1002/cm.970290408; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1993, J BIOL CHEM, V268, P26911; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1994, J BIOL CHEM, V269, P3963; Murphy CT, 1996, BIOCHEM J, V313, P83, DOI 10.1042/bj3130083; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; TORNQUIST K, 1993, BIOCHEM J, V290, P443; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21522	21528		10.1074/jbc.271.35.21522	http://dx.doi.org/10.1074/jbc.271.35.21522			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702937				2022-12-25	WOS:A1996VE47700083
J	Richardson, LV; Richardson, JP				Richardson, LV; Richardson, JP			Rho-dependent termination of transcription is governed primarily by the upstream Rho utilization (rut) sequences of a terminator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; LAMBDA-PR PROMOTER; CRO MESSENGER-RNA; PROTEIN-RHO; RELEASE; REGION; SITES; BACTERIOPHAGE-T7; INVITRO; SIGNAL	A Rho-dependent transcription terminator in Escherichia coli DNA consists of an upstream part for Rho utilization (rut) and the transcription stop point (tsp) region. To test the role of the tsp region variants of the coliphage lambda cro gene terminator, tR1, containing inserts of non-terminator sequences between its rot and tsp regions were tested for termination function. The results showed that termination occurred with high efficiency at multiple sites in each of the new sequences with the positions of the sites coinciding with transcriptional pause points in the insert sequence and that the efficiency of termination was not directly proportional to the extent of pausing at those points. Thus, in contrast to the rut sequences, which are relatively rare in DNA, many different sequence segments can function as a tsp region, Studies with isolated transcripts showed that a rat element and sequences 3' of the rut element were both needed to activate ATP hydrolysis by Rho factor with the degree of activation depending on the length and the specific sequence of the 3' segment, These results support models for Rho action in which ATP hydrolysis is coupled to interactions of Rho protein with RNA 3' of the rut region.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIAID NIH HHS [AI10142] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010142, R37AI010142] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS C, 1985, J BIOL CHEM, V260, P5826; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CONE KC, 1983, J BIOL CHEM, V258, P1296; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GALLUPPI G, 1976, RNA POLYMERASE, P657; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; HART CM, 1991, J BIOL CHEM, V266, P24140; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1989, METHOD ENZYMOL, V183, P281; LAU LF, 1984, NUCLEIC ACIDS RES, V12, P1287, DOI 10.1093/nar/12.2.1287; LAU LF, 1983, J BIOL CHEM, V258, P9391; LAU LF, 1985, J BIOL CHEM, V260, P574; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; SHIGESADA K, 1980, NUCLEIC ACIDS RES, V8, P3355, DOI 10.1093/nar/8.15.3355; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; ZALATAN F, 1993, J BIOL CHEM, V268, P17051; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	37	60	61	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21597	21603		10.1074/jbc.271.35.21597	http://dx.doi.org/10.1074/jbc.271.35.21597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702947	hybrid			2022-12-25	WOS:A1996VE47700093
J	Yuan, D; Ma, XG; Ma, J				Yuan, D; Ma, XG; Ma, J			Sequences outside the homeodomain of bicoid are required for protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; STEROID-HORMONE RECEPTORS; HOMEO DOMAIN PROTEIN; SINGLE AMINO-ACID; DROSOPHILA EMBRYO; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL ACTIVATION; COOPERATIVE INTERACTIONS; POSITIVE CONTROL; RECOGNITION	The Drosophila morphogenetic protein Bicoid (Bcd) is required for the development of anterior structures of the embryo. Bcd, a homeodomain protein, is distributed as an anterior-to-posterior gradient ill the embryo. It stimulates the expression of the hunchback (hb) gene in the anterior half in an all-or-none fashion. We have recently shown that Bcd binds cooperatively to a hb enhancer element and proposed that cooperative DNA binding is facilitated by an interaction between Bcd molecules. In this report, we further analyze the interaction between Bcd molecules and define regions important for protein-protein interaction. We show that the homeodomain of Bcd alone fails to interact with another Bcd molecule efficiently. The protein sequence flanking either side of the homeodomain restores the protein-protein interaction function. Mutations in the homeodomain that affect DNA binding do not adversely affect the protein-protein interaction function, suggesting that the surfaces for DNA binding and protein-protein interaction are separable. Finally, we demonstrate that the homeodomain of Bcd alone, unlike the intact Bcd, fails to bind DNA cooperatively. These results further support the notion that cooperative DNA binding is facilitated by the interaction between Bcd molecules. They strongly suggest that protein-protein interaction is an important property of Bcd for its biological activities.	UNIV CINCINNATI,CHILDRENS HOSP RES FDN,COLL MED,DIV DEV BIOL,GRAD PROGRAM DEV BIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Cincinnati			Ma, Jun/GLT-4809-2022	Ma, Jun/0000-0002-1609-3294				ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Driever W., 1992, TRANSCRIPTIONAL REGU, P1221; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Ma XG, 1996, DEVELOPMENT, V122, P1195; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maniatis T., 1982, MOL CLONING; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RICHARDFOY H, 1994, NATURE, V370, P417, DOI 10.1038/370417a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TREISMAN J, 1989, CELL, V59, P553; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	62	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21660	21665		10.1074/jbc.271.35.21660	http://dx.doi.org/10.1074/jbc.271.35.21660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702955	hybrid			2022-12-25	WOS:A1996VE47700101
J	Hardig, Y; Dahlback, B				Hardig, Y; Dahlback, B			The amino-terminal module of the C4b-binding protein beta-chain contains the protein S-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT; ENZYMATIC AMPLIFICATION; LIMITED PROTEOLYSIS; CLASSICAL PATHWAY; HUMAN-PLASMA; ULTRASTRUCTURE; PURIFICATION; POLYMERASE; CLONING; DNA	Human C4b-binding protein (C4BP) is composed of multiple alpha-chains associated with a single beta-chain, Each chain is composed of homologous, tandemly arranged repeats of so-called short consensus repeats (SCRs), We have previously shown that the three SCR modules of the beta-chain contain a high affinity binding site for anti-coagulant vitamin K-dependent protein S, On the basis of experiments using synthetic peptides, residues 31-45 of the amino-terminal SCR (SCR-1) in the beta-chain were suggested to be involved in protein S binding, but it is not known whether SCR-1 contains the entire protein S-binding site, To address this question, two different truncated forms of the beta-chain (beta 1,2 and beta 2,3) were expressed in a prokaryotic expression system. The beta 1,2 construct (SCR-1 + SCR-2) contained the high affinity binding site for protein S in contrast to beta 2,3 (SCR-2 + SCR-3), which did not bind protein S, Unfortunately, it was not possible to express SCR-1 alone in this system. To further elucidate whether the protein S-binding site is fully contained in SCR-1 or whether SCR-2 is also required, recombinant alpha/beta-chain chimeras were constructed, These chimeras were composed of alpha-chains with one, two, or three of the amino-terminal SCR modules replaced by the beta-chain counterpart and were expressed in a eukaryotic expression system, All recombinant variants were retained within the cells and could be extracted in biologically active forms, The three alpha/beta-chain chimeras bound protein S equally well, with a K-alpha of similar to 2.3 x 10(8) +/- 0.2 M(-1) as compared with 2.1 x 10(8) +/- 0.3 M(-1) for plasma-purified C4BP. These results show that the entire protein S-binding site on C4BP is contained within beta-chain SCR-1.	LUND UNIV,MALMO UNIV HOSP,DEPT CLIN CHEM,S-20502 MALMO,SWEDEN	Lund University; Skane University Hospital				Dahlback, Bjorn/0000-0003-1546-0328				BLOBEL GG, 1975, J CELL BIOL, V17, P835; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; FERNANDEZ JA, 1994, J BIOL CHEM, V269, P2535; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HARDIG Y, 1995, BIOCHEM J, V308, P795; HARDIG Y, 1993, J BIOL CHEM, V268, P3033; HILLARP A, 1987, J BIOL CHEM, V262, P11300; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; Maizel JV, 1971, METHOD VIROL, V5, P179; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Villoutreix BO, 1995, PROTEIN ENG, V8, P1253, DOI 10.1093/protein/8.12.1253; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	27	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20861	20867		10.1074/jbc.271.34.20861	http://dx.doi.org/10.1074/jbc.271.34.20861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702842	hybrid			2022-12-25	WOS:A1996VD33700094
J	Berkower, C; Taglicht, D; Michaelis, S				Berkower, C; Taglicht, D; Michaelis, S			Functional and physical interactions between partial molecules of STE6, a yeast ATP-binding cassette protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE TRANSPORT-SYSTEM; A-FACTOR TRANSPORTER; HUMAN P-GLYCOPROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MULTIDRUG-RESISTANCE; MUTATIONAL ANALYSIS; NUCLEOTIDE-BINDING; ABC TRANSPORTERS; CYSTIC-FIBROSIS	The Saccharomyces cerevisiae a-factor transporter, STE6, is a member of the ATP binding cassette (ABC) transporter superfamily, ABC proteins consist of four modular units that comprise two membrane spanning domains (MSDs) and two nucleotide-binding domains (NBDs). Like many ABC proteins, STE6 contains these four domains in a single polypeptide; certain other ABC proteins are encoded as pairs of "half-molecules" or are further subdivided. Our previous studies demonstrated that STE6 can be expressed as two half-molecules that are functional when co-expressed, Here we dissect the interactions between modules of STE6 in greater detail, We show by co-immunoprecipitation that STE6 half-molecules interact physically, supporting the view that they co-assemble in vivo to form a functional transporter, We also demonstrate a physical interaction between a STE6 half-molecule and full-length STE6; such complexes appear to be functional, based on the striking finding that the defective activity of full-length STE6 mutated in one of its NBDs can be corrected by co-expression of the corresponding "wild-type" half-molecule. We also show that a quarter-molecule consisting solely of the N-terminal MSD of STE6 can interact physically and functionally with a C-terminal three-quarter molecule of STE6, indicating that information directing the assembly of STE6 from partial molecules is contained, at least in part, within its membrane spans.	JOHNS HOPKINS SCH MED, DEPT ANAT & CELL BIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BERKOWER C, 1996, IN PRESS MEMBRANE PR; BERKOWER C, 1993, MOL BIOL FUNCTION CA, P130; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWART GD, 1994, J BIOL CHEM, V269, P10370; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; GOTTESMAN MM, 1995, ANNU REV GENET, V29, P307; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Michaelis S, 1993, Semin Cell Biol, V4, P17, DOI 10.1006/scel.1993.1003; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Michaelis S, 1995, COLD SPRING HARB SYM, V60, P291, DOI 10.1101/SQB.1995.060.01.034; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; OSTEDGAARD LS, 1994, MOL BIOL CELL, V5, P191; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; SIKORSKI RS, 1989, GENETICS, V122, P19; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	34	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22983	22989		10.1074/jbc.271.38.22983	http://dx.doi.org/10.1074/jbc.271.38.22983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798485	hybrid			2022-12-25	WOS:A1996VH76800011
J	Holtmann, MH; Roettger, BF; Pinon, DI; Miller, LJ				Holtmann, MH; Roettger, BF; Pinon, DI; Miller, LJ			Role of receptor phosphorylation in desensitization and internalization of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PROTEIN-COUPLED RECEPTORS; BINDING; SEQUENCE; POLYPEPTIDE; HORMONE; CELLS; SEQUESTRATION; IODINATION; HISTIDINE	The secretin receptor is prototypic of a recently described family of G protein-coupled receptors. We recently demonstrated its phosphorylation in response to agonist stimulation and elimination of this covalent modification by C-terminal truncation (F. Ozcelebi et al, (1995) Mol. Pharmacol. 48, 818-824). Here, we explore the functional impact of receptor phosphorylation and structural determinants for desensitization by comparing receptor behavior after agonist exposure in cell lines expressing wild-type and truncated receptor. To characterize receptor internalization, a novel fluorescent full agonist, [rat secretin-27]-Gly-rhodamine, was developed, which bound specifically and with high affinity. Both receptor constructs bound secretin normally, leading to normal G protein coupling and cAMP accumulation and prompt receptor internalization. Exposure to 10 nM secretin for 5 min or 12 h prior to washing and restimulation with a full range of concentrations demonstrated absent cAMP responses in wild-type receptor-bearing cells and responses 25 to 30% of control and shifted 1 order of magnitude to the right in the truncated receptor-bearing cells. Thus, the major mechanism of desensitization was phosphorylation-independent receptor internalization. Phosphorylation was associated with a distinct process that likely represents interference with G protein coupling, manifest as a reduced rate of cAMP stimulation. Thus, dual distinct mechanisms of desensitization exist in the secretin receptor family that should help protect receptor bearing cells from overstimulation.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905	Mayo Clinic					NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577, R56DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BAWAB W, 1991, BIOSCIENCE REP, V11, P33, DOI 10.1007/BF01118603; BOISSARD C, 1986, CANCER RES, V46, P4406; CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DONNELLY D, 1989, FEBS LETT, V251, P109, DOI 10.1016/0014-5793(89)81438-3; FOURNIER A, 1993, ANAL BIOCHEM, V211, P305, DOI 10.1006/abio.1993.1274; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; IZZO RS, 1984, INT J PEPT PROT RES, V23, P292; IZZO RS, 1989, ENDOCRINOLOGY, V124, P2252, DOI 10.1210/endo-124-5-2252; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; ODONNELL M, 1991, J BIOL CHEM, V266, P6389; OZCELEBI F, 1995, MOL PHARMACOL, V48, P818; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SLICE LW, 1994, J BIOL CHEM, V269, P21755; STAUNOLSEN P, 1982, J NEUROCHEM, V39, P1242, DOI 10.1111/j.1471-4159.1982.tb12561.x; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O	32	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23566	23571		10.1074/jbc.271.38.23566	http://dx.doi.org/10.1074/jbc.271.38.23566			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798566	hybrid			2022-12-25	WOS:A1996VH76800092
J	Chigorno, V; Tettamanti, G; Sonnino, S				Chigorno, V; Tettamanti, G; Sonnino, S			Metabolic processing of gangliosides by normal and Salla human fibroblasts in culture - A study performed by administering radioactive G(M3) ganglioside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; LONG-CHAIN BASE; GM1 GANGLIOSIDE; FATTY-ACID; BIOSYNTHESIS; SPHINGOSINE; COMPLEXES; BRAIN; DIFFERENTIATION; FRACTIONATION	Cultured fibroblasts from normal subjects and from subjects affected by Salla disease, characterized by the lack or misfunction of the membrane carrier responsible for the egress of sialic acid from lysosomes, were fed with ganglioside G(M3) labeled at the sialic acid acetyl group, [Neu5Ac-H-3]G(M3), or at C-3 of sphingosine (Sph), [Sph-H-3]G(M3), or at C-1 of stearoyl chain, [stearoyl-C-14]G(M3). After a 15-h pulse the total amount of cell-bound G(M3) corresponded to about 2% of the endogenous ganglioside content. Cells were then subjected to a 72-h chase, and the radioactive products from both ganglioside catabolism and salvage processes of catabolic fragments were measured. These data indicated that about 50% of the cell-bound ganglioside underwent metabolic processing, suggesting a ganglioside half-life of 2-3 days. [Neu5Ac-H-3] formed from [Neu5Ac-H-3]G(M3) degradation was mostly re-cycled for the biosynthesis of gangliosides and sialoglycoproteins, only a minor part being degraded to [H-3]water, which constituted only 1.6% of total metabolite linked radioactivity. [Sph-H-3] from the [Sph-H-3]G(M3) degradation was partly re-cycled for the biosynthesis of gangliosides, neutral glycosphingolipids and sphingomyelin, and partly (about 20% of the total metabolite linked radioactivity) degraded to [H-3]water. In Salla fibroblasts metabolic processing of [Neu5Ac-H-3]G(M3) produced large amounts of free [H-3]Neu5Ac, and a reduced incorporation of radioactivity into glycoconjugates (as compared to normal cells). However, the accumulation of free Neu5Ac was not accompanied by an increase of tritiated water. LacCer and Cer from [stearoyl-C-14]G(M3) catabolism were found to accumulate in Salla fibroblasts, an indication that the enzymes of glycosphingolipid metabolism were affected by the impairment of Neu5Ac egress from lysosomes. Particularly relevant was the accumulation of ceramide which was hardly detectable in control cells.	UNIV MILAN,SCH MED,DEPT MED CHEM & BIOCHEM,STUDY CTR FUNCT BIOCHEM BRAIN LIPIDS,I-20133 MILAN,ITALY	University of Milan			Sonnino, Sandro/R-4154-2017	Sonnino, Sandro/0000-0001-8180-5908				BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Chigorno V, 1985, GLYCOCONJUGATE J, VV2, P279; DAWSON G, 1972, J BIOL CHEM, V247, P5944; GAHL WA, 1989, METABOLIC BASIS INHE, P2619; Gazzotti G, 1984, GLYCOCONJUGATE J, V1, P111, DOI 10.1007/bf01213725; GHIDONI R, 1976, J NEUROCHEM, V27, P511, DOI 10.1111/j.1471-4159.1976.tb12275.x; GHIDONI R, 1983, BIOCHEM J, V213, P321, DOI 10.1042/bj2130321; HANCOCK LW, 1983, BIOCHIM BIOPHYS ACTA, V760, P42, DOI 10.1016/0304-4165(83)90122-8; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAUTTECOEUR B, 1985, BIOCHIM BIOPHYS ACTA, V833, P303, DOI 10.1016/0005-2760(85)90202-4; IUB-IUPAC Joint Commission on Biochemical Nomenclature (JCBN), 1982, J BIOL CHEM, V257, P3347, DOI [10.1016/S0021-9258(18)34777-X, DOI 10.1016/S0021-9258(18)34777-X]; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; LEON A, 1981, J NEUROCHEM, V37, P350, DOI 10.1111/j.1471-4159.1981.tb00462.x; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIETTINEN T, 1959, ACTA CHEM SCAND, V13, P856, DOI 10.3891/acta.chem.scand.13-0856; Negroni E, 1996, GLYCOCONJUGATE J, V13, P347, DOI 10.1007/BF00731466; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PARTRIDGE SM, 1948, BIOCHEM J, V42, P238, DOI 10.1042/bj0420238; RADSAK K, 1982, H-S Z PHYSIOL CHEM, V363, P263, DOI 10.1515/bchm2.1982.363.1.263; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; RIBONI L, 1990, NEUROCHEM RES, V15, P1175, DOI 10.1007/BF01208577; RIBONI L, 1993, FEBS LETT, V322, P257, DOI 10.1016/0014-5793(93)81582-K; SAQR HE, 1993, J NEUROCHEM, V61, P395; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SCHWARZMANN G, 1987, NATO ASI SERIES H, V7, P217; SONNINO S, 1986, CHEM PHYS LIPIDS, V42, P3, DOI 10.1016/0009-3084(86)90040-X; SONNINO S, 1985, J LIPID RES, V26, P248; SONNINO S, 1990, CHEM PHYS LIPIDS, V52, P231, DOI 10.1016/0009-3084(90)90119-C; SONNINO S, 1989, BIOCHEMISTRY-US, V28, P77, DOI 10.1021/bi00427a012; SONNINO S, 1984, J NEUROSCI RES, V12, P193, DOI 10.1002/jnr.490120207; STAHL E, 1962, DUNNSCHICHT CHROMATO, P498; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TOMASI M, 1980, EUR J BIOCHEM, V111, P315, DOI 10.1111/j.1432-1033.1980.tb04944.x; TRINCHERA M, 1990, BIOCHEM J, V270, P815, DOI 10.1042/bj2700815; VALSECCHI M, 1992, CHEM PHYS LIPIDS, V60, P247, DOI 10.1016/0009-3084(92)90076-2; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VASKOVSKY VE, 1968, J LIPID RES, V9, P396; VENERANDO B, 1982, BIOCHIM BIOPHYS ACTA, V692, P18, DOI 10.1016/0005-2736(82)90497-7; Wiegandt H., 1985, NEW COMPREHENSIVE BI, P199; 1977, LIPIDS, V12, P455	43	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21738	21744		10.1074/jbc.271.36.21738	http://dx.doi.org/10.1074/jbc.271.36.21738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702969	hybrid			2022-12-25	WOS:A1996VF61200011
J	Pan, ZQ; Ge, H; Amin, AA; Hurwitz, J				Pan, ZQ; Ge, H; Amin, AA; Hurwitz, J			Transcription-positive cofactor 4 forms complexes with HSSB (RPA) on single-stranded DNA and influences HSSB-dependent enzymatic synthesis of simian virus 40 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; LARGE TUMOR-ANTIGEN; POLYMERASE-ALPHA; T-ANTIGEN; REPLICATION INVITRO; BINDING-PROPERTIES; SV40 ORIGIN; INITIATION; PROTEIN; DELTA	The replication of simian virus 40 (SV40) DNA in vitro requires a trimeric single-stranded DNA (ssDNA)-binding protein called HSSB or RPA. HSSB supports the unwinding of DNA containing the SV40 origin in the presence of the viral-encoded T antigen and is required for the initiation of RNA primer synthesis as well as processive elongation of DNA catalyzed by the DNA polymerase delta holoenzyme. In this report we show that the transcription positive cofactor 4 (PC4), a ssDNA-binding protein, forms complexes with HSSB on ssDNA and markedly affects the replication functions of HSSB. PC4 supports T antigen-catalyzed unwinding of SV40 origins in lieu of HSSB but inhibits both RNA primer synthesis and polymerase delta-catalyzed DNA chain elongation reactions. These inhibitory effects can be reversed by the addition of excess HSSB. Depending on the concentration of HSSB, PC4 is capable of either inhibiting or activating SV40 DNA replication measured in both mono- and dipolymerase systems. The possible role of PC4 in the initiation of DNA replication is discussed.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892; MEM SLOAN KETTERING CANC CTR,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Memorial Sloan Kettering Cancer Center	Pan, ZQ (corresponding author), MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029, USA.				NIGMS NIH HHS [GM38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1994, J BIOL CHEM, V269, P7735; BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1992, J BIOL CHEM, V267, P7284; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	30	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22111	22116		10.1074/jbc.271.36.22111	http://dx.doi.org/10.1074/jbc.271.36.22111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703021	hybrid			2022-12-25	WOS:A1996VF61200063
J	Rossig, L; Zolyomi, A; Catt, KJ; Balla, T				Rossig, L; Zolyomi, A; Catt, KJ; Balla, T			Regulation of angiotensin II-stimulated Ca2+ oscillations by Ca2+ influx mechanisms in adrenal glomerulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; CALCIUM OSCILLATIONS; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; ACINAR-CELLS; CHANNELS; WAVES; MOBILIZATION; ACTIVATION; METABOLISM	In adrenal glomerulosa cells, angiotensin II (Ang II) evokes repetitive [Ca2+](i) transients and increases Ca2+ influx through voltage-sensitive calcium channels (VSCCs) as well as the capacitative Ca2+ entry pathway. This study analyzed the relationships between these Ca2+ influx pathways and intracellular Ca2+ signaling in bovine glomerulosa cells, in which Ca2+ oscillation frequency was regulated by Ang II concentration over the range of 50-300 pM. In the absence of external. Ca2+, such oscillations were maintained for prolonged periods of time, but their frequency was significantly reduced (0.23 min(-1) versus 0.38 min(-1)). Restoration of [Ca2+](o) to 0.6 mM increased the frequency of Ca2+ oscillations in cells that showed narrow spikes of constant amplitude and caused a plateau response in cells with broad spikes of rapidly decreasing amplitude. In the presence of Ca2+, nifedipine reduced the frequency of the oscillatory Ca2+ response to 100 pM Ang II by 49%, and BAY K 8644 increased oscillation frequency by 86%, or caused plateau-type responses typical of higher Ang II concentrations. In contrast to their prominent actions on Ca2+ spiking frequency, dihydropyridines caused only minor changes in Ang II (100 pM)-induced inositol phosphate production. Dihydropyridines also had minimal effects on the nonoscillatory Ca2+ signals evoked by high Ang II concentrations (10 nM). These findings indicate that Ca2+ influx through VSCCs modulates the frequency of Ca2+ oscillations induced by low agonist concentrations by a mechanism that does not involve major changes in inositol trisphosphate formation. However, VSCCs make relatively little contribution to the nonoscillatory Ca2+ signals generated by high agonist concentrations, when Ca2+ influx occurs predominantly through the capacitative Ca2+ entry pathway.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Balla, Tamas/0000-0002-9077-3335				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; BALLA T, 1994, J BIOL CHEM, V269, P16101; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P18382; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN CJ, 1988, P NATL ACAD SCI USA, V85, P2412, DOI 10.1073/pnas.85.7.2412; DURROUX T, 1988, J PHYSIOL-LONDON, V404, P713, DOI 10.1113/jphysiol.1988.sp017315; ELY JA, 1991, J BIOL CHEM, V266, P18635; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GUILLEMETTE G, 1987, BIOCHEM BIOPH RES CO, V142, P15, DOI 10.1016/0006-291X(87)90445-1; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOHNSON EIM, 1989, J ENDOCRINOL, V122, P391, DOI 10.1677/joe.0.1220391; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KEIZER J, 1995, MOL BIOL CELL, V6, P945, DOI 10.1091/mbc.6.8.945; MATSUNAGA H, 1987, BIOCHEM BIOPH RES CO, V149, P1049, DOI 10.1016/0006-291X(87)90514-6; MCCARTHY RT, 1993, P NATL ACAD SCI USA, V90, P3260, DOI 10.1073/pnas.90.8.3260; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; QUINN SJ, 1988, P NATL ACAD SCI USA, V85, P5754, DOI 10.1073/pnas.85.15.5754; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROSSIER MF, 1995, J BIOL CHEM, V270, P15137, DOI 10.1074/jbc.270.25.15137; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; STOJILKOVIC SS, 1993, J BIOL CHEM, V268, P7713; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; TOMIC M, 1995, ENDOCRINOLOGY, V136, P3422, DOI 10.1210/en.136.8.3422; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	36	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22063	22069						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703014				2022-12-25	WOS:A1996VF61200056
J	Thomas, MJ; Umayahara, Y; Shu, H; Centrella, M; Rotwein, P; McCarthy, TL				Thomas, MJ; Umayahara, Y; Shu, H; Centrella, M; Rotwein, P; McCarthy, TL			Identification of the cAMP response element that controls transcriptional activation of the insulin-like growth factor-I gene by prostaglandin E(2) in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; ENHANCER-BINDING-PROTEIN; PARATHYROID-HORMONE; CYCLIC-AMP; FACTOR-BETA; IGF-I; DEOXYRIBONUCLEIC-ACID; COLLAGEN-SYNTHESIS; ENRICHED CULTURES; MESSENGER-RNA	Insulin-like growth factor-I (IGF-I), a multifunctional growth factor, plays a key role in skeletal growth and can enhance bone cell replication and differentiation. We previously showed that prostaglandin E(2) (PGE(2)) and other agents that increase cAMP activated IGF-I gene transcription in primary rat osteoblast cultures through promoter 1 (P1), the major IGF-I promoter, and found that transcriptional induction was mediated by protein kinase A. We now have identified a short segment of P1 that is essential for full hormonal regulation and have characterized inducible DNA-protein interactions involving this site. Transient transfections of IGF-I P1 reporter genes into primary rat osteoblasts showed that the 328-base pair untranslated region of exon 1 was required for a full 5.3-fold response to PGE(2); mutation in a previously footprinted site, HS3D (base pairs +193 to +215), reduced induction by 65%. PGE(2) stimulated nuclear protein binding to HS3D. Binding, as determined by gel mobility shift assay, was not seen in nuclear extracts from untreated osteoblast cultures, was detected within 2 h of PGE(2) treatment, and was maximal. by 4 h. This DNA-protein interaction was not observed in cytoplasmic extracts from PGE(2)-treated cultures, indicating nuclear localization of the protein kinase A-activated factor(s). Activation of this factor was not blocked by cycloheximide (Chx), and Chx did not impair stimulation of IGF-I gene expression by PGE(2). In contrast, binding to a consensus cAMP response element (CRE; 5'-TGACGTCA-3') from the rat somatostatin gene was not modulated by PGE(2) or Chx. Competition gel mobility shift analysis using mutated DNA probes identified 5'-CGCAATCG-3' as the minimal sequence needed for inducible binding. All modified IGF-I P1 promoter-reporter genes with mutations within this CRE sequence also showed a diminished functional response to PGE(2). These results identify the CRE within the 5'-untranslated region of IGF-I exon 1 that is required for hormonal activation of IGF-I gene transcription by cAMP in osteoblasts.	YALE UNIV,SCH MED,SECT PLAST SURG,NEW HAVEN,CT 06520; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52246; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Yale University; University of Iowa; Washington University (WUSTL)			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NICHD NIH HHS [HD20805] Funding Source: Medline; NIDDK NIH HHS [DK37449, DK47421] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421, R01DK037449] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; ADAMO ML, 1993, ENDOCRINOLOGY, V132, P935, DOI 10.1210/en.132.2.935; AMANO S, 1994, J BONE MINER RES, V9, P465; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CAO QP, 1989, MOL ENDOCRINOL, V3, P2005, DOI 10.1210/mend-3-12-2005; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1996, IN PRESS NY ACAD SCI; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHYUN YS, 1984, PROSTAGLANDINS, V27, P97, DOI 10.1016/0090-6980(84)90223-5; COLLINS DA, 1991, J BONE MINER RES, V6, P157; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756-3282(90)90078-D; KAJIMOTO Y, 1990, MOL ENDOCRINOL, V4, P217, DOI 10.1210/mend-4-2-217; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; KLEINNULEND J, 1990, ENDOCRINOLOGY, V126, P1070, DOI 10.1210/endo-126-2-1070; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LOWE WL, 1992, BIOCHEM BIOPH RES CO, V189, P972, DOI 10.1016/0006-291X(92)92299-D; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCARTHY TL, 1993, ADV EXP MED BIOL, V343, P407; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075; MULLER M, 1990, NUCLEIC ACIDS RES, V18, P364, DOI 10.1093/nar/18.2.364; NGAN P, 1990, ARCH ORAL BIOL, V35, P717, DOI 10.1016/0003-9969(90)90094-Q; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OKAZAKI R, 1995, BIOCHEM BIOPH RES CO, V207, P963, DOI 10.1006/bbrc.1995.1279; PAPAVASSILIOU AG, 1994, ANTICANCER RES, V14, P1801; Parker D, 1996, MOL CELL BIOL, V16, P694; PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658; PUSH JM, 1995, ENDOCRINOLOGY, V136, P33; RAISZ LG, 1974, PROSTAGLANDINS, V8, P377, DOI 10.1016/0090-6980(74)90113-0; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SHAMBLOTT MJ, 1992, P NATL ACAD SCI USA, V89, P8913, DOI 10.1073/pnas.89.19.8913; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711	70	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21835	21841		10.1074/jbc.271.36.21835	http://dx.doi.org/10.1074/jbc.271.36.21835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702983	hybrid			2022-12-25	WOS:A1996VF61200025
J	Blochl, A; Sirrenberg, C				Blochl, A; Sirrenberg, C			Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75(Lntr) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; HIPPOCAMPAL-NEURONS; SUBSTANTIA-NIGRA; MESSENGER-RNA; BINDING CHARACTERISTICS; SIGNAL-TRANSDUCTION; SPHINGOMYELIN CYCLE; 2ND MESSENGER; PC12 CELLS	We analyzed the short term effect of neurotrophins on mesencephalic neuronal cultures of embryonic (E14) rats with respect to which receptors mediate the actions, Brain-derived neurotrophic factor (BDNF) or neurotrophin-3 enhanced within minutes in a dose-dependent manner (2, 20, 100 ng/ml for 5 min) depolarization-induced (KCl, 30 mM 5 min) and basal dopamine release, but nerve growth factor (NGF) was only effective at high doses (100 ng/ml), The effect of BDNF, but not of NGF, was blacked by K252a or K252b, BDNF, but not NGF, phosphorylated trkB receptors, The NGF-induced, but not the BDNF-induced effect upon the release of dopamine was blocked by anti-p75 antibody MC192. C-2-ceramide, an analogue of ceramide, the second messenger of the sphingomyelin pathway, and sphingomyelinase itself induced a release of dopamine comparable with the effect of NGF, NGF, but not BDNF, increased ceramide production, in addition, simultaneous treatment with BDNF and NGF led to a partial prevention of the NGF-stimulated, p75(Lntr)-mediated effect. We conclude that BDNF stimulates the release of dopamine by activation of the trkB receptor, whereas NGF affects the release via the p75(Lntr) receptor inducing the sphingomyelin pathway.			Blochl, A (corresponding author), MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.							ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347; ALTAR CA, 1994, EXP NEUROL, V130, P31, DOI 10.1006/exnr.1994.1182; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Berzaghi M. P., 1995, Society for Neuroscience Abstracts, V21, P545; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; Blochl A, 1996, MOL CELL NEUROSCI, V7, P173, DOI 10.1006/mcne.1996.0014; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DECHANT G, 1993, DEVELOPMENT, V119, P545; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; GIBBS RB, 1994, J COMP NEUROL, V341, P324, DOI 10.1002/cne.903410304; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; Griesbeck O., 1995, Society for Neuroscience Abstracts, V21, P1046; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; KNIPPER M, 1994, EUR J NEUROSCI, V6, P668, DOI 10.1111/j.1460-9568.1994.tb00312.x; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LESSMANN V, 1994, NEUROREPORT, V6, P21; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MARTINIVERSON MT, 1994, J NEUROSCI, V14, P1262, DOI 10.1523/JNEUROSCI.14-03-01262.1994; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; NISHIO T, 1992, EXP NEUROL, V116, P76, DOI 10.1016/0014-4886(92)90178-S; OFFENHAUSER N, 1995, EUR J NEUROSCI, V7, P917, DOI 10.1111/j.1460-9568.1995.tb01079.x; OKAZAWA H, 1992, FEBS LETT, V313, P138, DOI 10.1016/0014-5793(92)81430-T; PALMER MR, 1993, EXP BRAIN RES, V93, P226; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SOBREVIELA T, 1994, J COMP NEUROL, V350, P587, DOI 10.1002/cne.903500407; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; STUDER L, 1995, EUR J NEUROSCI, V7, P223, DOI 10.1111/j.1460-9568.1995.tb01058.x; SUTER U, 1992, J NEUROSCI, V12, P306; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	64	150	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21100	21107						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702878				2022-12-25	WOS:A1996VE47700024
J	Eder, PS; Srinivasan, A; Fishman, MC; Altman, S				Eder, PS; Srinivasan, A; Fishman, MC; Altman, S			The RNA subunit of ribonuclease P from the zebrafish, Danio rerio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE; INVITRO; MOIETY; ENZYME; CELLS	A simple strategy has been devised to identify the gene encoding the RNA subunit of RNase P from the zebrafish, Danio rerio. The sequence obtained by amplification of genomic DNA with primers based on sequences common to two other vertebrates was confirmed by reverse transcription and amplification of RNA from a partially purified preparation of the holoenzyme. The 5' and 3' ends were determined by cyclizing the RNA, followed by reverse transcription and sequencing across the ligated RNA junction, The zebrafish sequence is 63% identical to that of Xenopus laevis nuclear RNase P RNA and 69% identical to the human RNase P RNA, A consensus secondary structure was constructed based on these nucleotide identities and on the many compensatory base changes in several regions among these three RNAs. The strategy used to obtain the zebrafish sequence should be useful in deriving analogous gene sequences from diverse classes of eukaryotes.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129	Yale University; Harvard University; Massachusetts General Hospital								ALTMAN S, 1993, GENOMICS, V18, P418, DOI 10.1006/geno.1993.1488; Altman Sidney, 1995, P67; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; DRAINAS D, 1989, FEBS LETT, V251, P84, DOI 10.1016/0014-5793(89)81433-4; ERFIELD M, 1995, ZEBRAFISH BOOK GUIDE; GOPALAN V, 1995, RNA PROTEIN INTERACT, P103; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; JAEGER JA, 1993, ANNU REV BIOCHEM, V62, P255; JAYANTHI GP, 1992, ARCH BIOCHEM BIOPHYS, V296, P264, DOI 10.1016/0003-9861(92)90571-D; LI K, 1995, J BIOL CHEM, V270, P25281, DOI 10.1074/jbc.270.42.25281; LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514; LIU MH, 1994, MOL CELL BIOCHEM, V130, P75, DOI 10.1007/BF01084270; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; SHINSHI H, 1976, BIOCHEMISTRY-US, V15, P2185, DOI 10.1021/bi00655a024; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TRANGUCH AJ, 1993, J BIOL CHEM, V268, P14045; WESTHOF E, 1994, P NATL ACAD SCI USA, V91, P5133, DOI 10.1073/pnas.91.11.5133; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006	27	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21031	21036		10.1074/jbc.271.35.21031	http://dx.doi.org/10.1074/jbc.271.35.21031			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702867	hybrid			2022-12-25	WOS:A1996VE47700013
J	Krippner, A; MatsunoYagi, A; Gottlieb, RA; Babior, BM				Krippner, A; MatsunoYagi, A; Gottlieb, RA; Babior, BM			Loss of function of cytochrome c in Jurkat cells undergoing Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC ATPASE INHIBITOR; TUMOR-NECROSIS-FACTOR; THYMOCYTE APOPTOSIS; MITOCHONDRIA; DEATH; INVOLVEMENT; RECEPTOR; PROTEINS; PROTEASE; F1F0-ATPASE	Mitochondrial function was examined in Jurkat cells undergoing Fas-mediated apoptosis. With succinate or ascorbate/tetramethylphenylenediamine as substrate, oxygen uptake by digitonin-permeabilized apoptotic mitochondria was greatly decreased as compared with control. Assessment of the function of the cytochrome c-cytochrome oxidase segment of the electron transport chain of apoptotic mitochondria showed that the activity of cytochrome oxidase appeared to be normal, but that of cytochrome c was greatly diminished. A death protease was found to participate in the events leading to the loss of cytochrome c activity, but the cytochrome did not seem to be extensively degraded during the course of apoptosis. Our results suggest that a rapid loss in mitochondrial function due at least in part to the inhibition or inactivation of cytochrome c is a potentially fatal component of the apoptosis program of Jurkat cells.			Krippner, A (corresponding author), SCRIPPS RES INST, DEPT MOL & EXPT MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/CA-01345] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASS WT, 1988, ANAL BIOCHEM, V171, P330, DOI 10.1016/0003-2697(88)90494-0; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHERNYAK BV, 1991, ARCH BIOCHEM BIOPHYS, V286, P604, DOI 10.1016/0003-9861(91)90087-Y; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; DEGOMEZPUYOU MT, 1983, J BIOL CHEM, V258, P3680; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Errede B, 1978, Methods Enzymol, V53, P40; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1983, J BIOCHEM-TOKYO, V94, P715, DOI 10.1093/oxfordjournals.jbchem.a134411; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; ICHIKAWA N, 1990, J BIOL CHEM, V265, P6274; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOPEZMEDIAVILLA C, 1993, EUR J BIOCHEM, V215, P487, DOI 10.1111/j.1432-1033.1993.tb18058.x; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MACHO A, 1995, BLOOD, V86, P2481; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MIMURA H, 1993, J BIOCHEM-TOKYO, V113, P350, DOI 10.1093/oxfordjournals.jbchem.a124050; NEAMATI N, 1995, J IMMUNOL, V154, P3788; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Piacentini M, 1995, Curr Top Microbiol Immunol, V200, P163; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; TAN A, 1989, JOY LUCK CLUB, P102; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; YAMADA EW, 1983, BIOSCIENCE REP, V3, P947, DOI 10.1007/BF01140664; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	35	187	193	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21629	21636		10.1074/jbc.271.35.21629	http://dx.doi.org/10.1074/jbc.271.35.21629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702951	hybrid			2022-12-25	WOS:A1996VE47700097
J	Tougu, K; Marians, KJ				Tougu, K; Marians, KJ			The interaction between helicase and primase sets the replication fork clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-III; COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; HOLOENZYME; PURIFICATION; IDENTIFICATION; CONVERSION; PROTEINS; RECONSTITUTION	The synthesis of an Okazaki fragment occurs once every 1-2 s at the Escherichia coli replication fork and requires precise coordination of the enzymatic activities required. We have shown previously that the primase is recruited anew from solution for each cycle of Okazaki fragment synthesis and that association of primase with the replication fork is via a protein-protein interaction with the helicase, DnaB, We describe here mutant primases that have an altered interaction with DnaB and that direct the synthesis of Okazaki fragments of altered length compared to the wild-type. The mutant primases were deficient only in their ability to participate in replication reactions where their entry to the DNA was provided by the initial protein-protein interaction with DnaB. The primer synthesis capacity of these proteins remained unaffected, as was their ability to interact with the DNA polymerase III holoenzyme. Neither replication fork rate nor the efficiency of primer utilization was affected at replication forks programmed by the mutant enzymes. Thus, the interaction between DnaG and DnaB at the replication fork is the primary regulator of the cycle of Okazaki fragment synthesis.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Tougu, K (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MOK M, 1987, J BIOL CHEM, V262, P16644; MUNN MM, 1991, J BIOL CHEM, V266, P20034; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SELICK HE, 1987, DNA REPLICATION RECO, P183; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P1983; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER W, 1974, J BIOL CHEM, V249, P6244; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHEL K, 1975, J BIOL CHEM, V250, P4684; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	33	112	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21398	21405		10.1074/jbc.271.35.21398	http://dx.doi.org/10.1074/jbc.271.35.21398			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702921	hybrid			2022-12-25	WOS:A1996VE47700067
J	Wu, K; Yuan, J; Lasky, LA				Wu, K; Yuan, J; Lasky, LA			Characterization of a novel member of the macrophage mannose receptor type C lectin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SELECTIN-DEFICIENT MICE; BINDING PROTEIN; ANIMAL LECTINS; LIGAND; OLIGOSACCHARIDE; IDENTIFICATION; MUTAGENESIS; EXPRESSION; CLONING	The recognition of a diversity of carbohydrates by the various calcium dependent (type C) lectin family members has been shown to be critical for a variety of processes ranging from cell adhesion to antigen presentation, Examination of the expressed sequence tag (EST) data base for novel type C lectins using E-selectin as a probe resulted in the identification of a distantly related short polypeptide sequence containing many of the conserved residues found in these carbohydrate-binding proteins. Cloning of the full-length murine cDNA containing this region revealed that this protein is a novel member of the family that includes the macrophage mannose, the phospholipase A(2), and the DEC 205 receptors, with a cysteine-rich domain, a fibronectin type 2 domain, eight type C lectin domains, a transmembrane domain, and a short cytoplasmic carboxyl terminus, Genomic Southern analysis suggests that this is a conserved protein, and examination of a human homologue revealed a high degree of sequence homology with the murine form. Northern blot analysis revealed expression of a large transcript in a number of different human and murine tissues and tumor cells and an alternatively spliced smaller transcript with a divergent 5' sequence was expressed specifically in the human fetal liver. Analysis of the genomic structure revealed that the gene encoding this lectin was interrupted by a large number of introns, and the intron structure was similar to the macrophage mannose receptor gene, Finally, in situ hybridization analysis demonstrated that the transcript encoding this lectin was found in a number of highly endothelialized sites as well as in chondrocytes in cartilaginous regions of the embryo.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ALON R, 1995, IN PRESS NATURE; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HARRIS N, 1994, BIOCHEM BIOPH RES CO, V198, P682, DOI 10.1006/bbrc.1994.1099; HARRIS N, 1992, BLOOD, V80, P2363; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; IOBST ST, 1994, J BIOL CHEM, V269, P15505; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KIM SJ, 1992, GENOMICS, V14, P721, DOI 10.1016/S0888-7543(05)80174-0; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	27	77	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21323	21330		10.1074/jbc.271.35.21323	http://dx.doi.org/10.1074/jbc.271.35.21323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702911	hybrid			2022-12-25	WOS:A1996VE47700057
J	Dong, DLY; Xu, ZS; Hart, GW; Cleveland, DW				Dong, DLY; Xu, ZS; Hart, GW; Cleveland, DW			Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTERMEDIATE FILAMENTS; N-ACETYLGLUCOSAMINE MOIETIES; MAMMALIAN NEUROFILAMENTS; PHOSPHORYLATION SITES; AXONAL-TRANSPORT; TRANSGENIC MICE; SCHWANN-CELLS; LINKED GLCNAC; IN-VIVO; IDENTIFICATION	Neurofilaments, the major intermediate filaments in large myelinated neurons, are essential for specifying proper axonal caliber. Mammalian neurofilaments are obligate heteropolymers assembled from three polypeptides, neurofilament (NF)-H, NF-M, and NF-L, each of which undergoes phosphorylation at multiple sites. NF-M and NF-L are known to be modified by O-linked N-acetylglucosamine (O-GlcNAc) (Dong, D. L.-Y., Xu, Z.-S., Chevrier, M. R., Cotter, R. J., Cleveland, D. W., and Hart, G. W. (1993) J. Biol. Chem. 268, 16679-16687), Here we further report that NF-H is extensively modified by O-GlcNAc at Thr(53), Ser(54), and Ser(56) in the head domain and, somewhat surprisingly, at multiple sites within the Lys-Ser-Pro repeat motif in the tail domain, a region in assembled neurofilaments known to be nearly stoichiometrically phosphorylated on each of the similar to 50 KSP repeats. Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr(19) and Ser(34) of NF-M and Ser(34) and Ser(48) of MF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly, The proximity of O-GlcNAc and phosphorylation sites in both head and tail domains of each subunit indicates that these modifications may influence one another and play a role in filament assembly and network formation.	UNIV CALIF SAN DIEGO, LUDWIG INST CANC RES, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, LUDWIG INST CANC RES, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682; Hart, Gerald/0000-0001-7812-4351	NICHD NIH HHS [HD13563] Funding Source: Medline; NINDS NIH HHS [NS27036] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027036, R01NS027036] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1991, J CELL SCI, V99, P335; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHOU CF, 1992, J BIOL CHEM, V267, P3901; Cleveland DW, 1996, CELL, V84, P663, DOI 10.1016/S0092-8674(00)81044-2; Cleveland DW, 1995, RES PER ALZ, P180; COLE JS, 1994, J NEUROSCI, V14, P6956; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DONG DLY, 1994, THESIS J HOPKINS U B; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; GOTOW T, 1994, J CELL SCI, V107, P1949; Haltiwanger R S, 1993, Methods Mol Biol, V14, P175; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1995, PURE APPL CHEM, V67, P1637, DOI 10.1351/pac199567101637; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HART GW, 1993, C MOSBACH, V44, P91; HIRANO A, 1991, ADV NEUROL, V56, P91; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HSIEH ST, 1994, J NEUROSCI, V14, P6392; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; SAKAGUCHI T, 1993, NEUROSCI LETT, V153, P65, DOI 10.1016/0304-3940(93)90078-Y; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SIHAG RK, 1995, MOL BIOL CELL, V6, P375; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; XU ZS, 1990, J NEUROSCI, V10, P1838; Xu ZS, 1996, J CELL BIOL, V133, P1061, DOI 10.1083/jcb.133.5.1061; XU ZS, 1992, J BIOL CHEM, V267, P4467; XU ZS, 1990, THESIS WASHINGTON U; Xu Zuoshang, 1994, Current Opinion in Neurobiology, V4, P655, DOI 10.1016/0959-4388(94)90006-X; YAMASAKI H, 1992, LAB INVEST, V66, P734	58	96	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20845	20852		10.1074/jbc.271.34.20845	http://dx.doi.org/10.1074/jbc.271.34.20845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702840	hybrid			2022-12-25	WOS:A1996VD33700092
J	Horstmeyer, A; Cramer, H; Sauer, T; MullerEsterl, W; Schroeder, C				Horstmeyer, A; Cramer, H; Sauer, T; MullerEsterl, W; Schroeder, C			Palmitoylation of endothelin receptor A - Differential modulation of signal transduction activity by post-translational modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; HAMSTER OVARY CELLS; SMOOTH-MUSCLE CELLS; CHROMOSOMAL ASSIGNMENT; ADENYLATE-CYCLASE; CYTOPLASMIC TAIL; LIGAND-BINDING; ACTIVATION	Post-translational modifications such as phosphorylation and palmitoylation play important roles for the function and regulation of receptors coupled to heterotrimeric guanyl nucleotide binding proteins. Here we demonstrate that the human endothelin receptor A (ET(A)) incorporates [H-3]palmitate, Mutation of a cluster of five cysteine residues present in the cytoplasmic tail of ET(A) into serine or alanine residues completely prevented palmitoylation of the receptor. The ligand binding affinity of the non-palmitoylated ET(A) mutants was essentially unchanged as compared to the palmitoylated wild type ET(A) suggesting that the replacement of the cysteine residues did not alter the overall structure of the receptor, Furthermore, the ligand-induced stimulation of adenylyl cyclase by the mutant ET(A) was unaffected by the mutation, In contrast, the mutated non-palmitoylated receptors but not the wild type receptor failed to stimulate phosphatidylinositol hydrolysis by phospholipase C activation upon challenge by endothelin-1. Furthermore, the mutant receptors failed to stimulate the ligand-induced transient increase in the cytoplasmic calcium seen with the wild type ET(A), Endothelin-1 induced mitogenic stimuli via the wild type receptors but not through the mutated receptors suggesting an important role for phospholipase C in this signal transduction pathway, The differential regulation of distinct signal transduction pathways by post-translational modification suggests that palmitoylation of the ET(A) provides a novel mechanism of modulating ET(A) receptor activity.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-65099 MAINZ, GERMANY	Johannes Gutenberg University of Mainz								ALLA SA, 1993, J BIOL CHEM, V268, P17277; ARAI H, 1993, J BIOL CHEM, V268, P3463; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COLLINS S, 1991, VITAM HORM, V46, P1; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; EISTETTER HR, 1991, CELL REGUL, V2, P767, DOI 10.1091/mbc.2.10.767; FELDER CC, 1989, J BIOL CHEM, V264, P20356; HARTMAN JC, 1995, ANN THORAC SURG, V60, P789, DOI 10.1016/0003-4975(95)00192-N; HASHIDO K, 1993, CELL MOL BIOL RES, V39, P3; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOSODA K, 1992, J BIOL CHEM, V267, P18797; JANAKIDEVI K, 1992, AM J PHYSIOL, V263, pC1295, DOI 10.1152/ajpcell.1992.263.6.C1295; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KHOUJA A, 1992, J DEV PHYSIOL, V18, P263; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PEPPERBERG DR, 1995, METHOD ENZYMOL, V250, P348; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; RESINK TJ, 1990, EUR J BIOCHEM, V189, P415, DOI 10.1111/j.1432-1033.1990.tb15504.x; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SUMMER MD, 1987, AGR EXPT STATION B, V1555; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; YAMADA M, 1994, MOL PHARMACOL, V46, P470; YANAGISAWA M, 1988, J HYPERTENS, V6, pS188, DOI 10.1097/00004872-198812040-00056; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	44	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20811	20819		10.1074/jbc.271.34.20811	http://dx.doi.org/10.1074/jbc.271.34.20811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702836	hybrid			2022-12-25	WOS:A1996VD33700088
J	Mallardo, M; Dragonetti, E; Baldassarre, F; Ambrosino, C; Scala, G; Quinto, I				Mallardo, M; Dragonetti, E; Baldassarre, F; Ambrosino, C; Scala, G; Quinto, I			An NF-kappa B site in the 5'-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kappa B-activating stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR USF; TATA-BINDING PROTEIN; FACTOR-ALPHA; NUCLEAR FACTOR; COOPERATIVE INTERACTION; HIV-1 TRANSCRIPTION; INITIATOR ELEMENT; HUMAN-LYMPHOCYTES	The 5'-untranslated leader region of human immunodeficiency virus, type 1 (HIV-1), includes a complex array of putative regulatory elements whose role in the viral expression is not completely understood. Here we demonstrate the presence of an NF-kappa B-responsive element in the trans-activation response (TAR) region of HIV-1 that confers the full induction of HIV-1 long terminal repeat (LTR) in response to NF-kappa B-activating stimuli, such as DNA alkylating agents, phorbol 12-myristate 13-acetate, and tumor necrosis factor-alpha. The TAR NF-kappa B site GGGAGCTCTC spans from positions +31 to +40 and cooperates with the NF-kappa B enhancer upstream of the TATA box in the NF-kappa B-mediated induction of HIV-1 LTR. The conclusion stems from the following observations: (i) deletion of the two NF-kappa B sites upstream of the TATA box reduces, but does not abolish, the HIV-1 LTR activation by NF-kappa B inducers; (ii) deletion or base pair substitutions of the TAR NF-kappa B site significantly reduce the HIV-1 LTR activation by NF-kappa B inducers; (iii) deletions of both the NF-kappa B sites upstream of the TATA box and the TAR NF-kappa B site abolish the activation of HIV-1 LTR in response to NF-kappa B inducers. Moreover, the p50 . p65 NF-kappa B complex binds to the TAR NF-kappa B sequence and trans-activates the TAR NF-kappa B-directed expression. The identification of an additional NF-kappa B site in the HIV-1 LTR points to the relevance of NF-kappa B factors in the HIV-1 Life cycle.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria			SCALA, GIUSEPPE/A-3280-2009	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ANTONI BA, 1994, VIROLOGY, V202, P684, DOI 10.1006/viro.1994.1390; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldassarre F, 1995, J BIOL CHEM, V270, P31244, DOI 10.1074/jbc.270.52.31244; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DEROSSI A, 1990, EUR J IMMUNOL, V20, P2041, DOI 10.1002/eji.1830200924; DIFAGAGNA FD, 1995, J VIROL, V69, P2765, DOI 10.1128/JVI.69.5.2765-2775.1995; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HARRICH D, 1994, J VIROL, V68, P5899, DOI 10.1128/JVI.68.9.5899-5910.1994; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM JYH, 1993, J VIROL, V67, P1658, DOI 10.1128/JVI.67.3.1658-1662.1993; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LI YC, 1994, J BIOL CHEM, V269, P30616; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MALLON R, 1990, J VIROL, V64, P6282, DOI 10.1128/JVI.64.12.6282-6285.1990; MARGOLIS DM, 1993, VIROLOGY, V192, P370, DOI 10.1006/viro.1993.1046; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MONROE JE, 1988, J VIROL, V62, P3497, DOI 10.1128/JVI.62.9.3497-3500.1988; Myers G., 1993, HUMAN RETROVIRUSES A; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PARROTT C, 1991, VIROLOGY, V65, P1414; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POPIK W, 1993, J VIROL, V67, P1094, DOI 10.1128/JVI.67.2.1094-1099.1993; QUINTO I, 1993, J BIOL CHEM, V268, P26719; QUINTO I, 1991, LIGHT LASERS SYNCHRO, P247; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823	63	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20820	20827		10.1074/jbc.271.34.20820	http://dx.doi.org/10.1074/jbc.271.34.20820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702837	hybrid			2022-12-25	WOS:A1996VD33700089
J	Katzmann, DJ; Hallstrom, TC; Mahe, Y; MoyeRowley, WS				Katzmann, DJ; Hallstrom, TC; Mahe, Y; MoyeRowley, WS			Multiple Pdr1p/Pdr3p binding sites are essential for normal expression of the ATP binding cassette transporter protein-encoding gene PDR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-ASSOCIATED PROTEIN; YEAST MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; DRUG-RESISTANCE; DEPENDENT TRANSPORT; PLEIOTROPIC DRUG; CELLS; OVEREXPRESSION; HOMOLOGY; PRODUCT	Saccharomyces cerevisiae has large number of genes that can be genetically altered to produce a multiple or pleiotropic drug resistance phenotype. The homologous zinc finger transcription factors Pdr1p and Pdr3p both elevate resistance to many drugs, including cycloheximide, This elevation in cycloheximide tolerance only occurs in the presence of an intact copy of the PDR5 gene that encodes a plasma membrane-localized ATP binding cassette transporter protein. Previously, we have found that a single binding site for Pdr3p present in the PDR5 promoter is sufficient to provide Pdr3p-responsive gene expression. In this study, we have found that there are three sites in the PDR5 5'-noncoding region that are closely related to one another and are bound by both Pdr1p and Pdr3p, These elements have been designated Pdr1p/Pdr3p response elements (PDREs), and their role in the maintenance of normal PDR5 expression has been analyzed, Mutations have been constructed in each PDRE and shown to eliminate Pdr1p/Pdr3p binding in vitro. Analysis of the effect of these mutant PDREs on normal PDR5 promoter function indicates that each element is required for wild-type expression and drug resistance. A single PDRE placed upstream of a yeast gene lacking its normal upstream activation sequence is sufficient to confer Pdr1p responsiveness to this heterologous promoter.	UNIV IOWA, PROGRAM MOL BIOL, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM	University of Iowa; University of Iowa; Universite Catholique Louvain			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEXTER D, 1994, GENETICS, V136, P505; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; WU AL, 1993, J BIOL CHEM, V268, P18850	32	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23049	23054		10.1074/jbc.271.38.23049	http://dx.doi.org/10.1074/jbc.271.38.23049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798494	hybrid			2022-12-25	WOS:A1996VH76800020
J	Roseman, NA; Evans, RK; Mayer, EL; Rossi, MA; Slabaugh, MB				Roseman, NA; Evans, RK; Mayer, EL; Rossi, MA; Slabaugh, MB			Purification and characterization of the vaccinia virus deoxyuridine triphosphatase expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DUTP PYROPHOSPHATASE; URACIL DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE; REPLICATION; ENCODES; ENZYME; MUTANT; CELLS	The deoxyuridine triphosphatase gene of vaccinia vi rus, encoded by the open reading frame F2L, was cloned into Escherichia coli and expressed under the control of a bacteriophage T7 promoter. After induction of T7 RNA polymerase by isopropyl beta-D-thiogalactopyranoside, a 16.5-kDa peptide accumulated to high levels. This 16.5-kDa protein was purified to homogeneity and characterized. Gel filtration of the purified protein revealed a trimeric native structure. Biochemical analysis revealed the enzyme to be a metalloenzyme; enzymatic activity is inhibited by EDTA. This inhibition was reversed by the addition of Mg2+, Mn2+, or Zn2+. While the enzyme activity was highly specific for dUTP with an apparent K-m of 0.94 mu m, inhibition studies show that 8-azido-ATP acted as a competitive inhibitor of dUTP with a K-i of approximately 173 mu m. Also, protection studies demonstrated that nucleotide competitors inhibit photoincorporation of the photoaffinity analogues [gamma-P-32]5-azido-dUTP and [gamma-P-32]8-azido-ATP. This suggests that while catalytic activity is limited to dUTP, other nucleotides can bind the active site.	WILLIAMS COLL, DEPT CHEM, WILLIAMSTOWN, MA 01267 USA; OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Williams College; Oregon State University	Roseman, NA (corresponding author), WILLIAMS COLL, DEPT BIOL, WILLIAMSTOWN, MA 01267 USA.				PHS HHS [A124294] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BROYLES SS, 1993, VIROLOGY, V195, P863, DOI 10.1006/viro.1993.1446; CANMAN CE, 1993, CANCER RES, V53, P5219; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; CLIMIE S, 1994, PROTEIN EXPRES PURIF, V5, P252, DOI 10.1006/prep.1994.1038; CURTIN NJ, 1991, CANCER RES, V51, P2346; DUNCAN BK, 1981, ENZYMES, V1, P565; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; GIROIR IE, 1987, J BIOL CHEM, V262, P130; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HOKARI S, 1987, ARCH BIOCHEM BIOPHYS, V253, P350, DOI 10.1016/0003-9861(87)90188-3; HRUBY DE, 1982, J VIROL, V43, P403, DOI 10.1128/JVI.43.2.403-409.1982; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; KOPPE B, 1994, J VIROL, V68, P2313; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LICHTENSTEIN DL, 1995, J VIROL, V69, P2881, DOI 10.1128/JVI.69.5.2881-2888.1995; LIRETTE R, 1990, J CELL BIOCHEM, V43, P339, DOI 10.1002/jcb.240430406; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MCINTOSH EM, 1994, CURR GENET, V26, P415, DOI 10.1007/BF00309928; MILLNS AK, 1994, VIROLOGY, V198, P504, DOI 10.1006/viro.1994.1061; MOSS B, 1996, VIROLOGY, P2637; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; PARDO EG, 1990, EXP CELL RES, V186, P90, DOI 10.1016/0014-4827(90)90214-U; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; SLABAUGH MB, 1989, P NATL ACAD SCI USA, V86, P4152, DOI 10.1073/pnas.86.11.4152; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; STEAGALL WK, 1995, VIROLOGY, V210, P302, DOI 10.1006/viro.1995.1347; STRAHLER JR, 1993, P NATL ACAD SCI USA, V90, P4991, DOI 10.1073/pnas.90.11.4991; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; TRAKTMAN P, 1990, CURR TOP MICROBIOL, V163, P93; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; WAGAMAN PC, 1993, VIROLOGY, V196, P451, DOI 10.1006/viro.1993.1501; WARNER HR, 1978, NATURE, V272, P32, DOI 10.1038/272032a0; WILLIAMS MV, 1979, J BIOL CHEM, V254, P2897; WOHLRAB F, 1980, P NATL ACAD SCI-BIOL, V77, P1872, DOI 10.1073/pnas.77.4.1872; ZALUD P, 1995, PURINE PYRIMIDINE ME, V7, P135	45	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23506	23511		10.1074/jbc.271.38.23506	http://dx.doi.org/10.1074/jbc.271.38.23506			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798559	hybrid			2022-12-25	WOS:A1996VH76800085
J	Yamada, H; Denzer, AJ; Hori, H; Tanaka, T; Anderson, LVB; Fujita, S; FukutaOhi, H; Shimizu, T; Ruegg, MA; Matsumura, K				Yamada, H; Denzer, AJ; Hori, H; Tanaka, T; Anderson, LVB; Fujita, S; FukutaOhi, H; Shimizu, T; Ruegg, MA; Matsumura, K			Dystroglycan is a dual receptor for agrin and laminin-2 in Schwann cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; CONGENITAL MUSCULAR-DYSTROPHY; PERIPHERAL-NERVE; EXTRACELLULAR-MATRIX; CHAIN GENE; COMPLEX; BINDING; MEROSIN; IDENTIFICATION; EXPRESSION	We have shown previously that alpha-dystroglycan with a molecular mass of 120 kDa is a Schwann cell receptor of laminin-2, the endoneurial isoform of laminin comprised of the alpha 2, beta 1, and gamma 1 chains. In this paper, we show that Schwann cell alpha-dystroglycan is also a receptor of agrin, an acetylcholine receptor aggregating molecule having partial homology to laminin alpha chains in the C terminus. Immunochemical analysis demonstrates that the peripheral nerve isoform of agrin is a 400-kDa component of the endoneurial basal lamina and is colocalized with alpha-dystroglycan surrounding the outermost layer of myelin sheath of peripheral nerve fibers. Blot overlay analysis demonstrates that both endogenous peripheral nerve agrin and laminin-2 bind to Schwann cell alpha-dystroglycan. Recombinant C-terminal fragment of the peripheral nerve isoform of agrin also binds to Schwann cell alpha-dystroglycan, confirming that the binding site for Schwann cell alpha-dystroglycan resides in the C terminus of agrin molecule. Furthermore, the binding of recombinant agrin C-terminal fragment to Schwann cell alpha-dystroglycan competes with that of laminin-2. All together, these results indicate that alpha-dystroglycan is a dual receptor for agrin and laminin-2 in the Schwann cell membrane.	TEIKYO UNIV, SCH MED, DEPT NEUROL & NEUROSCI, TOKYO 173, JAPAN; UNIV BASEL, BIOZENTRUM, DEPT PHARMACOL, CH-4056 BASEL, SWITZERLAND; TOKYO MED & DENT UNIV, MED RES INST, DEPT TISSUE PHYSIOL, TOKYO 101, JAPAN; SAITAMA RED CROSS, CTR BLOOD, YONO, SAITAMA 338, JAPAN; UNIV NEWCASTLE UPON TYNE, SCH NEUROSCI, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND; NEWCASTLE GEN HOSP, REG NEUROSCI CTR, MUSCULAR DYSTROPHY GRP LABS, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND	Teikyo University; University of Basel; Tokyo Medical & Dental University (TMDU); Newcastle University - UK; Newcastle General Hospital			Ruegg, Markus/X-7256-2019	Ruegg, Markus/0000-0002-4974-9384				ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CULLEN MJ, 1994, ACTA NEUROPATHOL, V87, P349; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Hopf C, 1996, J BIOL CHEM, V271, P5231; HORI H, 1994, J BIOCHEM-TOKYO, V116, P1212, DOI 10.1093/oxfordjournals.jbchem.a124666; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711	37	96	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23418	23423		10.1074/jbc.271.38.23418	http://dx.doi.org/10.1074/jbc.271.38.23418			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798547				2022-12-25	WOS:A1996VH76800073
J	Yano, S; Fukunaga, K; Takiguchi, M; Ushio, Y; Mori, M; Miyamoto, E				Yano, S; Fukunaga, K; Takiguchi, M; Ushio, Y; Mori, M; Miyamoto, E			Regulation of CCAAT/enhancer-binding protein family members by stimulation of glutamate receptors in cultured rat cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; TRANSCRIPTIONAL ACTIVATOR PROTEIN; GROWTH-FACTOR EXPRESSION; LEUCINE ZIPPER PROTEINS; LONG-TERM POTENTIATION; ACUTE-PHASE RESPONSE; 3 C/EBP ISOFORMS; KINASE-II; C-FOS; HIPPOCAMPAL-NEURONS	Regulation of mRNA levels, DNA binding activities, and phosphorylation of CCAAT/enhancer-binding protein (C/EBP) family members by stimulation of glutamate receptors were studied in cultured rat cortical astrocytes. Indirect immunofluorescence and immunoblot analyses with specific antibodies to C/EBP family members revealed that both C/EBP beta and C/EBP delta but not C/EBP alpha are expressed in the nuclei of astrocytes. After exposure to glutamate, C/EBP beta mRNA levels increased within 10 min, reached the maximal level at about 1 h, and returned to the basal level within 6 h, In contrast, C/EBP delta mRNA levels decreased by 6 h and were recovered within 12 h, These changes in mRNA levels were accompanied by an increase and a decrease in proteins for C/EBP beta and C/EBP delta, respectively. Elevation of C/EBP beta mRNA levels by glutamate treatment required an increase in intracellular Ca2+ concentration and depended on activations of protein kinase C and calmodulin-dependent protein kinases. Gel mobility shift analysis using nuclear extracts from the glutamate-treated cells showed increases in C/EBP site binding activities 2 h after the exposure to glutamate, Moreover, glutamate stimulated phosphorylation of C/EBP beta in P-32-labeled astrocytes in a Ca2+-dependent manner. These results suggest that glutamate regulates functions of C/EBP family members in brain astrocytes through changes in mRNA levels of C/EBP beta and C/EBP delta as well as through phosphorylation of C/EBP beta.	KUMAMOTO UNIV, SCH MED, DEPT PHARMACOL, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT NEUROSURG, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT MOL GENET, KUMAMOTO 860, JAPAN	Kumamoto University; Kumamoto University; Kumamoto University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; AN G, 1992, BIOCHEM BIOPH RES CO, V188, P1104, DOI 10.1016/0006-291X(92)91345-Q; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BRADFORD MM, 1976, ANAL CHEM, V226, P203; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CONDORELLI DF, 1993, J NEUROCHEM, V60, P877, DOI 10.1111/j.1471-4159.1993.tb03232.x; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LADENHEIM RG, 1993, J NEUROCHEM, V60, P260, DOI 10.1111/j.1471-4159.1993.tb05846.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NISHIZAWA M, 1991, FEBS LETT, V282, P95, DOI 10.1016/0014-5793(91)80452-9; Osada S, 1996, J BIOL CHEM, V271, P3891; PECHAN PA, 1993, NEUROSCI LETT, V153, P111, DOI 10.1016/0304-3940(93)90089-4; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAY BK, 1994, EUR J BIOCHEM, V222, P891, DOI 10.1111/j.1432-1033.1994.tb18937.x; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ JP, 1990, CELL MOL NEUROBIOL, V10, P447, DOI 10.1007/BF00711186; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YANO S, 1994, J BIOL CHEM, V269, P5428; ZAFRA F, 1992, J NEUROSCI, V12, P4793	58	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23520	23527		10.1074/jbc.271.38.23520	http://dx.doi.org/10.1074/jbc.271.38.23520			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798561				2022-12-25	WOS:A1996VH76800087
J	DebBurman, SK; Ptasienski, J; Benovic, JL; Hosey, MM				DebBurman, SK; Ptasienski, J; Benovic, JL; Hosey, MM			G protein-coupled receptor kinase GRK2 is a phospholipid-dependent enzyme that can be conditionally activated by G protein beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MUSCARINIC ACETYLCHOLINE-RECEPTOR; HETEROTRIMERIC G-PROTEINS; 3RD INTRACELLULAR LOOP; BRUTON TYROSINE KINASE; RHODOPSIN KINASE; PH DOMAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; G(BETA-GAMMA) SUBUNITS; CHOLINERGIC RECEPTORS	G protein-coupled receptor kinases (GRKs) mediate agonist;dependent phosphorylation of G protein-coupled receptors (GPRs) and initiate homologous receptor desensitization. Previously, we reported that charged phospholipids directly interacted with the two GRK isoforms, GRK2 and GRK3, via a pleckstrin homology (PH) domain to regulate GRK activity (DebBurman, S. K., Ptasienski, J., Boetticher, E., Lomasney, J. W., Benovic, J. L., and Hosey, M. M. (1995) J. Biol. Chem. 270: 5742-5747). Here, evidence is provided to support the hypothesis that charged phospholipids are required for agonist-dependent phosphorylation of receptors by GRK2. In the absence of charged phospholipids, the purified human m2 muscarinic acetylcholine receptor (hm2mAChR) reconstituted in pure phosphatidylcholine vesicles or in a noninhibitory detergent was not a substrate for GRK2. However, these receptor preparations were stoichiometrically phosphorylated in an agonist-dependent manner upon addition of charged phospholipids. The known ability of G protein beta gamma subunits to stimulate mAChR phosphorylation also was found to be absolutely dependent on the presence of charged phospholipids, including phosphatidylinositol 4,5-bisphosphate (PIP2). Phospholipids also regulated GRK-mediated phosphorylation of casein, a nonreceptor-soluble substrate. Among lipids tested, lipid inositol phosphates, PIP2 and phosphatidylinositol 4-monophosphate, were found to be the most potent activators of GRK2 and were the only lipids that regulated GRK2 in a complex biphasic manner. At low mu M concentrations, PIP2 activated GRK2 via an interaction with the GRK pleckstrin homology domain; however, at high mu M concentrations, PIP2 inhibited GRK2, apparently via another mechanism. PIP2-mediated inhibition could be partly relieved by increasing ATP. The results support the hypothesis that GRK2 is a lipid-dependent protein kinase that requires charged phospholipids for enzyme activation, for regulation by G(beta gamma) subunits, and potentially for membrane association.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,INST NEUROSCI,CHICAGO,IL 60611; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Northwestern University; Northwestern University; Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50121] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DEBBURMAN SK, 1995, MOL B INT U, P209; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1994, REGULATION CELLULAR, P71; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERSON GL, 1995, J BIOL CHEM, V270, P17808, DOI 10.1074/jbc.270.30.17808; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; QUINN PJ, 1976, MOL BIOL CELL MEMBRA, P33; REN Q, 1993, J BIOL CHEM, V268, P16483; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SIBLEY DR, 1987, CELL, V48, P914; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TSUGA H, 1994, J BIOL CHEM, V269, P32522; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	79	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22552	22562		10.1074/jbc.271.37.22552	http://dx.doi.org/10.1074/jbc.271.37.22552			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798423	hybrid			2022-12-25	WOS:A1996VG67200042
J	Friedman, TM; Reddy, AP; Wassell, R; Jameson, BA; Korngold, R				Friedman, TM; Reddy, AP; Wassell, R; Jameson, BA; Korngold, R			Identification of a human CD4-CDR3-like surface involved in CD4(+) T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS GP120; TYROSINE-PROTEIN-KINASE; CLASS-II MHC; CROSS-LINKING; MONOCLONAL-ANTIBODY; RECEPTOR COMPLEX; LYMPHOCYTES-T; ANTIGEN; CD8; BINDING	The CD4 molecule is expressed on the surface of helper T cells, This molecule contains four tandem external immunoglobulin-like domains (D1-D4), a transmembrane domain, and a cytoplasmic tail, Through the use of molecular modeling techniques, peptide analogs of the CDR3-like region of the human CD4 molecule, analog hPGP, a cyclized peptide 13 amino acids long, was synthesized and tested for its ability to inhibit proliferation in human mixed lymphocyte reactions. A conservative amino acid substitution was made at position 5 (D --> N) to increase its activity and designated hPGP(N), A series of alanine substitution peptides were synthesized based on the sequence of hPGP(N) to determine the importance of each residue to the peptide's function, The substitutions of amino acids in positions 3, 7, and 8 had essentially no effect on the inhibitory activity of hPGP(N), while substitutions of amino acids in positions 4 and 6 increased its inhibitory effect. Alanine substitutions of amino acids in positions 2, 5, and 9 dramatically decreased the inhibitory effect of analog hPGP(N), Molecular modeling of the native CD4-CDR3-like domain suggested that the residues corresponding to positions 2, 5, and 9 of the peptide formed a contiguous surface representing the active site.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University			Korngold, Robert/AAF-2686-2020					ANDERSON P, 1987, J IMMUNOL, V139, P678; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1987, EUR J IMMUNOL, V17, P529, DOI 10.1002/eji.1830170415; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MCDONNELL JM, 1992, IMMUNOMETHODS, V1, P33; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; RIVAS A, 1988, J IMMUNOL, V140, P2912; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1985, NATURE, V314, P579, DOI 10.1038/314579a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZERBIB AC, 1994, J EXP MED, V179, P1973, DOI 10.1084/jem.179.6.1973	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22635	22640		10.1074/jbc.271.37.22635	http://dx.doi.org/10.1074/jbc.271.37.22635			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798434	hybrid			2022-12-25	WOS:A1996VG67200053
J	Hill, JS; Davis, RC; Yang, D; Wen, J; Philo, JS; Poon, PH; Phillips, ML; Kempner, ES; Wong, H				Hill, JS; Davis, RC; Yang, D; Wen, J; Philo, JS; Poon, PH; Phillips, ML; Kempner, ES; Wong, H			Human hepatic lipase subunit structure determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIPOPROTEIN-LIPASE; HIGH-DENSITY-LIPOPROTEINS; RECEPTOR-RELATED PROTEIN; AMINO-ACID SEQUENCE; TRIGLYCERIDE LIPASE; RADIATION INACTIVATION; PANCREATIC LIPASE; RAT-LIVER; CHIMERIC LIPASE; MOLECULAR-SIZE	Chinese hamster ovary cells were stably transfected with a human hepatic lipase (HL) cDNA. The recombinant enzyme was purified from culture medium in milligram quantities and shown to have a molecular weight, specific activity, and heparin affinity equivalent to HL present in human post-heparin plasma. The techniques of intensity light scattering, sedimentation equilibrium, and radiation inactivation were employed to assess the subunit structure of HL. For intensity light scattering, purified enzyme was subjected to size exclusion chromatography coupled to three detectors in series: an ultraviolet absorbance monitor, a differential refractometer, and a light scattering photometer. The polypeptide molecular weight (without carbohydrate contributions) was calculated using the measurements from the three detectors combined with the extinction coefficient of human HL. A single protein peak containing HL activity was identified and calculated to have a molecular mass of 107,000 in excellent agreement with the expected value for a dimer of HL (106.8 kDa). In addition, sedimentation equilibrium studies revealed that HL had a molecular mass (with carbohydrate contributions) of 121 kDa, Finally, to determine the smallest structural unit required for lipolytic activity, HL was subjected to radiation inactivation, Purified HL was exposed to various doses of high energy electrons at -135 degrees C; lipase activity decreased as a single exponential function of the radiation dose to less than 0.01% remaining activity, The target size of functional HL was calculated to be 109 kDa, whereas the size of the structural unit was determined to be 63 kDa. These data indicate that two HL monomer subunits are required for lipolytic activity, consistent with an HL homodimer. A model for active dimeric hepatic lipase is presented with implications for physiological function.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90024; AMGEN INC,THOUSAND OAKS,CA 91320; NIAMS,PHYS BIOL LAB,NIH,BETHESDA,MD 20892	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Amgen; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hill, JS (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,LIPID RES LAB,11301 WILSHIRE BLVD,BLDG 113,RM 312,LOS ANGELES,CA 90073, USA.			Philo, John/0000-0003-3418-0356	NHLBI NIH HHS [HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; BARRANS A, 1994, J BIOL CHEM, V269, P11572; BENZEEV O, 1987, BIOCHIM BIOPHYS ACTA, V919, P13, DOI 10.1016/0005-2760(87)90212-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG CF, 1985, J BIOL CHEM, V260, P720; CLAY MA, 1991, ARTERIOSCLER THROMB, V11, P415, DOI 10.1161/01.ATV.11.2.415; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; DICHEK HL, 1993, J LIPID RES, V34, P1393; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HIDE WA, 1992, J LIPID RES, V33, P167; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; HORNICK CA, 1992, J BIOL CHEM, V267, P3396; IKEDA Y, 1989, BIOCHIM BIOPHYS ACTA, V1003, P254, DOI 10.1016/0005-2760(89)90231-2; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; JI ZS, 1994, J BIOL CHEM, V269, P13429; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; MARTEAU C, 1988, LIFE SCI, V42, P533, DOI 10.1016/0024-3205(88)90094-X; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; Olive C, 1975, Methods Enzymol, V41, P196; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; ROVERY M, 1978, BIOCHIM BIOPHYS ACTA, V525, P373, DOI 10.1016/0005-2744(78)90232-2; SHAFI S, 1994, J LIPID RES, V35, P709; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; TAKAGI T, 1983, J CHROMATOGR, V280, P124; TWU JS, 1984, BIOCHIM BIOPHYS ACTA, V792, P330, DOI 10.1016/0005-2760(84)90201-7; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG H, 1994, J BIOL CHEM, V269, P10319; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	48	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22931	22936		10.1074/jbc.271.37.22931	http://dx.doi.org/10.1074/jbc.271.37.22931			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798474	hybrid			2022-12-25	WOS:A1996VG67200093
J	Lefebvre, V; Mechin, MC; Louckx, MP; Rider, MH; Hue, L				Lefebvre, V; Mechin, MC; Louckx, MP; Rider, MH; Hue, L			Signaling pathway involved in the activation of heart 6-phosphofructo-2-kinase by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; PHOSPHATIDYLINOSITOL 3-KINASE; RAT-HEART; FRUCTOSE-2,6-BISPHOSPHATE CONTENT; GLUCOSE-UTILIZATION; MOLECULAR-CLONING; S6 KINASE; 2 FORMS; INHIBITION	Incubation of isolated rat cardiomyocytes with insulin increased 2-deoxyglucose uptake, glycogen synthesis, and fructose 2,6-bisphosphate content. Half-maximal effects were obtained with 1-2 nM insulin. The insulin-induced increase in fructose 2,6-bisphosphate content was preceded by a 2-3-fold activation of 6-phosphofructo-2-kinase, which was independent of glucose transport. Insulin activated phosphatidylinositol 3-kinase and p70 ribosomal S6 kinase (p70 S6 kinase), but had no significant effect on mitogen-activated protein kinase, although phorbol 12-myristate 13-acetate activated the latter, The effect of insulin on fructose 2,6-bisphosphate, 6-phosphofructo-2-kinase, and phosphatidylinositol 3-kinase was blocked by wortmannin. However, rapamycin, which inhibited p70 S6 kinase activation, and PD 98059, an inhibitor of the mitogen-activated protein kinase pathway, had no effect on the insulin-induced activation of 6-phosphofructo-2-kinase. Heart 6-phosphofructo-2-kinase can therefore be regarded as a glycolytic target of insulin. Its activation by insulin might be mediated by phosphatidylinositol 3-kinase.	UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOL PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DEPRE C, 1993, J BIOL CHEM, V268, P13274; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FISCHER Y, 1991, LIFE SCI, V49, P1679, DOI 10.1016/0024-3205(91)90310-8; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HUE L, 1982, J BIOL CHEM, V257, P4308; HUE L, 1995, BIOCHEM SOC T, V23, P311, DOI 10.1042/bst0230311; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; HUE L, 1988, BIOCHEM J, V251, P541, DOI 10.1042/bj2510541; HUNTER T, 1995, CELL, V89, P1; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAWSON JWR, 1987, J BIOL CHEM, V262, P3165; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MOWBRAY J, 1973, EUR J BIOCHEM, V36, P362, DOI 10.1111/j.1432-1033.1973.tb02920.x; OKADA T, 1994, J BIOL CHEM, V269, P3563; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118	36	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22289	22292		10.1074/jbc.271.37.22289	http://dx.doi.org/10.1074/jbc.271.37.22289			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798384	hybrid			2022-12-25	WOS:A1996VG67200003
J	Simonian, PL; Grillot, DAM; Merino, R; Nunez, G				Simonian, PL; Grillot, DAM; Merino, R; Nunez, G			Pax can antagonize Bcl-X(L) during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-X(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 HOMOLOG BAK; APOPTOSIS; SURVIVAL; EXPRESSION; GENE; MODULATION; PROTEINS; DISTINCT; CANCER; FAMILY	Bax, a member of the Bcl-2 family of proteins, has been shown to promote apoptosis while other members of the family, including Bcl-X(L) and Bcl-2, inhibit cell death induced by a variety of stimuli. The mechanism by which Bax promotes cell death is poorly understood. In the present report, we assessed the ability of Pax to antagonize the death repressor activity of Bcl-X(L) during chemotherapy-induced apoptosis in the lymphoid cell line, FL5.12. Expression of wild-type Bax countered the repressor activity of Bcl-X(L) against cell death mediated by VP-16 and cisplatin. We performed site-directed mutagenesis of the BH1, BH2, and BH3 homology regions in Bax to determine the ability of wild-type and mutant Bax to heterodimerize with Bcl-X(L) and to antagonize the protective effect of Bcl-X(L) against chemotherapy-induced apoptosis. Bax proteins expressing alanine substitutions of the highly conserved amino acids glycine 108 in BH1, tryptophan 151 and 158 in BH2, and glycine 67 and aspartic acid 68 in BH3 retained their ability to promote chemotherapy-induced cell death that was inhibited by Bcl-X(L) and to form heterodimers with Bcl-X(L). Bax proteins containing deletions of the most highly conserved amino acids in BH1 (Delta 102-112) and BH2 (Delta 151-159) maintained the ability of Pax to antagonize the death repressor activity of Bcl-X(L) and to associate with Bcl-X(L). However, Bax with BH3 deleted did not form heterodimers with Bcl-X(L), but retained its ability to counter the death repressor activity of Bcl-X(L). These results demonstrate that the conserved BH3, but not BH1 or BH2, homology region of Pax is necessary for its interaction with Bcl-X(L) in mammalian cells. Furthermore, our results indicate that Pax does not require BH1, BH2, BH3, or heterodimerization with Bcl-X(L) to counter the death repressor activity of Bcl-X(L). Therefore, Pax can antagonize Bcl-X(L) during VP-16 and, in a lesser degree, during cisplatin-induced cell death independent of its heterodimerization with Bcl-X(L).	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, CTR COMPREHENS CANC, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Merino, Ramón/L-1310-2014; Nuñez, Gabriel/A-7160-2014	Merino, Ramón/0000-0002-5306-0635; 	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HAN Z, 1996, GENE DEV, V10, P461; Innis MA, 1990, PCR PROTOCOLS GUIDE; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MERINO R, 1995, J IMMUNOL, V155, P3830; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1993, BLOOD, V81, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	28	102	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22764	22772		10.1074/jbc.271.37.22764	http://dx.doi.org/10.1074/jbc.271.37.22764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798452	hybrid			2022-12-25	WOS:A1996VG67200071
J	Vexler, ZS; Symons, M; Barber, DL				Vexler, ZS; Symons, M; Barber, DL			Activation of Na+-H+ exchange is necessary for RhoA-induced stress fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; BINDING PROTEIN; DICTYOSTELIUM-DISCOIDEUM; RAS TRANSFORMATION; HL-60 CELLS; ANTIPORTER; GROWTH; KINASE; FIBROBLASTS; DEPENDENCE	The ubiquitously expressed Na+-H+ exchanger isoform, NHE1, functions in regulating intracellular pH and cell volume, We recently determined that the GTPase G alpha 13 stimulates NHE1 activity through a RhoA-dependent mechanism (Hooley, R., Yu, C.-Y., Symons, M., and Barber, D. L. (1996) J. Biol. Chem. 271, 6152-6158). RhoA belongs to the Ras superfamily of GTPases and is a key regulator of actin stress fiber formation. We therefore investigated the relationship between RhoA, NHE1 activity, and the regulation of stress fiber assembly, Using two independent approaches, pharmacological inhibition of NHE1 and NHE1-deficient cells, we determined that the induction of stress fibers by lysophosphatidic acid and RhoA is dependent on increased NHE1 activity. These results indicate that stimulation of NHE1 acts downstream of RhoA in a pathway that controls stress fiber formation.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; ONYX PHARMACEUT,RICHMOND,CA 94806	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40259] Funding Source: Medline; NIGMS NIH HHS [GM 47413] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; HAZAV P, 1989, CANCER RES, V49, P72; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KITRAMURA K, 1995, AM J PHYSIOL, V268, pC101; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MALY K, 1989, J BIOL CHEM, V264, P11839; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHMIDT JM, 1993, BIOCHEM BIOPH RES CO, V197, P660, DOI 10.1006/bbrc.1993.2530; SCHWARTZ MA, 1990, J BIOL CHEM, V265, P1327; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	30	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22281	22284		10.1074/jbc.271.37.22281	http://dx.doi.org/10.1074/jbc.271.37.22281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798382	hybrid			2022-12-25	WOS:A1996VG67200001
J	Darmon, AJ; Bleackley, RC				Darmon, AJ; Bleackley, RC			An interleukin-1 beta converting enzyme-like protease is a key component of Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; CELL-DEATH; GRANZYME-B; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; DNA FRAGMENTATION; INVOLVEMENT; HYBRIDOMAS; ENCODES	Cytotoxic T lymphocytes (CTLs) are able to kill target cells bearing foreign antigen through two distinct mechanisms: granule- and Fas-mediated cytotoxicity. The exact events involved in the induction of target cell apoptosis remain elusive, but research indicates a role for members of the interleukin-lp converting enzyme (ICE)/Ced-3 family of cysteine proteases, The exact nature of the protease(s) involved is yet to be determined. Here we use activity assays and peptide inhibitors of ICE/Ced-3 proteases to study their role in Fas-mediated killing. We find that while certain inhibitors block DNA fragmentation and chromium release, others do not. Most notably, potent inhibitors of CPP32 and ICE could not inhibit DNA fragmentation during all cases of Fas-mediated cytotoxicity although an ''ICE'' inhibitor could suppress Cr-51 release. Additionally, we find that CPP32 is not cleaved in all target cells during Fas killing. Although ICE activity (as measured by a fluorogenic substrate) is present in cell lysates from anti-Fas-treated cells, we found no pro-IL-1 beta-cleaving activity in these lysates. Taken together, our results suggest that an alternate pathway to DNA fragmentation exists, which does not involve CPP32 activity, and that CPP32 and ICE activities are not essential to Fas-mediated killing.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GARNER R, 1994, J IMMUNOL, V153, P5413; HELGASON CD, 1992, EUR J IMMUNOL, V22, P3187, DOI 10.1002/eji.1830221225; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2502, DOI 10.1073/pnas.78.4.2502; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Podack E R, 1995, Curr Top Microbiol Immunol, V198, P121; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21699	21702		10.1074/jbc.271.36.21699	http://dx.doi.org/10.1074/jbc.271.36.21699			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702962	hybrid			2022-12-25	WOS:A1996VF61200004
J	Hayashida, W; Horiuchi, M; Dzau, VJ				Hayashida, W; Horiuchi, M; Dzau, VJ			Intracellular third loop domain of angiotensin II type-2 receptor - Role in mediating signal transduction and cellular function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SMOOTH-MUSCLE CELLS; G-PROTEIN; CYTOPLASMIC DOMAINS; TRANSCRIPTION FACTOR; MAP KINASE; INHIBITION; EXPRESSION; PHOSPHATASE; CLONING	The present study tests the hypothesis that the unique intracellular third loop domain of angiotensin II type-2 (AT2) receptor is essential for the subsequent intracellular signaling and plays an important role in mediating receptor function, Synthetic intracellular third loop peptide of the AT2 receptor (AT2-3LP, 22 amino acids) and control peptide consisting of the same amino acid composition in random sequence were delivered into adult rat aortic vascular smooth muscle cells by cationic liposome-mediated transfection. Successful intracellular peptide delivery was confirmed by microscopic localization of the fluorescein-labeled AT2-3LP within the cells and also by co-immunoprecipitation of the I-125-labeled 3LP complexed with G(i) protein using anti-G(i) alpha antibody. The AT2-3LP-transfected cells showed reduction of serum-stimulated DNA synthesis and cell proliferation as well as a decrease in mitogen-activated protein kinase activity, simulating the effects of AT2 receptor stimulation. The antagonistic effect of the AT2-3LP on mitogen-activated protein kinase activity and DNA synthesis were reversed by pertussis toxin and sodium orthovanadate. Thus, our data suggest that the intracellular third loop domain of the AT2 receptor is closely linked with the cellular signaling pathways of vascular smooth muscle cells in which G(i) and protein-phosphotyrosine phosphatase are involved, resulting in the alteration of mitogen-activated protein kinase activity and in growth inhibition.	STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, STANFORD, CA 94305 USA	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035252, R01HL035610, R37HL035610, R01HL046631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35252, HL46631, HL35610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; ELLWART J, 1985, CYTOMETRY, V6, P513, DOI 10.1002/cyto.990060605; FLOIO T, 1992, J BIOL CHEM, V267, P24169; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; HADCOCK JR, 1994, MOL PHARMACOL, V45, P410; HAWES BE, 1994, J BIOL CHEM, V269, P15776; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1995, AM J PHYSIOL-CELL PH, V268, pC278, DOI 10.1152/ajpcell.1995.268.1.C278; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; LIN MF, 1993, BIOCHEM BIOPH RES CO, V192, P413, DOI 10.1006/bbrc.1993.1431; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104; SADOSHIMA J, 1995, CIRC RES, V76, P1; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; TOBE K, 1991, J BIOL CHEM, V266, P24793; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZHANG JS, 1995, HYPERTENSION, V26, P567	35	94	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21985	21992		10.1074/jbc.271.36.21985	http://dx.doi.org/10.1074/jbc.271.36.21985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703004				2022-12-25	WOS:A1996VF61200046
J	Knofler, M; Krapp, A; Hagenbuchle, O; Wellauer, PK				Knofler, M; Krapp, A; Hagenbuchle, O; Wellauer, PK			Constitutive expression of the gene for the cell-specific p48 DNA-binding subunit of pancreas transcription factor 1 in cultured cells is under control of binding sites for transcription factors Sp1 and alpha Cbf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PTF1; DIFFERENTIAL EXPRESSION; INSULIN GENE; FORK-HEAD; PROMOTER; FAMILY; MYOD; RECOGNITION; DROSOPHILA; PROTEINS	We have cloned and characterized the rat gene that encodes the p48 DNA-binding subunit of pancreas transcription factor 1 (Ptf1), a cell-specific basic region helix-loop-helix (bHLH) protein, The ptf1-p48 gene measures 1.8 kilobases in size and occurs as a single copy in the haploid genome. Run-on transcription assays suggest that this gene is subject to transcriptional control since no activity of its promoter is detected in nonproducing cells. The gene specifies two mRNAs that encode the same protein and originate from transcription initiation at alternative sites. Expression analysis of hybrid genes bearing deletions of the gene's 5'-flanking region fused to a reporter gene defines a promoter region within the gene-proximal 260 base pairs of DNA. The cis-acting elements that control promoter activity include binding sites for transcription factors Sp1 and alpha Cbf, a 60-kDa CCAAT box-binding protein. The gene promoter, however, functions not only in exocrine pancreatic cells but also in cells of other origin. No cell-specific transcriptional control element was detected in as much as 10 kilobases of 5'-flanking region. We discuss models of how the cell-specific expression of the endogenous ptf1-p48 gene might be established during development of the animal.	SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research								BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GROUDINE M, 1982, CELL, V30, P131, DOI 10.1016/0092-8674(82)90019-8; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HAGENBUCHLE O, 1984, CELL, V38, P737, DOI 10.1016/0092-8674(84)90269-1; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; KRAPP A, 1996, IN PRESS EMBO J, V15; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PETRUCCO S, 1990, MOL CELL BIOL, V10, P254, DOI 10.1128/MCB.10.1.254; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WELLAUER PK, 1977, CELL, V10, P193, DOI 10.1016/0092-8674(77)90214-8; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0	47	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21993	22002						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703005				2022-12-25	WOS:A1996VF61200047
J	Ludlow, LB; Schick, BP; Budarf, ML; Driscoll, DA; Zackai, EH; Cohen, A; Konkle, BA				Ludlow, LB; Schick, BP; Budarf, ML; Driscoll, DA; Zackai, EH; Cohen, A; Konkle, BA			Identification of a mutation in a GATA binding site of the platelet glycoprotein Ib beta promoter resulting in the Bernard-Soulier Syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; LEUCINE-RICH REPEAT; GPIB-BETA; CHROMOSOMAL REGION; POINT MUTATION; IX COMPLEX; CELL-LINE; GENE; ALPHA; EXPRESSION	Bernard-Soulier Syndrome (BSS) is a rare congenital bleeding disorder due to absent or decreased expression of the glycoprotein Ib-IX-V (GpIb-IX-V) receptor complex on the platelet surface. To date, only mutations in GpIb alpha or GpIX have been reported in patients with BSS. GpIb beta differs from the other proteins in this receptor in that the gene is more complex, and an alternative form is expressed in cells of non-megakaryocytic lineage, including endothelial cells. It appears that the megakaryocytic and endothelial cell mRNA species are transcribed from different start sites and have different proximal promoter regions. We have identified a patient with ESS who has a deletion on one chromosome 22, resulting in velocardiofacial syndrome. The GpIb beta gene has been mapped to this deleted (22q11.2) region of chromosome 22. The patient has greatly reduced levels of GpIb beta mRNA and no detectable platelet GpIb beta protein, suggesting that his BSS results from a mutation in his remaining GpIb beta allele. Sequence analysis revealed that the coding region of GpIb beta is normal, but the 5'-upstream region contains a C to G transversion at base -133 from the transcription start site used in megakaryocytes. The mutation changes a GATA consensus binding site, disrupts GATA-1 binding to the mutated site, and decreases promoter activity by 84%. Thus, in this patient, Bernard-Soulier syndrome results from a deletion of one copy of GpIb beta and a mutated GATA binding site in the promoter of the remaining allele, resulting in decreased promoter function and GpIb beta gene transcription.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET & MOL BIOL,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA 19104	Jefferson University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Konkle, Barbara A/AAD-7712-2022; Konkle, Barbara/GPX-3325-2022	Konkle, Barbara A/0000-0002-3959-8797; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044956, P50HL051533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC002027] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44956, HL51533] Funding Source: Medline; NIDCD NIH HHS [DC02027] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BASTIAN LS, 1994, BLOOD, V84, pA471; BLOCK KL, 1994, BLOOD, V84, P3385; BUDARF ML, 1995, HUM MOL GENET, V4, P763, DOI 10.1093/hmg/4.4.763; CLEMETSON JM, 1994, BLOOD, V84, P1124; DELASALLE C, 1995, BRIT J HAEMATOL, V89, P386, DOI 10.1111/j.1365-2141.1995.tb03316.x; DEMARCO L, 1986, ACTA HAEMATOL-BASEL, V75, P203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DA, 1993, J MED GENET, V30, P813, DOI 10.1136/jmg.30.10.813; Emanuel Beverly S., 1993, V384, P207; FUGMAN DA, 1990, BLOOD, V75, P1252; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GOLDMUNTZ E, 1993, J MED GENET, V30, P807, DOI 10.1136/jmg.30.10.807; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; KELLY MD, 1994, J CLIN INVEST, V93, P2417, DOI 10.1172/JCI117249; KONKLE BA, 1994, BLOOD S, V84, P319; KUNISHIMA S, 1994, BLOOD, V84, P3356; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MILLER JL, 1992, BLOOD, V79, P439; NARAYANAN R, 1986, BIOCHEM BIOPH RES CO, V141, P1018, DOI 10.1016/S0006-291X(86)80146-2; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; SIMESK S, 1994, THROMB HAEMOSTASIS, V72, P444; SIMESK S, 1994, BRIT J HAEMATOL, V88, P839; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; UZAN G, 1991, J BIOL CHEM, V266, P8932; VIEILLEGROSJEAN I, 1995, J BIOL CHEM, V270, P4544, DOI 10.1074/jbc.270.9.4544; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WARE J, 1990, P NATL ACAD SCI USA, V87, P2026, DOI 10.1073/pnas.87.5.2026; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WRIGHT SD, 1993, BLOOD, V81, P2339; YAGI M, 1994, J BIOL CHEM, V269, P17424	37	117	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22076	22080		10.1074/jbc.271.36.22076	http://dx.doi.org/10.1074/jbc.271.36.22076			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703016	hybrid			2022-12-25	WOS:A1996VF61200058
J	Wang, HY; Johnson, GL; Liu, XX; Malbon, CC				Wang, HY; Johnson, GL; Liu, XX; Malbon, CC			Repression of adipogenesis by adenylyl cyclase stimulatory G-protein alpha subunit is expressed within region 146-220	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL LINE; NEOPLASTIC TRANSFORMATION; 3T3 CELLS; DIFFERENTIATION; MUTANT; FIBROBLASTS; ACTIVATION; CONVERSION; ADIPOCYTES; CULTURE	The heterotrimeric G-protein alpha subunit stimulatory with respect to adenylyl cyclase (G(s alpha)) represses adipogenesis of 3T3-L1 mouse embryonic fibroblasts. Derepression occurs in response to inducers, to oligodeoxynucleotides antisense to G(s alpha), and to overexpression of heterotrimeric G-protein alpha subunit 2, inhibitory with respect to adenylyl cyclase (G(i alpha 2)). Constitutive expression of G(s alpha) blocks adipogenesis and was exploited as an assay, in which chimeras of G(i alpha 2) and G(s alpha) were expressed stably in 3T3-L1 cells to define the region controlling adipogenesis. N-terminal analysis revealed region 146-220 of G(s alpha) as a repressor of adipogenesis; substitution of G(i alpha 2) abolished the ability of the chimera to repress adipogenesis in response to inducers. Expression of a chimera in which the 146-235 region of G(s alpha) was embedded in G(i alpha 2) fully repressed adipogenesis in response to the inducers. C-terminal analysis revealed no loss of function for truncated G(s alpha), lacking the terminal 38 residues. The repressor domain for adipogenesis maps to a region that includes switch domains I and II and is spatially distinct from the regions mapped for control of adenylyl cyclase.	SUNY STONY BROOK, UNIV MED CTR, DIABET & METAB DIS RES PROGRAM, DEPT MOL PHARMACOL, STONY BROOK, NY 11794 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT BASIC SCI, DENVER, CO 80206 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; National Jewish Health	Wang, HY (corresponding author), SUNY STONY BROOK, UNIV MED CTR, DEPT PHYS & BIOPHYS, STONY BROOK, NY 11794 USA.		malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang HY, 1996, INT J OBESITY, V20, pS26; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WATKINS DC, 1989, J BIOL CHEM, V264, P4186; WONG YH, 1995, ONCOGENE, V10, P1927	28	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22022	22029		10.1074/jbc.271.36.22022	http://dx.doi.org/10.1074/jbc.271.36.22022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703008				2022-12-25	WOS:A1996VF61200050
J	Cook, JL; Potter, TA; Bellgrau, D; Routes, BA				Cook, JL; Potter, TA; Bellgrau, D; Routes, BA			E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes	ONCOGENE			English	Article						oncogenes; NK cells; cytotoxic-T-lymphocytes; effector molecules; signaling molecules	NECROSIS-FACTOR-ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGENS; ADENOVIRUS-TRANSFORMED CELLS; CELLULAR CYTO-TOXICITY; MEDIATED CYTOTOXICITY; ACTIVATED MACROPHAGES; SURFACE ANTIGEN; MOUSE CELLS; C-MYC; LYSIS	E1A oncogene expression increases the susceptibility of cells from several species to lysis by natural killer lymphocytes (NK cells), We asked whether this E1A-induced cellular phenotypic conversion is specific for NK cell recognition interactions with target cells or whether it results from an E1A effect that is mediated independently of recognition, E1A-positive and E1A-negative cell pairs were compared for cytolytic susceptibility to other types of killer cells that use recognition mechanisms different from those of NK cells, E1A-positive, NK-susceptible target cells were also preferentially lysed by cytotoxic T lymphocytes (CTL) that recognize only foreign MHC molecules, lymphokine-activated T cells that lack recognition specificity, and CTL whose conventional recognition mechanisms were bypassed by lectin treatment of target cells, E1A expression increased cellular susceptibility to both major mechanisms of killer cell lysis-perforin/granzyme lysis and Fas-dependent lysis, Furthermore, anti-Fas antibody lysed E1A-positive, but not E1A-negative, cells expressing comparable levels of cell surface Fas antigen, These results indicate that a major mechanism by which E1A induces cellular susceptibility to lysis involves a stage in the interaction of killer cells with their targets that follows and is independent of cell surface recognition.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC IMMUNOL,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cook, JL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,ROBERT W LISLE RES LAB IMMUNOL & TUMOR CELL BIOL,DENVER,CO 80206, USA.				NCI NIH HHS [CA-43187] Funding Source: Medline; NIAID NIH HHS [AI-28115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELL SM, 1985, EUR J IMMUNOL, V15, P59, DOI 10.1002/eji.1830150112; BELLGRAU D, 1988, J VIROL, V62, P1513, DOI 10.1128/JVI.62.5.1513-1519.1988; BELLGRAU D, 1983, J EXP MED, V157, P1505, DOI 10.1084/jem.157.5.1505; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BONAVIDA B, 1985, J IMMUNOL, V135, P1616; BRADLEY TP, 1984, CELL IMMUNOL, V83, P199, DOI 10.1016/0008-8749(84)90239-9; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; COOK JL, 1982, INT J CANCER, V30, P795, DOI 10.1002/ijc.2910300619; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1993, ONCOGENE, V8, P625; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P2155, DOI 10.1128/JVI.61.7.2155-2161.1987; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GORMAN KC, 1987, J IMMUNOL, V138, P1014; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HADDADA H, 1986, P NATL ACAD SCI USA, V83, P9684, DOI 10.1073/pnas.83.24.9684; HADDADA H, 1988, ELL, V61, P2755; HUNIG T, 1984, J EXP MED, V159, P551, DOI 10.1084/jem.159.2.551; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KENYON DJ, 1991, VIROLOGY, V180, P818, DOI 10.1016/0042-6822(91)90099-W; KEREN Z, 1984, CELL IMMUNOL, V89, P458, DOI 10.1016/0008-8749(84)90347-2; KNALL C, 1995, INT IMMUNOL, V7, P995, DOI 10.1093/intimm/7.6.995; KOHL NE, 1987, ONCOGENE, V2, P41; Krantz CK, 1996, VIROLOGY, V217, P23, DOI 10.1006/viro.1996.0089; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1984, CURR TOP MICROBIOL, V110, P1; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PHILLIPS JH, 1986, J IMMUNOL, V136, P1579; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROUTES JM, 1990, J IMMUNOL, V144, P2763; ROUTES JM, 1995, VIROLOGY, V210, P421, DOI 10.1006/viro.1995.1358; SHANAHAN F, 1986, J IMMUNOL, V137, P723; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	51	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					833	842						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761305				2022-12-25	WOS:A1996VD43300019
J	Hofmann, TJ; Cole, MD				Hofmann, TJ; Cole, MD			The TAL1/Scl basic helix-loop-helix protein blocks myogenic differentiation and E-box dependent transactivation	ONCOGENE			English	Article						TAL1; leukemogenesis; bHLH; transactivation; myogenesis	T-CELL LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL-ACTIVATION; MYELOID DIFFERENTIATION; ENHANCER-BINDING; IN-VIVO; GENE; MOTIF; ONCOPROTEIN; ASSOCIATION	The TAL1 gene is transcriptionally activated by chromosomal translocation in the most common genetic lesion associated with T-cell acute lymphoblastic leukemia. TAL1 encodes a bHLH protein that exhibits sequence-specific DNA binding activity when it forms dimers with another bHLH protein such as E2A. We show that ectopic expression of TAL1 blocks the ability of the bHLH gene myogenin to induce myotube differentiation in C3H10T1/2 cells. Cotransfection of TAL1 with either myogenin or E2-5 suppresses the transcriptional activation function of each gene on its respective reporter constructs. TAL1 was as effective as Id in both transcriptional suppression and inhibition of differentiation. Deletion of the C-terminal domain of TAL1 reduces or eliminates its ability to suppress transcription while preserving the bHLH domain that determines the sequence-specificity of DNA binding. These data suggest that the C-terminal domain of TAL1 may directly mask the transactivation domain of E2A-related proteins. Since E2A-related genes are involved in lymphocyte differentiation, the dominant inhibition of E2A-related proteins may be the primary mechanism by which the TAL1 oncogene promotes leukemia.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University								APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BAIN G, 1994, CELL, V79, P85; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOYLE K, 1994, J BIOL CHEM, V269, P12099; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GOLDFARB AN, 1995, BLOOD, V85, P465; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	41	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					617	624						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760303				2022-12-25	WOS:A1996VB32800019
J	Duncan, JA; Gilman, AG				Duncan, JA; Gilman, AG			Autoacylation of G protein alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; BETA-GAMMA SUBUNITS; LIPID MODIFICATIONS; ESCHERICHIA-COLI; SF9 CELLS; PALMITOYLATION; ACYLATION; MYRISTOYLATION; PURIFICATION; EXPRESSION	The palmitoylation or S-acylation of at least some G protein cu subunits is a dynamic process that is regulated in vivo by the activation of associated receptors. Highly purified, myristoylated G(i alpha 1) and other G protein alpha subunits react spontaneously with palmitoyl-CoA in vitro to form thioesterified proteins. This reaction requires native G(i alpha 1) and occurs exclusively at Cys(3), the same residue that is palmitoylated in vivo. The reaction proceeds to completion, and its rate is roughly equal to the rate of loss of palmitate observed in pulse-chase experiments in vivo. The rate of autoacylation is significantly enhanced by the G protein py subunit complex. Autoacylation may play a role in the dynamic thioesterification of some cellular proteins.			Duncan, JA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM34497, T32 GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497, T32GM007062] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHIAUME L, 1995, J BIOL CHEM, V270, P22399; BHARADWAJ M, 1995, J NEUROCHEM, V65, P1805; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CAMP LA, 1993, J BIOL CHEM, V268, P22566; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEGTYAREV MY, 1995, J BIOL CHEM, V269, P30893; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON DR, 1994, ANN REV BIOCH, P63869; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NADLER MJS, 1994, BBA-LIPID LIPID MET, V1213, P100, DOI 10.1016/0005-2760(94)90227-5; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	34	162	164	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23594	23600		10.1074/jbc.271.38.23594	http://dx.doi.org/10.1074/jbc.271.38.23594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798571	hybrid			2022-12-25	WOS:A1996VH76800097
J	Funk, CD; Keeney, DS; Oliw, EH; Boeglin, WE; Brash, AR				Funk, CD; Keeney, DS; Oliw, EH; Boeglin, WE; Brash, AR			Functional expression and cellular localization of a mouse epidermal lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; CDNA CLONING; MOLECULAR-BIOLOGY; PLATELET-TYPE; SKIN; 12-LIPOXYGENASE; KERATINOCYTES; CELLS; 8-LIPOXYGENASE; 5-LIPOXYGENASE	Three distinct murine lipoxygenase genes have been functionally characterized: 5-lipoxygenase (Chen, X.-S., Naumann, T. A., Kurre, U., Jenkins, N. A., Copeland, N. G., and Funk, C. D. (1995) J. Biol. Chem. 270, 17993-17999), platelet-type 12-lipoxygenase and leukocyte-type 12-lipoxygenase (Chen, X.-S., Kurre, U., Jenkins, N. A., Copeland, N. G., and Funk, C. D. (1994) J. Biol. Chem. 269, 13979-13987). Here, we describe the cloning and functional characterization of a fourth lipoxygenase gene in mice. Using a polymerase chain reaction-based approach together with partial sequence information from a genomic clone, we isolated a novel lipoxygenase cDNA hom the RNA of 3-6-day old mouse epidermis. The open reading frame predicts a 662-amino acid lipoxygenase that displays 60% identity with both murine 12-lipoxygenase isozymes and 40% identity to 5-lipoxygenase; the sequence is identical to a genomic sequence reported recently (van Dijk, K. W., Steketee, K., Havekes, L., Frants, R., and Hofker, M. (1995) Biochim. Biophys. Acta 1259, 4-8). A full-length clone was expressed in human embryonic kidney 293 cells and homogenates from disrupted cells produced 12 hydroxyeicosatetraenoic acid (12-HETE) and minor amounts of 15-HETE from arachidonic acid. Chiral phase analysis indicated that the 12-HETE is exclusively the 12S enantiomer. In situ hybridization revealed highly specific expression of epidermal lipoxygenase in differentiated keratinocytes of the epidermis and in restricted regions of the root sheath and bulb of hair follicles. High expression was also detected in conjunctiva of the eyelid and in cells of Meibomian and preputial (sebaceous) glands. A 2.4-kilobase mRNA was detected in mouse epidermis by Northern blot analysis and its abundance was not affected by phorbol ester treatment. The epidermal lipoxygenase gene (Aloxe) resides on mouse chromosome 11 closely linked with the two 12-lipoxygenase genes (Alox12p and Alox12l).	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	Funk, CD (corresponding author), UNIV PENN,CTR EXPT THERAPEUT,STELLAR CHANCE LABS,RM 805,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233; Oliw, Ernst/0000-0002-7986-8130	NHLBI NIH HHS [HL53558] Funding Source: Medline; NIAMS NIH HHS [AR41943] Funding Source: Medline; NIGMS NIH HHS [GM49502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARENBERGER P, 1992, EUR J IMMUNOL, V22, P2469, DOI 10.1002/eji.1830220944; BICKERS DR, 1982, MOL PHARMACOL, V21, P239; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAMERON GS, 1990, J INVEST DERMATOL, V94, P292, DOI 10.1111/1523-1747.ep12874434; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWNING DT, 1992, J LIPID RES, V33, P301; FISCHER SM, 1988, CANCER RES, V48, P658; FREIREMOAR J, 1995, BBA-LIPID LIPID MET, V1254, P112, DOI 10.1016/0005-2760(94)00199-9; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GROSS E, 1990, J INVEST DERMATOL, V94, P446, DOI 10.1111/1523-1747.ep12874543; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; HENKE D, 1986, BIOCHIM BIOPHYS ACTA, V876, P271, DOI 10.1016/0005-2760(86)90284-5; HOGAN B, 1994, MANIPULATING MOUSE E, P327; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; JANSSENTIMMEN U, 1995, P NATL ACAD SCI USA, V92, P6966, DOI 10.1073/pnas.92.15.6966; KRIEG P, 1995, MOL CARCINOGEN, V14, P118, DOI 10.1002/mc.2940140208; MURRAY AW, 1980, J INVEST DERMATOL, V75, P508, DOI 10.1111/1523-1747.ep12524327; NAKADATE T, 1986, PROSTAG LEUKOTR ESS, V21, P305, DOI 10.1016/0262-1746(86)90051-X; NICOLAIDES N, 1974, SCIENCE, V186, P19, DOI 10.1126/science.186.4158.19; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; RUZICKA T, 1983, BIOCHIM BIOPHYS ACTA, V751, P369, DOI 10.1016/0005-2760(83)90295-3; RUZICKA T, 1992, EICOSANOIDS, V5, pS63; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; STEWART ME, 1995, J INVEST DERMATOL, V105, P613, DOI 10.1111/1523-1747.ep12323736; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P16443; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; VANDIJK KW, 1995, BBA-LIPID LIPID MET, V1259, P4, DOI 10.1016/0005-2760(95)00158-9; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	35	82	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23338	23344		10.1074/jbc.271.38.23338	http://dx.doi.org/10.1074/jbc.271.38.23338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798535	hybrid			2022-12-25	WOS:A1996VH76800061
J	Milani, D; Mazzoni, M; Borgatti, P; Zauli, G; Cantley, L; Capitani, S				Milani, D; Mazzoni, M; Borgatti, P; Zauli, G; Cantley, L; Capitani, S			Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; HIV-1 TAT; STIMULATES PRODUCTION; KINASE; PROLIFERATION; ADHESION; IDENTIFICATION; INHIBITION; APOPTOSIS; RECEPTORS	We have here investigated the effect of the regulatory Tat protein of the human immunodeficiency virus type 1 (HIV-1) on the PI 3-kinase catalytic activity in PC12 rat pheochromocytoma cells. After as early as 1 min from the beginning of the treatment with recombinant HIV-1 Tat protein, a significant increase in the tyrosine phosphorylation levels of the p85 regulatory subunit of PI 3-kinase was noticed in 48 h serum-starved PC12 cells. Moreover, the addition of Tat to PC12 cells induced a great increase in PI 3-kinase immunoprecipitated with an anti-phosphotyrosine antibody with a peak of activity (19-fold increase with respect to the basal levels) after a 15-min treatment. This increase in PI 3-kinase activity was significantly higher in PC12 cell cultures supplemented with Tat protein than in cultures stimulated by 100 ng/ml nerve growth factor (NGF; 8-fold increase with respect to the basal levels). Further experiments showed that Tat protein was able to specifically activate PI 3-kinase at picomolar concentrations, In fact: (i) maximal activation of PI 3-kinase was observed at concentrations as low as 1 ng/ml and was specifically blocked by anti-Tat neutralizing antibody; (ii) a Tat-dependent activation was also observed in experiments in which PI 3-kinase activity was evaluated in either anti-Tyr(P) or anti-p85 immunoprecipitates; (iii) 100 nM wortmannin completely blocked the Tat-mediated increase in PI 3-kinase activity both in vitro and in vivo. Our data strongly support the concept that extracellular Tat acts as a cell stimulator, inducing intracellular signal transduction in uninfected cells.	UNIV FERRARA,INST HUMAN ANAT,I-44100 FERRARA,ITALY; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02215	University of Ferrara; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center			Cantley, Lewis C/D-1800-2014; Zauli, Giorgio/ABE-8001-2020; Milani, Daniela/G-5579-2015	Cantley, Lewis C/0000-0002-1298-7653; Milani, Daniela/0000-0002-9540-7801; Zauli, Giorgio/0000-0002-3750-8698; CAPITANI, Silvano/0000-0003-2795-6814	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890, GM41890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LI CJ, 1995, SCIENCE, V268, P229; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3563; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WEEKS BS, 1993, J BIOL CHEM, V268, P5279; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306; ZAULI G, 1992, BLOOD, V80, P3036	27	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22961	22964		10.1074/jbc.271.38.22961	http://dx.doi.org/10.1074/jbc.271.38.22961			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798481	hybrid			2022-12-25	WOS:A1996VH76800007
J	Iwamoto, T; Watano, T; Shigekawa, M				Iwamoto, T; Watano, T; Shigekawa, M			A novel isothiourea derivative selectively inhibits the reverse mode of Na+/Ca2+ exchange in cells expressing NCX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; SMOOTH-MUSCLE CELLS; CARDIAC SARCOLEMMAL VESICLES; NA+-CA2+ EXCHANGER; AMILORIDE ANALOGS; PRIMARY CULTURE; MECHANISM; MYOCYTES; CLONING; ISOFORMS	No.7943 (2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulfonate), a selective inhibitor of the Na+/Ca2+ exchanger (NCX1), has been newly synthesized, It dose-dependently inhibited Na-i(+)-dependent Ca-45(2+) uptake and Na-i(+)-dependent [Ca2+](i) increase in cardiomyocytes, smooth muscle cells, and NCX1-transfected fibroblasts (IC50 = 1.2-2.4 mu M). Inhibition was observed without prior incubation with the agent and was completely reversed by washing cells with buffer for 1 min. Interestingly, No.7943 was much less potent in inhibiting Na-o(+)-dependent Ca-45(2+) efflux and Na-o(+)-induced [Ca2+](i) decline (IC50 = >30 mu M), indicating that it selectively blocks the reverse mode of Na+/Ca2+ exchange in intact cells. In cardiac sarcolemmal preparations consisting mostly of inside-out vesicles, the agent inhibited Na-i(+)-dependent Ca-45(2+) uptake and Na-o(+)-dependent Ca-45(2+) efflux with similar, but slightly lower, potencies (IC50 = 5.4-13 mu M). Inhibition was noncompetitive with respect to Ca2+ and Na+ in both cells and sarcolemmal vesicles. These results suggest that No.7943 primarily acts on external exchanger site(s) other than the transport sites in intact cells, although it is able to inhibit the exchanger from both sides of the plasma membrane, No.7943 at up to 10 mu M does not affect many other ion transporters nor several cardiac action potential parameters. This agent at these concentrations also did not influence either diastolic [Ca2+](i) or spontaneous beating in cardiomyocytes. Furthermore, No.7943 markedly inhibited Ca2+ overloading into cardiomyocytes under the Ca2+ paradox conditions. Thus, No.7943 is not only useful as a tool with which to study the transport mechanism and physiological role of the Na+/Ca2+ exchanger but also has therapeutic potential as a selective blocker of excessive Ca2+ influx mediated via the Na+/Ca2+ exchanger under pathological conditions.	NATL CARDIOVASC CTR, RES INST, DEPT MOL PHYSIOL, SUITA, OSAKA 565, JAPAN; KANEBO LTD, NEW DRUG RES LABS, OSAKA 534, JAPAN	National Cerebral & Cardiovascular Center - Japan								BERS DM, 1991, ANN NY ACAD SCI, V639, P375, DOI 10.1111/j.1749-6632.1991.tb17326.x; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P1; BOUCHARD RA, 1993, J PHYSIOL-LONDON, V469, P583, DOI 10.1113/jphysiol.1993.sp019831; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; CHAPMAN RA, 1987, PROG BIOPHYS MOL BIO, V50, P67, DOI 10.1016/0079-6107(87)90004-6; CHEN CM, 1971, J PHARMACOL EXP THER, V209, P415; Fiske CH, 1925, J BIOL CHEM, V66, P375; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; JONES LR, 1988, METHOD ENZYMOL, V157, P85; KACZOROWSKI GJ, 1989, SODIUM CALCIUM EXCHA, P66; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOHMOTO O, 1994, CIRC RES, V74, P550, DOI 10.1161/01.RES.74.3.550; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; Nakamura Aki, 1996, Japanese Journal of Pharmacology, V71, p310P; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OHSHIMA N, 1994, J BIOCHEM, V116, P274, DOI 10.1093/oxfordjournals.jbchem.a124519; Philipson K D, 1993, Int Rev Cytol, V137C, P199; PHILIPSON KD, 1985, BIOCHIM BIOPHYS ACTA, V821, P367, DOI 10.1016/0005-2736(85)90107-5; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SLAUGHTER RS, 1988, BIOCHEMISTRY-US, V27, P2403, DOI 10.1021/bi00407a023; TANI M, 1990, ANNU REV PHYSIOL, V52, P543; VEMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258, DOI 10.1016/0005-2736(88)90248-9; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467	36	438	450	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22391	22397		10.1074/jbc.271.37.22391	http://dx.doi.org/10.1074/jbc.271.37.22391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798401	hybrid			2022-12-25	WOS:A1996VG67200020
J	ONeill, TJ; Rose, DW; Pillay, TS; Hotta, K; Olefsky, JM; Gustafson, TA				ONeill, TJ; Rose, DW; Pillay, TS; Hotta, K; Olefsky, JM; Gustafson, TA			Interaction of a GRB-IR splice variant (a human GRB10 homolog) with the insulin and insulin-like growth factor I receptors - Evidence for a role in mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; YEAST HO GENE; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE AUTOPHOSPHORYLATION; INDUCED ACTIVATION; GLUCOSE-TRANSPORT; INTACT-CELLS; NPEY MOTIF; PROTEIN	We have utilized the yeast two-hybrid system to identify proteins that interact with the cytoplasmic domain of the insulin receptor. We identified a human cDNA that is a splice variant of the human GRB10 homolog GRB-IR, which we term GRB10/IR-SV1 (for GRB10/GRB-IR splice variant 1). The protein encoded by the GRB10/IR-SV1 cDNA contains an SH2 domain and a pleckstrin homology domain. Cloning of a full-length human cDNA revealed a predicted coding sequence that was similar to the mouse GRB10 protein, although GRB10/IR-SV1 contained an 80-amino acid deletion. The GRB10/IR-SV1 cDNA is a splice variant of the GRB-IR cDNA such that GRB10/IR-SV1 contains an intact pleckstrin homology domain and a distinct amino terminus. The interaction of GRB10/IR-SV1 with the insulin receptor and the insulin-like growth factor I (IGF-I) receptor is mediated by the SH2 domain, and we show that glutathione S-transferase-SH2 domain fusion proteins interact specifically in vitro with the insulin receptor derived from mammalian cells. The GRB10/IR-SV1 SH2 domain also interacted with an similar to 135-kDa phosphoprotein from unstimulated cell lysates, an interaction that decreased after insulin stimulation. We present evidence that the GRB10/IR-SV1 protein plays a functional role in insulin and IGF-I signaling by showing that microinjection of an SH2 domain fusion protein inhibited insulin- and IGF-I-stimulated mitogenesis in fibroblasts, yet had no effect on mitogenesis induced by epidermal growth factor. Our findings suggest that GRB10/IR-SV1 may serve to positively link the insulin and IGF-I receptors to an uncharacterized mitogenic signaling pathway.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego				pillay, tahir/0000-0002-9982-9710; Hotta, Kikuko/0000-0003-2427-6354	NIDDK NIH HHS [DK44093, DK50602, DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050602, R29DK044093, R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Miller J.H., 1972, EXPT MOL GENETICS; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1610; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUBIN R, 1995, LAB INVEST, V73, P311; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, J BIOL CHEM, V263, P2969; XIAO S, 1994, J BIOL CHEM, V269, P21244; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG B, 1991, J BIOL CHEM, V266, P990	53	129	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22506	22513		10.1074/jbc.271.37.22506	http://dx.doi.org/10.1074/jbc.271.37.22506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798417	hybrid			2022-12-25	WOS:A1996VG67200036
J	Ziober, BL; Kramer, RH				Ziober, BL; Kramer, RH			Identification and characterization of the cell type-specific and developmentally regulated alpha 7 integrin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; CREATINE-KINASE ENHANCER; RECEPTOR EPSILON-SUBUNIT; TRANS-ACTING FACTOR; CAT BINDING-FACTOR; TROPONIN-C GENE; SKELETAL-MUSCLE; CARDIAC-MUSCLE; CYTOPLASMIC DOMAINS; CD18 PROMOTER	Expression of alpha 7 is mainly confined to skeletal and cardiac muscle in which it appears to be the major laminin-binding integrin. When myoblasts differentiate to myotubes, alpha 7 mRNA and protein expression is up-regulated. To explore the mechanisms involved in the tissue-specific and developmentally regulated expression of alpha 7, we isolated and characterized a genomic clone containing similar to 2.8 kilobase pairs (kb) of the 5'-flanking region of the murine alpha 7 gene. The 5'-flanking region lacks both TATA and CCAAT boxes but contains five putative Sp1 binding sites located in a CpG island. Two transcription start sites, located near an initiator-like sequence, are 176 and 170 base pairs upstream of the translation start site. There are numerous binding sites for developmental and cell type-specific transcription factors, including AP-1, AP-2, GATA, and several AT-rich sites, There are also eight consensus E-boxes that bind the basic helix-loop-helix family of muscle-specific transcription factors. The similar to 2.8-kb 5'-flanking region was an active promoter in C2C12 skeletal myoblasts and exhibited increased expression upon conversion to myotubes but was inactive in HtLM2 cells, a mouse breast carcinoma epithelial cell line that does not express alpha 7. Deletion analysis identified both positive and negative regulatory elements within the similar to 2.8-kb fragment. In 10T1/2 fibroblasts the similar to 2.8-kb alpha 7 promoter was trans-activated by the myogenic basic helix-loop-helix proteins myogenin and MyoD but not by MRF4 and myf5. These results suggest that muscle-specific transcription factors play a role in regulating the cell-type expression of the alpha 7 gene during development.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA51884] Funding Source: Medline; NIDCR NIH HHS [DE10564, DE10306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306, R01DE010564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGURA ED, 1992, BLOOD, V79, P602; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOSMAN FT, 1993, HISTOCHEM J, V25, P469, DOI 10.1007/BF00159282; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BRANN TE, 1990, EMBO J, V9, P821; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P1156; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; COLLO G, 1993, J BIOL CHEM, V268, P19019; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAUFMAN SJ, 1985, J CELL BIOL, V100, P1977, DOI 10.1083/jcb.100.6.1977; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; LEUNG E, 1993, INT IMMUNOL, V5, P551, DOI 10.1093/intimm/5.5.551; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; Maniatis T, 1989, DECONTAMINATION DILU; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NUEDA A, 1993, J BIOL CHEM, V268, P19305; Olson EN, 1990, GENE DEV, V4, P1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSMARIN AG, 1992, BLOOD, V79, P2598; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; VILLAGARCIA M, 1994, BLOOD, V83, P668, DOI 10.1182/blood.V83.3.668.bloodjournal833668; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YANG JT, 1995, DEVELOPMENT, V121, P549; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	67	39	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22915	22922		10.1074/jbc.271.37.22915	http://dx.doi.org/10.1074/jbc.271.37.22915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798472	hybrid			2022-12-25	WOS:A1996VG67200091
J	Arai, H; Charo, IF				Arai, H; Charo, IF			Differential regulation of G-protein-mediated signaling by chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; HUMAN INTERLEUKIN-8 RECEPTOR; BETA-GAMMA-SUBUNITS; FUNCTIONAL EXPRESSION; THROMBIN RECEPTOR; CHEMOTACTIC CYTOKINES; MOLECULAR-CLONING; PHOSPHOLIPASE-C; CELLS; TRANSDUCTION	Monocyte chemoattractant protein-1 (MCP-1) is a member of a family of chemotactic cytokines that induce directed migration of leukocytes via activation of seven-transmembrane domain receptors. To identify G-proteins that couple to the two forms of the MCP-1 receptor, as well as to related chemokine receptors, we have performed cotransfection experiments in mammalian cells. In COS-7 cells, the type A and type B MCP-1 receptors coupled to G alpha(i), G alpha(q), and G alpha(16), whereas the macrophage inflammatory protein-1 alpha/RANTES (regulated on activation, normal T cell-expressed and secreted) receptor (C-CR1) coupled to G alpha(i) and G alpha(q) but failed to couple to G alpha(16). In HEK-293 cells, however, the MCP-1 receptors and C-CR1 coupled to G alpha(q) but failed to couple to G alpha(16). In contrast, the interleukin-8 and C5a receptors did not couple to G alpha(q) in either COS-7 or HEK-293 cells but did couple to G alpha(16). Exchange of intracellular loops between the MCP-1 and interleukin-8 receptors to create chimeric receptors revealed that the third loop of the MCP-1 receptor accounted for virtually all of the coupling to G alpha(q). We conclude that the MCP-1 and related chemokine receptors couple to multiple G-proteins, that coupling is cell type-specific, and that the third intracellular loop of the C-C type receptors mediates G alpha(q) coupling.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849	NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1993, J BIOL CHEM, V268, P9780; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kuang YN, 1996, J BIOL CHEM, V271, P3975; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SOZZANI S, 1991, J IMMUNOL, V147, P2215; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAUB DD, 1993, CYTOKINE, V5, P175, DOI 10.1016/1043-4666(93)90001-L; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; VANZEE KJ, 1992, J IMMUNOL, V148, P1746; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252	37	167	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21814	21819		10.1074/jbc.271.36.21814	http://dx.doi.org/10.1074/jbc.271.36.21814			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702980	hybrid			2022-12-25	WOS:A1996VF61200022
J	Jacquemin, P; Hwang, JJ; Martial, JA; Dolle, P; Davidson, I				Jacquemin, P; Hwang, JJ; Martial, JA; Dolle, P; Davidson, I			A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; SOMATOMAMMOTROPIN GENE ENHANCER; HEAVY-CHAIN GENE; UBIQUITOUS NUCLEAR PROTEINS; ALPHA-ACTIN GENE; SV40 ENHANCER; M-CAT; SACCHAROMYCES-CEREVISIAE; PLACENTAL-LACTOGEN; FACTOR TEF-1	We describe the molecular cloning of two novel human and murine transcription factors containing the TEA/ATTS DNA binding domain and related to transcriptional enhancer factor-1 (TEF-1). These factors bind to the consensus TEA/ATTS cognate binding site exemplified by the GT-IIC and Sph enhansons of the SV40 enhancer but differ in their ability to bind cooperatively to tandemly repeated sites. The human TEFs are differentially expressed in cultured cell lines and the mouse (m)TEFs are differentially expressed in embryonic and extra-embryonic tissues in early post-implantation embryos, Strikingly, at later stages of embryogenesis, mTEF-3 is specifically expressed in skeletal muscle precursors, whereas mTEF-1 is expressed not only in developing skeletal muscle but also in the myocardium. Together with previous data, these results point to important, partially redundant, roles for these TEF proteins in myogenesis and cardiogenesis. In addition, mTEF-1 is strongly coexpressed with mTEF-4 in mitotic neuroblasts, while accentuated mTEF-4 expression is also observed in the gut and the nephrogenic region of the kidney. These observations suggest additional roles for the TEF proteins in central nervous system development and organogenesis.	COLL FRANCE, CNRS INSERM ULP, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV LIEGE, INST CHIM B6, LAB BIOL MOL & GENIE GENET, B-4000 Sart Tilman Par Liege, BELGIUM	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Liege			Jacquemin, Patrick/ABA-7932-2021; Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090; Davidson, Irwin/0000-0001-5533-1171				ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CASAZ P, 1991, J VIROL, V65, P6535, DOI 10.1128/JVI.65.12.6535-6543.1991; CHAUDHARY S, 1995, J BIOL CHEM, V270, P3631, DOI 10.1074/jbc.270.8.3631; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GRUDA MC, 1991, J VIROL, V65, P3553, DOI 10.1128/JVI.65.7.3553-3558.1991; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; INAMDAR M, 1993, J NEUROGENET, V9, P123, DOI 10.3109/01677069309083454; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JACQUEMIN P, 1994, DNA CELL BIOL, V13, P1037, DOI 10.1089/dna.1994.13.1037; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KELLY JJ, 1991, NUCLEIC ACIDS RES, V19, P6799, DOI 10.1093/nar/19.24.6799; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; LYTRAS A, 1994, MOL ENDOCRINOL, V8, P478, DOI 10.1210/me.8.4.478; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649	66	107	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21775	21785		10.1074/jbc.271.36.21775	http://dx.doi.org/10.1074/jbc.271.36.21775			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702974	hybrid			2022-12-25	WOS:A1996VF61200016
J	LuKuo, JM; Austen, KF; Katz, HR				LuKuo, JM; Austen, KF; Katz, HR			Post-transcriptional stabilization by interleukin-1 beta of interleukin-6 mRNA induced by c-kit ligand and interleukin-10 in mouse bone marrow-derived mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); TUMOR-NECROSIS-FACTOR; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; 3' UNTRANSLATED REGION; STIMULATORY FACTOR-II; MESSENGER-RNA; IL-6 PRODUCTION; RICH SEQUENCES; EXPRESSION; GENE	We demostrate that a specific combination of cytokines elicits high levels of interleukin (IL)-6 gene expression in mast cells and define the cellular mechanisms of the exogenous cytokine action, The addition of c-hit ligand (KL) and IL-10 to IL-3-derived mouse bone marrow mast cells (BMMC) elicited an similar to 2-fold increase in steady-state IL-6 mRNA levels that peaked after 0.5 h and was followed by the release of similar to 0.2 ng of IL-6/10(6) cells by 5-7 h. The addition of IL-1 beta to KL + IL-10 elicited a prolonged similar to 12-fold increase in the level of IL-6 mRNA by 3-5 h and an similar to 50-fold increase in the level of IL-6 protein released by 7 h. As determined by nuclear run-on analysis, KL + IL-10 stimulated IL-6 gene transcription within 0.5 h, and the addition of IL-1 beta did not increase transcription. Instead, IL-1 beta slowed by similar to 8-fold the decay of IL-6 mRNA as compared to its decay in BMMC stimulated with KL + IL-10 alone, The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by similar to 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1 beta induces the synthesis of a protein that stabilizes IL-6 mRNA. The stabilization of IL-6 mRNA was inhibited by the addition of actinomycin D at 0.5 but not 3 h after BMMC were stimulated with IL-1 beta in combination with KL + IL-10, suggesting that once transcribed, the stabilizing protein is long-lived, The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1 beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA. Thus, there exists a novel Fc epsilon receptor type I-independent mechanism by which a mast cell can provide substantial amounts of IL-6 protein in response to the synergistic action of KL and IL-10 to induce IL-6 gene transcription, and IL-1 beta to stabilize otherwise short-lived IL-6 transcripts.	BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	LuKuo, JM (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,250 LONGWOOD AVE,RM 607,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031599, R37AI022531, R01AI022531, U01AI031599, T32AI007306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07306, AI-22531, AI-31599] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belasco J. G., 1993, CONTROL MESSENGER RN, P475; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1993, J IMMUNOL, V151, P3853; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CLARK SC, 1989, ANN NY ACAD SCI, V557, P438; ELIAS JA, 1991, J IMMUNOL, V146, P3437; ELIAS JA, 1990, J IMMUNOL, V145, P161; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NG SB, 1994, J BIOL CHEM, V269, P19021; OKADA S, 1995, J ALLERGY CLIN IMMUN, V95, P1236, DOI 10.1016/S0091-6749(95)70081-1; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAKAI Y, 1988, J IMMUNOL, V140, P508; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	34	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22169	22174		10.1074/jbc.271.36.22169	http://dx.doi.org/10.1074/jbc.271.36.22169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703029	hybrid			2022-12-25	WOS:A1996VF61200071
J	Pantaloni, C; Brabet, P; Bilanges, B; Dumuis, A; Houssami, S; Spengler, D; Bockaert, J; Journot, L				Pantaloni, C; Brabet, P; Bilanges, B; Dumuis, A; Houssami, S; Spengler, D; Bockaert, J; Journot, L			Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; SYMPATHETIC NEUROBLASTS; STRUCTURAL REQUIREMENTS; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; CHROMAFFIN CELLS; VIP RECEPTOR; I RECEPTOR; RAT-BRAIN	Pituitary adenylate cyclase-activating polypeptide (PACAP)-27 and PACAP-38 are neuropeptides of the vasoactive intestinal peptide/secretin/glucagon family. We previously described alternative splicing of the region encoding the third intracellular loop of the PACAP receptor generating six isoforms with differential signal transduction properties (Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H., and Journot, L. (1993) Nature 365, 170-175). In addition, we demonstrated that She potencies of the two forms of PACAP are similar for adenylate cyclase stimulation, whereas PACAP-38 is more potent than PACAP-27 in phospholipase C activation. In the present work, we document the existence of a new splice variant of the PACAP receptor that was characterized by a 21-amino-acid deletion in the N-terminal extracellular domain. We demonstrate that this domain modulates receptor selectivity with respect to PACAP-27 and -38 binding and controls the relative potencies of the two agonists in phospholipase C stimulation.	CNRS,INSERM,CTR PHARMACOL ENDOCRINOL,UPR 9023,F-34094 MONTPELLIER 05,FRANCE; MAX PLANCK INST PSYCHIAT,D-80804 MUNICH,GERMANY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Max Planck Society			Journot, Laurent/T-9652-2018; Brabet, Philippe/AAO-8522-2020; Bilanges, Benoit/AAP-6078-2020	Journot, Laurent/0000-0003-3499-8887; Brabet, Philippe/0000-0003-2739-1622; Bilanges, Benoit/0000-0003-4400-3716				AINO H, 1995, GENE, V164, P301, DOI 10.1016/0378-1119(95)00391-I; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; BASILLE M, 1995, J NEUROCHEM, V65, P1318; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLSON P, 1992, AM J PHYSIOL, V263, pE1054; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FAVIT A, 1995, NEUROENDOCRINOLOGY, V61, P377, DOI 10.1159/000126859; FRODIN M, 1995, NEUROSCIENCE, V65, P599, DOI 10.1016/0306-4522(94)00522-7; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; GOURLET P, 1991, EUR J BIOCHEM, V193, P535; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOSOYA M, 1993, BIOCHEM BIOPH RES CO, V194, P133, DOI 10.1006/bbrc.1993.1795; HOU X, 1994, NEUROPHARMACOLOGY, V33, P1189, DOI 10.1016/S0028-3908(05)80009-7; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; ISOKOBE K, 1993, ENDOCRINOLOGY, V132, P1757; JOURNOT L, 1994, SEMIN CELL BIOL, V5, P283; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; RAWLINGS SR, 1994, J BIOL CHEM, V269, P5680; RAWLINGS SR, 1993, ENDOCRINOLOGY, V132, P1447, DOI 10.1210/en.132.4.1447; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V195, P881, DOI 10.1006/bbrc.1993.2127; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; VIGH S, 1993, PEPTIDES, V14, P59, DOI 10.1016/0196-9781(93)90011-5; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; YADA T, 1993, PEPTIDES, V14, P235, DOI 10.1016/0196-9781(93)90035-F	41	186	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22146	22151		10.1074/jbc.271.36.22146	http://dx.doi.org/10.1074/jbc.271.36.22146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703026	hybrid			2022-12-25	WOS:A1996VF61200068
J	Ernstsson, S; Pierrou, S; Hulander, M; Cederberg, A; Hellqvist, M; Carlsson, P; Enerback, S				Ernstsson, S; Pierrou, S; Hulander, M; Cederberg, A; Hellqvist, M; Carlsson, P; Enerback, S			Characterization of the human forkhead gene FREAC-4 - Evidence for regulation by Wilms' tumor suppressor gene (WT-1) and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING MOTIF; CASEIN KINASE-II; TRANSCRIPTION FACTOR; ALVEOLAR RHABDOMYOSARCOMA; HEAD DOMAIN; WT1 GENE; MOUSE EMBRYOGENESIS; EXPRESSION; FAMILY; PROTEIN	We describe the cloning and sequence analysis of a nearly full-length cDNA as well as a corresponding 5.2-kilobase pair genomic fragment encoding FREAC-4, a member of the forkhead family of transcription factors, The cDNA is collinear with respect to the coding region of the intronless genomic clone. The conceptual translation product predicts a protein of 465 amino acids with a hyperacidic amino-terminal end, a DNA binding forkhead domain and a carboxyl-terminal part that is rich in homopolymeric runs of prolines and alanines. The transcription start is identified using an RNase protection assay. A 2.7-kilobase pair genomic DNA fragment, located immediately upstream of the translation start, was fused to a luciferase reporter gene. Significant levels of luciferase activity were detected when this construct was transfected into two kidney-derived cell lines, 293 and COS-7 cells, whereas only background reporter gene expression was observed in a cell line of nonkidney origin. Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with mutated p53, and a 4-fold repression with wild-type p53. A 5'-promoter deletion series delimits a DNA fragment necessary for WT-1 inducibility in cotransfection experiments. This fragment is shown to contain at least one cis-element that is capable of interacting with recombinant WT-1.	GOTHENBURG UNIV,DEPT MOL BIOL,LUNDBERG LAB,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg			Carlsson, Peter/B-5551-2008	Carlsson, Peter/0000-0001-6535-5927				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V119, P1301; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BRESLAUSIDERIUS EJ, 1993, HUM GENET, V92, P481, DOI 10.1007/BF00216455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DOWNING JR, 1995, AM J PATHOL, V146, P626; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; Frazier Gail C., 1994, Journal of Biological Chemistry, V269, P8892; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFMANN W, 1993, ONCOGENE, V8, P3123; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1993, ONCOGENE, V8, P1713; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MCGILLIVRAY BC, 1990, AM J MED GENET, V35, P10, DOI 10.1002/ajmg.1320350103; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHNEIDER S, 1993, HUM GENET, V91, P599; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHARMA PM, 1992, CANCER RES, V52, P6407; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	56	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21094	21099		10.1074/jbc.271.35.21094	http://dx.doi.org/10.1074/jbc.271.35.21094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702877	hybrid			2022-12-25	WOS:A1996VE47700023
J	Lechner, MS; Dressler, GR				Lechner, MS; Dressler, GR			Mapping of Pax-2 transcription activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED DOMAIN; TRANSACTIVATION PROPERTIES; SEQUENCE RECOGNITION; DNA-BINDING; WILMS-TUMOR; GENE; PROTEIN; CONSERVATION; MUTATION; ANIRIDIA	Pax genes encode transcription factors known to play crucial roles during the development of specific embryonic tissues. In humans and mice, several abnormalities have been linked to deficiencies in Pax gene dosage, indicating that normal development is particularly sensitive to the level of Pax gene expression. Despite these facts, relatively little is known about how these proteins act as transcriptional regulators, In this study we define the transactivation domains of murine Pax-2, an essential factor in kidney organogenesis. Within the COOH terminus of Pax-2, amino acids 279-373 are essential for transactivation. However, this region alone is insufficient for full transactivation when fused to the paired domain alone or to a heterologous DNA binding domain. Mutation or deletion of the conserved octapeptide sequence results in increased transactivation by Pax proteins. The octapeptide-mediated repression is also seen within a heterologous context using the GAL4 DNA binding domain. Thus transactivation by Pax-2 relies upon several regions within the COOH terminus and is down-modulated by the octapeptide element.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan								ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLST BD, 1994, J BIOL CHEM, V269, P22245; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Song DL, 1996, DEVELOPMENT, V122, P627; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; STUART ET, 1993, ANNU REV GENET, V27, P219; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Torres M, 1995, DEVELOPMENT, V121, P4057; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	32	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21088	21093		10.1074/jbc.271.35.21088	http://dx.doi.org/10.1074/jbc.271.35.21088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702876	hybrid			2022-12-25	WOS:A1996VE47700022
J	Shih, ML; Malbon, CC				Shih, ML; Malbon, CC			Protein kinase C deficiency blocks recovery from agonist-induced desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; CHROMOSOMAL LOCALIZATION; PHOSPHORYLATION SITES; CATALYTIC SUBUNIT; CALCINEURIN; ACTIVATION; PATHWAYS; CLONING; CELLS	Protein phosphorylation is central. to agonist-induced attenuation of the function of G-protein-linked receptors. Stable expression of RNA antisense to specific protein kinase mRNAs permitted analysis of loss-of-function mutants of A431 human epidermoid carcinoma cells, lacking protein kinase A, protein kinase C, or beta-adrenergic receptor kinase. Deficiency of protein kinase C, but not the others, amplified rather than attenuated agonist-induced desensitization. In wild-type cells, the t1/2 for recovery from desensitization was similar to 25 min following removal of agonist, In the protein kinase C-deficient cells, no resensitization was observed even 60 min after agonist removal. Like protein kinase C-deficiency, inhibition of protein kinase C with bisindolylmaleimide or calphostin C blocked resensitization. Resensitization was suppressed by FK506, all inhibitor of protein phosphatase 2B, mimicking protein kinase C-deficiency, but in a non-additive manner, The data reveal protein kinase C and protein phosphatase 2B to be critical elements of resensitization.	SUNY STONY BROOK,CTR MED,DEPT MOL PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1996, J BIOL CHEM, V271, P14939; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1991, FEBS LETT, V283, P122, DOI 10.1016/0014-5793(91)80568-N; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BURNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Sambrook J., 2002, MOL CLONING LAB MANU; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	33	27	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21478	21483		10.1074/jbc.271.35.21478	http://dx.doi.org/10.1074/jbc.271.35.21478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702931	hybrid			2022-12-25	WOS:A1996VE47700077
J	Tougu, K; Marians, KJ				Tougu, K; Marians, KJ			The extreme C terminus of primase is required for interaction with DnaB at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; POLYMERASE-III HOLOENZYME; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; IDENTIFICATION; PROTEINS; GENE; TRANSFORMATION; EFFICIENCY; MECHANISM	We have shown previously that a protein-protein interaction between DnaG and DnaB is required to attract the primase to the replication fork. This interaction was mediated by the C-terminal 16 kDa domain (p16) of the primase. A screen was developed that allowed the detection of mutant p16 proteins that did not interact with DnaB. Various mutagenesis protocols were used to localize this interaction domain to the extreme C terminus of the primase. A mutant primase missing only the C-terminal 16 amino acids was isolated and its activities examined. This mutant enzyme was fully active as a primase, but was incapable of interacting with DnaB. Thus, the mutant primase could not support DNA synthesis in either the general priming reaction or during phi X174 complementary strand DNA replication. Alanine cluster mutagenesis and deletion analysis in p16 allowed the further localization of the interaction domain to the extreme C-terminal 8 amino acids in primase.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Tougu, K (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1985, TRENDS GENET, V1, P26, DOI 10.1016/0168-9525(85)90011-3; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GROMPE M, 1991, J BACTERIOL, V173, P1268, DOI 10.1128/jb.173.3.1268-1278.1991; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Miller J.H., 1972, EXPT MOL GENETICS; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; MORTON RM, 1989, GENE, V77, P61; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SELICK HE, 1987, DNA REPLICATION RECO, P183; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WELCH MM, 1982, J BACTERIOL, V152, P351; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	34	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21391	21397		10.1074/jbc.271.35.21391	http://dx.doi.org/10.1074/jbc.271.35.21391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702920	hybrid			2022-12-25	WOS:A1996VE47700066
J	Wang, N; Weng, W; Breslow, JL; Tall, AR				Wang, N; Weng, W; Breslow, JL; Tall, AR			Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores - In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE UPTAKE; ESTERS; RAT; MECHANISM; LIVER; CELLS	Scavenger receptor BI (SR-BI), a putative high density lipoprotein (HDL) receptor, mediates the selective uptake of HDL cholesteryl ester into cells and is highly expressed in adrenal gland (Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996) Science 271, 518-520). Apolipoprotein A-I knock-out (apoA-I0) mice have decreased HDL cholesterol, depleted adrenal cholesterol stores and impaired corticosteroid synthesis (Plump, A. S., Erickson, S. K., Weng, W., Partin, J. S., Breslow, J. L., and Williams, D. L. (1996) J. Clin. Invest. 97, 2660-2671). We now show up-regulation of adrenal SR-BI mRNA and protein in apoA-I0 mice, but not in apoA-II0, LDL receptor 0, apoE0, or cholesteryl ester transfer protein transgenic mice. Adrenal SR-BI mRNA and protein are also increased and cholesterol stores decreased in female mice with knockout of hepatic lipase, an enzyme previously shown to increase selective uptake in cell culture. SR-BI mRNA is increased in stressed wild type mice and in Y1 adrenal cells treated with adrenocorticotropic hormone; the latter effect is inhibited by HDL. These findings provide in vivo evidence showing SR-BI is a functional HDL receptor under feedback control. The action of hepatic lipase on apoA-I-containing lipoproteins may facilitate the SR-BI-mediated uptake of HDL lipid.	COLUMBIA UNIV,DIV MOL MED,DEPT MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University			Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NHLBI NIH HHS [HL22682, HL54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, R37HL022682, R01HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; EISENBERG S, 1984, J LIPID RES, V25, P1017; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; NEWNHAM HH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P57, DOI 10.1016/0005-2760(90)90218-M; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; SMYTHE GA, 1983, ENDOCRINOLOGY, V113, P1062, DOI 10.1210/endo-113-3-1062; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837	16	194	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21001	21004		10.1074/jbc.271.35.21001	http://dx.doi.org/10.1074/jbc.271.35.21001			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8798380	hybrid			2022-12-25	WOS:A1996VE47700008
J	Liu, YZ; Dawson, SJ; Gerster, T; Friedl, E; Pengue, G; Matthias, P; Lania, L; Latchman, DS				Liu, YZ; Dawson, SJ; Gerster, T; Friedl, E; Pengue, G; Matthias, P; Lania, L; Latchman, DS			The ability of the inhibitory domain of the POU family transcription factor Oct-2 to interfere with promoter activation by different classes of activation domains is dependent upon the nature of the basal promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; IMMEDIATE-EARLY GENES; INFECTABLE SENSORY NEURONS; RNA-POLYMERASE-II; B-CELL; IMMUNOGLOBULIN GENES; REMOTE ENHANCER; MAMMALIAN GENE; OCTAMER MOTIF; PROTEIN	The Oct-2 transcription factor contains an inhibitory domain which is able to repress transcription following DNA binding, Here we show that within the neuronally expressed Oct-2.5 form, the inhibitory domain can strongly inhibit activation by transcription factor activation domains which are either composed predominantly of acidic residues or contain the HOB motif, whereas it has a weaker effect or no effect on proline-rich activation domains and on a glutamine rich domain, In contrast, the isolated inhibitory domain of Oct-2 can efficiently repress all types of activation domains, This effect is observed however, only on TATA box containing promoters and not on promoters containing an initiator motif. This widespread inhibition of different activation domains and its dependence on the nature of the basal promoter elements indicate that the inhibitory domain is likely to act by contacting a common downstream target of activation domains within the basal transcriptional complex bound at the TATA box rather than quenching specific activation domains by direct interaction, These effects are discussed in terms of the functional role of the inhibitory domain within Oct-2.5 and the mechanism by which it acts.	UCL, SCH MED, DEPT MOL PATHOL, LONDON W1P 6DB, ENGLAND; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND; UNIV NAPLES FEDERICO II, DIPARTIMENTO GENET, I-80134 NAPLES, ITALY	University of London; University College London; UCL Medical School; Friedrich Miescher Institute for Biomedical Research; University of Basel; University of Naples Federico II				Dawson, Sally/0000-0002-4421-2043				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BZIK DJ, 1986, NUCLEIC ACIDS RES, V14, P929, DOI 10.1093/nar/14.2.929; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAWSON SJ, 1994, NUCLEIC ACIDS RES, V22, P1023, DOI 10.1093/nar/22.6.1023; DENT CL, 1991, BIOCHEM J, V277, P541, DOI 10.1042/bj2770541; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; FRIEDL EM, 1995, EUR J BIOCHEM, V234, P308, DOI 10.1111/j.1432-1033.1995.308_c.x; GELMAN IH, 1987, J VIROL, V61, P3167, DOI 10.1128/JVI.61.10.3167-3172.1987; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LALLI E, 1994, J BIOL CHEM, V269, P17359; LATCHMAN DS, 1990, J EXP PATHOL, V71, P133; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILLYCROP KA, 1995, MOL BIOL REP, V21, P87, DOI 10.1007/BF00986498; LILLYCROP KA, 1994, MOL CELL BIOL, V14, P7633, DOI 10.1128/MCB.14.11.7633; LILLYCROP KA, 1992, J BIOL CHEM, V267, P24960; LILLYCROP KA, 1993, VIROLOGY, V196, P888, DOI 10.1006/viro.1993.1552; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MADDEN SL, 1993, ONCOGENE, V8, P1713; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROIZMAN B, 1987, ANNU REV MICROBIOL, V41, P543, DOI 10.1146/annurev.mi.41.100187.002551; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH RL, 1992, VIROLOGY, V188, P311, DOI 10.1016/0042-6822(92)90760-M; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STOYKOVA AS, 1992, NEURON, V841, P841; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHEATLEY SC, 1992, MOL BRAIN RES, V12, P149, DOI 10.1016/0169-328X(92)90078-P; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	61	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20853	20860		10.1074/jbc.271.34.20853	http://dx.doi.org/10.1074/jbc.271.34.20853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702841	hybrid			2022-12-25	WOS:A1996VD33700093
J	Pelicci, G; Dente, L; DeGiuseppe, A; VerducciGalletti, B; Giuli, S; Mele, S; Vetriani, C; Giorgio, M; Pandolfi, PP; Cesareni, G; Pelicci, PG				Pelicci, G; Dente, L; DeGiuseppe, A; VerducciGalletti, B; Giuli, S; Mele, S; Vetriani, C; Giorgio, M; Pandolfi, PP; Cesareni, G; Pelicci, PG			A family of Shc related proteins with conserved PTB, CH1 and SH2 regions	ONCOGENE			English	Article						Shc related proteins; modular organization; Shc family	PHOSPHOTYROSINE INTERACTION DOMAIN; GROWTH-FACTOR RECEPTOR; GRB2 ADAPTER PROTEINS; TYROSINE KINASES; SIGNAL-TRANSDUCTION; CONSTITUTIVE PHOSPHORYLATION; NUCLEOTIDE EXCHANGE; INSULIN-RECEPTOR; BETA-RECEPTOR; ERBB-2 KINASE	Shc proteins are targets of activated tyrosine kinases and have been implicated in the transmission of activation signals to Ras. Upon phosphorylation, Shc proteins form stable complexes with cellular tyrosine-phosphorylated proteins and with the Grb2 adaptor protein, Two Shc isoforms of 52 and 46 kDa have been characterized. They share a C-terminal SH2 domain, a proline- and glycine-rich region (collagen homologous region 1; CH1) and a N-terminal phospho-tyrosine binding domain (PTB), We report here the initial characterization of two Shc related human cDNAs: ShcB and ShcC. The ShcB and ShcC cDNAs code for proteins that are highly similar and share the same modular organization as Shc. PTB and SH2 domains of ShcB and ShcC have similar binding specificities in vitro and bind to activated EGFR in a phosphotyrosine-dependent manner. Based on these findings we propose to rename Shc as ShcA. Anti-ShcB and anti-ShcC antibodies recognize specific polypeptides of 52, 47 kDa (ShcB) and 54 kDa (ShcC) in mammalian cells. Since these two genes are predominantly expressed in specific brain tissues, these Shc family members may be involved in cell type-specific signaling, in the nervous system.	UNIV ROMA TOR VERGATA, DIPARTIMENTO BIOL, I-00173 ROME, ITALY; MEM SLOAN KETTERING CANC CTR, DEPT GENET, NEW YORK, NY 10021 USA; UNIV PERUGIA, IST MED INTERNA & SCI ONCOL, I-06122 PERUGIA, ITALY	University of Rome Tor Vergata; Memorial Sloan Kettering Cancer Center; University of Perugia	Pelicci, G (corresponding author), DEPT EXPTL ONCOL, IST EUROPEO ONCOL, VIA RIPAMONTI 435, I-20141 MILAN, ITALY.		Pelicci, Pier Giuseppe/AAL-6572-2020; Giorgio, Marco/I-9425-2012; Pelicci, Giuliana/AAA-8921-2022	Giorgio, Marco/0000-0002-5842-6042; Pelicci, Giuliana/0000-0003-0986-8255; DENTE, LUCIANA/0000-0002-9617-0922				BALDARI CT, 1995, ONCOGENE, V10, P1141; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CROWE AJ, 1994, ONCOGENE, V9, P537; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOTTI LV, 1995, IN PRESS MOL CELL BI; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	119	127	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					633	641						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760305				2022-12-25	WOS:A1996VB32800021
J	Gotz, C; Wagner, P; Issinger, OG; Montenarh, M				Gotz, C; Wagner, P; Issinger, OG; Montenarh, M			p21(WAF1/CIP1) interacts with protein kinase CK2	ONCOGENE			English	Article						p21(WAF1/CIP1); protein kinase CK2; phosphorylation; p53	DNA-BINDING FUNCTION; BETA-SUBUNIT; CASEIN KINASE-2; CELLULAR-REGULATION; SUPPRESSOR PROTEIN; ALPHA-SUBUNITS; XENOPUS-LAEVIS; HUMAN TUMORS; II ACTIVITY; P53	p21(WAF1/CIP1) which belongs to a class of regulatory proteins that interact with cyclin dependent kinases is a potent inhibitor of these kinases. The inhibition of the cyclin dependent kinases induces an arrest of cells in the G(1) phase of the cell cycle. In addition p21(WAF1/CIP1) associates with PCNA and inhibits DNA replication. Here, we show that p21(WAF1/CIP1) binds to the regulatory beta-subunit of protein kinase CK2 but not to the catalytic alpha-subunit. Binding of p21(WAF1/CIP1) down regulates the kinase activity of CK2 with respect to the phosphorylation of the beta-subunit of CK2, casein and the C-terminus of p53. This study demonstrates a new binding partner for the regulatory beta-subunit of protein kinase CK2 which regulates the activity of the holoenzyme.	UNIV SAARLAND, INST MED BIOCHEM, D-66421 HOMBURG, GERMANY; ODENSE UNIV, INST BIOKEM, DK-5230 ODENSE, DENMARK	Saarland University; University of Southern Denmark			Montenarh, Mathias/AAB-6689-2020					ALGHISI GC, 1994, CELL MOL BIOL RES, V40, P563; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BOLDYREFF B, 1994, CELL MOL BIOL RES, V40, P391; BOLDYREFF B, 1993, EUR J BIOCHEM, V218, P515, DOI 10.1111/j.1432-1033.1993.tb18404.x; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1995, INT J ONCOL, V7, P889; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOTZ C, 1995, EUR J BIOCHEM, V233, P327, DOI 10.1111/j.1432-1033.1995.327_1.x; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPER JW, 1993, CELL, V75, P805; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINRICHS MV, 1993, BIOCHEMISTRY-US, V32, P7310, DOI 10.1021/bi00079a030; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; KRAISS S, 1990, ONCOGENE, V5, P845; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIN WJ, 1994, BIOCHEMISTRY-US, V33, P6998, DOI 10.1021/bi00188a032; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LORENZ A, 1992, INT J ONCOL, V1, P571; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAENPAA PH, 1977, BIOCHIM BIOPHYS ACTA, V498, P294, DOI 10.1016/0304-4165(77)90267-7; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; MURRAY A, 1993, CELL CYCLE; NASTAINCZYK W, 1995, HYBRIDOMA, V14, P335, DOI 10.1089/hyb.1995.14.335; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PROWALD K, 1984, FEBS LETT, V176, P479, DOI 10.1016/0014-5793(84)81222-3; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SCHMIDTSPANIOL I, 1992, HYBRIDOMA, V11, P53, DOI 10.1089/hyb.1992.11.53; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; STURZBECHER HW, 1990, ONCOGENE, V5, P795; WAGNER P, 1994, INT J ONCOL, V4, P491; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	66	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					391	398						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710378				2022-12-25	WOS:A1996VA25200018
J	Daly, SE; Lane, LK; Blostein, R				Daly, SE; Lane, LK; Blostein, R			Structure/function analysis of the amino-terminal region of the alpha 1 and alpha 2 subunits of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; ADENOSINE-TRIPHOSPHATASE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; K+; NA+,K+-ATPASE; TRANSPORT; SODIUM; NA+; SUBSTITUTIONS	The alpha 2 isoform of the Na,K-ATPase exhibits kinetic behavior distinct from that of the alpha 1 isoform. The distinctive behavior is apparent when the reaction is carried out under conditions (micromolar ATP concentration) in which the K+ deocclusion pathway of the reaction cycle is rate-limiting; the alpha 1 activity is inhibited by K+, whereas alpha 2 is stimulated. When 32 NH2-terminal amino acid residues are removed from alpha 1, the kinetic behavior of the mutant enzyme (alpha 1M32) is similar to that of alpha 2 (Daly, S. E., Lane, L. K., and Blostein, R. (1994) J. Biol. Chem. 269, 23944-23948). In the current study, the region of the alpha 1 NH2 terminus involved in modulating this kinetic behavior has been localized to the highly charged sequence comprising residues 24-32. Within this nonapeptide, differences between alpha 1 and alpha 2 are conservative and are confined to residues 25-27. The behavior of two chimeric enzymes: (i) alpha 1 with the first 32 residues identical to the alpha 2 sequence, alpha 1 (1-32 alpha 2), and (ii) alpha 2 with the first 32 residues identical to the alpha 1 sequence, alpha 2(1-32 alpha 1), indicates that the distinctive kinetic behavior of alpha 1 and alpha 2 is not due to the 24-32 NH2-terminal domain, per se, but rather to its interaction with other, isoform-specific region(s) of the alpha 1-protein. We also demonstrate that the distinct K+ activation profiles of either alpha 2 or alpha 1M32, compared to alpha 1 is due to a faster release of K+ from the K+-occluded enzyme, and to a higher affinity for ATP. This was determined in studies using two approaches: (i) kinetic analysis of the reaction modeled according to a branched pathway of K+ deocclusion through low and high affinity ATP pathways and, (ii) measurements of the (rapid) phosphorylation of the enzyme (E(1) conformation) by [gamma-P-32]ATP following the rate-limiting formation of the K+-free enzyme from the K+-occluded state (E(2)(K) --> E(1) + K+). The observed kinetic differences between alpha 2 and alpha 1 suggest that these Na,K-ATPase isoforms differ in the steady-state distribution of E(1) and E(2) conformational states.	MCGILL UNIV, DEPT MED, MONTREAL, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA	McGill University; University of Cincinnati					NHLBI NIH HHS [HL 49204] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049204] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; DALY SE, 1994, J BIOL CHEM, V269, P23944; EISNER DA, 1981, J PHYSIOL-LONDON, V319, P403, DOI 10.1113/jphysiol.1981.sp013917; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1991, SOC GEN PHY, V46, P211; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1977, BIOCHIM BIOPHYS ACTA, V466, P97, DOI 10.1016/0005-2736(77)90211-5; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1993, J BIOL CHEM, V268, P17930; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Markwell M A, 1981, Methods Enzymol, V72, P296; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; POST RL, 1972, J BIOL CHEM, V247, P6530; SHANBAKY NM, 1994, AM J PHYSIOL, V267, pC590, DOI 10.1152/ajpcell.1994.267.2.C590; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; VASILETS LA, 1993, EUR BIOPHYS J BIOPHY, V21, P433, DOI 10.1007/BF00185871; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	27	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23683	23689		10.1074/jbc.271.39.23683	http://dx.doi.org/10.1074/jbc.271.39.23683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798590				2022-12-25	WOS:A1996VJ44200019
J	Hopf, FW; Reddy, P; Hong, J; Steinhard, RA				Hopf, FW; Reddy, P; Hong, J; Steinhard, RA			A capacitative calcium current in cultured skeletal muscle cells is mediated by the calcium-specific leak channel and inhibited by dihydropyridine compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PROTEIN-TYROSINE PHOSPHORYLATION; NEGATIVE MEMBRANE-POTENTIALS; PANCREATIC ACINAR-CELLS; ELEVATED FREE CALCIUM; MUSCULAR-DYSTROPHY; PERMEABLE CHANNELS; PLASMA-MEMBRANE; HUMAN PLATELETS; T-LYMPHOCYTES	Calcium stores from cultured skeletal muscle cells were depleted using cyclopiazonic acid (CPA), a reversible inhibitor of Ca2+-ATPases at the sarcoplasmic reticulum. Store depletion led to activation of the calcium-specific leak channel, as assayed using single-channel patch clamp analysis and rates of manganese influx and quenching of fura-2 fluorescence. Two novel dihydropyridine compounds inhibited this single-channel leak channel activity, the resting and depletion-induced manganese influx, and refilling of the CPA-depleted intracellular calcium store. These compounds represent the first antagonists for a calcium leak channel and for a channel that mediates a capacitative current. The development of the skeletal muscle capacitative current was inhibited by genistein, a tyrosine kinase inhibitor, but was not affected by okadaic acid, a phosphatase inhibitor, or econazole. Thus, the capacitative current in cultured skeletal muscle cells was mediated by the calcium leak channel and was inhibited by pharmacological antagonists and may provide a model system for uncovering the complete set of signals leading from store depletion to channel activation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041129] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR41129] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BAKKER AJ, 1993, J PHYSIOL-LONDON, V460, P1; Benham C D, 1987, Soc Gen Physiol Ser, V42, P45; BLINKS JR, 1978, J PHYSIOL-LONDON, V277, P291, DOI 10.1113/jphysiol.1978.sp012273; BRINKMEIER H, 1993, J ANIM SCI, V71, P1154, DOI 10.2527/1993.7151154x; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHUA M, 1991, BIOPHYS J, V59, P1251, DOI 10.1016/S0006-3495(91)82340-2; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CONSTANTIN B, 1993, CELL CALCIUM, V14, P135, DOI 10.1016/0143-4160(93)90083-I; COULOMBE A, 1989, J MEMBRANE BIOL, V111, P57, DOI 10.1007/BF01869209; COYNE MD, 1987, J MEMBRANE BIOL, V97, P205, DOI 10.1007/BF01869223; DENETCLAW WF, 1994, MOL BIOL CELL, V5, P1159, DOI 10.1091/mbc.5.10.1159; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, J PHYSIOL-LONDON, V427, P361, DOI 10.1113/jphysiol.1990.sp018176; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V416, P210, DOI 10.1007/BF00370245; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAVERSTICK DM, 1993, MOL BIOL CELL, V4, P173, DOI 10.1091/mbc.4.2.173; HAWS CM, 1991, P ROY SOC B-BIOL SCI, V245, P173, DOI 10.1098/rspb.1991.0105; HOPF FW, 1996, IN PRESS AM J PHYS; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; KIMURA M, 1994, J HYPERTENS, V12, P199; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG613, DOI 10.1152/ajpgi.1994.266.4.G613; KOIKE Y, 1994, CELL CALCIUM, V15, P381, DOI 10.1016/0143-4160(94)90013-2; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LEIPZIGER J, 1994, PFLUG ARCH EUR J PHY, V426, P427, DOI 10.1007/BF00388306; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; LUTTGAU HC, 1979, J PHYSIOL-LONDON, V296, P411; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATHES C, 1994, J GEN PHYSIOL, V104, P107, DOI 10.1085/jgp.104.1.107; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; MONTERO M, 1994, J BIOL CHEM, V269, P3963; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; NEGULESCU PA, 1995, AM J PHYSIOL-GASTR L, V269, pG770, DOI 10.1152/ajpgi.1995.269.5.G770; NEGULESCU PA, 1992, AM J PHYSIOL, V263, pC1310, DOI 10.1152/ajpcell.1992.263.6.C1310; NEHER E, 1992, NATURE, V355, P298, DOI 10.1038/355298a0; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RAYMOND G, 1987, CAN J PHYSIOL PHARM, V65, P704, DOI 10.1139/y87-116; ROED A, 1991, GEN PHARMACOL-VASC S, V22, P313, DOI 10.1016/0306-3623(91)90455-F; ROSENBERG RL, 1988, J GEN PHYSIOL, V92, P27, DOI 10.1085/jgp.92.1.27; ROTHMAN SM, 1983, ANN NEUROL, V13, P176, DOI 10.1002/ana.410130212; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; TEPEL M, 1994, J BIOL CHEM, V269, P26239; TSIEN RW, 1987, PROTEINS EXCITABLE M, P167; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; TURNER PR, 1993, J MEMBRANE BIOL, V133, P243; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; WILLIAMS JH, 1990, MUSCLE NERVE, V13, P1118, DOI 10.1002/mus.880131206; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	73	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22358	22367		10.1074/jbc.271.37.22358	http://dx.doi.org/10.1074/jbc.271.37.22358			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798397	hybrid			2022-12-25	WOS:A1996VG67200016
J	Kosovsky, MJ; Huan, BF; Siddiqui, A				Kosovsky, MJ; Huan, BF; Siddiqui, A			Purification and properties of rat liver nuclear proteins that interact with the hepatitis B virus enhancer 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTOR; DNA-BINDING SPECIFICITY; GENE-EXPRESSION; FORK-HEAD; HEPATOCELLULAR-CARCINOMA; POLYACRYLAMIDE GELS; DEFINITIVE ENDODERM; NUCLEOCAPSID GENE; PROMOTER ACTIVITY; CORE PROMOTER	The hepatitis B virus enhancer 1 element plays a fundamental role in the liver-specific regulation of hepatitis B virus gene expression. A central region of enhancer 1, the enhancer core domain, contains at least four cis-acting sequence motifs that are essential for enhancer 1 activity, In this study, we have investigated an essential motif within the core domain previously defined as footprint V (FPV). Transient transfection analyses demonstrate that FPV is capable of independently functioning in a liver-specific manner to activate transcription, Therefore, to further examine the liver-specific properties of FPV-mediated enhancer 1 activity, we have carried out the biochemical purification and characterization of FPV binding activity from rat liver nuclei. This study has conclusively identified hepatocyte nuclear factor 3 beta (HNF-3 beta), a liver-enriched member of the HNF-3/forkhead gene family, as the predominant purified protein that interacts with the FPV motif. Moreover, a cellular protein(s) that copurified with HNF-3 beta specifically interacts with a novel sequence motif that partially overlaps FPV. Since this novel motif contains a palindromic sequence, we have tentatively referred to the protein(s) that binds to this site as palindrome-binding factor (PBF), Additional evidence indicates that HNF-3 beta and PBF cooperatively interact with enhancer 1. Therefore, this study supports the hypothesis that FPV-mediated enhancer activity involves a cooperative interplay between HNF-3 beta and at least one other enhancer 1-binding protein, PBF.	UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM MOL BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA65671] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065671] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; ANTONUCCI TK, 1989, J VIROL, V63, P579, DOI 10.1128/JVI.63.2.579-583.1989; BEASLEY RP, 1981, LANCET, V2, P1129; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; CHEN M, 1994, VIROLOGY, V205, P127, DOI 10.1006/viro.1994.1627; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEGROOTE J, 1978, GUT, V19, P510, DOI 10.1136/gut.19.6.510; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUO WT, 1991, J VIROL, V65, P6686, DOI 10.1128/JVI.65.12.6686-6692.1991; GUSTIN K, 1993, VIROLOGY, V193, P653, DOI 10.1006/viro.1993.1173; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; HU KQ, 1991, VIROLOGY, V181, P721, DOI 10.1016/0042-6822(91)90906-R; HUAN BF, 1995, J VIROL, V69, P547, DOI 10.1128/JVI.69.1.547-551.1995; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; JOHNSON JL, 1995, VIROLOGY, V208, P147, DOI 10.1006/viro.1995.1138; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOSOVSKY MJ, 1996, IN PRESS HEPATITIS B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; ORI A, 1995, VIROLOGY, V207, P98, DOI 10.1006/viro.1995.1055; ORI A, 1994, VIROLOGY, V204, P600, DOI 10.1006/viro.1994.1574; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PATEL NU, 1989, J VIROL, V63, P5293, DOI 10.1128/JVI.63.12.5293-5301.1989; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SCHALLER H, 1991, CURR TOP MICROBIOL, V168, P21; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAUL Y, 1991, MOL BIOL HEPATITIS B, P193; SIDDIQUI A, 1991, MOL BIOL HEPATITIS B, P95; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; Szmuness W, 1978, Prog Med Virol, V24, P40; TOGNONI A, 1985, NUCLEIC ACIDS RES, V13, P7457, DOI 10.1093/nar/13.20.7457; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; VALLET V, 1995, MOL CELL BIOL, V15, P5453; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; YEN TSB, 1993, SEMIN VIROL, V4, P33; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990; ZHANG P, 1992, VIROLOGY, V191, P31, DOI 10.1016/0042-6822(92)90163-J; ZHANG P, 1994, VIROLOGY, V202, P430, DOI 10.1006/viro.1994.1359	76	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21859	21869		10.1074/jbc.271.36.21859	http://dx.doi.org/10.1074/jbc.271.36.21859			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702987	hybrid			2022-12-25	WOS:A1996VF61200029
J	Sando, GN; Howard, EJ; Madison, KC				Sando, GN; Howard, EJ; Madison, KC			Induction of ceramide glucosyltransferase activity in cultured human keratinocytes - Correlation with culture differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; FETAL-RAT EPIDERMIS; BARRIER FUNCTION; BETA-GLUCOCEREBROSIDASE; PERMEABILITY BARRIER; LAMELLAR GRANULES; LIPID-COMPOSITION; STRATUM-CORNEUM; GAUCHER DISEASE; CHOLESTEROL SULFOTRANSFERASE	Ceramides are the major component of the extracellular lipids that comprise the epidermal permeability barrier. They are derived from glucosylceramides (GlcCer) upon their extrusion from lamellar granules into the extracellular space in the upper layers of the epidermis. To better understand the regulation of the unique pathway for ceramide production in epidermis, we have studied the activity of the enzyme responsible for GlcCer synthesis, ceramide glucosyltransferase (CerGlc transferase), during keratinocyte culture differentiation. Human keratinocyte cultures were expanded in low calcium keratinocyte growth medium (KGM) and then switched to either normal calcium KGM (nKGM) or ''complete'' Dulbecco's modified Eagle's medium/Ham's F-12 (3:1) supplemented with 10% fetal bovine serum (cDMEM). At 7 and 10 days after the medium switch, electron microscopy revealed that cDMEM cultures were more fully differentiated morphologically and contained numerous lamellar granules. The GlcCer/DNA content of cDMEM cultures increased to 6 times that of day 0 cultures and was nearly 4 times greater than that of nKGM cultures, whereas the total lipid/DNA content of cDMEM cultures increased to only 1.8 times that of day 0 cultures and was similar to 1.2 times that of nKGM cultures. CerGlc transferase activity/DNA increased 6 times in cDMEM cultures but <1.5 times in nKGM cultures. By contrast, beta-glucocerebrosidase activity, which is responsible for the conversion of GlcCer to ceramide, increased to a similar extent in both differentiating culture systems. Treatment of cultures with the reversible CerGlc transferase inhibitor. DL-threo-1-phenyl-2-(palmitoylamino)3-morpholino-1-propanol, prevented the increase of GlcCer in cDMEM cultures, and blocked conversion of exogenously added ceramide to GlcCer. A low level of CerGlc transferase activity, relative to that in differentiated keratinocytes, was detected in cultures of other human cell types. These results indicate that CerGlc transferase activity is induced during epidermal differentiation and that regulation of this enzyme may be an important determinant of the specialized production and compartmentalization of epidermal sphingolipids.			Sando, GN (corresponding author), UNIV IOWA, COLL MED, DEPT DERMATOL, MARSHALL DERMATOL RES LABS, 270 ML, IOWA CITY, IA 52242 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041728, R55AR041728] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41728] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BJARE U, 1988, INT J BIOCHEM, V20, P1291, DOI 10.1016/0020-711X(88)90234-0; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHANG F, 1993, COMP BIOCHEM PHYS A, V105, P251; CONSTANTINOCECC.E, 1989, J NEUROCHEM, V53, P205; DIDONATO S, 1988, NEUROLOGY, V38, P1107; DINUR T, 1984, ANAL BIOCHEM, V136, P223, DOI 10.1016/0003-2697(84)90329-4; DOWNING DT, 1992, J LIPID RES, V33, P301; DURIEUX I, 1990, INT J BIOCHEM, V22, P709, DOI 10.1016/0020-711X(90)90005-N; DURIEUX I, 1990, BIOCHIM BIOPHYS ACTA, V1024, P263, DOI 10.1016/0005-2736(90)90352-O; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; FIELD FJ, 1987, J LIPID RES, V28, P1057; FREINKEL RK, 1985, J INVEST DERMATOL, V85, P295, DOI 10.1111/1523-1747.ep12276831; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRAYSON S, 1985, J INVEST DERMATOL, V85, P289, DOI 10.1111/1523-1747.ep12276826; HEDBERG CL, 1988, J INVEST DERMATOL, V91, P169, DOI 10.1111/1523-1747.ep12464438; HOLLERAN WM, 1992, J LIPID RES, V33, P1201; HOLLERAN WM, 1990, J LIPID RES, V31, P1655; HOLLERAN WM, 1994, J CLIN INVEST, V93, P1756, DOI 10.1172/JCI117160; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; ICHIKAWA S, 1996, P NATL ACAD SCI USA, V93, P2287; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; JETTEN AM, 1990, J INVEST DERMATOL, V95, pS44, DOI 10.1111/1523-1747.ep12505757; JIN K, 1994, ACTA DERM-VENEREOL, V74, P337; KAGEHARA M, 1994, BBA-LIPID LIPID MET, V1215, P183, DOI 10.1016/0005-2760(94)90109-0; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANDMANN L, 1988, ANAT EMBRYOL, V178, P1, DOI 10.1007/BF00305008; LEIGH IM, 1994, KERATINOCYTE HDB, P43; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADISON KC, 1989, J INVEST DERMATOL, V93, P10, DOI 10.1111/1523-1747.ep12277335; MADISON KC, 1995, J INVEST DERMATOL, V104, P561; MADISON KC, 1990, J INVEST DERMATOL, V95, P657, DOI 10.1111/1523-1747.ep12514333; MAK VHW, 1991, J INVEST DERMATOL, V96, P323, DOI 10.1111/1523-1747.ep12465212; MATSUO N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P97, DOI 10.1016/0304-4165(92)90105-4; MELNIK B, 1990, ARCH DERMATOL RES, V282, P549, DOI 10.1007/BF00371952; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MILNER ME, 1992, J INVEST DERMATOL, V99, P824, DOI 10.1111/1523-1747.ep12614791; MOTTA S, 1994, ARCH DERMATOL, V130, P452, DOI 10.1001/archderm.130.4.452; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PONEC M, 1988, J LIPID RES, V29, P949; PONEC M, 1994, KERATINOCYTE HDB, P351; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROBSON KJ, 1994, J LIPID RES, V35, P2060; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; SANDO GN, 1985, J BIOL CHEM, V260, P5186; SCHURER NY, 1989, J INVEST DERMATOL, V92, P196, DOI 10.1111/1523-1747.ep12276723; SIDRANSKY E, 1992, PEDIATR RES, V32, P494, DOI 10.1203/00006450-199210000-00023; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANT HOF W, 1994, CURR TOP MEMBR, V40, P539, DOI 10.1016/S0070-2161(08)60995-8; VANTHOF W, 1990, J CELL BIOL, V111, P977, DOI 10.1083/jcb.111.3.977; WERTZ PW, 1992, SEMIN DERMATOL, V11, P106; WERTZ PW, 1984, J INVEST DERMATOL, V83, P193, DOI 10.1111/1523-1747.ep12263553; WILLIAMS ML, 1993, ARCH DERMATOL, V129, P626, DOI 10.1001/archderm.129.5.626	65	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22044	22051		10.1074/jbc.271.36.22044	http://dx.doi.org/10.1074/jbc.271.36.22044			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703011	hybrid			2022-12-25	WOS:A1996VF61200053
J	AvidorReiss, T; Nevo, I; Levy, R; Pfeuffer, T; Vogel, Z				AvidorReiss, T; Nevo, I; Levy, R; Pfeuffer, T; Vogel, Z			Chronic opioid treatment induces adenylyl cyclase V superactivation - Involvement of G beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT-BRAIN; DEPENDENT ACTIVATION; CELL-LINES; RECEPTOR; EXPRESSION; CLONING; SUBUNITS; STIMULATION; MORPHINE	It has been known for some time that chronic treatment of neuronal cells and tissues with opioids, contrary to their acute effect, leads to an increase in cAMP accumulation. This phenomenon, defined as adenylyl cyclase superactivation, has been implicated in opiate addiction, yet the mechanism by which it is induced remains unclear. Here, we show that this phenomenon can be reproduced and studied in COS-7 cells cotransfected with adenylyl cyclase type V and mu-opioid receptor cDNAs. These cells display acute opioid inhibition of adenylyl cyclase activity, whereas prolonged exposure to the mu-agonist morphine or [D-Ala(2), N-methyl-Phe(4), Gly-ol(5)]enkephalin leads to a time-dependent superactivation of adenylyl cyclase. This superactivated state is reversible, because it is gradually lost following agonist withdrawal, Adenylyl cyclase superactivation can be prevented by pertussis toxin pretreatment, indicating the involvement of G(i/o) proteins, or by cotransfection with the carboxyl terminus of beta-adrenergic receptor kinase or with alpha-transducin (scavengers of G(beta gamma) dimers), indicating a role for the G protein beta gamma dimers in adenylyl cyclase superactivation. However, contrary to several other G(beta gamma)-dependent signal transduction mechanisms (e.g. the extracellular signal-regulated kinase 2/MAP kinase pathway), adenylyl cyclase superactivation is not affected by the Has dominant negative mutant N17-Ras.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; UNIV DUSSELDORF, DEPT PHYSIOL CHEM 2, D-40225 DUSSELDORF, GERMANY	Weizmann Institute of Science; Heinrich Heine University Dusseldorf			Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NIDA NIH HHS [DA-06265] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMMER H, 1993, MOL PHARMACOL, V43, P556; AVIDORREISS T, 1995, FEBS LETT, V361, P70, DOI 10.1016/0014-5793(95)00154-2; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIES TJ, 1991, EUR J PHARM-MOLEC PH, V208, P97, DOI 10.1016/0922-4106(91)90059-Q; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FURUYAMA T, 1993, MOL BRAIN RES, V19, P165, DOI 10.1016/0169-328X(93)90163-J; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GRIFFIN MT, 1985, J NEUROCHEM, V45, P1585, DOI 10.1111/j.1471-4159.1985.tb07230.x; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LIM K, 1989, BIOTECHNIQUES, V7, P576; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; THOMAS JM, 1987, TRENDS PHARMACOL SCI, V8, P308, DOI 10.1016/0165-6147(87)90124-6; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANVLIET BJ, 1991, EUR J PHARM-MOLEC PH, V208, P105, DOI 10.1016/0922-4106(91)90060-U; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WANG Z, 1994, LIFE SCI, V54, P339; WESTLINDDANIELSSON A, 1988, J NEUROCHEM, V51, P38, DOI 10.1111/j.1471-4159.1988.tb04832.x; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x	63	160	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21309	21315		10.1074/jbc.271.35.21309	http://dx.doi.org/10.1074/jbc.271.35.21309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702909	hybrid			2022-12-25	WOS:A1996VE47700055
J	Hagstrom, JE; Fautsch, MP; Perdok, M; Vrabel, A; Wieben, ED				Hagstrom, JE; Fautsch, MP; Perdok, M; Vrabel, A; Wieben, ED			Exons lost and found - Unusual evolution of a seminal vesicle transglutaminase substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN; HUMAN-SEMEN; ELASTASE INHIBITOR; GENE; SEQUENCE; IDENTIFICATION; SEMENOGELIN; CLONING; ELAFIN; ACID	The GP1G gene codes for three of the four abundant androgen-regulated secretory proteins produced by the guinea pig seminal vesicle, Sequencing of the entire 6.3-kilobase gene and comparison with other mammalian seminal vesicle secretory protein genes reveals a common three-exon, two-intron organization, However, significant sequence similarity between this group of genes is largely limited to their 5'-flanking regions and first exons, which code almost exclusively for signal peptides in each case, The first intron of GP1G does contain a region with high similarity to the coding exon of a human seminal vesicle secretory protein gene, semenogelin II. The 3' half of the GP1G gene appears to share a common ancestry with the human SKALP/elafin gene. Sequences related to the elafin promoter, coding, untranslated regions, and introns are clearly identifiable within the GP1G sequence. The elafin gene codes for a serine protease inhibitor and is expressed in a variety of different human tissues. To determine if the GP1G gene was also active outside of the seminal vesicle, RNA from a variety of guinea pig tissues was hybridized to a GP1G cDNA probe, At least three novel RNA bands hybridizing to the GP1G probe were detected in testis RNA samples, and GP1G-related mRNAs were also found in other tissues. These data suggest that these seminal vesicle secretory proteins may have functional roles outside the reproductive system.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Mayo Clinic								ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Aumuller G, 1990, Int Rev Cytol, V121, P127, DOI 10.1016/S0074-7696(08)60660-9; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN YH, 1987, MOL ENDOCRINOL, V1, P707, DOI 10.1210/mend-1-10-707; DIMICCO B, 1994, BIOCHEM PHARMACOL, V48, P345, DOI 10.1016/0006-2952(94)90106-6; DODD JG, 1986, MOL CELL ENDOCRINOL, V47, P191, DOI 10.1016/0303-7207(86)90112-7; *GEN COMP GROUP IN, 1994, PROGR MAN WISC PACK; HAGSTROM JE, 1989, MOL ENDOCRINOL, V3, P1797, DOI 10.1210/mend-3-11-1797; HARRIS SE, 1990, J BIOL CHEM, V265, P9896; HARRIS SE, 1983, P NATL ACAD SCI-BIOL, V80, P6460, DOI 10.1073/pnas.80.21.6460; LILJA H, 1992, P NATL ACAD SCI USA, V89, P4559, DOI 10.1073/pnas.89.10.4559; LILJA H, 1987, J CLIN INVEST, V80, P281, DOI 10.1172/JCI113070; MCDONALD CJ, 1984, EMBO J, V3, P2517, DOI 10.1002/j.1460-2075.1984.tb02166.x; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NOTIDES AC, 1967, P NATL ACAD SCI USA, V58, P1991, DOI 10.1073/pnas.58.5.1991; PORTA R, 1991, BIOCHEMISTRY-US, V30, P3114, DOI 10.1021/bi00226a019; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SALLENAVE JM, 1993, AM J RESP CELL MOL, V8, P439, DOI 10.1165/ajrcmb/8.4.439; SWANSON WJ, 1995, P NATLA CAD SCI US, V92, P49557; TSENG H, 1988, CELL, V54, P491, DOI 10.1016/0092-8674(88)90070-0; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; VENEZIALE CM, 1976, ANDROLOGIA, V8, P73; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILLIAMS.HG, 1972, P NATL ACAD SCI USA, V69, P2322, DOI 10.1073/pnas.69.8.2322; WILLIAMS L, 1985, NUCLEIC ACIDS RES, V13, P659, DOI 10.1093/nar/13.3.659; YOOWARREN H, 1993, J EXP ZOOL, V265, P653, DOI 10.1002/jez.1402650607	30	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21114	21119		10.1074/jbc.271.35.21114	http://dx.doi.org/10.1074/jbc.271.35.21114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702880	hybrid			2022-12-25	WOS:A1996VE47700026
J	Li, H; Ko, HP; Whitlock, JP				Li, H; Ko, HP; Whitlock, JP			Induction of phosphoglycerate kinase 1 gene expression by hypoxia - Roles of Arnt and HIF1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; HYDROCARBON DIOXIN RECEPTOR; PROTEIN-DNA INTERACTIONS; LIGANDED AH RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ENHANCER; INDUCIBLE FACTOR-1; FUNCTIONAL DOMAINS; IDENTIFICATION; CLONING	To identify new dimerization partners for the aromatic hydrocarbon receptor nuclear translocator (Arnt), we used its N-terminal region (amino acids 1-470) as a target in a two-hybrid screening procedure, and we cloned the murine form of hypoxia-inducible factor 1 alpha (HIF1 alpha). Sequence comparisons reveal substantial identity between mouse and human HIF1 alpha. Hypoxia induces a 10-fold accumulation of phosphoglycerate kinase 1 mRNA in wild type mouse hepatoma (Hepa 1c1c7) cells; the induction mechanism is Arnt dependent because induction does not occur in Arnt-defective cells, Furthermore, induction of phosphoglycerate kinase 1 mRNA requires Arnt's N-terminal region, which mediates DNA binding and heterodimerization; in contrast, induction does not require Arnt's C-terminal region, which mediates transactivation. We also show that a GAL4-HIF1 alpha fusion protein transactivates a GAL4-dependent gene in the absence of Arnt, that HIF1 alpha's transactivation capability is inducible by hypoxia, and that both hypoxia responsiveness and transactivation capability reside within the C-terminal 83 amino acids of HIF1 alpha. Our findings generate new insights into the mechanism by which Amt and HIF1 alpha induce transcription in response to hypoxia.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R35CA053887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005665] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA53887] Funding Source: Medline; NIEHS NIH HHS [NRSA ES 05665] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BACSI SG, 1995, MOL PHARMACOL, V47, P432; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CONNEY AH, 1982, CANCER RES, V42, P4875; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEAR WS, 1996, IN PRESS METHODS GEN; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SHEN ES, 1989, J BIOL CHEM, V264, P17754; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157	47	138	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21262	21267		10.1074/jbc.271.35.21262	http://dx.doi.org/10.1074/jbc.271.35.21262			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702901	hybrid			2022-12-25	WOS:A1996VE47700047
J	Neufeld, EB; Cooney, AM; Pitha, J; Dawidowicz, EA; Dwyer, NK; Pentchev, PG; BlanchetteMackie, EJ				Neufeld, EB; Cooney, AM; Pitha, J; Dawidowicz, EA; Dwyer, NK; Pentchev, PG; BlanchetteMackie, EJ			Intracellular trafficking of cholesterol monitored with a cyclodextrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; LEYDIG TUMOR-CELLS; PLASMA-MEMBRANE; CULTURED FIBROBLASTS; GOLGI-APPARATUS; C FIBROBLASTS; BREFELDIN-A; SPHINGOMYELIN DEGRADATION; RAT-LIVER	The sterol binding agent 2-hydroxypropyl-beta-cyclodextrin is shown to be a convenient and useful experimental tool to probe intracellular pathways of cholesterol transport. Biochemical and cytochemical studies reveal that cyclodextrin specifically removes plasma membrane cholesterol. Depletion of plasma membrane sphingomyelin greatly accelerated cyclodextrin-mediated cholesterol removal. Cholesterol arriving at the plasma membrane from lysosomes and the endoplasmic reticulum was also removed by cyclodextrin. Cellular cholesterol esterification linked to the mobilization of cholesterol from lysosomes was strongly attenuated by cyclodextrin, suggesting that the major portion of endocytosed cholesterol is delivered from lysosomes to the endoplasmic reticulum via the plasma membrane. Evidence for translocation of lysosomal cholesterol to the endoplasmic reticulum by a plasma membrane-independent pathway is provided by the finding that cyclodextrin loses its ability to suppress esterification when plasma membrane sphingomyelin is depleted. The Golgi apparatus appears to play an active role in directing the relocation of lysosomal cholesterol to the plasma membrane since brefeldin A also abrogated cyclodextrin-mediated suppression of cholesterol esterification. Using cyclodextrin we further show that attenuated esterification of lysosomal cholesterol in Niemann-Pick C cells reflects defective translocation of cholesterol to the plasma membrane that may be linked to abnormal Golgi trafficking.	NINCDS, DEV & METAB NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; NIA, GERONTOL RES CTR, NIH, BALTIMORE, MD 21224 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Marine Biological Laboratory - Woods Hole	Neufeld, EB (corresponding author), NIDDK, LIPID CELL BIOL SECT,LAB CELL BIOCHEM & BIOL,NIH, BLDG 8,RM 427, 8 CTR DR, BETHESDA, MD 20892 USA.		Neufeld, Edward/R-3819-2019					ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BLOCH K, 1991, BIOCH LIPIDS LIPOPRO, P363; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; COXEY RA, 1993, J LIPID RES, V34, P1165; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; GAMBLE W, 1978, J LIPID RES, V19, P1068; GERLOCZY A, 1994, J PHARM SCI, V83, P193, DOI 10.1002/jps.2600830215; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIEGER M, 1986, METHOD ENZYMOL, V128, P608; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1988, ENDOCRINOLOGY, V123, P81, DOI 10.1210/endo-123-1-81; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Liscum Laura, 1994, Current Opinion in Lipidology, V5, P221, DOI 10.1097/00041433-199405030-00010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; OKWU AK, 1994, J LIPID RES, V35, P644; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PENTCHEV PG, 1986, J BIOL CHEM, V261, P2772; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; PORN MI, 1995, BIOCHEM J, V308, P269; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rothblat G H, 1986, Methods Enzymol, V129, P628; SILBERKANG M, 1983, J BIOL CHEM, V258, P8503; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; SZETLI J, 1988, CYCLODEXTRIN TECHNOL, P79; TABAS I, 1988, J BIOL CHEM, V263, P1266; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284	57	320	322	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21604	21613		10.1074/jbc.271.35.21604	http://dx.doi.org/10.1074/jbc.271.35.21604			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702948	hybrid			2022-12-25	WOS:A1996VE47700094
J	Reyes, JG; Robayna, IG; Delgado, PS; Gonzalez, IH; Aguiar, JQ; Rosas, FE; Fanjul, LF; deGalarreta, CMR				Reyes, JG; Robayna, IG; Delgado, PS; Gonzalez, IH; Aguiar, JQ; Rosas, FE; Fanjul, LF; deGalarreta, CMR			c-Jun is a downstream target for ceramide-activated protein phosphatase in A431 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SPHINGOLIPID BREAKDOWN PRODUCTS; SIGNAL-TRANSDUCTION; CELLULAR-REGULATION; FACTOR-ALPHA; HA-RAS; NEUTRAL SPHINGOMYELINASE; GRANULOSA-CELLS; KINASE-ACTIVITY; PHORBOL ESTER	Stimulation of [H-3]serine-labeled A431 cells with tumor necrosis factor-alpha (TNF alpha) or bacterial sphingomyelinase (SMase) resulted in a rapid decrease (similar to 50% by 15 min) in cellular [H-3]sphingomyelin content and generation of the lipid moiety [H-3]ceramide, which remained elevated 60 min later, Sphingomyelin hydrolysis in response to TNF alpha or bacterial SMase resulted in a time-dependent decrease in the phosphorylation state of c-Jun protein, an effect that was also observed in cells treated with the membrane-permeable ceramide analogue N-hexanoylsphingosine (C-6-ceramide). The rapid dephosphorylation of the c-Jun gene product in response to TNF alpha, SMase, or C-6-ceramide was not observed in A431 cells treated with the serine-threonine phosphatase inhibitor okadaic acid. After the initial steps of previously described methods for the purification of a ceramide-activated protein phosphatase termed CAPP (Dobrowsky, R, T., Kamibayashi, C,, Mumby, M, C., and Hannun, Y. A, (1993) J, Biol, Chen. 268, 15523-15530), we obtained a cytosolic fraction from A431 cells that specifically dephosphorylated P-32(i)-labeled c-Jun protein used as substrate in an immunocomplex phosphatase assay, Phosphatase activity in vitro was apparent only in the presence of ceramide (5 mu m) and was specifically abrogated when okadaic acid (1 nM) was included in the immunocomplex phosphatase assay, These results provide strong evidence for c-Jun as a downstream target for CAPP activated in response to post-TNF signaling in A431 cells.	UNIV LAS PALMAS,SCH MED,DEPT ENDOCRINOL CELULAR & MOL,LAS PALMAS 35016,SPAIN	Universidad de Las Palmas de Gran Canaria			Gonzalez Robayna, Ignacio/K-9671-2014; Quintana, José/K-5709-2014; Estévez, Francisco/K-5125-2014; Gonzalez, Ignacio/ABG-2221-2020	Gonzalez Robayna, Ignacio/0000-0002-7650-4454; Quintana, José/0000-0001-8225-4538; Estévez, Francisco/0000-0002-9728-2774; Gonzalez, Ignacio/0000-0002-7838-4329; Santana-Delgado, Pino/0000-0002-4093-2692; Hernandez, Inmaculada/0000-0002-9305-1442				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAI TN, 1995, ONCOGENE, V10, P849; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DEGROOT RP, 1992, ONCOGENE, V7, P841; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOBROWSKI T, 1994, ADV PROTEIN PHOSPHAT, V8, P27; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FANJUL LF, 1992, BIOCHEM BIOPH RES CO, V188, P198, DOI 10.1016/0006-291X(92)92369-9; GOODE N, 1992, J BIOL CHEM, V267, P16878; HAKAMORI S, 1981, ANNU REV BIOCHEM, V50, P733; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1994, J BIOL CHEM, V269, P4125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WESTWICK JK, 1995, J BIOL CHEM, V270, P22699; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P241; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P423	59	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21375	21380		10.1074/jbc.271.35.21375	http://dx.doi.org/10.1074/jbc.271.35.21375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702918	hybrid			2022-12-25	WOS:A1996VE47700064
J	Wong, L; Johnson, GR				Wong, L; Johnson, GR			Epidermal growth factor induces coupling of protein-tyrosine phosphatase 1D to GRB2 via the COOH-terminal SH3 domain of GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; FACTOR RECEPTOR; RAS; INSULIN; KINASE; CORKSCREW; SH-PTP2; SYP; PHOSPHORYLATION	The Src homology 2 (SH2) and SH3 domain-containing adaptor protein GRB2 and the SH2 domain-containing protein-tyrosine phosphatase 1D (PTP1D, also called SHPTP2, PTP2C, SHPTP3, Syp, or SHP-2) function as positive mediators of growth factor-induced mitogenesis, Epidermal growth factor (EGF) is a potent mitogen for MCF-10A human mammary epithelial cells and EGF receptor-expressing mouse NR6 fibroblasts, Western blot analysis of anti-PTP1D immune complexes derived from EGF-treated cells demonstrated a ligand-dependent coupling between the phosphatase and GRB2 in vivo. Probing of lysates from these cells with glutathione S-transferase (GST) fusion proteins corresponding to the individual domains of GRB2 revealed that this interaction was mediated exclusively by the COOH-terminal SH3 domain of GRB2. Importantly, a GST fusion protein containing the PTP1D SH2 domains was not capable of generating the EGF-induced linkage to GRB2. Additional experiments indicated that neither the binding of the nucleotide exchange factor Sos to GRB2 nor tyrosine phosphorylation of PTP1D was required for EGF-stimulated coupling of PTP1D to GRB2. This is the first demonstration of a growth factor- or cytokine-induced coupling of a protein through an SH3 domain and suggests that GRB2 functions to target PTP1D, in addition to Sos, to the plasma membrane in response to EGF.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Allard JD, 1996, DEVELOPMENT, V122, P1137; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	28	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20981	20984		10.1074/jbc.271.35.20981	http://dx.doi.org/10.1074/jbc.271.35.20981			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702859	hybrid			2022-12-25	WOS:A1996VE47700003
J	Smith, JA; Francis, SH; Walsh, KA; Kumar, S; Corbin, JD				Smith, JA; Francis, SH; Walsh, KA; Kumar, S; Corbin, JD			Autophosphorylation of type I beta cGMP-dependent protein kinase increases basal catalytic activity and enhances allosteric activation by cGMP or cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOPHOSPHATE-BINDING-PROTEINS; PEPTIDE-STIMULATED NEUTROPHILS; PIG CORONARY-ARTERIES; CYCLIC-GMP; REGULATORY SUBUNIT; BOVINE AORTA; RAT-TISSUES; SMOOTH-MUSCLE; ADENOSINE; PHOSPHORYLATION	Autophosphorylation of purified bovine I beta isozyme of cGMP-dependent protein kinase (I beta cGK) in the presence of cGMP or cAMP increased basal kinase activity (-cGMP) as much as 4-fold and reduced the R(alpha) for both cGMP and cAMP; maximum catalytic activity (+cGMP) was not altered. Autophosphorylation proceeded with at least two rate components. The faster rate correlated with phosphorylation of Ser-63. The slower rate, as well as the increase in basal kinase activity and decrease in K-alpha for cyclic nucleotides, correlated with phosphorylation of Ser-79. Autophosphorylation of either residue was an intramolecular reaction. Autophosphorylation of a proteolytically generated I beta cGK monomer lacking amino-terminal residues 1-64 increased basal activity (3-fold) and decreased K-alpha for cAMP (15-fold). This indicated that autophosphorylation of Ser-79 did not require dimeric cGK and that the phosphorylation of Ser-79 in the monomer was sufficient to alter enzymatic characteristics of I beta cGK. These studies suggested that increases in intracellular cGMP or cAMP could result in autophosphorylation of I beta cGK; which would increase basal kinase activity as well as the sensitivity of cGK to activation by cGMP or to cross-activation by cAMP. Autophosphorylation could also prolong the increased kinase activity after decline of the second messenger.	VANDERBILT UNIV, SCH MED, DEPT MOL PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Vanderbilt University; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; CHAVANIEU A, 1994, EUR J BIOCHEM, V224, P115, DOI 10.1111/j.1432-1033.1994.tb20002.x; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P1; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; ERNEUX C, 1986, BIOCHEM J, V234, P193, DOI 10.1042/bj2340193; FLOCKHART DA, 1980, J BIOL CHEM, V255, P4435; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FRANCIS S, 1993, FASEB J, V7, pA1123; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; GEAHLEN RL, 1982, ADV ENZYME REGUL, V20, P195, DOI 10.1016/0065-2571(82)90016-4; GEAHLEN RL, 1981, J BIOL CHEM, V256, P4536; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFMANN F, 1983, FEBS LETT, V164, P350, DOI 10.1016/0014-5793(83)80315-9; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HOFMANN F, 1983, FEBS LETT, V151, P71, DOI 10.1016/0014-5793(83)80345-7; JIANG H, 1992, J BIOL CHEM, V267, P1015; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1989, CELL SIGNAL, V1, P303, DOI 10.1016/0898-6568(89)90049-1; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; MCCUNE RW, 1979, J BIOL CHEM, V254, P5083; MILLER JP, 1981, BIOCHEM PHARMACOL, V30, P509, DOI 10.1016/0006-2952(81)90637-7; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PRYZWANSKY KB, 1990, BLOOD, V76, P612; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SMITH J, 1993, FASEB J, V7, pA1123; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SMITH JA, 1992, FASEB J, V6, pA315; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WALTER U, 1981, EUR J BIOCHEM, V118, P339; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; WYATT TA, 1991, J BIOL CHEM, V266, P21274	56	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20756	20762		10.1074/jbc.271.34.20756	http://dx.doi.org/10.1074/jbc.271.34.20756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702828	hybrid			2022-12-25	WOS:A1996VD33700080
J	Ljungman, M; Zhang, FF				Ljungman, M; Zhang, FF			Blockage of RNA polymerase as a possible trigger for uv light-induced apoptosis	ONCOGENE			English	Article						preferential repair; p53; xeroderma pigmentosum; Cockayne's syndrome; uv light; ionizing radiation	TRANSCRIPTION-COUPLED REPAIR; XERODERMA PIGMENTOSUM-CELLS; DNA-DAMAGE; COCKAYNES-SYNDROME; NUCLEAR ACCUMULATION; TORSIONAL TENSION; EXCISION-REPAIR; STRAND BREAKS; ACTIVE GENES; GROUP-C	To study the triggering mechanism(s) of the induction of apoptosis following exposure to u.v. light, we used a genetic approach involving cell strains derived from patients with inherited deficiencies in nucleotide excision repair, It was found that cells from patients with Cockayne's syndrome, which are deficient in the processing of u.v.-induced pyrimidine dimers from the transcribed DNA strand, are induced to undergo apoptosis at much lower doses of u.v. light than cells with proficient strand-specific repair, The induction of apoptosis correlated to the induction of p53 and to the inhibition of total RNA and poly(A) mRNA synthesis, We also show that active p53 proteins accumulate following u.v.-irradiation without any apparent requirement for DNA strand breaks or excision repair intermediates, We propose that the blockage of RNA polymerases at DNA lesions in the transcribed strand triggers the induction of a pathway leading to apoptosis, These findings may help explain a long standing enigma of why, despite the DNA repair deficiency, patients with Cockayne's syndrome do not experience an elevated risk for skin cancer since potentially pre-mutagenic cells are eliminated by an easily triggered apoptotic pathway.			Ljungman, M (corresponding author), UNIV MICHIGAN, MED CTR, DEPT RADIAT ONCOL, DIV CANC BIOL, ANN ARBOR, MI 48109 USA.				NCI NIH HHS [P30-CA46592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CLEAVER JE, 1995, AM J HUM GENET, V56, P1257; CLEAVER JE, 1975, ANNU REV GENET, V9, P19, DOI 10.1146/annurev.ge.09.120175.000315; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUNN WC, 1979, MOL PHARMACOL, V15, P367; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FISCELLA M, 1993, ONCOGENE, V8, P1519; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORNACE AJ, 1983, RADIAT RES, V93, P107, DOI 10.2307/3575948; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOTTLIEB T, 1994, TIBS             NOV, P500; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LEHMANN AR, 1979, CANCER RES, V39, P4237; Leonard C J, 1995, Important Adv Oncol, P33; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCHNIK AN, 1988, NUCLEIC ACIDS RES, V16, P5175, DOI 10.1093/nar/16.11.5175; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RODI CP, 1989, J CELL PHYSIOL, V141, P346, DOI 10.1002/jcp.1041410216; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SQUIRES S, 1982, MUTAT RES, V95, P389, DOI 10.1016/0027-5107(82)90273-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VITO P, 1996, NATURE, V271, P521; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; WHITACRE CM, 1995, CANCER RES, V55, P3697; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	48	313	314	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					823	831						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761304				2022-12-25	WOS:A1996VD43300018
J	DeAngelis, PL; Achyuthan, AM				DeAngelis, PL; Achyuthan, AM			Yeast-derived recombinant DG42 protein of Xenopus can synthesize hyaluronan in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCOSE DEHYDROGENASE; STREPTOCOCCUS-PYOGENES; SENSITIVE METHOD; GENE; SYNTHASE; IDENTIFICATION; BIOSYNTHESIS; SEQUENCE; PRODUCT; ACID	We demonstrate in this report that the Xenopus DG42 gene product made in the yeast Saccharomyces cerevisiae can synthesize authentic high molecular weight hyaluronan (hyaluronic acid; HA) in vitro. Saccharomyces are eukaryotes that do not naturally produce HA or any other molecules known to contain glucuronic acid, Therefore bakers' yeast is a good model system to determine the enzymatic activity of the DG42 protein, which is the topic of recent debate. Membrane extracts prepared from cells expressing DG42 encoded on a plasmid incorporated [C-14]glucuronic acid and N-[H-3]acetylglucosamine from exogenously supplied UDP-sugar nucleotides into a high molecular mass (10(6) to 10(7) Da) polymer in the presence of magnesium ions. Both sugar precursors were simultaneously required for elongation. Control extracts prepared from cells with the vector plasmid alone or the DG42 cDNA in the antisense orientation did not display this activity. The double-labeled polysaccharide product synthesized in vitro was deemed to be HA by enzymatic analyses; specific HA lyase could degrade the polymer, but it was unaffected by protease or chitinase treatments. The fragments generated by HA lyase were identical to fragments derived from authentic vertebrate HA as compared by high performance liquid chromatography. We conclude that DG42 is a membrane-associated HA synthase capable of transferring both glucuronic acid and N-acetylglucosamine groups.			DeAngelis, PL (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,940 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73190, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATKINSON EM, 1992, MOL PLANT MICROBE IN, V5, P439, DOI 10.1094/MPMI-5-439; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; GHEREZGHIHER T, 1987, J CHROMATOGR-BIOMED, V413, P9, DOI 10.1016/0378-4347(87)80208-6; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LIND T, 1993, J BIOL CHEM, V268, P20705; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P307; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; Varki A, 1996, P NATL ACAD SCI USA, V93, P4523, DOI 10.1073/pnas.93.10.4523	21	44	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23657	23660		10.1074/jbc.271.39.23657	http://dx.doi.org/10.1074/jbc.271.39.23657			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798586				2022-12-25	WOS:A1996VJ44200015
J	Costa, C; Moura, JJG; Moura, I; Wang, YN; Huynh, BH				Costa, C; Moura, JJG; Moura, I; Wang, YN; Huynh, BH			Redox properties of cytochrome c nitrite reductase from Desulfovibrio desulfuricans ATCC 27774	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES; NITRATE REDUCTION; ESCHERICHIA-COLI; PURIFICATION; MOSSBAUER	The dissimilatory nitrite reductase from Desulfovibrio desulfuricans ATCC 27774 catalyzes the reduction of nitrite to ammonia. Previous spectroscopic investigation revealed that it is a hexaheme cytochrome containing one high spin ferric heme and five low spin ferric hemes in the oxidized enzyme. The current study uses the high resolution of Mossbauer spectroscopy to obtain redox properties of the six heme groups. Correlating the Mossbauer findings with the EPR data reveals the pairwise spin-spin coupling among four of the heme groups. The other two hemes are found to be magnetically isolated. Reduction with dithionite and reaction with CO further indicate that only the high spin heme is capable of binding small exogenous ligands. These results confirm our previous finding that Desulfovibrio desulfuricans nitrite reductase contains six heme groups and that the high spin ferric heme is the substrate and inhibitor binding site.	EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,CTR QUIM FINA & BIOTECNOL,P-2825 MONTE DE CAPARICA,PORTUGAL	Emory University; Universidade Nova de Lisboa; Universidade Nova de Lisboa			Moura, Isabel/D-6339-2013; costa, cristina/P-5924-2014; Costa, Cristina/A-9966-2012; Moura, José J G/D-6426-2013	Moura, Isabel/0000-0003-0971-4977; costa, cristina/0000-0002-6549-4553; Costa, Cristina/0000-0002-8611-9023; Moura, José J G/0000-0002-4726-2388	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039803] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47295, GM 39803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ANDERSSON KK, 1986, J BIOL CHEM, V261, P1126; BLACKMORE R, 1986, BIOCHEM J, V233, P553, DOI 10.1042/bj2330553; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; BLACKMORE RS, 1990, FEBS LETT, V264, P257, DOI 10.1016/0014-5793(90)80262-H; COSTA C, 1990, J BIOL CHEM, V265, P14382; COSTA C, 1994, THESIS U NOVA LISBOA; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DEVRIES W, 1980, ARCH MICROBIOL, V124, P221, DOI 10.1007/BF00427730; Dutton P L, 1978, Methods Enzymol, V54, P411; HADJIPETROU LP, 1965, J GEN MICROBIOL, V38, P29, DOI 10.1099/00221287-38-1-29; HASAN SM, 1975, J GEN MICROBIOL, V87, P120, DOI 10.1099/00221287-87-1-120; KAJIE SI, 1986, EUR J BIOCHEM, V154, P457, DOI 10.1111/j.1432-1033.1986.tb09419.x; KEITH SM, 1982, ARCH MICROBIOL, V132, P62, DOI 10.1007/BF00690819; Kretchmar S A, 1988, Biol Met, V1, P26, DOI 10.1007/BF01128014; LANG G, 1966, P PHYS SOC LOND, V87, P3, DOI 10.1088/0370-1328/87/1/302; LIU MC, 1987, FEBS LETT, V218, P227, DOI 10.1016/0014-5793(87)81051-7; LIU MC, 1981, J BIOL CHEM, V256, P3159; LIU MC, 1988, ARCH BIOCHEM BIOPHYS, V262, P259, DOI 10.1016/0003-9861(88)90187-7; LIU MC, 1983, FEMS MICROBIOL LETT, V19, P201, DOI 10.1016/0378-1097(83)90060-5; NASRI H, 1991, J AM CHEM SOC, V113, P717, DOI 10.1021/ja00002a075; REHR B, 1986, FEMS MICROBIOL LETT, V35, P325, DOI 10.1111/j.1574-6968.1986.tb01551.x; SCHUMACHER W, 1994, BIOCHEM BIOPH RES CO, V205, P911, DOI 10.1006/bbrc.1994.2751	23	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23191	23196		10.1074/jbc.271.38.23191	http://dx.doi.org/10.1074/jbc.271.38.23191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798514	hybrid			2022-12-25	WOS:A1996VH76800040
J	Panneels, V; Macours, P; VandenBergen, H; Braekman, JC; VanSande, J; Boeynaems, JM				Panneels, V; Macours, P; VandenBergen, H; Braekman, JC; VanSande, J; Boeynaems, JM			Biosynthesis and metabolism of 2-iodohexadecanal in cultured dog thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS ALDOSE REDUCTASE; LIPID-PEROXIDATION; ALDEHYDE PRODUCTS; CYCLIC-AMP; INHIBITION; IDENTIFICATION; IODIDE; THYROTROPIN; OXIDATION; CYCLASE	2-Iodohexadecanal (2-IHDA) is a major thyroid iodolipid. It mimics the main regulatory effects of iodide on thyroid metabolism: inhibition of H2O2 production and of adenylyl cyclase, The biosynthesis of 2-IHDA and its metabolism have been investigated in cultured dog thyroid cells maintained in a differentiated state by forskolin, Incubation of these cells with [9,10-H-3]hexadecan-1-ol or [9,10-H-3]palmitic acid labeled several phospholipids, but [9,10-H-3]hexadecan-1-ol was selectively incorporated into plasmenylethanolamine. In the presence of an exogenous H2O2 generating system (glucose oxidase), iodide induced the production of [9,10-H-3]2-IHDA from [9,10-H-3]hexadecan-1-ol-labeled cells but not from [9,10-H-3]palmitic acid-labeled cells, 2-IHDA was also generated during the lactoperoxidase-catalyzed iodination of brain and heart plasmalogens, and of ethyl hexadec-1-enyl ether, a synthetic vinyl ether-containing compound, Taken together, these results show that thyroid 2-IHDA is derived from plasmenylethanolamine via an attack of reactive iodine on the vinyl ether group. 2-Iodohexadecan-1-ol (2-IHDO) was also detected in these studies; it was formed later than 2-IHDA, and thyroid cells converted exogenous 2-IHDA into 2-IHDO in a time-dependent way, The ratio of 2-IHDO/2-IHDA increased with H2O2 production and decreased as a function of iodide concentration, An aldehyde-reducing activity was detected in subcellular fractions of the horse thyroid No formation of 2-iodohexadecanoic acid could be detected, Reduction into the biologically inactive 2-IHDO is thus a major metabolic pathway of 2-IHDA in dog thyrocytes.	FREE UNIV BRUSSELS,FAC SCI,BIOORGAN CHEM LAB,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,ERASME HOSP,DEPT MED CHEM,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel				Panneels, Valerie/0000-0001-8899-3366				BARLUENGA J, 1986, SYNTHESIS-STUTTGART, V8, P678; BENARD B, 1971, UNION MED CAN, V100, P701; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CANUTO RA, 1994, CARCINOGENESIS, V15, P1359, DOI 10.1093/carcin/15.7.1359; COCHAUX P, 1985, FEBS LETT, V179, P303, DOI 10.1016/0014-5793(85)80539-1; COCHAUX P, 1987, EUR J BIOCHEM, V170, P435, DOI 10.1111/j.1432-1033.1987.tb13718.x; CORVILAIN B, 1988, BIOCHEM BIOPH RES CO, V154, P1287, DOI 10.1016/0006-291X(88)90279-3; DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2; DELCORSO A, 1987, BIOCHEM BIOPH RES CO, V148, P369, DOI 10.1016/0006-291X(87)91120-X; FERRELL WJ, 1970, ANAL BIOCHEM, V37, P227, DOI 10.1016/0003-2697(70)90042-4; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; KAYGANICH KA, 1992, ANAL CHEM, V64, P2965, DOI 10.1021/ac00047a015; LAGROU A, 1974, LIPIDS, V9, P870, DOI 10.1007/BF02532612; MANCUSO AJ, 1978, J ORG CHEM, V43, P2480, DOI 10.1021/jo00406a041; MARMER WN, 1986, LIPIDS, V21, P648, DOI 10.1007/BF02537215; MCLAFFERTY FW, 1966, J CHEM SOC CHEM COMM, P78; MILLIGAN N, 1982, EPILEPSIA, V23, P323, DOI 10.1111/j.1528-1157.1982.tb06198.x; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MUKHERJEE KD, 1980, EUR J BIOCHEM, V107, P289, DOI 10.1111/j.1432-1033.1980.tb04649.x; OHAYON R, 1994, MOL CELL ENDOCRINOL, V99, P133, DOI 10.1016/0303-7207(94)90156-2; PANNEELS V, 1994, MOL CELL ENDOCRINOL, V106, P41, DOI 10.1016/0303-7207(94)90184-8; PANNEELS V, 1994, MOL CELL ENDOCRINOL, V102, P167, DOI 10.1016/0303-7207(94)90110-4; PANNEELS V, 1995, THYROID S1, V5, P123; PEREIRA A, 1990, J BIOL CHEM, V265, P17018; RABINOWITZ JL, 1976, BIOCHEM J, V160, P463, DOI 10.1042/bj1600463; RAPOPORT B, 1977, ENDOCRINOLOGY, V100, P755, DOI 10.1210/endo-100-3-755; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; ROGER PP, 1985, EUR J BIOCHEM, V152, P239, DOI 10.1111/j.1432-1033.1985.tb09189.x; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; TASAYCO ML, 1990, J BIOL CHEM, V265, P3094; THOMAS SE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P125, DOI 10.1016/0005-2760(92)90282-Z; ULLRICH O, 1994, FEBS LETT, V352, P84, DOI 10.1016/0014-5793(94)00922-8; VANSANDE J, 1985, MOL CELL ENDOCRINOL, V40, P181, DOI 10.1016/0303-7207(85)90174-1; WOLFF J, 1989, ADV EXP MED BIOL, V261, P211; YOON NM, 1973, J ORG CHEM, V38, P2786, DOI 10.1021/jo00956a011	40	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23006	23014		10.1074/jbc.271.38.23006	http://dx.doi.org/10.1074/jbc.271.38.23006			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798488	hybrid			2022-12-25	WOS:A1996VH76800014
J	Reaume, AG; Howland, DS; Trusko, SP; Savage, MJ; Lang, DM; Greenberg, BD; Siman, R; Scott, RW				Reaume, AG; Howland, DS; Trusko, SP; Savage, MJ; Lang, DM; Greenberg, BD; Siman, R; Scott, RW			Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a ''humanized'' A beta sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL FRAGMENT; TRANSGENIC MICE; MISSENSE MUTATION; SECRETED FORMS; MESSENGER-RNA; STEM-CELLS; PEPTIDE; BRAIN; CLEAVAGE; APP	The processing of the beta-amyloid precursor protein (APP) in vivo has been characterized in a novel animal model that recapitulates, in part, the APP genotype of a familial form of Alzheimer's disease (AD). A gene-targeting strategy was used to introduce the Swedish familial AD mutations and convert mouse A beta to the human sequence. The mutant APP is expressed at normal levels in brain, and cleavage at the mutant beta-secretase site is both accurate and enhanced. Furthermore, human A beta production is significantly increased to levels 9-fold greater than those in normal human brain while nonamyloidogenic processing is depressed. The results on A beta production extend similar findings obtained in cell culture to the brain of an animal and substantiate A beta as a etiological factor in Swedish familial AD. These animals provide several distinguishing features over others created by conventional transgenic methodologies. The spatial and temporal expression patterns of human A beta are expected to be faithfully reproduced because the gene encoding the mutant APP remains in its normal chromosomal context. Thus, the neuropathological consequences of human A beta overproduction can be evaluated longitudinally in the absence of potential mitigating effects of APP overexpression or presence of the mouse A beta peptide.	CEPHALON INC, W CHESTER, PA 19380 USA	Teva Pharmaceutical Industries; Cephalon Inc.								ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI E, 1995, AMYLOID, V2, P100, DOI 10.3109/13506129509031894; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DYRKS T, 1994, FEBS LETT, V349, P210, DOI 10.1016/0014-5793(94)00671-7; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; Hogan B, 1986, MANIPULATING MOUSE E, P89; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; HUNG AY, 1993, J BIOL CHEM, V268, P22959; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; MANN DMA, 1988, MECH AGEING DEV, V43, P99, DOI 10.1016/0047-6374(88)90041-3; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAUER B, 1990, New Biologist, V2, P441; SAVAGE MJ, 1994, NEUROSCIENCE, V60, P607, DOI 10.1016/0306-4522(94)90490-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SIMAN R, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P675; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	71	116	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23380	23388		10.1074/jbc.271.38.23380	http://dx.doi.org/10.1074/jbc.271.38.23380			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798542	hybrid			2022-12-25	WOS:A1996VH76800068
J	Bojovic, B; Rodrigues, N; Dehbi, M; Bedard, PA				Bojovic, B; Rodrigues, N; Dehbi, M; Bedard, PA			Multiple signaling pathways control the activation of the CEF-4/9E3 cytokine gene by pp60(v-src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VIRUS-TRANSFORMED FIBROBLASTS; NF-KAPPA-B; V-SRC; HA-RAS; PROSTAGLANDIN SYNTHASE; SELECTIVE ACTIVATION; TRANSCRIPTION FACTOR; PHOSPHOLIPASE-C; MAMMALIAN-CELLS	The CEF-4/9E3 cytokine gene is expressed aberrantly in chicken embryo fibroblasts (CEF) transformed by the Rous sarcoma virus. The expression of CEF-4 is dependent on both transcriptional and post-transcriptional mechanisms of regulation. The characterization of the promoter region indicated that three distinct regulatory elements corresponding to an AP-1 binding site (or TRE), a PRDII/kappa B domain, and a CAAT box are involved in the activation by pp60(v-src). In this report we investigate the signaling pathways controlling the expression of the TRE and PRDII domain. The expression of a dominant negative mutant of p21(ras) reduced the activity of both elements. In contrast a similar mutant of c-Raf-1 affected modestly the activation dependent on the TRE but not PRDII. The stress-activated protein kinase (SAPK)/Jun N-terminal kinase (JNK) pathway was important for the activity of PRDII and the TRE but was not markedly stimulated by pp60(v-src). The addition of calphostin C and the inhibition of protein kinase C (PKC) diminished the accumulation of the CEF-4 mRNA and reduced the activity of a TRE-controlled promoter. Likewise, the depletion of PHC by chronic treatment with phorbol esters inhibited the activation of the TRE. Rous sarcoma virus-transformed CEF treated with calphostin C were also flatter, did not display a high degree of criss-crossing, and appeared morphologically normal. Hence PKC was important for the activation of AP-1 and the morphological transformation of CEF. The constitutive expression of CEF-4 was correlated with transformation only when dependent on the TRE. This was not true for PRDII, which was the only element required for the constitutive activation to the CEF-4 promoter in nontransformed cells treated chronically with phorbol esters.	UNIV MONTREAL, DEPT BIOCHIM, MONTREAL, PQ H3C 3J7, CANADA; YORK UNIV, DEPT BIOL, N YORK, ON M3J 1P3, CANADA	Universite de Montreal; York University - Canada								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATLING AD, 1993, ONCOGENE, V8, P1875; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEHBI M, 1994, ONCOGENE, V9, P2399; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GOODE N, 1992, J BIOL CHEM, V267, P16878; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, ONCOGENE, V7, P2259; SPRANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WASYLYK C, 1994, ONCOGENE, V9, P3665; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YAN MH, 1994, NATURE, V372, P798; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	59	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22528	22537		10.1074/jbc.271.37.22528	http://dx.doi.org/10.1074/jbc.271.37.22528			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798420	hybrid			2022-12-25	WOS:A1996VG67200039
J	Capdevila, JH; Wei, SZ; Helvig, C; Falck, JR; Belosludtsev, Y; Truan, G; GrahamLorence, SE; Peterson, JA				Capdevila, JH; Wei, SZ; Helvig, C; Falck, JR; Belosludtsev, Y; Truan, G; GrahamLorence, SE; Peterson, JA			The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; BACILLUS-MEGATERIUM; CRYSTAL-STRUCTURE; 18-HYDROXYEICOSATETRAENOIC ACIDS; OMEGA-HYDROXYLATION; RAT-KIDNEY; EPOXYGENASE; EXPRESSION; MONOOXYGENATION; BIOSYNTHESIS	Cytochrome P450BM-3 catalyzes NADPH-dependent metabolism of arachidonic acid to nearly enantiomerically pure 18(R-hydroxyeicosatetraenoic acid and 14(S),15(R)-epoxyeicosatrienoic acid (80 and 20% of total products, respectively), P450BM-3 oxidizes arachidonic acid with a rate of 3.2 +/- 0.4 mu mol/min/nmol at 30 degrees C, the fastest ever reported for an NADPH dependent, P450-catalyzed reaction, Fatty acid, oxygen, and NADPH are utilized in an approximately 1:1:1 molar ratio, demonstrating efficient coupling of electron transport to monooxygenation. Eicosapentaenoic and eicosatrienoic acids, two arachidonic acid analogs that differ in the properties of the C-15-C-18 carbons, are also actively metabolized by P450BM-3 (1.4 +/- 0.2 and 2.9 +/- 0.1 mu mol/min/nmol at 30 degrees C, respectively). While the 17,18-olefinic bond of eicosapentaenoic acid is epoxidized with nearly absolute regio- and stereochemical selectivity to 17(S),18(R)-epoxyeicosatetraenoic acid (greater than or equal to 99% of total products, 97% optical purity), P450BM-3 is only moderately regioselective during hydroxylation of the eicosatrienoic acid omega-1, omega-2, and omega-3 sp(3) carbons, with 17-, 18-, and 19-hydroxyeicosatrienoic acid formed in a ratio of 2.4:2.2:1, respectively. Based on the above and on a model of arachidonic acid-bound P450BM-3, we propose: 1) the formation by P450BM-3 of a single oxidant species capable of olefinic bond epoxidation and sp(3) carbon hydroxylation and 2) that product chemistry and, thus, catalytic outcome are critically dependent on active site spatial coordinates responsible for substrate binding and productive orientation between heme-bound active oxygen and acceptor carbon bond(s).	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MOL GENET, DALLAS, TX 75235 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University; Vanderbilt University			; Truan, Gilles/C-7044-2019	Falck, John/0000-0002-9219-7845; Truan, Gilles/0000-0002-3560-8302	NIGMS NIH HHS [GM37922, GM31278, GM43479] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043479, R01GM031278] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILAJH, 1995, CYTOCHROME P450 STRU, P443; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FALCK JR, 1992, TETRAHEDRON LETT, V33, P4893, DOI 10.1016/S0040-4039(00)61226-1; Groves John T., 1995, P3; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HO PP, 1976, BIOCHIM BIOPHYS ACTA, V431, P249, DOI 10.1016/0005-2760(76)90145-4; IMAOKA S, 1989, BIOCHEM INT, V18, P731; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1993, J BIOL CHEM, V268, P13565; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; Kuhn H, 1988, Basic Life Sci, V49, P945; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MIURA Y, 1974, J BIOL CHEM, V249, P1880; NARHI LO, 1986, J BIOL CHEM, V261, P7160; OLIW EH, 1991, ADV PROSTAG THROMB L, V21, P197; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSTER T, 1991, J BIOL CHEM, V266, P22718; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; PETERSON JA, 1975, CYTOCHROMES P450 B5, P311; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; ROSSITER BE, 1984, J ORG CHEM, V49, P3707, DOI 10.1021/jo00194a007; SEVRIOUKOVA IF, 1995, BIOCHIMIE, V77, P562, DOI 10.1016/0300-9084(96)88172-7; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; WEN LP, 1987, J BIOL CHEM, V262, P6676	38	144	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22663	22671		10.1074/jbc.271.37.22663	http://dx.doi.org/10.1074/jbc.271.37.22663			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798438				2022-12-25	WOS:A1996VG67200057
J	Hiraki, Y; Inoue, H; Kondo, J; Kamizono, A; Yoshitake, Y; Shukunami, C; Suzuki, F				Hiraki, Y; Inoue, H; Kondo, J; Kamizono, A; Yoshitake, Y; Shukunami, C; Suzuki, F			A novel growth-promoting factor derived from fetal bovine cartilage, chondromodulin II - Purification and amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT COSTAL CHONDROCYTES; V-MYB; MIM-1 GENE; FACTOR-BETA; C-MYB; CELLS; EXPRESSION; MUTATIONS; PROTEIN; DIFFERENTIATION	During endochondral bone formation, cartilage cells show increased matrix synthesis and rapid proliferation. We found that cartilage matrix contains at least two types of heparin binding growth-promoting components, One, with a higher affinity to heparin, was identified as chondromodulin I (Hiraki, Y., Tanaka, H., Inoue, H., Kondo, J., Kamizono, A., and Suzuki, F. (1991) Biochem, Biophys, Res, Commun, 175, 871-977), In this study, we isolated a novel growth-promoting component, chondromodulin II, which has a lower heparin affinity, from the dissociative extracts of fetal bovine epiphyseal cartilage. Chondromodulin II stimulated the proteoglycan synthesis in rabbit cultured growth plate chondrocytes, an expression of the differentiated phenotype of chondrocytes. It also stimulated DNA synthesis in chondrocytes in both the absence and the presence of fibroblast growth factor-2. The apparent molecular mass of chondromodulin II on SDS-polyacrylamide gel electrophoresis was 16 kDa, Its complete amino acid sequence was determined by overlapping sequences of the peptides released by endopeptidase digestion and CNBr cleavage, Chondromodulin II consists of 133 amino acids (calculated M(r) = 14,548). The sequence was unique but homologous to the repeats 1 and 2 of the deduced amino acid sequence of the chicken mim-1 gene, which is specifically transactivated by the v-Myb oncogene product in promyelocytes. We also found a minor component with a higher heparin affinity, chondromodulin III, in cartilage extracts, Chondromodulin III stimulated DNA synthesis in chondrocytes in vitro, and its N-terminal sequence was identical with ribosomal protein L31 lacking the N-terminal three amino acids, These findings suggest that the growth and differentiation of chondrocytes are regulated by multiple components in the cartilage matrix.	OSAKA UNIV,FAC DENT,DEPT BIOCHEM & CALCIFIED TISSUE METAB,SUITA,OSAKA 565,JAPAN; MITSUBISHI KAGAKU CORP,RES CTR,KANAGAWA 227,JAPAN; KANAZAWA MED UNIV,DEPT BIOCHEM,KANAZAWA,ISHIKAWA 92002,JAPAN	Osaka University; Kanazawa Medical University			Shukunami, Chisa/G-2887-2019	Shukunami, Chisa/0000-0001-5616-6761				BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHESTER KA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P297, DOI 10.1016/0167-4781(89)90119-X; ELLINGSWORTH LR, 1986, J BIOL CHEM, V261, P2362; FUJITA Y, 1994, BIOCHEM BIOPH RES CO, V199, P706, DOI 10.1006/bbrc.1994.1286; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; HAWKE DH, 1987, ANAL BIOCHEM, V166, P298, DOI 10.1016/0003-2697(87)90578-1; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; HIRAKI Y, 1991, J BONE MINER RES, V6, P1373; HIRAKI Y, 1986, EUR J BIOCHEM, V158, P333, DOI 10.1111/j.1432-1033.1986.tb09755.x; HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167-4889(88)90092-4; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KATO Y, 1983, EUR J BIOCHEM, V129, P685; KATO Y, 1984, J CELL PHYSIOL, V120, P354, DOI 10.1002/jcp.1041200314; KATO Y, 1985, J CELL BIOL, V100, P486, DOI 10.1083/jcb.100.2.486; KONDO J, 1989, MITUSBISHIKASEI R D, V3, P110; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; QUEVA C, 1992, DEVELOPMENT, V114, P125; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SHIMBARA N, 1993, FEBS LETT, V322, P235, DOI 10.1016/0014-5793(93)81577-M; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SULLIVAN R, 1985, J BIOL CHEM, V260, P2399; SUZUKI F, 1987, METHOD ENZYMOL, V146, P313; TANAKA T, 1987, EUR J BIOCHEM, V162, P45, DOI 10.1111/j.1432-1033.1987.tb10539.x; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; YAMADA K, 1992, CELL STRUCT FUNCT, V17, P9, DOI 10.1247/csf.17.9	29	57	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22657	22662		10.1074/jbc.271.37.22657	http://dx.doi.org/10.1074/jbc.271.37.22657			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798437	hybrid			2022-12-25	WOS:A1996VG67200056
J	Ishibashi, S; Perry, S; Chen, Z; Osuga, J; Shimada, M; Ohashi, K; Harada, K; Yazaki, Y; Yamada, N				Ishibashi, S; Perry, S; Chen, Z; Osuga, J; Shimada, M; Ohashi, K; Harada, K; Yazaki, Y; Yamada, N			Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants - A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HERITABLE HYPERLIPIDEMIC RABBITS; HEPATIC-UPTAKE; WHHL RABBITS; IN-VIVO; PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR; RETINYL PALMITATE; CULTURED-CELLS; E DEFICIENCY; RAT-LIVER	Two receptor pathways are thought to mediate the hepatic clearance of chylomicron remnants, (i) the low density lipoprotein receptor (LDLR) pathway and (ii) non-LDLR pathway. The current study was undertaken to quantitatively assess the contribution of each receptor pathway to hepatic catabolism of chylomicron remnants, by using mice that are deficient in apolipoprotein E (apoE) (apoE(-/-)), the LDLR (LDLR(-/-)), and both (apoE(-/-);LDLR(-/-)). Vitamin A fat tolerance tests showed that the area under the curves of the plasma excursions of retinyl ester in the LDLR(-/-), apoE(-/-), and apoE(-/-);LDLR(-/-) mice were 4, 12, and 12 times larger than those in wild-type mice. The retinyl ester accumulated in the plasma of the LDLR(-/-) mice was distributed in larger subfractions of triglyceride-rich lipoproteins, chylomicrons through very low density lipoprotein-C. These results indicate that the LDLR constitutes the major pathway for the clearance of retinyl ester, In support of this, agarose gel electrophoresis revealed that an oral fat load resulted in retention of chylomicrons in the LDLR(-/-) mice, which was not seen in wild-type mice. The observation that the apoE(-/-) mice showed larger retinyl ester excursion than LDLR(-/-) mice indicates that an apoE-dependent non-LDLR pathway is involved in the rest of the clearance of the retinyl ester. Together, we conclude that the LDLR pathway plays a significant role in the chylomicron remnant metabolism in mice fed a normal chow.			Ishibashi, S (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEAUMONT JL, 1990, ATHEROSCLEROSIS, V85, P103, DOI 10.1016/0021-9150(90)90102-O; BOWLER A, 1991, BIOCHEM J, V276, P381, DOI 10.1042/bj2760381; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DEMACKER PNM, 1992, BIOCHEM J, V285, P641, DOI 10.1042/bj2850641; DIETSCHY JM, 1988, HYPERLIPIDAEMIA ATHE, P17; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEL RJ, 1995, CURR OPIN LIPIDOL, V6, P312, DOI 10.1097/00041433-199510000-00011; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAIN MM, 1995, J BIOL CHEM, V270, P8578, DOI 10.1074/jbc.270.15.8578; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; JACKLE S, 1992, J LIPID RES, V33, P419; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; JI ZW, 1995, ARTERIOSCLER THROMB, V14, P2025; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRISETHERTON PM, 1980, J LIPID RES, V21, P435; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; MAHLEY RW, 1994, METABOLIC BASES INHE, P1953; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDGRAVE TG, 1979, J LIPID RES, V20, P217; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHAFI S, 1994, J LIPID RES, V35, P709; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; WADE DP, 1986, EUR J BIOCHEM, V159, P333, DOI 10.1111/j.1432-1033.1986.tb09872.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WILSON DE, 1987, BIOCHIM BIOPHYS ACTA, V922, P247, DOI 10.1016/0005-2760(87)90047-6; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553; YAMADA N, 1988, J CLIN INVEST, V82, P2106, DOI 10.1172/JCI113832; ZHANG SH, 1992, SCIENCE, V258, P458	47	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22422	22427		10.1074/jbc.271.37.22422	http://dx.doi.org/10.1074/jbc.271.37.22422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798405	hybrid			2022-12-25	WOS:A1996VG67200024
J	Quaggin, SE; VandenHeuvel, GB; Golden, K; Bodmer, R; Igarashi, P				Quaggin, SE; VandenHeuvel, GB; Golden, K; Bodmer, R; Igarashi, P			Primary structure, neural-specific expression, and chromosomal localization of Cux-2, a second murine homeobox gene related to Drosophila cut	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; SENSORY ORGAN IDENTITY; DNA-BINDING SPECIFICITY; HOMEODOMAIN PROTEIN; MOUSE CHROMOSOME-5; LOCUS; TRANSFORMATION; PATTERNS; PROMOTER; ENHANCER	The cut locus of Drosophila encodes a diverged homeodomain-containing protein that is required for the development of external sensory (es) organs and other tissues. A homologous gene (Cux-1) that encodes a transcriptional repressor has been identified in the mouse and other mammals. We have identified a second murine homeobox-containing gene (designated Cux-2) that is structurally related to Drosophila cut. The murine Cux-2 homeobox was similar to Drosophila cut and encoded a homeodomain that contained a characteristic histidine residue at position 50. The predicted Cux-2 protein contained 1426 amino acids and included three internal 60-amino acid repeats (Cut repeats) that were previously found in Drosophila Cut and murine Cux-1. Unlike Cux-1, expression of Cux-2 was restricted to neural tissue. In the adult brain, Cux-2 was prominently expressed in neurons in the thalamus and limbic system. In embryos, Cux-2 was expressed in the developing central and peripheral nervous systems, including the telencephalon and peripheral ganglia of the trigeminal and glossopharyngeal nerves. A glutathione S-transferase fusion protein containing the carboxyl-terminal Cut repeat and homeodomain of Cux-2 exhibited sequence-specific binding to oligonucleotides derived from the promoter of the Ncam gene. Using an interspecific backcross panel, Cux-1 and Cux-2 were mapped to distinct loci that were genetically linked on distal chromosome 5. These results demonstrate that a family of homeobox genes related to Drosophila cutis located on chromesome 5 in the mouse. Cux-2 is expressed exclusively in the central and peripheral nervous systems, and the Cux-2 gene product binds to DNA in a sequence-specific manner. Cux-2 may encode a transcription factor that is involved in neural specification in mammals.	YALE UNIV, SCH MED, NEPHROL SECT, NEW HAVEN, CT 06520 USA; UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	Yale University; University of Michigan System; University of Michigan				Igarashi, Peter/0000-0001-8698-1185; Vanden Heuvel, Gregory/0000-0003-1477-0236	NIDDK NIH HHS [R01 DK-45678] Funding Source: Medline; NINDS NIH HHS [R01 NS-29119] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029119] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BALLYCUIF L, 1993, DEVELOPMENT, V117, P543; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HUNT P, 1991, DEVELOPMENT, P187; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK CA, 1994, MAMM GENOME, V5, pS65; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LIU S, 1991, GENETICS, V127, P151; MANAK JR, 1994, DEVELOPMENT, P61; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MUENKE M, 1994, P NATL ACAD SCI USA, V91, P8102, DOI 10.1073/pnas.91.17.8102; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PETERS LL, 1994, GENOMICS, V22, P490, DOI 10.1006/geno.1994.1418; Quaggin S. E., 1994, Molecular Biology of the Cell, V5, p85A; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SCHERER SW, 1993, GENOMICS, V15, P695, DOI 10.1006/geno.1993.1130; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; VALARCHE I, 1993, DEVELOPMENT, V119, P881; YOON SO, 1994, J BIOL CHEM, V269, P18453	39	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22624	22634		10.1074/jbc.271.37.22624	http://dx.doi.org/10.1074/jbc.271.37.22624			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798433	hybrid			2022-12-25	WOS:A1996VG67200052
J	Huang, QL; Neuenschwander, PF; Rezaie, AR; Morrissey, JH				Huang, QL; Neuenschwander, PF; Rezaie, AR; Morrissey, JH			Substrate recognition by tissue factor-factor VIIa - Evidence for interaction of residues Lys(165) and Lys(166) of tissue factor with the 4-carboxyglutamate-rich domain of factor X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-VII; COFACTOR FUNCTION; BLOOD-COAGULATION; PROTEOLYTIC ACTIVATION; ENZYME COMPLEXES; FACTOR-IX; BINDING; CALCIUM; PROTEIN	Tissue factor (TF) is the protein cofactor for factor VIIa (FVIIa), the first serine protease of the clotting cascade. Previous studies using alanine mutagenesis have identified TF residues Lys(165) and Lys(166) as important for factor X (FX) activation, hypothesizing either that these residues interact with phospholipid head groups or that they directly or indirectly promote macromolecular substrate binding. In the recently reported x-ray crystal structure of the isolated extracellular domain of TF, both Lys(165) and Lys(166) are solvent-exposed and predicted to be near the phospholipid surface in intact TF. We hypothesized that these residues may in fact be ideally positioned to interact with the 4-carboxy-glutamate-rich domain (Gla domain) of FX. We therefore predicted that mutations at Lys(165) and Lys(166) should have no effect on the activation of Gla domainless FX. To test this hypothesis, we mutated both residues Lys(165) and Lys(166) of TF to Ala, Glu, or Gln and examined the ability of these double mutants to support FVIIa-mediated activation of FX, Gla domainless FX, and factor IX (FM). Each TF mutant was equivalent to wild-type TF in both FVIIa binding and promotion of FVIIa amidolytic activity, However, all three mutants were markedly deficient in supporting FIX and FX activation, with FX activation rates decreased more than FIX activation rates. In both reactions, the TF mutants exhibited different extents of activity: Gln(165)-Gln(166) > Ala(165)-Ala(166) > Glu(165)-Glu(166). In sharp contrast, all three TF mutants were equivalent to wild-type TF in supporting activation of Gla domainless FX by FVIIa. Interestingly, the deficiency of the mutants in FX activation was less pronounced when Gla domainless FVIIa was used in place of native FVIIa, Together, these findings suggest that TF residues Lys(165) and Lys(166) contribute to a binding site for the Gla domain of FX (and perhaps other substrates) and that this interaction may be facilitated by the presence of the Gla domain of FVIIa.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center			Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014, P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804, R01 HL47014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FIORE MM, 1992, BLOOD, V80, P3127; FIORE MM, 1994, J BIOL CHEM, V269, P143; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARTIN DMA, 1995, FASEB J, V9, P852, DOI 10.1096/fasebj.9.10.7615155; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P16983; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PERSSON E, 1991, J BIOL CHEM, V266, P2453; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAO LVM, 1995, BIOCHEMISTRY-US, V34, P10867, DOI 10.1021/bi00034a020; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SAKAI T, 1990, J BIOL CHEM, V265, P1890; THOMPSON AR, 1977, J CLIN INVEST, V59, P900, DOI 10.1172/JCI108712; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; ZUR M, 1978, J BIOL CHEM, V253, P2203	44	80	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21752	21757		10.1074/jbc.271.36.21752	http://dx.doi.org/10.1074/jbc.271.36.21752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702971				2022-12-25	WOS:A1996VF61200013
J	McCright, B; Rivers, AM; Audlin, S; Virshup, DM				McCright, B; Rivers, AM; Audlin, S; Virshup, DM			The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; DNA-REPLICATION; TUMOR-ANTIGEN; T-ANTIGEN; KINASE-A; FORMS; PHOSPHORYLATION; ASSOCIATION; EXPRESSION; MECHANISM	Protein phosphatase 2A is a heterotrimeric protein serine/threonine phosphatase consisting of a 36-kDa catalytic C subunit, a 65-kDa structural A subunit, and a variable regulatory B subunit. The B subunits determine the substrate specificity of the enzyme. There have been three families of cellular B subunits identified to date: B55, B56 (B'), and PR72/130, We have now cloned five genes encoding human B56 isoforms. Polypeptides encoded by all but one splice variant (B56 gamma 1) are phosphoproteins, as shown by mobility shift after treatment with alkaline phosphatase and metabolic labeling with [P-32]phosphate. All labeled isoforms contain solely phosphoserine. Indirect immunofluorescence microscopy demonstrates distinct patterns of intracellular targeting by different B56 isoforms. Specifically, B56 alpha, B56 beta, and B56 epsilon complexed with the protein phosphatase 2A A and C subunits localize to the cytoplasm, whereas B56 delta, B56 gamma 1, and B56 gamma 3 are concentrated in the nucleus. Two isoforms (B56 beta and B56 delta) are highly expressed in adult brain; here we show that mRNA for these isoforms in creases severalfold when neuroblastoma cell lines are induced to differentiate by retinoic acid treatment, These studies demonstrate an increasing diversity of regulatory mechanisms to control the activity of this key intracellular protein phosphatase and suggest distinct functions for isoforms targeted to different intracellular locations.	UNIV UTAH, SCH MED, DEPT ONCOL SCI, DIV MOL BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, PROGRAM HUMAN MOL BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, COMBINED PROGRAM MOL BIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NATIONAL CANCER INSTITUTE [P30CA042014, T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031657] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA42014, T32-CA09602] Funding Source: Medline; NIAID NIH HHS [R01 AI-31657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOSMA PJ, 1991, J BIOL CHEM, V266, P17845; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; GARDNER J, 1995, SEQVU 1 0; *GEN COMP GROUP IN, 1994, PROGR MAN WISC PACK; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MCCRIGHT B, 1996, IN PRESS GENOMICS; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NISHIKAWA M, 1994, CANCER RES, V54, P4879; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEIDTMANN KH, 1986, VIROLOGY, V150, P85, DOI 10.1016/0042-6822(86)90268-0; SHU YM, 1995, MOL CELL BIOL, V15, P5618; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Virshup DM, 1993, ADV PROTEIN PHOSPHAT, V7, P271; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	44	318	333	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22081	22089		10.1074/jbc.271.36.22081	http://dx.doi.org/10.1074/jbc.271.36.22081			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703017	hybrid			2022-12-25	WOS:A1996VF61200059
J	Chatila, T; Anderson, KA; Ho, N; Means, AR				Chatila, T; Anderson, KA; Ho, N; Means, AR			A unique phosphorylation-dependent mechanism for the activation of Ca2+/calmodulin-dependent protein kinase type IV/GR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CAM-KINASE; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; B-LYMPHOCYTES; CDNA SEQUENCE; IV KINASE; CALMODULIN; GENE; GR	The activity of the Ca2+/calmodulin-dependent protein kinase IV/Gr (CaMKIV/Gr) is shown to be strictly regulated by phosphorylation of three residues both in vitro and in response to antigen receptor-mediated signaling in lymphocytes. One residue, Thr-200, is indispensable for enhancement of Ca2+/calmodulin-dependent basal activity by CaMKIV/Gr kinase. This event requires Ca2+/calmodulin in the full-length CaMKIV/Gr but is Ca2+/calmodulin-independent when a truncated version of CaMKIV/Gr is used as a substrate (Delta CaMKIV/Gr(1-317) (Delta 1-317)). The other two residues, Ser(12) and Ser(13), are apparently autophosphorylated by the Ca2+/calmodulin-bound CaMKIV/Gr. Phosphorylation of neither Ser(12)-Ser(13) nor Thr(312) (the residue in a homologous position to Thr(286) of CaMKII alpha influences the development of Ca2+/calmodulin-independent activity or any other property of CaMKIV/Gr examined. Similarly, removal of the NH2-terminal 20 amino acids has no effect on the activation or function of CaMKIV/Gr. However, mutation of both Ser(12) and Ser(13) residues to Ala in Delta 1-317 completely abrogates activity, while individual substitutions have no effect. These results indicate that the NH2-terminal Ser cluster mediates a novel type of intrasteric inhibition and suggest that three events are required for CaMKIV/Gr activation: 1) Ca2+/calmodulin binding; 2) phosphorylation of the Ca2+/calmodulin-bound enzyme on Thr(200) by a Ca2+/calmodulin-dependent protein kinase kinase; and 3) autophosphorylation of Ser(12)-Ser(13). This three-step requirement is unique among the multifunctional Ca2+/calmodulin-dependent kinases.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University	Chatila, T (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL RHEUMATOL,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.			Chatila, Talal/0000-0001-7439-2762				BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LOU LL, 1989, J NEUROSCI, V9, P2020; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MATHEWS RP, 1994, MOL CELL BIOL, V14, P6107; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MENEZES J, 1975, BIOMEDICINE, V22, P276; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER CL, 1993, J VIROL, V67, P3087, DOI 10.1128/JVI.67.6.3087-3094.1993; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIKELA JM, 1990, GENOMICS, V8, P579, DOI 10.1016/0888-7543(90)90048-Y; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN ZM, 1995, J BIOL CHEM, V270, P29507, DOI 10.1074/jbc.270.49.29507; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903	45	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21542	21548		10.1074/jbc.271.35.21542	http://dx.doi.org/10.1074/jbc.271.35.21542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702940	hybrid			2022-12-25	WOS:A1996VE47700086
J	Yankovskaya, V; Sablin, SO; Ramsay, RR; Singer, TP; Ackrell, BAC; Cecchini, G; Miyoshi, H				Yankovskaya, V; Sablin, SO; Ramsay, RR; Singer, TP; Ackrell, BAC; Cecchini, G; Miyoshi, H			Inhibitor probes of the quinone binding sites of mammalian complex II and Escherichia coli fumarate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE	The structural and catalytic properties of beef heart succinate dehydrogenase (succinate-ubiquinone oxidoreductase, complex II) and Escherichia coli fumarate reductase are remarkably similar, One exception is that whereas electron exchange between the mammalian enzyme and its quinone pool is inhibited by thenoyltrifluoroacetone. and carboxanilides, the enzyme from E. coli is not sensitive to these inhibitors, The lack of good inhibitors has seriously hampered the elucidation of the mechanism of quinone oxidation/reduction in the E. coli enzyme, We have previously reported (Tan, A. K., Ramsay, R. R., Singer, T. P., and Miyoshi, H. (1993) J. Biol. Chem. 268, 19328-19333) that 2-alkyl-4,6-dinitrophenols inhibit mammalian complexes I, II, and III, but with different potencies and kinetic characteristics. Based on these studies we have selected a series of 2-alkyl-4,6-dinitrophenols which proved to be very effective noncompetitive inhibitors of mammalian complex II, particularly when acting in the direction of quinone reduction, the physiological event. These compounds turned out to be even more potent inhibitors E. coli fumarate reductase, particularly when acting in the direction of quinol oxidation, again, the physiological event. Kinetic analysis revealed that with both enzymes 2 inhibitor binding sites seem to be involved in the oxidation of succinate by quinone, but one seems to be functioning when fumarate is reduced by external quinol, Since the E. coli enzyme can be modified by site-directed mutagenesis, these studies were extended to four mutants of fumarate reductase, impaired by single amino acid substitutions at either of the putative quinone binding sites (Q(A) or Q(B)) of the enzyme. The results were analyzed in terms of the model of these dual sites of quinone binding in fumarate reductase, as well as the nature of the substituent in the 2-position of the dinitrophenol inhibitors.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT SCI,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,DIV MOL BIOL,SAN FRANCISCO,CA 94121; KYOTO UNIV,DEPT AGR CHEM,KYOTO 606,JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kyoto University			Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008	Ramsay, Rona R./0000-0003-1535-4904	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16251] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1977, ARCH BIOCHEM BIOPHYS, V182, P107, DOI 10.1016/0003-9861(77)90288-0; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; CHOUDHRY ZM, 1986, BIOCHIM BIOPHYS ACTA, V850, P131, DOI 10.1016/0005-2728(86)90017-4; Hansch C, 1979, SUBSTITUENT CONSTANT; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; TAN AK, 1993, J BIOL CHEM, V268, P19328; TAPPEL AL, 1960, BIOCHEM PHARMACOL, V3, P289, DOI 10.1016/0006-2952(60)90094-0; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WHITE GA, 1971, BIOCHEM BIOPH RES CO, V44, P1212, DOI 10.1016/S0006-291X(71)80215-2	12	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21020	21024		10.1074/jbc.271.35.21020	http://dx.doi.org/10.1074/jbc.271.35.21020			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702865	hybrid			2022-12-25	WOS:A1996VE47700011
J	Soldi, R; Sanavio, F; Aglietta, M; Primo, L; Defilippi, P; Marchisio, PC; Bussolino, F				Soldi, R; Sanavio, F; Aglietta, M; Primo, L; Defilippi, P; Marchisio, PC; Bussolino, F			Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125(FAK)) in human endothelial cells	ONCOGENE			English	Article						PAF; endothelial cells; FAK; cytoskeleton; cell motility	HEPATOCYTE GROWTH-FACTOR; IN-VIVO ANGIOGENESIS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLOOXYGENASE PRODUCTS; EXTRACELLULAR-MATRIX; CYTOKINE REGULATION; HUMAN NEUTROPHILS; CROSS-TALK; PP125(FAK)	Platelet-activating factor (PAF) is a potent activator of angiogenesis and controls the motility and the shape of vascular endothelium. The mechanism(s) whereby PAF exerts its action are in part known. Here we report that the biological active (R)PAF enantiomer administrated to cultured endothelial cells induces the early phosphorylation in tyrosine residues of focal (p125(FAK)) and paxillin, two molecules early signaling and cytoskeleton assembly in cells that undergo integrin-mediated adhesion or are challenged by neuropeptides or lysophosphatidic acid. The phenomenon is rapidly turned on, lasts for a few minutes and is adhesion-independent indicating that the chain of events induced by (R)PAF, including p125(FAK) activation, precedes adhesion. The inhibitory effect of WEB2086, a PAF receptor antagonist, and the lack of activity exerted by the (S)PAF enantiomer, indicate that (R)PAF-mediated p125(FAK) activation, is PAF receptor-dependent. Calphostin C, an inhibitor of protein kinase C blocks the effect of (R)PAF on p125(FAK); phosphorylation suggesting that protein kinase C activation is up-stream the activation of this tyrosine kinase. When endothelial cells are exposed to a substratum that allows adhesion and spreading. (R)PAF-stimulated cells, change their adhesive phenotype and start migrating. Inhibitors of tyrosine kinases, like 3-(1,4,-dihydroxytetralyl) methy-len-2-oxindole and herbimycin A, reduce the cells migration, the transendothelial flux of albumin and the enhancement of p125(FAK) activity induced by (R)PAF. The observation that increased tyrosine phosphorylation of p125(FAK) and its ensuing association with focal adhesion occurs rapidly upon (R)PAF challenge indicates that this signaling molecule has a primary and independent role also in the signaling cascade initiated by (R)PAF.	UNIV TURIN,DEPT GENET BIOL & MED CHEM,I-10126 TURIN,ITALY; UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY; IST SCI SAN RAFFAELE,DEPT BIOL & TECHNOL RES,I-20132 MILAN,ITALY	University of Turin; University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			DEFILIPPI, Paola/L-2232-2014; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Bussolino, Federico/0000-0002-5348-1341; PRIMO, Luca/0000-0002-1294-0441; Defilippi, Paola/0000-0001-6427-4906; AGLIETTA, Massimo/0000-0002-2255-7972				ANDRADE SP, 1994, J LIPID MEDIAT CELL, V9, P117; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; BUSSOLINO F, 1995, EUR J BIOCHEM, V229, P327, DOI 10.1111/j.1432-1033.1995.tb20472.x; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DERYCKX S, 1992, J IMMUNOL, V148, P1465; DHAR A, 1994, J BIOL CHEM, V269, P9123; DHAR A, 1991, J BIOL CHEM, V266, P18797; DHUMIERES S, 1986, EUR J PHARMACOL, V131, P13, DOI 10.1016/0014-2999(86)90510-8; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANDLEY DA, 1984, IMMUNOPHARMACOLOGY, V8, P137, DOI 10.1016/0162-3109(84)90017-1; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUMPHREY DM, 1982, LAB INVEST, V46, P422; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JUNCOS LA, 1993, J CLIN INVEST, V91, P1374, DOI 10.1172/JCI116339; KIM DY, 1995, AM J PHYSIOL-HEART C, V268, pH399, DOI 10.1152/ajpheart.1995.268.1.H399; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER R, 1988, BIOCHEM BIOPH RES CO, V153, P805, DOI 10.1016/S0006-291X(88)81167-7; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Mariani M., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P381; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCMANUS LM, 1993, LAB INVEST, V69, P639; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; NOURSHARGH S, 1995, BLOOD, V85, P2553, DOI 10.1182/blood.V85.9.2553.bloodjournal8592553; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHWERTSCHLAG US, 1988, KIDNEY INT, V34, P779, DOI 10.1038/ki.1988.249; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SILVESTRO L, 1994, SEMIN THROMB HEMOST, V20, P214, DOI 10.1055/s-2007-1001905; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMITH CS, 1994, J IMMUNOL, V153, P3997; STOSSEL TP, 1994, BLOOD, V84, P367; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	67	33	34	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					515	525						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760293				2022-12-25	WOS:A1996VB32800009
J	Ishihara, H; Shibasaki, Y; Kizuki, N; Katagiri, H; Yazaki, Y; Asano, T; Oka, Y				Ishihara, H; Shibasaki, Y; Kizuki, N; Katagiri, H; Yazaki, Y; Asano, T; Oka, Y			Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol-4-phosphate 5-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; PANCREATIC-ISLETS; CA2+-ACTIVATED SECRETION; SIGNAL-TRANSDUCTION; INSULIN-SECRETION; MAMMALIAN-CELLS; GLUCOSE; ATP; PHOSPHOLIPIDS; METABOLISM	Accumulating evidence suggests that phosphatidylinositol metabolism is essential for membrane traffic in the cell, Of particular importance, phosphatidylinositol transfer protein and the type I phosphatidylinositol-4-phosphate 5-kinase (PI4P5K) have been identified as cytosolic components required for ATP-dependent, Ca2+-activated secretion. In order to identify PI4P5K isoforms that may play important roles in regulated insulin secretion from pancreatic beta-cells, we employed the polymerase chain reaction with degenerate primers and screening of a cDNA library of the murine pancreatic beta-cell line MIN6, Two novel cDNAs, designated PI4P5K-I alpha and PI4P5K-I beta, were identified, which contained complete coding sequences encoding 539- or 546-amino acid proteins, respectively. These cDNAs were expressed in mammalian cells with an adenoviral expression vector. Proteins of both isoforms migrated at 68 kDa on SDS-polyacrylamide gel electrophoresis and exhibited phosphatidylinositol-4-phosphate 5-kinase activity, which was activated by phosphatidic acid, indicating that these proteins were type I isoforms, While these isoforms share a marked amino acid sequence homology in their central portion, the amino- and carboxyl-terminal regions differ significantly. Northern blot analysis depicted that tissue distributions differed between the two isoforms. Molecular identification of type I PI4P5K isoforms in insulin-secreting cells should provide insights into the role of phosphatidylinositol metabolism in regulated exocytosis of insulin-containing large dense core vesicles.	YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	Yamaguchi University	Ishihara, H (corresponding author), UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DUNLOP ME, 1985, BIOCHEM BIOPH RES CO, V132, P467, DOI 10.1016/0006-291X(85)91157-X; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FARESE RV, 1986, ENDOCRINOLOGY, V118, P1498, DOI 10.1210/endo-118-4-1498; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; METZ SA, 1990, ARCH BIOCHEM BIOPHYS, V283, P417, DOI 10.1016/0003-9861(90)90663-J; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORITZ A, 1992, J BIOL CHEM, V267, P7207; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; SHIBASAKI Y, 1996, DIABETES S1, V45, pA243; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416	32	171	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23611	23614		10.1074/jbc.271.39.23611	http://dx.doi.org/10.1074/jbc.271.39.23611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798574	hybrid			2022-12-25	WOS:A1996VJ44200003
J	Gupta, D; Kirkland, TN; Viriyakosol, S; Dziarski, R				Gupta, D; Kirkland, TN; Viriyakosol, S; Dziarski, R			CD14 is a cell-activating receptor for bacterial peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LPS BINDING-PROTEIN; LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN; NECROSIS-FACTOR-ALPHA; LIPID-A; STAPHYLOCOCCUS-AUREUS; SIGNAL-TRANSDUCTION; LIPOTEICHOIC ACID; HUMAN MONOCYTES; MACROPHAGES	The hypothesis that CD14 (an endotoxin receptor present on macrophages and neutrophils) acts as a cell-activating receptor for bacterial peptidoglycan was tested using mouse 70Z/3 cells transfected with human CD14. 70Z/3 cells transfected with an empty vector were unresponsive to insoluble and soluble peptidoglycan, as well as to low concentrations of endotoxin, 70Z/3-CD14 cells were responsive to both insoluble and soluble peptidoglycan, as well as to low concentrations of endotoxin, as measured by the expression of surface IgM, activation of NF-kappa B, and degradation of I kappa B-alpha. Peptidoglycan also induced activation of NF-kappa B and degradation of I kappa B-alpha in macrophage RAW264.7 cells. These peptidoglycan-induced effects (in contrast to endotoxin-induced effects) were not inhibited by polymyxin B. Both peptidoglycan- and endotoxin-induced activation of NF-kappa B were inhibited by anti-CD14 mAb. The N-terminal 151 amino acids of CD14 were sufficient for acquisition of full responsiveness to both peptidoglycan and endotoxin, but CD14 deletion mutants lacking four small regions within the N-terminal 65 amino acids showed differentially diminished responses to peptidoglycan and endotoxin. These results identify CD14 as the functional receptor for peptidoglycan and demonstrate that similar, but not identical sequences in the N-terminal 65-amino acid region of CD14 are critical for the NF-kappa B and IgM responses to both peptidoglycan and endotoxin.	INDIANA UNIV,SCH MED,NW CTR MED EDUC,GARY,IN 46408; UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT PATHOL,SAN DIEGO,CA 92161	Indiana University System; Indiana University Northwest; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28797] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DOKTER WHA, 1994, J BIOL CHEM, V269, P4201; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; DZIARSKI R, 1996, IN PRESS J INFECT DI, V174; DZIARSKI R, 1986, BIOL PROPERTIES PEPT, P229; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GUPTA D, 1995, J IMMUNOL, V155, P2620; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; Heymer B., 1985, IMMUNOLOGY BACTERIAL, P11; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; KIRIKAE T, 1994, FEMS IMMUNOL MED MIC, V8, P13; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; MATHISON JC, 1992, J IMMUNOL, V149, P200; MIRELMAN D, 1974, BIOCHEMISTRY-US, V13, P5045, DOI 10.1021/bi00721a028; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; ROONEY JW, 1990, IMMUNOGENETICS, V31, P73, DOI 10.1007/BF00661216; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 1996, INFECT IMMUN, V64, P653, DOI 10.1128/IAI.64.2.653-656.1996; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZEIGER AR, 1982, INFECT IMMUN, V37, P1112, DOI 10.1128/IAI.37.3.1112-1118.1982	38	183	188	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23310	23316		10.1074/jbc.271.38.23310	http://dx.doi.org/10.1074/jbc.271.38.23310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798531	hybrid			2022-12-25	WOS:A1996VH76800057
J	Kuroda, S; Fukata, M; Kobayashi, K; Nakafuku, M; Nomura, N; Iwamatsu, A; Kaibuchi, K				Kuroda, S; Fukata, M; Kobayashi, K; Nakafuku, M; Nomura, N; Iwamatsu, A; Kaibuchi, K			Identification of IQGAP as a putative target for the small GTPases, Cdc42 and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RAC; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; KB CELLS; RHO P21; KINASE; INSULIN; ACTIVATION; DROSOPHILA; EXPRESSION	Cdc42 and Rac1 have been implicated in the regulation of various cell functions such as cell morphology, polarity, and cell proliferation. We have partially purified a Cdc42- and Rac1-associated protein with molecular mass of about 170 kDa (p170) from bovine brain cytosol. This protein interacted with guanosine 5'-(3-O-thio)triphosphate (GTP gamma S)-glutathione S-transferase (GST)-Cdc42 and GTP gamma-GST-Rac1, or GTP gamma S-GST-RhoA). We identified p170 as an IQGAP, which is originally identified as putative Ras GTPase-activating protein. Recombinant IQGAP specifically interacted with GTP gamma S-Cdc42 and GTP gamma S-Rac1. The C-terminal fragment of IQGAP was specifically immunoprecipitated with dominant-active Cdc42(Val12) or Rac1(Val12) from the COS7 cells expressing Cdc42(Val12) or Rac1(Val12), respectively, Immunofluorescence analysis revealed that IQGAP was accumulated at insulin- or Rac1-induced membrane ruffling areas. This accumulation of IQGAP was blocked by the microinjection of the dominant-negative Rac1(Asn17) or Cdc42(Asn17). Moreover, IQGAP was accumulated at the cell-cell junction in MDCK cells, where alpha-catenin and ZO-1 were localized. These results suggest that IQGAP is a novel target molecule for Cdc42 and Rac1.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; KAZUSA DNA RES INST,KISARAZU,CHIBA 292,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Hiroshima University; Kazusa DNA Research Institute; Kirin Brewery Company Limited			Nakafuku, Masato/J-3068-2013; KURODA, SHINYA/G-4961-2014; Fukata, Masaki/AAZ-2476-2021	Fukata, Masaki/0000-0001-5200-9806; Nakafuku, Masato/0000-0001-7783-9005				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DERRY JMJ, 1994, CELL, V79, P923; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MACKAY D, 1995, TRENDS NEUROSCI, V81, P496; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAKAISHI K, 1995, ONCOGENE, V11, P39; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	49	260	265	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23363	23367		10.1074/jbc.271.38.23363	http://dx.doi.org/10.1074/jbc.271.38.23363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798539	hybrid			2022-12-25	WOS:A1996VH76800065
J	UshioFukai, M; Zafari, AM; Fukui, T; Ishizaka, N; Griendling, KK				UshioFukai, M; Zafari, AM; Fukui, T; Ishizaka, N; Griendling, KK			p22(phox) is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; GLOMERULAR MESANGIAL CELLS; GTP-BINDING PROTEIN; NADPH-OXIDASE; HYDROGEN-PEROXIDE; HUMAN-FIBROBLASTS; ARACHIDONIC-ACID; CYTOCHROME-B; EXPRESSION; RELEASE	Superoxide anion formation is vital to the microbicidal activity of phagocytes. Recently, however, there is accumulating evidence that it is also involved in cell growth in vascular smooth muscle cells (VSMCs). We have shown that the hypertrophic agent angiotensin II stimulates superoxide production by activating the membrane-bound NADH/NADPH oxidase and that inhibition of this oxidase attenuates vascular hypertrophy. However, the molecular identity of this oxidase in VSMCs is unknown, We have recently cloned the cytochrome b(558) alpha-subunit, p22(phox) (one of the key electron transfer elements of the NADPH oxidase in phagocytes), from a rat VSMC cDNA library, but its role in VSMC oxidase activity remains unclarified. Here we report that the complete inhibition of p22(phox) mRNA expression by stable transfection of antisense p22(phox) cDNA into VSMCs results in a decrease in cytochrome b content, which is accompanied by a significant inhibition of angiotensin II-stimulated NADH/NADPH-dependent superoxide production, subsequent hydrogen peroxide production, and [H-3]leucine incorporation. We provide the first evidence that p22(phox) is a critical component of superoxide-generating vascular NADH/NADPH oxidase and suggest a central role for this oxidase system in vascular hypertrophy.	EMORY UNIV, SCH MED, DIV CARDIOL, DEPT MED, ATLANTA, GA 30322 USA	Emory University			Zafari, Abarmard/GRF-6849-2022	Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL38206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038206, R01HL038206, R29HL038206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; JONES OTG, 1993, BIOCHEM SOC T, V21, P343, DOI 10.1042/bst0210343; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MALY FE, 1993, J EXP MED, V178, P2047, DOI 10.1084/jem.178.6.2047; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MOHAZZABH KM, 1994, AM J PHYSIOL-LUNG C, V267, pL823, DOI 10.1152/ajplung.1994.267.6.L823; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765; Tsai JC, 1996, J BIOL CHEM, V271, P3667; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	33	669	697	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23317	23321		10.1074/jbc.271.38.23317	http://dx.doi.org/10.1074/jbc.271.38.23317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798532	hybrid			2022-12-25	WOS:A1996VH76800058
J	Cantu, C; Huang, WZ; Palzkill, T				Cantu, C; Huang, WZ; Palzkill, T			Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; HYDROLYSIS; CEPHALOSPORINS; MUTAGENESIS; RESISTANCE; CEFOTAXIME; MUTANTS; EFFICIENCY; RESOLUTION	Recently, natural variants of TEM-1 beta-lactamase with amino acid substitutions at residues 237-240 have been identified that have increased hydrolytic activity for extended-spectrum antibiotics such as ceftazidime. To identify the sequence requirements in this region for a given antibiotic, a random library was constructed that contained all possible amino acid combinations for the S-residue region 237-240 (ABL numbering system) of TEM-1 beta-lactamase. An antibiotic disc diffusion method was used to select mutants with wild-type level activity or greater for the extended-spectrum cephalosporin ceftazidime and the monobactam aztreonam. Mutants that were selected for optimal ceftazidime hydrolysis contained a conserved Ala at position 237, a Ser for Gly substitution at position 238, and a Lys for Glu at position 240. Mutants selected for aztreonam hydrolysis exhibited a Gly for Ala substitution at position 237, a Ser for Gly substitution at position 238, and a Lys/Arg for Glu at position 240. The role of the A237G substitution in differentiating between ceftazidime and aztreonam was further investigated by kinetic analysis of the A237G, E240K, G238S:E240K, and A237G:G238S:E240K enzymes. The A237G single mutant and the G238S:E240K, double mutant exhibited increases in catalytic efficiency for both ceftazidime and aztreonam. However, the triple mutant A237G:G238S:E240K, displayed a 12-fold decrease in catalytic efficiency for ceftazidime but a 3-fold increase for aztreonam relative to the G238S:E240K double mutant. Thus, the A237G substitution increases ceftazidime hydrolysis when present alone but antagonizes ceftazidime hydrolysis when it is combined with the G238S:E240K substitutions. In contrast, the A237G substitution acts additively with the G238S:E240K substitutions to increase aztreonam hydrolysis.	BAYLOR COLL MED, STRUCT & COMPUTAT BIOL & MOLEC BIOPHYS PROGRAM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIAID NIH HHS [AI32956] Funding Source: Medline; NIGMS NIH HHS [GM17581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI032956, R01AI032956, R37AI032956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM017581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; APPELBAUM PC, 1994, J ANTIMICROB CHEMOTH, V33, P33, DOI 10.1093/jac/33.1.33; Bevington PR, 1969, DATA REDUCTION ERROR; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1982, ANTIMICROB AGENTS CH, V22, P414, DOI 10.1128/AAC.22.3.414; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; DUBOIS SK, 1995, J ANTIMICROB CHEMOTH, V35, P7; Fersht A., 1985, ENZYME STRUCTURE MEC; HEALEY WJ, 1989, PROTEINS, V6, P275, DOI 10.1002/prot.340060310; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; NEU HC, 1965, J BIOL CHEM, V240, P3685; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; PALZKILL T, 1991, METHODS COMPANION ME, V3, P155; Petrosino JF, 1996, J BACTERIOL, V178, P1821, DOI 10.1128/jb.178.7.1821-1828.1996; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; VENKATACHALAM KV, 1994, J BIOL CHEM, V269, P23444; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	31	61	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22538	22545		10.1074/jbc.271.37.22538	http://dx.doi.org/10.1074/jbc.271.37.22538			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798421	hybrid			2022-12-25	WOS:A1996VG67200040
J	Gerlitz, B; Grinnell, BW				Gerlitz, B; Grinnell, BW			Mutation of protease domain residues Lys(37-39) in human protein C inhibits activation by the thrombomodulin-thrombin complex without affecting activation by free thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; SERINE PROTEASES; RESISTANT; ANTICOAGULANT; MUTANT; MODELS; PAI-1; CA2+; CDNA	Activated protein C (aPC) is an important feedback regulator of the clotting cascade. In vivo, the conversion of protein C (PC) from its zymogen to activated form is mediated primarily by thrombin bound to thrombomodulin (TM), an endothelial cell surface protein, Molecular modeling suggests residues Lys(37)-Lys(38)-Lys(39) of protein C's serine protease domain reside in a surface-exposed loop (variable region 1) whose high concentration of positive charge might be involved in protein-protein interactions, In this study, we have examined the role of the conserved tribasic Lys(37-39) charge center in human protein C activation, This sequence was changed to acidic by substitution with Asp(37)-Glu(38)-Asp(39) (DED) and Glu(37)-Glu(38)-Glu(39) (EEE), or to neutrality by substitution with Gly(37)-Gly(38)-Gly(39) (GGG). These mutant PCs, expressed and purified from recombinant human 293 cells, appeared normal with regard to intracellular processing, ability to be secreted, and formation of a viable active site for tripeptidyl-p-nitroanilide substrate cleavage, For activation by free thrombin, wild-type (wt) and mutant PCs displayed equivalent activation rates, as well as identical calcium-dependent inhibition of such activation, Activation of wt-PC with a soluble TM-thrombin complex yielded a 2,000-fold faster rate compared with that by free thrombin at the same (physiological) calcium level, In contrast,the acidic mutants DED and EEE exhibited virtually no TM-mediated increase in activation rate, while the neutral mutant GGG was somewhat intermediate with a 30-fold stimulation of activation rate, These reductions in activation rate were independent of the presence of chondroitin sulfate on TM, Our observations represent the first identification of residues whose mutation essentially uncouples activation by the TM-thrombin complex without affecting activation by free thrombin, Further, our results suggest that VR1 residues within the zymogen form of a serine protease can be important for recognition by physiological activators.	LILLY CORP CTR,LILLY RES LABS,DEPT CARDIOVASC RES,INDIANAPOLIS,IN 46285	Eli Lilly								ADAMS DS, 1991, J BIOL CHEM, V266, P8476; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; COOPER ST, 1995, BIOCHEMISTRY-US, V34, P12991, DOI 10.1021/bi00040a009; DAHLBACK B, 1995, THROMB HAEMOSTASIS, V74, P139; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FISHER CL, 1994, PROTEIN SCI, V3, P588; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LIU LW, 1994, J BIOL CHEM, V269, P11807; LONG GL, 1984, P NATL ACAD SCI-BIOL, V81, P5653, DOI 10.1073/pnas.81.18.5653; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; RICHARDSON MA, 1994, PROTEIN SCI, V3, P711; TADA N, 1992, J BIOCHEM-TOKYO, V111, P491, DOI 10.1093/oxfordjournals.jbchem.a123785; TESTA JE, 1995, FIBRINOLYSIS, V9, P93, DOI 10.1016/S0268-9499(95)80070-0; TOMA K, 1989, J MOL GRAPHICS, V7, P146, DOI 10.1016/0263-7855(89)80018-9; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655	28	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22285	22288		10.1074/jbc.271.37.22285	http://dx.doi.org/10.1074/jbc.271.37.22285			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798383	hybrid			2022-12-25	WOS:A1996VG67200002
J	Klein, S; Bikfalvi, A; Birkenmeier, TM; Giancotti, FG; Rifkin, DB				Klein, S; Bikfalvi, A; Birkenmeier, TM; Giancotti, FG; Rifkin, DB			Integrin regulation by endogenous expression of 18-kDa fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; MOLECULAR-WEIGHT FORMS; HEPARIN-LIKE MOLECULES; FACTOR RECEPTOR GENES; SIGNAL-TRANSDUCTION; FIBRONECTIN RECEPTOR; ELEVATED LEVELS; BLOOD-VESSELS; FACTOR-II; BINDING	The three high molecular weight (HMW) forms of fibroblast growth factor-2 (FGF-2) have a distinct intracellular localization and differentially affect cell mobility and growth compared with the fourth 18-kDa form. To characterize further the effects of the 18-kDa and HMW forms of FGF-2, we have examined their ability to modulate integrin expression. Transfected NIH 3T3 cells expressing only 18-kDa FGF-2 exhibited increased cell surface levels of alpha 5 beta 1, whereas cells expressing only HMW FGF-2 exhibited cell surface alpha 5 beta 1 levels similar to parental cells. When cells synthesizing 18-kDa FGF-2 were transfected with a cDNA encoding a dominant negative FGF receptor, alpha 5 beta 1 cell surface levels decreased. Immunoprecipitation of biosynthetically labeled cells indicated that expression of 18-kDa FGF-2 increased the biosynthesis and rate of maturation of alpha 5. Northern blot analysis showed that 18-kDa FGF-2 increases the level of the alpha 5 subunit mRNA but does not affect beta 1 subunit transcript levels. Experiments utilizing luciferase reporter gene activity revealed increased alpha 5 promoter activity in cells expressing 18-kDa FGF-S indicating that the enhanced alpha 5 transcript level is due to modulation of the transcription rate. Therefore, interaction of 18-kDa FGF-2 with FGF receptors results in changes in alpha 5 beta 1 biosynthesis and processing. In contrast, endogenous expression of HMW FGF-2 does not mediate this effect.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,RAYMOND & BEVERLY SACKLER FDN LAB,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV BORDEAUX 1,LAB GROWTH FACTORS & CELL DIFFERENTIAT,F-33405 TALENCE,FRANCE; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110	New York University; New York University; New York University; UDICE-French Research Universities; Universite de Bordeaux; Washington University (WUSTL)	Klein, S (corresponding author), NYU,MED CTR,DEPT CELL BIOL,MSB 650,550 1ST AVE,NEW YORK,NY 10016, USA.				NATIONAL CANCER INSTITUTE [R01CA034282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007238] Funding Source: NIH RePORTER; NCI NIH HHS [CA23753, CA34282] Funding Source: Medline; NIGMS NIH HHS [5T32GM07238-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BEAUVAIS A, 1995, J CELL BIOL, V128, P699, DOI 10.1083/jcb.128.4.699; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BISCHOFF J, 1995, TRENDS CELL BIOL, V5, P69, DOI 10.1016/S0962-8924(00)88949-7; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; DRAKE CJ, 1992, DEV DYNAM, V193, P83, DOI 10.1002/aja.1001930111; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; LIU L, 1993, DEV BIOL, V157, P507, DOI 10.1006/dbio.1993.1153; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIESE J, 1995, MECH DEVELOP, V49, P13, DOI 10.1016/0925-4773(94)00296-Y; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sambrook J., 2002, MOL CLONING LAB MANU; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SMITH JC, 1990, DEVELOPMENT, V108, P229; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; UENO H, 1992, J BIOL CHEM, V267, P1470; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	59	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22583	22590		10.1074/jbc.271.37.22583	http://dx.doi.org/10.1074/jbc.271.37.22583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798427	hybrid			2022-12-25	WOS:A1996VG67200046
J	Rosok, MJ; Yelton, DE; Harris, LJ; Bajorath, J; Hellstrom, KE; Hellstrom, I; Cruz, GA; Kristensson, K; Lin, H; Huse, WD; Glaser, SM				Rosok, MJ; Yelton, DE; Harris, LJ; Bajorath, J; Hellstrom, KE; Hellstrom, I; Cruz, GA; Kristensson, K; Lin, H; Huse, WD; Glaser, SM			A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESHAPING HUMAN-ANTIBODIES; MONOCLONAL-ANTIBODY; RECOMBINANT IMMUNOTOXIN; HYPERVARIABLE REGIONS; FRAMEWORK RESIDUES; VARIABLE DOMAINS; MOUSE; MUTAGENESIS; ANTIGEN; CONFORMATION	We have used a combinatorial mutagenesis strategy to humanize BR96, a monoclonal antibody that binds to the Lewis Y class of tumor antigens. This approach allows simultaneous assessment of hundreds of humanized variable regions to identify the molecules that best preserve affinity, thus overcoming the major drawback of current humanization procedures, the requirement to construct and analyze each humanized antibody separately. Murine residues of BR96 were mutated to human if they were solvent-exposed residues that did not participate in the formation of the antigen binding site and were not at the interface of the light and heavy chain. At positions that might be involved in binding to antigen, the choice between the murine and human residue was more difficult. Murine and human alternatives were incorporated into a combinatorial library at positions representing buried residues that might affect the structural integrity of the antigen binding site. By encoding this library of humanized BR96 Fabs in an M13 phage vector, we rapidly identified several candidates with nearly identical antigen binding, within 2-fold, of the chimeric Fab. Additional mutagenesis directed at sites suggested in the literature as potentially important for antigen binding in a similar anti-Lewis Y antibody yielded no further improvements.	IXSYS INC, SAN DIEGO, CA 92121 USA		Rosok, MJ (corresponding author), BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, 3005 1ST AVE, SEATTLE, WA 98121 USA.		Bajorath, Jürgen/F-7493-2014					BAJORATH J, 1994, BIOCONJUGATE CHEM, V5, P213, DOI 10.1021/bc00027a006; BENHAR I, 1994, P NATL ACAD SCI USA, V91, P12051, DOI 10.1073/pnas.91.25.12051; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CO MS, 1992, J IMMUNOL, V148, P1149; COUTO JR, 1995, CANCER RES, V55, P1717; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GLASER S, 1995, ANTIBODY ENG; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HALE G, 1988, LANCET, V2, P1394; HARRIS L, 1995, PROTEIN SCI, V4, P306; HELLSTROM I, 1990, CANCER RES, V50, P2183; HSIAO KC, 1994, PROTEIN ENG, V7, P815, DOI 10.1093/protein/7.6.815; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773; KHAZAELI MB, 1994, J IMMUNOTHER, V15, P42, DOI 10.1097/00002371-199401000-00006; KRISTENSSON K, 1995, VACCINES, V95, P39; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MILLER RA, 1983, BLOOD, V62, P988; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; NEAR RI, 1992, BIOTECHNIQUES, V12, P88; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; PASTAN I, 1991, CANCER RES, V51, P3781; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; ROGUSKA MA, 1994, P NATL ACAD SCI USA, V91, P969, DOI 10.1073/pnas.91.3.969; ROUTLEDGE EG, 1993, PROTEIN ENG ANTIBODY, P14; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHROFF RW, 1985, CANCER RES, V45, P879; SINGER II, 1993, J IMMUNOL, V150, P2844; STUDNICKA GM, 1994, PROTEIN ENG, V7, P805, DOI 10.1093/protein/7.6.805; TESSIER DC, 1993, BIOTECHNIQUES, V15, P498; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; YELTON DE, 1995, J IMMUNOL, V155, P1994	44	50	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22611	22618		10.1074/jbc.271.37.22611	http://dx.doi.org/10.1074/jbc.271.37.22611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798431	hybrid			2022-12-25	WOS:A1996VG67200050
J	Franzke, CW; Baici, A; Bartels, J; Christophers, E; Wiedow, O				Franzke, CW; Baici, A; Bartels, J; Christophers, E; Wiedow, O			Antileukoprotease inhibits stratum corneum chymotryptic enzyme - Evidence for a regulative function in desquamation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCUS PROTEINASE-INHIBITOR; AMINO-ACID-SEQUENCE; LEUKOCYTE PROTEASE INHIBITOR; ELASTASE-SPECIFIC INHIBITOR; HUMAN SKIN; HUSI-I; PURIFICATION; HOMOLOGY; ELAFIN	The stratum corneum chymotryptic enzyme (SCCE) has been previously purified from human stratum corneum and resembles a chymotryptic serine endopeptidase involved in physiological detachment of corneocytes from human stratum corneum. From human stratum corneum two inhibitory activities of SCCE could be extracted. These were due to serine protease inhibitors already known to be present in human epidermis, antileukoprotease (secretory leukocyte protease inhibitor) and elafin (skin-derived antileukoprotease). The Inhibition of SCCE by antileukoprotease shows a hyperbolic, mixed type inhibition with an equilibrium dissociation constant of 63 nM. Antileukoprotease also inhibits detachment of corneocytes from human plantar callus in vitro almost completely (>96%). In addition, elafin was shown to be a weak inhibitor for SCCE activity, and elafin significantly reduces the shedding of corneocytes. Thus, antileukoprotease, which is known to be produced by human keratinocytes, is likely to be the major physiological inhibitor of SCCE in the epidermis. It seems to be involved in the regulation of desquamation under physiological and pathophysiological conditions.	CHRISTIAN ALBRECHTS UNIV KIEL,DEPT DERMATOL,D-24105 KIEL,GERMANY; UNIV ZURICH HOSP,DEPT RHEUMATOL,CH-8091 ZURICH,SWITZERLAND	University of Kiel; University of Zurich; University Zurich Hospital			Bartels, Joachim H./B-2802-2009; Wiedow, Oliver/B-7414-2009	Baici, Antonio/0000-0002-2980-0541; Bartels, Joachim/0000-0003-4395-4552				BAICI A, 1981, EUR J BIOCHEM, V119, P9, DOI 10.1111/j.1432-1033.1981.tb05570.x; BOTTS J, 1953, T FARADAY SOC, V49, P696, DOI 10.1039/tf9534900696; BOUDIER C, 1992, J BIOL CHEM, V267, P4370; BRAUN NJ, 1987, BIOL CHEM H-S, V368, P299, DOI 10.1515/bchm3.1987.368.1.299; CHRISTENSEN MS, 1978, J INVEST DERMATOL, V71, P289, DOI 10.1111/1523-1747.ep12529180; EGELRUD T, 1993, ACTA DERM-VENEREOL, V73, P181; EGELRUD T, 1993, J INVEST DERMATOL, V101, P200, DOI 10.1111/1523-1747.ep12363804; EGELRUD T, 1991, ARCH DERMATOL RES, V283, P108, DOI 10.1007/BF00371618; FRITZ H, 1988, BIOL CHEM H-S, V369, P79; HANNSON L, 1994, BIOCH MOL BIOL, V269, P19420; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; LUNDSTROM A, 1988, J INVEST DERMATOL, V91, P340, DOI 10.1111/1523-1747.ep12475679; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; SALLENAVE JM, 1991, BIOL CHEM H-S, V372, P13, DOI 10.1515/bchm3.1991.372.1.13; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SONDELL B, 1995, J INVEST DERMATOL, V104, P819, DOI 10.1111/1523-1747.ep12607007; SONDELL B, 1994, J HISTOCHEM CYTOCHEM, V42, P459, DOI 10.1177/42.4.7510318; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SZEDLACSEK SE, 1987, BIOCHEM J, V254, P311; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; WIEDOW O, 1993, J INVEST DERMATOL, V101, P305, DOI 10.1111/1523-1747.ep12365430; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WIEDOW O, 1995, ISOLIERUNG CHARAHTER	23	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21886	21890		10.1074/jbc.271.36.21886	http://dx.doi.org/10.1074/jbc.271.36.21886			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702990	hybrid			2022-12-25	WOS:A1996VF61200032
J	Henry, NL; Bushnell, DA; Kornberg, RD				Henry, NL; Bushnell, DA; Kornberg, RD			A yeast transcriptional stimulatory protein similar to human PC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GENE-TRANSCRIPTION; PURIFICATION; ACTIVATION; COACTIVATOR; INITIATION; BINDING; IDENTIFICATION; HOLOENZYME; ALIGNMENT	A yeast protein has been identified that stimulates basal transcription by RNA polymerase II, binds both single- and double-stranded DNA, and interacts with both a general transcription factor and a transcriptional activator. Phosphorylation appears to regulate these interactions. The gene for the transcriptional stimulatory protein, termed TSP1, was cloned and found to be dispensable for yeast cell viability. The deduced amino acid sequence is similar to that of mammalian coactivator protein PC4.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659, GM07276-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Guthrie C., 1991, METHODS ENZYMOLOGY G; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SOMA GI, 1984, BIOCHEM BIOPH RES CO, V124, P164, DOI 10.1016/0006-291X(84)90931-8; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	33	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21842	21847		10.1074/jbc.271.36.21842	http://dx.doi.org/10.1074/jbc.271.36.21842			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702984	hybrid			2022-12-25	WOS:A1996VF61200026
J	Tischer, E; Cordell, B				Tischer, E; Cordell, B			beta-amyloid precursor protein - Location of transmembrane domain and specificity of gamma-secretase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; TRANSGENIC MICE; CULTURED-CELLS; CATHEPSIN-D; MUTATION; PEPTIDE; GENERATION; DEPOSITS; AMINO; TERMINUS	The formation of beta-amyloid by processing of its precursor protein is a characteristic of Alzheimer's disease. Two proteolytic cleavages produce the amino and carboxyl termini of beta-amyloid, with the latter cleavage site located within the transmembrane domain. Using DNA mutagenesis, we investigated the membrane position and sequence requirements for carboxyl-terminal processing of the beta-amyloid domain. Substitution of negatively charged residues across positions 40-46 of the beta-amyloid domain precluded both beta-amyloid formation and precursor maturation associated with secretory protein transport. In contrast, identical substitutions from positions 48-50 had no adverse effects. Since charged residues typically prevent protein membrane insertion, these data define the membrane boundary to position 46/47, a location allowing greater access to carboxyl-terminal processing of beta-amyloid, possibly without membrane destruction. Deletions within the carboxyl-terminal domain, including 4 residues spanning positions 39-42 of beta-amyloid, resulted in formation of the beta-amyloid peptide. Substituting residues 38-47 or 39-56 of the beta-amyloid domain in the precursor with a transmembrane sequence from another protein yielded a similar to 4-kDa beta-amyloid peptide, reflecting a loose residue specificity for carboxyl-terminal processing to beta-amyloid.	SCIOS NOVA INC,MT VIEW,CA 94043	Scios								ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P1072; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; ISHIURA S, 1990, NEUROSCI LETT, V115, P329, DOI 10.1016/0304-3940(90)90477-Q; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LADROR US, 1994, J BIOL CHEM, V269, P18422; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MUNDY DI, 1994, BIOCHEM BIOPH RES CO, V204, P333, DOI 10.1006/bbrc.1994.2464; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; ZHONG ZY, 1994, J BIOL CHEM, V269, P627; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	42	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21914	21919		10.1074/jbc.271.36.21914	http://dx.doi.org/10.1074/jbc.271.36.21914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702994	hybrid			2022-12-25	WOS:A1996VF61200036
J	Kim, CG; Park, D; Rhee, SG				Kim, CG; Park, D; Rhee, SG			The role of carboxyl-terminal basic amino acids in G(q)alpha-dependent activation, particulate association, and nuclear localization of phospholipase C-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDASE-C-BETA; PROTEIN ALPHA-SUBUNIT; BOVINE BRAIN; EXPRESSION SYSTEM; VACCINIA VIRUS; DNA-POLYMERASE; CELLS; PURIFICATION; ISOZYMES	The phospholipase C (PLC)-beta isozymes differ from the PLC-gamma and PLC-delta isozymes in that they possess a long COOH-terminal sequence downstream of their catalytic domain, are activated by alpha subunits of the G(q) class of G proteins, associate with the particulate subcellular fraction, and are present in the nucleus. Most of the COOH-terminal domain of PLC-beta isozymes is predicted to be helical, and three regions in this domain, PLC-beta 1 residues 911-928 (region 1), 1055-1072 (region 2), and 1109-1126 (region 3), contain a high proportion of basic residues that are highly conserved. Projection of the sequences of these three regions in helical wheels reveals clustering of the basic residues. The role of the COOH terminus and the clustered basic residues in PLC-beta 1 was investigated by either truncating the entire COOH-terminal domain (mutant Delta C) or replacing two or three clustered basic residues with isoleucine (or methionine), and expressing the mutant enzymes in CV-1, Rat-2, or Swiss 3T3 cells. The Delta C mutant no longer showed the ability to be activated by G(q) alpha, to translocate to the nucleus, or to associate with the particulate fraction. Substitution of clusters of basic residues in regions 1 and 2 generally reduced the extent of activation by G(q) alpha, whereas substitution of a basic cluster in region 3 had no effect. Substitution of the cluster of lysine residues 914, 921, and 925 in region 1 had the most marked effect, reducing G(q) alpha-dependent activity to 10% of that of wild type. All substitution mutants, with the exception of that in which lysine residues 1056, 1063, and 1070 in region 2 were substituted with isoleucine, behaved like the wild-type enzyme in showing an approximately equal distribution between cytoplasm and nucleus; only 12% of the region 2 mutant was present in the nucleus. None of the basic clusters appeared critical for particulate association; however, replacement of each cluster reduced the amount of PLC-beta 1 in the particulate fraction by some extent, suggesting that all the basic residues contribute to the association, presumably by interacting with acidic residues in the particulate fraction, Membrane localization of PLC-beta isozymes is therefore likely mediated by both the COOH-terminal domain and the pleckstrin homology domain, the latter of which is known to bind phosphatidylinositol 4,5-biphosphate.	NHLBI,LAB CELL SIGNALING,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P720, DOI 10.1016/0006-291X(89)90054-5; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1995, BIOCHEM J, V312, P63, DOI 10.1042/bj3120063; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUKUI T, 1988, J BIOL CHEM, V263, P17730; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JHON DY, 1993, J BIOL CHEM, V268, P8654; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; LASKEY RA, 1993, CELL, V74, P385; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LEE SB, 1993, J BIOL CHEM, V268, P25952; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MARTELLI AM, 1994, CANCER RES, V54, P2536; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WU DQ, 1993, J BIOL CHEM, V268, P3704; YORK JD, 1994, J BIOL CHEM, V269, P7847	41	188	191	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21187	21192		10.1074/jbc.271.35.21187	http://dx.doi.org/10.1074/jbc.271.35.21187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702889	hybrid			2022-12-25	WOS:A1996VE47700035
J	Kridel, SJ; Chan, WW; Knauer, DJ				Kridel, SJ; Chan, WW; Knauer, DJ			Requirement of lysine residues outside of the proposed pentasaccharide binding region for high affinity heparin binding and activation of human antithrombin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE CHEMICAL MODIFICATION; THROMBIN REACTION; SITE; IDENTIFICATION; PURIFICATION; ACCELERATION; MECHANISM; CELLS; GLYCOSYLATION; ARGININE-129	Variant forms of human antithrombin III with glutamine or threonine substitutions at Lys(114), Lys(125), Lys(133), Lys(136), and Lys(139) were expressed in insect cells to evaluate their roles in heparin binding and activation. Recombinant native ATIII and all of the variants had very similar second order rate constants for thrombin inhibition in the absence of heparin, ranging from 1.13 x 10(5) M(-1)min(-1) to 1.66 x 10(5) M(-1)min(-1). Direct binding studies using I-125-fluoresceinamine-heparin yielded a K-d of 6 nM for the recombinant native ATIII and K136T, whereas R114Q and K139Q bound heparin so poorly that a K-d could not be determined. K125Q had a moderately reduced affinity. Heparin binding affinity correlated directly with heparin cofactor activity. Recombinant native ATIII was nearly identical to plasma-purified ATIII, whereas K114Q and K139Q were severely impaired in heparin cofactor activity. K125Q and K136T were only slightly impaired. Based on these data, Lys(114) and Lys(139) which are outside of the putative pentasaccharide binding site, play pivotal roles in the high affinity binding of heparin to ATIII and the activation of thrombin inhibitory activity.	UNIV CALIF IRVINE,SCH BIOL SCI,DEPT DEV & CELL BIOL,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01-GM34001-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETHELL GS, 1979, J BIOL CHEM, V254, P2572; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DD, 1987, BEHAV RES THER, V25, P223, DOI 10.1016/0005-7967(87)90049-0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHANG JY, 1989, J BIOL CHEM, V264, P3111; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P494; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DUCHANGE N, 1987, THROMB RES, V45, P115, DOI 10.1016/0049-3848(87)90263-5; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; FAN BQ, 1993, J BIOL CHEM, V268, P17588; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; Higuchi R, 1988, NUCLEIC ACIDS RES, V16, P7352; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LIU CS, 1987, J BIOL CHEM, V262, P17356; LIU CS, 1987, EUR J BIOCHEM, V167, P247, DOI 10.1111/j.1432-1033.1987.tb13330.x; MEAGHER JL, 1996, INT S CHEM BIOL SERP; MOLLOY C, 1989, THROMB RES, V55, P657, DOI 10.1016/0049-3848(89)90399-X; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OWEN MC, 1987, BLOOD, V69, P1275; PECON JM, 1984, J BIOL CHEM, V259, P935; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENFELD L, 1987, BIOCHEMISTRY-US, V12, P639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH JW, 1990, BIOCHEMISTRY-US, V29, P8950, DOI 10.1021/bi00490a010; SMITH JW, 1987, J BIOL CHEM, V262, P11964; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; WICKHAM TJ, 1993, BIOTECHNOL PROGR, V9, P25, DOI 10.1021/bp00019a004	41	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20935	20941		10.1074/jbc.271.34.20935	http://dx.doi.org/10.1074/jbc.271.34.20935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702852	hybrid			2022-12-25	WOS:A1996VD33700104
J	Li, HM; Lahti, JM; Kidd, VJ				Li, HM; Lahti, JM; Kidd, VJ			Alternatively spliced cyclin C mRNA is widely expressed, cell cycle regulated, and encodes a truncated cyclin box	ONCOGENE			English	Article						cyclin C; alternative splicing; cell cycle	ACUTE LYMPHOBLASTIC-LEUKEMIA; RNA-POLYMERASE-II; PROTEIN-KINASE; CLN FUNCTION; GENE; CHILDHOOD; YEAST; IDENTIFICATION; ARREST	The cyclin C protein has recently been shown to associate with a unique cyclin dependent protein kinase (cdk8) and it has been proposed that this complex may regulate RNA transcription during the cell cycle. In addition, the human cyclin C gene has been localized to human chromosome 6q21 and it was found to be frequently deleted in a subset of acute lymphoblastic leukemias (ALL's). Screening of an avian T-cell cDNA library resulted in the isolation of a cyclin C homologue as well as an abundant, yet distinct, cyclin C-related cDNA. The predicted open reading frame (ORF) of the cyclin C cDNA predicted a 283 amino acid protein that was >99% identical to the human protein and 72% identical to the Drosophila melanogaster protein. However, the predicted ORF of the cyclin C-related cDNA predicted a much smaller 105 amino acid protein that was identical to cyclin C well into the cyclin-box region (amino acid residue 98), where it abruptly diverges and then terminates. Using PCR analysis of cDNA derived from a range of cell lines and tissues, alternative splicing of the avian cyclin C gene has been demonstrated. Furthermore, a smaller similar to 19 kDa protein that co-migrates with the in vitro transcribed and translated truncated cyclin C protein was detected in normal and virally-transformed avian cells with a cyclin C-specific antibody, Expression of alternatively spliced cyclin C mRNA and protein is regulated in a cell cycle-dependent manner reminiscent of cyclin B2. The function of this truncated cyclin C protein is not known, but its expression in avian cells suggest that this truncated cyclin C protein may participate as an early endogenously encoded cyclin C inhibitor.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765, R01CA067938] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67938, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DEMETRICK DJ, 1995, CYTOGENET CELL GENET, V69, P190, DOI 10.1159/000133960; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EIPERS PG, 1992, GENOMICS, V13, P613, DOI 10.1016/0888-7543(92)90132-C; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; KEYOMARSI K, 1995, ONCOGENE, V15, P2612; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOWALCZYK JR, 1985, CANCER GENET CYTOGEN, V15, P47, DOI 10.1016/0165-4608(85)90130-X; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LAHTI JM, 1991, P NATL ACAD SCI USA, V88, P10595; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; LI HM, 1995, GENE, V153, P237, DOI 10.1016/0378-1119(94)00801-X; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ONEILL EM, 1995, NATURE, V374, P121, DOI 10.1038/374121a0; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PRIGOGINA EL, 1988, CANCER GENET CYTOGEN, V32, P183, DOI 10.1016/0165-4608(88)90281-6; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; XIANG JL, 1994, J BIOL CHEM, V269, P15786	29	17	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					705	712						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761291				2022-12-25	WOS:A1996VD43300005
J	BrownAugsburger, P; Chang, D; Rust, K; Crouch, ED				BrownAugsburger, P; Chang, D; Rust, K; Crouch, ED			Biosynthesis of surfactant protein D - Contributions of conserved NH2-terminal cysteine residues and collagen helix formation to assembly and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HISTOCOMPATIBILITY COMPLEX-MOLECULES; ALVEOLAR MACROPHAGES; ENDOPLASMIC-RETICULUM; DISULFIDE BOND; CARBOHYDRATE; CALNEXIN; MEMBRANE; BINDING; OLIGOSACCHARIDE	Surfactant protein D (SP-D) is preferentially secreted as dodecamers consisting of four collagenous trimers cross-linked by disulfide bonds, In these studies, we examined the biosynthesis of wild-type rat SP-D (RrSP-D) and selected mutants by stably transfected CHO-KI cells to determine the roles of a conserved N-linked oligosaccharide, the collagen helix, and interchain disulfide bonds in SP-D assembly and secretion, The major intracellular form of RrSP-D accumulated in the RER as complexes containing up to four trimeric subunits. Disulfide cross-link formation and RrSP-D secretion were selectively inhibited by 2,2'-dipyridyl, an inhibitor of prolyl and lysyl hydroxylase, and by 2 mM dithiothreitol, but unaffected by tunicamycin or elimination of the consensus sequence for glycosylation at Asn(70), Although mutants with serine substituted for Cys(15) and Cys(20) (RrSP-Dser15/20) are secreted as trimeric subunits, proteins with single cysteine substitutions were retained in the cell, Surprisingly, the secretion of RrSP-Dser15/20 was unaffected by 2,2'-dipyridyl. These studies strongly suggest that the most important and rate-limiting step for the secretion of SP-D involves the association of crosslinked trimeric subunits to form dodecamers stabilized by specific inter-subunit disulfide cross-links, Interference with collagen helix formation prevents secretion by interfering with efficient disulfide cross-linking of the NH2-terminal domain.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [HL29594, 5T32HL07317, HL44015] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015, T32HL007317, P01HL029594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORN JL, 1992, AM J PHYSIOL, V262, pL437, DOI 10.1152/ajplung.1992.262.4.L437; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BROWNAUGSBURGER P, 1996, IN PRESS J BIOL CHEM; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; COLLEY KJ, 1987, J BIOL CHEM, V262, P3415; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1991, AM J PATHOL, V139, P765; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1994, J BIOL CHEM, V269, P15808; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P456, DOI 10.1042/bst0210456; Hartshorn KL, 1996, BLOOD, V87, P3450, DOI 10.1182/blood.V87.8.3450.bloodjournal8783450; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; LIMPER AH, 1995, J LAB CLIN MED, V126, P416; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MAGARGAL WW, 1978, J BIOL CHEM, V253, P8311; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MORAND JN, 1986, ANAL BIOCHEM, V159, P157, DOI 10.1016/0003-2697(86)90321-0; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WRIGHT JR, 1995, AM J PHYSIOL-LUNG C, V268, pL772, DOI 10.1152/ajplung.1995.268.5.L772; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	44	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18912	18919		10.1074/jbc.271.31.18912	http://dx.doi.org/10.1074/jbc.271.31.18912			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8756121	hybrid			2022-12-25	WOS:A1996VB68300091
J	Loughran, O; Malliri, A; Owens, D; Gallimore, PH; Stanley, MA; Ozanne, B; Frame, MC; Parkinson, EK				Loughran, O; Malliri, A; Owens, D; Gallimore, PH; Stanley, MA; Ozanne, B; Frame, MC; Parkinson, EK			Association of CDKN2A/p16(INK4A) with human head and neck keratinocyte replicative senescence: Relationship of dysfunction to immortality and neoplasia	ONCOGENE			English	Article						CDKN2; p16; immortality; keratinocyte; senescence; SCC	SQUAMOUS-CELL CARCINOMA; HUMAN-DIPLOID FIBROBLASTS; PRIMARY TUMORS; GENE-PRODUCT; TELOMERASE ACTIVITY; CYCLE INHIBITION; P16/CDKN2 GENE; LUNG-CANCER; LINES; EXPRESSION	We have previously suggested that a gene mapping to chromosome 9p21 could contribute to replicative senescence and suppress cullular immortality in squamous neoplasia. Two candidate genes, the cyclin D-1/cyclin-dependent kinase inhibitors CDKN2A/p16(INK4A) (p16) and CDKN2B/p15(INK4B) (p15) have now been identified in this region and we show here that p16 is upregulated when normal human keratinocytes undergo replicative senescence but not when they undergo differentiation. Furthermore, all of 19 immortal neoplastic keratinocyte head and neck lines, including nine showing loss of heterozygosity (LOH) at 9p21, showed undetectable p16 expression, whereas five of six senescent neoplastic cultures showed normal levels of expression. The retinoblastoma protein (pRb) appeared functional in all the cell lines and cultures examined. The mechanism of p16 inactivation appeared to be transcriptional silencing in 10 of 18 lines and homozygous deletions in the rest. Treatment of two of the immortal cell lines which had transcriptionally silent wild type p16 genes with 5aza-2deoxycytidine resulted in the re-expression of p16, thus implicating DNA methylation as one mechanism of transcriptional silencing in the immortal SCC-HN lines. We observed no cases of p16 point mutation. In contrast, the p15 gene was rarely transcriptionally silent and was not deleted in any of the cell lines which showed p16 deletions. Our results show that p16 dysfunction correlates strongly with keratinocyte immortalisation but less strongly with the stage of tumour progression. P16 dysfunction was not related to the neoplastic state or the length of time spent in vitro. The results also suggest that p16 but not p15 is involved in the keratinocyte replicative senescence programme. However, two neoplastic cell cultures which lacked p16 expression were still mortal, suggesting that the loss of p16 is a necessary but insufficient condition for human keratinocyte immortality.	BEATSON INST CANC RES,CRC BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV BIRMINGHAM,SCH MED,CRC INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	Beatson Institute; University of Birmingham; University of Cambridge								ARAP W, 1995, CANCER RES, V55, P1351; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BERRY IJ, 1994, MOL CARCINOGEN, V9, P134, DOI 10.1002/mc.2940090305; BROWN KW, 1987, BRIT J CANCER, V56, P545, DOI 10.1038/bjc.1987.240; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; BURNS JE, 1994, BRIT J CANCER, V70, P591, DOI 10.1038/bjc.1994.356; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHANG SE, 1992, INT J CANCER, V52, P896, DOI 10.1002/ijc.2910520612; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAUFMANN WF, 1995, CANCER RES, V55, P493; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LOIS AF, 1995, CANCER RES, V55, P4010; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LOUGHRAN O, 1996, UNPUB; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAGAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, CELL, V83, P993; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; VANDERRIET P, 1994, CANCER RES, V54, P1156; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WILKE MS, 1988, LAB INVEST, V58, P660; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YEAGER T, 1995, CANCER RES, V55, P493; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG SY, 1994, CANCER RES, V54, P5050	59	127	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					561	568						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760298				2022-12-25	WOS:A1996VB32800013
J	Tarunina, M; Grimaldi, M; Ruaro, E; Pavlenko, M; Schneider, C; Jenkins, JR				Tarunina, M; Grimaldi, M; Ruaro, E; Pavlenko, M; Schneider, C; Jenkins, JR			Selective loss of endogenous p21(waf1/cip1) induction underlies the G(1) checkpoint defect of monomeric p53 proteins	ONCOGENE			English	Article						p53; oligomerisation; G(1) checkpoint; p21(waf1/cip1); induction; apoptosis	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL NUCLEAR ANTIGEN; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TRANS-ACTIVATION; GENE; APOPTOSIS; TRANSFORMATION	Wild-type p53 protein displays a spectrum of activities including the ability to suppress transformed cell growth, to direct apoptotic cell death and to mediate G(1) checkpoint in response to cellular DNA damage. Earlier work showed that a self-association defective p53 protein retained transformation suppressor activity in rat embryo fibroblast based assays, but that monomerisation of tumour mutant p53 proteins resulted in loss of dominant transforming activity. In order to acquire a more detailed understanding of the biological consequences attendant on disruption of p53:p53 association we have carried out a study of the wild-type-like activities that are retained by monomeric p53 proteins and which are associated with the suppression of transformation. Here we show that monomeric p53 proteins are G(1) checkpoint defective. Although able to stimulate transcription via a p53 DNA binding motif from the p21(waf1/cip1) gene promoter in episome based assays these p53 proteins are unable to transactivate the chromosomal p21(waf1/cip1) gene and are sensitive both to degeneracy of consensus binding site and to half site spacing. Monomeric p53 proteins fail to trigger apoptosis in a BRK cell line transformed with E7 and ras. However, they retain wild type transformation suppressor activity in BRK cell based transformation assays. Our results indicate that p21(waf1/cip1) induction and all related p53 dependent G(1) checkpoint activities are dispensable for the p53 directed suppression of transformed cell growth, and that such transformation suppression by monomeric p53 proteins may occur in the absence of an apoptotic response.	MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND; LAB NAZL CONSORZIO INTERUNIV BIOTECNOL,I-34012 TRIESTE,ITALY; RUSSIAN ACAD SCI,INST CYTOL,ST PETERSBURG 194064,RUSSIA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HIRANO Y, 1995, ONCOGENE, V10, P1879; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI YJ, 1995, ONCOGENE, V10, P599; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; TARUNINA M, 1993, CHALL MOD MED, V1, P221; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; YOUDALE T, 1975, J CELL PHYSIOL, V86, P495, DOI 10.1002/jcp.1040860306; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHANG W, 1994, ONCOGENE, V9, P2513	68	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					589	598						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760300				2022-12-25	WOS:A1996VB32800016
J	Niikura, M; Dornadula, G; Zhang, H; Mukhtar, M; Duan, LX; Khalili, K; Bagasra, O; Pomerantz, RJ				Niikura, M; Dornadula, G; Zhang, H; Mukhtar, M; Duan, LX; Khalili, K; Bagasra, O; Pomerantz, RJ			Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell	ONCOGENE			English	Article						HIV-1; astrocytes; glia; transcription; tat	IMMUNE-DEFICIENCY SYNDROME; LONG TERMINAL REPEAT; HIV-1 TAT PROTEIN; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; RNA-BINDING PROTEIN; TRANS-ACTIVATION; HUMAN-BRAIN; INDEPENDENT ACTIVATION; GENE-EXPRESSION	Unique transcriptional transactivation by the human immunodeficiency virus type 1 (HIV-1) Tat protein of long terminal repeat (LTR)-driven RNA expression, in the absence of the transactivator responsive element (TAR), was previously demonstrated in central nervous system (CNS)-derived astrocytic cell-lines, including U87MG. In the present study, RNase protection assays were utilized to reveal the molecular mechanism(s) underlying transactivation of the HIV-1-LTR in these cells. Short transcripts, which represent abortive HIV-1 transcription, could not be detected either in the absence or presence of Tat, and no differences in transcript levels were detected using 5' probes, as compared to 3' probes, in the experiments. Thus, the transactivational effects of Tat, in U87MG cells, were potentially based on the increase of transcriptional initiation, both in TAR-dependent and -independent states. Further, by using newly established stable cellular transformant, containing HIV-1-LTR-reporter gene constructs, TAR-independent transactivation was demonstrated to efficiently function primarily in transiently-transfected U87MG cells. U87MG cells, stably-transfected with the intact HIV-1 proviral genome, produced very low levels of virus after long-term culture, as previously reported in other astrocytic cells. These cells demonstrated profoundly restricted transcription of the HIV-1 genome, with no detectable levels of HIV-1-specific RNA by Northern blotting, indicating that the restriction of viral production in these cells is principally due to the low level of overall transcription from the 5' HIV-1-LTR. Transcription of HIV-1 RNA in this cell could not be significantly up-regulated by various stimulators, such as phorbol 12-myristate 13-acetate (PMA), tumor necrosis factor-alpha (TNF-alpha) and sodium butyrate. These data suggest that the restriction of HIV-1 transcription in these cells may be controlled by different mechanism(s) from those in lymphocytic or monocytic cells.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,DORRANCE H HAMILTON LABS,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,JEFFERSON INST MOL MED,MOL NEUROVIROL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030916] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31836] Funding Source: Medline; NINDS NIH HHS [NS30916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ALDOVINI A, 1990, TECHNIQUES HIV RES, P147; BAGASRA O, 1992, J VIROL, V66, P7522, DOI 10.1128/JVI.66.12.7522-7528.1992; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BLUMBERG BM, 1994, VIRUS RES, V32, P253, DOI 10.1016/0168-1702(94)90044-2; BRACKWERNER R, 1992, AIDS, V6, P273, DOI 10.1097/00002030-199203000-00003; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DUAN LX, 1994, VIROLOGY, V199, P474, DOI 10.1006/viro.1994.1148; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FUNKE I, 1987, J EXP MED, V165, P1230, DOI 10.1084/jem.165.4.1230; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; HARRICH D, 1994, J VIROL, V68, P5899, DOI 10.1128/JVI.68.9.5899-5910.1994; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JEANG KT, 1992, J B IOL CHEM, V25, P17891; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESSLER M, 1991, P NATL ACAD SCI USA, V88, P10018, DOI 10.1073/pnas.88.22.10018; KOVAL V, 1995, J VIROL, V69, P1645, DOI 10.1128/JVI.69.3.1645-1651.1995; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAUGHLIN MA, 1993, VIROLOGY, V196, P496, DOI 10.1006/viro.1993.1505; LEE SHC, 1993, AM J PATHOL, V143, P1032; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MICHAELS J, 1988, ACTA NEUROPATHOL, V76, P373, DOI 10.1007/BF00686974; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; NAHREINI P, 1995, J VIROL, V69, P1296, DOI 10.1128/JVI.69.2.1296-1301.1995; NEUMANN M, 1995, J VIROL, V69, P2159, DOI 10.1128/JVI.69.4.2159-2167.1995; NEWSTEIN M, 1990, J VIROL, V64, P4565, DOI 10.1128/JVI.64.9.4565-4567.1990; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RHODES RH, 1993, HUM PATHOL, V24, P1189, DOI 10.1016/0046-8177(93)90215-3; Sambrook J., 2002, MOL CLONING LAB MANU; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SESHAMMA T, 1992, J VIROL METHODS, V40, P331, DOI 10.1016/0166-0934(92)90091-Q; SHAHABUDDIN M, 1992, PATHOBIOLOGY, V60, P195, DOI 10.1159/000163723; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SUNE C, 1995, J VIROL, V69, P3098; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1995, ONCOGENE, V10, P395; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; ZHU M, 1996, IN PRESS AIDS RES HU	66	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					313	322						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710370				2022-12-25	WOS:A1996VA25200010
J	Aldabe, R; Barco, A; Carrasco, L				Aldabe, R; Barco, A; Carrasco, L			Membrane permeabilization by poliovirus proteins 2B and 2BC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; ANIMAL VIRUSES; PHOSPHOLIPASE-ACTIVITY; ESCHERICHIA-COLI; BREFELDIN-A; REPLICATION; INHIBITION; INDUCTION; PROLIFERATION; EXPRESSION	Poliovirus infection leads to drastic alterations in membrane permeability late during infection. Transient expression of each nonstructural protein of poliovirus by means of recombinant vaccinia virus encoding the T7 RNA polymerase indicates that proteins 2B and 2BC strongly enhance membrane permeability to hygromycin B in HeLa cells, Almost no effect on expression of proteins 2C, 3A, 3AB, and 3C was found. Deletions and point mutations in 2B and 2BC have identified sequences in 2B involved in membrane permeabilization. Regions located at both ends of 2B are necessary to bring about these permeability alterations. A deletion of 11 amino acids of 2BC at the junction between 2B and 2C, as well as long deletions in 2C encompassing the GTPase motifs of this protein, do not impair the capacity of 2BC to modify the permeability of the membrane. The release of compounds such as choline or uridine from preloaded cells is also augmented by 2B and 2BC expression.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Carrasco, Luis/H-3001-2017; Barco, Angel/C-3062-2008; Barco, Angel/ABF-1864-2021; Aldabe, Rafael/F-3112-2015; Carrasco, Luis/E-2435-2012	Carrasco, Luis/0000-0003-3833-8835; Barco, Angel/0000-0002-0653-3751; Barco, Angel/0000-0002-0653-3751; Aldabe, Rafael/0000-0002-9461-020X; 				ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1983, VIROLOGY, V131, P39, DOI 10.1016/0042-6822(83)90531-7; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1994, FEBS LETT, V350, P151, DOI 10.1016/0014-5793(94)00780-2; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CARRASCO L, 1981, VIROLOGY, V113, P623, DOI 10.1016/0042-6822(81)90190-2; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; EGBERTS E, 1977, J VIROL, V22, P591, DOI 10.1128/JVI.22.3.591-597.1977; Feduchi E, 1995, EUR J BIOCHEM, V234, P849, DOI 10.1111/j.1432-1033.1995.849_a.x; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; GUINEA R, 1989, J BIOL CHEM, V264, P21923; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; GUINEA R, 1995, J VIROL, V69, P2306, DOI 10.1128/JVI.69.4.2306-2312.1995; IRURZUN A, 1993, J GEN VIROL, V74, P1063, DOI 10.1099/0022-1317-74-6-1063; IRURZUN A, 1992, VIROLOGY, V191, P166, DOI 10.1016/0042-6822(92)90178-R; LACAL JC, 1982, EUR J BIOCHEM, V127, P359, DOI 10.1111/j.1432-1033.1982.tb06880.x; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; LOPEZRIVAS A, 1987, J GEN VIROL, V68, P335, DOI 10.1099/0022-1317-68-2-335; MAYNELL LA, 1992, J VIROL, V66, P1985, DOI 10.1128/JVI.66.4.1985-1994.1992; NAIR CN, 1984, J GEN VIROL, V65, P1135, DOI 10.1099/0022-1317-65-6-1135; PEREZ L, 1993, J VIROL, V67, P4543; PEREZ L, 1993, VIROLOGY, V194, P28, DOI 10.1006/viro.1993.1231; SARNOW P, 1990, CURR TOP MICROBIOL, V161, P155; SCHAEFER A, 1982, J VIROL, V44, P444, DOI 10.1128/JVI.44.2.445-449.1982; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033	33	110	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23134	23137		10.1074/jbc.271.38.23134	http://dx.doi.org/10.1074/jbc.271.38.23134			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798506				2022-12-25	WOS:A1996VH76800032
J	Meh, DA; Siebenlist, KR; Mosesson, MW				Meh, DA; Siebenlist, KR; Mosesson, MW			Identification and characterization of the thrombin binding sites on fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; CLOT-BOUND THROMBIN; AMINO-ACID-SEQUENCES; GAMMA-CHAIN; EQUILIBRIUM BINDING; HIRUDIN; PLATELETS; INHIBITOR; MECHANISM; EXOSITE	Thrombin binds to fibrin at two classes of non-substrate sites, one of high affinity and the other of low affinity, We investigated the location of these thrombin binding sites by assessing the binding of thrombin to fibrin lacking or containing gamma' chains, which are fibrinogen gamma chain variants that contain a highly anionic carboxyl-terminal sequence, We found the high affinity thrombin binding site to be located exclusively in D domains on gamma' chains (K-alpha, 4.9 x 10(6) M(-1); n, 1.05 per gamma' chain), whereas the low affinity thrombin binding site was in the fibrin E domain (K-alpha, 0.29 x 10(6) M(-1); n, 1.69 per molecule), The amino terminal beta 15-42 fibrin sequence is an important constituent of low affinity binding, since thrombin binding at this site is greatly diminished in fibrin molecules lacking this sequence. The tyrosine-sulfated, thrombin exosite-binding hirudin peptide, S-Hir(53-64) (hirugen), inhibited both low and high affinity thrombin binding to fibrin (IC50 1.4 and 3.0 mu M, respectively), The presence of the high affinity gamma' chain site on fibrinogen molecules did not inhibit fibrinogen conversion to fibrin as assessed by thrombin time measurements, and thrombin exosite binding to fibrin at either site did not inhibit its catalytic activity toward a small thrombin substrate, S-2238. We infer from these findings that there are two low affinity non substrate thrombin binding sites, one in each half of the dimeric fibrin E domain, and that they may represent a residual aspect of thrombin binding and cleavage of its substrate fibrinogen, The high affinity thrombin binding site on gamma' chains is a constitutive feature of fibrin as well as fibrinogen.	MARQUETTE UNIV,SCH DENT,DEPT BASIC HLTH SCI,MILWAUKEE,WI 53233	Marquette University	Meh, DA (corresponding author), UNIV WISCONSIN,SCH MED,SINAI SAMARITAN MED CTR,WINTE RES BLDG,836 N 12TH ST,MILWAUKEE,WI 53233, USA.				NHLBI NIH HHS [HL-47000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BINNIE CG, 1993, BLOOD, V81, P3186; BINNIE CG, 1991, THROMB HAEMOSTASIS, V65, P165; BOURDON P, 1990, BIOCHEMISTRY-US, V29, P6379, DOI 10.1021/bi00479a006; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DIMINNO G, 1991, ARTERIOSCLER THROMB, V11, P785, DOI 10.1161/01.ATV.11.4.785; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FINLAYSON JS, 1964, BIOCHIM BIOPHYS ACTA, V82, P415, DOI 10.1016/0304-4165(64)90318-6; FRANCIS CW, 1983, J LAB CLIN MED, V102, P220; HAIDARIS PJ, 1989, BLOOD, V74, P2437; HANNA LS, 1984, BIOCHEMISTRY-US, V23, P4681, DOI 10.1021/bi00315a025; HARFENIST EJ, 1984, BLOOD, V64, P1163; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HOGG DH, 1978, THROMB RES, V12, P953, DOI 10.1016/0049-3848(78)90051-8; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HOMANDBERG GA, 1985, THROMB RES, V39, P263, DOI 10.1016/0049-3848(85)90221-X; HORTIN GL, 1989, BIOCHEM INT, V19, P1355; KACZMAREK E, 1988, J BIOL CHEM, V263, P13896; KAMINSKI M, 1983, J BIOL CHEM, V258, P530; KAMINSKI M, 1987, BIOCHEM J, V242, P881, DOI 10.1042/bj2420881; KANAIDE H, 1975, J LAB CLIN MED, V85, P574; KIRSCHBAUM NE, 1992, BLOOD, V79, P2643; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; KOOPMAN J, 1992, P NATL ACAD SCI USA, V89, P3478, DOI 10.1073/pnas.89.8.3478; KUMAR R, 1994, THROMB HAEMOSTASIS, V72, P713; KUMAR R, 1995, THROMB HAEMOSTASIS, V74, P962; LEGRELE CD, 1982, BIOCHEM BIOPH RES CO, V105, P521, DOI 10.1016/0006-291X(82)91466-8; LIU CY, 1980, J BIOL CHEM, V255, P7627; LIU CY, 1979, J BIOL CHEM, V254, P421; LIU CY, 1986, FIBRINOGEN FIBRIN FO, P79; LOEWY AG, 1961, J BIOL CHEM, V236, P625; Lorand L., 1970, METHOD ENZYMOL, V19, P770; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; LORD ST, 1995, J BIOL CHEM, V270, P24790, DOI 10.1074/jbc.270.42.24790; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; MARTINELLI RA, 1980, BIOCHEMISTRY-US, V19, P2343, DOI 10.1021/bi00552a010; MATHUR A, 1993, BIOCHEMISTRY-US, V32, P7568, DOI 10.1021/bi00080a031; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; MOSESSON MW, 1983, ANN NY ACAD SCI, V408, P97, DOI 10.1111/j.1749-6632.1983.tb23237.x; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; MOSESSON MW, 1963, J LAB CLIN MED, V62, P663; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NOE G, 1988, J BIOL CHEM, V263, P11729; PANDY BV, 1991, BIOCHEMISTRY-US, V30, P162, DOI 10.1021/bi00215a024; PARRY MAA, 1994, BIOCHEMISTRY-US, V33, P14807, DOI 10.1021/bi00253a020; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOPES RK, 1982, PROTEIN PURIFICATION, P241; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; SIEBENLIST KR, 1990, J BIOL CHEM, V265, P18650; STATHAKIS NE, 1978, THROMB RES, V13, P467, DOI 10.1016/0049-3848(78)90132-9; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VALI Z, 1988, BIOCHEMISTRY-US, V27, P1956, DOI 10.1021/bi00406a023; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; WOLFENSTEINTODEL C, 1981, BIOCHEMISTRY-US, V20, P6146, DOI 10.1021/bi00524a036	70	112	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23121	23125		10.1074/jbc.271.38.23121	http://dx.doi.org/10.1074/jbc.271.38.23121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798504	Green Published, hybrid			2022-12-25	WOS:A1996VH76800030
J	Mendoza, I; Quintero, FJ; Bressan, RA; Hasegawa, PM; Pardo, JM				Mendoza, I; Quintero, FJ; Bressan, RA; Hasegawa, PM; Pardo, JM			Activated calcineurin confers high tolerance to ion stress and alters the budding pattern and cell morphology of yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; BUD-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; POTASSIUM-TRANSPORT; DIFFERENTIAL EXPRESSION; B-SUBUNIT; GROWTH; CALMODULIN; MUTANTS	The PP2B protein phosphatase, also known as calcineurin, is a regulator of ion homeostasis in yeast cells. We have investigated the physiological consequences of constitutive expression of a recombinant form of calcineurin in which the Ca2+/calmodulin-binding and autoinhibitory domains of the catalytic subunit were deleted. The concomitant expression of the regulatory subunit along with the truncated catalytic subunit re suited in high tolerance to toxic levels of Na+ and Li+. This activated form of calcineurin substituted for the Na+ stress signal to promote the expression of the ENA1 gene, encoding a P-ATPase pump, and to induce the transition of the K+ uptake system to the high affinity mode that restricts influx of Na+ and Li+. In addition, the transcriptional responsiveness of ENA1 to Na+ stress was enhanced. These results demonstrate that calcineurin has a pivotal role in a signaling cascade activated by ion stress in yeast. Moreover, we found that changes in the level of calcineurin activity affected budding pattern and cell morphology. Cells expressing the truncated calcineurin were elongated and budded in an unipolar pattern, whereas calcineurin-deficient mutants budded randomly. These results suggest that calcineurin may also act in the establishment of cell polarity.	PURDUE UNIV, CTR PLANT ENVIRONM STRESS PHYSIOL, W LAFAYETTE, IN 47907 USA; CSIC, INST RECURSOS NAT & AGROBIOL, E-41080 SEVILLE, SPAIN	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)			Pardo, Jose M/AAB-5866-2022; Quintero, Francisco J./AAG-2924-2019; Quintero, Francisco J/C-3086-2014; Pardo, Jose M./B-4652-2009	Pardo, Jose M/0000-0003-4510-8624; Quintero, Francisco J./0000-0001-8718-2975; Quintero, Francisco J/0000-0001-8718-2975; Pardo, Jose M./0000-0003-4510-8624; Mendoza, Imelda/0000-0002-2673-3961				BANUELOS MA, 1995, BBA-BIOENERGETICS, V1229, P233, DOI 10.1016/0005-2728(95)00006-5; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; FOOR F, 1992, NATURE, V360, P682; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMENWAY CS, 1995, GENETICS, V141, P833; HU GZ, 1994, J BIOL CHEM, V269, P3429; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KRON SJ, 1994, MOL BIOL CELL, V5, P1003, DOI 10.1091/mbc.5.9.1003; LYNCH J, 1989, PLANT PHYSIOL, V90, P1271, DOI 10.1104/pp.90.4.1271; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STRATFORD M, 1994, YEAST, V10, P1741, DOI 10.1002/yea.320101307; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; YOSHIDA T, 1994, J CELL SCI, V107, P1725; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZYL W, 1992, MOL CELL BIOL, V12, P4946	45	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23061	23067		10.1074/jbc.271.38.23061	http://dx.doi.org/10.1074/jbc.271.38.23061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798496	hybrid			2022-12-25	WOS:A1996VH76800022
J	Sudhakar, K; Fay, PJ				Sudhakar, K; Fay, PJ			Exposed hydrophobic sites in factor VIII and isolated subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FLUORESCENCE ENERGY-TRANSFER; PROCOAGULANT ACTIVITY; TRYPTOPHAN RESIDUES; A1/A3-C1-C2 DIMER; MOLTEN GLOBULE; PROTEIN; THROMBIN; COAGULANT; BINDING	Hydrophobic sites on the surface of factor VIII, factor Villa, and their derived subunits were evaluated using the fluorescent, apolar probe, bisanilinonapthalsulfonic acid (bis-ANS). Two hydrophobic sites, with indicated affinities for the probe, were identified on factor VIII (K-d = 0.2 and 1.22 mu M), the isolated heavy chain (HC; K-d = 0.21 and 1.44 mu M), and light chain (LC; K-d = 0.04 and 0.22 mu M), Comparison of these values and fluorescence emission maxima parameters suggested that the higher affinity site on each isolated subunit contributes to the divalent metal ion-dependent, intersubunit interaction while the two lower affinity sites are retained on the surface of the factor VIII heterodimer, A single bis-ANS site was identified on both the A1/A3-C1-C2 dimer (K-d = 0.19 mu M) and A2 subunit (K-d = 0.11 mu M), whereas two sites, equivalent to the sites of factor VIII, were observed on factor VIIIa. These results suggested the absence of interactive hydrophobic sites between A2 subunit and dimer, a major conformational change around the hydrophobic site in A2 upon dissociation, and the lack of accessible hydrophobic regions on the B domain of HC, Ca2+ reduced the emission intensity of bis-ANS bound to the isolated LC, HC, and A1 subunit; but not the A2 subunit, Reconstitution of factor VIII activity from isolated HC and LC was inhibited by >90% in the presence of 20 mu M bis-ANS, whereas this concentration of probe had no effect on the reconstitution of FVIIIa from the A1/A3-C1-C2 dimer and A2 subunit. These results indicate that intersubunit hydrophobic interactions are important for the metal ion-dependent association between A1 and A3 domains, but are not required for the metal ion-independent interaction between A2 subunit and the A1/A3-C1-C2 dimer in factor VIIIa.	UNIV ROCHESTER, MED CTR, HEMATOL UNIT, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NHLBI NIH HHS [HL38199, HL30616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CASILLAS G, 1971, COAGULATION, V4, P107; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; HOROWITZ PM, 1985, BIOCHEMISTRY-US, V24, P2587, DOI 10.1021/bi00332a001; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; PRASAD ARS, 1986, BIOCHEMISTRY-US, V25, P3536, DOI 10.1021/bi00360a010; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WANG JL, 1971, J BIOL CHEM, V246, P1185; WITZ G, 1973, J PHYS CHEM-US, V77, P648, DOI 10.1021/j100624a018; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	34	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23015	23021		10.1074/jbc.271.38.23015	http://dx.doi.org/10.1074/jbc.271.38.23015			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798489	hybrid			2022-12-25	WOS:A1996VH76800015
J	Rani, MRS; Foster, GR; Leung, S; Leaman, D; Stark, GR; Ransohoff, RM				Rani, MRS; Foster, GR; Leung, S; Leaman, D; Stark, GR; Ransohoff, RM			Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR; GAMMA-INTERFERON; ANTIVIRAL ACTIONS; CELL-LINE; RECEPTOR; SUBUNIT; PHOSPHORYLATION; ACTIVATION	We report preliminary characterization of a gene designated beta-R1, which is selectively expressed in response to interferon beta (IFN-beta) compared with IFN-alpha. In human astrocytoma cells, beta-R1 was induced to an equivalent extent by 10 IU/mL IFN-beta or 2500 IU/mL IFN-alpha 2. To address the mechanism of this differential response, we analyzed induction of the beta-R1 gene in fibrosarcoma cells and derivative mutant cells lacking components required for signaling by type I IFNs. beta-R1 was readily induced by IFN-beta in the parental 2fTGH cell line, but not by recombinant IFN-alpha 2, IFN-alpha Con1, or a mixture of IFN-alpha subtypes. IFN-alpha 8 induced beta-R1 weakly. beta-R1 was not induced by IFN-beta in mutant cell lines U2A, U3A, U4A, and U6A, which lack, respectively, p48, STAT1, JAK1, and STATE. U5A cells, which lack the Ifnar 2.2 component of the IFN-alpha and -beta receptor, also failed to express beta-R1. U1A cells are partially responsive to IFN-beta and IFN-alpha 8 but lacked beta-R1 expression, indicating that TYK2 protein is essential for induction of this gene. Taken together, these results suggest that the expression of beta-R1 in response to type I IFN requires IFN-stimulated gene factor 3 plus an additional component, which is more efficiently formed on induction by IFN-beta compared with IFN-alpha.	CLEVELAND CLIN FDN,RES INST,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT BIOL MOL,CLEVELAND,OH 44195; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT MED,LONDON W21 NY,ENGLAND	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Imperial College London					NCI NIH HHS [P01CA 62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P591, DOI 10.1093/nar/19.3.591; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; ESTES ML, 1990, J NEUROSCI RES, V27, P697, DOI 10.1002/jnr.490270430; FAN SX, 1993, AIDS RES HUM RETROV, V9, P1115, DOI 10.1089/aid.1993.9.1115; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GRESSER I, 1990, J INVEST DERMATOL, V95, P665; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; GUYER NB, 1995, J IMMUNOL, V155, P3472; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLEIN SB, 1993, J INTERFERON RES, V13, P341, DOI 10.1089/jir.1993.13.341; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TAYLOR JL, 1990, VIRUS RES, V15, P1, DOI 10.1016/0168-1702(90)90010-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WEIL J, 1983, NATURE, V301, P437, DOI 10.1038/301437a0; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965	54	148	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22878	22884		10.1074/jbc.271.37.22878	http://dx.doi.org/10.1074/jbc.271.37.22878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798467	hybrid			2022-12-25	WOS:A1996VG67200086
J	Quitschke, WW; Matthews, JP; Kraus, RJ; Vostrov, AA				Quitschke, WW; Matthews, JP; Kraus, RJ; Vostrov, AA			The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid beta-protein precursor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; REGULATORY ELEMENTS; BASAL TRANSCRIPTION; LESS PROMOTERS; DNA-BINDING; GENE; EXPRESSION	The TATA-less human amyloid beta-protein precursor promoter contains an initiator element with the sequence CGTCA(+1)GTT. Primary transcriptional start sites were identified at positions +1 and -4, Deletion of the upstream activator elements APB beta and APB alpha did not affect the selection of transcriptional start sites, although total transcriptional activity was reduced both in vitro and in vivo. Mutations within the initiator element shifted the transcriptional start sites and reduced transcriptional activity. Mutations between positions -6 and -35 changed the relative utilization of start sites +1 and -4 without affecting the total level of transcriptional activity, A 10-base pair deletion between position -40 and -31 increased in vitro transcriptional activity with a preeminent utilization of the start site at position -4. In contrast, a 20-base pair deletion between position -40 and -21. resulted in a reduction in transcriptional activity and in the primary utilization of the start site at position +1. Furthermore, transactivation by APB beta and APB alpha was eliminated. DNase I footprinting provided evidence for the existence of two binding domains designated UE (position -12 to -30) and Inr (position +7 to -7). The positions of these binding domains are altered in mutations and deletions that affect transcriptional activity.	UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Quitschke, WW (corresponding author), SUNY STONY BROOK, DEPT PSYCHIAT & BEHAV SCI, STONY BROOK, NY 11794 USA.				NCI NIH HHS [CA22443] Funding Source: Medline; NINDS NIH HHS [NS30994] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASO T, 1994, J BIOL CHEM, V269, P26575; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHERNAK JM, 1993, GENE, V133, P255, DOI 10.1016/0378-1119(93)90648-M; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; GAJDUSEK DC, 1991, BRAIN RES REV, V16, P83, DOI 10.1016/0165-0173(91)90021-Y; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOFFMAN PW, 1995, NUCLEIC ACIDS RES, V23, P2229, DOI 10.1093/nar/23.12.2229; HOFFMAN PW, 1994, BIOCHEM BIOPH RES CO, V201, P610, DOI 10.1006/bbrc.1994.1745; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LANS MS, 1994, J BIOL CHEM, V269, P14170; Maniatis T, 1989, MOL CLONING; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Maxam A M, 1980, Methods Enzymol, V65, P499; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; POLLWEIN P, 1993, BIOCHEM BIOPH RES CO, V190, P637, DOI 10.1006/bbrc.1993.1096; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Quitschke Wolfgang W., 1995, P79, DOI 10.1016/B978-012286965-5/50007-8; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; ROBAKIS NK, 1987, LANCET, V1, P384; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAIN DH, 1995, NUCLEIC ACIDS RES, V23, P1696, DOI 10.1093/nar/23.10.1696; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; Sucharov C, 1995, GENE EXPRESSION, V5, P93; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	53	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22231	22239		10.1074/jbc.271.36.22231	http://dx.doi.org/10.1074/jbc.271.36.22231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703038	hybrid			2022-12-25	WOS:A1996VF61200080
J	Saad, MJA; Carvalho, CRO; Thirone, ACP; Velloso, LA				Saad, MJA; Carvalho, CRO; Thirone, ACP; Velloso, LA			Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHOTYROSINE PROTEIN; SIGNAL-TRANSDUCTION; JANUS KINASE; CELLS; ACTIVATION; IDENTIFICATION; STIMULATION	The Janus kinase family of protein tyrosine kinases constitutes a novel type of signal transduction pathway activated in response to a wide variety of polypeptide ligands and has four known members: JAK1, JAK2, JAK3, and Tyk2. In this study, we examined the ability of insulin to stimulate JAK2 tyrosine phosphorylation in insulin-sensitive tissues of the intact rat using immunoprecipitation and immunoblotting. The results demonstrate that after an infusion of insulin, JAK2 is rapidly tyrosine phosphorylated (and the kinase is activated) in the liver, adipose tissue, skeletal muscle, heart, and isolated adipocytes. The presence of phosphorylated JAK2 was detectable after an infusion of insulin that increased serum insulin to physiological postprandial levels (40-70 microunits/ml). Co-immunoprecipitation with anti-insulin receptor antibody, anti JAK2 antibody, and anti-IRS-1 antibody showed that JAK2 interacts with the insulin receptor and IRS-1 to form stable complexes following stimulation by insulin. In two animal models of insulin resistance the regulation of JAK2 tyrosine phosphorylation after insulin infusion paralleled the phosphorylation of the insulin receptor and of IRS-1. In conclusion, our data indicate that after physiological stimulation by insulin in the intact animal, JAK2 associates with the insulin receptor and is tyrosine phosphorylated in insulin sensitive tissues in a time- and dose-dependent fashion.			Saad, MJA (corresponding author), UNIV ESTADUAL CAMPINAS,UNICAMP,FAC CIENCIAS MED,DEPT CLIN MED,CIDADE UNIV ZEFERINO VAZ,BR-13081970 CAMPINAS,SP,BRAZIL.		Carvalho, Carla R. O./H-6476-2018; Saad, Mario/ABD-8262-2020; Velloso, Licio/AAJ-3778-2020	Carvalho, Carla R. O./0000-0001-5824-8656; 				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carvalho CRO, 1996, ENDOCRINOLOGY, V137, P151, DOI 10.1210/en.137.1.151; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FLIER JS, 1983, ANNU REV MED, V34, P145, DOI 10.1146/annurev.me.34.020183.001045; FRIEDENBERG GR, 1985, J BIOL CHEM, V260, P12444; GRICHTING G, 1983, ENDOCRINOLOGY, V113, P1111, DOI 10.1210/endo-113-3-1111; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUI H, 1994, J BIOL CHEM, V269, P5364; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P1787; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKOLNIK EY, 1993, EMBO J, V12, P1926; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22100	22104		10.1074/jbc.271.36.22100	http://dx.doi.org/10.1074/jbc.271.36.22100			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703019	hybrid			2022-12-25	WOS:A1996VF61200061
J	Sumimoto, H; Hata, K; Mizuki, K; Ito, T; Kage, Y; Sakaki, Y; Fukumaki, Y; Nakamura, M; Takeshige, K				Sumimoto, H; Hata, K; Mizuki, K; Ito, T; Kage, Y; Sakaki, Y; Fukumaki, Y; Nakamura, M; Takeshige, K			Assembly and activation of the phagocyte NADPH oxidase - Specific interaction of the N-terminal Src homology 3 domain of p47(phox) with p22(phox) is required for activation of the NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; CYTOSOLIC PROTEINS P47-PHOX; NEUTROPHIL CYTOCHROME-B; BINDING-SITE; SH3 DOMAINS; DEFECTIVE TRANSLOCATION; FLAVOCYTOCHROME B(558); COMPONENTS P47(PHOX)	The phagocyte NADPH oxidase is activated during phagocytosis to produce superoxide, a precursor of microbicidal oxidants. The activation involves assembly of membrane-integrated cytochrome b(558) comprising gp91(phox) and p22(phox), two specialized cytosolic proteins (p47(phox) and p67(phox)), each containing two Src homology 3 (SH3) domains, and the small G protein Rac. In the present study, we show that the N-terminal SH3 domain of p47(phox) binds to the C-terminal cytoplasmic tail of p22(phox) with high affinity (K-D = 0.34 mu M). The binding is specific to this domain among several SH3 domains including the C-terminal one of p47(phox) and the two of p67(phox) and requires the Pro(156)-containing proline-rich sequence but not other putative SH3 domain-binding sites of p22(phox). Replacement of Trp(193) by Arg in the N-terminal SH3 domain completely abrogates the association with p22(phox). A mutant p47(phox) with this substitution is incapable of supporting superoxide production under cell-free activation conditions. These findings provide direct evidence that the interaction between the N-terminal SH3 domain of p47(phox) and the proline-rich region of p22(phox) is essential for activation of the NADPH oxidase.	UNIV TOKYO,INST MED SCI,CTR HUMAN GENOME,TOKYO 108,JAPAN; NAGASAKI UNIV,INST TROP MED,NAGASAKI 852,JAPAN; KYUSHU UNIV,INST GENET INFORMAT,FUKUOKA 812,JAPAN	University of Tokyo; Nagasaki University; Kyushu University	Sumimoto, H (corresponding author), KYUSHU UNIV,SCH MED,DEPT BIOCHEM,HIGASHI KU,3-1-1 MAIDASHI,FUKUOKA 81282,JAPAN.			Ito, Takashi/0000-0001-6097-2803				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; AOYAGI K, 1991, BIOCHEM BIOPH RES CO, V186, P391; BRIDGE RB, 1993, SCIENCE, V262, P1522; CHALKLEY GE, 1994, EUR J BIOCHEM, V221, P167, DOI 10.1111/j.1432-1033.1994.tb18726.x; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MIZUNO T, 1992, J BIOL CHEM, V267, P10125; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NOZAKI M, 1990, EUR J BIOCHEM, V187, P335, DOI 10.1111/j.1432-1033.1990.tb15310.x; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WANG W, 1995, NAT GENET, V10, P194; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	55	155	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22152	22158		10.1074/jbc.271.36.22152	http://dx.doi.org/10.1074/jbc.271.36.22152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703027	hybrid			2022-12-25	WOS:A1996VF61200069
J	Domin, J; Dhand, R; Waterfield, MD				Domin, J; Dhand, R; Waterfield, MD			Binding to the platelet-derived growth factor receptor transiently activates the p85 alpha-p110 alpha phosphoinositide 3-kinase complex in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PDGF BETA-RECEPTOR; MIDDLE-T-ANTIGEN; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; TYROSINE PHOSPHORYLATION; 85-KDA SUBUNIT; SH2 DOMAINS; REGULATORY SUBUNIT	Ligand stimulation of the platelet-derived growth factor (PDGF) receptor results in its association with phosphoinositide 3-kinase activity and a corresponding synthesis of 3'-phosphorylated lipids, Early studies that examined this interaction in vivo employed anti-phosphotyrosine antiserum or antiserum against the PDGF receptor. The recent identification of multiple isoforms of both the regulatory and the catalytic subunit of the enzyme have led us to utilize antisera against p85 alpha and p110 alpha to characterize the association of this particular phosphoinositide 3-kinase complex with the PDGF receptor following ligand stimulation of murine fibroblasts. Both the p85 alpha and p110 alpha subunits rapidly associated with the ligand-activated receptor resulting in a transient, 2-fold increase in the total pool of p110 alpha lipid kinase activity. This association was stable for 15 min after initial stimulation. Subsequently, both subunits began to dissociate from the receptor with similar kinetics. By 60 min this process was complete, demonstrating that p85 alpha and p110 alpha both associate with the receptor and dissociate from the receptor as a dimeric complex. At this time, marked PDGF receptor down-regulation was observed. Immunoprecipitation from metabolically labeled cells revealed that p85 alpha is constitutively phosphorylated on serine residues in quiescent cultures. Upon PDGF stimulation, this phosphorylation upon serine residues was maintained in addition to tyrosine phosphorylation of this subunit. No phosphorylation of the p110 alpha subunit was detected in either quiescent or PDGF-stimulated cells. Quantitation of Western blot analysis demonstrated that only 5% of the total pool of p85 alpha associated with the PDGF receptor upon ligand stimulation. The 2-fold increase in the lipid kinase activity measured in immunoprecipitates using either anti-p85 alpha or anti-p110 alpha) antiserum therefore reflects a far greater increase inn the specific activity of the enzyme upon its association with the PDGF receptor.	UCL, DEPT BIOCHEM & MOL BIOL, LONDON WCE 6BT, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	University of London; University College London; Ludwig Institute for Cancer Research								AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHOUDHURY GG, 1991, BIOCHEM BIOPH RES CO, V172, P154; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOMIN J, 1992, J BIOL CHEM, V267, P15217; DOWNING JR, 1991, ONCOGENE, V6, P607; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OKAMOTO M, 1993, BIOCHEM J, V290, P327, DOI 10.1042/bj2900327; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1992, J BIOL CHEM, V267, P12266; PONS S, 1995, MOL CELL BIOL, V15, P4453; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RANKIN S, 1994, J BIOL CHEM, V269, P704; REIF K, 1993, J BIOL CHEM, V268, P10780; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SHEPEINER H, 1996, J CELL BIOL, V132, P595; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUSA M, 1992, J BIOL CHEM, V267, P22951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WESTERMARK B, 1991, CANCER RES, V51, P5087; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	69	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21614	21621		10.1074/jbc.271.35.21614	http://dx.doi.org/10.1074/jbc.271.35.21614			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702949	hybrid			2022-12-25	WOS:A1996VE47700095
J	Galera, P; Park, RW; Ducy, P; Mattei, MG; Karsenty, G				Galera, P; Park, RW; Ducy, P; Mattei, MG; Karsenty, G			c-Krox binds to several sites in the promoter of both mouse type I collagen genes - Structure/function study and developmental expression analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; OSTEOGENESIS IMPERFECTA; REGULATORY FACTORS; HUMAN-FIBROBLASTS; MESSENGER-RNAS; CULTURED-CELLS; DNA-BINDING; ELEMENTS	We have previously shown that c-Krox is a zinc finger protein that can increases the transcriptional activity of the mouse alpha 1(I) collagen promoter through its binding to two GC-rich sequences (Galera, P,, Musso, Ri,, Ducy, P,, and Karsenty, G, (1994) Proc, Natl, Acad, Sci, U, S. A, 91, 9372-9376), In this report we show that c-Krox can bind to an additional site in the promoter of the alpha 1(I) collagen gene and to three sites in the promoter of the alpha 2(I) collagen gene, the other gene coding for type I collagen, One of the binding sites present in both promoters is adjacent to the CCAAT box, We have performed a structure/function analysis of c-Krox locating the transactivation domain in the zinc finger and C-terminal domains and the dimerization domain in the C-terminal end of the protein, We also demonstrate that c-Krox is an early response gene, whose expression is detectable as early as 9.5-day postcoitum in mouse embryos, Whole-mount in situ hybridization shows that c-Krox is expressed in dermatomes, the somite derivatives that generate dermis, and section in situ hybridization shows that c-Krox and alpha 1(I) collagen mRNAs colocalized in skin but not in bone during development, This result is consistent with the predominant expression of c-Krox in skin in postnatal life, Thus, our findings suggest that c-Krox is one transcription factor controlling the coordinated expression of the two type I collagen genes in skin.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030; HOP ENFANTS LA TIMONE,INSERM,CTR GENET MED,U242,F-13385 MARSEILLE,FRANCE	University of Texas System; UTMD Anderson Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille					NIAMS NIH HHS [AR-41059] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041059] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMSON ED, 1979, CELL, V16, P953, DOI 10.1016/0092-8674(79)90110-7; BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; BUCHMEYER S, 1995, J BIOL CHEM, V270, P30213; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEWET WJ, 1983, J BIOL CHEM, V258, P4385; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KAHARI VM, 1987, ACTA DERM-VENEREOL, V67, P199; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; KHILLAN JS, 1986, P NATL ACAD SCI USA, V83, P725, DOI 10.1073/pnas.83.3.725; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; UITTO J, 1985, P NATL ACAD SCI USA, V82, P5935, DOI 10.1073/pnas.82.17.5935; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P257; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	53	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21331	21339		10.1074/jbc.271.35.21331	http://dx.doi.org/10.1074/jbc.271.35.21331			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702912	hybrid			2022-12-25	WOS:A1996VE47700058
J	Moore, JL; Gorshkova, II; Brown, JW; McKenney, KH; Schwarz, FP				Moore, JL; Gorshkova, II; Brown, JW; McKenney, KH; Schwarz, FP			Effect of cAMP binding site mutations on the interaction of cAMP receptor protein with cyclic nucleoside monophosphate ligands and DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; ENTHALPY-ENTROPY COMPENSATION; ESCHERICHIA-COLI; TRANSCRIPTION ACTIVATION; LAC PROMOTER; AMP; CAP; COMPLEX; MUTANTS; RECOGNITION	Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser(128) --> Ala does not, whereas the double CRP mutant Thr(127) --> Leu/ Ser(128) --> Ala activates transcription even in the absence of cNMP. Isothermal titration calorimetry measurements on the cNMP binding reactions to the S128A and T127L/S128A mutants show that the reactions are mainly entropically driven as is cAMP binding to CRP. In contrast to cAMP binding to CRP, the binding reactions are noncooperative and exothermic with binding enthalpies (Delta H-b) ranging from -23.4 +/- 0.9 kJ mol(-1) for cAMP binding to S128A at 39 degrees C to -4.1 +/- 0.6 kJ mol(-1) for cAMP binding to T127L/S128A at 24 degrees C and exhibit enthalpy-entropy compensation. To account for the inactivity of the S128A mutant, in vitro and in vivo DNA binding experiments were performed on the cAMP-ligated S128A mutant. The cAMP-ligated S128A mutant binds to the consensus DNA binding site with approximately the same affinity as that of cAMP-ligated CRP but forms a different type of complex, which may account for loss of transcriptional activity by the mutant, Energy minimization computations on the cAMP-ligated S128A mutant show that amino acid conformational differences between S128A and CRP occur at Ser(179), Glu(181), and Thr(182) in the center of the DNA binding site, implying that these conformational changes may account for the difference in DNA binding.	NIST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; RUSSIAN ACAD SCI,INST BIOORGAN CHEM,NOVOSIBIRSK 630090,RUSSIA	National Institute of Standards & Technology (NIST) - USA; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences								AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BLAZY B, 1986, J BIOL CHEM, V261, P1645; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHAN B, 1989, GENE, V84, P227, DOI 10.1016/0378-1119(89)90496-4; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1985, J MOL BIOL, V182, P91, DOI 10.1016/0022-2836(85)90030-0; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P3884, DOI 10.1021/bi00285a025; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GARGES S, 1987, J BACTERIOL, V170, P1417; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GORSHKOVA I, 1995, J BIOL CHEM, V270, P21679, DOI 10.1074/jbc.270.37.21679; HARMAN JG, 1988, J BIOL CHEM, V263, P8072; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; KOOP AH, 1985, BIOCHIMIE, V67, P161, DOI 10.1016/S0300-9084(85)80244-3; LANG L, 1966, ABSORPTION SPECTRA U, V1, P326; LODGE J, 1990, FEMS MICROBIOL LETT, V67, P221, DOI 10.1016/0378-1097(90)90199-Z; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; Miller JH, 1972, EXPT MOL GENETICS, P47; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; MOORE JL, 1993, THESIS G WASHINGTON; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; REN YL, 1990, NUCLEIC ACIDS RES, V18, P5127, DOI 10.1093/nar/18.17.5127; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIMPSON RB, 1980, NUCLEIC ACIDS RES, V8, P759; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	43	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21273	21278		10.1074/jbc.271.35.21273	http://dx.doi.org/10.1074/jbc.271.35.21273			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702903	hybrid			2022-12-25	WOS:A1996VE47700049
J	Wangsgard, WP; Meixell, GE; Dasgupta, M; Blumenthal, DK				Wangsgard, WP; Meixell, GE; Dasgupta, M; Blumenthal, DK			Activation and inhibition of phosphorylase kinase by monospecific antibodies raised against peptides from the regulatory domain of the gamma-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ANTIPEPTIDE ANTIBODY; CATALYTIC DOMAIN; I RECEPTOR; IDENTIFICATION; PURIFICATION; SUBSTRATE; COMPLEXES	The C terminus of the catalytic gamma-subunit of phosphorylase kinase comprises a regulatory domain that contains regions important for subunit interactions and autoinhibitory functions. Monospecific antibodies raised against four synthetic peptides from this region, PhK1 (362-368), PhK5 (342-366), PhK9 (322-346), and PhK13 (302-326), were found to have significant effects on the catalytic activities of phosphorylase kinase holoenzyme and the gamma .delta complex. Antibodies raised against the very C terminus of the gamma-subunit, anti-PhK1 and anti-PhK5, markedly activated both holoenzyme and the gamma .delta complex, in the presence and absence of Ca2+. In the presence of Ca2+ at pH 8.2, anti-PhK1 activated the holoenzyme more than 11-fold and activated the gamma .delta complex 2.5-fold. Activation of the holoenzyme and the gamma .delta complex by anti-PhK5 was 50-70% of that observed with anti-PhK1. Prior phosphorylation of the holoenzyme by the cAMP-dependent protein kinase blocked activation by both anti-PhK1 and anti-PhK5. Antibodies raised against the peptides from the N terminus of the regulatory domain, anti-PhK9 and anti-PhK13, were inhibitory, with their greatest effects on the gamma .delta complex. These data demonstrate that the binding of antibodies to specific regions within the regulatory domain of the gamma-subunit can augment or inhibit structural changes and subunit interactions important in regulating phosphorylase kinase activity.	UNIV UTAH, DEPT PHARMACOL & TOXICOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA; UNIV TEXAS, CTR HLTH, DEPT BIOCHEM, TYLER, TX 75710 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)				/0000-0002-7260-3746; Blumenthal, Donald/0000-0002-8614-1167	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039290] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29-GM39290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN KFJ, 1982, J BIOL CHEM, V257, P5939; CHARLTON LA, 1992, J BIOL CHEM, V267, P8840; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; CRABB JW, 1984, J BIOL CHEM, V259, P6346; DASGUPTA M, 1995, J BIOL CHEM, V270, P22283, DOI 10.1074/jbc.270.38.22283; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Fasman G.D., 1989, PRACTICAL HDB BIOCH; FISCHER EH, 1962, METHOD ENZYMOL, V5, P369, DOI 10.1016/S0076-6879(62)05243-X; GIBSON AL, 1988, PROTEINS, V3, P155, DOI 10.1002/prot.340030304; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HERRERA R, 1986, J BIOL CHEM, V261, P2489; HESSOVA Z, 1985, J BIOL CHEM, V260, P111; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; JENNISSEN HP, 1985, EUR J BIOCHEM, V147, P619; KALIMAN P, 1992, J BIOL CHEM, V267, P10645; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEE SM, 1986, J BIOL CHEM, V261, P4732; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; NEWSHOLME P, 1992, BIOCHEM J, V283, P845, DOI 10.1042/bj2830845; NUNNALLY MH, 1987, BIOCHEMISTRY-US, V26, P5885, DOI 10.1021/bi00392a046; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; Pickett-Gies CA., 1986, ENZYMES, V17, P395; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; SEGEL IH, 1975, ENZYME KINETICS BEHA, P166; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; WILKINSON DA, 1994, FASEB J, V8, pA1225; WILKINSON DA, 1993, THESIS U TENNESSEE M	32	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21126	21133		10.1074/jbc.271.35.21126	http://dx.doi.org/10.1074/jbc.271.35.21126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702882				2022-12-25	WOS:A1996VE47700028
J	Garcia, P; Cales, C				Garcia, P; Cales, C			Endoreplication in megakaryoblastic cell lines is accompanied by sustained expression of G1/S cyclins and downregulation of cdc25C	ONCOGENE			English	Article						cell cycle; endoreplication; megakaryocyte differentiation; cyclins; cdc2; cdc25C	DEPENDENT KINASE-4 CDK4; FISSION YEAST CDC25; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; ACTIVATING KINASE; DEVELOPMENTAL CONTROL; DNA-REPLICATION; MITOTIC INDUCER; G(1) CYCLINS	In most eukaryotic cells, a link between S and M phases of the cell cycle must be assured in order to maintain the ploidy of newly divided cells. However, in some cell types, e.g. the precursors of platelets megakaryocytes, extra S-phases can occur in the absence of concomitant mitoses, resulting in polyploidy, We have used two established cell lines with megakaryoblastic characteristics (HEL and MEG-01) to investigate the molecular events that lead these cells to bypass the regular control checkpoints that govern the interdependency of S and M phases. In the presence of the phorbol ester TPA, both cell lines stopped proliferating and displayed additional megakaryocytic features, including polyploidization. Analysis of key cell cycle regulatory factors implicated in the control of G1/S and G2/M transitions revealed a number of differences compared to normally cycling cells. Differentiating megakaryocytes were found to maintain high levels of cdk2, and cyclins E and A, This was accompanied by the appearance of the retinoblastoma protein in the hyperphosphorylated, functionally inactivated form, In addition, TPA-treated cells showed high levels of cyclin B and cdc2 proteins, however no activation of cdc2 was detected, This lack of cdc2 activation which should occur for entry into M phase appeared to be related to the down regulation of cdc25C phosphatase found in both differentiated HEL and MEG-01 cells, Together, our results suggest that in differentiating megakaryoblastic cells endoreplication is accompanied by sustained levels of cyclins A and E, and a lack of cdc2 activation, which is probably mediated through down regulation of cdc25C protein phosphatase.	UNIV AUTONOMA MADRID,CSIC,INST INVEST BIOMED,DEPT BIOQUIM,MADRID 28029,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Calés, Carmela/AAB-1595-2019	Garcia, Paloma/0000-0001-5582-8575; Cales, Carmela/0000-0002-6987-2259				BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; GREENBERG SM, 1990, BLOOD, V76, P533; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAYASHI S, 1993, DEVELOPMENT, V118, P105; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOFFMAN R, 1989, BLOOD, V74, P1196; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Krishan A, 1990, Methods Cell Biol, V33, P121; KUTER DJ, 1992, BLOOD, V79, P619; LARRICK JW, 1980, J IMMUNOL, V125, P6; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORUZZI EV, 1993, BIOCHEM BIOPH RES CO, V196, P1248; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; NURSE P, 1994, CURR OPIN CELL BIOL, V6, P867; OGURA M, 1988, BLOOD, V72, P49; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROBERTS JR, 1990, CANCER RES, V50, P710; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH AV, 1991, DEVELOPMENT, V112, P997; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STERN B, 1993, DEVELOPMENT, V117, P219; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VANDERLOO B, 1993, EUR J CLIN INVEST, V23, P621; VARMUZA S, 1988, DEVELOPMENT, V102, P127; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YEN A, 1993, CANCER RES, V53, P3085; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	75	52	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					695	703						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761290				2022-12-25	WOS:A1996VD43300004
J	Theile, M; Seitz, S; Arnold, W; Jandrig, B; Frege, R; Schlag, PM; Haensch, W; Guski, H; Winzer, KJ; Barrett, JC; Scherneck, S				Theile, M; Seitz, S; Arnold, W; Jandrig, B; Frege, R; Schlag, PM; Haensch, W; Guski, H; Winzer, KJ; Barrett, JC; Scherneck, S			A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer	ONCOGENE			English	Article						breast cancer; tumor suppressor genes; chromosome 6q; LOH analysis; microcell-mediated chromosome transfer; estrogen receptor	ESTROGEN-RECEPTOR GENE; IMMORTAL HUMAN FIBROBLASTS; HUMAN OVARIAN CARCINOMAS; HUMAN-MALIGNANT MELANOMA; 2 DISTINCT REGIONS; FREQUENT LOSS; LINKAGE MAP; CELL-LINES; HUMAN GENOME; WILD-TYPE	Recent evidence obtained by cytogenetic and molecular studies indicates that in breast cancer chromosome 6q is often affected by genetic changes suggesting the existence of putative tumor suppressor genes (TSGs). However the function of gene(s) on this chromosome in breast cancer suppession is not understood. To substantiate further the presence of breast cancer related TSGs at 60 and to define their location, we first performed microcell-mediated transfer of chromosome 6 to CAL51 breast cancer cells for studying possible suppression of malignant phenotype and secondly, we analysed DNAs from 46 primary breast cancers for loss of constitutive heterozygosity (LOH) using 24 polymorphic microsatellite markers, The chromosome transfer resulted in loss of tumorigenicity and reversion of other neoplastic properties of the microcell hybrids. Polymorphism analysis of single hybrids revealed that they harbored only a small donor chromosome fragment defined by the marker D6S310 (6q23.3-q25) and flanked by D65292 and D6S311, The LOH data suggest that four tumor suppressor gene loci mapped to the central and distal portion of 6q may be independently deleted in breast cancer. One of these regions corresponds to the region identified by chromosome transfer.	MAX DELBRUCK CTR MOL MED,FORSCH GRP ONKOL & TUMORIMMUNOL,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,ROBERT ROSSLE KLIN,ABT CHIRURG & CHIRURG ONKOL,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,D-10117 BERLIN,GERMANY; NIEHS,MOL CARCINOGENESIS LAB,NIH,RES TRIANGLE PK,NC 27709	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Theile, M (corresponding author), MAX DELBRUCK CTR MOL MED,ARBEITSGRP TUMORGENET,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							ANDERSEN TI, 1994, HUM GENET, V94, P665; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CASTLES CG, 1995, BRIT J CANCER, V71, P974, DOI 10.1038/bjc.1995.188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Del Senno L., 1992, Human Molecular Genetics, V1, P354; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FUQUA SAW, 1990, J NATL CANCER I, V82, P858, DOI 10.1093/jnci/82.10.858; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; LASTOWSKA MA, 1994, CANCER GENET CYTOGEN, V77, P99, DOI 10.1016/0165-4608(94)90222-4; LEBEAU MM, 1986, BLOOD, V67, P844; LEE JH, 1990, CANCER RES, V50, P2724; LU YJ, 1993, CANCER GENET CYTOGEN, V69, P91, DOI 10.1016/0165-4608(93)90081-V; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320; MILLIKIN D, 1991, CANCER RES, V51, P5449; MORITA R, 1991, CANCER RES, V51, P5817; NEGRINI M, 1994, CANCER RES, V54, P1331; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; STEINARSDOTTIR M, 1995, GENE CHROMOSOME CANC, V13, P239, DOI 10.1002/gcc.2870130403; THEILE M, 1995, ONCOGENE, V10, P439; THEILE M, 1994, INT J ONCOL, V4, P1067; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; VISAKORPI T, 1995, CANCER RES, V55, P342; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WAN MH, 1994, INT J ONCOL, V5, P1043; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WELCH DR, 1994, ONCOGENE, V9, P255; YAICH L, 1992, CANCER RES, V52, P77; YAMADA H, 1990, ONCOGENE, V5, P1141; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	60	118	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					677	685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761288				2022-12-25	WOS:A1996VD43300002
J	Pang, YP; Quiram, P; Jelacic, T; Hong, F; Brimijoin, S				Pang, YP; Quiram, P; Jelacic, T; Hong, F; Brimijoin, S			Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase - Steps toward novel drugs for treating Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUPERZINE-A; BUTYRYLCHOLINESTERASE; TETRAHYDROAMINOACRIDINE; DYNAMICS; BINDING; TORPEDO; ANALOGS; INVITRO; CHANNEL	We report highly potent, selective, and low cost bifunctional acetylcholinesterase (AChE) inhibitors developed by our two-step prototype optimization strategy utilizing computer modeling of ligand docking with target proteins: 1) identify low affinity sites normally missed by x-ray crystallography; and 2) design bifunctional analogs capable of simultaneous binding at the computer-determined low affinity site and the x-ray-identified high affinity site. Applying this strategy to 9-amino-1,2,3,4-tetrahydroacridine (THA), a drug for Alzheimer's disease, we obtained alkylene linked bis-THA analogs. These analogs were up to 10,000-fold more selective and 1,000-fold more potent than THA in inhibiting rat AChE and yet required one simple reaction to synthesize. Additionally, alkylene linked benzyl-THA analogs were developed to examine the specificity of the docking-derived low affinity THA peripheral site in AChE. The present work and our previous computational studies strongly suggest that a low affinity THA peripheral site exists in AChE. This peripheral site provides a structural basis for design of improved cholinesterase ligands for treating Alzheimer's disease and for other health-related purposes.	MAYO FDN MED EDUC & RES,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic	Pang, YP (corresponding author), MAYO FDN MED EDUC & RES,4500 SAN PABLO RD,JACKSONVILLE,FL 32224, USA.		Jelacic, Tanya/S-3173-2019	Jelacic, Tanya/0000-0002-1584-5300; Pang, Yuan-Ping/0000-0003-0838-2560	NINDS NIH HHS [NS29646] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029646] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERMAN HA, 1992, MOL PHARMACOL, V41, P412; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; DAVIS KL, 1995, LANCET, V345, P625, DOI 10.1016/S0140-6736(95)90526-X; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; EICHLER J, 1994, MOL PHARMACOL, V45, P335; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FLYNN DD, 1989, J PHARMACOL EXP THER, V250, P573; GALANAKIS D, 1995, J MED CHEM, V38, P595, DOI 10.1021/jm00004a005; GAO J, 1989, SCIENCE, V244, P1069, DOI 10.1126/science.2727695; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; KOSHLAND DE, 1962, J THEOR BIOL, V2, P75, DOI 10.1016/0022-5193(62)90037-1; LIU JS, 1986, CAN J CHEM, V64, P837, DOI 10.1139/v86-137; MESULAM MM, 1994, ANN NEUROL, V36, P722, DOI 10.1002/ana.410360506; NELSON ME, 1994, MOL PHARMACOL, V46, P151; OSTERRIEDER W, 1987, BRIT J PHARMACOL, V92, P521, DOI 10.1111/j.1476-5381.1987.tb11352.x; PANG YP, 1994, J COMPUT AID MOL DES, V8, P669, DOI 10.1007/BF00124014; PANG YP, 1995, PESEPCT DRUG DISCOVE, V6, P106; PATOCKA J, 1976, COLLECT CZECH CHEM C, V41, P816, DOI 10.1135/cccc19760816; POMPONI M, 1992, MED CHEM RES, V2, P306; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Segel I.H., 1975, ENZYME KINETICS; SHUTSKE GM, 1989, J MED CHEM, V32, P1805, DOI 10.1021/jm00128a024; Steinberg G M, 1975, J Med Chem, V18, P1057; SUGIMOTO H, 1992, BIOORG MED CHEM LETT, V8, P871; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR JL, 1994, MOL PHARMACOL, V45, P74; VILLALOBOS A, 1995, J MED CHEM, V38, P2802, DOI 10.1021/jm00015a002; WILSON IB, 1955, BIOCHIM BIOPHYS ACTA, V18, P168, DOI 10.1016/0006-3002(55)90040-8	32	388	403	0	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23646	23649		10.1074/jbc.271.39.23646	http://dx.doi.org/10.1074/jbc.271.39.23646			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798583	hybrid			2022-12-25	WOS:A1996VJ44200012
J	Platanias, LC; Uddin, S; Domanski, P; Colamonici, OR				Platanias, LC; Uddin, S; Domanski, P; Colamonici, OR			Differences in interferon alpha and beta signaling - Interferon beta selectively induces the interaction of the alpha and beta(L) subunits of the Type I interferon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TYROSINE PHOSPHORYLATION; IFN-ALPHA; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; PROTEIN; KINASE; EXPRESSION; CLONING; ASSOCIATION; P135(TYK2)	All Type I interferons (IFN alpha, IFN beta, IFN omega) bind to the Type I IFN receptor (IFNR) and elicit a common set of signaling events, including activation of the Jak/Stat and IRS pathways. However, IFN beta selectively induces the association of the alpha subunit of the Type I IFNR with p100, a tyrosyl phosphoprotein, to transduce IFN beta-specific signals. Using antibodies raised against the different components of the Type I IFNR, we identified p100 as the long form of the beta subunit (beta(L) subunit) of the Type I IFNR, This was also confirmed in experiments with mouse L-929 cells transfected with truncated forms of beta(L). Thus, IFN beta stimulation of human cells or mouse L-929 transfectants expressing the human alpha and beta(L) subunits, selectively induces the formation of a signaling complex containing the alpha and beta(L) subunits of the receptor, The IFN beta-regulated interaction of the alpha and beta(L) chains is rapid and transient and follows a similar time course with the tyrosine phosphorylation of these receptor components, These data demonstrate that the signaling specificity for different Type I IFNs is established early in the signaling cascade, at the receptor level, and results from distinct interactions between components of the Type I IFNR.	UNIV ILLINOIS,HEMATOL ONCOL SECT,MBRB,DEPT MED,CHICAGO,IL 60607; W SIDE VET AFFAIRS HOSP,CHICAGO,IL 60607; LOYOLA UNIV,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; VET AFFAIRS EDWARD HINES JR HOSP,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Tennessee System; University of Tennessee Health Science Center				Uddin, Shahab/0000-0003-1886-6710	NCI NIH HHS [CA73381, CA55079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055079, R29CA073381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Platanias Leonidas C., 1995, Current Opinion in Oncology, V7, P560, DOI 10.1097/00001622-199511000-00015; RANI MRS, 1995, J INTERFERON CYTO S1, V15, pS107; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179	29	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23630	23633		10.1074/jbc.271.39.23630	http://dx.doi.org/10.1074/jbc.271.39.23630			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798579	hybrid			2022-12-25	WOS:A1996VJ44200008
J	Schmidt, PP; Andersson, KK; Barra, AL; Thelander, L; Graslund, A				Schmidt, PP; Andersson, KK; Barra, AL; Thelander, L; Graslund, A			High field EPR studies of mouse ribonucleotide reductase indicate hydrogen bonding of the tyrosyl radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOTOSYSTEM-II; RECOVERY EPR; SPECTROSCOPY; PROTEIN; RESONANCE; SATURATION; R2	Ribonucleotide reductase catalyzes by free radical chemistry the reduction of ribonucleotides to deoxyribonucleotides. The R2 protein of a class 1 ribonucleotide reductase contains a stable tyrosyl radical of neutral phenoxy character, which is necessary for normal enzymatic activity, Here we present the EPR spectra from the tyrosyl free radical in the R2 protein from mouse at 9.62, 115, and 245 GHz. We show that the g-value anisotropy of the mouse R2 radical, when precisely determined from high field EPR spectra, is similar to that of the hydrogen bonded dark stable Y-D(.) tyrosyl radical of photosystem II and different from that of the Escherichia coli R2 radical. Because the g-value anisotropy is an important indicator of the hydrogen bonding status of the tyrosyl radical, this result suggests that the mouse R2 radical has its tyrosylate oxygen hydrogen bonded with a D2O exchangeable proton, whereas this hydrogen bond is absent in the E. coli enzyme. It is suggested that the observed proton may be derived from the tyrosine that will become a tyrosyl radical.	UNIV OSLO,DEPT BIOCHEM,N-0316 OSLO,NORWAY; STOCKHOLM UNIV,ARRHENIUS LABS,DEPT BIOPHYS,S-10691 STOCKHOLM,SWEDEN; CNRS,MPI,HIGH FIELD MAGNET LAB,F-38042 GRENOBLE,FRANCE; UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	University of Oslo; Stockholm University; Centre National de la Recherche Scientifique (CNRS); Umea University			Andersson, K Kristoffer/F-9624-2010					Allard P, 1996, J AM CHEM SOC, V118, P895, DOI 10.1021/ja9529192; Andersson K. K., 1995, ADV INORG CHEM, V43, P359; Atta M, 1996, J BIOL INORG CHEM, V1, P210, DOI 10.1007/s007750050045; BARRA AL, 1990, CHEM PHYS LETT, V165, P107, DOI 10.1016/0009-2614(90)87019-N; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BERNHARD WA, 1989, J MAGN RESON, V82, P156, DOI 10.1016/0022-2364(89)90176-5; BURGHAUS O, 1993, J PHYS CHEM-US, V97, P7639, DOI 10.1021/j100131a037; EHRENBERG A, 1988, CHEM SCRIPTA, V28A, P27; GALLI C, 1995, J AM CHEM SOC, V117, P740, DOI 10.1021/ja00107a017; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; HIRSH DJ, 1992, J AM CHEM SOC, V114, P7475, DOI 10.1021/ja00045a021; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MULLER F, 1989, REV SCI INSTRUM, V60, P3681, DOI 10.1063/1.1140474; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; THELANDER L, 1993, MET IONS BIOL SYST, V30, P109; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; UN S, 1994, P NATL ACAD SCI USA, V91, P5262, DOI 10.1073/pnas.91.12.5262; UN S, 1995, J AM CHEM SOC, V117, P10713, DOI 10.1021/ja00148a013; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; WARNCKE K, 1994, J AM CHEM SOC, V116, P7332, DOI 10.1021/ja00095a042	31	66	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23615	23618		10.1074/jbc.271.39.23615	http://dx.doi.org/10.1074/jbc.271.39.23615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798575	hybrid			2022-12-25	WOS:A1996VJ44200004
J	Batiza, AF; Schulz, T; Masson, PH				Batiza, AF; Schulz, T; Masson, PH			Yeast respond to hypotonic shock with a calcium pulse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED ION CHANNELS; SACCHAROMYCES-CEREVISIAE; VOLUME REGULATION; CATION CHANNELS; MAMMALIAN-CELLS; PKC1; MECHANISMS; MEMBRANE	We have used the transgenic AEQUORIN calcium reporter system to monitor the cytosolic calcium ([Ca2+](cyt)) response of Saccharomyces cerevisiae to hypotonic shock. Such a shock generates an almost immediate and transient rise in [Ca2+](cyt) which is eliminated by gadolinium, a blocker of stretch-activated channels. In addition, this transient rise in [Ca2+](cyt) which is initially insensitive to 1,2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), an extracellular calcium chelator. However, BAPTA abruptly attenuates the maintenance of that transient rise. These data show that hypotonic shock generates a stretch-activated channel-dependent calcium pulse in yeast. They also suggest that the immediate calcium influx is primarily generated from intracellular stores, and that a sustained increase in [Ca2+](cyt) depends upon extracellular calcium.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV WISCONSIN,CELL & MOL BIOL PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048053] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48053] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BAGNASCO SM, 1993, AM J PHYSIOL, V264, pC1165, DOI 10.1152/ajpcell.1993.264.5.C1165; BARGMANN CI, 1994, CELL, V78, P729; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHRISTENSEN O, 1987, NATURE, V330, P66, DOI 10.1038/330066a0; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COBBOLD PH, 1991, CELLULAR CALCIUM PRA, P51; CORNET M, 1993, J MEMBRANE BIOL, V133, P161; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DAVIDSON RM, 1993, J MEMBRANE BIOL, V131, P81, DOI 10.1007/BF02258536; DING JP, 1991, HEARING RES, V56, P19, DOI 10.1016/0378-5955(91)90149-4; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Moore DD, 1995, GLOB MOB SURV; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PIERCE SK, 1990, ANNU REV PHYSIOL, V52, P27, DOI 10.1146/annurev.ph.52.030190.000331; ROTHSTEIN A, 1990, AM J PHYSIOL, V258, pC827, DOI 10.1152/ajpcell.1990.258.5.C827; RUSSELL P, 1986, CELL, V45, P781, DOI 10.1016/0092-8674(86)90550-7; SIKORSKI RS, 1989, GENETICS, V122, P19; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; SUZUKI M, 1990, AM J PHYSIOL, V258, pF690, DOI 10.1152/ajprenal.1990.258.3.F690; TILLY BC, 1993, J BIOL CHEM, V268, P19919; WATANABE M, 1994, J BIOL CHEM, V269, P16829; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	42	139	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23357	23362		10.1074/jbc.271.38.23357	http://dx.doi.org/10.1074/jbc.271.38.23357			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798538	hybrid			2022-12-25	WOS:A1996VH76800064
J	FernandezBusquets, X; Kammerer, RA; Burger, MM				FernandezBusquets, X; Kammerer, RA; Burger, MM			A 35-kDa protein is the basic unit of the core from the 2 x 10(4)-kDa aggregation factor responsible for species-specific cell adhesion in the marine sponge Microciona prolifera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; MOLECULAR-CLONING; CARTILAGE PROTEOGLYCAN; SEXUAL AGGLUTINATION; POLYACRYLAMIDE GELS; HANSENULA-WINGEI; BINDING; GLYCOSAMINOGLYCANS; IDENTIFICATION	Dissociated sponge cells quickly reaggregate in a species-specific manner, differentiate, and reconstruct tissue, providing a very handy system to investigate the molecular basis of more complex intercellular recognition processes. Species specific cell adhesion in the marine sponge Microciona prolifera is mediated by a supramolecular complex with a M-r = 2 x 10(7), termed aggregation factor, Guanidinium hydrochloride/cesium chloride dissociative gradients and rhodamine B isothiocyanate staining indicated the presence of several proteins with different degrees of glycosylation. Hyaluronate has been found to be associated with the aggregation factor. Chemical deglycosylation revealed a main component accounting for nearly 90% of the total protein. The cDNA-deduced amino acid sequence predicts a 35-kDa protein (MAFp3), the first sponge aggregation factor core protein ever described, The open reading frame is uninterrupted upstream from the amino terminus of the mature protein, and the deduced amino acid sequence for this region has been found to contain a long stretch sharing homology with the Na+-Ca2+ exchanger protein. A putative hyaluronic acid binding domain and several putative N- and O-glycosylation signals are present in MAFp3, as well as eight cysteines, some of them involved in intermolecular disulfide bridges. Northern blot data suggest variable expression, and Southern blot analysis reveals the presence of other related gene sequences. According to the respective molecular masses, one aggregation factor molecule would contain about 300 MAFp3 units, suggesting that sponge cell adhesion might be based on the assembly of multiple small glycosylated protein subunits.	MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Marine Biological Laboratory - Woods Hole	FernandezBusquets, X (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Fernàndez-Busquets, Xavier/K-1323-2014	Fernàndez-Busquets, Xavier/0000-0002-4622-9631; Kammerer, Richard/0000-0003-4570-5197				ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURDON MA, 1986, J BIOL CHEM, V261, P2534; CAULDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051, DOI 10.1021/bi00740a017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; FERNANDEZBUSQUETS X, 1995, ANAL BIOCHEM, V227, P394, DOI 10.1006/abio.1995.1299; GRAMZOW M, 1988, EXP CELL RES, V179, P243, DOI 10.1016/0014-4827(88)90363-1; GRAMZOW M, 1988, J HISTOCHEM CYTOCHEM, V36, P205, DOI 10.1177/36.2.3335775; GRAMZOW M, 1986, J CELL BIOL, V102, P1344, DOI 10.1083/jcb.102.4.1344; HANSON AN, 1983, ANAL BIOCHEM, V130, P32, DOI 10.1016/0003-2697(83)90646-2; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HUMPHREYS S, 1977, J SUPRAMOL STR CELL, V7, P339, DOI 10.1002/jss.400070307; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KREIS T, 1993, GUIDEBOOK EXTRACELLU; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LI ZP, 1994, J BIOL CHEM, V269, P17434; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; LYON M, 1986, BIOCHIM BIOPHYS ACTA, V881, P22, DOI 10.1016/0304-4165(86)90092-9; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MCDEVITT CA, 1971, ANAL BIOCHEM, V44, P612, DOI 10.1016/0003-2697(71)90250-8; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MISEVIC GN, 1989, METHOD ENZYMOL, V179, P95; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; MULLER WEG, 1977, J BIOL CHEM, V252, P3836; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; ROBITZKI A, 1990, BIOCHEM J, V271, P415, DOI 10.1042/bj2710415; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAJDERA S, 1969, J BIOL CHEM, V244, P77; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; Showalter AM, 1990, ORG ASSEMBLY PLANT A, P247; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; TAYLOR NW, 1971, BIOCHEMISTRY-US, V10, P2043, DOI 10.1021/bi00787a012; TEMPLETON DM, 1992, CRIT REV CL LAB SCI, V29, P141, DOI 10.3109/10408369209114599; TREVELYAN WE, 1952, BIOCHEM J, V50, P298, DOI 10.1042/bj0500298; TURNER RS, 1973, NATURE, V244, P509, DOI 10.1038/244509a0; VARNER JA, 1995, J CELL SCI, V108, P3119; VARNER JA, 1988, J BIOL CHEM, V263, P8498; VILIM V, 1991, ANAL BIOCHEM, V197, P34, DOI 10.1016/0003-2697(91)90351-S; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YEN PH, 1974, BIOCHEMISTRY-US, V13, P2428, DOI 10.1021/bi00708a030	66	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23558	23565		10.1074/jbc.271.38.23558	http://dx.doi.org/10.1074/jbc.271.38.23558			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798565	hybrid			2022-12-25	WOS:A1996VH76800091
J	Luo, W; Skalnik, DG				Luo, W; Skalnik, DG			Interferon regulatory factor-2 directs transcription from the gp91(phox) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CCAAT DISPLACEMENT PROTEIN; BETA GENE-EXPRESSION; LEUKEMIA CELL-LINE; FC-GAMMA RECEPTOR; FACTOR-I; GP91-PHOX PROMOTER; CYTOCHROME B(558); FACTOR IRF-2; ACTIVATION	Repressor elements in the gp91(phox) promoter are necessary to restrict tissue-specific transcription to mature phagocytes. Deletion of these elements leads to significant promoter activity in cell lines such as HEL and K562 that do not normally express gp91(phox). The -100 to +12 base pair gp91(phox) promoter region is sufficient to direct maximal de repressed transcription in these cells. However, promoter activity is dramatically decreased following a 16-base pair truncation that deletes an interferon-stimulated response element. This element interacts with IRF-1 and IRF-2, members of the interferon regulatory factor family of transcription factors. In addition, this promoter region is bound by a factor with properties similar to BID, a DNA-binding protein that also interacts with three upstream sites within the gp91(phox) promoter. Transient transfection studies using mutated promoters indicate that both the IRF and BID binding sites are required for maximal gp91(phox) promoter activity. Overexpression of IRF-1 or IRF-2 in K562 cells leads to transactivation of gp91(phox) promoter constructs, which is dependent on the presence of an intact IRF binding site. IRF-2 predominates in macrophages that express the gp91(phox) gene as well as in HEL and K562 cells. We conclude that IRF-2 and BID activate gp91(phox) promoter activity in the absence of transcriptional repression.	JAMES WHITCOMB RILEY HOSP CHILDREN,HERMAN B WELLS CTR PEDIAT RES,SECT PEDIAT HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PEDIAT,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CANCER INSTITUTE [R01CA058947, R29CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Babior B M, 1995, Curr Opin Hematol, V2, P55; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GEY GO, 1952, CANCER RES, V12, P264; GOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE TC, 1994, ONCOGENE, V9, P1047; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LIN RT, 1994, J BIOL CHEM, V269, P17542; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 1989, MOL CLONING; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TUCKER KA, 1987, BLOOD, V70, P372; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITESIDE ST, 1994, J BIOL CHEM, V269, P27059; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WOODMAN RC, 1995, BLOOD, V85, P231, DOI 10.1182/blood.V85.1.231.bloodjournal851231; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	50	63	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23445	23451		10.1074/jbc.271.38.23445	http://dx.doi.org/10.1074/jbc.271.38.23445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798551	hybrid			2022-12-25	WOS:A1996VH76800077
J	Parent, JL; LeGouill, C; Escher, E; RolaPleszczynski, M; Stankova, J				Parent, JL; LeGouill, C; Escher, E; RolaPleszczynski, M; Stankova, J			Identification of transmembrane domain residues determinant in the structure-function relationship of the human platelet-activating factor receptor by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MOLECULAR-CLONING; PHOSPHOLIPASE-C; EXPRESSION; PHOSPHORYLATION; CDNA; PAF; HYDROLYSIS; ANALOG; KINASE	Platelet-activating factor (PAF) is a potent phospholipid mediator that produces a wide range of biological responses. The PAF receptor is a member of the seven-transmembrane GTP binding regulatory protein-coupled receptor superfamily. This receptor binds PAF with high affinity and couples to multiple signaling pathways, leading to physiological responses that can be inhibited by various structurally distinct PAF antagonists. We have used site-directed mutagenesis and functional expression studies to examine the role of the Phe(97) and Phe(98) residues located in the third transmembrane helix and Asn(285) and Asp(289) of the seventh transmembrane helix in ligand binding and activation of the human PAF receptor in transiently transfected COS-7 cells. The double mutant FFGG (Phe(97) and Phe(98) mutated into Gly residues) showed a 3-4-fold decrease in affinity for PAF, but not for the specific antagonist WEB2086, when compared with the wild-type (WT) receptor. The FFGG mutant receptor, however, displayed normal agonist activation, suggesting that these two adjacent Phe residues maintain the native PAF receptor conformation rather than interacting with the ligand. On the other hand, substitution of Ala for Asp(289) increased the receptor affinity for PAF but abolished PAF-dependent inositol phosphate accumulation; it did not affect WEB2086 binding. Substitution of Asn for Asp(289), however, resulted in a mutant receptor with normal binding and activation characteristics. When Asn(285) was mutated to Ala, the resulting receptor was undistinguishable from the WT receptor. Surprisingly, substitution of Ile for Asn(285) led to a loss of ligand binding despite normal cell surface expression levels of this mutant, as verified by flow cytometric analysis. Our data suggest that residues 285 and 289 are determinant in the structure and activation of the PAF receptor but not in direct ligand binding, as had been recently proposed in a PAF receptor molecular model.	UNIV SHERBROOKE,FAC MED,DEPT PEDIAT,DIV IMMUNOL,SHERBROOKE,PQ J1H 5N4,CANADA; UNIV SHERBROOKE,FAC MED,DEPT PHARMACOL,SHERBROOKE,PQ J1H 5N4,CANADA	University of Sherbrooke; University of Sherbrooke				Escher, Emanuel/0000-0001-6601-987X				ALI H, 1994, J BIOL CHEM, V269, P24557; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1987, PROSTAGLANDINS, V34, P143, DOI 10.1016/0090-6980(87)90190-0; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; FRANKLIN RA, 1995, BIOCHEM BIOPH RES CO, V209, P1111, DOI 10.1006/bbrc.1995.1612; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; KAJIHARA A, 1994, J LIPID MEDIAT CELL, V9, P185; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KURUVILLA A, 1993, J IMMUNOL, V151, P637; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; Parent JL, 1996, BIOCHEM BIOPH RES CO, V219, P968, DOI 10.1006/bbrc.1996.0341; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RODRIGUEZ CG, 1995, J BIOL CHEM, V270, P25178, DOI 10.1074/jbc.270.42.25178; SAWYER DB, 1989, BIOCHIM BIOPHYS ACTA, V987, P129, DOI 10.1016/0005-2736(89)90464-1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; SVARESE T, 1992, BIOCHEM J, V283, P1; TAKANO T, 1994, J BIOL CHEM, V269, P22453; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; ZHOU W, 1994, MOL PHARMACOL, V45, P165	35	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23298	23303		10.1074/jbc.271.38.23298	http://dx.doi.org/10.1074/jbc.271.38.23298			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798529	hybrid			2022-12-25	WOS:A1996VH76800055
J	Feron, O; Belhassen, L; Kobzik, L; Smith, TW; Kelly, RA; Michel, T				Feron, O; Belhassen, L; Kobzik, L; Smith, TW; Kelly, RA; Michel, T			Endothelial nitric oxide synthase targeting to caveolae - Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; PALMITOYLATION; PARTICULATE; CULTURE	The endothelial isoform of nitric oxide synthase (eNOS) modulates cardiac myocyte function and is expressed in the particulate subcellular fraction. We have previously shown that eNOS is targeted to plasmalemmal caveolae in endothelial cells, Caveolae, specialized domains of the plasma membrane, may serve to sequester signaling proteins; a family of transmembrane proteins, the caveolins, form a key structural component of these microdomains, Caveolae in cardiac tissues contain the muscle-specific isoform caveolin-3, and caveolae in endothelial cells contain the widely expressed isoform caveolin-1, which shares limited sequence identity with caveolin-3. Our immunohistochemical analyses of rat cardiac muscle used isoform-specific caveolin antibodies to reveal prominent caveolin-3 staining in myocyte sarcolemmal membranes and at intercalated discs, whereas caveolin-1 staining was prominent in the vascular endothelium. Caveolin or eNOS antibodies were utilized to immunoprecipitate cardiac myocyte or cultured aortic endothelial cell lysates, which then were analyzed in immunoblots, In endothelial cells, we found that eNOS is quantitatively immunoprecipitated by antibodies to caveolin-1. In cardiac myocyte lysates, nearly all the eNOS is immunoprecipitated instead by antibodies to caveolin-3 and, conversely, eNOS antiserum immunoprecipitated primarily caveolin-3, These studies establish expression of eNOS in cardiac myocyte caveolae and document tissue-specific and quantitative associations of eNOS with caveolin, These findings may have important implications for the regulation of eNOS by caveolin isoforms and by other signaling proteins targeted to caveolae.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT RESP BIOL,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286	NHLBI NIH HHS [HL52320, HL46457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; KELLY RA, 1996, IN PRESS CIRC RES; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SASE K, 1996, IN PRESS TRENDS CARD; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SHAUL PW, 1996, J BIOL CHEM, V271, P618; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255	26	580	595	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22810	22814		10.1074/jbc.271.37.22810	http://dx.doi.org/10.1074/jbc.271.37.22810			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798458	hybrid			2022-12-25	WOS:A1996VG67200077
J	Gaymard, F; Cerutti, M; Horeau, C; Lemaillet, G; Urbach, S; Ravallec, M; Devauchelle, G; Sentenac, H; Thibaud, JB				Gaymard, F; Cerutti, M; Horeau, C; Lemaillet, G; Urbach, S; Ravallec, M; Devauchelle, G; Sentenac, H; Thibaud, JB			The baculovirus/insect cell system as an alternative to Xenopus oocytes - First characterization of the AKT1 K+ channel from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; SACCHAROMYCES-CEREVISIAE; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; ION CHANNELS; INSECT CELLS; GUARD-CELLS; VOLTAGE; PURIFICATION; CLONING	Two plant (Arabidopsis thaliana) K+ transport systems, KAT1 and AKT1, have been expressed in insect cells (Sf9 cell line) using recombinant baculoviruses. Microscopic observation after immunogold staining revealed that the expressed AKT1 and KAT1 polypeptides were mainly associated with internal membranes, but that a minute fraction was targeted to the cell membrane, KAT1 was known, from earlier electrophysiological characterization in Xenopus oocytes, to be an inwardly rectifying voltage-gated channel highly selective for K+, while similar experiments had failed to characterize AKT1. Insect cells expressing KAT1 displayed an exogenous inwardly rectifying K+ conductance reminiscent of that described previously in Xenopus oocytes expressing KAT1. Under similar conditions, cells expressing AKT1 showed a disturbed cell membrane electrical stability that precluded electrophysiological analysis. Use of a baculovirus transfer vector designed so as to decrease the expression level allowed the first electrophysiological characterization of AKT1. The baculovirus system can thus be used as an alternative method when expression in Xenopus oocytes is unsuccessful for electrophysiological characterization of the ion channel of interest. The plant AKT1 protein has been shown in this way to be an inwardly rectifying voltage gated channel highly selective for K+ ions and sensitive to cGMP.	INRA, LAB PATHOL COMPAREE, CNRS, URA 1184, F-30380 ST CHRISTOL LES ALES, FRANCE	Centre National de la Recherche Scientifique (CNRS); INRAE	Gaymard, F (corresponding author), ECOLE NATL SUPER AGRON MONTPELLIER, INRA, LAB BIOCHIM & PHYSIOL MOL PLANTES, CNRS, URA 2133, F-34060 MONTPELLIER 1, FRANCE.			Sentenac, Herve/0000-0003-3641-4822; THIBAUD, Jean-Baptiste/0000-0002-0824-6465				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Basset M, 1995, PLANT MOL BIOL, V29, P947, DOI 10.1007/BF00014968; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BROWN AM, 1993, ANNU REV BIOPH BIOM, V22, P173, DOI 10.1146/annurev.bb.22.060193.001133; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; DAVRINCHE C, 1993, BIOCHEM BIOPH RES CO, V195, P469, DOI 10.1006/bbrc.1993.2067; GARNIER L, 1995, J VIROL, V69, P4060, DOI 10.1128/JVI.69.7.4060-4068.1995; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEDRICH R, 1995, EUR BIOPHYS J, V24, P107, DOI 10.1007/BF00211406; HEUSTERSPREUTE M, 1985, GENE, V39, P299, DOI 10.1016/0378-1119(85)90327-0; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; KOCHIAN LV, 1988, ADV BOT RES, V15, P93, DOI DOI 10.1016/S0065-2296(08)60045-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Luttge U., 1989, Progress in Botany, V50, P51; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MINET M, 1992, PLANT J, V2, P417; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; PAJOTAUGY E, 1995, J MOL ENDOCRINOL, V14, P51, DOI 10.1677/jme.0.0140051; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P1295, DOI 10.1021/bi00172a002; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VERY AA, 1994, PFLUG ARCH EUR J PHY, V428, P422, DOI 10.1007/BF00724528; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; ZITTLAU KE, 1991, PFLUG ARCH EUR J PHY, V418, P190, DOI 10.1007/BF00370470	41	130	137	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22863	22870		10.1074/jbc.271.37.22863	http://dx.doi.org/10.1074/jbc.271.37.22863			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798465	Green Published, hybrid			2022-12-25	WOS:A1996VG67200084
J	Gibbs, E; Pan, ZQ; Niu, HW; Hurwitz, J				Gibbs, E; Pan, ZQ; Niu, HW; Hurwitz, J			Studies on the in vitro phosphorylation of HSSB-p34 and -p107 by cyclin-dependent kinases - Cyclin-substrate interactions dictate the efficiency of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DNA-BINDING PROTEIN; NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; RETINOBLASTOMA PROTEIN; COMPLEX-FORMATION; P107 PROTEIN; CDK2 KINASE; T-ANTIGEN	Cyclin-dependent kinases (Cdks) are required for cell cycle progression. Two potentially significant Cdk substrates in human cells are the human single-stranded binding protein (HSSB or RPA), which plays an essential role in DNA replication, repair, and recombination, and the tumor suppressor p107 which acts to negatively regulate cell growth. In this report we describe the in vitro phosphorylation of these two proteins by Cdks in an attempt to understand how cyclin-substrate interactions direct phosphorylation efficiencies. We show that cyclin A-Cdk2 efficiently phosphorylates the p34 subunit of HSSB (HSSB-p34) alone or as a part of the heterotrimeric complex. In contrast, cyclin E-Cdk2 that is active in phosphorylating histone H1, does not support the phosphorylation of the p34 subunit of HSSB. We provide evidence that this differential phosphorylation results from a specific interaction between HSSB-p34 and cyclin Abut not cyclin E. Thus the observed cell cycle-dependent phosphorylation of HSSB-p34 at the G(1) to S transition is most likely catalyzed by cyclin A-Cdk2 initiated by the direct interaction between cyclin A and the HSSB-p34 subunit. These studies are consistent with our previous observation that p107, which directly binds cyclin A, is efficiently phosphorylated by cyclin A-Cdk2 but not cyclin B-associated kinases. Here we further demonstrate that cyclin A only complexes with p107 in its unphosphorylated form. These data suggest a catalytic mechanism by which Cdk acts: substrate targeting by a cyclin-substrate interaction followed by dissociation of the Cdk upon phosphate incorporation allowing the Cdk to become available for the next cycle of phosphorylation.	MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [GM38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1994, J BIOL CHEM, V269, P7735; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO J, 1993, GENE DEV, V7, P331; KENNY MK, 1990, J BIOL CHEM, V265, P769; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; LUCHE RM, 1993, MOL CELL BIOL, V13, P5749, DOI 10.1128/MCB.13.9.5749; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1993, J BIOL CHEM, V268, P20433; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	47	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22847	22854		10.1074/jbc.271.37.22847	http://dx.doi.org/10.1074/jbc.271.37.22847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798463	hybrid			2022-12-25	WOS:A1996VG67200082
J	Sheu, FS; Mahoney, CW; Seki, K; Huang, KP				Sheu, FS; Mahoney, CW; Seki, K; Huang, KP			Nitric oxide modification of rat brain neurogranin affects its phosphorylation by protein kinase C and affinity for calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; BINDING DOMAIN; SUBSTRATE RC3; SUBCELLULAR-FRACTIONS; DEPENDENT TARGET; NMDA RECEPTORS; NEUROMODULIN; IDENTIFICATION; SITE; PEROXYNITRITE	Neurogranin (Ng) is a prominent protein kinase C (PKC) substrate which binds calmodulin (CaM) in the absence of Ca2+. Rat brain Ng contains four cysteine residues that were readily oxidized by nitric oxide (NO) donors, 1,1-diethyl-2-hydroxy-2-nitrosohydrazine (DEANO) and sodium nitroprusside, and by oxidants, H2O2 and o-iodosobenzoic acid, NO oxidation of Ng resulted in a conformational change detectable by increased electrophoretic mobility upon SDS-polyacrylamide gel electrophoresis. The NO-mediated mobility shift was reversed by treatment with dithiothreitol and was blocked by modification of Ng sulfhydryl groups with 4-vinylpyridine. Both the nonphosphorylated and PKC-phosphorylated Ng were susceptible to NO oxidation. Modification of Ng by DEANO was blocked by CaM in the absence of Ca2+; while in the presence of Ca2+, CaM did not protect Ng from oxidation by DEANO. CaM also failed to protect DEANO-mediated oxidation of PKC-phosphorylated Ng with or without Ca2+. Oxidation of Ng by the various oxidants apparently resulted in the formation of intramolecular disulfide bond(s) as judged by a reduction of apparent M(r) on SDS-polyacrylamide gel electrophoresis; this oxidized form, unlike the reduced form, did not bind to CaM-affinity column. The oxidized Ng was also a poorer substrate for PKC; both the reduced and oxidized forms had similar K-m values, but the V-max of the oxidized form was about one fourth of the reduced one. When comparing the rate of DEANO-mediated nitrosation of Ng with other sulfhydryl-containing compounds, it became evident that Ng ranked as one of the best NO accepters among those tested, including serum albumin, glutathione, and dithiothreitol. Ng present in the rat brain synaptosomal preparations was also oxidized by DEANO in a dose-dependent manner when analyzed by immunoblot with a polyclonal antibody against this protein. These results suggest that Ng is a likely target of NO and other oxidants and that oxidation/reduction may serve as a mechanism for controlling both the PKC phosphorylation and the CaM-binding affinity of this protein.	NICHHD, METAB REGULAT SECT, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			SHEU, Fwu-Shan/G-6435-2011	SHEU, Fwu-Shan/0000-0002-2784-2529				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONN PJ, 1994, PROTEIN KINASE C, P199; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FEROROV NB, 1995, EUR J NEUROSCI, V7, P819; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; HUANG KP, 1986, J BIOL CHEM, V261, P4781; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KIM DS, 1987, J BIOL CHEM, V262, P14250; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; NOACK E, 1991, OXIDATIVE STRESS OXI, P445; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; RADI R, 1991, J BIOL CHEM, V266, P4244; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; SLEMMON JR, 1994, BIOCHEMISTRY-US, V33, P5653, DOI 10.1021/bi00184a039; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WINTERBOURN CC, 1995, METHOD ENZYMOL, V251, P81, DOI 10.1016/0076-6879(95)51112-1	50	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22407	22413		10.1074/jbc.271.37.22407	http://dx.doi.org/10.1074/jbc.271.37.22407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798403	hybrid			2022-12-25	WOS:A1996VG67200022
J	vandenBorn, J; Jann, K; Assmann, KJM; Lindahl, U; Berden, JHM				vandenBorn, J; Jann, K; Assmann, KJM; Lindahl, U; Berden, JHM			N-acetylated domains in heparan sulfates revealed by a monoclonal antibody against the Escherichia coli K5 capsular polysaccharide - Distribution of the cognate epitope in normal human kidney and transplant kidney with chronic vascular rejection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; GLOMERULAR-BASEMENT-MEMBRANE; MOLECULAR-ORGANIZATION; PROTEIN INTERACTIONS; ENDOTHELIAL-CELLS; BINDING SEQUENCE; LYMPHOCYTES-T; PROTEOGLYCANS; CHAINS	The Escherichia coli K5 capsular polysaccharide has the same (GlcUA-->GlcNAc)(n) structure as the nonsulfated heparan sulfate/heparin precursor polysaccharide. A monoclonal antibody (mAb 865) against the K5 polysaccharide has been described (Peters, H., Jurs, M., Jann, B., Jann, K., Timmis, K. N., and Bitter-Sauermann, D. (1985) Infect. Immun. 50, 459-466). In this report, we demonstrate the binding of anti-K5 mAb 865 to N-acetylated sequences in heparan sulfates and heparan sulfate proteoglycans but not to heparin. This is shown by direct binding and fluid phase inhibition of mAb 865 in an enzyme-linked immunosorbent assay. In this system we found that the binding of the mAb decreased with increasing sulfate content of the polysaccharide. By testing chemically modified K5 and heparin polysaccharides, we found that each of the modifications that occur during heparan sulfate (HS) synthesis (N-sulfation, C-5 epimerization, and O-sulfation) prevents recognition by mAb 865. Samples of heparan sulfate from human aorta (HS-II) were selectively degraded so as to allow the separate isolation of N-sulfated and N-acetylated block structures. N-Sulfated oligosaccharides (obtained after N-deacetylation by hydrazinolysis followed by nitrous acid deamination at pH 3.9) were not recognized by mAb 865, in contrast to N-acetylated oligosaccharides (obtained after nitrous acid deamination at pH 1.5), although the reactivity was lower than for intact HS-II. Analysis of the latter's pH 1.5 deamination products by gel filtration indicated that a minimal size of 18 saccharide units was necessary for antibody binding. These results lead us to propose bivalent antibody-heparan sulfate interaction, in which both F(ab) domains of the mAb interact with their epitopes, both of which are present in a single large (greater than or equal to 18 saccharide units) N-acetylated domain and additionally with single epitopes present in two N-acetylated sequences (each < 18 saccharide units) bridged by a short N-sulfated domain. Immunohistochemistry with mAb 865 on cryostat sections of normal human kidney tissue, revealed its binding to most but not all renal basement membranes. However, all renal basement membranes contain heparan sulfate, as shown by a mAb against heparitinase-digested heparan sulfate stubs (mAb 3G10). This finding indicates that not all heparan sulfate chains present in basement membranes express the mAb 865 epitopes. Besides the normal distribution, mAb 865 staining was found in fibrotic and sclerotic lesions in vessels, interstitium, and mesangium in transplant kidneys with chronic vascular rejection. Occasionally, a decrease of staining was observed within tubulo-interstitium and glomeruli. These findings show that N-acetylated sequences in heparan sulfates can be demonstrated by anti-K5 mAb 865 in normal and diseased kidneys.	UNIV NIJMEGEN ST RADBOUD HOSP,DEPT PATHOL,NL-6500 HB NIJMEGEN,NETHERLANDS; MAX PLANCK INST IMMUNBIOL,D-79011 FREIBURG,GERMANY; UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Radboud University Nijmegen; Max Planck Society; Uppsala University	vandenBorn, J (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DIV NEPHROL,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		Berden, J.H.M./H-8009-2014					BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; GORDON PB, 1989, J CELL PHYSIOL, V140, P584, DOI 10.1002/jcp.1041400325; GROGGEL GC, 1990, AM J PHYSIOL, V258, pF259, DOI 10.1152/ajprenal.1990.258.2.F259; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; IOZZO RV, 1989, J BIOL CHEM, V264, P2690; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KATO M, 1994, J BIOL CHEM, V269, P18881; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN J, 1982, IMMUNOLOGY SCI SELF, P156; LIDER O, 1995, P NATL ACAD SCI USA, V92, P5037, DOI 10.1073/pnas.92.11.5037; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1988, J BIOL CHEM, V263, P5197; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PEJLER G, 1994, J BIOL CHEM, V269, P14451; PETERS H, 1985, INFECT IMMUN, V50, P459, DOI 10.1128/IAI.50.2.459-466.1985; SAVION N, 1984, J CELL PHYSIOL, V118, P169, DOI 10.1002/jcp.1041180209; SCHMIDT A, 1990, EUR J CELL BIOL, V52, P229; SCHMIDT A, 1992, EUR J CELL BIOL, V59, P322; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHARMA AK, 1993, KIDNEY INT, V44, P774, DOI 10.1038/ki.1993.312; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; THUNBERG L, 1982, J BIOL CHEM, V257, P278; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1993, KIDNEY INT, V43, P454, DOI 10.1038/ki.1993.67; VANDENBORN J, 1995, DIABETOLOGIA, V38, P161, DOI 10.1007/s001250050266; VANDENHEUVEL LPWJ, 1989, BIOCHEM J, V264, P457, DOI 10.1042/bj2640457; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2	52	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22802	22809		10.1074/jbc.271.37.22802	http://dx.doi.org/10.1074/jbc.271.37.22802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798457	Green Published, hybrid			2022-12-25	WOS:A1996VG67200076
J	Alonso, CR; Pesce, CG; Kornblihtt, AR				Alonso, CR; Pesce, CG; Kornblihtt, AR			The CCAAT-binding proteins CP1 and NF-I cooperate with ATF-2 in the transcription of the fibronectin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; RNA-POLYMERASE-II; DNA-BINDING; YEAST HAP2; PROMOTER; EXPRESSION; CAMP; BOX; ACTIVATION; MOUSE	We have previously proposed a molecular interaction between the liver factors that bind to the cyclic AMP response element (CRE) and CCAAT sites of the fibronectin (FN) gene based on the following evidence: (i) the close spacing of 20 base pairs between CRE and CCAAT elements is conserved in the FN genes from rats, mice, and humans; (ii) footprinting competitions showed that CRE oligonucleotides are able to detach both liver factors; (iii) CCAAT binding and transcriptional activity of liver extracts are reduced when the distance between the CRE and CCAAT elements is increased; and (iv) CCAAT-binding is stimulated by the addition of a liver extract fraction containing the CRE-binding factor ATF-2. This report provides binding and immunochemical evidence that nuclear factor I (CTF/NF-I) and CP1 (NF-Y or CBF) are the only liver factors that bind to the -150 CCAAT element of the FN gene, forming distinct complexes, We show that these factors bind less efficiently to the CCAAT site of a FN promoter in which the -170 CRE has been disrupted by site directed mutagenesis and that each element contributes positively to the liver transcriptional activity assessed in vitro with a G-less cassette construct and in vivo by transfection of hepatoma cells with CAT constructs, Furthermore, using a method that combines UV crosslinking and immunoprecipitation, we show that antibodies specific to ATF-2 are able to specifically precipitate protein-protein-DNA complexes containing NF-I and CP1. This simple method preserves weak macromolecular interactions, avoiding the disruptive electrophoresis conditions of gel mobility shifts assays.	CONSEJO NACL INVEST CIENT & TECN ARGENTINA,INST INVEST INGN GENET & BIOL MOL,RA-1428 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,DEPT CIENCIAS BIOL,RA-1428 BUENOS AIRES,DF,ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires				Kornblihtt, Alberto/0000-0003-4322-0831				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ANDRISANI O, 1990, J BIOL CHEM, V265, P3212; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BERNATH VA, 1990, J BIOL CHEM, V265, P18219; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Hynes RO, 1990, FIBRONECTINS; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; JONES KA, 1987, CELL, V48, P78; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; MIAO S, 1993, HEPATOLOGY, V17, P882, DOI 10.1002/hep.1840170519; MURO AF, 1993, TRENDS GENET, V9, P337, DOI 10.1016/0168-9525(93)90025-D; MURO AF, 1992, J BIOL CHEM, V267, P12767; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHWEIZERGROYER G, 1994, NUCLEIC ACIDS RES, V22, P1583, DOI 10.1093/nar/22.9.1583; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SREBROW A, 1993, FEBS LETT, V327, P25, DOI 10.1016/0014-5793(93)81031-T; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	46	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22271	22279		10.1074/jbc.271.36.22271	http://dx.doi.org/10.1074/jbc.271.36.22271			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703044	hybrid			2022-12-25	WOS:A1996VF61200086
J	Ilg, T; Stierhof, YD; Craik, D; Simpson, R; Handman, E; Bacic, A				Ilg, T; Stierhof, YD; Craik, D; Simpson, R; Handman, E; Bacic, A			Purification and structural characterization of a filamentous, mucin-like proteophosphoglycan secreted by Leishmania parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-PHOSPHATASE; DONOVANI LIPOPHOSPHOGLYCAN; MONOCLONAL-ANTIBODIES; PHLEBOTOMUS-PAPATASI; DENTIN PHOSPHOPHORYN; MAJOR PROMASTIGOTES; N-GLYCOSYLATION; MEXICANA; BIOSYNTHESIS; PSYCHODIDAE	Parasitic protozoa of the genus Leishmania secrete a filamentous macromolecule that forms networks and appears to be associated with cell aggregation. We report here the purification of this parasite antigen from Leishmania major culture supernatant and its compositional (75.6% carbohydrate, 20% phosphate, 4.4% amino acids, w/w), structural, and ultrastructural characterization as a highly unusual proteophosphoglycan (PPG). Mild acid hydrolysis, which cleaves preferentially hexose 1-phosphate bonds, releases the PPG glycans. Their structures are Gal beta 1-4Man, Man alpha 1-2Man, Gal beta 1-3Gal beta 1-4Man, PO4-6(Gal beta 1-3)(0-2)Gal beta 1-4Man, and PO4-6(Ara beta 1-2Gal beta 1-3)Gal beta 1-4Man. These glycans are also components of the parasite glycolipid lipophosphoglycan, but their relative abundance and structural organization in PPG are different. Some of them represent novel forms of protein glycosylation. P-31 NMR on native PPG demonstrates that phosphate is exclusively in phosphodiester bonds and that the basic structure R-Man alpha 1-PO4-6-Gal-R connects the glycans. A phosphodiester linkage to phosphoserine (most likely R-Man alpha 1-PO4-Ser) anchors the PPG oligosaccharides to the polypeptide. PPG has a unique amino acid composition; glycosylated phosphoserine (>43 mol %), serine, alanine, and proline account for more than 87 mol % and appear to be clustered in large proteinase-resistant domains. Electron microscopy of purified PPG reveals cable-like, flexible, long (to 6 mu m), and unbranched filaments. The overall structure of PPG shows many similarities to mammalian mucins. Potential functions of this novel mucin-like molecule for the parasites are discussed.	MAX PLANCK INST BIOL,D-72076 TUBINGEN,GERMANY; UNIV QUEENSLAND,CTR DRUG DESIGN & DEV,BRISBANE,QLD 4072,AUSTRALIA; LUDWIG INST CANC RES,MELBOURNE,VIC 3050,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,JOINT PROT STRUCT LAB,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,SCH BOT,PLANT CELL BIOL RES CTR,PARKVILLE,VIC 3052,AUSTRALIA	Max Planck Society; University of Queensland; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; University of Melbourne	Ilg, T (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Simpson, Richard/A-6947-2012; Craik, David/B-1695-2010	Craik, David/0000-0003-0007-6796; Simpson, Richard/0000-0002-9834-0796; Bacic, Tony/0000-0001-7483-8605				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BAX A, 1988, CARBOHYD RES, V173, P53, DOI 10.1016/S0008-6215(00)90802-4; BEACH R, 1985, AM J TROP MED HYG, V34, P278; *BOEHR MANNH, 1987, BOEHR MANN BIOCH INF; BYRNE BM, 1984, BIOCHEMISTRY-US, V23, P4275, DOI 10.1021/bi00314a003; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CORFIELD T, 1992, GLYCOCONJUGATE J, V9, P217; ERUN R, 1979, ACTA TROP, V36, P289; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FOX A, 1989, ANAL CARBOHYDRATES G; GREIS KD, 1992, J BIOL CHEM, V267, P5876; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HELANDER A, 1992, CARBOHYD RES, V230, P299; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HO C, 1969, BIOCHEMISTRY-US, V8, P2074, DOI 10.1021/bi00833a044; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1995, EUR J CELL BIOL, V66, P205; ILG T, 1994, J BIOL CHEM, V269, P24073; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; ILG T, 1992, J BIOL CHEM, V267, P6834; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; ILG T, 1992, THESIS EBERHARD KARL; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; JEFFERIES D, 1986, ACTA TROP, V43, P43; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KILLICKKENDRICK R, 1988, PARASITOL RES, V74, P586, DOI 10.1007/BF00531639; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG T, 1991, EUR J CELL BIOL, V55, P362; LAU E, 1993, J CHROMATOGR, V637, P100, DOI 10.1016/0021-9673(93)83104-Z; LAWYER PG, 1990, AM J TROP MED HYG, V43, P31, DOI 10.4269/ajtmh.1990.43.31; LAWYER PG, 1987, J MED ENTOMOL, V24, P347, DOI 10.1093/jmedent/24.3.347; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LOVELACE JK, 1986, AM J TROP MED HYG, V35, P1121, DOI 10.4269/ajtmh.1986.35.1121; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MOODY SF, 1993, J BIOL CHEM, V268, P18457; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; OXLEY D, 1995, GLYCOBIOLOGY, V5, P517, DOI 10.1093/glycob/5.5.517; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRESCOTT DJ, 1969, J BIOL CHEM, V244, P4517; RICKWOOD D, 1984, CENTRIFUGATION PRACT, P95; ROSE M, 1992, AM J PHYSIOL, V7, pL413; SABSAY B, 1991, BIOCHEM J, V276, P699, DOI 10.1042/bj2760699; SHAW N, 1974, BIOCHEM J, V143, P461, DOI 10.1042/bj1430461; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Taborsky G, 1974, Adv Protein Chem, V28, P1, DOI 10.1016/S0065-3233(08)60230-2; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; TYLER JM, 1980, J CELL BIOL, V85, P489, DOI 10.1083/jcb.85.2.489; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; WALTERS LL, 1989, AM J TROP MED HYG, V40, P19, DOI 10.4269/ajtmh.1989.40.19; WALTERS LL, 1987, AM J TROP MED HYG, V36, P294, DOI 10.4269/ajtmh.1987.36.294; WALTERS LL, 1989, AM J TROP MED HYG, V41, P295, DOI 10.4269/ajtmh.1989.41.295; WARBURG A, 1986, AM J TROP MED HYG, V35, P926, DOI 10.4269/ajtmh.1986.35.926; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; [No title captured]	73	100	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21583	21596		10.1074/jbc.271.35.21583	http://dx.doi.org/10.1074/jbc.271.35.21583			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702946	hybrid			2022-12-25	WOS:A1996VE47700092
J	Nishitoh, H; Ichijo, H; Kimura, M; Matsumoto, T; Makishima, F; Yamaguchi, A; Yamashita, H; Enomoto, S; Miyazono, K				Nishitoh, H; Ichijo, H; Kimura, M; Matsumoto, T; Makishima, F; Yamaguchi, A; Yamashita, H; Enomoto, S; Miyazono, K			Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEINS; SERINE THREONINE KINASE; TGF-BETA; OSTEOGENIC PROTEIN-1; ACTIVIN RECEPTOR; EXPRESSION CLONING; SUPERFAMILY; DIFFERENTIATION; FAMILY	Growth/differentiation factor-5 (GDF-5) is a member of the bone morphogenetic protein (BMP) family, which plays an important role in bone development in vivo. Mutations in the GDF-5 gene result in brachypodism in mice and Hunter-Thompson type chondrodysplasia in human. BMPs transduce their effects through binding to two different types of serine/threonine kinase receptors, type I and type II. However, binding abilities appear to be different among the members of the BMP family. BMP-4 binds to two different type I receptors, BMP receptors type IA (BMPR-IA) and type IB (BMPR-IB), and a type II receptor, BMP receptor type II (BMPR-II). In addition to these receptors, osteogenic protein-1 (OP-1, also known as BMP-7) binds to activin type I receptor (ActR-I) as well as activin type II receptors (ActR-II and ActR-IIB). Here we investigate the binding and signaling properties of GDF-5 through type I and type II receptors. GDF-5 induced alkaline phosphatase activity in a rat osteoprogenitor-like cell line, ROB-C26. I-125-GDF-5 bound to BMPR-IB and BMPR-II but not to BMPR-IA in ROB-C26 cells and other nontransfected cell lines. Analysis using COS-1 cells transfected with the receptor cDNAs revealed that GDF-5 bound to BMPR-IB but not to the other type I receptors when expressed alone. When COS-1 cells were transfected with type II receptor cDNAs, GDF-5 bound to ActR-II, ActR-IIB, and BMPR-II but not to transforming growth factor-beta type II receptor, In the presence of type II receptors, GDF-5 bound to different sets of type I receptors, but the binding was most efficient to BMPR-IB compared with the other type I receptors. Moreover, a transcriptional activation signal was efficiently transduced by BMPR-IB in the presence of BMPR-II or ActR-II after stimulation by GDF-5. These results suggest that BMPR-IB mediates certain signals for GDF-5 after forming the heteromeric complex with BMPR-II or ActR-II.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; TOKYO MED & DENT UNIV,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN; HOECHST JAPAN LTD,DRUG DISCOVERY RES LABS,PHARMA RES & DEV DIV,KAWAGOE,SAITAMA 35011,JAPAN; SHOWA UNIV,SCH DENT,DEPT ORAL PATHOL,SHINAGAWA KU,TOKYO 142,JAPAN; UNIV TOKYO,FAC MED,DEPT OPHTHALMOL,BUNKYO KU,TOKYO 113,JAPAN	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU); Showa University; University of Tokyo				Nishitoh, Hideki/0000-0002-8652-4109; Ichijo, Hidenori/0000-0002-5005-6438				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; ASAHINA I, 1993, J CELL BIOL, V123, P921, DOI 10.1083/jcb.123.4.921; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHANG SC, 1994, J BIOL CHEM, V269, P28227; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HOTTEN G, 1994, BIOCHEM BIOPH RES CO, V204, P646, DOI 10.1006/bbrc.1994.2508; Hotten GC, 1996, GROWTH FACTORS, V13, P65, DOI 10.3109/08977199609034567; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Miyazono Kohei, 1994, Seminars in Cell Biology, V5, P389, DOI 10.1006/scel.1994.1046; NISTER M, 1991, J BIOL CHEM, V266, P16755; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1994, J BIOL CHEM, V269, P765; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; VERSCHUEREN K, 1995, MECH DEVELOP, V52, P109, DOI 10.1016/0925-4773(95)00395-H; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217	56	273	288	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21345	21352		10.1074/jbc.271.35.21345	http://dx.doi.org/10.1074/jbc.271.35.21345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702914	hybrid			2022-12-25	WOS:A1996VE47700060
J	Patten, M; Hartogensis, WE; Long, CS				Patten, M; Hartogensis, WE; Long, CS			Interleukin-1 beta is a negative transcriptional regulator of alpha(1)-adrenergic induced gene expression in cultured cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; PROTEIN-KINASE-C; ALPHA-ACTIN GENE; ISOLATED MESENTERIC-ARTERY; RAT MYOCARDIAL-CELLS; HEAVY-CHAIN PROMOTER; ENHANCER FACTOR-I; NITRIC-OXIDE; GROWTH-FACTOR; RETINOBLASTOMA PROTEIN	We recently reported that interleukin-1 beta (IL-1 beta) induces a novel form of cardiac myocyte hypertrophy characterized by an increase in protein content but an absence of the fetal program of skeletal alpha-actin or beta-myosin heavy chain (beta-MHC) gene expression (Palmer, J. N., Hartogensis, W. E., Fatten, M., Fortuin, F. D., and Long, C. S. (1995) J. Clin. Invest. 95, 2555-2564). Because of the apparent disparity between this myocardial phenotype and that seen with other hypertrophic agents in culture, such as catecholamines, we investigated the effect of IL-1 beta on alpha(1)-induced cardiomyocyte hypertrophy. Although there was no augmentation in total protein when IL-1 beta and phenylephrine were given simultaneously, IL-1 beta attenuated the increase in contractile protein mRNAs (skeletal alpha-actin and beta-MHC) in response to phenylephrine. Transient transfection studies with skeletal alpha-actin and beta-MHC promoter constructs linked to the chloramphenicol acetyltransferase (CAT)-reporter gene indicate that repression occurred at the level of gene transcription. In view of the previously reported activity of the zinc finger protein YY1 in the negative regulation of the skeletal alpha-actin promoter in cardiomyocytes (MacLellan, W. R., Lee, T. C., Schwartz, R. J., and Schneider, M. D. (1994) J. Biol. Chem. 269, 16754-16760), we investigated the potential role of this factor in the IL-1 beta-mediated effects. Using transient transfection, we found that a mutation in the YY1 binding site of the skeletal alpha-actin promoter abolished the inhibitory effect of IL-1 beta. We further found that the 127-base pair fragment of the skeletal alpha-actin promoter required for the IL-1 beta effect is also required for inhibition by the overexpression of YY1 in the myocytes. Furthermore, increased levels of YY1 protein are found in IL-1 beta treated myocytes. Taken together these results suggest that the repression of contractile protein gene transcription by IL-1 beta may be due, at least in part, to activation of the negative transcription factor YY1.	VET AFFAIRS MED CTR, DIV CARDIOL 111C8, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, RES SERV, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco				Long, Carlin/0000-0001-7251-2847				BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753; COREA L, 1984, AM J CARDIOL, V53, P1299, DOI 10.1016/0002-9149(84)90083-3; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; FINKEL MS, 1993, AM J CARDIOL, V71, P1231, DOI 10.1016/0002-9149(93)90654-U; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GULICK T, 1988, BIOCHEM BIOPH RES CO, V150, P1, DOI 10.1016/0006-291X(88)90478-0; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KINUGAWA K, 1994, CIRC RES, V75, P285, DOI 10.1161/01.RES.75.2.285; LANGE LG, 1992, TRENDS CARDIOVAS MED, V2, P145, DOI 10.1016/1050-1738(92)90022-K; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE TC, 1994, ONCOGENE, V9, P1047; LIU S, 1995, AM J PHYSIOL-CELL PH, V268, pC339, DOI 10.1152/ajpcell.1995.268.2.C339; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MARCEAU F, 1991, BRIT J PHARMACOL, V103, P1367, DOI 10.1111/j.1476-5381.1991.tb09795.x; MEDFORD RM, 1983, J BIOL CHEM, V258, P1063; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NOSE PS, 1993, J CARDIAC SURG, V8, P305; PALMER JN, 1995, J CLIN INVEST, V95, P2555, DOI 10.1172/JCI117956; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PETITCLERC E, 1994, J PHARMACOL EXP THER, V268, P1419; PETITCLERC E, 1992, J CARDIOVASC PHARM, V19, P821; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; ROKOSH DG, 1994, BIOCHEM BIOPH RES CO, V200, P1177, DOI 10.1006/bbrc.1994.1575; SHINDO T, 1995, CARDIOVASC RES, V29, P813, DOI 10.1016/S0008-6363(96)88617-2; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; TRINKLE LA, 1992, AM J PHYSIOL, V262, pC828, DOI 10.1152/ajpcell.1992.262.4.C828; TSUJINO M, 1994, CIRCULATION, V90, P375, DOI 10.1161/01.CIR.90.1.375; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WESTLIN W, 1989, CIRCULATION, V80, P1828, DOI 10.1161/01.CIR.80.6.1828; WU CJ, 1992, TRANSPLANTATION, V54, P326, DOI 10.1097/00007890-199208000-00024; Wu P. S., 1995, Journal of Investigative Medicine, V43, p224A; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834	52	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21134	21141		10.1074/jbc.271.35.21134	http://dx.doi.org/10.1074/jbc.271.35.21134			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702883	hybrid			2022-12-25	WOS:A1996VE47700029
J	Zhao, JQ; Schmieg, FI; Logsdon, N; Freedman, D; Simmons, DT; Molloy, GR				Zhao, JQ; Schmieg, FI; Logsdon, N; Freedman, D; Simmons, DT; Molloy, GR			p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription	ONCOGENE			English	Article						p53; creatine kinase genes; energy metabolism; in vitro transactivation	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL NUCLEAR ANTIGEN; DNA-BINDING; RESPONSIVE ELEMENT; INDUCED APOPTOSIS; MDM2 EXPRESSION; MICE DEFICIENT; BRAIN; IDENTIFICATION	The rat muscle creatine kinase (CKM) gene promoter is unusual since it is one of the few cellular promoters containing a p53 response element which is located proximally (bp -168 to -57) to the transcription start site. We have previously shown that p53wt transactivates transcription in vivo of rat CKM, in CV-1 monkey kidney cells, through this 112 bp promoter-proximal fragment which contains at least five degenerate p53-binding elements. In this report, we employed the gel-shift assay and demonstrated that recombinant, immunoaffinity-purified mouse p53wt binds to this 112 bp CKM sequence and activates the in vitro transcription of the proximal CKM promoter by nuclear extracts from CV-1 cells. Also, a competitor plasmid containing this 112 bp CKM fragment interferred with the in vivo transactivation of CKM by p53. This CKM fragment, when cloned upstream of the rat br ain creatine kinase (CKB) promoter, mediated the p53 transactivation of CKB. Analyses of p53 wt and a series of missense mutants (altered in conserved region II of p53) showed that binding of p53 to the CKM promoter was required but was not sufficient for transactivation. The results are discussed in relation to the possible role of p53wt in the expression of CKM in cell types which may not express the myogenic transcription factors.	UNIV DELAWARE,DEPT BIOL,NEWARK,DE 19716	University of Delaware					NCI NIH HHS [CA 55234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V250, P1576; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EDMONDOSN EG, 1993, J BIOL CHEM, V268, P755; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GASDAR AF, 1981, CANCER RES, V41, P2773; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAMES BD, 1993, IRL PRESS, V136; HARPER JW, 1993, CELL, V75, P805; HEMMER W, 1993, DEV NEUROSCI-BASEL, V15, P249, DOI 10.1159/000111342; HEMMER W, 1994, EUR J NEUROSCI, V6, P538, DOI 10.1111/j.1460-9568.1994.tb00298.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KERN SE, 1991, SCIENCE, V252, P1707; KLEY N, 1992, NUCLEIC ACIDS RES, V17, P3645; KLEY SE, 1992, SCIENCE, V17, P3645; KUZHIKANDATHIL EV, 1994, J NEUROSCI RES, V39, P70, DOI 10.1002/jnr.490390110; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3219; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MANOS P, 1993, DEV NEUROSCI-BASEL, V15, P271, DOI 10.1159/000111344; MANOS P, 1991, J NEUROCHEM, V56, P2101, DOI 10.1111/j.1471-4159.1991.tb03472.x; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MIYASHITA T, 1995, CELL, V80, P293; MOLLOY GR, 1992, J NEUROCHEM, V59, P1925, DOI 10.1111/j.1471-4159.1992.tb11028.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILSON CD, 1993, J NEUROSCI RES, V35, P92, DOI 10.1002/jnr.490350111; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	79	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					293	302						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710368				2022-12-25	WOS:A1996VA25200008
J	Filatov, D; Bjorklund, S; Johansson, E; Thelander, L				Filatov, D; Bjorklund, S; Johansson, E; Thelander, L			Induction of the mouse ribonucleotide reductase R1 and R2 genes in response to DNA damage by UV light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-SPECIFIC EXPRESSION; EXCISION-REPAIR; PROMOTER; HYDROXYUREA; SUBUNIT; BINDING; CELLS; ELEMENT; BREAKS; ACID	Ribonucleotide reductase is responsible for the production of deoxyribonucleotides required for DNA synthesis and consists of two nonidentical subunits, proteins R1 and R2. Here we show that the R1 promoter can be induced up to 3-fold, and the R2 promoter is induced up to 10-fold by UV light in a dose-dependent manner. This was demonstrated using serum-starved, synchronized G(0)/G(1) mouse fibroblast 3T3 cells stably transformed with different R1 and R2 promoter-luciferase reporter gene constructs, R2 promoter activation requires a minimal promoter, containing a TTTAAA element plus the transcription start, and either three upstream DNA-protein binding regions or one proximal, NF-Y binding region. This is different from proliferation-specific activation of the R2 promoter. Using Northern blotting we show a preferential accumulation of the minor, 1.6-kilobase R2 transcript in irradiated cells, whereas the levels of the major 2.1-kilobase transcript are unchanged. No R2 promoter activation was observed after treatment of mouse cells with agents reported to induce the ribonucleotide reductase genes in Saccharomyces cerevisiae such as hydroxyurea or methylmethane sulfonate. This indicates that activation of ribonucleotide reductase gene expression is specific for nucleotide excision repair in mammalian cells and not part of a general response to DNA damage.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	Umea University				Johansson, Erik/0000-0002-8526-6224				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BJORKLUND S, 1993, P NATL ACAD SCI USA, V90, P11322, DOI 10.1073/pnas.90.23.11322; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAS IW, 1985, J BIOL CHEM, V260, P7015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; FRIEDBERG EC, 1995, DNA REPAIR; HOLMBERG M, 1989, MUTAT RES, V218, P33, DOI 10.1016/0921-8777(89)90044-X; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KUSEWITT DF, 1991, MUTAT RES, V255, P1, DOI 10.1016/0921-8777(91)90012-E; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; MANN GJ, 1988, CANCER RES, V48, P5151; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSEN CF, 1992, AM J PHYSIOL, V263, pC1103, DOI 10.1152/ajpcell.1992.263.5.C1103; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Sambrook J., 2002, MOL CLONING LAB MANU; SLAMENOVA D, 1990, MUTAT RES, V242, P127, DOI 10.1016/0165-1218(90)90038-4; SNYDER RD, 1984, MUTAT RES, V131, P163, DOI 10.1016/0167-8817(84)90057-9; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; YEW FFH, 1979, BIOCHIM BIOPHYS ACTA, V562, P240, DOI 10.1016/0005-2787(79)90170-9	33	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23698	23704		10.1074/jbc.271.39.23698	http://dx.doi.org/10.1074/jbc.271.39.23698			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798592	hybrid			2022-12-25	WOS:A1996VJ44200021
J	Kuwayama, H; VanHaastert, PJM				Kuwayama, H; VanHaastert, PJM			Regulation of guanylyl cyclase by a cGMP-binding protein during chemotaxis in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PHOSPHORYLATION; CYCLIC-GMP; MYOSIN-II; MUTANTS; PHOSPHODIESTERASE; CYTOSKELETON; CLONING; CELLS	Chemoattractants transiently activate guanylyl cyclase in Dictyostelium discoideum cells. Mutant analysis demonstrates that the produced cGMP plays an essential role in chemotactic signal transduction, controlling the actomyosin-dependent motive force. Guanylyl cyclase activity is associated with the particulate fraction of a cell homogenate. The addition of the cytosol stimulates guanylyl cyclase activity, whereas the cytosol plus ATP/Mg2+ inhibits enzyme activity, We have analyzed the regulation of guanylyl cyclase in chemotactic mutants and present evidence that a cGMP-binding protein mediates both stimulation and ATP-dependent inhibition of guanylyl cyclase. Upon chromatography of cytosolic proteins, cGMP binding activity co-elutes with both guanylyl cyclase-stimulating and ATP-dependent-inhibiting activities. In addition, ATP-dependent inhibition of guanylyl cyclase activity is enhanced by the cGMP analogue 8-Br-cGMP, suggesting that a cGMP-binding protein regulates guanylyl cyclase activity, Mutant KI-4 has an aberrant cGMP binding activity with very low K-d and shows a very small chemoattractant-mediated cGMP response; the cytosol from this mutant does not stimulate guanylyl cyclase, In contrast to KI-4, the aberrant cGMP binding activity of mutant KI-7 has a very high K-d and chemoattractants induce a prolonged cGMP response. The cytosol of this mutant stimulates guanylyl cyclase activity, but ATP does not inhibit the enzyme. Thus, two previously isolated chemotactic mutants are defective in the activation and inhibition of guanylyl cyclase, respectively. The positive and negative regulation of guanylyl cyclase by its product cGMP may well explain how cells process the temporospatial information of chemotactic signals, which is necessary for sensing the direction of the chemoattractant.	UNIV GRONINGEN, DEPT BIOCHEM, NL-9747 AG GRONINGEN, NETHERLANDS	University of Groningen								BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; COUKELL MB, 1986, DEV GENET, V6, P163; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; JANSSENS PMW, 1989, J BIOL CHEM, V264, P4329; JANSSENS PMW, 1988, BIOCHEM BIOPH RES CO, V150, P405, DOI 10.1016/0006-291X(88)90535-9; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; Kuwayama H, 1996, SCIENCE, V271, P207, DOI 10.1126/science.271.5246.207; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; KUWAYAMA H, 1995, BBA-MOL CELL RES, V1268, P214, DOI 10.1016/0167-4889(95)00082-4; LIU G, 1993, J CELL SCI, V106, P591; LIU G, 1991, J CELL SCI, V98, P483; Mato J., 1977, DEV DIFFERENTIATION, P93; MATO JM, 1977, FEBS LETT, V79, P331, DOI 10.1016/0014-5793(77)80814-4; MATO JM, 1978, FEBS LETT, V90, P261, DOI 10.1016/0014-5793(78)80381-0; MATO JM, 1975, P NATL ACAD SCI USA, V72, P4991, DOI 10.1073/pnas.72.12.4991; PARISSENTI AM, 1989, J CELL SCI, V92, P291; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; ROSS FM, 1981, J GEN MICROBIOL, V127, P339; SCHOEN CD, 1992, THESIS U AMSTERDAM; SCHULKES CCGM, 1992, BIOCHIM BIOPHYS ACTA, V1135, P73, DOI 10.1016/0167-4889(92)90168-B; SPUDICH JA, 1989, CELL REGUL, V1, P1; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VALKEMA R, 1992, BIOCHEM BIOPH RES CO, V186, P263, DOI 10.1016/S0006-291X(05)80802-2; VANHAASTERT PJM, 1982, MOL CELL ENDOCRINOL, V25, P171, DOI 10.1016/0303-7207(82)90050-8; VANHAASTERT PJM, 1982, J CELL BIOL, V94, P271, DOI 10.1083/jcb.94.2.271; VANHAASTERT PJM, 1982, FEBS LETT, V147, P149, DOI 10.1016/0014-5793(82)81029-6; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P347, DOI 10.1083/jcb.96.2.347; VANHAASTERT PJM, 1993, SENSORY TRANSDUCTION, P359; YUMURA S, 1992, J CELL BIOL, V117, P1231, DOI 10.1083/jcb.117.6.1231	36	21	21	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23718	23724		10.1074/jbc.271.39.23718	http://dx.doi.org/10.1074/jbc.271.39.23718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798595	Green Published, hybrid			2022-12-25	WOS:A1996VJ44200024
J	Xu, XF; Colombini, M				Xu, XF; Colombini, M			Self-catalyzed insertion of proteins into phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; NEUROSPORA-CRASSA; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; RECEPTOR COMPLEX; ION CHANNEL; IMPORT; TRANSLOCATION; PORIN; VDAC	We present evidence that the mitochondrial channel, VDAC, when reconstituted into a phospholipid membrane, can catalyze the insertion of other VDAC channels. This property called ''auto-directed insertion'' was first proposed by Ziti et al. (1995) to explain observations on asymmetric VDAC channels, We found that 2 M urea or guanidinium chloride (GdmCl) caused a burst of insertions of VDAC channels when added to the same side as VDAC addition. More strikingly, when added to the opposite side they caused a 10-60-fold sustained yet reversible increase in insertion rate. Protein stabilization by sarcosine eliminated the effect of urea and GdmCl on VDAC insertion, Control experiments showed that water flow, ionic strength, osmotic force, phospholipid type, and membrane potential were not involved. Therefore, although both urea and GdmCl affect the properties of phospholipid membranes, it is more likely that these agents act either by changing the structure of the pre-inserted channels, allowing them to be more effective catalysts for VDAC insertion, or by flowing through the channels and acting on nearby VDAC channels inducing them to insert, Either way, insertion must be occurring next to pre-inserted channels, Urea and GdmCl may mimic chaperones by partially unfolding VDAC and keeping it in an insertion-competent state, ''Auto-directed insertion'' may ensure both correct targeting and orientation of nascent proteins in vivo.	UNIV MARYLAND,DEPT ZOOL,CELL BIOL LAB,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014					ANCHORDOGUY TJ, 1990, ARCH BIOCHEM BIOPHYS, V283, P356, DOI 10.1016/0003-9861(90)90654-H; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GASSER SM, 1983, J BIOL CHEM, V258, P3427; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HILLE B, 1992, IONIC CHANNELS EXCIT, P296; HINES V, 1993, J BIOL CHEM, V268, P449; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MANNELLA CA, 1984, BIOCHIM BIOPHYS ACTA, V774, P206, DOI 10.1016/0005-2736(84)90293-1; MANNELLA CA, 1990, BIOPHYS J, V57, P23, DOI 10.1016/S0006-3495(90)82503-0; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; ORBACH E, 1980, J GEN PHYSIOL, V75, P427, DOI 10.1085/jgp.75.4.427; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1987, EMBO J, V6, P2635, DOI 10.1002/j.1460-2075.1987.tb02554.x; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFALLER R, 1985, J BIOL CHEM, V260, P8188; PFANNER N, 1988, J BIOL CHEM, V263, P4049; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; YEAGLE PL, 1986, BIOCHEMISTRY-US, V25, P7518, DOI 10.1021/bi00371a039; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZIZI M, 1995, J MEMBRANE BIOL, V144, P121	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23675	23682		10.1074/jbc.271.39.23675	http://dx.doi.org/10.1074/jbc.271.39.23675			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798589	hybrid			2022-12-25	WOS:A1996VJ44200018
J	Driscoll, JE; Seachord, CL; Lupisella, JA; Darveau, RP; Reczek, PR				Driscoll, JE; Seachord, CL; Lupisella, JA; Darveau, RP; Reczek, PR			Ligand-induced conformational changes in the human retinoic acid receptor gamma detected using monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; BINDING DOMAIN; THYROID-HORMONE; CO-REPRESSOR; CRYSTAL-STRUCTURE; X-RECEPTORS; ALPHA; BETA; IMMUNODETECTION; PHOSPHORYLATION	The mechanism by which the naturally occurring ligand for a nuclear hormone receptor regulates transcription remains largely unknown, One approach combines the specificity of monoclonal antibodies, which recognize a three-dimensional epitope, with ligand binding. Using purified retinoic acid receptor gamma D and E domains, a panel of six unique monoclonal antibodies were isolated and characterized using solid-state receptor binding and retinoic acid receptor (RAR)-RXR heterodimer supershift formation. Three antibodies are specific for RAR gamma (mAbI, mAbII, and mAbV) and four recognize a three dimensional epitope (mAbI, mAbIV, mAbV, and mAbVI). Three antibodies (mAbIII, mAbV, and mAbVI) dissociate from the receptor in electrophoretic mobility shift assays upon the addition of retinoic acid. In particular, the binding characteristics of mAbIII, whose epitope was mapped to a region identified as an Omega-loop (amino acids 207-222), suggest a model for ligand binding to the receptor, In this model, ligand binding causes a positioning of helix 12 into a favorable conformation for interaction with the transcriptional machinery. The Omega-loop then closes in order to stabilize this "active" position. The results reported here also suggest that a region of the hinge or D domain of the receptor (amino acids 156-188), an area that can play a role in protein-protein interactions, may also be important in ligand-induced functional changes.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOL BIOL, BUFFALO, NY 14213 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT IMMUNOL, SEATTLE, WA 98121 USA	Bristol-Myers Squibb; Bristol-Myers Squibb				Lupisella, John/0000-0003-1343-6412				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DE LUCA LM, 1991, FASEB J, V5, P2924; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GAUB MP, 1989, P NATL ACAD SCI USA, V86, P3089, DOI 10.1073/pnas.86.9.3089; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TAM MR, 1982, INFECT IMMUN, V36, P1042, DOI 10.1128/IAI.36.3.1042-1053.1982; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	35	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22969	22975		10.1074/jbc.271.38.22969	http://dx.doi.org/10.1074/jbc.271.38.22969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798483	hybrid			2022-12-25	WOS:A1996VH76800009
J	Guillon, JM; Heiss, S; Soutourina, J; Mechulam, Y; Laalami, S; GrunbergManago, M; Blanquet, S				Guillon, JM; Heiss, S; Soutourina, J; Mechulam, Y; Laalami, S; GrunbergManago, M; Blanquet, S			Interplay of methionine tRNAs with translation elongation factor Tu and translation initiation factor 2 in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONINE TRANSFER-RNA; PROTEIN-SYNTHESIS; FACTOR-II; RIBOSOMAL-SUBUNIT; ANTICODON STEM; ACCEPTOR STEM; SEQUENCE; MUTANTS; GENE; INVIVO	According to their role in translation, tRNAs specifically interact either with elongation factor Tu (EFTu) or with initiation factor 2 (IF2). We here describe the effects of overproducing EFTu and IF2 on the elongator versus initiator activities of various mutant tRNA(Met) species in vivo, The data obtained indicate that the selection of a tRNA through one or the other pathway of translation depends on the relative amounts of the translational factors. A moderate overexpression of EFTu is enough to lead to a misappropriation of initiator tRNA in the elongation process, whereas overproduced IF2 allows the initiation of translation to occur with unformylated tRNA species. In addition, we report that a strain devoid of formylase activity can be cured by the overproduction of tRNA(f)(Met). The present study brings additional evidence for the importance of formylation in defining tRNA(f)(Met) initiator identity, as well as a possible explanation for the residual growth of bacterial strains lacking a functional formylase gene such as observed in Guillon, J. M., Mechulam, Y., Schmitter, J.-M., Blanquet, S., and Fayat, G. (1992) J. Bacteriol. 174, 4294-4301.	ECOLE POLYTECH,BIOCHIM LAB,CNRS,URA 1970,F-91128 PALAISEAU,FRANCE; INST BIOL PHYSICOCHIM,CNR,URA 1139,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Soutourina, Julie/F-8305-2014; Guillon, Jean-Michel/N-7892-2018; Mechulam, Yves/F-3313-2019	Soutourina, Julie/0000-0001-5218-2350; Guillon, Jean-Michel/0000-0002-0178-2521; Mechulam, Yves/0000-0003-3586-3554				Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BREVET A, 1995, J BIOL CHEM, V270, P14439, DOI 10.1074/jbc.270.24.14439; CANONACO MA, 1986, FEBS LETT, V207, P198, DOI 10.1016/0014-5793(86)81488-0; CLARK BFC, 1966, J MOL BIOL, V17, P394, DOI 10.1016/S0022-2836(66)80150-X; EISENSTADT J, 1966, SCIENCE, V154, P524; GUALERZI CO, 1986, FEBS LETT, V202, P1, DOI 10.1016/0014-5793(86)80637-8; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; HARVEY RJ, 1973, J BACTERIOL, V114, P309, DOI 10.1128/JB.114.1.309-322.1973; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LEE CP, 1991, J BIOL CHEM, V266, P18012; MAJUMDAR A, 1976, J BIOL CHEM, V251, P137; MANGROO D, 1995, J BIOL CHEM, V270, P12203, DOI 10.1074/jbc.270.20.12203; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MECHULAM Y, 1985, J BACTERIOL, V164, P63, DOI 10.1128/JB.164.1.63-69.1985; MEINNEL T, 1993, J MOL BIOL, V229, P26, DOI 10.1006/jmbi.1993.1005; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; MEINNEL T, 1995, J BIOL CHEM, V270, P15908, DOI 10.1074/jbc.270.26.15908; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JH, 1983, J MOL BIOL, V164, P59, DOI 10.1016/0022-2836(83)90087-6; MIYAJIMA A, 1980, FEBS LETT, V119, P215, DOI 10.1016/0014-5793(80)80255-9; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PETERSEN HU, 1979, BIOCHEM BIOPH RES CO, V91, P1068, DOI 10.1016/0006-291X(79)91989-2; PETERSEN HU, 1981, FEBS LETT, V128, P161, DOI 10.1016/0014-5793(81)81105-2; PLUMBRIDGE JA, 1983, J MOL BIOL, V167, P227, DOI 10.1016/S0022-2836(83)80333-7; SCHULMAN LH, 1974, J BIOL CHEM, V249, P7102; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SEONG BL, 1989, J BIOL CHEM, V246, P6504; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; VARSHNEY U, 1992, J BACTERIOL, V174, P7819, DOI 10.1128/JB.174.23.7819-7826.1992; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; WEIEL J, 1982, J BIOL CHEM, V257, P1215; WREDE P, 1979, P NATL ACAD SCI USA, V76, P3289, DOI 10.1073/pnas.76.7.3289	43	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22321	22325		10.1074/jbc.271.37.22321	http://dx.doi.org/10.1074/jbc.271.37.22321			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798391	hybrid			2022-12-25	WOS:A1996VG67200010
J	Miglarese, MR; Richardson, AF; Aziz, N; Bender, TP				Miglarese, MR; Richardson, AF; Aziz, N; Bender, TP			Differential regulation of c-Myb-induced transcription activation by a phosphorylation site in the negative regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NORMAL HUMAN-LYMPHOCYTES; CELL-CYCLE REGULATION; CASEIN KINASE-II; V-MYB; LEUCINE-ZIPPER; TYROSINE PHOSPHORYLATION; ERYTHROLEUKEMIA-CELLS; FUNCTIONAL DOMAINS; ONCOGENE PRODUCT	The c-myb protooncogene encodes a highly conserved 75-89-kDa transcription factor that contains three functional domains, an amino-terminal DNA binding domain (DBD), a central acidic transactivation domain, and a carboxyl-terminal negative regulatory domain (NRD), Two acute transforming retroviruses, avian myeloblastosis virus and the E26 leukemia virus, transduced portions of c-myb and encode Myb proteins that are truncated in both the DBD and the NRD, Several conserved potential sites for phosphorylation by proline-directed serine/threonine protein kinases reside in or near the NRD, suggesting that phosphorylation might play a role in regulating c-Myb. We have previously demonstrated that serine 528, located in the NRD, is a target for p42(mapk) in vitro. Serine 528 is phosphorylated in vivo in several cell lines, and substitution of serine 528 to alanine (S528A) resulted in an increased ability of Myb to transactivate a synthetic promoter containing five copies of the mim-1A Myb-responsive element and a minimal herpes th promoter, We have tested the ability of S528A Myb to transactivate a series of cellular target promoters and report that the serine to alanine substitution increased the ability of Myb to activate transcription from the CD34 promoter but not the c-myc or mim-1 promoters, This suggests that phosphorylation of serine 528 may differentially regulate c-Myb activity at different promoters, The DNA binding and multimerization activities of c-Myb appear to be unaffected by the 5528A substitution, suggesting that phosphorylation of serine 528 may mediate its effect on the transcription transactivating activity of c-Myb by regulating interactions with other proteins.	UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia				Aziz, Natasha/0000-0001-8195-1446	NCI NIH HHS [CA-09109, CA-40042] Funding Source: Medline; NIGMS NIH HHS [GM-07055] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BADING H, 1989, ONCOGENE, V4, P33; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CIVIN CI, 1990, EXP HEMATOL, V18, P461; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; ESS KC, 1995, MOL CELL BIOL, V15, P5707; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FAVIER D, 1994, ONCOGENE, V9, P305; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUERIN M, 1990, ONCOGENE, V5, P131; HE XY, 1994, BLOOD, V83, P1822, DOI 10.1182/blood.V83.7.1822.bloodjournal8371822; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	74	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22697	22705		10.1074/jbc.271.37.22697	http://dx.doi.org/10.1074/jbc.271.37.22697			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798443	hybrid			2022-12-25	WOS:A1996VG67200062
J	Palaniappan, C; Wisniewski, M; Wu, WM; Fay, PJ; Bambara, RA				Palaniappan, C; Wisniewski, M; Wu, WM; Fay, PJ; Bambara, RA			Misincorporation by HIV-1 reverse transcriptase promotes recombination via strand transfer synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MISPAIR EXTENSION KINETICS; RETROVIRAL SHUTTLE VECTOR; SITE-SPECIFIC MUTAGENESIS; SINGLE REPLICATION CYCLE; DNA POLYMERASE-ALPHA; GENETIC-VARIATION; CLEAVAGE SPECIFICITY; PHENOTYPIC SELECTION; ANGSTROM RESOLUTION	Genome heterogeneity in retroviruses derives from poor fidelity of the reverse transcriptase (RT) and recombination via RT-catalyzed strand transfer synthesis, RTs lack proofreading ability, and they proficiently extend primers with mismatched termini. Recombination reactions carried out in vitro are accompanied by a high frequency of base substitution errors, suggesting a relationship. Here we provide evidence that misincorporation during RNA-directed DNA synthesis promotes strand transfer recombination. Experiments involved measurement of DNA synthesis, RNase H-directed cleavage, and strand transfer synthesis from preformed mismatched primers on RNA templates by human immunodeficiency virus (HIV) RT in, vitro. A significant pause in synthesis occurred from a G(primer). rA(template) mismatch compared to the synthesis from a correctly paired (T . rA) primer. The misincorporation-induced pause allowed an unusually large area of RT-RNase H-directed cleavage of the template RNA beneath the primer. Strand transfer to an acceptor molecule with sequence identical to the template RNA was about 50% more efficient than if the primer had had a correctly paired terminus. Overall transfer was measured over a large region of homology. Assuming that enhanced transfer occurs primarily at the site of the mismatch, the actual increase in transfer at that site must have been 1-2 orders of magnitude. Inclusion of a different acceptor molecule with complete complementarity to the originally mismatched 3' primer terminus resulted in an additional 2-fold increase in strand transfer efficiency. Overall, these results suggest the mechanism by which misincorporation during minus strand DNA synthesis in retroviral replication would promote high frequency recombination.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKHANASHVILI M, 1993, FEBS LETT, V319, P201, DOI 10.1016/0014-5793(93)80067-5; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1994, BBA-GENE STRUCT EXPR, V1219, P380, DOI 10.1016/0167-4781(94)90062-0; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HU WS, 1993, REVERSE TRANSCRIPTAS, P251; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JI JP, 1994, VIROLOGY, V199, P323, DOI 10.1006/viro.1994.1130; JI JP, 1994, NUCLEIC ACIDS RES, V22, P47, DOI 10.1093/nar/22.1.47; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PULSINELLI GA, 1994, P NATL ACAD SCI USA, V91, P9490, DOI 10.1073/pnas.91.20.9490; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Wu WM, 1996, NUCLEIC ACIDS RES, V24, P1710, DOI 10.1093/nar/24.9.1710; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; YU H, 1992, J BIOL CHEM, V267, P10888; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22331	22338		10.1074/jbc.271.37.22331	http://dx.doi.org/10.1074/jbc.271.37.22331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798393	hybrid			2022-12-25	WOS:A1996VG67200012
J	Delporte, C; OConnell, BC; He, XJ; Ambudkar, IS; Agre, P; Baum, BJ				Delporte, C; OConnell, BC; He, XJ; Ambudkar, IS; Agre, P; Baum, BJ			Adenovirus-mediated expression of aquaporin-5 in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; WATER CHANNELS; GENE-TRANSFER; CDNA; ERYTHROCYTE; SALIVARY; VECTOR	A recombinant adenovirus coding for rat aquaporin-5 was constructed and plaque purified. The recombinant adenovirus (AdrAQP5) mediated the expression of aquaporin-5 in rat and human salivary cell lines and in dog kidney cells in vitro as demonstrated by Northern blot and Western blot analyses, and by confocal microscopy after immunofluorescent labeling. In kidney cells, expression of the transgene was optimal if cells were infected at their basolateral surface, a phenomenon associated with the distribution of integrin receptors on these cells. The expressed aquaporin-5 protein was functionally active because viral-mediated gene transfer resulted in a significant increase in the osmotically directed net fluid secretion rate across monolayers of kidney cells. AdrAQP5 should provide an efficient and useful means to impart facilitated water permeability to cells lacking such a pathway.	NIDR, CLIN INVEST & PATIENT CARE BRANCH, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Johns Hopkins University			Delporte, Christine/A-5733-2012	O'Connell, Brian/0000-0003-4529-7664; Delporte, Christine/0000-0003-0385-5824	NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; DAI YS, 1991, AM J PHYSIOL, V261, pC1063, DOI 10.1152/ajpcell.1991.261.6.C1063; DENKER BM, 1988, J BIOL CHEM, V263, P15634; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HE X, 1989, J CELL PHYSL, V138, P5294; HE XJ, 1990, BIOCHEM BIOPH RES CO, V170, P336, DOI 10.1016/0006-291X(90)91279-2; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; MASTRANGELI A, 1994, AM J PHYSIOL, V266, pG1146, DOI 10.1152/ajpgi.1994.266.6.G1146; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MITANI K, 1994, HUM GENE THER, V5, P941, DOI 10.1089/hum.1994.5.8-941; Neufeld TK, 1991, J TISS CULT METHODS, V13, P229; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SILVERBERG M, 1978, J BIOL CHEM, V253, P95	23	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22070	22075		10.1074/jbc.271.36.22070	http://dx.doi.org/10.1074/jbc.271.36.22070			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703015	hybrid			2022-12-25	WOS:A1996VF61200057
J	Park, DS; Stefanis, L; Yan, CYI; Farinelli, SE; Greene, LA				Park, DS; Stefanis, L; Yan, CYI; Farinelli, SE; Greene, LA			Ordering the cell death pathway - Differential effects of BCL2, an interleukin-1-converting enzyme family protease inhibitor, and other survival agents on JNK activation in serum nerve growth factor-deprived PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYMPATHETIC NEURONS; C-ELEGANS; CAENORHABDITIS-ELEGANS; GENE CED-3; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IL-1-BETA-CONVERTING ENZYME; PHEOCHROMOCYTOMA CELLS; PROTOONCOGENE BCL-2; FACTOR DEPRIVATION; SENSORY NEURONS	Previous studies indicate that activation of c-Jun kinase (JNK) is necessary for apoptosis of trophic factor-deprived PC12 cells and that death in this system is suppressed by multiple agents, including BCL2, inhibitors of the interleukin-1-converting enzyme (ICE) family of proteases, blockers of transcription, and a variety of small molecules with differing modes of action. Here, we determine the order in which these agents block apoptosis relative to JNK activation. Overexpression of BCL2 promotes PC12 cell survival and blocks JNK activation caused by trophic factor withdrawal. Similarly, the survival-promoting agents aurintricarboxylic acid, N-acetylcysteine, the nitric oxide generator diethylenetriamine nitric oxide, 8-bromo-cGMP, and 8-(4-chlorophenylthio)-cAMP act upstream to inhibit JNK activation. In contrast, zVAD-fluoromethylketone (a permeant ICE family inhibitor), actinomycin D, and the G(1)/S cell cycle inhibitor deferoxamine, all promote survival after trophic factor withdrawal, but do not affect JNK activation. These findings are consistent with the presence of an ordered cell death pathway triggered by trophic factor deprivation in which 1) BCL2 and a number of survival-promoting agents act upstream of JNK, 2) ICE family protease actions, regulated genes required for cell death, and certain cell cycle blockers lie either downstream of JNK or on independent pathways required for apoptotic death.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	Park, DS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Yan, Chao Yun Irene/B-4700-2011; Stefanis, Leonidas/AAD-7192-2019	Yan, Chao Yun Irene/0000-0003-0527-5719; Park, David/0000-0002-4490-3784				BASTITATOU A, 1991, J CELL BIOL, V115, P461; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BURNSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LIU A, 1995, SCIENCE, V268, P286; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WANG HG, 1994, ONCOGENE, V9, P2751; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; YAN CYI, 1995, SOC NEUR ABSTR; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	64	200	200	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21898	21905		10.1074/jbc.271.36.21898	http://dx.doi.org/10.1074/jbc.271.36.21898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702992	hybrid			2022-12-25	WOS:A1996VF61200034
J	Agrawal, RK; Burma, DP				Agrawal, RK; Burma, DP			Sites of ribosomal RNAs involved in the subunit association of tight and loose couple ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; PROTEIN-SYNTHESIS; 70S RIBOSOMES; 50S RIBOSOMES; 16S; NUCLEOTIDES; INITIATION; MECHANISM; PROBES; TRANSLOCATION	It was demonstrated previously by kethoxal treatment studies that tight (TC) and loose (LC) couple ribosomes use different sites of the 16 S and 23 S RNAs for subunit association (Burma, D. P., Srivastava, A. K., Srivastava, S., and Dash, D. (1985) J. Biol. Chem. 260, 10517-10525). To localize these sites, a number of oligodeoxynucleotides complementary to the suspected sites of the 16 S and 23 S RNAs were synthesized, and their binding to ribosomes and effects on subunit association were studied, Some of the probes inhibit the association of both TC and LC ribosomes, some inhibit the association of TC but not LC ribosomes, and some inhibit the association of LC but not TC ribosomes. It appears that both TC and LC ribosomes use one common site of association, bases 818-823 of the 16 S and 2308-2313 of the 23 S RNA. The second site, 788-793 of the 16 S RNA and 2753-2758 of the 23 S RNA for TC ribosomes, and 783-791 of the 16 S RNA and 2295-2303 of the 23 S RNA for LC ribosomes, is not shared. This suggests a spatial movement of the ribosomal subunits with respect to one another and lends further support to the model of translocation based on the interconversion of TC and LC ribosomes.	BANARAS HINDU UNIV,INST MED SCI,MOL BIOL UNIT,VARANASI 221005,UTTAR PRADESH,INDIA	Banaras Hindu University (BHU)								AGRAWAL RK, 1992, INDIAN J BIOCHEM BIO, V29, P148; BURMA DP, 1985, J BIOL CHEM, V260, P517; BURMA DP, 1983, P NATL ACAD SCI-BIOL, V80, P4875, DOI 10.1073/pnas.80.16.4875; BURMA DP, 1984, BIOCHEM BIOPH RES CO, V124, P970, DOI 10.1016/0006-291X(84)91053-2; BURMA DP, 1988, INDIAN J BIOCHEM BIO, V25, P467; BURMA DP, 1985, J BIOSCIENCE, V8, P757, DOI 10.1007/BF02702774; BURMA DP, 1984, J BIOSCIENCE, V6, P419, DOI 10.1007/BF02703897; Chaconas G, 1980, Methods Enzymol, V65, P75; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DASH D, 1987, J BIOSCIENCE, V11, P561, DOI 10.1007/BF02704705; DASH D, 1988, INDIAN J BIOCHEM BIO, V25, P226; DEY DN, 1991, INDIAN J BIOCHEM BIO, V28, P369; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HILL WE, 1986, STRUCTURE FUNCTION G, P233; LANGER JA, 1984, BIOCHEMISTRY-US, V23, P6171, DOI 10.1021/bi00320a043; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MURALIKRISHNA P, 1989, BIOCHEMISTRY-US, V28, P7505, DOI 10.1021/bi00445a002; NAG B, 1985, IND J CHEM SOC, V62, P1008; NAG B, 1983, CURR SCI, V51, P1158; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OAKES MI, 1990, J MOL BIOL, V211, P897, DOI 10.1016/0022-2836(90)90082-W; SANTER M, 1990, P NATL ACAD SCI USA, V87, P3700, DOI 10.1073/pnas.87.10.3700; SONENBERG N, 1975, P NATL ACAD SCI USA, V72, P4332, DOI 10.1073/pnas.72.11.4332; TAPPRICH WE, 1989, P NATL ACAD SCI USA, V86, P4927, DOI 10.1073/pnas.86.13.4927; TAPPRICH WE, 1986, P NATL ACAD SCI USA, V83, P556, DOI 10.1073/pnas.83.3.556; VANDIGGELEN OP, 1973, EUR J BIOCHEM, V39, P511; Wahba A. J, 1967, METHOD ENZYMOL, V12, P524; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	34	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21285	21291		10.1074/jbc.271.35.21285	http://dx.doi.org/10.1074/jbc.271.35.21285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702905	hybrid			2022-12-25	WOS:A1996VE47700051
J	Aletta, JM; Selbert, MA; Nairn, AC; Edelman, AM				Aletta, JM; Selbert, MA; Nairn, AC; Edelman, AM			Activation of a calcium-calmodulin-dependent protein kinase I cascade in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; RAT-BRAIN; SUBSTRATE RECOGNITION; PHOSPHORYLATION SITES; CDNA CLONING; AUTOPHOSPHORYLATION; IDENTIFICATION; PURIFICATION; EXPRESSION; TRANSCRIPTION	It has been observed that the activity of Ca2+-calmodulin (CaM)-dependent protein kinase I is enhanced up to 50-fold by its phosphorylation in vitro by a distinct CaM kinase I kinase (Lee, J. C., and Edelman, A. M. (1994) J, Biol. Chem. 269, 2158-2164). It has, however, been unclear whether this event represents an acute form of cellular regulation. We demonstrate here the phosphorylation and activation of CaM kinase I in PC12 pheochromocytoma cells in response to elevation of intracellular Ca2+. Treatment of PC12 cells with the Ca2+-ionophore, ionomycin, or with a depolarizing concentration of KCl, led to rapid, biphasic phosphorylation of CaM kinase I and to increases in CaM kinase I activity of 5.1- and 7.3-fold, respectively. Depolarization-induced activation of CaM kinase I was reduced by similar to 80% by blockade of Ca2+ influx through L-type voltage-dependent Ca2+ channels and completely abolished by removal of extracellular Ca2+. The ability of PC12 cell CaM kinase I to be phosphorylated and activated by purified CaM kinase I kinase in vitro was markedly reduced by prior depolarization of the cells, consistent-with intracellular phosphorylation and activation of CaM kinase I by CaM kinase I kinase. These results demonstrate the existence in PC12 cells of a CaM kinase I cascade, the function of which may be to sensitize cells to signal-induced elevations of intracellular Ca2+.	ROCKEFELLER UNIV,MOL & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Rockefeller University	Aletta, JM (corresponding author), SUNY BUFFALO,DEPT PHARMACOL & TOXICOL,BUFFALO,NY 14214, USA.			Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24738] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; EDELMAN AM, 1995, PROTEIN KINASE FACTS, P128; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1994, ADV 2 MESSENGER PHOS, V30, P1; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOLEM M, 1995, J NEUROSCI, V15, P5966; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TENG KK, 1993, J NEUROSCI, V13, P3124; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOKUMITSU H, 1996, J BIOL CHEM, V271, P6617; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG WY, 1995, J CELL PHYSIOL, V162, P348, DOI 10.1002/jcp.1041620307; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	56	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20930	20934		10.1074/jbc.271.34.20930	http://dx.doi.org/10.1074/jbc.271.34.20930			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702851	hybrid			2022-12-25	WOS:A1996VD33700103
J	Gurniak, CB; Berg, LJ				Gurniak, CB; Berg, LJ			A new member of the Eph family of receptors that lacks protein tyrosine kinase activity	ONCOGENE			English	Article						Eph family tyrosine kinase; catalytically inactive tyrosine kinase; alternatively spliced receptor; thymus; brain	T-CELL DEVELOPMENT; SIGNAL-TRANSDUCTION; IL-2 RECEPTOR; JANUS KINASE; GAMMA-CHAIN; ZETA-CHAIN; IDENTIFICATION; ASSOCIATION; EXPRESSION; ACTIVATION	Using a PCR-based screen to identify tyrosine kinases involved in T cell development, we have cloned a new member of the Eph-family of receptor tyrosine kinases (Mep, for murine eph-family protein). At the amino acid level Mep is 60% identical to the chicken embyronic kinase Cek9. Sequence analysis indicates that the predicted extracellular portion of Mep bears an Ig-like domain, a cysteine-rich region, and sequences homologous to fibronectin type III. The transmembrane region of Mep is followed by a kinase domain. Surprisingly, this kinase domain carries amino acid substitutions in the highly conserved consensus motifs found in all protein tyrosine kinases and known to be crucial for kinase activity. We demonstrate that a bacterial fusion protein of the Mep kinase domain does not have protein tyrosine kinase activity. Analysis of Mep mRNA levels in a variety of mouse tissues shows that Mep is highly expressed in thymus and brain. We have also isolated two additional Mep cDNA clones from thymocytes which are predicted to encode secreted forms of the Mep extracellular domain; mRNAs encoding these secreted isoforms are also expressed in mouse brain.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRESCHER U, 1995, CELL, V82; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS WA, 1995, NEURON, V15, P241, DOI 10.1016/0896-6273(95)90000-4; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOZUMI K, 1994, INT IMMUNOL, V6, P1451, DOI 10.1093/intimm/6.9.1451; HUEBER AO, 1994, BRAZ J MED BIOL RES, V27, P275; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1988, ONCOGENE, V3, P629; LU YL, 1992, J IMMUNOL, V149, P24; MACNEIL I, 1993, J IMMUNOL, V151, P6913; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOTT R, 1992, B MATH BIOL, V54, P59, DOI 10.1007/BF02458620; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TAYLOR V, 1994, NEUROSCIENCE, V63, P163, DOI 10.1016/0306-4522(94)90014-0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, IMMUNOL REV, V101, P21; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	57	84	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					777	786						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761299				2022-12-25	WOS:A1996VD43300013
J	Milia, E; DiSomma, MM; Baldoni, F; Chiari, R; Lanfrancone, L; Pelicci, PG; Telford, JL; Baldari, CT				Milia, E; DiSomma, MM; Baldoni, F; Chiari, R; Lanfrancone, L; Pelicci, PG; Telford, JL; Baldari, CT			The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP-70 and mediates TCR dependent gene activation	ONCOGENE			English	Article						Shr; ZAP-70; PTB domain; TCR; T-cell	CELL ANTIGEN RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; PROTEIN-TYROSINE KINASE; GRB2 ADAPTER PROTEIN; JURKAT T-CELLS; SIGNAL-TRANSDUCTION; ZETA-CHAIN; LYMPHOCYTE-ACTIVATION; NUCLEOTIDE EXCHANGE; PHOSPHORYLATION	T-cell antigen receptor stimulation results in recruitment to the zeta chain and phosphorylation both of the syk family protein tyrosine kinase ZAP-70 and of the She adaptor protein, which transduces activating signals to Pas, Both ZAP-70 and Pas are required for T-cell activation. We have investigated the functional link between these two molecules in TCR signaling, She was found to associate with ZAP-70 in response to TCR triggering. This association was dependent on the presence of the aminoterminal phosphotyrosine binding (PTB) domain of She. The analysis of She binding to a potential PTB domain binding site on ZAP-70 confirmed the interaction of the She PTB domain with ZAP-70 and identified the ZAP-70 phosphotyrosine residue involved in this interaction, To test the role of the She PTB domain in transducing TCR derived signals we measured the effects of the isolated She PTB domain on the activation of the T-cell specific transcription factor NF-AT, The isolated She PTB domain was designed to compete non productively with endogenous She for binding to upstream tyrosine phosphorylated proteins and thus interfere with coupling to regulators of Pas activation, A significant inhibition of NP-AT activation by TCR triggering was observed, showing a functional involvement of She in TCR signaling through its PTB domain and suggesting an important role for She association with ZAP-70.	UNIV SIENA,DEPT EVOLUTIONARY BIOL,I-53100 SIENA,ITALY; IRIS,I-53100 SIENA,ITALY; MONTELUCE POLICLIN,MED CLIN 1,I-06100 PERUGIA,ITALY; IST EUROPEO ONCOL,MILAN,ITALY	University of Siena; Novartis; IRCCS European Institute of Oncology (IEO)			Telford, John Laird/ABG-8144-2020; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Pier Giuseppe/AAL-6572-2020	Lanfrancone, Luisa/0000-0002-4523-3815; chiari, rita/0000-0002-7649-273X	Telethon [E.0207] Funding Source: Medline	Telethon(Fondazione Telethon)		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1995, EUR J IMMUNOL, V25, P1843, DOI 10.1002/eji.1830250708; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BALDARI CT, 1995, ONCOGENE, V10, P1141; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BORST J, 1990, HUM IMMUNOL, V2, P175; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LAMINET A, 1996, IN PRESS J BIOL CHEM; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	53	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					767	775						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761298				2022-12-25	WOS:A1996VD43300012
J	Ferre, T; Riu, E; Bosch, F; Valera, A				Ferre, T; Riu, E; Bosch, F; Valera, A			Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver	FASEB JOURNAL			English	Article						P-enolpyruvate carboxykinase gene promoter; bu glycolysis	PYRUVATE-KINASE GENE; CARBOHYDRATE RESPONSE ELEMENT; DEPENDENT DIABETES-MELLITUS; TRANSCRIPTIONAL CONTROL; MAMMALIAN GLUCOKINASE; ADIPOSE-TISSUE; CYCLIC-AMP; INSULIN; EXPRESSION; DEFINITION	To study the role of glucokinase (GK) in the control of glucose metabolism in the liver, transgenic mice were generated in which GK was overexpressed under control of the P-enolpyruvate carboxykinase gene promoter, Whereas the expression of the GK gene in starved control mice was blocked, this promoter was able to direct the expression of the enzyme to the liver of starved transgenic mice, Furthermore, starved transgenic mice showed levels of GK activity fourfold higher than those of starved control and similar to those of fed control, This activation of GEC led to an increase in the intracellular concentration. of glucose 6-phosphate, which was also related ito an induction of glycogen accumulation, In addition, L-pyruvate kinase (L-PK) activity increased in transgenic mice, which when starved showed similar levels of activity to control fed mice, The induction of L-PK caused an increase in the hepatic lactate concentration, Furthermore, hepatocytes in primary culture from transgenic mice incubated with 20 mM glucose produced levels of lactate threefold higher than controls, but no difference was noted when the hepatocytes from control and transgenic mice were incubated with 2 mM glucose. These results demonstrated in vivo that the activation of GK is a rate-limiting step in the induction of glycolysis and glycogen synthesis. These changes in liver glucose metabolism led to a marked reduction in blood glucose (30%) and insulin (40%) concentrations. Furthermore, transgenic mice showed lower levels of blood glucose after an intraperitoneal glucose tolerance test, indicating that GK overexpression caused an increase in blood glucose disposal by the Liver, All these findings show the key role of liver GK in the control of whole-body glucose homeostasis.	UNIV AUTONOMA BARCELONA, FAC VET, DEPT BIOQUIM & BIOL MOL, BELLATERRA 08193, SPAIN; UNIV AUTONOMA BARCELONA, FAC VET, SERV BIOTECNOL ANIM, BELLATERRA 08193, SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona				BOSCH, FATIMA/0000-0002-7705-5515; Ferre, Tura/0000-0001-9713-0829; Riu, Efren/0000-0002-2574-3578				BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DOIRON B, 1994, J BIOL CHEM, V269, P10213; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; HOGAN B, 1986, MANIPULATING MOUSE E; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LECAM A, 1976, EXP CELL RES, V98, P382, DOI 10.1016/0014-4827(76)90448-1; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; VALERA A, 1994, FASEB J, V8, P440, DOI 10.1096/fasebj.8.6.8168695; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0	35	162	179	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1996	10	10					1213	1218		10.1096/fasebj.10.10.8751724	http://dx.doi.org/10.1096/fasebj.10.10.8751724			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751724				2022-12-25	WOS:A1996VD42900013
J	Deed, RW; Armitage, S; Norton, JD				Deed, RW; Armitage, S; Norton, JD			Nuclear localization and regulation of Id protein through an E protein-mediated chaperone mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; DNA-BINDING; MUSCLE DIFFERENTIATION; GENE; E2A; MYOD; SITE; IDENTIFICATION; EXPRESSION; COMPLEXES	Members of the Id family of helix-loop-helix proteins function as negative regulators of DNA binding, E protein, helix-loop-helix transcription factors in the control of cell growth, differentiation, and development. By using transient transfection analysis of COS cells, we show that in the absence of its E protein target, the Id3 protein is localized exclusively to the cytoplasm/perinuclear region. Co-transfection with E protein (E47) results in nuclear translocation of the Id3 protein, a process requiring both a functional Id helix-loop-helix dimerization domain and an E protein nuclear localization signal. Id3 that is associated with E protein displays an extended half-life, while the E protein itself is more rapidly turned over. These observations demonstrate that E protein, by nuclear chaperoning Id, can regulate the available cellular pool of its own inhibitory partner.	CHRISTIE HOSP NATL HLTH SERV TRUST,DEPT GENE REGULAT,PATERSON INST CANC RES,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research								BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEED RW, 1994, BBA-GENE STRUCT EXPR, V1219, P160, DOI 10.1016/0167-4781(94)90261-5; DEED RW, 1993, ONCOGENE, V8, P599; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LAVERONE A, 1994, GENE DEV, V8, P1270; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; MEYER KB, 1995, EUR J IMMUNOL, V25, P1770, DOI 10.1002/eji.1830250643; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; VASTRIK I, 1995, ONCOGENE, V11, P553; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WATERS CM, 1990, ONCOGENE, V5, P669; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WIBLEY J, 1996, BIOCHIM BIOPHYS ACTA, V1924, P138	27	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23603	23606		10.1074/jbc.271.39.23603	http://dx.doi.org/10.1074/jbc.271.39.23603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798572	hybrid			2022-12-25	WOS:A1996VJ44200001
J	Kammer, W; Lischke, A; Moriggl, R; Groner, B; Ziemiecki, A; Gurniak, CB; Berg, LJ; Friedrich, K				Kammer, W; Lischke, A; Moriggl, R; Groner, B; Ziemiecki, A; Gurniak, CB; Berg, LJ; Friedrich, K			Homodimerization of interleukin-4 receptor alpha chain can induce intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON GAMMA-CHAIN; TRANSCRIPTION FACTOR; KINASE; DOMAIN; IL-4; PHOSPHORYLATION; LYMPHOCYTES; PROTEIN; SURFACE; BINDING	The possible role of homodimerization events in intracellular signal transduction triggered by the bipartite human interleukin-4 receptor was addressed, We generated cell lines functionally expressing derivatives of the two receptor subunits alpha and gamma, which allow for a specific and background-free experimental induction of intracellular homo- and heterodimers, A heterodimer of alpha and gamma released an intracellular signal, whereas a gamma-gamma homodimer did not, Unexpectedly, we found the intracellular domain of interleukin-4 receptor alpha chain to evoke cell proliferation and activation of tyrosine kinase Jak1 as well as of transcription factor State upon homodimerization. Both recruitment of the common gamma chain and activation of kinase Jak3 were shown to be dispensible for these processes.	THEODOR BOVERI INST BIOWISSENSCH BIOZENTRUM,D-97074 WURZBURG,GERMANY; INST EXPT CANC RES,TUMOR BIOL CTR,D-79106 FREIBURG,GERMANY; LAB CLIN & EXPT CANC RES,CH-3004 BERN,SWITZERLAND; HARVARD UNIV,DEPT MOL & CELL BIOL,CAMBRIDGE,MA 02138	Harvard University			Moriggl, Richard/H-8118-2019	Moriggl, Richard/0000-0003-0918-9463				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BONSCH D, 1995, J BIOL CHEM, V270, P8452, DOI 10.1074/jbc.270.15.8452; DUSCHL A, 1995, EUR J BIOCHEM, V228, P305; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HARADA N, 1992, J BIOL CHEM, V267, P22752; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; LISCHKE A, 1995, EUR J BIOCHEM, V234, P100, DOI 10.1111/j.1432-1033.1995.100_c.x; Lischke A, 1996, ANAL BIOCHEM, V236, P322, DOI 10.1006/abio.1996.0173; Nelson BH, 1996, MOL CELL BIOL, V16, P309; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAUL WE, 1991, BLOOD, V77, P1859; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sambrook J., 2002, MOL CLONING LAB MANU; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1994, J BIOL CHEM, V269, P26614	29	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23634	23637		10.1074/jbc.271.39.23634	http://dx.doi.org/10.1074/jbc.271.39.23634			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798580				2022-12-25	WOS:A1996VJ44200009
J	Stella, N; Magistretti, PJ				Stella, N; Magistretti, PJ			Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons - Evidence for a cAMP-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA-RECEPTOR ACTIVATION; CEREBELLAR GRANULE CELLS; C-DEPENDENT PROCESSES; SPINAL-CORD NEURONS; RAT VISUAL-CORTEX; PRIMARY CULTURES; SYNAPTIC TRANSMISSION; SIGNAL-TRANSDUCTION; CEREBRAL-CORTEX; PHOSPHOLIPASE-C	Glutamatergic neurotransmission is associated with release of arachidonic acid (AA) from membrane phospholipids of both neurons and astrocytes. Since free AA has been shown to enhance glutamate mediated synaptic transmission, it can be postulated that glutamate release and AA formation constitute a positive feed-back mechanism for sustained excitatory neurotransmission. In the present study, we examined whether the glutamate-evoked release of AA could be modulated by peptides. Using mouse cortical neurons in primary cultures, we show that the release of AA evoked by glutamate is potentiated by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide (PACAP). This effect is mediated through the activation of PACAP I receptors. However, several arguments show that this potentiating mechanism does not involve the cAMP/PKA pathway. 1) Increasing intracellular cAMP by either cholera toxin, forskolin, or 8-Br-cAMP treatments does not affect the glutamate evoked release of AA; 2) potentiation of the glutamate response by PACAP is not prevented by the PKA inhibitor 8-Br-R(p)-cAMPS. Also, an involvement of the phospholipase C protein kinase C pathways is unlikely since inhibitors of both phospholipase C (i.e. U-73122) and protein kinase C (i.e. Ro 31-8220) do not affect the potentiation of the glutamate response by PACAP. These observations indicate an effect mediated by PACAP I receptors, which does not involve the second messenger pathways classically associated with activation of this type of receptors. Furthermore, results indicate that this potentiating mechanism mediated by PACAP I receptor acts at a level downstream of the glutamate receptor-mediated calcium influx.	UNIV LAUSANNE,FAC MED,CHUV,SERV NEUROL,CH-1005 LAUSANNE,SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Stella, N (corresponding author), UNIV LAUSANNE,FAC MED,INST PHYSIOL,LAB RECH NEUROL,7 RUE BUGNON,CH-1005 LAUSANNE,SWITZERLAND.			Magistretti, Pierre Julius/0000-0002-6678-320X				ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHNEIWEISS H, 1985, J NEUROCHEM, V44, P779, DOI 10.1111/j.1471-4159.1985.tb12883.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DRAPEAU C, 1990, NEUROSCI LETT, V115, P286, DOI 10.1016/0304-3940(90)90470-T; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; ELETR M, 1992, J NEUROSCI, V12, P1363; GIRAULT JA, 1988, P NATL ACAD SCI USA, V85, P7790, DOI 10.1073/pnas.85.20.7790; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJOS F, 1988, ANAT EMBRYOL, V178, P207, DOI 10.1007/BF00318224; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAGISTRETTI PJ, 1984, NATURE, V308, P280, DOI 10.1038/308280a0; MAGISTRETTI PJ, 1990, TRENDS PHARMACOL SCI, V11, P250, DOI 10.1016/0165-6147(90)90253-5; MAGISTRETTI PJ, 1988, NEUROSCIENCE, V24, P367, DOI 10.1016/0306-4522(88)90338-7; MARTIN JL, 1992, BRAIN RES, V587, P1, DOI 10.1016/0006-8993(92)91423-C; MARTIN JL, 1995, J NEUROCHEM, V65, P1; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MORRISON JH, 1984, BRAIN RES, V292, P269, DOI 10.1016/0006-8993(84)90763-7; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; PETERS A, 1988, J COMP NEUROL, V267, P409, DOI 10.1002/cne.902670310; PETROU S, 1993, TRENDS BIOCHEM SCI, V18, P41, DOI 10.1016/0968-0004(93)90050-W; PIOMELLI D, 1991, P NATL ACAD SCI USA, V88, P6770, DOI 10.1073/pnas.88.15.6770; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; PREZEAU L, 1994, MOL PHARMACOL, V45, P570; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STELLA N, 1995, J NEUROSCI, V15, P3307; STELLA N, 1994, J NEUROSCI, V14, P568; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YU ACH, 1986, J NEUROCHEM, V47, P1181; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	49	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23705	23710		10.1074/jbc.271.39.23705	http://dx.doi.org/10.1074/jbc.271.39.23705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798593	hybrid			2022-12-25	WOS:A1996VJ44200022
J	Carlson, SA; Chatterjee, TK; Fisher, RA				Carlson, SA; Chatterjee, TK; Fisher, RA			The third intracellular domain of the platelet-activating factor receptor is a critical determinant in receptor coupling to phosphoinositide phospholipase C activating G proteins - Studies using intracellular domain minigenes and receptor chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUTURE CLINICAL IMPLICATIONS; BETA-ADRENERGIC RECEPTORS; FORMYL PEPTIDE RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; BETA-2-ADRENERGIC RECEPTOR; CELLULAR EXPRESSION; INHIBITION; CLONING; LOOP	Platelet activating factor (PAF) is a potent phospholipid mediator which elicits a diverse array of biological actions by interacting with G protein-coupled PAF receptors (PAFR). Binding of PAF to PAFRs leads to activation of G protein(s) that stimulate phosphoinositide phospholipase C and subsequent intracellular signaling responses. To identify the potential role of intracellular domains of the rat PAFR (rPAFR) in signaling, we examined effects of transfecting minigenes encompassing rPAFR intracellular domains 1 (1i), 2 (2i), and 3 (3i) on inositol phosphate (IP) production mediated by the cotransfected rPAFR cDNA. Although transfection of the rPAFR1i and rPAFR2i minigenes had no effects on PAF-stimulated signaling, transfection of the rPAFR3i minigene inhibited PAF-stimulated IP production by approximately 50% compared to controls. The rPAFR3i domain did not inhibit IP production mediated by the multifunctional rat pituitary adenylate cyclase-activating polypeptide receptor (rPACAPR), demonstrating the specificity of the competition by the rPAFR3i domain, In further experiments, the rPAFR3i domain was engineered onto the homologous domain of a monofunctional transmembrane variant of the rPACAPR (rPACAPR(2)) that activates only adenylyl cyclase. The rPACAPR(2)/rPAFR3i chimera responded to PACAP with increases in IP production which were attenuated nearly completely in cells cotransfected with the rPAFR3i domain. In contrast, PACAP had no effects on IP production in a receptor chimera expressing a mutated form of the rPAFR3i domain (rPACAPR(2)/rPAFR3i(mut)). These results demonstrate the ability of the rPAFR3i domain to confer a phospholipase C-signaling phenotype to a receptor deficient in this activity and show that this activity is specific for the engineered rPAFR3i domain. These results suggest that the third intracellular loop of the rPAFR is a primary determinant in its coupling to phosphoinositide phospholipase C-activating G proteins, providing the first insight into the molecular basis of interaction of PAFRs with signal transducing G proteins.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa			Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041071, R29HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41071] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BROWN E, 1984, J NEUROCHEM, V42, P1379, DOI 10.1111/j.1471-4159.1984.tb02798.x; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHATTERJEE TK, 1995, METHODS NEUROSCIENCE; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DELCERRO S, 1990, BEHAV NEURAL BIOL, V54, P213, DOI 10.1016/0163-1047(90)90595-W; DHAR A, 1991, J BIOL CHEM, V266, P18797; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HASLAM RJ, 1982, J BIOL CHEM, V257, P6879; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOLTAI M, 1991, DRUGS, V42, P174, DOI 10.2165/00003495-199142020-00002; KOLTAI M, 1991, DRUGS, V42, P9, DOI 10.2165/00003495-199142010-00002; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NAKASHIMA S, 1989, J IMMUNOL, V143, P1295; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SIRGANIAN RP, 1971, J IMMUNOL, V106, P1244; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TAKANO T, 1994, J BIOL CHEM, V269, P22453; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219	48	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23146	23153		10.1074/jbc.271.38.23146	http://dx.doi.org/10.1074/jbc.271.38.23146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798508	hybrid			2022-12-25	WOS:A1996VH76800034
J	Davletov, BA; Shamotienko, OG; Lelianova, VG; Grishin, EV; Ushkaryov, YA				Davletov, BA; Shamotienko, OG; Lelianova, VG; Grishin, EV; Ushkaryov, YA			Isolation and biochemical characterization of a Ca2+-independent alpha-latrotoxin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; FROG NEUROMUSCULAR-JUNCTION; HIGH-AFFINITY BINDING; TRANSMITTER RELEASE; RAT-BRAIN; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; TOXIN BINDING; RECEPTOR; MEMBRANE	alpha-Latrotoxin, a black widow spider neurotoxin, can bind to high affinity receptors on the presynaptic plasma membrane and stimulate massive neurotransmitter release in the absence of Ca2+. Neurexins, previously isolated as Lu-latrotoxin receptors, require Ca2+ for their interaction with the toxin and, thus, may not participate in the Ca2+-independent cu-latrotoxin activity, We now report the isolation of a novel protein that binds alpha-latrotoxin with high affinity in the presence of various divalent cations (Ca2+, Mg2+, Ba2+, and Sr2+) as well as in EDTA. This protein, termed here latrophilin, has been purified from detergent-solubilized bovine brain membranes by affinity chromatography on immobilized alpha-latrotoxin and concentrated on a wheat germ agglutinin affinity column. The single polypeptide chain of latrophilin is N-glycosylated and has an apparent molecular weight of 120,000. Sucrose gradient centrifugations demonstrated that latrophilin and alpha-latrotoxin form a stable equimolar complex, In the presence of the toxin, anti-alpha-latrotoxin antibodies precipitated iodinated latrophilin, whose binding to immobilized toxin was characterized by a dissociation constant of 0.5-0.7 nM. This presumably membrane-bound protein is localized to and differentially distributed among neuronal tissues, with about four times more latrophilin expressed in the cerebral cortex than in the cerebellum; subcellular fractionation showed that the protein is highly enriched in synaptosomal plasma membranes, Our data suggest that latrophilin may represent the Ca2+-independent receptor and/or molecular target for alpha-latrotoxin.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; SHEMYAKIN & OVCHINNIKOV INST BIOORGAN CHEM,MOSCOW 117871,RUSSIA	Imperial College London; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Davletov, Bazbek/ABA-8569-2021; Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Davletov, Bazbek/0000-0003-4658-3275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORDIER C, 1981, J BIOL CHEM, V256, P1604; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GORDONWEEKS PR, 1987, NEUROCHEMISTRY PRACT; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; HURLBUT WP, 1990, J PHYSIOL-LONDON, V425, P501, DOI 10.1113/jphysiol.1990.sp018115; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; HURLBUT WP, 1979, NEUROTOXINS TOOLS NE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALGAROLI A, 1989, NEUROSCIENCE, V32, P393, DOI 10.1016/0306-4522(89)90088-2; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MELDOLESI J, 1983, NEUROSCIENCE, V10, P997, DOI 10.1016/0306-4522(83)90238-5; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; MISLER S, 1979, P NATL ACAD SCI USA, V76, P991, DOI 10.1073/pnas.76.2.991; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; PASHKOV V, 1993, NEUROSCIENCE, V56, P695, DOI 10.1016/0306-4522(93)90366-N; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SCHEER H, 1986, EMBO J, V5, P2643, DOI 10.1002/j.1460-2075.1986.tb04546.x; STORCHAK LG, 1994, FEBS LETT, V351, P267, DOI 10.1016/0014-5793(94)00790-X; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1986, BIOORG KHIM+, V12, P71; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V121, P538, DOI 10.1016/0006-291X(84)90215-8	30	124	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23239	23245		10.1074/jbc.271.38.23239	http://dx.doi.org/10.1074/jbc.271.38.23239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798521	hybrid			2022-12-25	WOS:A1996VH76800047
J	Yan, SR; Berton, G				Yan, SR; Berton, G			Regulation of Src family tyrosine kinase activities in adherent human neutrophils - Evidence that reactive oxygen intermediates produced by adherent neutrophils increase the activity of the p58(c-fgr) and p53/56(lyn) tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; HYDROGEN-PEROXIDE; RESPIRATORY BURST; PHOSPHATASE INHIBITOR; BIOLOGICAL SURFACES; PROTEIN-KINASE; NADPH OXIDASE; CELL-SURFACE; FACTOR-ALPHA	Src family tyrosine kinases have been implicated in the adhesion-dependent activation of neutrophil functions (Yan, S. R., Fumagalli, L., and Berton, G. (1995) J. Inflamm. 45, 297-312; Lowell, C. A., Fumagalli, L., and Berton, G. (1996) J. Cell Biol, 133, 895-910). Because the activity of tyrosine kinases can be affected by oxidants, we investigated whether reactive oxygen intermediates (ROI) produced by adherent neutrophils regulate Src family kinase activities. Inhibition of ROI production by diphenylene iodonium, an inhibitor of NADPH oxidase, or degradation of H2O2 by exogenously added catalase inhibited the adhesion-stimulated activities of p58(c-fgr) and p53/56(lyn). In addition, adhesion-stimulated p58(c-fgr) and p53/56(lyn) activities were greatly reduced in neutrophils from patients with chronic granulomatous disease (CGD) that are deficient in the production of ROI. Exogenously added H2O2 increased p58(c-fgr) and p53/56(lyn) activities in nonadherent neutrophils. Although ROI regulated the activities of p58(c-frg) and p53/56(lyn), they did not affect the redistribution of the two kinases to a Triton X-100-insoluble, cytoskeletal fraction that occurs in adherent neutrophils. Tyrosine phosphorylation of proteins in adherent, CGD neutrophils was only partially inhibited, suggesting that the full activation of p58(c-fgr) and p53/56(lyn), which depends on endogenously produced ROI, does not represent an absolute requirement for protein tyrosine phosphorylation. The adhesion stimulated activity of the tyrosine kinase p72(syk) was not affected by catalase in normal neutrophils, and it was comparable in normal and CGD neutrophils. These findings suggest that ROI endogenously produced by adherent neutrophils regulate Src family kinases activity selectively and establish the existence of a cross-talk between reorganization of the cytoskeleton, production of ROI, and Src family tyrosine kinase activities in signaling by adhesion.	UNIV VERONA,IST PATOL GEN,I-37134 VERONA,ITALY	University of Verona								BELLAVITE P, 1992, J LEUKOCYTE BIOL, V51, P329, DOI 10.1002/jlb.51.4.329; BENNETT PA, 1993, J CELL SCI, V106, P891; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BERTON G, 1996, IN PRESS INT J CLIN; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRI P, 1991, INT J TISSUE REACT, V13, P193; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LAUDANNA C, 1990, BIOCHEM BIOPH RES CO, V166, P308, DOI 10.1016/0006-291X(90)91946-P; LAUDANNA C, 1993, BIOCHEM BIOPH RES CO, V190, P935, DOI 10.1006/bbrc.1993.1139; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; QIN S, 1955, BIOCHEM J, V308, P347; RICHTER J, 1989, J IMMUNOL, V142, P3199; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SMITH RM, 1991, BLOOD, V77, P673; SUCHARD SJ, 1994, J IMMUNOL, V152, P290; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yan SR, 1995, J INFLAMM, V45, P297; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	59	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23464	23471		10.1074/jbc.271.38.23464	http://dx.doi.org/10.1074/jbc.271.38.23464			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798554	hybrid			2022-12-25	WOS:A1996VH76800080
J	Bhat, GJ; Abraham, ST; Baker, KM				Bhat, GJ; Abraham, ST; Baker, KM			Angiotensin II interferes with interleukin 6-induced Stat3 signaling by a pathway involving mitogen-activated protein kinase kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; EPIDERMAL GROWTH-FACTOR; RAT CARDIAC FIBROBLASTS; DNA-BINDING ACTIVITY; PC12 CELLS; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; GENE-EXPRESSION; AT(1A) RECEPTOR; IN-VITRO	We reported recently that angiotensin II (AII) and phorbol 12-myristate 13-acetate (PMA) transiently inhibit interleukin 6 (IL-6)-stimulated tyrosine phosphorylation of signal transducers and activators of transcription 3 (Stat3) and subsequent formation of sis-inducing factor-A (SIF-A), However, the AII-mediated inhibition was independent of PMA-sensitive isoforms of protein kinase C (Bhat, G. J., Thekkumkara, T. J. Thomas, W. G., Conrad, K. M., and Baker, K. M. (1995) J, Biol, Chem. 270, 19059-19065), In this study, we demonstrate that the inhibition of IL-6-induced Stat3/SIF-A by AII is concentration-dependent and does not involve degradation of Stat3 protein, We hypothesized that the activation profile of the AII- and PMA-induced mitogen-activated protein (MAP) kinase cascade may be different from that of IL-6 and could contribute to the inhibitory effect; therefore, blocking the MAP kinase pathway at the level of MAPK kinase (MAPKK) would attenuate this inhibitory effect, AII and PMA rapidly induced high levels of MAP kinase activity (8-fold), which contrasted with the delayed and weak activation by IL-6 (1.7-fold), Treatment of cells with PD98059, a specific inhibitor of MAPKK1, attenuated the inhibitory effects of AII and PMA on IL-6-induced Stat3 tyrosine phosphorylation and SIF-A formation, These data suggest that differences in magnitude and/or duration of activation of the MAP kinase cascade differentially affects the status of Stat3 tyrosine phosphorylation, and that MAPKK1 or a downstream intermediate is involved in the inhibition of IL-6-induced Stat3 by AII and PMA, Modulatory cross-talk between AII and IL-6 may have relevance in pathophysiological conditions such as cardiac hypertrophy and in acute phase and inflammatory responses.			Bhat, GJ (corresponding author), WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA.							ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BOOZ GW, 1995, CARDIOVASC RES, V30, P537, DOI 10.1016/S0008-6363(96)88507-5; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; CASTELL JV, 1989, ANN NY ACAD SCI, V557, P87; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KUSHNER I, 1989, ANN NY ACAD SCI, V557, P19; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1995, J MOL CELL CARDIOL, V27, P1151, DOI 10.1016/0022-2828(95)90051-9; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	39	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22447	22452		10.1074/jbc.271.37.22447	http://dx.doi.org/10.1074/jbc.271.37.22447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798409	hybrid			2022-12-25	WOS:A1996VG67200028
J	Lin, X; VoynoYasenetskaya, TA; Hooley, R; Lin, CY; Orlowski, J; Barber, DL				Lin, X; VoynoYasenetskaya, TA; Hooley, R; Lin, CY; Orlowski, J; Barber, DL			G alpha 12 differentially regulates Na+-H+ exchanger isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; SOMATOSTATIN RECEPTORS; MOLECULAR-CLONING; INTRACELLULAR PH; ALPHA-SUBUNITS; INDEPENDENT MECHANISM; CELLS; EXPRESSION; ANTIPORTER; PROTEINS	Activation of several GTPases stimulates Na+-H+ exchange, resulting in an increased efflux of intracellular H+. These GTPases include alpha subunits of the heterotrimeric G proteins G(q) and G13, as well as the low molecular weight GTP-binding proteins Ras, Cdc42, and Rho (Hooley, R., Yu, C.-Y., Simon, M., and Barber, D. L. (1996) J. Biol. Chem. 271, 6152-6158). GTPases coupled to the inhibition of Na+-H+ exchange, however, have not been identified. Several neurotransmitters, including somatostatin and dopamine, inhibit Na+-H+ exchange through a guanine-nueleotide dependent mechanism, suggesting the involvement of a GTPase. In this study we determined that mutational activation of the alpha subunit of G12 inhibits the ubiquitously expressed Na+-H+ exchanger isoform, NBE1. Transient expression of mutationally activated Glu12 inhibited serum- and G alpha 13-stimulated NHE1 activity in HEK293 cells and CCL39 fibroblasts. In addition, in NHE-deficient AP1 cells stably expressing specific NHE isoforms, mutationally activated G alpha 12 inhibited NHE1 activity but stimulated activities of the Na+-H+ exchanger (NHE) isoforms NHE2 and NHE3. In contrast, mutationally activated G alpha 13, another member of the G alpha 12/13 family. stimulated all three NHE isoforms. Although previous studies have identified a parallel action of G alpha 12 and G alpha 13 in regulating MAP (mitogen-activated protein) kinases and cell growth, these GTPases have opposing effects on NHE1 activity.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; McGill University				Orlowski, John/0000-0001-7371-175X	NIDDK NIH HHS [DK 40259] Funding Source: Medline; NIGMS NIH HHS [GM 47413] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040259, R01DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1991, CELL SIGNAL, V3, P387, DOI 10.1016/0898-6568(91)90069-7; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; Fukushima T, 1996, J CELL BIOL, V132, P1037, DOI 10.1083/jcb.132.6.1037; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HOU CF, 1994, J BIOL CHEM, V269, P10357; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; MALY K, 1989, J BIOL CHEM, V264, P11839; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; ROTIN D, 1989, AM J PHYSIOL, V257, pC1148; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; VARIO G, 1992, J BIOL CHEM, V267, P19043; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YUN CHC, 1993, J BIOL CHEM, V268, P206; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	46	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22604	22610		10.1074/jbc.271.37.22604	http://dx.doi.org/10.1074/jbc.271.37.22604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798430	hybrid			2022-12-25	WOS:A1996VG67200049
J	Watanabe, G; Lee, RJ; Albanese, C; Rainey, WE; Batlle, D; Pestell, RG				Watanabe, G; Lee, RJ; Albanese, C; Rainey, WE; Batlle, D; Pestell, RG			Angiotensin II activation of cyclin D1-dependent kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIDE-CHAIN CLEAVAGE; FASCICULATA-RETICULARIS CELLS; BOVINE ADRENOCORTICAL-CELLS; EPIDERMAL GROWTH-FACTOR; NIH 3T3 CELLS; C-JUN; PROTEIN-KINASE; TRANSCRIPTION FACTOR; MAP KINASE	Angiotensin II (AII) binds to specific G protein-coupled receptors and is mitogenic in adrenal, liver epithelial, and vascular smooth muscle cells. Since the cyclin D1 gene encodes the regulatory subunit of the cyclin D1-dependent kinase (CD1K) required for phosphorylation of the retinoblastoma protein (pRB), an essential and rate-limiting step in G(1) phase progression of the cell cycle, we examined the effect of AII. on cyclin D1 expression and CD1K activity in the human adrenal cell line H295R. AII (10(-6) M) stimulated G(1) phase progression within 12 h, with a maximal effect after 72 h. This action was antedated by the induction of cyclin D1 mRNA (3-fold), cyclin D1 nuclear protein abundance (4-fold), and CD1K activity (4-fold). AT(1) induced cyclin D1 promoter activity 4-fold, via the AT(1) receptor through an enhancer sequence at -954 base pairs. c-Fos and c-Jun bound the cyclin D1 -954 enhancer sequence, and the abundance of c-Fos within this complex was increased by All treatment, AII induced extracellular signal-regulated kinase (ERK) activity 7-fold, and dominant-negative mutants of either p21(ras) or ERK reduced AII stimulated cyclin D1 promoter activity. These findings suggest that AII may stimulate mitogenesis by increasing CD1K activity through a p21(ras)/ERK/activator protein 1 pathway.	NORTHWESTERN UNIV, SCH MED, DIV ENDOCRINOL METAB & MOL MED, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV NEPHROL & HYPERTENS, CHICAGO, IL 60611 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Northwestern University; Northwestern University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BIRD IM, 1993, ENDOCRINOLOGY, V133, P1555, DOI 10.1210/en.133.4.1555; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CAMPBELLBOSWELL M, 1981, EXP MOL PATHOL, V35, P265, DOI 10.1016/0014-4800(81)90066-6; CAPPONI AM, 1989, ADRENAL HYPERTENSION, P45; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLYNE CD, 1993, ENDOCRINOLOGY, V132, P2206, DOI 10.1210/en.132.5.2206; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; JIANG W, 1993, ONCOGENE, V8, P3447; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; KHOCHBIN S, 1988, CYTOMETRY, V9, P499, DOI 10.1002/cyto.990090516; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KUMABE T, 1992, NUCLEIC ACIDS RES, V20, P2598, DOI 10.1093/nar/20.10.2598; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBRETHON MC, 1994, J CLIN ENDOCR METAB, V78, P1212, DOI 10.1210/jc.78.5.1212; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NATARAJAN R, 1992, ENDOCRINOLOGY, V131, P1174, DOI 10.1210/en.131.3.1174; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PESTELL RG, 1993, J MOL ENDOCRINOL, V10, P297, DOI 10.1677/jme.0.0100297; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; Pestell Richard G., 1995, P59; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SETH A, 1992, J BIOL CHEM, V267, P24796; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; VIARD I, 1992, ENDOCRINOLOGY, V130, P1193, DOI 10.1210/en.130.3.1193; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	73	127	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22570	22577		10.1074/jbc.271.37.22570	http://dx.doi.org/10.1074/jbc.271.37.22570			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798425	hybrid			2022-12-25	WOS:A1996VG67200044
J	Hu, DD; Barbas, CF; Smith, JW				Hu, DD; Barbas, CF; Smith, JW			An allosteric Ca2+ binding site on the beta 3 integrins that regulates the dissociation rate for RGD ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATION REGULATION; BONE-RESORPTION; CELL-ADHESION; CRYSTAL-STRUCTURE; CALCIUM-BINDING; IN-VITRO; GLYCOPROTEIN; SUBUNIT; DOMAIN; ALPHA(V)BETA(3)	Here we use a model RGD-containing ligand to study how Ca2+ and Mg2+ regulate ligand binding to beta 3-integrins, Fab-9, an antibody that contains an optimized RGD loop in its antigen binding site (Barbas, C. F., Languino, L., and Smith, J. W. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 10003-10007), was used as the model ligand. Across a physiologic range of Mg2+, Fab-9 bound to both alpha v beta 3 and alpha IIb beta 3 with a monophasic binding isotherm. Across the same range of Ca2+, the binding of Fab-9 to the beta 3-integrins was biphasic. Low concentrations of Ca2+ (mu M) promoted the binding of Fab-9. Higher concentrations of Ca2+ (mM) blocked Fab-9 binding. These data suggest that Ca2+ binds to two distinct classes of sites on the beta 3-integrins, with the low affinity Ca2+ binding site(s) being an inhibitory site. We designate this inhibitory site(s) as the I site. Further biochemical characterization showed that the I site has the following characteristics: 1) it is specific for Ca2+; 2) it is allosteric to the ligand binding site; 3) its occupation increases the dissociation rate between integrin and RGD ligand; and 4) occupation of the I site can induce cellular deadhesion.	BURNHAM INST, CTR CANC RES, PROGRAM CELL ADHES, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOL BIOL MB11, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute					NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56483] Funding Source: Medline; NIAMS NIH HHS [AR 42750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; GULINO D, 1992, J BIOL CHEM, V267, P1001; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MIYAUCHI A, 1993, OSTEOPOROSIS INT, V3, pS132; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MULLER B, 1993, J BIOL CHEM, V268, P6800; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; ROSS FP, 1993, J BIOL CHEM, V268, P9901; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1994, J BIOL CHEM, V269, P960; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUIVER I, 1996, IN PRESS J CELL PHYS; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003; ZAIDI M, 1991, J CELL PHYSIOL, V149, P422, DOI 10.1002/jcp.1041490310	35	80	81	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21745	21751		10.1074/jbc.271.36.21745	http://dx.doi.org/10.1074/jbc.271.36.21745			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702970	hybrid			2022-12-25	WOS:A1996VF61200012
J	Onodera, H; Motto, DG; Koretzky, GA; Rothstein, DM				Onodera, H; Motto, DG; Koretzky, GA; Rothstein, DM			Differential regulation of activation-induced tyrosine phosphorylation and recruitment of SLP-76 to Vav by distinct isoforms of the CD45 protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; T-CELL; PHOSPHOTYROSINE PHOSPHATASE; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; EXCHANGE PROTEIN; SH2 DOMAIN; KINASE; EXPRESSION	The CD45 family of transmembrane protein-tyrosine phosphatases plays a critical role in T cell activation signaling by regulating the tyrosine phosphorylation of protein-tyrosine kinases and their substrates. Multiple alternatively spliced CD45 isoforms, differing only in their extracellular domains, are differentially expressed by subsets of T cells with distinct functional repertoires. However, the physiological function of the various iso forms remains elusive, Using a novel panel of Jurkat T cell clones that uniquely express either the smallest (CD45(0)) or the largest (CD45(ABC)) isoform, we previously demonstrated CD45 isoform-specific differences in interleukin-a secretion and tyrosine phosphorylation of Vav. We now demonstrate differential activation-induced tyrosine phosphorylation of a 76-kDa Vav-associated protein (pp76) by cells expressing distinct CD45 isoforms. The tyrosine phosphorylation of Vav and associated pp76 follow parallel kinetics. pp76 interacts with the SH2 and SH3 domains of Vav. We have identified pp76 as SLP-76, a recently cloned Grb2-binding protein. After activation with anti-CD3, CD45(ABC) transfectants demonstrate increased tyrosine phosphorylation and physical association of SLP-76 with Vav compared to transfectants expressing CD45(0). These results establish a novel physical link between Vav and SLP-76 that is differentially regulated by CD45 isoform expression.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEPHROL SECT,NEW HAVEN,CT 06520; UNIV IOWA,SCH MED,DEPT INTERNAL MED,IOWA CITY,IA	Yale University; University of Iowa			Koretzky, Gary/AAU-5381-2021					AKBAR AN, 1988, J IMMUNOL, V140, P2171; ANDERSON P, 1988, IMMUNOL TODAY, V9, P199, DOI 10.1016/0167-5699(88)91213-3; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURNS CM, 1994, J BIOL CHEM, V269, P13594; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BYRNE JA, 1988, J IMMUNOL, V141, P3249; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FURAKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; MACHIDE M, 1995, ONCOGENE, V11, P619; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATSUYAMA T, 1988, EUR J IMMUNOL, V18, P1473, DOI 10.1002/eji.1830180926; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24949, DOI 10.1074/jbc.270.42.24949; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; REIF K, 1994, J BIOL CHEM, V269, P14081; ROTHSTEIN DM, 1993, INT IMMUNOL, V5, P409, DOI 10.1093/intimm/5.4.409; ROTHSTEIN DM, 1990, CELL IMMUNOL, V129, P449, DOI 10.1016/0008-8749(90)90220-L; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; RUDD CE, 1987, J EXP MED, V166, P1758, DOI 10.1084/jem.166.6.1758; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHASTRY L, 1995, ONCOGENE, V11, P1107; SMITH SH, 1986, IMMUNOLOGY, V58, P63; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TEDDER TF, 1985, J IMMUNOL, V134, P2983; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WENG WK, 1994, J BIOL CHEM, V269, P32514; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	61	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22225	22230		10.1074/jbc.271.36.22225	http://dx.doi.org/10.1074/jbc.271.36.22225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703037	hybrid			2022-12-25	WOS:A1996VF61200079
J	Ouyang, XM; Gulliford, T; Zhang, HY; Huang, GC; Epstein, R				Ouyang, XM; Gulliford, T; Zhang, HY; Huang, GC; Epstein, R			Human cancer cells exhibit protein kinase C-dependent c-erbB-2 transmodulation that correlates with phosphatase sensitivity and kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR PHOSPHORYLATION; NORMAL HUMAN-FIBROBLASTS; HUMAN BREAST-CANCER; TYROSINE KINASE; NEU ONCOGENE; DOWN-REGULATION; EGF RECEPTOR; PHORBOL ESTERS; TUMOR PROMOTER	The c-erbB-2 receptor tyrosine kinase is often overexpressed in human tumors, but the functional implications of this phenotype remain unclear. We previously used phosphorylation-specific antibodies to define major differences in c-erbB-2 tyrosine kinase activity between overexpressing human tumor cell lines (Epstein, R. J., Druker, B. J., Roberts, T.M., and Stiles, C. D. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 10435-10439). Here we extend this approach to define the relationship between c-erbB-2 tyrosine phosphorylation and protein kinase C (PRC)-dependent transmodulation. Phosphorylation-specific antibodies to the juxtamembrane PKC site Thr(686) recognize tyrosine-dephosphorylated wild-type c-erbB-2 following G8/DHFR 3T3 cell treatment with PKC agonists. B104-1-1 cells transformed by activated c-erbB-2 express a subset of tyrosine-phosphorylated receptors that are homologously phosphorylated on Thr(686), indicating that Thr(686) phosphorylation alone is insufficient to abrogate receptor tyrosine phosphorylation, Similarly, the c-erbB-2-overexpressing human cancer cell lines SK-Ov-3 and BT-474 express constitutively Thr(686)-phosphorylated receptors. SK-Ov-3 cells express predominantly kinase-inactive c-erbB-2 that is heavily Thr(686)-phosphorylated, indicating that Thr(686) phosphorylation in this line is heterologous in origin. In contrast, BT-474 cells express constitutively autophosphorylated c-erbB-2 despite Thr(686) phosphorylation. These results indicate that Thr(686) phosphorylation does not directly abolish c-erbB-2 activity and suggest that such phosphorylation reflects constitutive PKC activity induced by either receptor-activating mutations or heterologous growth factors. The latter possibility suggests in turn that c-erbB-2 interacts in an as yet undefined way with heterologous growth factor receptors in human tumor cells.	CHARING CROSS HOSP,DEPT MED ONCOL,CANC RES CAMPAIGN LABS,LONDON W6 8RF,ENGLAND; CHARING CROSS HOSP,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND; UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DIV CELL MOL & ONCOL RES,LONDON W6 8RF,ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of London					NCI NIH HHS [R01 CA61953] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CAO HN, 1991, ONCOGENE, V6, P705; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P4080, DOI 10.1073/pnas.82.12.4080; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DUMONT JA, 1992, CANCER RES, V52, P1195; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1995, ONCOGENE, V11, P315; EPSTEIN RJ, 1992, CELL GROWTH DIFFER, V3, P157; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; KING AC, 1982, J BIOL CHEM, V257, P3053; KING CS, 1986, J BIOL CHEM, V261, P73; LEMOINE NR, 1990, ONCOGENE, V5, P237; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUND KA, 1990, J BIOL CHEM, V265, P20517; MORRISON P, 1993, J BIOL CHEM, V268, P15536; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YEE NS, 1994, J BIOL CHEM, V269, P31991	52	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21786	21792		10.1074/jbc.271.36.21786	http://dx.doi.org/10.1074/jbc.271.36.21786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702975	hybrid			2022-12-25	WOS:A1996VF61200017
J	DellaLonga, S; Ascone, I; Bianconi, A; Bonfigli, A; Castellano, AC; Zarivi, O; Miranda, M				DellaLonga, S; Ascone, I; Bianconi, A; Bonfigli, A; Castellano, AC; Zarivi, O; Miranda, M			The dinuclear copper site structure of Agaricus bisporus tyrosinase in solution probed by X-ray absorption spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOCYANIN ACTIVE-SITE; NEAR-EDGE STRUCTURE; NEUROSPORA TYROSINASE; FINE-STRUCTURE; XANES; OXYHEMOCYANIN; COORDINATION; LACCASE; SUSCEPTIBILITY; COMPLEXES	We have measured the x-ray absorption near edge structure (XANES) spectra of the enzyme tyrosinase from the mushroom Agaricus bisporus in solution in the oxy and deoxy forms, The spectra, obtained under the same conditions as the analogous forms of mollusc hemocyanin (Hc), show that the oxidation state of copper changes from Cu(II) (oxy form) to Cu(I) (deoxy form), and the copper active site(s) of A. bisporus tyrosinase in solution undergoes the same main conformational changes as Hc. We have applied the multiple scattering theory to simulate the XANES spectra of various alternative geometries of the copper site, accounting for the residual differences between Hc and tyrosinase. While oxy-Hc is reasonably fitted only by the pseudo-square-pyramidal geometry reported by its crystallographic data, oxytyrosinase can be fitted, starting from the Hc coordinates, either by distortions toward a pseudo-tetrahedral geometry, with inequivalent copper sites, or by an apically distorted square-pyramidal geometry (with an elongation of the apical distance of no more than 0.2 Angstrom).	UNIV AQUILA,DIPARTIMENTO BIOL BASE APPLICATA,I-67100 LAQUILA,ITALY; CNRS,CEA,MEN,LAB UTILISAT,RAYONNEMENT ELECTROMAGNET,F-91405 ORSAY,FRANCE; UNIV ROMA LA SAPIENZA,DIPARTIMENTO FIS,I-00185 ROME,ITALY	University of L'Aquila; CEA; Centre National de la Recherche Scientifique (CNRS); Sapienza University Rome	DellaLonga, S (corresponding author), UNIV AQUILA,DIPARTIMENTO MED SPERIMENTALE,VIA VETOIO,LOC COPPITO II,I-67100 LAQUILA,ITALY.		Bianconi, Antonio/J-3997-2013; Zarivi, Osvaldo/AAB-2150-2022; Zarivi, Osvaldo/ABG-8795-2021; Zarivi, Osvaldo/V-2939-2018; Ascone, Isabella/A-8599-2010	Bianconi, Antonio/0000-0001-9795-3913; Zarivi, Osvaldo/0000-0002-8312-9955; Zarivi, Osvaldo/0000-0002-8312-9955; della longa, stefano/0000-0002-8157-9530				BIANCONI A, 1988, TOP CURR CHEM, V145, P29; BIANCONI A, 1985, NATURE, V318, P685, DOI 10.1038/318685a0; BLACKBURN NJ, 1989, INORG CHEM, V28, P1349, DOI 10.1021/ic00306a027; BROWN JM, 1980, J AM CHEM SOC, V102, P4210, DOI 10.1021/ja00532a037; CO MS, 1981, J AM CHEM SOC, V103, P3200, DOI 10.1021/ja00401a044; CO MS, 1981, J AM CHEM SOC, V103, P984, DOI 10.1021/ja00394a066; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DELLALONGA S, 1995, PHYSICA B, V208, P743, DOI 10.1016/0921-4526(94)01020-2; DELLALONGA S, 1993, BIOPHYS J, V65, P2680, DOI 10.1016/S0006-3495(93)81330-4; DELLALONGA S, 1995, COMP MATER SCI, V4, P199, DOI 10.1016/0927-0256(95)00027-N; DELLALONGA S, 1994, EUR BIOPHYS J BIOPHY, V23, P361, DOI 10.1007/BF00188660; DOOLEY DM, 1978, P NATL ACAD SCI USA, V75, P3019, DOI 10.1073/pnas.75.7.3019; DURHAM PJ, 1982, COMPUT PHYS COMMUN, V25, P193, DOI 10.1016/0010-4655(82)90035-2; DURHAM PJ, 1988, XRAY ABSORPTION, P53; EISENSTEIN O, 1992, ARCH BIOCHEM BIOPHYS, V296, P247, DOI 10.1016/0003-9861(92)90569-I; ELLERTON HD, 1983, PROG BIOPHYS MOL BIO, V41, P143, DOI 10.1016/0079-6107(83)90028-7; FEITERS MC, 1990, COMMENTS INORG CHEM, V11, P131; FRANSSON G, 1974, ACTA CHEM SCAND A, VA 28, P578, DOI 10.3891/acta.chem.scand.28a-0578; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x; HIMMELWRIGHT RS, 1980, J AM CHEM SOC, V102, P7339, DOI 10.1021/ja00544a031; HITCHCOCK AP, 1984, J CHEM PHYS, V80, P3927, DOI 10.1063/1.447274; HONG MK, 1990, BIOPHYS J, V58, P429, DOI 10.1016/S0006-3495(90)82388-2; JIMBOW K, 1976, J INVEST DERMATOL, V67, P72, DOI 10.1111/1523-1747.ep12512500; JOLLEY RL, 1974, J BIOL CHEM, V249, P335; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; LARRABEE JA, 1980, J AM CHEM SOC, V102, P4217, DOI 10.1021/ja00532a038; LERCH K, 1983, MOL CELL BIOCHEM, V52, P125; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MAGNUS K, 1992, Journal of Inorganic Biochemistry, V47, P20, DOI 10.1016/0162-0134(92)84091-Z; MIRANDA M, 1988, BIOCHIM BIOPHYS ACTA, V966, P276, DOI 10.1016/0304-4165(88)90077-3; Natoli C. R., 1983, EXAFS and Near Edge Structures. Proceedings of the International Conference, P43; PALLADINO L, 1993, J CHEM PHYS, V98, P2720, DOI 10.1063/1.464153; PARAK F, 1987, EUR BIOPHYS J BIOPHY, V15, P237, DOI 10.1007/BF00577072; PATE JE, 1989, J AM CHEM SOC, V111, P5198, DOI 10.1021/ja00196a029; PIN S, 1994, METHOD ENZYMOL, V232, P266; ROBB DA, 1984, COPPER PROTEINS COPP, V2, P207; SALVATO B, 1990, LIFE CHEM REPORTS, V8, P1; SOLOMON EI, 1976, J AM CHEM SOC, V98, P1029, DOI 10.1021/ja00420a035; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; Volbeda A., 1986, P135; WOOLERY GL, 1984, J AM CHEM SOC, V106, P86, DOI 10.1021/ja00313a019; WOOLERY GL, 1984, BIOCHIM BIOPHYS ACTA, V788, P155, DOI 10.1016/0167-4838(84)90257-7	44	26	26	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21025	21030						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702866				2022-12-25	WOS:A1996VE47700012
J	Gaffen, SL; Lai, SY; Ha, M; Liu, XW; Henninghausen, L; Greene, WC; Goldsmith, MA				Gaffen, SL; Lai, SY; Ha, M; Liu, XW; Henninghausen, L; Greene, WC; Goldsmith, MA			Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; GAMMA-CHAIN; IL-2 RECEPTOR; CELL-PROLIFERATION; STAT PROTEINS; C-FOS; ERYTHROPOIETIN RECEPTOR; FUNCTIONAL COMPONENT; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAINS	To explore the basis for interleukin (IL)-2 receptor (IL-2R) signaling specificity, the roles of tyrosine-based sequences located within the cytoplasmic tails of the beta and gamma(c) chains were examined in the murine helper T cell line HT-2, Activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, cellular proliferation, and the induction of various genes were monitored, All four of the cytoplasmic tyrosine residues as well as the distal portion of the gamma(c) proved dispensable for the entire spectrum of IL-2R signaling responses studied. Conversely, select tyrosine residues within the beta chain were essential and differentially required for various signaling events, Specifically, activation of c-fos gene expression was found to occur exclusively through the most membrane proximal tyrosine, Tyr-338, whereas proliferation and the activation of STAT-5 were induced either through Tyr-338 or through the two C-terminal tyrosine residues, Tyr-392 and Tyr-510, These tyrosine residues mediated the induction of two different STAT-5 isoforms, which were found to form heterodimers upon receptor activation, In contrast to the tyrosine dependence of c-fos and STAT-5 induction, bcl-2 gene induction proceeded independently of all IL-2R beta tyrosine residues, Thus, the tyrosine-based modules present within the IL-2R beta cytoplasmic tail play a critical role in IL-2R signaling, mediating specificity, redundancy, and multifunctionality.	GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; NIDDK, LAB BIOCHEM & METAB, NATL INST HLTH, BETHESDA, MD 20892 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041; Hennighausen, Lothar/0000-0001-8319-9841; Lai, Stephen/0000-0001-8301-7286	NIAID NIH HHS [R01 AI36452] Funding Source: Medline; NIGMS NIH HHS [R01 GM54351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; COFFER P, 1995, ONCOGENE, V10, P985; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH M, 1994, INTERLEUKIN 2 INTERL; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUGAMURA K, 1990, LYMPHOKINE RES, V9, P539; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21381	21390		10.1074/jbc.271.35.21381	http://dx.doi.org/10.1074/jbc.271.35.21381			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702919	hybrid			2022-12-25	WOS:A1996VE47700065
J	ReifelMiller, AE; Conarty, DM; Valasek, KM; Iversen, PW; Burns, DJ; Birch, KA				ReifelMiller, AE; Conarty, DM; Valasek, KM; Iversen, PW; Burns, DJ; Birch, KA			Protein kinase C isozymes differentially regulate promoters containing PEA-3/12-O-tetradecanoylphorbol-13-acetate response element motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; PLASMINOGEN-ACTIVATOR; SIGNAL TRANSDUCTION; CELLULAR-REGULATION; COLLAGENASE GENE; MAMMALIAN-CELLS; PHORBOL-ESTER; LLC-PK1 CELLS; LAMIN-B; EXPRESSION	To investigate the regulation of promoters containing classical phorbol ester response sequences (PEA-3/12-O-tetradecanoylphorbol-13-acetate response element motifs) by protein kinase C (PRC) isozymes, co-transfections were performed in human dermal fibroblasts with a plasmid containing either the human collagenase promoter or the porcine urokinase plasminogen activator (uPA) promoter linked to the chloramphenicol acetyl-transferase gene and a plasmid expressing an individual PRC isozyme. Using this experimental design, seven PKC isozymes were analyzed for their ability to transactivate the collagenase and uPA promoters. Our results demonstrate that only PKC delta, epsilon, and eta trans-activated the collagenase promoter and that binding of Ap-l family members to the collagenase 12-O-tetradecanoylphorbol-13-acetate response element (TRE) was not responsible for the isozyme-specific trans-activation. in contrast, the uPA promoter was stimulated by all of the PKC isozymes examined (PKC alpha, beta II, gamma, delta, zeta, and eta) These results indicate that PKC isozymes differentially regulate promoters containing PEA-3/TRE motifs and suggest that individual isozymes play unique roles within the cell.	ELI LILLY & CO,LILLY RES LABS,DEPT STAT & MATH SCI,INDIANAPOLIS,IN 46285; SPHINX PHARMACEUT CORP,DURHAM,NC 27712	Eli Lilly	ReifelMiller, AE (corresponding author), ELI LILLY & CO,LILLY RES LABS,DEPT DIABET RES,BLDG 98-C,RM 2330,LILLY CORP CTR,INDIANAPOLIS,IN 46285, USA.							ABATE C, 1991, ONCOGENE, V6, P2179; ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P1761, DOI 10.1073/pnas.86.6.1761; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BIRCH KA, 1996, DIABETES, V42, P642; BORNER C, 1992, J BIOL CHEM, V267, P12892; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIERKSVENTLING C, 1989, INT J CANCER, V44, P865, DOI 10.1002/ijc.2910440520; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOODE N, 1992, J BIOL CHEM, V267, P16878; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMILTON JA, 1991, BLOOD, V77, P616; HATA A, 1993, J BIOL CHEM, V268, P9122; HE CJ, 1992, J CELL PHYSIOL, V150, P475, DOI 10.1002/jcp.1041500307; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IDO M, 1987, FEBS LETT, V219, P215, DOI 10.1016/0014-5793(87)81219-X; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KIESER A, 1995, FEBS LETT, V372, P189, DOI 10.1016/0014-5793(95)00975-F; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; NIEDBALA MJ, 1993, BLOOD, V81, P2608; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1994, J BIOL CHEM, V269, P17495; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAJABI MR, 1992, AM J OBSTET GYNECOL, V167, P194, DOI 10.1016/S0002-9378(11)91657-3; RICE JW, 1993, BIOTECHNIQUES, V15, P1052; RONDEAU E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P165, DOI 10.1016/0167-4889(90)90117-V; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	55	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21666	21671		10.1074/jbc.271.35.21666	http://dx.doi.org/10.1074/jbc.271.35.21666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702956	hybrid			2022-12-25	WOS:A1996VE47700102
J	Sasner, M; Buonanno, A				Sasner, M; Buonanno, A			Distinct N-methyl-D-aspartate receptor 2B subunit gene sequences confer neural and developmental specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMERIC NMDA RECEPTORS; TRANSGENIC MICE; RAT-BRAIN; MOLECULAR CHARACTERIZATION; NEURONAL MIGRATION; 5'-FLANKING REGION; MAMMALIAN-CELLS; MESSENGER-RNAS; I GENE; CHANNEL	Expression of the N-methyl-D-aspartate (NMDA) receptor 2B (NR2B) subunit is neural-specific and differentially regulated. It is expressed in the forebrain and in cerebellar granule cells at early postnatal stages and selectively repressed in the cerebellum after the second postnatal week, where it is replaced by the NR2C subunit. This switch confers distinct properties to the receptor. In order to understand the molecular mechanisms that differentially regulate the NR2B gene in the forebrain and cerebellum during development, we have isolated and characterized the promoter region of the NR2B gene. Two 5' noncoding exons and multiple transcription start sites were identified. Transcriptional analysis in transgenic mice reveals that an upstream 800-base pair region, which includes the first exon, is sufficient to direct neural-specific transcription. Developmental repression of the gene in the cerebellum requires additional regulatory elements residing in the first intron or second exon. Sequence elements that may participate in the regulation of the NR2B gene were identified by comparison to other neural genes. These studies provide insight into the molecular mechanisms regulating the switch of NMDA receptor subunit expression in the cerebellum, which ultimately account for the physiological changes in receptor function during development.	NICHHD,DEV NEUROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Sasner, Michael/0000-0002-6612-6111	NICHD NIH HHS [HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUDINAT E, 1994, EUR J NEUROSCI, V6, P1792, DOI 10.1111/j.1460-9568.1994.tb00572.x; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BANERJEE BS, 1993, MOL CELL BIOL, V13, P7019; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; Hogan B, 1994, MANIPULATING MOUSE E; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ishiguro H, 1995, MOL BRAIN RES, V34, P251, DOI 10.1016/0169-328X(95)00170-W; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; MADARNAS AR, 1994, MAMM GENOME, V5, P115, DOI 10.1007/BF00292339; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MOLINOFF PB, 1994, PROG BRAIN RES, V100, P39; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORAN J, 1989, BRAIN RES, V486, P15, DOI 10.1016/0006-8993(89)91272-9; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEDIVI E, 1992, J NEUROSCI, V12, P691; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; ROSSI DJ, 1993, NEUROPHARMACOLOGY, V32, P1239, DOI 10.1016/0028-3908(93)90018-X; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; Vallano ML, 1996, J NEUROSCI, V16, P631; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; WANG YH, 1995, J NEUROCHEM, V65, P176; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZHONG J, 1995, J NEUROCHEM, V64, P531; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	53	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21316	21322		10.1074/jbc.271.35.21316	http://dx.doi.org/10.1074/jbc.271.35.21316			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702910				2022-12-25	WOS:A1996VE47700056
J	Weitzmann, MN; Woodford, KJ; Usdin, K				Weitzmann, MN; Woodford, KJ; Usdin, K			The development and use of a DNA polymerase arrest assay for the evaluation of parameters affecting intrastrand tetraplex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERE-BINDING-PROTEIN; GENE; SEQUENCE; QUADRUPLEX; HAIRPIN; REGION; MODEL; ACID; CHROMOSOME; EXPRESSION	We show here that a K+-dependent block to DNA synthesis is a sensitive and specific indicator of intrastrand tetraplex formation that can be used, both to identify sequences with tetraplex-forming potential and to examine parameters that affect tetraplex formation, We show that tetraplex formation is determined by a complex combination of factors including the size and base composition of its constituent loops and stems, In the process of carrying out this study we have found that the number of sequences with the ability to form tetraplexes is larger than previously thought, and that such sequences are ubiquitous in eukaryote genomes.	NIDDK,NIH,BIOCHEM PHARMACOL LAB,SECT GENOM STRUCT & FUNCT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ABRAMSON RD, 1991, GENOMICS, V10, P126, DOI 10.1016/0888-7543(91)90492-W; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GUO Q, 1993, BIOCHEMISTRY-US, V32, P3596, DOI 10.1021/bi00065a010; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HAMMONDKOSACK MCU, 1992, J MOL ENDOCRINOL, V9, P221, DOI 10.1677/jme.0.0090221; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; Howell RM, 1996, J BIOL CHEM, V271, P5208; KANG S, 1992, J BIOL CHEM, V267, P1259; KASPAR P, 1989, NUCLEIC ACIDS RES, V17, P3616, DOI 10.1093/nar/17.9.3616; KEIME S, 1990, EUR J BIOCHEM, V190, P195, DOI 10.1111/j.1432-1033.1990.tb15564.x; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; LAU YT, 1988, SCIENCE, V240, P1321, DOI 10.1126/science.3375816; LEONARD GA, 1995, STRUCTURE, V3, P335, DOI 10.1016/S0969-2126(01)00165-4; LEWIS CD, 1988, GENE DEV, V2, P833; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; SAMADASHWILY GM, 1993, EMBO J, V12, P4975, DOI 10.1002/j.1460-2075.1993.tb06191.x; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VOLOSHIN ON, 1992, J BIOMOL STRUCT DYN, V9, P643, DOI 10.1080/07391102.1992.10507945; WARE VC, 1983, NUCLEIC ACIDS RES, V11, P7795, DOI 10.1093/nar/11.22.7795; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	37	91	95	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20958	20964		10.1074/jbc.271.34.20958	http://dx.doi.org/10.1074/jbc.271.34.20958			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702855	hybrid			2022-12-25	WOS:A1996VD33700107
J	Gaits, F; Li, RY; Bigay, J; Ragab, A; RagabThomas, JMF; Chap, H				Gaits, F; Li, RY; Bigay, J; Ragab, A; RagabThomas, JMF; Chap, H			G-protein beta gamma subunits mediate specific phosphorylation of the protein-tyrosine phosphatase SH-PTP1 induced by lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; ACTIVATED PLATELETS; THROMBIN-RECEPTOR; MAP KINASE; SH2 DOMAIN; CELLS; PATHWAY	SH-PTP1 is a protein-tyrosine phosphatase preferentially expressed in hematopoietic cells and bearing two SH2 ((s) under bar rc (h) under bar omology-(2) under bar) domains. In the human megakaryocytic cell line Dami, lysophosphatidic acid (LPA) promoted a rapid increase in SH-PTP1 phosphorylation on both serine and tyrosine residues. Only tyrosine phosphorylation was significantly inhibited by pertussis toxin and by the protein kinase C inhibitor GF109203X. Moreover, SH-PTP1 was phosphorylated upon challenge with other agonists acting via G-protein-coupled receptors such as alpha-thrombin, epinephrine, and ADP, whereas the closely related protein-tyrosine phosphatase SH-PTP2 failed to share such a regulation in Dami cells. We developed an in vitro assay that reproduced LPA-dependent phosphorylation of SH-PTP1 in a cell-free system. The fusion protein glutathione S-transferase-beta-adrenergic receptor kinase 1-(495-689) or the transducin subunit G alpha(t)-GDP, which act as specific antagonists of G beta gamma, inhibited SH-PTP1 phosphorylation. Moreover, purified transducin G beta gamma subunits mimicked the effect of LPA. Finally, stable expression of beta-adrenergic receptor kinase 1-(495-689) in Dami cells resulted in the inhibition of SH-PTP1 phosphorylation evoked by LPA. Our data thus identify SH-PTP1 as a specific target of protein kinases linked to G-protein-coupled receptors via G beta gamma subunits.	UNIV TOULOUSE 3,INST FED RECH IMMUNOL CELLULAIRE & MOL,F-31059 TOULOUSE,FRANCE; HOP PURPAN,INSERM,U326,CTR HOSP UNIV TOULOUSE,F-31059 TOULOUSE,FRANCE; CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur				Gaits-Iacovoni, Frederique/0000-0002-9853-0442; Joelle, BIGAY/0000-0002-7487-3416				AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; CHEN YH, 1994, J BIOL CHEM, V269, P27372; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FAURE M, 1994, J BIOL CHEM, V269, P7851; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LI FY, 1995, EMBO J, V14, P2519; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SALLES JP, 1993, J BIOL CHEM, V268, P12805; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZEGGARI M, 1994, BIOCHEM J, V303, P441, DOI 10.1042/bj3030441	46	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20151	20155						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8798377				2022-12-25	WOS:A1996VC66900080
J	Vater, CA; Bartle, LM; Dionne, CA; Littlewood, TD; Goldmacher, VS				Vater, CA; Bartle, LM; Dionne, CA; Littlewood, TD; Goldmacher, VS			Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53(-/-) mouse embryo fibroblasts	ONCOGENE			English	Article						p53; apoptosis; tamoxifen	WILD-TYPE P53; P53-DEPENDENT GROWTH ARREST; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; P53-DEFICIENT MICE; MUTANT P53; COLORECTAL-CARCINOMA; FUNCTION MUTATIONS; ESTROGEN-RECEPTOR; BINDING DOMAIN	A fusion gene consisting of wild-type p53 linked to a modified ligand binding domain of the murine estrogen receptor has been constructed and should be a useful tool for studying controlled activation of wild-type p53 function in a variety of experimental cell systems, The protein product of this gene, p53ER(TM), is expressed in cells constitutively but is not functional unless associated with tamoxifen or 4-hydroxytamoxifen, p53ER(TM) was introduced into p53-deficient mouse embryo fibroblasts (MEFs) expressing the EIA and T24 H-ras oncogenes, Activation of p53 in these transformed cells by the addition of tamoxifen or 4-hydroxytamoxifen resulted in apoptosis, In addition to engaging the apoptotic machinery, the tamoxifen-activated fusion protein exhibited other functions characteristic of wild-type p53, such as induction of WAF1 and MDM2 gene expression and activation of the p53-dependent spindle checkpoint in cells treated with nocodazole. Activation of p53ER(TM) expressed in p53-positive MEFs coexpressing E1A and ras had, at most, only a small cytotoxic effect, When three cell Lines of transformed p53(+/+) fibroblasts not expressing p53ER(TM) were tested for sensitivity to the DNA-damaging drug doxorubicin, the p53(+/+) clones displayed either comparable sensitivity, or at most an increase in drug sensitivity of less than fourfold, as compared to several p53(-/-) cell lines, Our data show that restoration of wild-type p53 activity is sufficient to trigger apoptosis in p53(-/-) MEFs transformed with EIA and T24 H-ras and suggest that rare propagable clones of p53-normal MEPs expressing the EIA and T24 H-ras oncogenes have suffered compensatory alterations that compromise the ability to undergo p53-dependent apoptosis.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Vater, CA (corresponding author), APOPTOSIS TECHNOL INC,148 SIDNEY ST,CAMBRIDGE,MA 02139, USA.			Goldmakher, Viktor/0000-0001-6130-4436				ALDERSON LM, 1995, CANCER RES, V55, P999; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BOND JA, 1994, ONCOGENE, V9, P1885; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHILOSI M, 1994, BLOOD, V84, P4295, DOI 10.1182/blood.V84.12.4295.bloodjournal84124295; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELROUBY S, 1993, BLOOD, V82, P3452; ESRIG D, 1994, NEW ENGL J MED, V331, P1259, DOI 10.1056/NEJM199411103311903; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, ONCOGENE, V8, P2457; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HSIAO M, 1994, AM J PATHOL, V145, P702; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OTTO A, 1993, ONCOGENE, V8, P2591; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RENZING J, 1995, ONCOGENE, V10, P1865; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; RUNNEBAUM IB, 1994, ANTICANCER RES, V14, P1137; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON TC, 1995, ONCOGENE, V10, P869; TSUKADA T, 1993, ONCOGENE, V8, P3313; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIGLER A, 1994, NATURE, V372, P773	55	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					739	748						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761295				2022-12-25	WOS:A1996VD43300009
J	Geimonen, E; Jiang, W; Ali, M; Fishman, GI; Garfield, RE; Andersen, J				Geimonen, E; Jiang, W; Ali, M; Fishman, GI; Garfield, RE; Andersen, J			Activation of protein kinase C in human uterine smooth muscle induces connexin-43 gene transcription through an AP-1 site in the promoter sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U937 LEUKEMIC-CELLS; DNA-BINDING; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; REGULATORY ELEMENTS; INDUCIBLE ENHANCER; ESTROGEN-RECEPTOR; HUMAN MYOMETRIUM; PRETERM LABOR; GAP-JUNCTIONS	Myometrial connexin-43 gap junctions are scarce throughout gestation but appear in large numbers at term to facilitate contractions during labor, The mechanisms that regulate this process are incompletely characterized. This report investigates the effects of protein kinase C activation on the regulation of connexin-43 gene transcription in human uterine smooth muscle cells. In primary myometrial cells treated with phorbol ester, transient increases in c-Fos and c-Jun protein levels were observed at 2-4 h, followed by significant increases in connexin-43 protein levels at 6-8 h. Nuclear run on transcription analysis showed an increase in connexin-43 transcription 3 h after phorbol ester treatment. AP-1 sites were identified in the sequence of the 5'-flanking promoter region of the human connexin-43 gene at 44 and 1000 base pairs upstream of transcription start. Transcription from a reporter plasmid containing the proximal human connexin-43 promoter was increased in transfected primary cultures treated with phorbol ester. Mutation of the proximal AP-1 site in the promoter abolished the phorbol ester dependent transactivation. This work provides evidence that transcription of the human connexin-43 gene is induced through protein kinase C activation in uterine smooth muscle cells, and that the induction involves up-regulation and activation of c-Jun and c-Fos.	SUNY STONY BROOK,SCH MED,DEPT OBSTET GYNECOL & REPROD MED,STONY BROOK,NY 11794; UNIV TEXAS,MED BRANCH,DEPT OBSTET & GYNECOL,GALVESTON,TX 77555; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,SECT MOL CARDIOL,BRONX,NY 10461	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Medical Branch Galveston; Yeshiva University; Albert Einstein College of Medicine				Fishman, Glenn/0000-0002-2366-8527	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030482] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002391] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02391] Funding Source: Medline; NICHD NIH HHS [HD 30482] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMBROSINO C, 1993, MOL ENDOCRINOL, V7, P1472, DOI 10.1210/me.7.11.1472; ANDERSEN J, 1995, J SOC GYNECOL INVEST, V2, P663, DOI 10.1016/1071-5576(95)00021-6; ANDERSEN J, 1993, AM J OBSTET GYNECOL, V169, P1266, DOI 10.1016/0002-9378(93)90293-R; ANDERSEN J, 1995, J SOC GYNECOL INVEST, V2, P542, DOI 10.1016/1071-5576(94)00053-4; AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P8; BALDUCCI J, 1993, AM J OBSTET GYNECOL, V168, P1609, DOI 10.1016/S0002-9378(11)90806-0; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; CHEN ZQ, 1995, J BIOL CHEM, V270, P3863, DOI 10.1074/jbc.270.8.4088; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAIREWATHES DC, 1982, J REPROD FERTIL, V65, P497; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAHL E, 1995, ANAT EMBRYOL, V191, P267; DELEON JR, 1994, J MOL CELL CARDIOL, V26, P379, DOI 10.1006/jmcc.1994.1047; DONAHUE HJ, 1995, J BONE MINER RES, V10, P881; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Garfield R.E., 1985, P143; GARFIELD RE, 1982, AM J OBSTET GYNECOL, V142, P21; GARFIELD RE, 1977, SCIENCE, V198, P958, DOI 10.1126/science.929182; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GOODENOUGH DA, 1975, COLD SPRING HARB SYM, V40, P37, DOI 10.1101/SQB.1976.040.01.006; HENDRIX EM, 1992, MOL REPROD DEV, V33, P27, DOI 10.1002/mrd.1080330105; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHAN SA, 1994, PROTOONCOGENES GROWT, P105; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; MACKENZIE LW, 1986, CAN J PHYSIOL PHARM, V64, P462, DOI 10.1139/y86-074; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NEPHEW KP, 1995, ENDOCRINOLOGY, V136, P3007, DOI 10.1210/en.136.7.3007; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; Salmi A, 1996, MOL CELL ENDOCRINOL, V117, P233, DOI 10.1016/0303-7207(95)03759-4; Sambrook J., 1989, MOL CLONING LAB MANU, P15; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SPELSBERG TC, 1994, PROTOONCOGENES GROWT, P69; STANCEL GM, 1994, PROTOONCOGENES GROWT, P87; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU W, 1994, P ROY SOC B-BIOL SCI, V255, P125, DOI 10.1098/rspb.1994.0018; Zhao K, 1996, BIOL REPROD, V54, P607, DOI 10.1095/biolreprod54.3.607	55	120	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23667	23674		10.1074/jbc.271.39.23667	http://dx.doi.org/10.1074/jbc.271.39.23667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798588	hybrid			2022-12-25	WOS:A1996VJ44200017
J	Roy, R; Kumar, A; Lee, JC; Mitra, S				Roy, R; Kumar, A; Lee, JC; Mitra, S			The domains of mammalian base excision repair enzyme N-methylpurine-DNA glycosylase - Interaction, conformational change, and role in DNA binding and damage recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL FRAGMENT; ESCHERICHIA-COLI; VINYL-CHLORIDE; 3-METHYLADENINE-DNA GLYCOSYLASE; LIMITED PROTEOLYSIS; ALKYLATING-AGENTS; ADAPTIVE RESPONSE; STRUCTURAL BASIS; POLYMERASE-BETA; GENE MAPS	Repair of a variety of alkylated base adducts in DNA is initiated by their removal by N-methylpurine-DNA glycosylase. The 31-kDa mouse N-methylpurine-DNA glycosylase, derived by deletion of 48 amino acid residues from the 333-residue wild type protein without loss of activity, was analyzed for the presence of protease-resistant domains with specific roles in substrate binding and catalysis. Increasing proteolysis with trypsin generated first a 29-kDa polypeptide by removal of 42 amino-terminal residues, followed by production of 8-, 6-, and 13-kDa fragments with defined, nonoverlapping boundaries. The 8- and 13-kDa domains include the amino and carboxyl termini, respectively. Based on DNA-affinity chromatography and the protease protection assay, it appears that the 6- and 13-kDa domains are necessary for nontarget DNA binding and that the 8-kDa domain, in cooperation with the other two domains, participates in recognition of damaged bases. Furthermore, chemical cross-linking studies indicated that, in the presence of substrate DNA, the 8- and 6-kDa domains undergo conformational changes reflected by both protection from proteolysis and reduced availability of cysteine residues for the thiol-exchange reaction.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston			Lee, James C/A-7849-2009		NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [CA53791] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHENG KC, 1991, P NATL ACAD SCI USA, V88, P9974, DOI 10.1073/pnas.88.22.9974; CHENG KC, 1992, J BIOL CHEM, V267, P166; COOPER LP, 1994, J MOL BIOL, V236, P1011, DOI 10.1016/0022-2836(94)90008-6; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRIEDBERG FC, 1995, DNA REPAIR MUTAGENES; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILBERT W, 1993, GENE, V135, P137, DOI 10.1016/0378-1119(93)90058-B; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; JANIN J, 1985, METHOD ENZYMOL, V115, P420; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KASAI H, 1991, OXIDATIVE STRESS OXI; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; PURCHASE IFH, 1987, FOOD CHEM TOXICOL, V25, P187, DOI 10.1016/0278-6915(87)90153-0; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2940, DOI 10.1021/bi00225a030; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; ROY R, 1996, IN PRESS CARCINOGENE; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VITA C, 1989, EUR J BIOCHEM, V183, P513, DOI 10.1111/j.1432-1033.1989.tb21079.x; VOLKERT MR, 1988, ENVIRON MOL MUTAGEN, V11, P241, DOI 10.1002/em.2850110210; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	53	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23690	23697		10.1074/jbc.271.39.23690	http://dx.doi.org/10.1074/jbc.271.39.23690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798591	hybrid			2022-12-25	WOS:A1996VJ44200020
J	Behrens, TW; Kearns, GM; Rivard, JJ; Bernstein, HD; Yewdell, JW; Staudt, LM				Behrens, TW; Kearns, GM; Rivard, JJ; Bernstein, HD; Yewdell, JW; Staudt, LM			Carboxyl-terminal targeting and novel post-translational processing of JAW1, a lymphoid protein of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; TRANSMEMBRANE PROTEINS; MEMBRANE-PROTEINS; MICROSOMAL-MEMBRANES; MAMMALIAN-CELLS; TRANSLOCATION; SEQUENCE; TRANSPORT; RETENTION; RESIDUES	Jaw1 is a lymphoid-restricted protein localized to the cytoplasmic face of the endoplasmic reticulum (ER) and is a member of a recently recognized class of integral membrane proteins that contain carboxyl-terminal membrane anchors. The carboxyl-terminal 71 amino acids of the Jaw1 protein, which contain a hydrophobic membrane spanning region, are sufficient to target a heterologous protein to the ER. By discontinuous sucrose gradient ultracentrifugation, differential sedimentation was noted for the four major Jaw1 protein isoforms, with two of the forms predominantly soluble and two microsome-bound. Pulse-chase immunoprecipitations suggest a post translational modification of two major isoforms of the protein resulting in an increase in mobility on SDS-polyacrylamide gel electrophoresis. In. vitro translation studies are compatible with a posttranslational processing event that results in cleavage of a short 36 amino acid lumenal domain. These findings define a carboxyl-terminal domain of the Jaw1 protein that is both necessary and sufficient for ER localization. In addition, the processing of the small lumenal domain of Jaw1 represents a novel post-translational protein modification performed by the endoplasmic reticulum.	NCI,METAB BRANCH,BETHESDA,MD 20892; NIDDK,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NIH,VIRAL DIS LAB,NIAID,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Behrens, TW (corresponding author), UNIV MINNESOTA,SCH MED,UMHC,DEPT MED,BOX 108,515 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.		Staudt, Louis/AAC-5324-2019; yewdell, jyewdell@nih.gov jonathan/A-1702-2012		NIAMS NIH HHS [AR01959] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001959] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; BEHRENS TW, 1994, J IMMUNOL, V153, P682; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, J CELL SCI, V105, P481; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JANTTI J, 1994, J CELL SCI, V107, P3623; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Simon S, 1993, CURR OPIN CELL BIOL, V5, P581, DOI 10.1016/0955-0674(93)90126-B; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113	37	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23528	23534		10.1074/jbc.271.38.23528	http://dx.doi.org/10.1074/jbc.271.38.23528			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798562	hybrid			2022-12-25	WOS:A1996VH76800088
J	Samkurashvili, I; Luse, DS				Samkurashvili, I; Luse, DS			Translocation and transcriptional arrest during transcript elongation by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEXES; FACTOR-SII; TERMINATION; CLEAVAGE; INVITRO; DNA; TEMPLATES; TFIIS	RNA polymerase II may stop transcription, or arrest, while transcribing certain DNA sequences. The molecular basis for arrest is not well understood, but a connection has been suggested between arrest and a transient failure of the polymerase to translocate along the template. We have investigated this question by monitoring the movement of RNA polymerase II along a number of templates, using exonuclease III protection as our assay. We found that normal transcription is accompanied by essentially coordinate movement of the active site and both the leading and trailing edges of the polymerase. However, as polymerase approaches an arrest site, translocation of the body of the polymerase stops while transcription continues, leading to an arrested complex in which the 3' end of the transcript is located much closer than normal to the front edge of the polymerase. Surprisingly, mutated arrest sites that no longer block transcription continue to direct the transient failure of polymerase translocation. As transcription proceeds through these sequences, the initially stationary polymerase moves forward 10-15 bases along the template in response to the addition of only 3 bases to the nascent RNA. Mutagenesis studies indicate that the sequences responsible for the transient block to polymerase movement are located downstream of the T-rich motif required for arrest, Our results indicate that blocking translocation is not sufficient to cause arrest.	CLEVELAND CLIN FDN,DEPT MOL BIOL,RES INST,CLEVELAND,OH 44195; UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; GU WG, 1993, J BIOL CHEM, V268, P25604; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SPENCER CA, 1990, ONCOGENE, V5, P777; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	26	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23495	23505		10.1074/jbc.271.38.23495	http://dx.doi.org/10.1074/jbc.271.38.23495			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798558	hybrid			2022-12-25	WOS:A1996VH76800084
J	ONeill, MA; Warrenfeltz, D; Kates, K; Pellerin, P; Doco, T; Darvill, AG; Albersheim, P				ONeill, MA; Warrenfeltz, D; Kates, K; Pellerin, P; Doco, T; Darvill, AG; Albersheim, P			Rhamnogalacturonan-II, a pectic polysaccharide in the walls of growing plant cell, forms a dimer that is covalently cross-linked by a borate ester - In vitro conditions for the formation and hydrolysis of the dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CHARACTERIZATION; MAGNETIC-RESONANCE; TOBACCO CELLS; GROWTH; BORON; ACID; LOCALIZATION; SPECTROSCOPY; ELONGATION; STABILITY	Rhamnogalacturonan II (RG-II) is a structurally complex pectic polysaccharide present in the walls of growing plant cells. We now report that RG-II, released by endopolygalacturonase treatment of the walls of suspension-cultured sycamore cells and etiolated pea stems, exists mainly as a dimer that is cross-linked by a borate ester. The borate ester is completely hydrolyzed at room temperature within 30 min at pH 1, partially hydrolyzed between pH 2 and 4, and stable above pH 4. The dimer is formed in vitro between pH 2.4 and 6.2 by treating monomeric RG-II (0.5 mM) with boric acid (1.2 mM); the dimer formed after 24 h at pH 3.4 and 5.0 accounts for similar to 30 and similar to 5%, respectively, of the RG-II. In contrast, the dimer accounts for similar to 80 and similar to 54% of the RG-II when the monomer is treated for 24 h at pH 3.4 and 5.0, respectively, with boric acid and 0.5 mM Sr2+, Pb2+, or Ba2+, The amount of dimer formed at pH 3.4 or 5.0 is not increased by addition of 0.5 mM Ca2+, Cd2+, Cu2+, Mg2+, Ni2+, and Zn2+. Steric considerations appear to regulate dimer formation since those divalent cations that enhance dimer formation have an ionic radius >1.1 Angstrom. Our data suggest that the borate ester is located on C-2 and C-3 of two of the four 3'-linked apiosyl residues of dimeric RG-II, Our results, taken together with the results of two previous studies (Kobayashi, M., Matoh, T., and Azuma, J.-I. (1996) Plant Physiol. 110, 1017-1020; Ishii, T., and Matsunaga, T. (1996) Carbohydr. Res. 284, 1-9) provide substantial evidence that this plant cell wall pectic polysaccharide is covalently cross-linked.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; INRA, INST PROD VIGNE, LAB POLYMERES & TECH PHYSICOCHIM, F-34060 MONTPELLIER, FRANCE	University System of Georgia; University of Georgia; INRAE	ONeill, MA (corresponding author), UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, 220 RIVERBEND RD, ATHENS, GA 30602 USA.			Doco, Thierry/0000-0002-1453-8683				ALBERSHEIM P, 1975, SCI AM, V232, P81; BARONEPEL O, 1988, PLANTA, V175, P389, DOI 10.1007/BF00396345; BROWN JA, 1993, PLANT PHYSIOL, V103, P993, DOI 10.1104/pp.103.3.993; BROWN PH, 1994, PHYSIOL PLANTARUM, V91, P435, DOI 10.1111/j.1399-3054.1994.tb02971.x; CALDEIRA MM, 1994, INORG CHIM ACTA, V221, P69; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; COSGROVE DJ, 1993, PLANT PHYSIOL, V102, P1, DOI 10.1104/pp.102.1.1; COSGROVE DJ, 1993, NEW PHYTOL, V124, P1, DOI 10.1111/j.1469-8137.1993.tb03795.x; DARVILL AG, 1978, PLANT PHYSIOL, V62, P418, DOI 10.1104/pp.62.3.418; Deuel H., 1954, NATURAL PLANT HYDROC, P51, DOI [10.1021/ba-1954-0011.ch009, DOI 10.1021/BA-1954-0011.CH009]; DOCO T, 1993, CARBOHYD RES, V243, P333, DOI 10.1016/0008-6215(93)87037-S; DRAKE LR, 1996, ANAL CHEM, V69, pA22; HU HI, 1994, PLANT PHYSIOL, V105, P681, DOI 10.1104/pp.105.2.681; Hu HN, 1996, J EXP BOT, V47, P227, DOI 10.1093/jxb/47.2.227; Ishii T, 1996, CARBOHYD RES, V284, P1, DOI 10.1016/0008-6215(96)00010-9; JACKSON PJ, 1990, J ENVIRON QUAL, V19, P644, DOI 10.2134/jeq1990.00472425001900040003x; KEEGSTRA K, 1973, PLANT PHYSIOL, V51, P188, DOI 10.1104/pp.51.1.188; KIM JB, 1992, PLANT PHYSIOL, V98, P646, DOI 10.1104/pp.98.2.646; Kobayashi M, 1996, PLANT PHYSIOL, V110, P1017, DOI 10.1104/pp.110.3.1017; KUTSCHERA U, 1994, NEW PHYTOL, V126, P549, DOI 10.1111/j.1469-8137.1994.tb02951.x; LOOMIS WD, 1992, BIOFACTORS, V3, P229; MAKKEE M, 1985, RECL TRAV CHIM PAY B, V104, P230; MARFA V, 1991, PLANT J, V1, P217, DOI 10.1111/j.1365-313X.1991.00217.x; MATOH T, 1993, PLANT CELL PHYSIOL, V34, P639; MCCANN MC, 1994, PLANT J, V5, P773, DOI 10.1046/j.1365-313X.1994.5060773.x; McCann MC, 1991, CYTOSKELETAL BASIS P, P109; MOHR MD, 1995, RAPID COMMUN MASS SP, V9, P809, DOI 10.1002/rcm.1290090919; ONEILL MA, 1991, METHODS PLANT BIOCH, V2, P415; PELLERIN P, 1996, IN PRESS CARBOHYDR R; PETERS JA, 1983, RECL TRAV CHIM PAY B, V102, P381; RAYLE DL, 1992, PLANT PHYSIOL, V99, P1271, DOI 10.1104/pp.99.4.1271; REDGWELL RJ, 1991, CARBOHYD RES, V209, P191, DOI 10.1016/0008-6215(91)80156-H; SALT DE, 1995, BIO-TECHNOL, V13, P468, DOI 10.1038/nbt0595-468; SHELP BJ, 1995, PHYSIOL PLANTARUM, V94, P356, DOI 10.1111/j.1399-3054.1995.tb05323.x; SPELLMAN MW, 1983, CARBOHYD RES, V122, P131, DOI 10.1016/0008-6215(83)88413-4; STEVENSON TT, 1988, CARBOHYD RES, V182, P207, DOI 10.1016/0008-6215(88)84004-7; THOMAS JR, 1987, PLANT PHYSIOL, V83, P659, DOI 10.1104/pp.83.3.659; THOMAS JR, 1989, CARBOHYD RES, V185, P261, DOI 10.1016/0008-6215(89)80041-2; VANDENBERG R, 1994, CARBOHYD RES, V253, P1, DOI 10.1016/0008-6215(94)80050-2; VANDUIN M, 1984, TETRAHEDRON, V40, P2901, DOI 10.1016/S0040-4020(01)91300-6; Weast R. C., 1983, HDB CHEM PHYS, pF; WELCH RM, 1995, CRIT REV PLANT SCI, V14, P49, DOI 10.1080/713608066; WHITCOMBE AJ, 1995, CARBOHYD RES, V271, P15, DOI 10.1016/0008-6215(94)00002-W; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	44	402	424	3	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22923	22930		10.1074/jbc.271.37.22923	http://dx.doi.org/10.1074/jbc.271.37.22923			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798473	hybrid, Green Published			2022-12-25	WOS:A1996VG67200092
J	Petrovic, N; Black, TA; Fabian, JR; Kane, C; Jones, CA; Loudon, JA; Abonia, JP; Sigmund, CD; Gross, KW				Petrovic, N; Black, TA; Fabian, JR; Kane, C; Jones, CA; Loudon, JA; Abonia, JP; Sigmund, CD; Gross, KW			Role of proximal promoter elements in regulation of renin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; MAMMALIAN-CELLS; CULTURED-CELLS; FACTOR PIT-1; REN-2 GENE; MOUSE; DNA; IDENTIFICATION; PROTEIN	Mouse As4.1 cells, obtained after transgene-targeted oncogenesis to induce neoplasia in renal renin-expressing cells, express high levels of renin mRNA from the endogenous Ren-1(c) gene. We have used these cells to characterize the role of the Ren-lc proximal promoter (+6 to -117) in the regulation of renin gene transcription. It was found that 4.1 kilobases (kb) of Ren-1(c) 5'-flanking sequence, in combination with the proximal promoter, are required for strong activation (similar to 2 orders of magnitude over the basal level of the promoter alone) of the chloramphenicol acetyltransferase reporter in transfection assays. Within the 4.1-kb fragment, a 241-base pair region was identified that retains full activity in an orientation-independent manner in combination with the promoter. The resulting transcripts initiate at the normal renin start site. Electrophoretic mobility shift assays identified a sequence at approximately position -60 in the promoter region that binds nuclear proteins specific for renin-expressing As4.1 cells. Mutations in this sequence, which disrupt binding of nuclear protein(s), completely abolish activation of transcription by the 4.1-kb fragment. Activation of transcription by the 241-base pair enhancer was still observed, although it was diminished in magnitude (60-fold over the mutated promoter alone). We present a model derived from the current data that suggests that regulation of renin expression is achieved through cooperation of transcription factors binding at the proximal promoter element and a distal enhancer element to abrogate or override the effects of an intervening negative regulatory region.	ROSWELL PK CANC INST, DEPT MOL & CELLULAR BIOL, BUFFALO, NY 14263 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, DIV CARDIOVASC DIS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Roswell Park Cancer Institute; University of Iowa; University of Iowa			Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459, R01HL035792] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056] Funding Source: Medline; NHLBI NIH HHS [HL35792, HL48459] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARRETT G, 1992, P NATL ACAD SCI USA, V89, P885, DOI 10.1073/pnas.89.3.885; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURT DW, 1989, J BIOL CHEM, V264, P7357; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; EKKER M, 1989, P NATL ACAD SCI USA, V86, P5155, DOI 10.1073/pnas.86.13.5155; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; FIELD LJ, 1984, HYPERTENSION, V6, P597, DOI 10.1161/01.HYP.6.4.597; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; FIELD LJ, 1984, MOL CELL BIOL, V4, P2321, DOI 10.1128/MCB.4.11.2321; GILBERT MT, 1994, J BIOL CHEM, V269, P28049; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF900, DOI 10.1152/ajprenal.1988.254.6.F900; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF582, DOI 10.1152/ajprenal.1988.254.4.F582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; HARTROFT PM, 1963, CIRC RES, V12, P525, DOI 10.1161/01.RES.12.5.525; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURTZ A, 1989, REV PHYSIOL BIOCH P, V113, P1; LINDOP GBM, 1986, HISTOPATHOLOGY, V10, P335, DOI 10.1111/j.1365-2559.1986.tb02489.x; MILLER CCJ, 1989, NUCLEIC ACIDS RES, V17, P3117, DOI 10.1093/nar/17.8.3117; MULLINS JJ, 1982, EMBO J, V1, P1461, DOI 10.1002/j.1460-2075.1982.tb01338.x; MULLINS JJ, 1989, EMBO J, V8, P4065, DOI 10.1002/j.1460-2075.1989.tb08590.x; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PANTHIER JJ, 1982, EMBO J, V1, P1417, DOI 10.1002/j.1460-2075.1982.tb01332.x; PHILBRICK WM, 1989, LIFE SCI ADV MOL GEN, V8, P21; PICCINI N, 1982, CELL, V30, P205, DOI 10.1016/0092-8674(82)90026-5; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; SIGMUND CD, 1990, P NATL ACAD SCI USA, V87, P7993, DOI 10.1073/pnas.87.20.7993; SIGMUND CD, 1991, AM J PHYSIOL, V260, pF249, DOI 10.1152/ajprenal.1991.260.2.F249; SMITH DL, 1991, MOL CELL ENDOCRINOL, V80, P139, DOI 10.1016/0303-7207(91)90150-Q; SOLA C, 1989, ONCOGENE RES, V5, P149; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SOUBRIER F, 1986, GENE, V41, P85, DOI 10.1016/0378-1119(86)90270-2; SUGIYAMA F, 1993, J VET MED SCI, V55, P537, DOI 10.1292/jvms.55.537; SUN JD, 1993, J BIOL CHEM, V268, P1505; SUN JD, 1994, CIRC RES, V75, P624, DOI 10.1161/01.RES.75.4.624; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TAMURA K, 1994, J CLIN INVEST, V94, P1959, DOI 10.1172/JCI117547; TRONIK D, 1987, EMBO J, V6, P983, DOI 10.1002/j.1460-2075.1987.tb04848.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156	54	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22499	22505		10.1074/jbc.271.37.22499	http://dx.doi.org/10.1074/jbc.271.37.22499			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798416	hybrid			2022-12-25	WOS:A1996VG67200035
J	Silve, S; Dupuy, PH; LabitLebouteiller, C; Kaghad, M; Chalon, P; Rahier, A; Taton, M; Lupker, J; Shire, D; Loison, G				Silve, S; Dupuy, PH; LabitLebouteiller, C; Kaghad, M; Chalon, P; Rahier, A; Taton, M; Lupker, J; Shire, D; Loison, G			Emopamil-binding protein, a mammalian protein that binds a series of structurally diverse neuroprotective agents, exhibits Delta 8-Delta 7 sterol isomerase activity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGEN USTILAGO-MAYDIS; SIGMA-RECEPTOR LIGAND; GUINEA-PIG LIVER; CHOLESTEROL-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ERG2 GENE; INHIBITION; FENPROPIMORPH	Delta 8-Delta 7 sterol isomerase is an essential enzyme on the sterol biosynthesis pathway in eukaryotes. This endoplasmic reticulum-resident membrane protein catalyzes the conversion of Delta 8-sterols to their corresponding Delta 7-isomers, No sequence data for high eukaryote sterol isomerase being available so far, we have cloned a murine sterol isomerase-encoding cDNA by functional complementation of the corresponding deficiency in the yeast. Saccharomyces cerevisiae. The amino acid sequence deduced from the cDNA open reading frame is highly similar to human emopamil-binding protein (EBP), a protein of unknown function that constitutes a molecular target for neuroprotective drugs. A yeast strain in which the sterol isomerase coding sequence has been replaced by that of human EBP or its murine homologue recovers the ability to convert Delta 8-sterol into Delta 7-sterol, both in vivo and in vitro. In these recombinant strains, both cell proliferation and the sterol isomerization reaction are inhibited by the high affinity EBP ligand trifluoperazine, as is the case in mammalian cells but not in wild type yeast cell. In contrast, the recombinant strains are much less susceptible to the sterol inhibition effect of haloperidol and fenpropimorph, as compared with wild type yeast strains, Our results strongly suggest that EBP and Delta 8-Delta 7 sterol isomerase are identical proteins in mammals.	SANOFI RECH,DEPT MICROBIOL,F-31676 LABEGE,FRANCE; SANOFI RECH,DEPT ANIM CELL TECHNOL,F-31676 LABEGE,FRANCE; SANOFI RECH,DEPT GENE MOL BIOL,F-31676 LABEGE,FRANCE; SANOFI RECH,DEPT ORGAN CHEM,F-31676 LABEGE,FRANCE; INST BOT,DEPT CELLULAR & MOL ENZYMOL,F-67083 STRASBOURG,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								ARTHINGTON BA, 1991, GENE, V107, P173, DOI 10.1016/0378-1119(91)90314-2; ASHMAN WH, 1991, LIPIDS, V26, P628, DOI 10.1007/BF02536427; BAILEY AM, 1994, EXP MYCOL, V18, P87, DOI 10.1006/emyc.1994.1009; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALOCH RI, 1987, PHYTOCHEMISTRY, V26, P663, DOI 10.1016/S0031-9422(00)84762-7; Bergeron R, 1996, J NEUROSCI, V16, P1193; CIGAN AM, 1987, GENE, V59, P1; CORIOCOSTET MF, 1988, BIOCHEM J, V256, P829, DOI 10.1042/bj2560829; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P317; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HAYASGU T, 1993, J PHARMACOL EXP THER, V267, P1423; KANG MK, 1995, J BIOCHEM-TOKYO, V117, P819, DOI 10.1093/oxfordjournals.jbchem.a124781; KAY G, 1983, BIOCHEM BIOPH RES CO, V110, P82, DOI 10.1016/0006-291X(83)91263-9; KEON JPR, 1994, CURR GENET, V25, P531, DOI 10.1007/BF00351674; Klette KL, 1995, BRAIN RES, V704, P31, DOI 10.1016/0006-8993(95)01103-X; LESAGE AS, 1995, SYNAPSE, V20, P156, DOI 10.1002/syn.890200210; MARCIREAU C, 1992, CURR GENET, V22, P267, DOI 10.1007/BF00317919; MARCIREAU C, 1990, ANTIMICROB AGENTS CH, V34, P989, DOI 10.1128/AAC.34.6.989; MOEBIUS FF, 1994, J BIOL CHEM, V269, P29314; MOEBIUS FF, 1993, MOL PHARMACOL, V44, P966; MOEBIUS FF, 1993, MOL PHARMACOL, V43, P139; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; OGORODNIKA TE, 1988, GENETIKA, V24, P1367; ONEILL M, 1995, EUR J PHARMACOL, V283, P217, DOI 10.1016/0014-2999(95)00356-P; PAIK YK, 1986, J BIOL CHEM, V261, P6470; POPJAK G, 1989, J BIOL CHEM, V264, P6230; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; Sambrook J., 2002, MOL CLONING LAB MANU; Silve S, 1996, MOL CELL BIOL, V16, P2719; SU TP, 1991, EUR J BIOCHEM, V200, P633, DOI 10.1111/j.1432-1033.1991.tb16226.x; TAKAHASHI H, 1995, STROKE, V26, P1676, DOI 10.1161/01.STR.26.9.1676; VANSICKLE WA, 1993, J PHARMACOL EXP THER, V267, P1243; YAMAGA N, 1978, J LIPID RES, V19, P375	36	108	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22434	22440		10.1074/jbc.271.37.22434	http://dx.doi.org/10.1074/jbc.271.37.22434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798407				2022-12-25	WOS:A1996VG67200026
J	Clarke, EM; Peterson, CL; Brainard, AV; Riggs, DI				Clarke, EM; Peterson, CL; Brainard, AV; Riggs, DI			Regulation of the RNA polymerase I and III transcription systems in response to growth conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TIF-IA; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; HORMONAL-REGULATION; GENE-TRANSCRIPTION; 5S RNA; MEDIATED TRANSCRIPTION; CELL-DIFFERENTIATION; PHORBOL ESTER; YEAST-CELLS	To better understand the mechanisms that regulate stable RNA synthesis, we have analyzed the RNA polymerase I and III transcriptional activities of extracts isolated from cells propagated under a variety of conditions, Under balanced growth conditions the levels of both RNA polymerase I- and III-specific transcription increased proportionally with growth rate, Upon nutritional starvation, RNA polymerase I transcription rapidly declined, followed by 5 S rDNA and eventually tDNA transcription, Transcriptional activities in extracts were restored when the nongrowing cultures were resuspended in fresh medium, although growth did not resume. The differential expression of 5 S rDNA and tDNA genes in extracts prepared from cells subjected to partial starvation was traced to a 5 S rDNA-specific inhibitor and not to a defect in any RNA polymerase III transcription factor. Characterization of this inhibitor indicated that it was not 5 S rRNA. It was sensitive to phenol extraction and resistant to RNase, and its target did not appear to be transcription factor IIIA. Not all treatments that slowed or stopped growth down-regulated the stable RNA transcription apparatus, Cells that have been subjected to either energy starvation or cycloheximide treatment still retain the ability to synthesize stable RNA in vitro, suggesting the presence of alternative regulatory mechanisms.	UNIV OKLAHOMA,DEPT BOT & MICROBIOL,NORMAN,OK 73019	University of Oklahoma System; University of Oklahoma - Norman					NIGMS NIH HHS [GM47881] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047881] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BROW DA, 1987, J BIOL CHEM, V262, P13953; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1983, J BIOL CHEM, V258, P9768; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3880, DOI 10.1128/MCB.7.11.3880; GARBER M, 1991, J BIOL CHEM, V266, P20598; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GRANOT D, 1993, YEAST, V9, P465, DOI 10.1002/yea.320090503; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; GRUMMT I, 1981, P NATL ACAD SCI-BIOL, V78, P727, DOI 10.1073/pnas.78.2.727; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KERMEKCHIEV M, 1993, NUCLEIC ACIDS RES, V21, P447, DOI 10.1093/nar/21.3.447; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LUDWIG JR, 1977, MOL GEN GENET, V158, P117; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16244; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MATTHEWS JL, 1995, MOL CELL BIOL, V15, P3327; MCGOLDRICK EM, 1989, J GEN MICROBIOL, V135, P2407; OLIVER SG, 1977, MOL GEN GENET, V154, P145, DOI 10.1007/BF00330830; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PAULE MR, 1993, TRANSCRIPTION, P83; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; REEDER RH, 1992, TRANSCRIPTIONAL REGU, V1, P315; RIGGS DL, 1995, J BIOL CHEM, V270, P6205, DOI 10.1074/jbc.270.11.6205; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SETHY I, 1995, J BIOL CHEM, V270, P28463; SHULMAN RW, 1977, J BIOL CHEM, V252, P1344; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VALLETT SM, 1993, MOL CELL BIOL, V13, P928, DOI 10.1128/MCB.13.2.928; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WALDRON C, 1977, J GEN MICROBIOL, V98, P215, DOI 10.1099/00221287-98-1-215; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983	45	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22189	22195		10.1074/jbc.271.36.22189	http://dx.doi.org/10.1074/jbc.271.36.22189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703032	hybrid			2022-12-25	WOS:A1996VF61200074
J	Fourier, TM; Kamikura, D; Teng, K; Park, M				Fourier, TM; Kamikura, D; Teng, K; Park, M			Branching tubulogenesis but not scatter of Madin-Darby canine kidney cells requires a functional Grb2 binding site in the met receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-CELLS; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; SH2 DOMAINS; MOTILITY; RAS	Hepatocyte growth factor is a multifunctional cytokine that induces mitogenesis, motility, invasion, and branching tubulogenesis of several epithelial and endothelial cell lines in culture. The receptor for hepatocyte growth factor has been identified as the Met tyrosine kinase, To investigate the signaling pathways that are involved in these events, we have generated chimeric receptors containing the colony stimulating factor-1 receptor fused to the transmembrane and intracellular domains of the Met receptor. Madin-Darby canine kidney epithelial cells expressing the Met chimera dissociate scatter and form branching tubules in response to colony stimulating factor-1. From structure-function analyses, tyrosine residue 1356 within the carboxyl terminus of the Met receptor is critical for these events. The amino acid sequence downstream from tyrosine 1356 represents a consensus binding site for the Grb2 adaptor protein and forms a multisubstrate binding site for the p85 subunit of phosphatidylinositol 3-kinase, phospholipase C gamma, and the Shc adaptor protein. To distinguish which of these signaling pathways are required, we generated a mutant receptor that selectively fails to associate with the Grb2 adaptor protein. Cells expressing this mutant receptor scattered but were unable to form branching tubules, indicating that a Grb2 binding site in the Met receptor is critical for morphogenic responses.	MCGILL UNIV, ROYAL VICTORIA HOSP, MOL ONCOL GRP, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, MOL ONCOL GRP, DEPT MED, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, MOL ONCOL GRP, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital								BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; FALETTO DL, 1989, HEPATOCYTE GROWTH FA, P107; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALABAN R, 1992, ONCOGENE, V7, P2195; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KOMADA M, 1993, ONCOGENE, V8, P2381; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1993, EXS, V65, P225; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAISHI K, 1994, ONCOGENE, V9, P273; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	61	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22211	22217		10.1074/jbc.271.36.22211	http://dx.doi.org/10.1074/jbc.271.36.22211			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703035	hybrid			2022-12-25	WOS:A1996VF61200077
J	Kohn, AD; Takeuchi, F; Roth, RA				Kohn, AD; Takeuchi, F; Roth, RA			Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL; REGION	Akt is a serine/threonine kinase that is stimulated by receptor tyrosine kinases and contains a pleckstrin homology domain. One model proposed to explain this activation suggests that receptor tyrosine kinases stimulate a phosphatidylinositol 3-kinase whose lipid products directly activate Akt kinase by interacting with its pleckstrin homology domain. In the present study, we show, in three cell types, that Akt does not require its pleckstrin homology domain to respond to either insulin or platelet-derived growth factor. Moreover, attachment of the are myristoylation signal to target Akt, without its pleckstrin homology domain, to the membrane constitutively activates Akt by causing an increase in its basal level of phosphorylation, This constitutively active form of Akt can also activate p70(S6K), indicating that the pleckstrin homology domain is not necessary for downstream interactions. Fusion of the inter src homology 2 domain from the p85 regulatory subunit of the phosphatidylinositol 3-kinase to Akt also constitutively activated Akt and induced an association with the lipid kinase. Phosphorylation of this fusion protein still critically contributes toward its increased activity. The sum of these results indicates that the primary mechanism of Akt activation is via protein phosphorylation.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R37DK034926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED NN, 1992, ONCOGENE, V8, P1957; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1996, ADV CELL REGUL, V8, P153; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FRANKE TF, 1995, CELL, V81, P757; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	17	402	407	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21920	21926		10.1074/jbc.271.36.21920	http://dx.doi.org/10.1074/jbc.271.36.21920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702995	hybrid			2022-12-25	WOS:A1996VF61200037
J	Libby, RD; Beachy, TM; Phipps, AK				Libby, RD; Beachy, TM; Phipps, AK			Quantitating direct chlorine transfer from enzyme to substrate in chloroperoxidase-catalyzed reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; KINETIC-ANALYSIS; HALOGENATION; MECHANISM; MYELOPEROXIDASE; INTERMEDIATE; OXIDATION; HOCL	Substrate competition methods that were previously used to quantitate the involvement of free Cl-2 in the chloride-dependent peroxidatic reactions catalyzed by chloroperoxidase (CPO) (Libby, R, D., Shedd, A. L., Phipps, K. A., Beachy, T.M., and Gerstberger, S. M., (1992) J. Biol. Chem. 267, 1769-1775) are extended to CPO-catalyzed halogenation reactions. Relative substrate specificities of halogen acceptor substrates (RHs) antipyrine tap), NADH, 2-chlorodimedone (2cd), and barbituric acid (ba) are compared with previously studied peroxidatic substrates catechol (cat) and 2,4,6-trimethylphenol (tmp) in their reactions with the CPO-H2O2-Cl system versus the hypochlorite-Cl system. Studies were carried out at pH 2.75 over a chloride concentration range of 1-100 mM and at pH 4.80 over a chloride concentration range of 100-400 mM. Competition studies involved successive pairwise comparisons of substrates of increasing enzyme specificity. The orders of specificities, ba > 2cd > ap > cat > tmp at pH 2.75 and ha > 2cd > NADH > ap > cat > tmp at pH 4.80, are the same for both the CPO-H2O2-Cl and hypochlorite-Cl systems. However, the magnitudes of the specificities are different between the two systems. In all comparisons except ap versus cat, the specificity of the CPO-H2O2-Cl system toward the preferred substrate is higher than that of the hypochlorite-Cl system. Quantitative comparisons between specificities of CPO-H2O2-Cl and hypochlorite-Cl systems indicate that at least 98% of the CPO-catalyzed halogenation reactions of ba, 2cd, NADH, and ap occur by mechanisms in which the substrate reacts directly with the enzyme. Thus, less than 2% of any of the CPO reactions could possibly involve a free oxidized halogen intermediate. All data are consistent with a mechanism in which RH binds to the CPO chlorinating intermediate (EOCl), and the chlorine atom is transferred directly from EOCl to RH. Further, the results indicate that any halogenation substrate with a higher CPO specificity than ap must also undergo direct chlorine transfer from the enzyme. These results underscore the critical need for quantitative kinetic evidence in establishing the extent of involvement of any potential reaction intermediate. Finally, this work calls into question the long held assumption of the obligatory involvement of hypochlorite as an intermediate in myeloperoxidase reactions. It supports the recent kinetic evidence presented by Marquet and Dunford for direct chlorine transfer in myeloperoxidase-catalyzed chlorination of tuarine.	COLBY COLL,DEPT CHEM,WATERVILLE,ME 04901	Colby College	Libby, RD (corresponding author), MORAVIAN COLL,DEPT CHEM,BETHLEHEM,PA 18018, USA.				NIGMS NIH HHS [7 R15 GM42078-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM042078] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAISO T, 1981, CAN J BIOCHEM CELL B, V59, P233, DOI 10.1139/o81-031; CARMICHAEL R, 1985, BIOTECHNOL LETT, V7, P289, DOI 10.1007/BF01042380; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DUNFORD HB, 1987, ARCH BIOCHEM BIOPHYS, V252, P292, DOI 10.1016/0003-9861(87)90034-8; GEIGERT J, 1986, BIOCHEM BIOPH RES CO, V136, P778, DOI 10.1016/0006-291X(86)90507-3; GEIGERT J, 1983, J BIOL CHEM, V258, P2273; GRIFFIN BW, 1985, ARCH BIOCHEM BIOPHYS, V239, P305, DOI 10.1016/0003-9861(85)90840-9; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HAGER LP, 1973, OXIDASES RELATED RED, P311; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; LAMBEIR AM, 1983, J BIOL CHEM, V258, P3558; LIBBY RD, 1992, J BIOL CHEM, V267, P1769; LIBBY RD, 1990, J BIOL CHEM, V265, P14808; LIBBY RD, 1989, J BIOL CHEM, V264, P15284; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MCCARTHY MB, 1983, J BIOL CHEM, V258, P9153; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; RAMAKRISHNAN K, 1983, BIOCHEMISTRY-US, V22, P3271, DOI 10.1021/bi00282a036; SHOEMAKER DP, 1989, EXPT PHYSICAL CHEM, P57; THOMAS JA, 1970, J BIOL CHEM, V245, P3135; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; WOLFRAM S, 1991, MATH SYSTEM DOING MA, P88	24	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21820	21827		10.1074/jbc.271.36.21820	http://dx.doi.org/10.1074/jbc.271.36.21820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702981	hybrid			2022-12-25	WOS:A1996VF61200023
J	Ahn, BC; Grossman, L				Ahn, BC; Grossman, L			The binding of UvrAB proteins to bubble and loop regions in duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI UVRAB; EXCISION NUCLEASE; ATPASE ACTIVITY; RNA-POLYMERASE; HELICASE-II; DAMAGED DNA; REPAIR; ENDONUCLEASE; COMPLEX; INCISION	Based on the binding of the UvrAB complex to a promoter region in transcription open complexes (Ahn, B., and Grossman, L, (1996) J. Biol. Chem. 271, 21453-21461) and the requirement of a single-stranded region for UVrAB helicase activity, we examined the binding of UvrAB proteins to synthetic bubble or loop regions in duplex DNA and the role of these regions in translocation of the UvrAB complex as well as incision of DNA damage. We found that the UvrAB complex was able to bind to bubble and loop regions with an affinity similar to that for damaged DNA in the absence of RNAP. The preferential recognition and incision of damaged sites by the UvAB complex was observed downstream of the bubble or loop region in the strand complementary to the strand along which the UVrAB complex translocates. These results imply that the bubble region generated in duplex DNA by RNAP serves as a preferred entry site for the translocation of the UvrAB complex, and that preferential binding and unidirectional translocation of the UvrAB complex predetermine where incision is to occur.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022846, R01GM122846, R37GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22846, GM RO-1-22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21453, DOI 10.1074/jbc.271.35.21453; AIYAR SE, 1994, J BIOL CHEM, V269, P13179; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; FRIEDBERG EC, 1995, DNA REPAIR; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Kornberg A., 1992, DNA REPLICATION; KOVALSKY OI, 1994, J BIOL CHEM, V269, P27421; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LINN SM, 1985, NUCLEASES; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OH EY, 1987, THESIS J HOPKINS U B; OLEYKOWSKI CA, 1993, J BIOL CHEM, V268, P7990; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; REARDON JT, 1993, J BIOL CHEM, V268, P21301; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; WANG JT, 1994, J BIOL CHEM, V269, P10771; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535	39	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21462	21470		10.1074/jbc.271.35.21462	http://dx.doi.org/10.1074/jbc.271.35.21462			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702929	hybrid			2022-12-25	WOS:A1996VE47700075
J	Jahroudi, N; Ardekani, AM; Greenberger, JS				Jahroudi, N; Ardekani, AM; Greenberger, JS			An NF1-like protein functions as a repressor of the von Willebrand factor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; HUMAN VONWILLEBRAND-FACTOR; DNA-BINDING PROTEIN; GENE-EXPRESSION; COLLAGEN PROMOTER; RECOGNITION SITE; NEGATIVE CONTROL; HELA-CELLS; SEQUENCE; BETA	The expression of the von Willebrand factor (vWf) gene is restricted to endothelial cells and megakaryocytes, We have previously reported the identification of a region of the vWf gene that regulates its cell-type-specific expression in cell culture, This region (spanning nucleotides -487 to +247) consists of a core promoter (spanning nucleotides -90 to +22), a positive regulatory region (spanning nucleotides +155 to +247), and a negative regulatory region spanning nucleotides -312 to -487. To identify the trans-acting factor(s) that interacts with the negative regulatory region, we carried out gel mobility and DNase1 footprint analyses of sequences -312 to -487, These analyses demonstrated that an NF1-like protein interacts with DNA sequences spanning -440 to -470 nucleotides in the negative regulatory region of the vWf promoter, Base substitution mutations of the NF1 binding site abolished the NF1-DNA interaction, Furthermore, mutation of the NF1 binding site in the promoter fragment (-487 to +155) that contained the core and the negative regulatory region resulted in activation of the mutant promoter in both endothelial and nonendothelial cells, The wild type promoter fragment (-487 to +155) was not activated in either cell type. These results demonstrate that an NF1-like protein functions as a repressor of vWf promoter activity, In contrast, the mutation of the same NF1 binding site, but now in the context of the larger 734-base pair endothelial cell-specific promoter fragment (-487 to +247), did not result in promoter activation in nonendothelial cells, The data indicate that there are additional repressor elements within the vWf promoter region suppressing its activity specifically, in nonendothelial cells, and suggest that there is a secondary repressor element(s) that is located in the terminal region of the first exon of this gene.	UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jahroudi, N (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT RADIAT ONCOL,PITTSBURGH,PA 15213, USA.				NATIONAL CANCER INSTITUTE [R01CA039851, R37CA039851] Funding Source: NIH RePORTER; NCI NIH HHS [CA39851] Funding Source: Medline; BHP HRSA HHS [PE08798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BHP HRSA HHS		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; DAVIES PF, 1988, ENDOTHELIAL CELLS, V2, P123; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5; GANDER I, 1988, BIOCHIM BIOPHYS ACTA, V951, P411, DOI 10.1016/0167-4781(88)90114-5; GIMBRONE MA, 1990, ANN NY ACAD SCI, V598, P77, DOI 10.1111/j.1749-6632.1990.tb42279.x; GIRMA JP, 1987, BLOOD, V70, P605; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MACIAG T, 1982, PROG HEMOSTASIS THRO, V7, P167; MACIAG T, 1988, ENDOTHELIAL CELLS, V2, P3; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; NOMURA S, 1989, J BIOL CHEM, V264, P12201; ORKIN SH, 1992, BLOOD, V80, P575; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PIOVELLA F, 1987, BRIT J HAEMATOL, V39, P209; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUGGERI ZM, 1987, BLOOD, V70, P895; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TUDDENHAM EGD, 1989, BLOOD REV, V3, P251, DOI 10.1016/0268-960X(89)90032-5	39	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21413	21421		10.1074/jbc.271.35.21413	http://dx.doi.org/10.1074/jbc.271.35.21413			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702923	hybrid			2022-12-25	WOS:A1996VE47700069
J	Trejo, J; Connolly, AJ; Coughlin, SR				Trejo, J; Connolly, AJ; Coughlin, SR			The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts - Loss of responses in fibroblasts from receptor knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; HAMSTER FIBROBLASTS; MAP KINASE; PROTEOLYTIC MECHANISM; SIGNALING PATHWAYS; PHOSPHOLIPASE-C; ALPHA-THROMBIN; GROWTH-FACTORS; CELLS; PEPTIDES	The mitogenic activity of thrombin on fibroblasts and smooth muscle cells may contribute to embryonic development and normal wound healing, and it may also play a role in pathological responses to vascular injury. To examine the importance of thrombin signaling in vivo and to define the cloned thrombin receptor's role, we disrupted the thrombin receptor gene (tr) in mice. Platelets from tr(-/-) mice responded normally to thrombin, but tr(-/-) fibroblasts showed no thrombin-induced calcium mobilization or phosphoinositide hydrolysis. Thus distinct thrombin receptors act in different tissues. This study focuses on the role of the thrombin receptor in thrombin-induced mitogenesis and mitogen-activated protein (MAP) kinase activation in mesenchymal cells. Thrombin and thrombin receptor agonist peptide both stimulated DNA synthesis and MAP kinase activation in fibroblasts derived from wild-type mice. These responses were selectively lost in fibroblasts from tr(-/-) mice. Activation of the cloned thrombin receptor is therefore necessary and sufficient for thrombin-induced mitogenesis and MAP kinase activation in mouse lung fibroblasts. The tr(-/-) mouse thus provides a valuable model for defining the role of thrombin-induced proliferative events in vivo. Because thrombin-induced MAP kinase activation was attributable to a single receptor expressed at natural levels, mouse lung fibroblasts presented an opportunity to define the pathways that normally mediate activation of MAP kinase by the thrombin receptor. Elimination of phorbol-sensitive protein kinase C by prolonged exposure to phorbol ester only partially inhibited MAP kinase activation by thrombin but completely blocked c-Raf kinase activation. Pertussis toxin partially inhibited MAP kinase activation by thrombin but had no significant effect on c-Raf kinase activation. Thus in mouse lung fibroblasts, one thrombin receptor utilizes two pathways for MAP kinase activation: one is protein kinase C- and c-Raf dependent, and a second is G(i)-dependent and c-Raf-independent.	UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050267] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline; NIDDK NIH HHS [DK50267] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLER BS, 1992, BIOCHEMISTRY-US, V31, P11713, DOI 10.1021/bi00162a007; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PARIS S, 1988, J BIOL CHEM, V263, P12893; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WINITZ S, 1993, J BIOL CHEM, V268, P19196	35	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21536	21541		10.1074/jbc.271.35.21536	http://dx.doi.org/10.1074/jbc.271.35.21536			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702939	hybrid			2022-12-25	WOS:A1996VE47700085
J	Lee, FJS; Pristupa, ZB; Ciliax, BJ; Levey, AI; Niznik, HB				Lee, FJS; Pristupa, ZB; Ciliax, BJ; Levey, AI; Niznik, HB			The dopamine transporter carboxyl-terminal tail - Truncations/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; GLUT4 GLUCOSE-TRANSPORTER; BRAIN GABA TRANSPORTER; H-3 WIN 35,428; SEROTONIN TRANSPORTER; RAT-BRAIN; NOREPINEPHRINE TRANSPORTERS; SACCHAROMYCES-CEREVISIAE; RADIATION INACTIVATION; COCAINE RECEPTORS	In order to delineate structural motifs regulating substrate affinity and recognition for the human dopamine transporter (DAT), we assessed [H-3]dopamine uptake kinetics and [H-3]CFT binding characteristics of COS-7 cells transiently expressing mutant DATs in which the COOH terminus was truncated or substituted, Complete truncation of the carboxyl tail from Ser(582) allowed for the expression of biphasic [H-3]dopamine uptake kinetics displaying both a low capacity (V-max similar to-0.4 pmol/10(5) cells/min) high affinity (K-m similar to 300 nM) component and one exhibiting low affinity (K-m similar to 15 mu M) and high capacity (V-max similar to 5 pmol/10(5) cells/min) with a concomitant 40% decrease in overall apparent V-max relative to wild type (WT) DAT. Truncation of the last 22 amino acids or substitution of the DAT-COOH tail with sequences encoding the intracellular carboxyl-terminal of either dopamine D1 or D5 receptors produced results that were identical to those with the fully truncated DAT, suggesting that the induction of biphasic dopamine uptake kinetics is likely conferred by removal of DAT-specific sequence motifs distal to Pro(597). The attenuation of WT transport activity, either by lowering levels of DAT expression or by pretreatment of cells with phorbol 12-myristate 13- acetate (1 mu M), did not affect the kinetics of [H-3]dopamine transport. The estimated affinity of dopamine (K-i similar to 180 nM) for all truncated/substituted DAT mutants was 10-fold lower than that of WT DAT (similar to 2000 nM) and appears selective for the endogenous substrate, since the estimated inhibitory constants for numerous putative substrates or uptake inhibitors were virtually identical to those obtained for WT DATs. In marked contrast, DAT truncation/substitution mutants displayed significantly reduced high affinity [H-3]CFT binding interactions with estimated K-i values for dopamine and numerous other substrates and inhibitors tested from 10-100-fold lower than that observed for WT DAT, Moreover, co-expression of truncated and/or substituted DATs with WT transporter failed to reconstitute functional or pharmacological activities associated with both transporters. Instead, complete restoration of uniphasic low affinity [H-3]dopamine uptake kinetics (K-m similar to 2000 nM) and high affinity substrate and inhibitor [H-3]CFT binding interactions attributable to WT DATs were evident. These data clearly suggest the functional independence and differential regulation of the dopamine translocation process from the characteristics exhibited by its ligand binding domain. The lack of functional phenotypic ex pression of mutant DAT activities in cells co-expressing WT transporter is consistent with the contention that native DATs may exist as multisubunit complexes, the formation and maintenance of which is dependent upon sequences encoded within the carboxyl tail.	CLARKE INST PSYCHIAT,MOL NEUROBIOL LAB,TORONTO,ON M5T 1R8,CANADA; UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5S 1A8,CANADA; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; Emory University			Levey, Allan/F-2104-2011; Lee, Frank J.S./D-5899-2017	Levey, Allan/0000-0002-3153-502X; Lee, Frank J.S./0000-0002-5768-3776				BARKER EL, 1994, MOL PHARMACOL, V46, P799; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BERGER SP, 1994, MOL PHARMACOL, V46, P726; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1993, MOL BIOL FUNCTION CA, P284; BOJA JW, 1992, NEUROREPORT, V3, P247, DOI 10.1097/00001756-199203000-00007; BOJA JW, 1994, DOPAMINE RECEPTORS T, P611; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15-03-01714.1995; CLINE EJ, 1992, J PHARMACOL EXP THER, V260, P1174; CODERRE PE, 1995, BIOCHEMISTRY-US, V34, P9762, DOI 10.1021/bi00030a014; COONS DM, 1995, J BACTERIOL, V177, P3251, DOI 10.1128/jb.177.11.3251-3258.1995; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; COREY JL, 1994, J BIOL CHEM, V269, P14759; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; DONOVAN DM, 1995, MOL BRAIN RES, V30, P327, DOI 10.1016/0169-328X(95)00018-N; DUE AD, 1995, BIOCHEMISTRY-US, V34, P5462, DOI 10.1021/bi00016a017; EDVARDSEN O, 1994, MOL BRAIN RES, V27, P265, DOI 10.1016/0169-328X(94)90009-4; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; ESHLEMAN AJ, 1995, J PHARMACOL EXP THER, V274, P276; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; GRACZ LM, 1995, J PHARMACOL EXP THER, V273, P1224; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; GU H, 1994, J BIOL CHEM, V269, P7124; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HABERLAND N, 1987, J NEURAL TRANSM, V68, P289, DOI 10.1007/BF02098504; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Hoffman B. J, 1994, DOPAMINE RECEPTORS T, P645; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; KATZ JL, 1993, J PHARMACOL EXP THER, V264, P183; KAUFMAN MJ, 1992, SYNAPSE, V12, P99, DOI 10.1002/syn.890120203; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MASSERANO JM, 1994, J PHARMACOL EXP THER, V270, P133; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RITZ MC, 1993, BIOCHEM SOC SYMP, P51; ROSENZWEIGLIPSON S, 1992, PSYCHOPHARMACOLOGY, V107, P186, DOI 10.1007/BF02245136; ROTHMAN RB, 1992, PHARMACOL BIOCHEM BE, V43, P1135, DOI 10.1016/0091-3057(92)90493-Y; SAADOUNI S, 1994, EUR J PHARM-MOLEC PH, V268, P187, DOI 10.1016/0922-4106(94)90188-0; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SNYDER SH, 1986, NEUROLOGY, V36, P250, DOI 10.1212/WNL.36.2.250; SPEALMAN RD, 1989, J PHARMACOL EXP THER, V251, P142; STALEY JK, 1994, J PHARMACOL EXP THER, V271, P1678; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TATE CG, 1994, J BIOL CHEM, V269, P26303; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VALCHAR M, 1993, J NEUROCHEM, V60, P469, DOI 10.1111/j.1471-4159.1993.tb03174.x; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; VAUGEOIS JM, 1993, EUR J PHARMACOL, V230, P195, DOI 10.1016/0014-2999(93)90802-O; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; VEHYL M, 1993, J BIOL CHEM, V268, P25041; WALL SC, 1995, MOL PHARMACOL, V47, P544; WILSON JM, 1996, IN PRESS ANN NEUROL; WITKIN JM, 1994, NEUROSCI BIOBEHAV R, V18, P121, DOI 10.1016/0149-7634(94)90042-6; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; XU C, 1995, BIOCHEM PHARMACOL, V49, P339, DOI 10.1016/0006-2952(94)00485-5; ZAMANILLO D, 1995, NEUROSCI LETT, V188, P183, DOI 10.1016/0304-3940(95)11428-Y; ZOTTOLA RJ, 1995, BIOCHEMISTRY-US, V34, P9734, DOI 10.1021/bi00030a011	85	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20885	20894		10.1074/jbc.271.34.20885	http://dx.doi.org/10.1074/jbc.271.34.20885			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702845	hybrid			2022-12-25	WOS:A1996VD33700097
J	Pastuszak, I; Drake, R; Elbein, AD				Pastuszak, I; Drake, R; Elbein, AD			Kidney N-acetylgalactosamine (GalNAc)-1-phosphate kinase, a new pathway of GalNAc activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; EXPRESSION; ANTIGENS; RECEPTOR; MUCINS	A new enzyme that phosphorylates GalNAc at position 1 to form GalNAc-alpha-1P was purified similar to 1275-fold from the cytosolic fraction of pig kidney, and the properties of the enzyme were determined. The kinase is quite specific for GalNAc as the phosphate acceptor and is inactive with GlcNAc, ManNAc, glucose, galactose, mannose, GalN, and GlcN, This enzyme is clearly separated from galactokinase by chromatography on phenyl-Sepharose. The GalNAc kinase has a pH optimum between 8.5 and 9.0 and requires a divalent cation in the order Mg2+ > Mn2+ > Co2+, with optimum Mg2+ concentration at similar to 5 mM. The enzyme was most active with ATP as the phosphate donor, but slight activity was observed with ITP, acetyl-P, and phosphoenolpyruvate, Enzyme activity was highest in porcine and human kidney and porcine liver, but was low in most other tissues, Cultured HT-29 cells also had high activity for this kinase, The purified enzyme fraction was incubated with azido-[P-32]ATP, exposed to UV light, and run on SDS gels, A 50-kDa protein was labeled, and this labeling showed saturation kinetics with increasing amounts of the probe and was inhibited by unlabeled ATP, Although the most purified GalNAc kinase preparation still had two bands that labeled with ATP, maximum labeling of the 5O-kDa protein, but not the 66-kDa band, was coincident with maximum GalNAc kinase activity on a column of DEAE-Cibacron blue, On Sephacryl S-300, the native enzyme has a molecular mass of 48-51 kDa, indicating that the active kinase is a monomer, The product of the reaction was characterized as GalNAc-alpha-1-P by various chemical procedures.			Pastuszak, I (corresponding author), UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOL BIOL, LITTLE ROCK, AR 72205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17783] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; DAVIDSON E, 1996, AMINOSUGARS, P2; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DUA VK, 1986, J BIOL CHEM, V261, P1599; FUKUDA MN, 1989, BLOOD, V73, P84; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; ILYAS AA, 1985, P NATL ACAD SCI USA, V82, P6697, DOI 10.1073/pnas.82.19.6697; KAUSHAL GP, 1990, BIOCHEMISTRY-US, V29, P2168, DOI 10.1021/bi00460a030; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALEY F, 1968, BIOCHEM J, V107, P637, DOI 10.1042/bj1070637; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; PASTUSZAK I, 1996, IN PRESS J BIOL CHEM; PATTABIRAMAN T, 1961, BIOCHIM BIOPHYS ACTA, V50, P129, DOI 10.1016/0006-3002(61)91068-X; RAO BNN, 1988, CARBOHYD RES, V180, P111; REDDY P, 1989, J BIOL CHEM, V264, P17329; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SADLER JE, 1979, J BIOL CHEM, V254, P2112; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; Szumilo T, 1996, J BIOL CHEM, V271, P13147, DOI 10.1074/jbc.271.22.13147	22	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20776	20782		10.1074/jbc.271.34.20776	http://dx.doi.org/10.1074/jbc.271.34.20776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702831	hybrid			2022-12-25	WOS:A1996VD33700083
J	Jiang, MC; YangYen, HF; Lin, JK; Yen, JJY				Jiang, MC; YangYen, HF; Lin, JK; Yen, JJY			Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells	ONCOGENE			English	Article						apoptosis; p53; c-Myc; Bcl-2; Bax; hepatoma	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CYCLE ARREST; IN-VIVO; HEPATOMA-CELLS; CURCUMA-LONGA; DNA-BINDING; DEATH	Apoptosis of HepG2 cells triggered by various agents is characterized in an attempt to delineate the common apoptosis signaling pathway in human hepatoma cells. Several hallmarks of apoptosis, including DNA laddering, chromatin condensation and fragmentation, and an apoptosis specific cleavage of 28S and 18S ribosomal RNA were observed after treatment with curcumin. Curcumin treatment however did not alter the expression levels of Bcl-2 and Bax proteins, p53 protein accumulated slowly and decreased abruptly after reaching the maximum. Conversely, c-Myc protein decreased initially and subsequently increased preceding the onset of apoptosis. The accumulation of p53 protein is not due to increased levels of p53 mRNA and does not result in growth arrest. Staurosporine, quinacrine, ultraviolet irradiation, hydrogen peroxide, and cyclohexamide are all capable of triggering apoptosis in HepG2 cells. While most of these agents affect the expression levels of p53 and c-Myc similarly, none of them altered the expression levels of the Bcl-2 and Bax proteins. In conclusion, these data suggest that p53 and c-Myc may play a more important role in the apoptosis signaling pathway in HepG2 cells, than the bcl-2 gene family.	ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL TAIWAN UNIV, SCH MED, INST BIOCHEM, TAIPEI 10764, TAIWAN	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University			Yen, Jeffrey Jong-Young/Q-5134-2018; Yang-Yen, Hsin-Fang/ABA-5808-2021	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Yang-Yen, Hsin-Fang/0000-0001-9048-4800				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAMPOS L, 1993, BLOOD, V81, P3091; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ERAY M, 1994, INT IMMUNOL, V6, P1817, DOI 10.1093/intimm/6.12.1817; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FUJIMOTO Y, 1994, CANCER RES, V54, P281; GILLARDON F, 1994, ONCOGENE, V9, P3219; GOVINDARAJAN VS, 1980, CRC CR REV FOOD SCI, V12, P199, DOI 10.1080/10408398009527278; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOSONO S, 1993, ONCOGENE, V8, P491; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; HOUGE G, 1993, FEBS LETT, V315, P16, DOI 10.1016/0014-5793(93)81123-H; HUBER BE, 1987, CANCER RES, V47, P3414; ITO N, 1990, JPN J CANCER RES, V81, P216, DOI 10.1111/j.1349-7006.1990.tb02552.x; JIANG MC, 1996, IN PRESS NUTR CANC; KANEKO Y, 1992, CANCER LETT, V66, P155, DOI 10.1016/0304-3835(92)90228-N; KASTAN MB, 1991, CANCER RES, V51, P6304; KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAKINO R, 1984, BIOCHEM BIOPH RES CO, V119, P1096, DOI 10.1016/0006-291X(84)90887-8; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NERENSTONE SR, 1988, CANCER TREAT REV, V15, P1, DOI 10.1016/0305-7372(88)90007-2; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLAH E, 1990, CANCER BIOCHEM BIOPH, V11, P107; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROH M S, 1990, Current Opinion in Oncology, V2, P725; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEU JC, 1992, CANCER RES, V52, P6098; STRANGE R, 1992, DEVELOPMENT, V115, P49; TAKEDA T, 1991, BIOCHEM BIOPH RES CO, V178, P378, DOI 10.1016/0006-291X(91)91824-V; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TISHLER RB, 1993, CANCER RES, V53, P2212; VENOOK AP, 1994, J CLIN ONCOL, V12, P1323, DOI 10.1200/JCO.1994.12.6.1323; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAP EPH, 1993, LANCET, V341, P251, DOI 10.1016/0140-6736(93)90124-Y; YEN JJY, 1995, J IMMUNOL, V154, P2144; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG XK, 1990, ONCOGENE, V5, P909	63	95	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					609	616						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760302				2022-12-25	WOS:A1996VB32800018
J	Shuai, K; Halpern, J; tenHoeve, J; Rao, XP; Sawyers, CL				Shuai, K; Halpern, J; tenHoeve, J; Rao, XP; Sawyers, CL			Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia	ONCOGENE			English	Article						JAK kinases; tyrosine phosphorylation; signal transduction	COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; PROTEIN-TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; PHILADELPHIA-CHROMOSOME; TRANSCRIPTION FACTOR; INTERFERON ACTIVATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSFORMATION	Using chronic myelogenous leukemia (CML) as a model, we tested the hypothesis that cytokine-independent growth of leukemia cells results from aberrant activation of cytokine signaling pathways. The STAT5 (signal transducer and activator of transcription) protein, which is activated transiently in normal myeloid cells by cytokines such as GM-CSF (granulocyte-macrophage colony stimulating factor), was constitutively activated in cell lines derived from CML patients, even in the absence of GM-CSF. STAT5 was also activated in primary mouse bone marrow cells acutely transformed by the CML-specific BCR-ABL oncogene, but not by the serine kinase oncogene v-MOS. Reconstitution experiments in non-hematopoietic cells show that STAT5 activation by BCR-ABL occurs independent of cytokines. Results using BCR-ABL mutants which specifically uncouple connections to known signal transduction pathways show that STATS activation is kinase dependent and correlates directly with ability to confer cytokine independent growth in hematopoietic cells. BCR-ABL also activates JAK kinases, which may a STAT activation. These provide mechanism for findings are consistent with hematopoietic transformation by BCR-ABL.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOL BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Anderson SM, 1996, BLOOD, V87, P238; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; CARLESSO N, 1994, ONCOGENE, V9, P149; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KEATING A, 1983, NORMAL NEOPLASTIC HE, P513; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANGE B, 1987, BLOOD, V70, P192; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; LOZZIO BB, 1976, J NATL CANCER I, V56, P627, DOI 10.1093/jnci/56.3.627; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA T, 1994, BLOOD, V83, P3457; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEDOGARO L, 1983, J NATL CANCER I, V70, P447; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMPSON BJ, 1981, BIOCHIM BIOPHYS ACTA, V662, P125, DOI 10.1016/0005-2744(81)90232-1; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	57	391	401	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					247	254						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710363				2022-12-25	WOS:A1996VA25200003
J	Daas, PJH; Wassenaar, RW; Willemsen, P; Theunissen, RJ; Keltjens, JT; vanderDrift, C; Vogels, GD				Daas, PJH; Wassenaar, RW; Willemsen, P; Theunissen, RJ; Keltjens, JT; vanderDrift, C; Vogels, GD			Purification and properties of an enzyme involved in the ATP-dependent activation of the methanol:2-mercaptoethanesulfonic acid methyltransferase reaction in Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTIVE ACTIVATION; METHIONINE SYNTHASE; METHANOL; 5-HYDROXYBENZIMIDAZOLYLCOBAMIDE; PROTEINS	In Methanosarcina barkeri the transfer of the methyl group from methanol to 2-mercaptoethanesulfonic acid is catalyzed by the concerted action of two methyltransferases. The first one is the corrinoid-containing methanol:5-hydroxybenzimidazolylcobamide methyltransferase (MT(1)), which binds the methyl group of methanol to its corrinoid prosthetic group. MT(1) is only catalytically active when the cobalt atom of the corrinoid is present in the highly reduced Co(I) state, In the course of its purification and even during catalysis, MT(1) becomes oxidatively inactivated. The enzyme, however, may be reductively reactivated by a suitable reducing system (hydrogen and hydrogenase), ATP, and an enzyme called methyltransferase activation protein (MAP). In order to elucidate its role in the reactivation process, MAP was purified to apparent homogeneity. The protein had an M(r) = 60,000. Preincubation of the enzymic components involved with 8-azido-ATP or with ATP demonstrated MAP to be the primary site of action of ATP. In agreement herewith, the protein was auto phosphorylated by [gamma-P-32]ATP in a 1:1 stoichiometry, Phosphorylated MAP substituted for ATP in the activation of MT(1), and the addition of increasing amounts of MAP phosphate resulted in a corresponding increase of active MT(1). However, in the presence of limiting amounts of MAP, maximal activation of MT(1) could be achieved during a lag phase provided ATP was present, indicating that MAP acts as a catalyst. This paper is the first to report on the presence, isolation, and function of a phosphorylated protein in a methanogenic archaeon.	UNIV NIJMEGEN,FAC SCI,DEPT MICROBIOL,NL-6525 ED NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			Keltjens, Jan/M-3002-2013					BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; CHUAN H, 1989, J BIOL CHEM, V264, P7981; COZZONE AJ, 1993, J CELL BIOCHEM, V51, P7, DOI 10.1002/jcb.240510103; Daas PJH, 1996, J BIOL CHEM, V271, P22346, DOI 10.1074/jbc.271.37.22346; DAAS PJH, 1995, ARCH BIOCHEM BIOPHYS, V319, P244, DOI 10.1006/abbi.1995.1288; DAAS PJH, 1993, J BACTERIOL, V175, P1278, DOI 10.1128/JB.175.5.1278-1283.1993; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUTTEN TJ, 1981, J BACTERIOL, V145, P27, DOI 10.1128/JB.145.1.27-34.1981; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MATTHEWS R G, 1990, Biofactors, V2, P147; STAHL E, 1967, DUNNSCHICHT CHROMATO; STUPPERICH E, 1993, FEMS MICROBIOL REV, V12, P349, DOI 10.1016/0168-6445(93)90012-X; VANDERMEIJDEN P, 1984, BIOCHEM BIOPH RES CO, V118, P760, DOI 10.1016/0006-291X(84)91460-8; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; VANDERMEIJDEN P, 1983, J BACTERIOL, V153, P6, DOI 10.1128/JB.153.1.6-11.1983	19	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22339	22345		10.1074/jbc.271.37.22339	http://dx.doi.org/10.1074/jbc.271.37.22339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798394	Green Published			2022-12-25	WOS:A1996VG67200013
J	Kudo, M; Osuga, Y; Kobilka, BK; Hsueh, AJW				Kudo, M; Osuga, Y; Kobilka, BK; Hsueh, AJW			Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITED PRECOCIOUS PUBERTY; PROTEIN-COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL HYDROLYSIS; ALPHA-1B-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; REGULATORY PROTEINS; ACTIVE MUTANTS; POINT MUTATION; LIGAND-BINDING	Gonadotropin receptors are members of the seven-transmembrane (TR-I) receptor family. Several point mutations in TM V and VI and the intracellular loop 3 (i3) have been identified in the luteinizing hormone (LH) receptor gene, leading to constitutive activation of the receptor. Because gonadotropin receptors are highly conserved, we mutated the follicle stimulating hormone (FSH) receptor at the corresponding amino acids. However, the FSH receptor mutants showed minimal increases in basal cAMP production. Taking advantage of this difference between the two receptors, we designed chimeric receptors with or without a point mutation in the i3 to identify the region in the LH receptor important for its constitutive activation, Introduction of the point mutation into chimeric receptors containing only TM V to VI from the LH receptor led to major increases in ligand-independent-cAMP production. Furthermore, a chimeric receptor with only TM V and VI derived from the LH receptor can be rendered constitutively active by the mutation in the i3 from the FSH receptor. These results suggest that interactions between TM V and VI of the FSH receptor are essential for maintaining the receptor in the more constrained state, whereas interactions between these domains of the LH receptor are permissive for constitutively activating mutations in the i3.	STANFORD UNIV,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NICHD NIH HHS [HD-23273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023273, R37HD023273] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HSUEH AJW, 1992, TRENDS ENDOCRIN MET, V3, P164, DOI 10.1016/1043-2760(92)90166-X; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KRAAIJ R, 1995, J CLIN ENDOCR METAB, V80, P3168, DOI 10.1210/jc.80.11.3168; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LAUE LL, 1996, IN PRESS BIOCH MOL M; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PARMA J, 1994, MOL CELL ENDOCRINOL, V100, P159, DOI 10.1016/0303-7207(94)90296-8; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RAYMOND JR, 1994, AM J PHYSIOL, V266, pF163, DOI 10.1152/ajprenal.1994.266.2.F163; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANDE JV, 1995, J CLIN ENDOCR METAB, V80, P2577; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; YANO K, 1994, J CLIN ENDOCR METAB, V79, P1818, DOI 10.1210/jc.79.6.1818	61	104	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22470	22478		10.1074/jbc.271.37.22470	http://dx.doi.org/10.1074/jbc.271.37.22470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798412	hybrid			2022-12-25	WOS:A1996VG67200031
J	Lankester, AC; Rood, PML; vanSchijndel, GMW; Hooibrink, B; Verhoeven, AJ; vanLier, RAW				Lankester, AC; Rood, PML; vanSchijndel, GMW; Hooibrink, B; Verhoeven, AJ; vanLier, RAW			Alteration of B-cell antigen receptor signaling by CD19 co-ligation - A study with bispecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEINS; LYMPHOCYTES-B; TRANSDUCTION COMPLEX; CYTOPLASMIC DOMAIN; PHOSPHOLIPASE-C; ACTIVATION; KINASE; LYN; PHOSPHATASE; CD22	The activation of B cell antigen receptor-associated protein tyrosine kinases is an early and crucial event in B-cell signaling. Apart from the B-cell antigen receptor (BCR), the B cell-specific transmembrane glycoprotein CD19 has also been shown to directly activate intracellular signaling cascades. In addition, because CD19 and the BCR are associated on the surface of activated B-cells, it has been proposed that close approximation between these two entities is crucial for optimal B-cell triggering. To test this hypothesis, bispecific antibodies were generated that bind membrane IgM and CD19 simultaneously, Although CD19 bispecific antibodies strongly induced tyrosine phosphorylation, they were, in contrast to mu F(ab)(2) fragments, unable to induce a proliferative response. Detailed analysis of the early signaling events showed that compared with mu F(ab)(2) fragments CD19 bispecific antibodies potently raised the intracellular [Ca2+], which was correlated with an efficient tyrosine phosphorylation of syk. Strikingly, the assembly of Grb2 complexes that may couple the BCR to p21(ras) was clearly altered by the CD19 bispecific antibody. In addition to the reported She and 145-kDa phosphoproteins, a prominent 90-95-kDa phosphoprotein resembling CD19 was detected in the Grb2 complexes. Thus, studies with CD19 bispecific antibodies show that CD19 co-ligation both quantitatively and qualitatively alters BCR signaling.	UNIV AMSTERDAM,EXPT & CLIN IMMUNOL LAB,NL-1066 CX AMSTERDAM,NETHERLANDS	University of Amsterdam	Lankester, AC (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PLESMANLAAN 125,NL-1066 CX AMSTERDAM,NETHERLANDS.			van Lier, Rene/0000-0002-3201-7144				BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P3745; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; GOLD MR, 1994, ADV IMMUNOL, V55, P221; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Krop I, 1996, EUR J IMMUNOL, V26, P238, DOI 10.1002/eji.1830260137; LANE PJL, 1991, J IMMUNOL, V146, P715; LANKESTER AC, 1995, BLOOD, V86, P1090; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LANKESTER AC, 1993, IMMUNOLOGY, V80, P45; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SHANAFELT MC, 1995, J IMMUNOL, V154, P1684; SMIT L, 1994, J BIOL CHEM, V269, P20209; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANLIER R, 1989, IMMUNOLOGY, V67, P333; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; ZHOU LJ, 1991, J IMMUNOL, V147, P1424; ZHOU LJ, 1994, MOL CELL BIOL, V14, P3884, DOI 10.1128/MCB.14.6.3884	41	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22326	22330		10.1074/jbc.271.37.22326	http://dx.doi.org/10.1074/jbc.271.37.22326			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798392				2022-12-25	WOS:A1996VG67200011
J	Qu, DF; Teckman, JH; Omura, S; Perlmutter, DH				Qu, DF; Teckman, JH; Omura, S; Perlmutter, DH			Degradation of a mutant secretory protein, alpha(1)-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; T-CELL; CALNEXIN; TRANSPORT; SUBUNIT; CFTR; OLIGOSACCHARIDE; GLYCOPROTEINS; LACTACYSTIN; ASSOCIATION	Degradation of proteins that are retained in the quality control apparatus of the endoplasmic reticulum (ER) has been attributed to a third proteolytic system, distinct from the lysosomal and the cytoplasmic ubiquitin-dependent proteosomal proteolytic pathways. However, several recent studies have shown that ER degradation of a mutant membrane protein, CFTR Delta F508, is at least in part mediated from the cytoplasmic side by the 26 S proteasome. In this study, we examined the possibility that ER degradation of mutant secretory protein alpha(1)-antitrypsin (alpha(1)-AT) Z, the mutant protein associated with infantile liver disease and adult-onset emphysema of alpha(1)-AT deficiency, is mediated by the proteasome. The results show that a specific proteasome inhibitor, lactacystin, inhibits ER degradation of alpha 1-ATZ in transfected human fibroblast cell lines and in a cell-free microsomal translocation system, Although it is relatively easy to conceptualize how a transmembrane protein like CFTR Delta F508 might be accessible on the cytoplasmic aspect of the ER membrane for ubiquitination and degradation by the proteasome, it is more difficult to conceptualize how this might occur for a luminal polypeptide, The results show that, once within the lumen of the ER, alpha(1)-ATZ interacts with the transmembrane molecular chaperone calnexin and specifically induces the polyubiquitination of calnexin, The results, therefore, provide evidence that the proteasome, from its cytoplasmic localization, induces the degradation of the luminal alpha(1)-ATZ molecule by first attacking the cytoplasmic tail of calnexin molecules that are associated with alpha(1)-ATZ.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110; CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110; KITASATO INST,TOKYO 108,JAPAN	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Kitasato University				Teckman, Jeffrey/0000-0002-4870-2621	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001379] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37784-DP] Funding Source: Medline; NIDDK NIH HHS [DK 01379-JT] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; INOUE S, 1992, J BIOL CHEM, V267, P9080; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Perlmutter D H, 1993, Prog Liver Dis, V11, P139; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014	27	279	284	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22791	22795		10.1074/jbc.271.37.22791	http://dx.doi.org/10.1074/jbc.271.37.22791			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798455	hybrid			2022-12-25	WOS:A1996VG67200074
J	Zorzato, F; Menegazzi, P; Treves, S; Ronjat, M				Zorzato, F; Menegazzi, P; Treves, S; Ronjat, M			Role of malignant hyperthermia domain in the regulation of Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; CA-2+ RELEASE; IDENTIFICATION; EXPRESSION; CALMODULIN; MUTATION; PROTEINS; CLONING; COMPLEX; SITES	A fusion protein encompassing Gly(341) of the skeletal muscle ryanodine receptor was used to raise monoclonal antibodies; epitope mapping demonstrates that monoclonal antibody 419 (mAb419) reacts with a sequence a few residues upstream from Gly(341). The mAb419 was then used to probe ryanodine receptor (EYE) functions. Our results show that upon incubation of triads vesicles with mAb419 the Ca2+-induced Ca2+ release rate at pCa 8 was increased. Equilibrium evaluation of [H-3]ryanodine binding at different [Ca2+] indicates that mAb419 shifted the half-maximal [Ca2+] for stimulation of ryanodine binding to lower value (0.1 versus 1.2 mu M). Such functional effects may be due to a direct action of the Ab on the Ca2+ binding domain of the RYR or to the perturbation by the Ab of the intramolecular interaction between the immunopositive region and regulatory domain of the RYR. The latter hypothesis was tested directly using the optical biosensor BIA-core (Pharmacia Biotech Inc.): we show that the immunopositive EYE polypeptide is able to interact with the native RYR complex. Ligand overlays with immunopositive digoxigenin-RYR fusion protein indicate that such an interaction might occur with a calmodulin binding domain (defined by residues 3010-3225) and with a polypeptide defined by residues 799-1172. In conclusion our results suggest that the stimulation by the mAb419 of the RYR channel activity is due to the perturbation of an intramolecular interaction between the immunopositive polypeptide and a Ca2+ regulatory site probably corresponding to a calmodulin binding domain.	UNIV FERRARA, INST GEN PATHOL, I-44100 FERRARA, ITALY; CEA, CENG,DEPT BIOL MOL & STRUCT,CNRS,URA 520, LAB BIOPHYS MOL & CELLULAIRE, F-38054 GRENOBLE 9, FRANCE	University of Ferrara; CEA; Centre National de la Recherche Scientifique (CNRS)				Treves, Susan/0000-0002-0007-9631; Ronjat, Michel/0000-0002-9728-6425	Telethon [655, 617] Funding Source: Medline	Telethon(Fondazione Telethon)		BURATTI R, 1995, BIOCHEM BIOPH RES CO, V213, P1082, DOI 10.1006/bbrc.1995.2238; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FRANZINIARMSTRONG C, 1980, FED PROC, V39, P2403; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GERSHONI JM, 1985, ANAL BIOCHEM, V144, P32, DOI 10.1016/0003-2697(85)90080-6; HRLOW E, 1988, ANTIBODIES LAB MANUA, P305; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Maniatis T, 1989, MOL CLONING; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MOUTIN MJ, 1988, J BIOL CHEM, V263, P4228; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SAITO A, 1984, J CELL BIOL, V99, P975; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TREVES S, 1993, BIOCHEM J, V291, P757, DOI 10.1042/bj2910757; TRIPATHY A, 1995, BIOPHYS J, V69, P103; YOUNG RA, 1985, P NATL ACAD SCI USA, V82, P2583, DOI 10.1073/pnas.82.9.2583; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22759	22763		10.1074/jbc.271.37.22759	http://dx.doi.org/10.1074/jbc.271.37.22759			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798451	hybrid			2022-12-25	WOS:A1996VG67200070
J	Kojima, N; Kono, M; Yoshida, Y; Tachida, Y; Nakafuku, M; Tsuji, S				Kojima, N; Kono, M; Yoshida, Y; Tachida, Y; Nakafuku, M; Tsuji, S			Biosynthesis and expression of polysialic acid on the neural cell adhesion molecule is predominantly directed by ST8Sia II/STX during in vitro neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; IN-VITRO; CLONING; FAMILY; STX; ALPHA-2,8-SIALYLTRANSFERASE; POLYSIALYLTRANSFERASE; MIGRATION; SYSTEM; BRAIN	We have reported recently that ST8Sia II/STX as well as ST8Sia IV/PST-1 is a neural cell, adhesion molecule (NCAM)-specific polysialic acid (PSA) synthase (Kojima, N., Tachida, Y., Yoshida, Y., and Tsuji, S. (1996) J. Biol. Chem. 271, 19457-19463). To investigate which of two PSA synthase (ST8Sia II and IV) are involved in the biosynthesis of PSA associated with NCAM, the expressions of PSA, PSA synthase activity, and the genes of two PSA synthases during in vitro neuronal differentiation of mouse embryonal carcinoma P19 cells were determined. PSA was not expressed on undifferentiated cells (day 0) or cell aggregates (days 1-3) induced with retinoic acid. Expression of PSA began after cell aggregates had been dissociated and re-plated on a dish (day 4) and increased up to day 7. The expression of the mouse ST8Sia II gene was negligible in both undifferentiated and aggregated cells, it beginning at day 4 then dramatically increasing, and reaching the maximum level at days 6-7. On the other hand, transcription of the ST8Sia IV gene remained at a very low level throughout the entire period, a significant increase in its expression during differentiation not being observed. PSA synthase activity was not detected in undifferentiated or aggregated P19 cells, it increasing in parallel with ST8Sia II gene expression during differentiation. In addition, the cells at day 7 were stained with an anti-mouse ST8Sia II antiserum. Similar up-regulation of the ST8Sia II gene were observed during the differentiation of rat MNS-8 cells, which were derived from E-12 rat neuroepithelium of the neural tube and shown to differentiate into neurons. These results indicate that ST8Sia II predominantly directs PSA expression during neuronal differentiation rather than ST8Sia IV.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; NARA INST SCI & TECHNOL,GRAD SCH BIOL SCI,DIV SIGNAL TRANSDUCT,NARA 63001,JAPAN	RIKEN; Nara Institute of Science & Technology			Nakafuku, Masato/J-3068-2013; Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Kono, Mari/0000-0003-2447-4350; Nakafuku, Masato/0000-0001-7783-9005				BOER PH, 1993, EXP CELL RES, V207, P421, DOI 10.1006/excr.1993.1210; Bruses JL, 1995, J NEUROSCI, V15, P8310; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HUSMANN M, 1989, DEV BIOL, V136, P194, DOI 10.1016/0012-1606(89)90141-3; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; TNAG J, 1994, NEURON, V13, P405; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WANG C, 1994, J NEUROSCI, V14, P4446; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	25	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22058	22062		10.1074/jbc.271.36.22058	http://dx.doi.org/10.1074/jbc.271.36.22058			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703013	hybrid			2022-12-25	WOS:A1996VF61200055
J	Johnson, JL; Fenton, S; Sheffield, LG				Johnson, JL; Fenton, S; Sheffield, LG			Prolactin inhibits epidermal growth factor-induced Ras-MAPK signaling in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EGF-RECEPTOR; TYROSINE PHOSPHORYLATION; INDUCED PROLIFERATION; PLASMA-MEMBRANE; DNA-SYNTHESIS; SH2 DOMAIN; MOUSE; ACTIVATION; DIFFERENTIATION	Previously, our laboratory has shown that prolactin (PRL) inhibits epidermal growth factor (EGF)-induced DNA synthesis. One pathway for the initiation of DNA synthesis is EGF-receptor (EGF-R) signaling through Ras and mitogen-activated protein kinase (MAPK). To determine the effects of PRL on EGF-induced MAPK activation and phosphorylation, MAPK or phosphotyrosine (Tyr(P)) was immunoprecipitated from normal murine mammary epithelial (NMuMG) cells treated with PRL (100 ng/ml) and/or EGF (10 ng/ml) for 10-min periods. EGF-induced phosphorylation and activation were then examined by Western analysis and a myelin basic protein (MBP)-specific kinase assay. The p42 isoform of MAPK showed a distinct decrease in activity and phosphorylation when cells were treated with PRL. Concluding that PRL affects EGF signaling upstream of MAPK, we examined the effect of PRL on EGF-induced Ras activity. NMuMG cells were incubated with [P-32]orthophosphoric acid, treated as described above, immunoprecipitated with an antibody specific to Ras, and nucleotides were eluted and separated by TLC. Ras activity as measured by GTP:GDP ratio was increased by EGF, but not by PRL. Additionally, PRL, in combination with EGF abolished the ability of EGF to induce Ras activity, Those studies suggest that PRL alters the EGF signaling pathway upstream of Ras. Because Ras activation by EGF involves EGF-stimulated association of EGF-R with Grb2, the EGF-R was immunoprecipitated and a Western blot was probed for Grb2. As expected we found that EGF stimulated an association of EGF-R with Grb2, PRL, however, blocked this association. When we looked at the ability of Shc to associate with the EGF-R, we found that PRL and EGF had little effect on this association. The studies demonstrate that PRL either directly or indirectly inhibits the ability of EGF to induce EGF-R association with Grb2, to activate Ras, and to activate and phosphorylate MAPK.	UNIV WISCONSIN, ENDOCRINOL REPROD PHYSIOL PROGRAM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD031532, R29HD024094] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24094, HD 31532] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANERJEE R, 1992, MOL CELL ENDOCRINOL, V90, P61, DOI 10.1016/0303-7207(92)90102-C; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FENTON SE, 1993, MOL BIOL CELL, V4, P773, DOI 10.1091/mbc.4.8.773; FENTON SE, 1991, BIOCHEM BIOPH RES CO, V181, P1063, DOI 10.1016/0006-291X(91)92045-L; FENTON SE, 1994, EXP CELL RES, V210, P102, DOI 10.1006/excr.1994.1015; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GILL GN, 1987, J CELL PHYSIOL, P35; Gill J.L., 1978, DESIGN ANAL EXPT ANI, V1st; Gotoh N, 1995, ONCOGENE, V11, P2525; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LI NX, 1994, ONCOGENE, V9, P3457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OWENS RB, 1974, J NATL CANCER I, V52, P1375, DOI 10.1093/jnci/52.4.1375; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2647, DOI 10.1073/pnas.80.9.2647; TAKETANI Y, 1983, ENDOCRINOLOGY, V113, P871, DOI 10.1210/endo-113-3-871; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERBOOM RJ, 1993, J CELL PHYSIOL, V156, P367, DOI 10.1002/jcp.1041560220; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; YANG J, 1980, ENDOCRINOLOGY, V107, P35, DOI 10.1210/endo-107-1-35; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	40	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21574	21578		10.1074/jbc.271.35.21574	http://dx.doi.org/10.1074/jbc.271.35.21574			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702944	hybrid			2022-12-25	WOS:A1996VE47700090
J	LeGac, NT; Villani, G; Hoffmann, JS; Boehmer, PE				LeGac, NT; Villani, G; Hoffmann, JS; Boehmer, PE			The UL8 subunit of the herpes simplex virus type-1 DNA helicase-primase optimizes utilization of DNA templates covered by the homologous single-strand DNA-binding protein ICP8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCTS; PRIMER SYNTHESIS; INSECT CELLS; REPLICATION; COMPLEX; POLYMERASE; BACTERIOPHAGE-T4; IDENTIFICATION; PURIFICATION; ASSOCIATION	The herpes simplex virus type-1 DNA helicase-primase is a heterotrimer encoded by the UL5, UL8, and UL52 genes. The core enzyme, specified by the UL5 and UL52 genes, retains DNA helicase, DNA-dependent nucleoside triphosphatase, and primase activities. The UL8 subunit has previously been implicated in increasing primer stability and in stimulating primer synthesis by the core enzyme. To further characterize the function of the UL8 subunit, we have examined its effect on the activities of the UL5/52 core enzyme using DNA templates covered by the herpes simplex virus type-1 single-strand DNA-binding protein ICP8. We found that while ICP8 stimulated the DNA helicase activity of the UL5/52 proteins up to 3-fold, maximum stimulation by ICP8 required the presence of UL8 protein. Moreover, UL8 protein was required to reverse the inhibitory effect of ICP8 on the DNA-dependent ATPase and primase activities of the UL5/52 proteins. These observations were specific for ICPS since the heterologous Escherichia coli single-strand DNA-binding protein could not substitute for ICP8. These data suggest that UL8 protein mediates an interaction between the UL5/52 core enzyme and ICP8 that optimizes the utilization of ICP8-covered DNA templates during DNA replication.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103; CNRS,INST PHARMACOL & BIOL STRUCT,F-31077 TOULOUSE,FRANCE	Rutgers State University New Brunswick; Rutgers State University Medical Center; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Boehmer, Paul/0000-0003-4479-0529	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARADARAN K, 1994, J VIROL, V68, P4251, DOI 10.1128/JVI.68.7.4251-4261.1994; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHALLBERG MD, 1991, SEMIN VIROL, V2, P247; CHIOU HC, 1985, VIROLOGY, V145, P213, DOI 10.1016/0042-6822(85)90155-2; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; GUPTE SS, 1991, J BIOL CHEM, V266, P11413; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Kornberg A., 1992, DNA REPLICATION; LEE CK, 1985, J VIROL, V54, P731, DOI 10.1128/JVI.54.3.731-738.1985; Liptak LM, 1996, J VIROL, V70, P1759, DOI 10.1128/JVI.70.3.1759-1767.1996; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lukonis CJ, 1996, J VIROL, V70, P1751, DOI 10.1128/JVI.70.3.1751-1758.1996; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; PARRY ME, 1993, J GEN VIROL, V74, P607, DOI 10.1099/0022-1317-74-4-607; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; THOMAS MS, 1992, J VIROL, V66, P1152, DOI 10.1128/JVI.66.2.1152-1161.1992; VAUGHAN PJ, 1985, J VIROL, V53, P501, DOI 10.1128/JVI.53.2.501-508.1985; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	39	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21645	21651						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702953				2022-12-25	WOS:A1996VE47700099
J	Riikonen, A; Rouvinen, J; Tikkanen, R; Julkunen, I; Peltonen, L; Jalanko, A				Riikonen, A; Rouvinen, J; Tikkanen, R; Julkunen, I; Peltonen, L; Jalanko, A			Primary folding of aspartylglucosaminidase - Significance of disulfide bridges and evidence of early multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; DIHYDROFOLATE-REDUCTASE; DNA-TRANSFECTION; MUTATION; CONSEQUENCES; PROTEASOME; COMPLEX; DISEASE; CDNA	Aspartylglucosaminidase (AGA) is a lysosomal enzyme involved in the degradation of N-linked glycoproteins in lysosomes. AGA is synthesized as an inactive precursor molecule, which is rapidly activated in the endoplasmic reticulum by a proteolytic cleavage into alpha- and beta-subunits. We have recently determined the three-dimensional structure of AGA and shown that it is a globular molecule with a heterotetrameric (alpha beta)(2) structure, On the basis of structural and functional analyses, AGA seems to be the first mammalian protein belonging to a newly described protein family, the N-tepminal nucleophile hydrolases, Because the activation of the prokaryotic members of the N-terminal nucleophile hydrolase family seems to be triggered by the assembly of the subunits, we have studied the initial folding and oligomerization of AGA and provide evidence that dimerization of two precursor molecules in the endoplasmic reticulum is a prerequisite for the activation of AGA To gain further information on the structural determinants influencing the early folding of AGA, we used site-specific mutagenesis of cysteine residues to define the role of intrachain disulfide bridges in the folding and activation of the enzyme. The N-terminal disulfide bridges in both the alpha- and beta-subunits seem to have only a stabilizing role, whereas the C-terminal disulfide bridge in both subunits evidently plays an important role in the early folding and activation of AGA.	NATL PUBL HLTH INST,DEPT HUMAN MOL GENET,FIN-00300 HELSINKI,FINLAND; NATL PUBL HLTH INST,DEPT VIROL,FIN-00300 HELSINKI,FINLAND; UNIV JOENSUU,DEPT CHEM,FIN-80101 JOENSUU,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Eastern Finland				Tikkanen, Ritva/0000-0002-8393-1825				BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IKONEN E, 1991, GENOMICS, V11, P206, DOI 10.1016/0888-7543(91)90120-4; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Peltola M, 1996, HUM MOL GENET, V5, P737, DOI 10.1093/hmg/5.6.737; POLLITT RJ, 1968, LANCET, V2, P253; RIIKONEN A, 1994, DNA CELL BIOL, V13, P257, DOI 10.1089/dna.1994.13.257; RUKONEN A, 1995, J BIOL CHEM, V270, P4903; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; TIKKANEN R, 1995, DNA CELL BIOL, V14, P305, DOI 10.1089/dna.1995.14.305; Tikkanen R, 1996, PROTEINS, V24, P253; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	24	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21340	21344		10.1074/jbc.271.35.21340	http://dx.doi.org/10.1074/jbc.271.35.21340			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702913	hybrid			2022-12-25	WOS:A1996VE47700059
J	Schaufele, F				Schaufele, F			CCAAT/Enhancer-binding protein alpha activation of the rat growth hormone promoter in pituitary progenitor GNFT1-5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-ZIPPER; GENE-EXPRESSION; ANTERIOR-PITUITARY; THYROID-HORMONE; TRANSCRIPTION FACTORS; RESPONSE ELEMENTS; TRANSGENIC MICE; MESSENGER-RNA; C/EBP-ALPHA; DNA-BINDING	High level, anterior pituitary-specific expression of the sat growth hormone (rGH) promoter requires cooperative actions of several different transcription factors, Previously, we described a series of multisubunit, tissue-general, transcription factor complexes that bound to the GHF3 activation site and strongly regulated rGH promoter activity, A 43-kDa DNA-binding subunit common to each of the different GHF3 complexes is identified here as the transcription factor, CCAAT/Enhancer-binding Protein alpha (C/EBP alpha). In human monocyte U937 cells, which do not express the endogenous or transfected GH genes, co-expression of C/EBP alpha and Pit-1 synergistically activated the transfected rGH promoter. Full-length C/EBP alpha was present in the GH-secreting GC, and prolactin-secreting 235-1, pituitary cell lines, but not in GNFT1-5 cells, which are transformed at a stage in development immediately prior to GH expression, Transient expression of C/EBP alpha in GHFTI-5 cells strongly activated the co-transfected rGH promoter through the GHF3 binding site; a second activation site mapped to evolutionary conserved GP promoter sequences between -106 and -33. C/EBP alpha activation was synergistic with phorbol 12-myristate 13-acetate and forskolin, activators of protein kinases C and A, respectively. Thus, C/EBP alpha is an important regulator of rGH promoter activity that appears to function in synergy with Pit-1, activators of A and C protein kinases and possibly other factors.			Schaufele, F (corresponding author), UNIV CALIF SAN FRANCISCO,METAB RES UNIT,HSW-1141,SAN FRANCISCO,CA 94143, USA.							ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KUO CF, 1990, DEVELOPMENT, V109, P473; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE KAW, 1992, J CELL SCI, V103, P9; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NISHIZUKA Y, 1983, TRENDS BIOCHEM SCI, V8, P13, DOI 10.1016/0968-0004(83)90061-0; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SCHAUFELE F, 1990, NUCLEIC ACIDS RES, V18, P5235, DOI 10.1093/nar/18.17.5235; SCHAUFELE F, 1994, PITUITARY GLAND, P91; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YE ZS, 1987, J BIOL CHEM, V262, P6313	54	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21484	21489		10.1074/jbc.271.35.21484	http://dx.doi.org/10.1074/jbc.271.35.21484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702932	hybrid			2022-12-25	WOS:A1996VE47700078
J	Schinke, T; Amendt, C; Trindl, A; Poschke, O; MullerEsterl, W; JahnenDechent, W				Schinke, T; Amendt, C; Trindl, A; Poschke, O; MullerEsterl, W; JahnenDechent, W			The serum protein alpha(2)-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells - A possible role in mineralization and calcium homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-HS GLYCOPROTEIN; HUMAN ALPHA-2-HS-GLYCOPROTEIN; BOVINE FETUIN; CRYSTAL-FORMATION; INSULIN-RECEPTOR; HS-GLYCOPROTEIN; TYROSINE KINASE; HUMAN-BONE; A-CHAIN; RAT	We present data suggesting a function of alpha(2)-HS glycoproteins/fetuins in serum and in mineralization, namely interference with calcium salt precipitation. Fetuins occur in high serum concentration during fetal life. They accumulate in bones and teeth as a major fraction of noncollagenous bone proteins, The expression pattern in fetal mice confirms that fetuin is predominantly made in the liver and is accumulated in the mineralized matrix of bones, We arrived at a hypothesis on the molecular basis of fetuin function in bones using primary rat calvaria osteoblast cultures and salt precipitation assays. Our results indicate that fetuins inhibit apatite formation both in cell culture and in the test tube, This inhibitory effect is mediated by acidic amino acids clustering in cystatin-like domain D1, Fetuins account for roughly half of the capacity of serum to inhibit salt precipitation. We propose that fetuins inhibit phase separation in serum and modulate apatite formation during mineralization.	UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY	Johannes Gutenberg University of Mainz			Jahnen-Dechent, Willi/A-7608-2011	Jahnen-Dechent, Willi/0000-0003-1315-4407				ASHTON BA, 1976, CALC TISS RES, V22, P27; BELLOWS CG, 1994, ENDOCRINOLOGY, V134, P2221, DOI 10.1210/en.134.5.2221; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BLUMENTHAL NC, 1975, CALC TISS RES, V18, P81, DOI 10.1007/BF02546228; BROWN WM, 1992, EUR J BIOCHEM, V205, P321, DOI 10.1111/j.1432-1033.1992.tb16783.x; CLARK G, 1981, STAINING PROCEDURES, P187; COLCLASURE GC, 1988, J CLIN ENDOCR METAB, V66, P187, DOI 10.1210/jcem-66-1-187; DICKSON IR, 1985, CONNECT TISSUE RES, V14, P77, DOI 10.3109/03008208509089845; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; Dziegielewska K., 1995, MOL BIOL INTELLIGENC; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; ELZANOWSKI A, 1988, FEBS LETT, V227, P167, DOI 10.1016/0014-5793(88)80890-1; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FALQUERHO L, 1991, GENE, V98, P209, DOI 10.1016/0378-1119(91)90175-B; GARNETT J, 1990, BIOCHEM J, V266, P863; HAYASE T, 1992, BIOCHEMISTRY-US, V31, P4915, DOI 10.1021/bi00135a024; HOGAN BL, 1995, MANIPULATING MOUSE E; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; JAHNENDECHENT W, 1994, EUR J BIOCHEM, V226, P59, DOI 10.1111/j.1432-1033.1994.tb20026.x; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; LEE CC, 1987, P NATL ACAD SCI USA, V84, P4403, DOI 10.1073/pnas.84.13.4403; MBUYI JM, 1982, CALCIFIED TISSUE INT, V34, P229, DOI 10.1007/BF02411242; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; NAGADOME H, 1993, FEBS LETT, V317, P128, DOI 10.1016/0014-5793(93)81506-U; OHNISHI T, 1993, J BONE MINER RES, V8, P367; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; RAJ PA, 1992, J BIOL CHEM, V267, P5968; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; Sambrook J, 1987, MOL CLONING LAB MANU; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; SUZUKI M, 1994, J EXP ZOOL, V270, P501, DOI 10.1002/jez.1402700603; TAKAGI Y, 1990, CALCIFIED TISSUE INT, V47, P40, DOI 10.1007/BF02555864; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; TRIFFITT JT, 1978, CALC TISS RES, V26, P155, DOI 10.1007/BF02013251; WATZLAWICK H, 1992, BIOCHEMISTRY-US, V31, P12198, DOI 10.1021/bi00163a032; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G; YANG FM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P149, DOI 10.1016/0167-4781(92)90522-2	38	307	313	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20789	20796		10.1074/jbc.271.34.20789	http://dx.doi.org/10.1074/jbc.271.34.20789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702833	hybrid			2022-12-25	WOS:A1996VD33700085
J	Lutz, W; Stohr, M; Schurmann, J; Wenzel, A; Lohr, A; Schwab, M				Lutz, W; Stohr, M; Schurmann, J; Wenzel, A; Lohr, A; Schwab, M			Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells	ONCOGENE			English	Article						tetracycline; cell cycle; Myc; immediate early gene; neuroblastoma	HUMAN NEURO-BLASTOMA; C-MYC; GENE-EXPRESSION; MAMMALIAN-CELLS; TRANSGENIC MICE; GROWTH-FACTOR; CYCLE ARREST; PROTEIN; AMPLIFICATION; APOPTOSIS	To elucidate the contribution of the N-Myc protein to neuroblastomas we have used a synthetic inducible expression system on the basis of the tetracycline repressor of E coli to reversibly express N-myc in a human neuroblastoma cell line in which expression of endogenous N-myc is barely detectable. Like the c-Myc protein, N-Myc up-regulates the expression of both alpha-prothymosin and ornithine decarboxylase. Induction of N-myc increases both the rate of DNA-synthesis and the proliferation rate, and shortens the G(1) phase of the cell cycle. A comparison of cell populations in which the presence of N-Myc protein was restricted to different parts of G(0)/G(1) revealed that N-Myc is rate-limiting for cell cycle progression during the first 5 h after serum stimulation of quiescent cells providing direct evidence that Myc-proteins act early after mitogenic stimulation of quiescent cells.	GERMAN CANC RES CTR, DIV CELL CYCLE & PHENOTYPE, DEPT CYTOGENET 0825, D-69120 HEIDELBERG, GERMANY; GERMAN CANC RES CTR, DIV CELL CYCLE & PHENOTYPE, DEPT APPL IMMUNOL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRONDYK WH, 1991, ONCOGENE, V6, P1269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; CORVI R, 1995, CANCER RES, V55, P3471; CROUCH DH, 1993, ONCOGENE, V8, P1849; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENRIKSSON M, 1996, IN PRESS; HERMEKING H, 1995, ONCOGENE, V11, P1409; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MURGRAUER G, 1988, J CELL BIOL, V107, P1325; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; Peverali FA, 1996, ONCOGENE, V12, P457; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETERNELLA CM, 1995, MOL CELL BIOL, V15, P6999; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STOHR M, 1978, STAIN TECHNOL, V53, P205; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZERLIN M, 1987, ONCOGENE, V1, P19; ZORNIG M, 1995, ONCOGENE, V11, P2165	61	273	277	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					803	812						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761302				2022-12-25	WOS:A1996VD43300016
J	Braverman, RH; Cooper, HL; Lee, HS; Prasad, GL				Braverman, RH; Cooper, HL; Lee, HS; Prasad, GL			Anti-oncogenic effects of tropomyosin: Isoform specificity and importance of protein coding sequences	ONCOGENE			English	Article						tropomyosin; isoforms; tumor suppressor	STIMULATES TYROSINE PHOSPHORYLATION; CHICKEN-EMBRYO FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; NON-MUSCLE TROPOMYOSINS; CARDIAC TROPONIN-T; TRANSFORMED-CELLS; ALPHA-TROPOMYOSIN; BETA-TROPOMYOSIN; GROWTH-FACTOR; HYPERTROPHIC CARDIOMYOPATHY	Suppression of muscle type isoforms of tropomyosin (TM) is a common biochemical event in malignantly transformed cells. To evaluate the role of TM proteins and isoform specificity in cellular transformation, cDNAs that consist of coding sequences of TM1 (product of beta gene) and TM2 (product of alpha gene), but lacking untranslated regions (UTRs), have been expressed separately in DT (v-Ki-ras transformed NIH3T3) cells, and elevated levels of the corresponding proteins were detected. DT cells which over express TM2 manifest growth in soft agar. Elevated levels of TM1 protein in DT cells resulted in flattened cell morphology and complete abolition of anchorage independent growth. Tumorigenesis in athymic nude mice was observed in the absence of transduced TM1 mRNA. Thus, expression of TM1 protein is sufficient for tumor suppression: the UTRs of TM1 are not required for the tumor suppressive effects. Expression of TM2 protein, on the other hand, has no effect on the transformed phenotype of DT cells. These data indicate that isoforms 1 and 2 of TMs perform distinct physiological roles.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; BHATTACHARYA B, 1988, ONCOGENE RES, V3, P51; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CANONNEHERGAUX F, 1994, NEUROCHEM INT, V25, P545, DOI 10.1016/0197-0186(94)90153-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; COTE GP, 1983, MOL CELL BIOCHEM, V57, P127, DOI 10.1007/BF00849190; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GRAMATIKOFF K, 1995, BIOL CHEM H-S, V376, P321; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; HITCHCOCKDEGREGORI SE, 1994, ADV EXP MED BIOL, V358, P85; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; JAMMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; LIANG NG, 1995, NAT GENET, V9, P75; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1990, J BIOL CHEM, V265, P3471; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; MACLEOD AR, 1987, BIOESSAYS, V6, P208, DOI 10.1002/bies.950060504; MAEKAWA S, 1994, BIOCHEM MOL BIOL INT, V33, P661; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MCINNES C, 1988, BIOCHIM BIOPHYS ACTA, V951, P117, DOI 10.1016/0167-4781(88)90031-0; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MULLAUER L, 1993, ONCOGENE, V8, P2531; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; Payne M R, 1985, Cell Muscle Motil, V6, P141; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TIKOO A, 1994, J BIOL CHEM, V269, P23387; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WEINBERGER RP, 1993, J CELL BIOL, V120, P205, DOI 10.1083/jcb.120.1.205; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; WIRTH PJ, 1992, ELECTROPHORESIS, V13, P305, DOI 10.1002/elps.1150130163	66	47	50	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					537	545						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760295				2022-12-25	WOS:A1996VB32800011
J	Smit, L; vanderHorst, G; Borst, J				Smit, L; vanderHorst, G; Borst, J			Formation of Shc/Grb2- and Crk adaptor complexes containing tyrosine phosphorylated Cbl upon stimulation of the B-cell antigen receptor	ONCOGENE			English	Article						B-cell antigen receptor; adaptor protein; Cbl; Shc/Grb2; Crk; Ras activation	NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; PROTOONCOGENE C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; LYMPHOCYTES-B; GRB2 ADAPTER; KINASE LYN; T-CELLS; SIGNAL TRANSDUCTION; EGF STIMULATION	B-cell antigen receptor (BCR) stimulation induces tyrosine phosphorylation of the She adaptor protein and its association with Grb2. The Shc/Grb2 complex may be involved in Ras activation, since Grb2 interacts with the guanine nucleotide exchange factor Sos. We reveal here an additional complexity of the BCR-induced Shc/Grb2 complex: it contains tyrosine phosphorylated proteins of 130, 110 and 75 kDa. The 130 kDa molecule inducibly associates with She, while the 75 kDa protein interacts with the carboxy-terminal SH3 domain of Grb2. The 110 kDa molecule is defined as Cbl, the product of the c-cbl oncogene, which is strongly phosphorylated on tyrosine upon BCR stimulation. Cbl constitutively interacts with the SH3 domains of Grb2, with a preference for the amino-terminal domain, and is in this way recruited to She upon BCR stimulation. Immunodepletion studies showed that Grb2-associated Cbl can be phosphorylated by BCR-induced tyrosine kinases independent of a Shc/Grb2 interaction. This indicates that the BCR can also couple to a Grb2 complex without the involvement of She. Cbl not only interacts with Grb2, but also with the adaptor protein Crk. In contrast to its constitutive interaction with Grb2, tyrosine-phosphorylated Cbl only associates with Crk after BCR stimulation. In summary, we observe that the BCR activates Shc/Grb2-, Grb2- and Crk adaptor complexes of distinct composition, which may allow selective coupling to different signal transduction cascades. Cbl participates in all three adaptor complexes and is tyrosine phosphorylated upon BCR stimulation, pointing to a central role for this molecule in the regulation of antigen receptor-induced B cell responses.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Smit, Linda/0000-0003-0025-269X; Borst, Jannie/0000-0002-8043-5009				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BLAKE TJ, 1991, ONCOGENE, V6, P653; BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKUZAWA T, 1995, J BIOL CHEM, V270, P19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SAXTON TM, 1994, J IMMUNOL, V153, P623; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SMIT L, 1994, J BIOL CHEM, V269, P20209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	61	45	46	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					381	389						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710377				2022-12-25	WOS:A1996VA25200017
J	Saltman, LH; Lu, Y; Zaharias, EM; Isberg, RR				Saltman, LH; Lu, Y; Zaharias, EM; Isberg, RR			A region of the Yersinia pseudotuberculosis invasin protein that contributes to high affinity binding to integrin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; ENTEROPATHOGENIC ESCHERICHIA-COLI; SITE-DIRECTED MUTAGENESIS; TISSUE-CULTURE CELLS; MAMMALIAN-CELLS; FIBROBLAST ADHESION; SYNTHETIC PEPTIDES; DIVALENT-CATIONS; GENETIC-LOCUS; FIBRONECTIN	The entry of Yersinia pseudotuberculosis into cultured mammalian cells is mediated by the bacterial protein invasin. The mammalian receptors for invasin are five beta(1) chain integrins. Site directed mutagenesis of the aspartate and lysine residues in the 192-amino acid integrin binding domain of invasin was performed to identify regions, in addition to the previously characterized 903-913 region, that are important for integrin binding. One mutation, D811A, resulted in depressed ability of invasin to bind purified alpha(5) beta(1) and to promote bacterial entry. Further mutational analysis of Asp-811 indicated that an oxygen-containing side chain is required at this position, A second nearby residue, Phe-808, was also shown to be important for integrin binding, as an alanine substitution at this site had properties similar to the Asp-811 mutation. This mutational analysis has therefore identified a second region that, in conjunction with residues 903-913, is required for wild type levels of integrin binding. The contribution to binding by two noncontiguous sites in the primary sequence parallels results that indicate two domains of fibronectin are involved in integrin binding.	TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MOL BIOL & MICROBIOL, BOSTON, MA 02111 USA	Howard Hughes Medical Institute; Tufts University; Tufts University					NIAID NIH HHS [R01-AI23538] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; AOTA S, 1991, J BIOL CHEM, V266, P15938; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DONNENBERG MS, 1990, INFECT IMMUN, V58, P1565, DOI 10.1128/IAI.58.6.1565-1571.1990; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GRUTZKAU A, 1990, GUT, V31, P1011, DOI 10.1136/gut.31.9.1011; HANSKI C, 1989, INFECT IMMUN, V57, P673, DOI 10.1128/IAI.57.3.673-678.1989; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1994, ANNU REV GENET, V28, P395, DOI 10.1146/annurev.ge.28.120194.002143; ISBERG RR, 1990, MOL BIOL MED, V7, P73; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEE KK, 1989, MOL MICROBIOL, V3, P1493, DOI 10.1111/j.1365-2958.1989.tb00135.x; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LUND B, 1988, MOL MICROBIOL, V2, P255, DOI 10.1111/j.1365-2958.1988.tb00027.x; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Maniatis T., 1982, MOL CLONING; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NHIEU GTV, 1993, EMBO J, V12, P1887; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PEPE JC, 1993, P NATL ACAD SCI USA, V90, P6473, DOI 10.1073/pnas.90.14.6473; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; RANKIN S, 1994, METHOD ENZYMOL, V236, P566; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; STEINER B, 1989, J BIOL CHEM, V264, P13102; STREETER HB, 1987, J CELL BIOL, V105, P507, DOI 10.1083/jcb.105.1.507; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SWANSON J, 1973, J EXP MED, V137, P571, DOI 10.1084/jem.137.3.571; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325	62	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23438	23444		10.1074/jbc.271.38.23438	http://dx.doi.org/10.1074/jbc.271.38.23438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798550	hybrid			2022-12-25	WOS:A1996VH76800076
J	Stein, E; Cerretti, DP; Daniel, TO				Stein, E; Cerretti, DP; Daniel, TO			Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; MOLECULAR CHARACTERIZATION; FAMILY; CLONING; TRANSFORMATION; YEAST; VECTORS; SIGNAL; BRAIN	ELK is a member of the Eph related tyrosine kinase family that includes receptors signaling axonal guidance, neuronal bundling, and angiogenesis. We recently identified ELK expression in human renal microvascular endothelial cells and sought to identify intracellular proteins through which it signals responses. The cytoplasmic domain of ELK was used as "bait" in a yeast two-hybrid screen to identify interactive proteins expressed from a randomly primed embryonic murine library (E9.5-10.5). Among interactive products of 76 cDNAs characterized, 10 nonidentical, overlapping clones encoded the SH2 domain of the recently reported Grb10 adapter protein, and an additional 3 encoded Grb2. A self-phosphorylated recombinant, baculovirus-expressed GST-ELKcy fusion protein bound Grb10 and Grb2 from human renal microvascular endothelial cell extracts, while the unphosphorylated fusion form did not. Site-directed mutation identified Tyr-929 as a putative phosphorylation site required for Grb10, but not Grb2, interaction in yeast and recombinant protein assays. The ELK ligand, LERK-2/Fc, stimulated tyrosine phosphorylation of ELK, and recruitment of Grb10 and Grb2 to endothelial ELK receptors recovered by wheat germ agglutinin lectin and immunoprecipitation. These findings define ligand-activated interaction between ELK and the SH2 domains of Grb2 and the newly identified Grb10 protein that shares homology with a Caenorhabditis elegans gene product implicated in neural cell migration.	VANDERBILT UNIV, SCH MED, DIV NEPHROL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University			Stein, Elke/E-8107-2013	Stein, Elke/0000-0001-8965-5692	NIDDK NIH HHS [DK47078, DK38517] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038517, R01DK047078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; *BIOR LAB INC, 1994, E COL PULS TRANSF AP; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARPENTER MK, 1995, J NEUROSCI RES, V42, P199, DOI 10.1002/jnr.490420207; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; GRUENWALD S, 1995, PHARMINGEN RES PRODU; GRUENWALD S, 1995, BACULOVIRUS EXPRESSI; HAUN RS, 1992, BIOTECHNIQUES, V13, P515; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Rose MD., 1990, METHODS YEAST GENETI; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; TANG XX, 1995, GENOMICS, V29, P426, DOI 10.1006/geno.1995.9985; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WOJTA J, 1989, J BIOL CHEM, V264, P2846; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	136	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23588	23593		10.1074/jbc.271.38.23588	http://dx.doi.org/10.1074/jbc.271.38.23588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798570	hybrid			2022-12-25	WOS:A1996VH76800096
J	Wang, YH; Griffith, J				Wang, YH; Griffith, J			Methylation of expanded CCG triplet repeat DNA from fragile X syndrome patients enhances nucleosome exclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; CPG BINDING-PROTEIN; DIHYDROFOLATE-REDUCTASE; CHROMATIN STRUCTURE; RNA-BINDING; TRANSCRIPTION; PROMOTER; SITE; EXPRESSION; SEQUENCE	Long tracts of CCG trinucleotide or CCGNN pentanucleotide repeats in DNA have previously been shown to resist assembly into nucleosomes. This may provide a molecular explanation for the nature of certain rare, folate-sensitive fragile sites in human chromosomes that contain expanded CCG triplet tracts, Further, it is known that methylation of CpG dinucleotides at or near these fragile sites enhances the fragile phenotype, Here DNAs containing 76 tandem CCG triplets or 48 CCGNN pentanucleotide repeats were methylated with SssI methylase at three different levels of methylation. Using competitive nucleosome reconstitution/gel shift assays, the ability of these DNAs and a mixed sequence DNA from the pUC19 plasmid were compared in their ability to assemble into nucleosomes, DNA methylation had no significant effect on nucleosome formation over the pUC 19 fragment. However, the highly methylated DNAs containing 76 CCG triplets or 48 CCGNN pentanucleotide repeats were 2.0 +/- 0.2-fold and 2.1 +/- 0.3-fold less efficient in nucleosome assembly than the respective unmethylated forms, and 4.4 +/- 0.4-fold and 12.6 +/- 1.6-fold less efficient than a pUC19 fragment of similar length.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; FELSENFELD G, 1982, COLD SPRING HARB SYM, V47, P577; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HOMSTRA IK, 1993, HUM MOL GENET, V2, P1659; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MATSUO K, 1994, NUCLEIC ACIDS RES, V22, P5354, DOI 10.1093/nar/22.24.5354; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SHIMADA T, 1986, J BIOL CHEM, V261, P1445; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG Y, 1996, UNPUB; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WANG YH, 1996, IN PRESS P NATL ACAD	37	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22937	22940		10.1074/jbc.271.38.22937	http://dx.doi.org/10.1074/jbc.271.38.22937			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798475	hybrid			2022-12-25	WOS:A1996VH76800001
J	delaCruz, IP; Nillni, EA				delaCruz, IP; Nillni, EA			Intracellular sites of prothyrotropin-releasing hormone processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; RAT-BRAIN; PROHORMONE CONVERTASES; SECRETORY GRANULES; MAMMALIAN-CELLS; TRH PROHORMONE; ATT20 CELLS; PRO-TRH; PEPTIDES; MEMBRANE	Post-translational processing of proteins plays a key role in regulating their subcellular localization, enzymatic activity, and protein-protein interactions by such diverse mechanisms as phosphorylation, glycosylation, and proteolytic cleavage, The prothyrotropin-releasing hormone (pro-TRH) precursor (26 kDa) undergoes proteolytic cleavage at either of two sites, generating a 15/10-kDa or a 9.5/16.5-kDa N/C-terminal pair of intermediates, Using transfected AtT20 cells encoding a prepro-TRH cDNA, we have previously reported that this initial set of cleavages occurs prior to entry into the secretory granules (Nillni, E. A., Sevarino, K. A., and Jackson, I. M. D. (1993) Endocrinology 132, 1271-1277). In this study, we set out to identify the subcellular compartment where this initial cleavage takes place as well as to determine the sites of processing of the intermediates produced, Our strategy was to block the transport of pro-TRH or its intermediates from one subcellular compartment to the next and to assay for the accumulation of intermediates, presumably because their processing occurs in a post-blockade compartment. Radiolabeling experiments in AtT20 cells in the presence of the drug brefeldin A, which blocks transport from the endoplasmic reticulum to the Golgi complex, led to an accumulation of the 26-kDa precursor, suggesting a post-endoplasmic reticulum site of processing, When Golgi complex-to-secretory granule transport was blocked at 20 degrees C, the processing of the 26-kDa precursor was not affected, suggesting a Golgi complex site of processing, At this temperature, the 15-kDa N-terminal intermediate accumulated, suggesting a post-Golgi complex processing site, while the 16.5-kDa C-terminal intermediate was processed in the Golgi complex to produce a 5.4-kDa peptide.	BROWN UNIV,RHODE ISL HOSP,SCH MED,DEPT MED,DIV ENDOCRINOL,PROVIDENCE,RI 02903	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								BOWERS CY, 1971, BIOCHEM BIOPH RES CO, V45, P1033, DOI 10.1016/0006-291X(71)90441-4; BULANT M, 1990, ENDOCRINOLOGY, V127, P1978, DOI 10.1210/endo-127-4-1978; BULANT M, 1988, J BIOL CHEM, V263, P17189; COCKLE SM, 1990, FEBS LETT, V264, P253, DOI 10.1016/0014-5793(90)80261-G; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Eipper B A, 1980, Endocr Rev, V1, P1; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; FRIEDMAN TC, 1995, ENDOCRINOLOGY, V136, P4462, DOI 10.1210/en.136.10.4462; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HALL ME, 1983, PEPTIDES, V4, P763, DOI 10.1016/0196-9781(83)90033-5; HEDNER J, 1981, NEUROSCI LETT, V24, P317; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; JACKSON IMD, 1994, REGULATION THYROTROP; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Lechan R.M., 1993, THYROID TODAY, V16, P1; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LECHAN RM, 1987, ENDOCRINOLOGY, V121, P1879, DOI 10.1210/endo-121-5-1879; LEGRADI G, 1996, IN PRESS BRAIN RES; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; METCALF G, 1974, NATURE, V252, P310, DOI 10.1038/252310a0; MILGRAM SL, 1994, J CELL SCI, V107, P737; Nicholson WE, 1996, ENDOCRINOLOGY, V137, P2171, DOI 10.1210/en.137.5.2171; Nillni E. A., 1995, Molecular Biology of the Cell, V6, p331A; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; NILLNI EA, 1996, IN PRESS ENDOCRINOLO; NILLNI EA, 1991, NEUROPEPTIDE TECHNOL, P51; REDEI E, 1995, ENDOCRINOLOGY, V136, P3557, DOI 10.1210/en.136.8.3557; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT REM, 1993, MOL ENDOCRINOL, V7, P585, DOI 10.1210/me.7.4.585; SEGERSON TP, 1987, ENDOCRINOLOGY, V121, P98, DOI 10.1210/endo-121-1-98; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEVARINO KA, 1989, J BIOL CHEM, V264, P21529; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; TAKAHARA J, 1974, P SOC EXP BIOL MED, V146, P831, DOI 10.3181/00379727-146-38200; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WILBER JF, 1967, P SOC EXP BIOL MED, V127, P488; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; ZHOU A, 1994, J BIOL CHEM, V269, P17440	46	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22736	22745		10.1074/jbc.271.37.22736	http://dx.doi.org/10.1074/jbc.271.37.22736			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798448	hybrid			2022-12-25	WOS:A1996VG67200067
J	Ding, Y; Kobayashi, S; Kopito, R				Ding, Y; Kobayashi, S; Kopito, R			Mapping of ankyrin binding determinants on the erythroid anion exchanger, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CYTOPLASMIC DOMAIN; MAJOR ANKYRIN; REPEAT DOMAIN; CELL-LINE; MEMBRANE; BAND-3; BRAIN; PROTEIN; KIDNEY	The association of ankryrin with the AE1 anion exchanger contributes an essential function to the mechanical and viscoelastic properties of the erythrocyte and constitutes the best understood link between the plasma membrane and the underlying membrane skeleton. The AE1 binding domain of ankyrin consists of 24 tandem repeats of a 33-amino acid motif that is present on a wide variety of otherwise unrelated proteins. The experiments described in this paper are aimed at identifying the specific amino acid sequences in AE1 that comprise the ankyrin binding site. We have exploited a cell-free binding assay to quantify the binding affinity of anion exchangers and a recombinant fragment of ANK1, R13-H. Our previous study (Ding, Y., Casey, J. R and Kopito, R. R. (1995) J. Biol. Chem. 269, 32201-32208) identified an essential role of the amino-terminal 79 AE1 residues in ankyrin binding. The present study extends these findings to show that these 79 amino acids, although necessary, are not sufficient for ankyrin binding. Using chimeras between AE1 and the closely related anion exchanger AE2, which does not bind ankyrin, we have defined a 40-residue region of AE1 between positions 155 and 195 that is also essential for ankyrin binding.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038543] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM38543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1992, J BIOL CHEM, V267, P8703; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DING Y, 1994, J BIOL CHEM, V269, P32201; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LI ZP, 1993, J BIOL CHEM, V268, P11489; LINN SC, 1992, J BIOL CHEM, V267, P7927; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; MORGANS CW, 1993, J CELL SCI, V105, P1137; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	34	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22494	22498		10.1074/jbc.271.37.22494	http://dx.doi.org/10.1074/jbc.271.37.22494			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798415	hybrid			2022-12-25	WOS:A1996VG67200034
J	Ji, L; Mochon, E; Arcinas, M; Boxer, LM				Ji, L; Mochon, E; Arcinas, M; Boxer, LM			CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; LIGATION-MEDIATED PCR; CHRONIC LYMPHOCYTIC-LEUKEMIA; RESPONSE ELEMENT; MALIGNANT-LYMPHOMA; BURKITTS-LYMPHOMA; EXPRESSION; GENE; TRANSCRIPTION; CELLS	The translocated and normal bcl-2 alleles in the DHL-4 cell line with the t(14;18) translocation were separated by pulsed field electrophoresis, An in vivo footprint over a cAMP response element (CRE) in the bcl-2 5'-flanking sequence was identified on the translocated allele, Electrophoretic mobility shift assays with the bcl-2 CRE demonstrated complexes with mobilities identical to those with a consensus CRE. UV cross-linking experiments revealed that proteins with molecular masses of 34, 43, and 67 kDa bound to the bcl-2 CRE site, Electrophoretic mobility shift assay with an antibody specific to the phosphorylated cAMP response-binding protein (CREB) demonstrated that phosphorylated CREB was present in DHL-4 cells. Treatment with phorbol 12-myristate 13-acetate (PMA) led to an increase in both the amount of phosphorylated CREB and the bcl-2 promoter activity, The response to PMA was dependent on an intact CRE site. The activity of the bcl-2 promoter was increased 20-fold in a construct with the immunoglobulin heavy chain enhancers, and mutation of the CRE site abolished most of the induction, The addition of PMA increased the activity of the bcl-2-immunoglobulin enhancer construct by 3.5-fold. Access to the CRE site is blocked in the silent normal bcl-2 allele, while CREB proteins bind to the site on the translocated allele. We conclude that the CRE site functions as a positive regulatory site for the translocated bcl-2 allele in t(14;18) lymphomas.	STANFORD UNIV,SCH MED,DIV HEMATOL,DEPT MED,STANFORD,CA 94305; PALO ALTO VET AFFAIRS MED CTR,CTR MOL BIOL & MED,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FRANKFURT OS, 1993, ONCOL RES, V5, P37; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HANADA M, 1993, BLOOD, V82, P1820; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIYASHITA T, 1994, CANCER RES, V54, P3131; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; XING LP, 1994, J BIOL CHEM, V269, P28732; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZELENETZ AD, 1991, BLOOD, V78, P1552	31	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22687	22691		10.1074/jbc.271.37.22687	http://dx.doi.org/10.1074/jbc.271.37.22687			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798441	hybrid			2022-12-25	WOS:A1996VG67200060
J	Matsumoto, K; Meric, F; Wolffe, AP				Matsumoto, K; Meric, F; Wolffe, AP			Translational repression dependent on the interaction of the Xenopus Y-box protein FRGY2 with mRNA - Role of the cold shock domain, tail domain, and selective RNA sequence recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEOPROTEIN PARTICLES; OOCYTE-SPECIFIC PROTEINS; ACID BINDING-PROTEINS; DEVELOPMENTAL REGULATION; TRANSCRIPTION FACTOR; BACILLUS-SUBTILIS; MASKING PROTEINS; SOMATIC-CELLS; DNA-BINDING; IN-VIVO	We have examined the determinants of the translational repression of mRNA by the Xenopus oocyte-specific Y-box protein FRGY2 using in vitro and in vivo assays. In vitro reconstitution of messenger ribonucleoprotein (mRNP) complexes demonstrates that the sequence-specific RNA-binding cold shock domain is not required for translational repression, whereas the RNA-binding C-terminal tail domain is essential. However, microinjection of reconstituted mRNPs into Xenopus oocytes demonstrates that although translational repression occurs in the absence of consensus RNA binding sequences for FRGY2, the presence of FRGY2 recognition elements within mRNA potentiates translational repression. Analysis of the in vivo assembly of mRNP shows that the cold shock domain alone is not stably incorporated into mRNP, whereas the C-terminal tail domain is sufficient for stable incorporation. We suggest that translational repression of mRNA by FRGY2 is favored by sequence-selective recognition of RNA sequences by the cold shock domain. However, translational repression in vitro and the assembly of mRNP in vivo requires the relatively nonspecific interaction of the C-terminal tail domain with mRNA. Thus two distinct domains of FRGY2 are likely to contribute to translational control.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CHO HS, 1994, GENE, V143, P233; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DINGWALL C, 1984, EMBO J, V3, P1933, DOI 10.1002/j.1460-2075.1984.tb02072.x; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GUNKEL N, 1995, NUCLEIC ACIDS RES, V23, P405, DOI 10.1093/nar/23.3.405; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SOMMERVILLE J, 1992, BIOESSAYS, V14, P337, DOI 10.1002/bies.950140509; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; STANDART N, 1992, SEMIN DEV BIOL, V3, P369; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TOYODA T, 1992, DEV BIOL, V153, P150, DOI 10.1016/0012-1606(92)90099-3; WICKENS M, 1992, SEM DEV BIOL, V3, P399; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804	43	107	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22706	22712		10.1074/jbc.271.37.22706	http://dx.doi.org/10.1074/jbc.271.37.22706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798444	hybrid			2022-12-25	WOS:A1996VG67200063
J	Miao, YJ; Wang, JYJ				Miao, YJ; Wang, JYJ			Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN FUNCTION; SEX-DETERMINING REGION; CELL-CYCLE; TRANSCRIPTION FACTOR; ALPHA-ENHANCER; HMG DOMAIN; PHOSPHORYLATION; COMPLEX; SITE; GENE	The c-Abl tyrosine kinase has been shown previously to bind DNA, Using polymerase chain reaction-based binding site-selection methods, no consensus high affinity binding site for c-Abl was found, Instead, oligonucleotides with runs of A/T sequences were isolated, and purified c-Abl was shown to bind A/T-containing oligo nucleotides better than those without A/T sequences, DNA binding of c-Abl was dependent on three high mobility group 1-like boxes (HLBs), which bound cooperatively to the A/T-rich oligonucleotides. To distinguish binding to A/T sequences per se from binding to nonspecific DNA with a bend at the A/T-rich region, two oligonucleotides were compared for binding to c-Abl, Both oligonucleotides contained A/T sequences, In one, the A/T motif was part of an 80-mer duplex DNA. In another, the A/T motif was in the duplex arm of an 80-mer ''bubble DNA'' containing an internal unpaired 20-mer region to provide a flexible hinge. Interestingly, the HLBs of c-Abl bound better to the oligonucleotide containing the bubble, suggesting a higher affinity for bent DNA rather than A/T sequences per se. Taken together, these observations define a new class of DNA binding domains, the HLBs, which do not bind DNA with a high degree of sequence specificity, but may selectively bind to bent DNA or to sequences that are easier to distort.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, CA 43054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	34	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22823	22830		10.1074/jbc.271.37.22823	http://dx.doi.org/10.1074/jbc.271.37.22823			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798460	hybrid			2022-12-25	WOS:A1996VG67200079
J	Bochkareva, E; Seluanov, A; Bibi, E; Girshovich, A				Bochkareva, E; Seluanov, A; Bibi, E; Girshovich, A			Chaperonin-promoted post-translational membrane insertion of a multispanning membrane protein lactose permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC CARRIER PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; GROEL; PURIFICATION; INVITRO; GENE; TRANSLOCATION; CHANNEL; HELIX	Using an in vitro membrane-free translation system from Escherichia coli, it is shown that chaperonin GroEL added cotranslationally interacts with newly synthesized lactose permease (LacY), a polytopic membrane protein, thereby preventing aggregation, Subsequently, when the isolated GroEL-LacY complex is incubated with inverted membrane vesicles, the permease is inserted into the membrane in a MgATP-dependent manner. Post-translational membrane insertion is also observed when aggregation of newly synthesized LacY is prevented by addition of the nonionic detergent n-dodecyl-beta,D-maltoside during translation in place of GroEL. No membrane integration occurs with right-side-out vesicles, indicating that LacY interacts specifically only with the cytosolic face of the membrane. Ligand thiodigalactoside protection against alkylation of the Cys-148 residue in the permease shows proper posttranslational insertion. Moreover, limited proteolysis of soluble LacY either complexed with GroEL or in detergent indicates that the newly synthesized protein assumes a conformation that is comparable to that of native, membrane-embedded permease prior to insertion into the membrane.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Bibi, Eitan/0000-0003-3700-2707; Seluanov, Andrei/0000-0003-3400-538X				AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; BEYREUTHER K, 1982, METHODS PROTEIN SEQU, P139; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BIESELER B, 1985, ANN NY ACAD SCI, V456, P309, DOI 10.1111/j.1749-6632.1985.tb14882.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CARTER JR, 1968, P NATL ACAD SCI USA, V60, P725, DOI 10.1073/pnas.60.2.725; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; CRAMER WA, 1992, FASEB J, V6, P3397, DOI 10.1096/fasebj.6.15.1464373; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; EHRING R, 1980, NATURE, V283, P537, DOI 10.1038/283537a0; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; GOVEZENSKY D, 1994, J BIOL CHEM, V269, P14003; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KABACK HR, 1983, J MEMBRANE BIOL, V76, P95; KNUDSEN P, 1978, MEMBRANE BIOCHEM, V1, P297, DOI 10.3109/09687687809063853; LEMAIRE M, 1983, EUR J BIOCHEM, V129, P525; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MORIMOTO T, 1983, METHOD ENZYMOL, V96, P121; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; PEBAYPEYROULA E, 1995, STRUCTURE, V3, P1051, DOI 10.1016/S0969-2126(01)00241-6; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SATO K, 1994, BIOCHEM BIOPH RES CO, V202, P258, DOI 10.1006/bbrc.1994.1921; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, TRENDS BIOCHEM SCI, V15, P369, DOI 10.1016/0968-0004(90)90230-9; STOCHAJ U, 1986, EUR J BIOCHEM, V158, P423, DOI 10.1111/j.1432-1033.1986.tb09770.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WRIGHT JK, 1983, METHOD ENZYMOL, V97, P158; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020	47	35	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22256	22261		10.1074/jbc.271.36.22256	http://dx.doi.org/10.1074/jbc.271.36.22256			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703042	hybrid			2022-12-25	WOS:A1996VF61200084
J	Brauchle, M; Funk, JO; Kind, P; Werner, S				Brauchle, M; Funk, JO; Kind, P; Werner, S			Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PERMEABILITY FACTOR; TYROSINE KINASE; CELL MITOGEN; ACTIVATION; RECEPTOR; GENE; UV; ANGIOGENESIS; PURIFICATION	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is strongly expressed by epidermal keratinocytes during wound healing, in psoriasis, and in bullous diseases such as erythema multiforme and bullous pemphigoid. All of these disorders are characterized by increased microvascular permeability and angiogenesis. Since the development of erythema as a result of hyperpermeable blood vessels is also a common feature after excess sun exposure, we speculated about an up-regulation of VEGF expression by ultraviolet (UV) light. To test this hypothesis, we analyzed the effect of UVB irradiation on VEGF expression in cultured keratinocytes. Thereby we found a large increase in VEGF mRNA and protein levels upon irradiation of quiescent keratinocytes with sublethal and physiologically relevant doses of UVB. Although H2O2 was also a potent inducer of VEGF expression, the effect of UVB irradiation is unlikely to be mediated by reactive oxygen species as determined by the use of antioxidants. Further experiments revealed that the UVB-induced overexpression of VEGF is dependent on de novo protein synthesis and might occur via release of soluble mediators, which subsequently turn on VEGF expression. In summary, our results suggest a novel role of VEGF in the induction of erythema after excess sun exposure.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOL BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,ABT MOL PATHOL,D-80337 MUNICH,GERMANY	Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich				Werner, Sabine/0000-0001-7397-8710				ANSEL JC, 1983, J INVEST DERMATOL, V81, P519, DOI 10.1111/1523-1747.ep12522862; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; BUSCHER M, 1988, ONCOGENE, V3, P301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS PD, 1993, BRIT J PHARMACOL, V109, P195, DOI 10.1111/j.1476-5381.1993.tb13553.x; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FUNK JO, 1994, J AM ACAD DERMATOL, V31, P999, DOI 10.1016/S0190-9622(94)70272-1; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; KRUTMANN J, 1995, J INVEST DERMATOL, V105, pS67, DOI 10.1111/1523-1747.ep12316095; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER CC, 1994, J BIOL CHEM, V269, P3529; PENTLAND AP, 1994, ADV EXP MED BIOL, V366, P87; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1990, CANCER RES, V50, P1774; SENGER DR, 1987, FED PROC, V46, P2102; SHEA CR, 1982, ARCH DERMATOL RES, V273, P233, DOI 10.1007/BF00409251; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	45	149	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21793	21797		10.1074/jbc.271.36.21793	http://dx.doi.org/10.1074/jbc.271.36.21793			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702976	hybrid			2022-12-25	WOS:A1996VF61200018
J	Charlet, M; Chernysh, S; Philippe, H; Hetru, C; Hoffmann, JA; Bulet, P				Charlet, M; Chernysh, S; Philippe, H; Hetru, C; Hoffmann, JA; Bulet, P			Innate immunity - Isolation of several cysteine-rich antimicrobial peptides from the blood of a mollusc, Mytilus edulis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; INSECT DEFENSIN-A; SEQUENCE HOMOLOGY; HOST-DEFENSE; SEA HARE; DROSOPHILA; PURIFICATION; SNAIL; MUCUS; TREES	We have isolated fi om the blood of immune-challenged and untreated mussels (Mytilus edulis) antibacterial and antifungal peptides. We have characterized two isoforms of a novel 34-residue, cysteine-rich, peptide with potent bactericidal activity and partially characterized a novel 6.2-kDa antifungal peptide containing 12 cysteines. We report the presence of two members of the insect defensin family of antibacterial peptides and provide a phylogenetic analysis that indicates that mollusc and arthropod defensins have a common ancestry. Our data argue that circulating antimicrobial peptides represent an ancient host defense mechanism that predated the separation between molluscs and arthropods at the root of the Cambrian, about 545 million years ago.	INST BIOL MOL & CELLULAIRE,CNRS,UNITE PROPRE RECH RESPONSE IMMUNITAIRE & DEV INSE,F-67084 STRASBOURG,FRANCE; ST PETERSBURG STATE UNIV,ENTOMOL LAB,ST PETERSBURG 198904,RUSSIA; UNIV PARIS 11,CNRS,UNITE RECH ASSOCIE DEV & MORPHOGENESE 1134,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Saint Petersburg State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			BULET, Philippe/C-8557-2014; Tulin, Dmitry/N-1039-2013	BULET, Philippe/0000-0001-9016-265X; Tulin, Dmitry/0000-0001-6357-0228				BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Hetru Charles, 1994, P43; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; IGUCHI SMM, 1982, COMP BIOCHEM PHYS A, V72, P571, DOI 10.1016/0300-9629(82)90123-2; KAMIYA H, 1984, EXPERIENTIA, V40, P947, DOI 10.1007/BF01946452; KUBOTA Y, 1985, COMP BIOCHEM PHYS C, V82, P345, DOI 10.1016/0742-8413(85)90173-2; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LERCHER RI, 1994, PHYLOGENETIC PERSPEC, P19; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; LOWENBERGER C, 1995, INSECT BIOCHEM MOLEC, V25, P867, DOI 10.1016/0965-1748(95)00043-U; MALOY LW, 1995, BIOPOLYMERS, V37, P105; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; OTSUKAFUCHINO H, 1992, COMP BIOCHEM PHYS C, V101, P607, DOI 10.1016/0742-8413(92)90094-N; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; Philippe Herve, 1996, P41; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SWOFFORD DL, 1993, PAUP VERSION 3 1 ILL; YAMAZAKI M, 1990, DEV COMP IMMUNOL, V14, P379, DOI 10.1016/0145-305X(90)90030-I	32	295	338	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21808	21813		10.1074/jbc.271.36.21808	http://dx.doi.org/10.1074/jbc.271.36.21808			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702979	hybrid			2022-12-25	WOS:A1996VF61200021
J	Kandror, KV; Pilch, PF				Kandror, KV; Pilch, PF			The insulin-like growth factor II mannose 6-phosphate receptor utilizes the same membrane compartments as GLUT4 for insulin-dependent trafficking to and from the rat adipocyte cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER-CONTAINING VESICLES; GLUCOSE-TRANSPORTER; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; GLUT4-ENRICHED VESICLES; SUBCELLULAR TRAFFICKING; TRANSFERRIN RECEPTORS; LYSOSOMAL-ENZYMES	The insulin-like growth factor II (IGF-II)/mannose 6-phosphate (Man-6-P) receptor recycles in adipose cells between the cell surface and an intracellular storage pool, and the rate of this trafficking is markedly enhanced by insulin, We show here that the IGF-II/Man-6-P receptor is a constituent of the GLUT4-containing compartment (''GLUT4 vesicles'') where it represents gp230, a major recycling protein detected earlier by cell surface biotinylation (Kandror, K. V., and Pilch, P. F. (1994) J. Biol. Chem. 269, 138-142). The GLUT4 vesicles include 10-15% of the total and all of the acutely insulin-responsive recycling population of the IGF-II/Man-6-P receptor. The main part of the IGF-II/Man-6-P receptor population is excluded from the pathway of GLUT4 trafficking and either resides permanently in intracellular membranes or has a much slower rate of cycling to the cell surface. Thus, GLUT4 vesicles mediate the insulin-dependent delivery to the cell surface of the IGF-II/Man-6-P receptor as well as the other recyclable proteins with extracellular functional domains (GLUT4 and the aminopeptidase gp160).	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Kandror, Konstantin/0000-0002-8601-9313; Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK44269, P30 DK46200, DK30425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, P01DK044269, R01DK030425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DELVECCHIO RL, 1991, J BIOLL CHEM, V266, P23865; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; OKA Y, 1986, J BIOL CHEM, V261, P9090; OKA Y, 1985, J BIOL CHEM, V260, P9435; OKA Y, 1988, J BIOL CHEM, V263, P13432; OPPENHEIMER CL, 1983, J BIOL CHEM, V258, P4824; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V73, P4379, DOI 10.1073/pnas.73.12.4379; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; STAGSTED J, 1993, J BIOL CHEM, V268, P22809; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	54	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21703	21708		10.1074/jbc.271.36.21703	http://dx.doi.org/10.1074/jbc.271.36.21703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702963	hybrid			2022-12-25	WOS:A1996VF61200005
J	Kurata, SI				Kurata, SI			Sensitization of the HIV-1-LTR upon long term low dose oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; KAPPA-B; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; ACTIVATION; SEQUENCES; PROMOTER; TYPE-1; ALPHA	Human lymphoid cell lines were transfected with HIV-1-LTR-CAT DNA and permanently transformed cell lines were obtained. These transformed cell lines were treated with 0.01 mM H2O2 for 25 days and the chloramphenicol acetyltransferase (CAT) activities of these cell lines were measured. The CAT activities of transformed cell lines were latent in normal culture conditions, but were activated by retreatment with 0.2 mM H2O2 for 1 h. On treatment with 0.05 mM H2O2 for 1 h, the CAT activity of these cell lines maintained in normal conditions remained latent, whereas cell lines pretreated with 0.01 mM H2O2 for 25 days were greatly activated by this treatment. Here, the HIV-1 promoter seemed latent in normal culture conditions, but it could be activated by a comparatively low concentration (0.05 mM) of H2O2 after treatment with a dilute H2O2 (0.01 mM) for about 1 month. Many patients infected with human immunodeficiency virus 1 (HIV-1) show a long latent period before development of AIDS. During this latent period, their infected cells may be subjected to oxidative stress due to metabolism and physical movement. The present results indicate that oxidative stress may cause activation of the HIV-1 promoter in patients with latent HIV-1.			Kurata, SI (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT BIOCHEM GENET,BUNKYO KU,TOKYO 113,JAPAN.							BLATTNER WA, 1985, ANN INTERN MED, V103, P665, DOI 10.7326/0003-4819-103-5-665; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAUCI AS, 1993, NEW ENGL J MED, V328, P429, DOI 10.1056/NEJM199302113280610; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; KURATA S, 1993, FEBS LETT, V321, P201, DOI 10.1016/0014-5793(93)80108-7; KURATA S, 1994, J BIOL CHEM, V269, P24553; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; METZGER S, 1993, J BIOL CHEM, V268, P16831; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SANDRIGOLDIN RM, 1981, MOL CELL BIOL, V1, P743, DOI 10.1128/MCB.1.8.743; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571	19	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21798	21802		10.1074/jbc.271.36.21798	http://dx.doi.org/10.1074/jbc.271.36.21798			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702977	hybrid			2022-12-25	WOS:A1996VF61200019
J	Talanian, RV; Dang, LC; Ferenz, CR; Hackett, MC; Mankovich, JA; Welch, JP; Wong, WW; Brady, KD				Talanian, RV; Dang, LC; Ferenz, CR; Hackett, MC; Mankovich, JA; Welch, JP; Wong, WW; Brady, KD			Stability and oligomeric equilibria of refolded interleukin-1 beta converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; MICE DEFICIENT; IN-VIVO; APOPTOSIS; INHIBITION	We report the preparation and characterization of interleukin-1 beta converting enzyme (ICE) refolded from its p20 and p10 protein fragments, Refolded ICE heterodimer (p20p10) was catalytically active but unstable, and in size exclusion chromatography eluted at an apparent molecular mass of 30 kDa, The mechanisms of the observed instability were pH-dependent dissociation at low enzyme concentrations, and autolytic degradation of the p10 subunit at high concentrations, Binding and subsequent removal of a high affinity peptidic inhibitor increased the apparent molecular mass to 43 kDa (by size exclusion chromatography), and significantly increased its stability and specific activity. Chemical cross-linking and SDS-polyacrylamide gel electrophoresis analysis of the 43-kDa size exclusion chromatography conformer revealed a 60-kDa species, which was absent in the 30-kDa conformer, suggesting that inhibitor binding caused formation of a (p20p10), homodimer, The observation of a reversible equilibrium between ICE (p20p10) and (p20p10)(2) suggests that analogous associations, possibly between ICE and ICE homologs, can occur in vivo, resulting in novel oligomeric protease species.			Talanian, RV (corresponding author), BASF BIORES CORP,WORCESTER,MA 01605, USA.							AYAIA JM, 1994, J IMMUNOL, V153, P2592; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ELFORD PR, 1995, BRIT J PHARMACOL, V115, P601, DOI 10.1111/j.1476-5381.1995.tb14974.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; POE M, 1991, J BIOL CHEM, V266, P98; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry Nancy A., 1995, Perspectives in Drug Discovery and Design, V2, P389, DOI 10.1007/BF02172032; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZIMMERMAN M, 1976, ANAL BIOCHEM, V70, P258, DOI 10.1016/S0003-2697(76)80066-8	37	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21853	21858		10.1074/jbc.271.36.21853	http://dx.doi.org/10.1074/jbc.271.36.21853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702986	hybrid			2022-12-25	WOS:A1996VF61200028
J	Imai, T; Yoshida, T; Baba, M; Nishimura, M; Kakizaki, M; Yoshie, O				Imai, T; Yoshida, T; Baba, M; Nishimura, M; Kakizaki, M; Yoshie, O			Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-3; COLONY FORMATION INVITRO; FUNCTIONAL EXPRESSION; MESSENGER-RNA; SECRETED PROTEINS; ENDOTHELIAL-CELLS; PROGENITOR CELLS; DUFFY ANTIGEN; RECEPTOR; GENE	Precursors of most secreted and cell surface molecules carry signal sequences at their amino termini. Here we describe an efficient signal sequence trap method and isolation of a novel CC chemokine. An expression library was constructed by inserting 5' portion-enriched cDNAs from phytohemagglutinin-stimulated peripheral blood mononuclear cells into upstream of signal sequence deleted CD4 cDNA in an Epstein-Barr virus shuttle vector. After electroporation into Raji cells, CD4 antigen-positive cells were enriched by repeated cell sorting and plasmids were recovered in Escherichia coli. Out of 100 plasmid clones examined, 42 clones directed expression of CD4 antigen on the cell surface. Among them were signal sequences of CD6, beta(2)-microglobulin, MGC-24, and T cell receptor epsilon-chain, and at least four novel potential signal sequences. A cDNA clone encoding a novel CC chemokine was isolated by using one of the trapped fragments. The gene designated as TARC from Thymus and Activation-Regulated Chemokine was expressed transiently in phytohemagglutinin-stimulated peripheral blood mononuclear cells and constitutively in thymus. Radiolabeled recombinant TARC specifically bound to T cell lines and peripheral T cells but not to monocytes or granulocytes. The binding of radiolabeled TARC to the high-affinity receptor (K-d, 2.1 nM) on Jurkat was displaced by TARC but not by interleukin-8, MIP-1 alpha, RANTES, or MCP-1. TARC also bound to the promiscuous chemokine receptor on erythrocytes (K-d, 17 nM). TARC induced chemotaxis in T cell lines Hut78 and Hut102. Pretreatment of Hut78 with pertussis toxin abolished the TARC-induced cell migration. Collectively, T cells express a highly selective receptor for TARC that is coupled to pertussis toxin-sensitive G-protein. TARC may a factor playing important roles in T cell development in thymus as well as in trafficking and activation of mature T cells.			Imai, T (corresponding author), SHIONOGI INST MED RES, 2-5-1 MISHIMA, SETTSU, OSAKA 566, JAPAN.			Yoshie, Osamu/0000-0003-4353-5809				ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; Baba M, 1996, INT J CANCER, V66, P124, DOI 10.1002/(SICI)1097-0215(19960328)66:1<124::AID-IJC21>3.3.CO;2-L; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BROXMEYER HE, 1990, BLOOD, V76, P1110; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HORGAN KJ, 1991, CURRENT PROTOCOLS IM; HORUK R, 1994, J BIOL CHEM, V269, P17730; IMAI T, 1995, J IMMUNOL, V155, P1229; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MASUZAWA Y, 1992, J BIOCHEM-TOKYO, V112, P609, DOI 10.1093/oxfordjournals.jbchem.a123948; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MILLER MD, 1989, J IMMUNOL, V143, P2907; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TURNER L, 1995, J IMMUNOL, V155, P2437; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	58	259	282	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21514	21521		10.1074/jbc.271.35.21514	http://dx.doi.org/10.1074/jbc.271.35.21514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702936	hybrid			2022-12-25	WOS:A1996VE47700082
J	Schumaker, KS; Gizinski, MJ				Schumaker, KS; Gizinski, MJ			G proteins regulate dihydropyridine binding to moss plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PERMEABLE CHANNELS; INWARD K+ CHANNEL; ALPHA-SUBUNIT; WHEAT ROOTS; FUNARIA; VESICLES; CELLS; SITES; TRANSDUCTION; PROTOPLASTS	The role of calcium as an activator and regulator of many biological processes is linked to the ability of the cell to rapidly change its cytoplasmic calcium levels, Calcium acts as an intracellular messenger in hormone-induced bud formation during the development of the moss Physcomitrella patens. Calcium transport and ligand binding studies have implicated plasma membrane-localized 1,4-dihydropyridine (DHP)-sensitive calcium channels in this increase in cellular calcium. To understand the regulation of the moss calcium channel, we investigated the involvement of GTP binding regulatory proteins (G proteins). Guanosine 5'-(gamma-thio)triphosphate (GTP gamma S), a nonhydrolyzable GTP analog that locks G proteins into their active state, stimulated DHP binding to high affinity receptors in the moss plasma membrane. DHP binding was measured as the ability of the DHP agonist Bay K8644 or the DHP antagonist nifedipine to compete with the DHP arylazide [H-3]azidopine for binding to moss plasma membranes, G protein stimulation of binding was seen when competition was carried out with either nifedipine or Bay K8644. G proteins regulated the rates of association and dissociation of bound [H-3]azidopine, and stimulation was dependent on GTP gamma S concentration. Guanosine 5'-(beta-thio)diphosphate, a GDP analog that locks G proteins into their inactivated state, did not affect the dose dependence of either the agonist or the antagonist. These results suggest that G proteins may act via a membrane-delimited pathway to regulate calcium channels in the moss plasma membrane.			Schumaker, KS (corresponding author), UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721, USA.							BERGAMASCHI S, 1988, BIOCHEM BIOPH RES CO, V156, P1279, DOI 10.1016/S0006-291X(88)80771-X; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; Boyd PJ, 1988, METHODS BRYOLOGY, P47; BRANDES H, 1986, PLANT PHYSIOL, V43, P827; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CONRAD PA, 1988, PLANT PHYSIOL, V86, P684, DOI 10.1104/pp.86.3.684; DUNN SMJ, 1991, BIOCHEMISTRY-US, V30, P5716, DOI 10.1021/bi00237a012; FAIRLEYGRENOT K, 1991, PLANT CELL, V3, P1037; GILROY S, 1992, P NATL ACAD SCI USA, V89, P3591, DOI 10.1073/pnas.89.8.3591; GOTTWALD R, 1988, METHODS BRYOLOGY, P73; HAHM SH, 1991, CELL CALCIUM, V12, P675, DOI 10.1016/0143-4160(91)90037-F; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HUANG JWW, 1994, P NATL ACAD SCI USA, V91, P3473, DOI 10.1073/pnas.91.8.3473; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA H, 1991, GENE, V107, P189; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MARKMANNMULISCH U, 1987, J PLANT PHYSIOL, V129, P155, DOI 10.1016/S0176-1617(87)80112-8; MARSHALL J, 1994, PLANT J, V5, P683, DOI 10.1111/j.1365-313X.1994.00683.x; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PINEROS M, 1995, PLANTA, V195, P478, DOI 10.1007/BF00195704; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SAUNDERS MJ, 1982, SCIENCE, V217, P943, DOI 10.1126/science.217.4563.943; SAUNDERS MJ, 1983, DEV BIOL, V99, P41, DOI 10.1016/0012-1606(83)90252-X; SAUNDERS MJ, 1981, PLANTA, V152, P272, DOI 10.1007/BF00385156; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUMAKER KS, 1993, P NATL ACAD SCI USA, V90, P10937, DOI 10.1073/pnas.90.23.10937; SCHUMAKER KS, 1995, J BIOL CHEM, V270, P23461, DOI 10.1074/jbc.270.40.23461; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TERRYN N, 1993, PLANT MOL BIOL, V22, P143, DOI 10.1007/BF00039002; THULEAU P, 1994, EMBO J, V13, P5843, DOI 10.1002/j.1460-2075.1994.tb06928.x; THULEAU P, 1994, EMBO J, V13, P2970, DOI 10.1002/j.1460-2075.1994.tb06595.x; WU WH, 1994, P NATL ACAD SCI USA, V91, P6310, DOI 10.1073/pnas.91.14.6310; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887	35	13	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21292	21296		10.1074/jbc.271.35.21292	http://dx.doi.org/10.1074/jbc.271.35.21292			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702906	hybrid			2022-12-25	WOS:A1996VE47700052
J	VoynoYasenetskaya, TA; Faure, MP; Ahn, NG; Bourne, HR				VoynoYasenetskaya, TA; Faure, MP; Ahn, NG; Bourne, HR			G alpha 12 and G alpha 13 regulate extracellular signal-regulated kinase and c-Jun kinase pathways by different mechanisms in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS-DEPENDENT ACTIVATION; MUTANT ALPHA-SUBUNITS; BETA-GAMMA-SUBUNITS; MAP KINASE; TRANSFORMATION; EXCHANGE; CAMP; TRANSDUCTION; FIBROBLASTS	Many growth factors and agonists for G protein-coupled receptors activate mitogen-activated protein (MAP) kinase pathways, including the extracellular signal-regulated kinase (ERK) pathway and the c-Jun kinase (JNK) pathway. Transient transfection of dominant negative and constitutively active pathway components in COS-7 cells shows that two G protein subunits, G alpha 12 and G alpha 13, inhibit the ERK pathway and stimulate the JNK pathway. Constitutively active (GTPase-deficient) G alpha 12 and G alpha 13 both inhibit ERK pathway activation by epidermal growth factor. A G alpha 13/alpha z chimera, which responds to stimulation by G(i)-coupled receptors, mediates inhibition of ERK via such a receptor, the dopamine-2 receptor. In addition, expression of a dominant negative mutant of the GTPase, Cdc42, blocks activation of the JNK pathway by G alpha 12 and G alpha 13 but does not alter inhibition of ERK activation by the same G alpha proteins; conversely, mutationally activated Cdc42 stimulates the JNK pathway but has no effect on the ERK pathway, Our results show that different mechanisms mediate two effects of G alpha 12 and G alpha 13: the ERK pathway inhibition is mediated at the level of MAP kinase kinase in a Ras- and Raf-independent fashion, whereas the JNK pathway stimulation is mediated by Cdc42.	UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL & MED,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; EGER R, 1995, FASEB J, V9, P726; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HART MJ, 1994, J BIOL CHEM, V269, P62; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MALY K, 1989, J BIOL CHEM, V264, P11839; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QUI RG, 1995, NATURE, V374, P457; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAN MH, 1994, NATURE, V372, P798	48	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21081	21087		10.1074/jbc.271.35.21081	http://dx.doi.org/10.1074/jbc.271.35.21081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702875	hybrid			2022-12-25	WOS:A1996VE47700021
J	Waltner, M; Hammen, PK; Weiner, H				Waltner, M; Hammen, PK; Weiner, H			Influence of the mature portion of a precursor protein on the mitochondrial signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; F1-ATPASE BETA-SUBUNIT; ALDEHYDE DEHYDROGENASE; PROCESSING PEPTIDASE; TERMINAL REGION; IMPORT; PRESEQUENCE; CLEAVAGE; CONFORMATION; SUFFICIENT	Most mitochondrial proteins are synthesized with an N-terminal signal sequence that targets these proteins to various compartments within the mitochondria. Signal sequences have been shown to be functional by fusing them to a nonmitochondrial passenger protein and observing import. In many cases, a signal sequence has been fused to passenger proteins, such as dihydrofolate reductase, and import occurred. There are, though, several unexplained instances in which a signal sequence was attached to a passenger protein and import was not observed. In this study, the N-terminal 23 residues of the matrix enzyme rhodanese could import several passenger proteins but were unable to import the mature form of mitochondrial aldehyde dehydrogenase (mALDH). However; if these same 23 residues were fused to the middle portion of mALDH, import was recovered, suggesting that the rhodanese signal sequence and N terminus of mALDH were incompatible for import. Circular dichroism data indicated that a peptide corresponding to the region of fusion between rhodanese and mALDH had less structure than corresponding peptides hom imported fusion proteins, suggesting that mALDH may alter the helix in the rhodanese signal sequence, thus preventing import.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIAAA NIH HHS [AA05812] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HAMMEN PK, 1996, IN PRESS J BIOL CHEM, V271; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1987, J BIOL CHEM, V262, P1420; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; JAUSSI R, 1995, EUR J BIOCHEM, V228, P551, DOI 10.1111/j.1432-1033.1995.tb20294.x; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KIMURA T, 1993, PLANT CELL PHYSIOL, V34, P345; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PAK YK, 1990, J BIOL CHEM, V265, P14298; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; SANGER F, 1977, P NATL ACAD SCI USA, V89, P11930; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VANSTEEG H, 1986, EMBO J, V5, P3643, DOI 10.1002/j.1460-2075.1986.tb04694.x; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5; WANG Y, 1993, J BIOL CHEM, V268, P4759; YANG JT, 1986, METHOD ENZYMOL, V130, P208	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21226	21230		10.1074/jbc.271.35.21226	http://dx.doi.org/10.1074/jbc.271.35.21226			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702895	hybrid			2022-12-25	WOS:A1996VE47700041
J	Huang, TS; Kuo, ML; Shew, JY; Chou, YW; Yang, WK				Huang, TS; Kuo, ML; Shew, JY; Chou, YW; Yang, WK			Distinct p53-mediated G(1)/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents	ONCOGENE			English	Article						apoptosis; cell growth arrest; G(1)/S checkpoint; MMS; gamma-radiation; TPA	CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CELLULAR-RESPONSE; GENE-EXPRESSION; BAX GENE; IN-VIVO; PROTEIN; APOPTOSIS	N-3T3 and P-3T3 cells, originally isolated from a NIH3T3 cell clone on the basis of their negative and positive transformation by v-Abl, v-Src and Bcr-Abl, were previously found to show distinct cyclin activity changes following 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, which is anti-mitogenic for N-3T3 cells and mitogenic for P-3T3 cells. We have found in this study that, while the G(1)/S arrest and cell death induced by serum starvation and TPA treatment in N-3T3 cells did not involve p53-mediated checkpoint or apoptosis, N-3T3 and P-3T3 cells evidently responded differently in these aspects of cell cycle regulation to DNA-damaging agents, methylmethane sulfonate (MMS) and gamma-radiation. In N-3T3 cells, DNA damages elicit cell growth arrest at G(1)/S transition with concomitant accumulation of p53 and p53-inducible Waf1/Cip1 proteins and also signs of apoptosis such as DNA ladder patterns and apoptotic (subgenomic) peak in flow cytograph. Conversely, P-3T3 cells treated with the DNA-damaging agents showed no cell cycle interruption nor accumulation of p53 or Waf1/Cip1. However, both P-3T3 and N-3T3 cells showed the same p53 protein half-life of 40 min or less, the same wild-type p53 DNA sequence and the same co-immunoprecipitable cellular proteins in complexes with p53, suggesting that an alteration in a signal transduction pathway upstream of p53 might account for the evasion of p53-mediated G(1) checkpoint in P-3T3 cells.	ACAD SINICA,NATL HLTH RES INST,CLIN RES INST,TAIPEI,TAIWAN; ACAD SINICA,INST BIOMED SCI,VGH TAIPEI,COOPERAT CLIN RES LAB,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST TOXICOL,TAIPEI 10764,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST BIOCHEM,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; National Health Research Institutes - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University			Kuo, Min-Liang/C-4872-2009; Huang, Tze-Sing/E-3667-2010; Huang, Tze-Sing/C-9361-2013	Huang, Tze-Sing/0000-0001-8736-4330; KUO, MIN-LIANG/0000-0002-7139-0144				CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLSON DC, 1993, ONCOGENE, V8, P2353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	34	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					625	632						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760304				2022-12-25	WOS:A1996VB32800020
J	Kondo, S; Kondo, Y; Yin, DL; Barnett, GH; Kaakaji, R; Peterson, JW; Morimura, T; Kubo, H; Takeuchi, J; Barna, BP				Kondo, S; Kondo, Y; Yin, DL; Barnett, GH; Kaakaji, R; Peterson, JW; Morimura, T; Kubo, H; Takeuchi, J; Barna, BP			Involvement of interleukin-1 beta-converting enzyme in apoptosis of bFGF-deprived murine aortic endothelial cells	FASEB JOURNAL			English	Article						ICE; MAE cell; cell viability; apoptosis; bFGF deprivation	FIBROBLAST GROWTH-FACTOR; PROTEIN-KINASE-C; CISPLATIN-INDUCED APOPTOSIS; DEATH GENE CED-3; IL-1-BETA-CONVERTING ENZYME; CONVERTING-ENZYME; CYSTEINE PROTEASE; BONE-MARROW; INDUCTION; IDENTIFICATION	Apoptosis (programmed cell death) is an essential physiological process that is genetically regulated and contributes to the balance between cell growth, differentiation, and the maintenance of normal cells. Recent studies show that deprivation of growth factor induces apoptosis in endothelial cells. However, the molecular mechanisms regulating apoptosis remain unclear. In this study, we demonstrate that deprivation of basic fibroblast growth factor (bFGF) increased the expression of interleukin-1 beta-converting enzyme (ICE) protein, and subsequently induced apoptosis in murine aortic endothelial (MAE) cells. In contrast, the proteins of the tumor suppressor p53 and c-myc were undetected during apoptosis. This apoptosis was suppressed by the tetrapeptide ICE inhibitor, Ac-YVAD-CMK. Overexpression of murine ICE, in addition, induced apoptosis in MAE cells using gene transfer techniques. These results strongly suggest that ICE may mediate apoptosis in bFGF-deprived endothelial cells, and the suppression of ICE function could represent a novel approach for the protection of endothelial cells from damages.	CLEVELAND CLIN FDN,CTR CANC,BRAIN TUMOR CTR,DEPT NEUROSCI,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO,JAPAN	Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,CTR CANC,BRAIN TUMOR CTR,DEPT NEUROSURG S80,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BECKER CG, 1973, AM J PATHOL, V71, P1; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DZAU VJ, 1993, CIRCULATION, V87, P705, DOI 10.1161/01.CIR.87.3.705; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIMBRONE MA, 1969, NATURE, V222, P33, DOI 10.1038/222033a0; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; Gospodarowicz D, 1976, Prog Clin Biol Res, V9, P1; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOWARD AD, 1991, J IMMUNOL, V147, P2964; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KONDO S, 1995, CANCER RES, V55, P6166; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1994, EXP CELL RES, V213, P428, DOI 10.1006/excr.1994.1219; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1994, CANCER RES, V54, P2928; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MASCARDO RN, 1984, ANN NY ACAD SCI, V435, P451, DOI 10.1111/j.1749-6632.1984.tb13849.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STRUM JM, 1972, J CELL BIOL, V54, P456, DOI 10.1083/jcb.54.3.456; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAZQUEZ A, 1991, EUR J IMMUNOL, V21, P2311, DOI 10.1002/eji.1830211004; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766	45	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1192	1197		10.1096/fasebj.10.10.8751721	http://dx.doi.org/10.1096/fasebj.10.10.8751721			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751721				2022-12-25	WOS:A1996VD42900010
J	Thomas, M; Matlashewski, G; Pim, D; Banks, L				Thomas, M; Matlashewski, G; Pim, D; Banks, L			Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation	ONCOGENE			English	Article						apoptosis; HPV; p53; transactivation; growth suppression	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CELL-CYCLE REGULATION; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TRANSFORMING ACTIVITY; MUTATIONAL ANALYSIS; GENE-EXPRESSION; TUMOR-ANTIGEN	Inhibition of p53 function is a common feature of many DNA tumour viruses. Human papillomavirus (HPV) E6 proteins from the oncogenic HPVs inhibit p53 function either by blocking its ability to bind DNA or by labelling newly synthesised p53 as a target for ubiquitin mediated degradation. In this study we have investigated the role of the degradation function of E6 with respect to p53 function. Using a panel of previously characterised p53 mutant proteins we have been able to establish a series of assays which separates p53 growth suppression from transformation suppression and from induction of apoptosis. Only wild type p53 inhibits the growth of p53 null 10(1) cells, whereas wild type, dimeric and monomeric mutants of p53 suppress transformed cell growth of both Saos-2 cells and baby rat kidney cells. Cells expressing the different oligomeric forms of p53 all retain the ability to induce apoptosis upon u.v. treatment. Using HPV E6 and E7 we have been able to show that E7 will overcome p53 growth suppressor activity with an efficiency similar to that observed with E6. However, in contrast to E6, E7 has no effect on the ability of p53 to suppress transformed cell growth. Finally, we show that the ability of E6 to label p53 for ubiquitin mediated degradation is prerequisite for its ability to overcome p53 inhibition of transformed cell growth and induction of apoptosis. These observations argue that E6 inhibits p53 mediated apoptosis and suppression of transformation while E7 inhibits p53 suppression of cell proliferation.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; MCGILL UNIV,INST PARASITOL,MONTREAL,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ,CANADA	International Center for Genetic Engineering & Biotechnology (ICGEB); McGill University; McGill University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1992, ONCOGENE, V7, P27; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEWART N, 1995, ONCOGENE, V10, P109; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; THOMAS M, 1995, ONCOGENE, V10, P261; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	61	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					265	273						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710365				2022-12-25	WOS:A1996VA25200005
J	Rouslin, W; Broge, CW				Rouslin, W; Broge, CW			IF1 function in situ in uncoupler-challenged ischemic rabbit, rat, and pigeon hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE 5'-TRIPHOSPHATASE; ATPASE INHIBITOR PROTEIN; CARDIAC-MUSCLE; LUFTS DISEASE; SLOW; BINDING; TRIPHOSPHATASE; AUTOLYSIS; TISSUES; INTACT	Rabbit, rat, and pigeon are species representative of three cardiac muscle mitochondrial ATPase regulatory classes, a, b and c, respectively, Class a species contain a full complement of higher affinity ATPase inhibitor subunit, IF1, in their cardiac muscle mitochondria and show marked IF1-mediated mitochondrial ATPase inhibition during myocardial ischemia. Class b species contain low levels of higher affinity IF1 and show very little IF1-mediated ATPase inhibition during ischemia. Class c species contain a full complement of a lower affinity form of IF1 and show a low-to-moderate level of IF1-mediated ATPase inhibition during ischemia, In the present study we perfused hearts of a member of each regulatory class through the coronary arteries with the uncoupler, carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), before making them ischemic, We then compared net rates of cell ATP depletion during ischemia in the FCCP-treated hearts to identically treated FCCP-free hearts, Thus, we tested the relative capacities of cardiac muscle mitochondria of the three species to avert a potentially greatly increased net rate of cell ATP depletion due to ATP hydrolysis by the fully uncoupled mitochondrial ATPase, We found that FCCP-uncoupling in situ had a relatively small effect on ATP depletion during ischemia in rabbit hearts, that it dramatically accelerated ATP depletion in ischemic rat hearts, and that it had an intermediate effect on GTP depletion in ischemic pigeon hearts. These results demonstrate for the first time the relative extents to which IF1-mediated mitochondrial ATPase inhibition can slow cell ATP depletion due to the fully uncoupled mitochondrial ATPase in these three classes of hearts. They show that, in contrast to the situation in rabbit hearts, the low level of higher affinity IF1 present in the cardiac muscle mitochondria of the rat is, under these conditions, essentially nonfunctional, while the full complement of the lower affinity form of IF1 present in the cardiac muscle mitochondria of the pigeon is partially functional in that it appeared to provide an intermediate level of protection against rapid cell ATP depletion.			Rouslin, W (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267, USA.				NHLBI NIH HHS [HL30926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON BS, 1987, AM J PHYSIOL, V252, pC349, DOI 10.1152/ajpcell.1987.252.4.C349; AW TY, 1987, AM J PHYSIOL, V252, pC356, DOI 10.1152/ajpcell.1987.252.4.C356; DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0; FRANGIONE B, 1981, P NATL ACAD SCI-BIOL, V78, P7403, DOI 10.1073/pnas.78.12.7403; ISHIKAWA N, 1990, J BIOL CHEM, V265, P6274; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; ROUSLIN W, 1986, J MOL CELL CARDIOL, V18, P1187, DOI 10.1016/S0022-2828(86)80044-X; ROUSLIN W, 1987, J MOL CELL CARDIOL, V19, P661, DOI 10.1016/S0022-2828(87)80374-7; ROUSLIN W, 1983, J BIOL CHEM, V258, P9657; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; ROUSLIN W, 1987, J BIOL CHEM, V262, P3472; ROUSLIN W, 1989, J BIOL CHEM, V264, P15224; ROUSLIN W, 1988, J MOL CELL CARDIOL, V20, P999, DOI 10.1016/0022-2828(88)90577-9; ROUSLIN W, 1993, ARCH BIOCHEM BIOPHYS, V303, P443, DOI 10.1006/abbi.1993.1307; ROUSLIN W, 1987, AM J PHYSIOL, V252, pH622, DOI 10.1152/ajpheart.1987.252.3.H622; ROUSLIN W, 1994, ANAL BIOCHEM, V222, P68, DOI 10.1006/abio.1994.1455; ROUSLIN W, 1990, AM J PHYSIOL, V259, pH1759, DOI 10.1152/ajpheart.1990.259.6.H1759; ROUSLIN W, 1995, J BIOENERG BIOMEMBR, V27, P117, DOI 10.1007/BF02110339; ROUSLIN W, 1990, ARCH BIOCHEM BIOPHYS, V280, P103, DOI 10.1016/0003-9861(90)90524-3; ROUSLIN W, 1993, AM J PHYSIOL, V264, pC209, DOI 10.1152/ajpcell.1993.264.1.C209; TZAGOLOF.A, 1968, J BIOL CHEM, V243, P2405; VANDESTADT RJ, 1974, BIOCHIM BIOPHYS ACTA, V347, P240, DOI 10.1016/0005-2728(74)90048-6; YAMADA EW, 1992, BIOCHIM BIOPHYS ACTA, V1139, P143, DOI 10.1016/0925-4439(92)90093-3; YOSHIDA Y, 1990, EUR J BIOCHEM, V192, P49, DOI 10.1111/j.1432-1033.1990.tb19193.x	26	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23638	23641		10.1074/jbc.271.39.23638	http://dx.doi.org/10.1074/jbc.271.39.23638			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798581	hybrid			2022-12-25	WOS:A1996VJ44200010
J	Hensold, JO; BarthBaus, D; Stratton, CA				Hensold, JO; BarthBaus, D; Stratton, CA			Inducers of erythroleukemic differentiation cause messenger RNAs that lack poly(A)-binding protein to accumulate in translationally inactive, salt-labile 80 S ribosomal complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; MALIGNANT TRANSFORMATION; INITIATION; EXPRESSION; CELLS; MATURATION; CAP; RAT; ELONGATION; SEQUENCES	Translation has an established role in the regulation of cell growth, Posttranslational modification of translation initiation and elongation factors or regulation of mRNA polyadenylation represent common means of regulating translation in response to mitogenic or developmental signals. Induced differentiation of Friend virus-transformed erythroleukemia cells is accompanied by a rapid decrease in the translation rate of these cells. Although inducers do not alter initiation factor modifications, characterization of their effect on mRNA translation provides evidence that this is mediated by the poly(A)-binding protein (PABP). Inducer exposure results in an increase in the amount of mRNA that sediments at 80 S and a decrease in the amount in polysomes, Although these 80 S ribosomes have characteristics previously attributed to "vacant ribosomal couples," including lability in 500 mM KCl and an inability to incorporate amino acids into protein, we provide evidence that these 80 S complexes are not vacant but contain mRNA that is stably bound to the 40 S subunit, whereas the 60 S subunit is dissociated from the complex by high salt. The absence of eukaryotic initiation factor 2 from these complexes suggests that translation has proceeded through subunit joining, Immunoblotting demonstrates that the mRNAs in these 80 S ribosomal complexes do not contain bound PABP and that this protein is found to be almost exclusively associated with translating polysomes. These data suggest that the PABP plays a role in the accumulation of these 80 S ribosomal mRNA complexes and may facilitate the formation of translationally active salt-stable ribosomes.	DEPT VET AFFAIRS MED CTR, CLEVELAND, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Hensold, JO (corresponding author), CASE WESTERN RESERVE UNIV, UNIV IRELAND CANC CTR, DEPT MED, 10900 EUCLID AVE, BRB ROOM 333, CLEVELAND, OH 44106 USA.				NIDDK NIH HHS [DK43414] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; FEINBERG AP, 1983, ANAL BIOCHEM, V12, P6; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GIEBEL LB, 1988, DEV BIOL, V125, P200, DOI 10.1016/0012-1606(88)90073-5; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Hensold JO, 1996, J BIOL CHEM, V271, P3385; HENSOLD JO, 1991, BLOOD, V77, P1362; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOGAN BLM, 1968, BIOCHIM BIOPHYS ACTA, V169, P129, DOI 10.1016/0005-2787(68)90014-2; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN A, 1987, J BIOL CHEM, V262, P14343; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MARTIN TE, 1969, J MOL BIOL, V43, P135, DOI 10.1016/0022-2836(69)90084-9; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PALATNIK CM, 1984, CELL, V36, P1017, DOI 10.1016/0092-8674(84)90051-5; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PAZ V, 1989, FEBS LETT, V251, P89, DOI 10.1016/0014-5793(89)81434-6; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHERTON CC, 1976, DEV BIOL, V48, P118, DOI 10.1016/0012-1606(76)90051-8; SIEKIERKA J, 1982, P NATL ACAD SCI USA, V81, P352; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Spirin A, 1986, RIBOSOME STRUCTURE P; STAEHELI.T, 1967, BIOCHIM BIOPHYS ACTA, V145, P105, DOI 10.1016/0005-2787(67)90659-4; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WARNER JR, 1963, P NATL ACAD SCI USA, V49, P122, DOI 10.1073/pnas.49.1.122; Wickens Marvin, 1992, Seminars in Developmental Biology, V3, P363; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZYLBER EA, 1970, BIOCHIM BIOPHYS ACTA, V204, P221, DOI 10.1016/0005-2787(70)90505-8	52	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23246	23254		10.1074/jbc.271.38.23246	http://dx.doi.org/10.1074/jbc.271.38.23246			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798522	hybrid			2022-12-25	WOS:A1996VH76800048
J	Pauly, RP; Rosche, F; Wermann, M; McIntosh, CHS; Pederson, RA; Demuth, HU				Pauly, RP; Rosche, F; Wermann, M; McIntosh, CHS; Pederson, RA; Demuth, HU			Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization time of flight mass spectrometry - A novel kinetic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION IONIZATION; QUANTITATIVE-ANALYSIS; HUMAN SERUM; IN-VITRO; IMPROVEMENT; INHIBITORS; RESOLUTION; PROTEINS; VIVO	The incretins glucose-dependent insulinotropic polypeptide (GIP1-42) and glucagon-like peptide-1-(7-36)-amide (GLP-1(7-36)), hormones that potentiate glucose induced insulin secretion from the endocrine pancreas, are substrates of the circulating exopeptidase dipeptidyl peptidase IV and are rendered biologically inactive upon cleavage of their N-terminal dipeptides. This study was designed to determine if matrix-assisted laser desorption/ionization-time of flight mass spectrometry is a useful analytical tool to study the hydrolysis of these hormones by dipeptidyl peptidase IV, including kinetic analysis. Spectra indicated that serum-incubated peptides were cleaved by this enzyme with only minor secondary degradation due to other serum protease activity. Quantification of the mass spectrometric signals allowed kinetic constants for both porcine kidney- and human serum dipeptidyl peptidase IV-catalyzed incretin hydrolysis to be calculated. The binding constants (K-m) of these incretins to purified porcine kidney-derived enzyme were 1.8 +/- 0.3 and 3.8 +/- 0.3 mu M, whereas the binding constants observed in human serum were 39 +/- 29 and 13 +/- 9 mu M for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1-(7-36)-amide respectively. The large range of K-m values found in human serum suggests a heterogeneous pool of enzyme. The close correlation between the reported kinetic constants and those previously described validates this novel approach to kinetic analysis.	UNIV BRITISH COLUMBIA,DEPT PHYSIOL,VANCOUVER,BC V6T 1Z3,CANADA; HANS KNOLL INST NAT PROD RES JENA,D-06120 HALLE,GERMANY	University of British Columbia; Hans Knoll Institute (HKI)								BROWN JC, 1981, PEPTIDES, V2, P241, DOI 10.1016/0196-9781(81)90038-3; BROWN JC, 1994, GUT PEPTIDES BIOCH P, P765; BROWN RS, 1995, ANAL CHEM, V67, P1998, DOI 10.1021/ac00109a015; CRAIG AG, 1994, BIOL MASS SPECTROM, V23, P519, DOI 10.1002/bms.1200230810; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; Demuth H U, 1990, J Enzyme Inhib, V3, P249, DOI 10.3109/14756369009030375; DEMUTH HU, 1995, DIPEPTIDYL PEPTIDASE, P1; Dockray JH., 1994, GUT PEPTIDES BIOCH P, P217; DUKECOHAN JS, 1995, J BIOL CHEM, V270, P14107, DOI 10.1074/jbc.270.23.14107; DukeCohan JS, 1996, J IMMUNOL, V156, P1714; DUNCAN MW, 1993, RAPID COMMUN MASS SP, V7, P1090, DOI 10.1002/rcm.1290071207; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GUSEV AI, 1995, ANAL CHEM, V67, P1034, DOI 10.1021/ac00102a003; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; HSIEH FYL, 1995, ANAL BIOCHEM, V229, P20, DOI 10.1006/abio.1995.1373; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; NELSON RW, 1994, ANAL CHEM, V66, P1408, DOI 10.1021/ac00081a008; SCHMIDT W E, 1986, European Journal of Clinical Investigation, V16, pA9; SCHON E, 1991, BIOL CHEM H-S, V372, P305, DOI 10.1515/bchm3.1991.372.1.305; SCHUERCH S, 1994, BIOL MASS SPECTROM, V23, P695, DOI 10.1002/bms.1200231108; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; TANG K, 1993, ANAL CHEM, V65, P2164, DOI 10.1021/ac00063a041; WOLF B, 1978, ACTA BIOL MED GER, V37, P409; YAMASHITA M, 1984, J PHYS CHEM-US, V88, P4451, DOI 10.1021/j150664a002; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; ZALUZEC EJ, 1995, PROTEIN EXPRES PURIF, V6, P109, DOI 10.1006/prep.1995.1014	30	141	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23222	23229		10.1074/jbc.271.38.23222	http://dx.doi.org/10.1074/jbc.271.38.23222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798518	hybrid			2022-12-25	WOS:A1996VH76800044
J	Tsytsikov, VN; Yurovsky, VV; Atamas, SP; Alms, WJ; White, B				Tsytsikov, VN; Yurovsky, VV; Atamas, SP; Alms, WJ; White, B			Identification and characterization of two alternative splice variants of human interleukin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; T-CELL LEUKEMIA; BLOOD MONONUCLEAR-CELLS; AFFINITY IL-2 RECEPTOR; ALPHA-CHAIN; BETA-CHAIN; CYTOKINE SECRETION; TAC ANTIGEN; BINDING; EXPRESSION	Our previous work showed that alternative splicing is used to make an inhibitory variant of human interleukin (IL)-4. Because of homology between IL-4 and IL-2 proteins and receptors, we tested whether alternative splicing is used to generate similar inhibitory variants of human IL-2, Messenger RNA from peripheral blood mononuclear cells was subjected to reverse transcription-polymerase chain reaction using IL-2 exon 1- and exon 4-specific primers. Two amplification products, named IL-2 delta 2 and IL-2 delta 3, were found in addition to the native IL-2 product. The IL-2 delta 2 cDNA sequence was identical to IL-2 cDNA throughout the entire coding region, except exon 2 was omitted by alternative splicing. In IL-2 delta 3 cDNA, the third exon of IL-2 was omitted by alternative splicing, Unlike IL-2, IL-2 delta 2 and IL-2 delta 3 did not stimulate T cell proliferation. However, both inhibited IL-2 costimulation of T cell proliferation, and both inhibited cellular binding of rhIL-2 to high affinity IL-2 receptors. Thus, IL-2 is the second cytokine that uses alternative splicing to generate variants that are competitive inhibitors.	VET AFFAIRS MED CTR,MED SERV,BALTIMORE,MD 21201; VET AFFAIRS MED CTR,RES SERV,BALTIMORE,MD 21201	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Tsytsikov, VN (corresponding author), UNIV MARYLAND,DEPT MED,DIV CLIN IMMUNOL & RHEUMATOL,MSTF ROOM 8-23,10 S PINE ST,BALTIMORE,MD 21201, USA.							Alms WJ, 1996, MOL IMMUNOL, V33, P361, DOI 10.1016/0161-5890(95)00154-9; ANASETTI C, 1994, BLOOD, V84, P1320; ANDREUSANCHEZ JL, 1991, J EXP MED, V173, P1323, DOI 10.1084/jem.173.6.1323; Atamas SP, 1996, J IMMUNOL, V156, P435; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BERNDT WG, 1994, BIOCHEMISTRY-US, V33, P6571, DOI 10.1021/bi00187a026; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BUCHLI P, 1993, ARCH BIOCHEM BIOPHYS, V307, P411, DOI 10.1006/abbi.1993.1608; CANTRELL DA, 1983, J EXP MED, V158, P1895, DOI 10.1084/jem.158.6.1895; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS MKL, 1990, EUR J IMMUNOL, V20, P573, DOI 10.1002/eji.1830200317; FLEMMING CL, 1993, EUR J IMMUNOL, V23, P917, DOI 10.1002/eji.1830230423; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOLDSMITH MA, 1994, CYTOKINE HDB, P14; GRANT AJ, 1992, P NATL ACAD SCI USA, V89, P2165, DOI 10.1073/pnas.89.6.2165; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HEATON KM, 1993, CANCER RES, V53, P2597; HEATON KM, 1993, CELL IMMUNOL, V147, P167, DOI 10.1006/cimm.1993.1057; HEATON KM, 1995, HUM IMMUNOL, V42, P274, DOI 10.1016/0198-8859(94)00106-Z; Hopkins SA, 1992, PHARM ENG, V12, P48; HOWARD MC, 1993, FUNDAMENTAL IMMUNOLO, P766; JU G, 1987, J BIOL CHEM, V262, P5723; KJELDSENKRAGH J, 1993, EUR J IMMUNOL, V23, P2092, DOI 10.1002/eji.1830230908; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KORSMEYER SJ, 1983, P NATL ACAD SCI USA, V80, P4255; KUZIEL WA, 1993, J IMMUNOL, V150, P3357; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; LOWENTHAL JW, 1991, CURRENT PROTOCOLS IM; MAEDA M, 1987, BLOOD, V70, P1407; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MOTT HR, 1992, BIOCHEMISTRY-US, V31, P7741, DOI 10.1021/bi00148a040; NEMOTO T, 1995, EUR J IMMUNOL, V25, P3001, DOI 10.1002/eji.1830251102; RINGHEIM GE, 1991, LYMPHOKINE CYTOK RES, V10, P219; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RONG Y, 1992, BIOCHEM BIOPH RES CO, V188, P949, DOI 10.1016/0006-291X(92)91147-I; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SCHWARTING R, 1985, J CLIN PATHOL, V38, P1196, DOI 10.1136/jcp.38.10.1196-b; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA J, 1995, LEUKEMIA LYMPHOMA, V16, P413, DOI 10.3109/10428199509054427; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TINUBU SA, 1994, J IMMUNOL, V153, P4330; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WALDMANN TA, 1984, J CLIN INVEST, V73, P1711, DOI 10.1172/JCI111379; WANG ZY, 1995, EUR J IMMUNOL, V25, P1212, DOI 10.1002/eji.1830250512; WEIDMANN E, 1992, CANCER RES, V52, P5963; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; WILKINSON PC, 1994, IMMUNOLOGY, V82, P134; YAMAMURA M, 1992, J IMMUNOL, V149, P1470	57	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23055	23060		10.1074/jbc.271.38.23055	http://dx.doi.org/10.1074/jbc.271.38.23055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798495	hybrid			2022-12-25	WOS:A1996VH76800021
J	Freeman, JL; Lambeth, JD				Freeman, JL; Lambeth, JD			NADPH oxidase activity is independent of p47(phox) in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; NEUTROPHIL FLAVOCYTOCHROME B(558); SRC HOMOLOGY-3 DOMAINS; RECOMBINANT P47-PHOX; ANIONIC AMPHIPHILE; PLASMA-MEMBRANE; BINDING; PROTEIN	The neutrophil superoxide generating NADPH oxidase is activated by the assembly of cytosolic protein components with a membrane-associated flavocytochrome. The activity can be reconstituted in vitro using purified cytosolic factors p47(phox), p67(phox), and Rac plus the phospholipid-reconstituted flavocytochrome b(558). Here, we demonstrate that activity is reconstituted in the absence of p47(phox) when high concentrations of p67(phox) and Rac are used. V-max values were the same in the presence or absence of p47(phox), yet p47(phox) increases the affinity of both p67(phox) and Rac for the oxidase complex by nearly 2 orders of magnitude, p67(phox)-(1-246), a truncated form of the protein which eliminates SH3 domains involved in binding to p47(phox), also supports superoxide generation, both in the presence and absence of p47(phox), providing further evidence for p47(phox) independent activity. In the absence of p47(phox), p67(phox)-(1-246) binds to the NADPH oxidase complex 3-fold more tightly than does native p67(phox) indicating that the C terminus contains a region which masks binding to the oxidase complex. Results indicate that p47(phox) does not play a direct role in regulating electron transfer. Rather, ifs function is to serve as an adaptor protein to enhance the assembly of the other cytosolic components with the flavocytochrome and possibly to unmask a binding region in the N terminus of p67(phox) by binding to its C-terminal domains. p67(phox) and/or Rac play a more direct role in regulating electron transfer.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NIAID NIH HHS [AI22809] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN E, 1995, METHODS ENZYMOLOGY S, P246; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANOCK SJ, 1992, P NATL ACAD SCI USA, V89, P10174, DOI 10.1073/pnas.89.21.10174; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1990, J CLIN INVEST, V85, P1583, DOI 10.1172/JCI114608; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; XU XM, 1994, J BIOL CHEM, V269, P23569	45	152	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22578	22582		10.1074/jbc.271.37.22578	http://dx.doi.org/10.1074/jbc.271.37.22578			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798426	hybrid			2022-12-25	WOS:A1996VG67200045
J	Ida, N; Hartmann, T; Pantel, J; Schroder, J; Zerfass, R; Forstl, H; Sandbrink, R; Masters, CL; Beyreuther, K				Ida, N; Hartmann, T; Pantel, J; Schroder, J; Zerfass, R; Forstl, H; Sandbrink, R; Masters, CL; Beyreuther, K			Analysis of heterogeneous beta A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; AMYLOID-BETA; A-BETA; PROTEIN-PRECURSOR; APOLIPOPROTEIN-E; SENILE PLAQUES; CORE PROTEIN; DEPOSITS; CELLS; A-BETA-42(43)	The beta A4 peptide, a major component of senile plaques in Alzheimer's disease (AD) brain, has been found in cerebrospinal fluid (CSF) and blood of both AD patients and normal subjects, Although beta A4 1-40 is the major form produced by cell metabolism and found in CSF, recent observations suggest that the long-tailed beta A4 1-42 plays a more crucial role in AD pathogenesis. Here, we established new monoclonal antibodies against the C-terminal end of beta A4 1-40 and 1-42, and used them for the specific Western blot detection. After optimizing the assay conditions, these antibodies detected low picogram amount of beta A4, and both beta A4 1-40 and 1-42 levels in CSF could be determined by direct loading of the samples. flood levels of beta A4 1-40 and 1-42 were also determined by specific immunoprecipitation followed by Western blot detection. We found that CSF beta A4 1-42 level is lower in AD patients compared with non-demented controls, although there was a significant overlap between the groups. The level of beta A4 1-40 in CSF, and of beta A4 1-40 as well as beta A4 1-42 in plasma, were not different between AD patients and controls. Besides the 4-kDa full-length beta A4 band, we could also detect several N-terminal variants of beta A4 in CSF and plasma of both AD patients and controls. Two N-terminally truncated beta A4 species migrating at the position of 3.3 and 3.7 kDa were found in CSF, while 3.7- and 5-kDa forms were found in plasma. The relative abundance of these various species were considerably different in the CSF and plasma, suggesting that the cellular source and/or clearance of beta A4 is different in these two compartments.	UNIV HEIDELBERG, CTR MOL BIOL HEIDELBERG, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, PSYCHIAT CLIN, D-69115 HEIDELBERG, GERMANY; CENT INST MENTAL HLTH, D-69159 MANNHEIM, GERMANY; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Central Institute of Mental Health; University of Melbourne			Hartmann, Tobias/AAB-8297-2022; Pantel, Johannes/ABC-6341-2020; förstl, hans/B-5869-2008	Forstl, Hans/0000-0002-6188-6883; Hartmann, Tobias/0000-0001-7481-6430				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLABEK A, 1995, NEUROSCI LETT, V191, P79, DOI 10.1016/0304-3940(95)11565-7; GOWING E, 1994, J BIOL CHEM, V269, P10987; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jensen M., 1995, Society for Neuroscience Abstracts, V21, P1501; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDA E, 1995, NEUROSCI LETT, V193, P105, DOI 10.1016/0304-3940(95)11678-P; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Simons M, 1996, J NEUROSCI, V16, P899; Song X.-H., 1995, Society for Neuroscience Abstracts, V21, P1501; SOTO C, 1995, NEUROSCI LETT, V186, P115, DOI 10.1016/0304-3940(95)11299-C; Southwick PC, 1996, J NEUROCHEM, V66, P259; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGOOL WA, 1995, ANN NEUROL, V37, P277, DOI 10.1002/ana.410370221; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMAGUCHI H, 1992, AM J PATHOL, V141, P249	46	465	503	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22908	22914		10.1074/jbc.271.37.22908	http://dx.doi.org/10.1074/jbc.271.37.22908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798471				2022-12-25	WOS:A1996VG67200090
J	Malik, N; Canfield, VA; Beckers, MC; Gros, P; Levenson, R				Malik, N; Canfield, VA; Beckers, MC; Gros, P; Levenson, R			Identification of the mammalian Na,K-ATPase beta 3 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+,K+-ATPASE ALPHA-SUBUNIT; TISSUE-SPECIFIC EXPRESSION; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; GENE; BETA-2-SUBUNIT; ASSIGNMENT	We have isolated and characterized cDNA clones encoding the human and rat Na,K-ATPase beta 3 subunit isoform, The human cDNA encodes a polypeptide of 279 amino acids that exhibits primary sequence and secondary structure similarities to Na,K-ATPase beta subunit isoforms. Sequence comparisons showed that the human beta 3 subunit closely resembles the beta 3 subunit of Xenopus laevis (59% amino acid identity) and is less similar to the human Na,K-ATPase beta 1 and beta 2 subunits (38% and 48% amino acid identity, respectively). By analyzing the segregation of restriction fragment length polymorphisms among recombinant inbred strains of mice, we localized the beta 3 subunit gene to murine chromosome 7. Northern blot analysis revealed that the beta 3 subunit gene encodes two transcripts that are expressed in a variety of rat tissues including testis, brain, kidney, lung, stomach, small intestine, colon, spleen, and liver. Identification of the mammalian beta 3 subunit suggests an even greater potential for Na,K-ATPase isoenzyme diversity than previously realized.	PENN STATE COLL MED,MILTON S HERSHEY MED CTR,DEPT PHARMACOL,HERSHEY,PA 17033; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; McGill University				Levenson, Robert/0000-0002-0936-8421	NHLBI NIH HHS [HL-39263] Funding Source: Medline; NIGMS NIH HHS [GM-49023] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049023] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CAMERON R, 1994, MOL BRAIN RES, V21, P338; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVISSON M, 1991, MOUSE GENOME, V89, P5; DEVREUX J, 1984, NUCLEIC ACIDS RES, V12, P387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLYNN IM, 1985, ENZYMES BIOL MEMBR, P35; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; GRENE MC, 1989, GENETIC VARIANTS STR, P773; HERRERA VL, 1987, J CELL BIOL, V105, P1055; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KENT RB, 1987, P NATL ACAD SCI USA, V84, P5369, DOI 10.1073/pnas.84.15.5369; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAS MV, 1993, BIOCHIM BIOPHYS ACTA, V1149, P339; MALO D, 1990, GENOMICS, V6, P697, DOI 10.1016/0888-7543(90)90507-Q; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; NESBITT M, 1990, MOUSE GENOME, V88, P113; SCHNEIDER BG, 1991, J HISTOCHEM CYTOCHEM, V39, P507, DOI 10.1177/39.4.1848572; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425	33	140	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22754	22758		10.1074/jbc.271.37.22754	http://dx.doi.org/10.1074/jbc.271.37.22754			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798450	hybrid			2022-12-25	WOS:A1996VG67200069
J	Tao, NB; Wagner, SJ; Lublin, DM				Tao, NB; Wagner, SJ; Lublin, DM			CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; MEMBRANE-PROTEIN; SIGNAL-TRANSDUCTION; LIMP-II; SR-BI; THROMBOSPONDIN; PLATELET; RECEPTOR; IDENTIFICATION; ADHESION	The membrane protein CD36 has been reported to carry out a wide range of potential functions, including serving as a receptor for thrombospondin, collagen, oxidized low density lipoprotein, fatty acids, anionic phospholipids, and Plasmodium falciparum malaria parasitized erythrocytes, This implicates CD36 in cellular adhesion, human atherosclerotic lesion formation, lipid metabolism, and malaria. A presumed rat homolog of CD36 was previously reported to be palmitoylated, We confirmed that human CD36 is palmitoylated and identified cysteines 3, 7, 464, and 466 as the palmitoylation sites using a mutagenesis approach, This result suggests that both the N- and C-terminal tails of CD36 are cyto plasmic. Published models for the topology of CD36 have the C terminus located in the cytoplasm but differ as to whether the N terminus is cytoplasmic or extracellular. To address this question, a C terminal truncation mutant of CD36 was made by introducing a stop codon just upstream of the C-terminal transmembrane domain. This mutant was found membrane-bound when expressed in human embryonic kidney 293 cells, indicating that the N-terminal hydrophobic domain serves as a transmembrane anchor, and thus supporting a CD36 topology with two transmembrane domains.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [T32 HL07038] Funding Source: Medline; NIGMS NIH HHS [GM 41297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM041297, R01GM041297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; CALVO D, 1993, J BIOL CHEM, V268, P18929; DAVIET L, 1995, BIOCHEM J, V305, P221, DOI 10.1042/bj3050221; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JOCHEN A, 1993, J LIPID RES, V34, P1783; KASHIWAGI H, 1995, J CLIN INVEST, V95, P1040, DOI 10.1172/JCI117749; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KULCZYCKI A, 1980, J IMMUNOL METHODS, V37, P133, DOI 10.1016/0022-1759(80)90198-2; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PEARCE SFA, 1994, BLOOD, V84, P384; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCHLESINGER MJ, 1994, LIPID MODIFICATIONS; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCHWEIZER A, 1995, J BIOL CHEM, V270, P9638, DOI 10.1074/jbc.270.16.9638; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	31	132	141	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22315	22320		10.1074/jbc.271.37.22315	http://dx.doi.org/10.1074/jbc.271.37.22315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798390	hybrid			2022-12-25	WOS:A1996VG67200009
J	Komiya, T; Mihara, K				Komiya, T; Mihara, K			Protein import into mammalian mitochondria - Characterization of the intermediates along the import pathway of the precursor into the matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; INNER MEMBRANE; OUTER-MEMBRANE; DYNAMIC INTERACTION; STIMULATION FACTOR; TRANSLOCATION; YEAST; ATP; PRESEQUENCE; RECEPTOR	We have characterized several intermediates in the mitochondrial import stimulation factor (MSF)-dependent import into mammalian mitochondria of a matrix-targeted precursor, preadrenodoxin (pAd). In the first step, pAd docks onto the 37-kDa protein of the outer membrane (OM37) as a complex with MSF (stage I intermediate). It is then transferred to the import pore of OM in the presence of ATP, but in the absence of Delta psi across the inner membrane (IM), to form stage II intermediate. Depletion of matrix ATP in the presence of both extramitochondrial ATP and Delta psi, induces accumulation of stage III intermediate, which is a mixture of the precursor with different intramitochondrial localizations: the precursor whose presequence had crossed either OM (IIIa) or both OM and IM (IIIb), but with a bulk portion remaining exposed to the cytosol and the precursor whose presequence had crossed both membranes, but with a residual portion staying within the intermembrane space (IIIc). These intermediates are on the correct import pathway and are characteristic in their protease accessibility, salt extractability, and antibody accessibility, as well as in their energy requirement for the chase reaction.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOL BIOL,FUKUOKA 812,JAPAN	Kyushu University								ALAM R, 1994, J BIOCHEM-TOKYO, V116, P416, DOI 10.1093/oxfordjournals.jbchem.a124541; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEASLEY E M, 1992, Current Opinion in Cell Biology, V4, P646, DOI 10.1016/0955-0674(92)90084-P; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1993, J BIOL CHEM, V268, P23751; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; IWAHASHI J, 1992, J BIOCHEM-TOKYO, V111, P451, DOI 10.1093/oxfordjournals.jbchem.a123778; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KOMIYA T, 1994, J BIOL CHEM, V269, P30893; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4202; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1987, J BIOL CHEM, V262, P7528; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; TERADA K, 1995, MOL CELL BIOL, V15, P3708; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465	40	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22105	22110		10.1074/jbc.271.36.22105	http://dx.doi.org/10.1074/jbc.271.36.22105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703020	hybrid			2022-12-25	WOS:A1996VF61200062
J	Hammen, PK; Waltner, M; Hahnemann, B; Heard, TS; Weiner, H				Hammen, PK; Waltner, M; Hahnemann, B; Heard, TS; Weiner, H			The role of positive charges and structural segments in the presequence of rat liver aldehyde dehydrogenase in import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; SIGNAL PEPTIDE; PROCESSING PEPTIDASE; MALATE-DEHYDROGENASE; PRECURSOR PROTEIN; TRANSIT PEPTIDE; CHEMICAL-SHIFT; SPECTROSCOPY; MEMBRANES	Most mitochondrial proteins are nucleus-encoded and translated in the cytosol. They have an N-terminal presequence that allows recognition by the mitochondrial import apparatus and subsequent import into mitochondria. These presequences are rich in positive charges, mainly arginines. The role of these positive charges in the 19-amino acid presequence of rat liver aldehyde dehydrogenase was investigated by systematically replacing them with the polar but uncharged residue, glutamine. The single substitution of any of the four Arg residues in the helical segments did not affect import. Substitution of both Arg residues in the N-terminal segment (R3Q/R10Q) caused a dramatic decrease in import competence. This could be restored by using the mutant lacking the three-amino acid (RGP) linker that separates the two helical domains, determined by two-dimensional NMR (Thornton, K., Wang, Y., Weiner, H., and Gorenstein, D. G. (1993) J. Biol. Chem. 268, 19906-19914), CD and NMR spectra of the peptide corresponding to the linker deleted presequence showed that it was substantially more prone to helix formation than the native peptide over its entire length. A similar analysis of the peptide corresponding to the R3Q/R10Q presequence revealed that this peptide was only somewhat more helical than the native peptide and that the greater helicity did not include the residues near the N terminus. It is concluded that positively charged residues in the presequence play a vital role in the import of precursor aldehyde dehydrogenase. One of the positive charges in the N terminal helical segment of the presequence is necessary for import competence. However, if both positive charges are removed, import competence can be retained as long as the presequence is capable of forming a relatively more stable alpha-helix near its N terminus.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00028, AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHU TW, 1987, J BIOL CHEM, V262, P12806; DEKROON AIP, 1993, NEW COMP BIOCH, V25, P107; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HOYT DW, 1991, J BIOL CHEM, V266, P21693; HTORNTON KH, 1988, THESIS PURDUE U W LA; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; JONES JD, 1994, BIOPHYS J, V67, P1546, DOI 10.1016/S0006-3495(94)80628-9; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer Thomas, 1994, V26, P53; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PAK YK, 1990, J BIOL CHEM, V265, P14298; PARK SH, 1993, BIOCHEMISTRY-US, V32, P12901, DOI 10.1021/bi00210a044; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5468; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; TAKAKUBO F, 1995, AM J HUM GENET, V57, P772; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VANHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5; WANG Y, 1994, BIOCHEMISTRY-US, V33, P12860, DOI 10.1021/bi00209a018; WANG Y, 1993, J BIOL CHEM, V268, P4759; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; ZHOU JZ, 1995, J BIOL CHEM, V270, P16689, DOI 10.1074/jbc.270.28.16689; [No title captured]	42	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21041	21048		10.1074/jbc.271.35.21041	http://dx.doi.org/10.1074/jbc.271.35.21041			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702869				2022-12-25	WOS:A1996VE47700015
J	Luo, YZ; Henle, ES; Linn, S				Luo, YZ; Henle, ES; Linn, S			Oxidative damage to DNA constituents by iron-mediated Fenton reactions - The deoxycytidine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED BASE DAMAGE; HYDROGEN-PEROXIDE; MAMMALIAN CHROMATIN; RADIATION; CYTOSINE; REPAIR; PATTERN	Damage by iron-mediated Fenton reactions under aerobic or anaerobic conditions to deoxycytidine, deoxycytidine 5'-monophosphate, d-CpC, d-CpCpC, and dCMP residues in DNA resulted in at least 26 distinguishable products. Of these, 24 were identified by high performance liquid chromatography retention times, radiolabeling, UV absorption spectra, chemical synthesis, fast atom bombardment mass spectrometry, high resolution fast atom bombardment mass spectrometry, and/or NMR. The nature of the products was qualitatively similar for each substrate except for d-CpC (and possibly d-CpCpC) under anaerobic conditions for which 5-hydroxy-deoxycytidine was uniquely present and 1-carbamoyl-1-carboxy-4-(2-deoxy-beta-D-erythropentofuranosyl) glycinamide was uniquely absent. Damage to dC, d-CpC, and d-CpCpC but not to dCMP or DNA was largely quenched by ethanol, indicating that iron is strongly associated only with dCMP and DNA. The presence of oxygen had little effect with dC or dCMP but had quantitative and qualitative effects with d-CpC and a significantly quantitative but not a qualitative effect with DNA. NADH could drive the Fenton reaction to cause damage to the dC family in vitro, consistent with a previous proposal that NADH was the reducing agent for the Fenton reaction in vivo (Imlay, J.A., and Linn, S. (1988) Science 240, 1302-1309). Finally, the damage spectrum of the dC family by the Fenton reaction is compared with that by ionizing radiation and chemical mechanisms leading to the formation of the 24 identified products are proposed.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM019020] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32ES070075] Funding Source: Medline; NIGMS NIH HHS [R29GM19020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUOMA OI, 1989, J BIOL CHEM, V264, P13024; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; BIAKELY WF, 1990, RADIAT RES, V121, P338; BIEDERMANN G, 1957, ACTA CHEM SCAND, V11, P731, DOI 10.3891/acta.chem.scand.11-0731; CADET J, 1981, CAN J CHEM, V59, P3313, DOI 10.1139/v81-490; DANIELS M, 1967, BIOCHIM BIOPHYS ACTA, V134, P481, DOI 10.1016/0005-2787(67)90031-7; DIZDAROGLU M, 1985, ANAL BIOCHEM, V144, P593, DOI 10.1016/0003-2697(85)90158-7; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P317, DOI 10.1016/0003-9861(91)90366-Q; DIZDAROGLU M, 1986, ANAL BIOCHEM, V156, P182, DOI 10.1016/0003-2697(86)90171-5; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 1984, RADIAT RES, V100, P41, DOI 10.2307/3576519; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; GRAF E, 1984, J BIOL CHEM, V259, P3620; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAZRA DK, 1983, J AM CHEM SOC, V105, P4380, DOI 10.1021/ja00351a042; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; HISSUNG A, 1978, Z NATURFORSCH B, V33, P321; HURST RO, 1952, J BIOL CHEM, V204, P847; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; KHATTAK MN, 1966, INT J RADIAT BIOL RE, V11, P131, DOI 10.1080/09553006614550891; LEUSSING DL, 1953, J AM CHEM SOC, V75, P2476, DOI 10.1021/ja01106a058; LUO HZ, 1994, METHOD ENZYMOL, V234, P51; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MYERS LS, 1970, J AM CHEM SOC, V92, P2871, DOI 10.1021/ja00712a045; POLVEREL.M, 1974, Z NATURFORSCH C, VC 29, P16; POLVEREL.M, 1974, Z NATURFORSCH C, VC 29, P12; POLVERELLI M, 1976, Z NATURFORSCH B, V31, P580; PONNAMPERUMA C, 1962, SCIENCE, V137, P605, DOI 10.1126/science.137.3530.605; Pullman B, 1969, Prog Nucleic Acid Res Mol Biol, V9, P327, DOI 10.1016/S0079-6603(08)60772-2; Sambrook J., 2002, MOL CLONING LAB MANU; SPIRO TG, 1974, IRON BIOCH MED, V1, P1; SUNG W, 1980, ENVIRON SCI TECHNOL, V14, P561, DOI 10.1021/es60165a006; Tan Z K, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P383; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; Van de Vorst A, 1978, Mol Biol Biochem Biophys, V27, P3; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WAGNER JR, 1990, METHOD ENZYMOL, V186, P502; WAGNER JR, 1988, THESIS U SHERBROOKE	44	102	102	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21167	21176		10.1074/jbc.271.35.21167	http://dx.doi.org/10.1074/jbc.271.35.21167			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702887	hybrid			2022-12-25	WOS:A1996VE47700033
J	Mundlos, S; Chan, D; Weng, YM; Sillence, DO; Cole, WG; Bateman, JF				Mundlos, S; Chan, D; Weng, YM; Sillence, DO; Cole, WG; Bateman, JF			Multiexon deletions in the type I collagen COL1A2 gene in osteogenesis imperfecta type IB - Molecules containing the shortened alpha 2(I) chains show differential incorporation into the bone and skin extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) CHAIN; TRIPLE-HELIX; CULTURED FIBROBLASTS; MESSENGER-RNA; CROSS-LINKING; N-PROPEPTIDE; LETHAL FORM; 3' END; SUBSTITUTION; PROCOLLAGEN	Osteogenesis imperfecta (OI) type IB is a rare subset of the mildest form of OI, clinically characterized by moderate bone fragility, blue sclera, and dentinogenesis imperfecta. Cultured skin fibroblasts from two unrelated individuals (OI-197 and OI-165) with the typical features of OI type IB produced shortened alpha 2(I) chains, Reverse transcription-polymerase chain reaction of the alpha 2(I)-cDNA revealed deletions in the triple helical domain of 5 exons (exons 7-11) in OI-197, and 8 exons (exons 10-17) in OI-165. This exon skipping was caused by genomic deletions in one allele of COL1A2 with the breakpoints located in introns 6 and 11 in OI-197, and introns 9 and 17 in OI-165, The secretion and deposition of the mutant collagen into the matrix was measured in vitro in cultures of skin fibroblasts and bone osteoblasts, grown in the presence of ascorbic acid to induce collagen matrix formation and maturation, as well as in collagen extracts from skin and bone. The secretion of mutant collagen was impaired and long term cultures of fibroblasts showed that the mutant collagen was not incorporated into the mature collagenous matrix produced in vitro by skin fibroblasts from both patients. Likewise, the shortened alpha 2(I) chain was not demonstrable in skin extracts. In contrast, bone extracts from OI-197 showed the presence of the mutant collagen, This incorporation of the abnormal collagen into the mature matrix was also demonstrated in long term cultures of the patient's osteoblasts, The deposition of the mutant collagen by bone osteoblasts but not by skin fibroblasts demonstrates a tissue specificity in the incorporation of mutant collagen into the matrix which may explain the primary involvement of bone and not skin in these patients.	UNIV MELBOURNE, ROYAL CHILDRENS HOSP, DEPT PAEDIAT, ORTHOPAED MOL BIOL RES UNIT, PARKVILLE, VIC 3052, AUSTRALIA; NEW CHILDRENS HOSP, DEPT CLIN GENET, PARRAMATTA, NSW 2124, AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne			Mundlos, Stefan/ABH-9585-2020; Chan, Danny/C-4203-2009	Bateman, John/0000-0001-8542-0730; Chan, Danny/0000-0003-3824-5778				BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BARSH GS, 1985, P NATL ACAD SCI USA, V82, P2870, DOI 10.1073/pnas.82.9.2870; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1993, AM J MED GENET, V45, P233, DOI 10.1002/ajmg.1320450216; BATEMAN JF, 1988, ANAL BIOCHEM, V168, P171, DOI 10.1016/0003-2697(88)90025-5; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1994, BIOCHEM J, V302, P729, DOI 10.1042/bj3020729; BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; BIENKOWSKI RS, 1983, BIOCHEM J, V214, P1; Byers Peter H., 1993, P317; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHIPMAN SD, 1992, J BONE MINER RES, V7, P793; CHU ML, 1983, NATURE, V304, P78, DOI 10.1038/304078a0; COHN DH, 1988, J BIOL CHEM, V263, P14605; DEAK SB, 1991, J BIOL CHEM, V266, P21827; DEWET W, 1987, J BIOL CHEM, V262, P16032; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; DOUGLAS AM, 1992, ANAL BIOCHEM, V201, P362, DOI 10.1016/0003-2697(92)90352-8; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; FEDARKO NS, 1992, J BONE MINER RES, V7, P921; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; KATZ EP, 1992, J MOL BIOL, V228, P963, DOI 10.1016/0022-2836(92)90878-N; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOTTES M, 1994, HUM GENET, V93, P681; MOTTES M, 1992, HUM GENET, V89, P480; MYERS JC, 1983, J BIOL CHEM, V258, P128; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; NIYIBIZI C, 1992, J BIOL CHEM, V267, P23108; OTSUBO K, 1992, BIOCHEMISTRY-US, V31, P396, DOI 10.1021/bi00117a013; PATERSON CR, 1983, J MED GENET, V20, P203, DOI 10.1136/jmg.20.3.203; SHAPIRO JR, 1992, J CLIN INVEST, V89, P567, DOI 10.1172/JCI115622; SILLENCE D, 1993, AM J MED GENET, V45, P183, DOI 10.1002/ajmg.1320450207; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; Steinmann Beat, 1993, P351; SUPERTIFURGA A, 1993, CONNECT TISSUE RES, V29, P31, DOI 10.3109/03008209309061964; SYKES B, 1990, AM J HUM GENET, V46, P293; VALLI M, 1993, EUR J BIOCHEM, V217, P77, DOI 10.1111/j.1432-1033.1993.tb18220.x; VASAN NS, 1991, AM J HUM GENET, V48, P305; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590; WILLING MC, 1993, AM J MED GENET, V45, P223, DOI 10.1002/ajmg.1320450214; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WILLING MC, 1994, AM J HUM GENET, V55, P638; WILLING MC, 1988, J BIOL CHEM, V263, P8398; Yamauchi M, 1988, COLLAGEN, P157; ZHUANG JP, 1993, HUM GENET, V91, P210	55	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21068	21074		10.1074/jbc.271.35.21068	http://dx.doi.org/10.1074/jbc.271.35.21068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702873	hybrid			2022-12-25	WOS:A1996VE47700019
J	Rudd, MD; Luse, DS				Rudd, MD; Luse, DS			Amanitin greatly reduces the rate of transcription by RNA polymerase II ternary complexes but fails to inhibit some transcript cleavage modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; MAJOR LATE PROMOTER; ALPHA-AMANITIN; NASCENT RNA; ABORTIVE INITIATION; TERMINATION SITES; LARGEST SUBUNIT; BETA' SUBUNIT; CALF THYMUS; C-MYC	The toxin alpha-amanitin is frequently employed to completely block RNA synthesis by RNA polymerase II. However, we find that polymerase II ternary transcription complexes stalled by the absence of NTPs resume RNA synthesis when NTPs and amanitin are added. Chain elongation with amanitin can continue for hours at approximately 1% of the normal rate. Amanitin also greatly slows pyrophosphorolysis by elongation-competent complexes. Complexes which are arrested (that is, which have paused in transcription for long periods in the presence of excess NTPs) are essentially incapable of resuming transcription in the presence of alpha-amanitin. Complexes traversing sequences that can provoke arrest are much more likely to stop transcription in the presence of the toxin. The substitution of IMP for GMP at the 3' end of the nascent RNA greatly increases the sensitivity of stalled transcription complexes to amanitin. Neither arrested nor stalled complexes display detectable SII-mediated transcript cleavage following amanitin treatment. However, arrested complexes possess a low level, intrinsic transcript cleavage activity which is completely amanitin-resistant; furthermore, pyrophosphorolytic transcript cleavage in arrested complexes is not affected by amanitin.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BARTOLOMEI MS, 1995, MOL GEN GENET, V246, P778, DOI 10.1007/BF00290727; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; COPPOLA JA, 1984, J MOL BIOL, V178, P415, DOI 10.1016/0022-2836(84)90151-7; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; GREENLEAF AL, 1983, J BIOL CHEM, V258, P3403; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JOB C, 1992, BIOCHEM J, V285, P85, DOI 10.1042/bj2850085; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUTTER LC, 1982, J BIOL CHEM, V257, P1577; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1991, NUCLEIC ACIDS RES, V19, P1783, DOI 10.1093/nar/19.8.1783; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VAISIUS AC, 1982, BIOCHEMISTRY-US, V21, P3097, DOI 10.1021/bi00256a010; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	49	57	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21549	21558		10.1074/jbc.271.35.21549	http://dx.doi.org/10.1074/jbc.271.35.21549			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702941	hybrid			2022-12-25	WOS:A1996VE47700087
J	Wolf, MJ; Gross, RW				Wolf, MJ; Gross, RW			The calcium-dependent association and functional coupling of calmodulin with myocardial phospholipase A(2) - Implications for cardiac cycle-dependent alterations in phospholipolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CALMODULIN; ARACHIDONIC-ACID; NUCLEOTIDE PHOSPHODIESTERASE; INDEPENDENT PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A2; PURIFICATION; BINDING; CELLS; PROTEIN; MUSCLE	Herein we demonstrate the calcium-dependent regulation of myocardial phospholipase A(2) activity, which is mediated by a cytosolic protein constituent that can be chromatographically resolved from, and subsequently reconstituted with, purified myocardial phospholipase A(2). Purification of this protein by sequential column chromatographies revealed an 18-kDa doublet, which was identified as calmodulin by Western blotting, calcium-dependent precipitation with W-7 agarose beads, and reconstitution of calcium-mediated phospholipase A(2) inhibition with authentic homogeneous calmodulin, Calcium-induced calmodulin-mediated inhibition of myocardial phospholipase A(2) was titrated by physiologic increments of calcium ion (K-d similar to 200 nM). Moreover, ternary complex affinity chromatography with calmodulin-Sepharose demonstrated that inhibition of myocardial phospholipase A(2) activity by calmodulin resulted from the direct interaction of calmodulin with the myocardial phospholipase A(2) catalytic complex, Exposure of cultured A-10 muscle cells to three structurally disparate calmodulin antagonists (W-7, trifluoperazine, and calmidazolium) resulted in the robust release of arachidonic acid, which was entirely ablated by pretreatment of cells with (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2-H-tetrahydropyran-2-one. Collectively, this study identifies a novel mechanism whereby latent phospholipase A(2) activity can be released from tonic inhibition by alterations in the interactions between the phospholipase A(2) catalytic complex, calcium ion, and the intracellular calcium transducer, calmodulin.	WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT MOL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			WOLF, MATTHEW/AHC-5201-2022; wolf, matthew/C-2315-2008	Wolf, Matthew/0000-0001-8004-4852				ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; BRANDES R, 1993, BIOPHYS J, V65, P1973, DOI 10.1016/S0006-3495(93)81274-8; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COYNE MD, 1985, ARCH BIOCHEM BIOPHYS, V236, P629, DOI 10.1016/0003-9861(85)90667-8; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1983, ENZYMES, P307; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; GIETZEN K, 1983, BIOCHEM J, V216, P611, DOI 10.1042/bj2160611; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; GROSS RW, 1995, J LIPID MEDIAT CELL, V12, P131, DOI 10.1016/0929-7855(95)00014-H; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; KIHARA Y, 1989, CIRC RES, V65, P1029, DOI 10.1161/01.RES.65.4.1029; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LEVIN RM, 1979, J PHARMACOL EXP THER, V208, P454; LEVIN RM, 1977, MOL PHARMACOL, V13, P690; MOORE PB, 1982, J BIOL CHEM, V257, P9663; OGANA Y, 1984, J BIOCHEM-TOKYO, V95, P19; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; SHARMA RK, 1990, J BIOL CHEM, V265, P1152; SHARMA RK, 1980, J BIOL CHEM, V255, P5916; TANAKA T, 1980, J BIOL CHEM, V255, P1078; THANDROYEN FT, 1991, CIRC RES, V69, P810, DOI 10.1161/01.RES.69.3.810; VANBELLE H, 1981, CELL CALCIUM, V2, P484; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WOLF RA, 1985, J BIOL CHEM, V260, P7259; XIAO YF, 1995, P NATL ACAD SCI USA, V92, P11000, DOI 10.1073/pnas.92.24.11000	40	83	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20989	20992		10.1074/jbc.271.35.20989	http://dx.doi.org/10.1074/jbc.271.35.20989			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702861	hybrid			2022-12-25	WOS:A1996VE47700005
J	Crespo, P; Bustelo, XR; Aaronson, DS; Coso, OA; LopezBarahona, M; Barbacid, M; Gutkind, JS				Crespo, P; Bustelo, XR; Aaronson, DS; Coso, OA; LopezBarahona, M; Barbacid, M; Gutkind, JS			Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav	ONCOGENE			English	Article						Vav; signal transduction; JNK; MAP kinases; GTP-binding proteins	GUANINE-NUCLEOTIDE EXCHANGE; DBL-ONCOGENE PRODUCT; RECEPTOR TYROSINE KINASE; GTP-BINDING PROTEINS; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; RAS; ACTIVATION; PHOSPHORYLATION	The protein product of the human vav oncogene, Vav, exhibits a number of structural motifs suggestive of a role in signal transduction pathways, including a leucine-rich region, a plekstrin homology (PH) domain, a cysteine-rich domain, two SH3 regions, an SH2 domain, and a central Dbl homology (DH) domain. However, the transforming pathway(s) activated by Vav has not yet been elucidated. Interestingly, DH domains are frequently found in guanine nucleotide-exchange factors for small GTP-binding proteins of the Ras and Rho families, and it has been recently shown that, whereas Ras controls the activation of mitogen activated kinases (MAPKs), two members of the Rho family of small GTPases, Rac 1 and Cdc42, regulate activity of stress activated protein kinases (SAPKs), also termed c-jun N-terminal kinases (JNKs). The structural similarity between Vav and other guanine nucleotide exchange factors for small GTP-binding proteins, together with the recent identification of biochemical routes specific for members of the Ras and Rho family of GTPases, prompted us to explore whether MAPK or JNK are downstream components of the Vav signaling pathways. Using the COS-7 cell transient expression system, we have found that neither Vav nor the product of the I,av proto-oncogene, proto-Vav, can enhance the enzymatic activity of a coexpressed, epitope tagged MAPK. On the other hand, we have observed that, whereas proto-Vav can slightly elevate JNK/SAPK activity, oncogenic Vav potently activates JNK/SAPK to an extent comparable to that elicited by two guanine-nucleotide exchange factors for Rho family members, Dbl and Ost. We also show that point mutations in conserved residues within the cysteine rich and DH domains of Vav both prevent its ability to activate JNK/SAPK and render Vav oncogenically inactive. In addition, we found that coexpression of the Rac-1 N17 dominant inhibitory mutant dramatically diminishes JNK/SAPK stimulation by Vav, as well as reduces the focus-forming ability of Vav in NIH3T3 murine fibroblasts. Taken together, these findings provide the first evidence that Rac-1 and JNK are integral components of the Vav signaling pathway.	NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,PRINCETON,NJ 08543	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Bristol-Myers Squibb			Bustelo, Xose R./AAD-2081-2022; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Bustelo, Xose R./0000-0001-9398-6072; Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P177; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	41	154	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					455	460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760286				2022-12-25	WOS:A1996VB32800002
J	Vadiveloo, PK; Vairo, G; Novak, U; Royston, AK; Whitty, G; Filonzi, EL; Cragoe, EJ; Hamilton, JA				Vadiveloo, PK; Vairo, G; Novak, U; Royston, AK; Whitty, G; Filonzi, EL; Cragoe, EJ; Hamilton, JA			Differential regulation of cell cycle machinery by various antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints	ONCOGENE			English	Article						cyclin; cdk; IFN gamma; dimethylamiloride; lipopolysaccharide; cAMP	STIMULATING FACTOR-I; DEPENDENT PROTEIN-KINASES; GROWTH-FACTOR-BETA; C-MYC EXPRESSION; S-PHASE ENTRY; TRANSCRIPTION FACTOR; TGF-BETA; RETINOBLASTOMA PROTEIN; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION	There is currently much interest in the mechanisms of action of antiproliferative agents and their effects on cell cycle machinery. In the present study we examined the mechanisms of action of four unrelated agents known to inhibit proliferation of CSF-1-stimulated bone marrow-derived macrophages (BMM). We report that 8-bromo-cAMP (8Br-cAMP) and lipopolysaccharide (LPS) potently reduced CSF-1-stimulated cyclin D1 protein, and cyclin-dependent kinase (cdk) 4 mRNA and protein levels, while the inhibitory effects of the Na+/ H+ antiport inhibitor 5-(N',N'-dimethyl) amiloride (DMA) and interferon gamma (IFN gamma) were only weak. All agents repressed CSF-1-stimulated retinoblastoma protein phosphorylation. Furthermore, 8Br-cAMP and to a lesser extent IFN gamma, also reduced CSF-1-stimulated levels of E2F DNA binding activity in a macrophage cell line, BAC1.2F5. An explanation for the different effects of the agents is that 8Br-cAMP and LPS were found to arrest BMM in early/mid-G1, while IFN gamma and DMA arrested cells in late G1 or early S phase. These data indicate that (1) different antiproliferative agents can arrest the same cell type at distinct checkpoints in G1 and (2) effects of antiproliferative agents on cell cycle machinery is Linked to the position at which they arrest cells in G1.	WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Walter & Eliza Hall Institute	Vadiveloo, PK (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; DEGREGORI J, 1995, MOL CELL BIOL, V15, P5846; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GAGELIN C, 1994, BIOCHEM BIOPH RES CO, V205, P923, DOI 10.1006/bbrc.1994.2753; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAMILTON JA, 1992, J IMMUNOL, V148, P4028; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KO TC, 1995, ONCOGENE, V10, P177; KREK W, 1995, METHOD ENZYMOL, V254, P114; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1992, SCIENCE, V258, P424; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; OKAMOTO Y, 1993, BIOCHEM BIOPH RES CO, V195, P84, DOI 10.1006/bbrc.1993.2013; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SEWING A, 1993, J CELL SCI, V104, P545; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1995, ONCOGENE, V10, P1969; VAIRO G, 1992, J BIOL CHEM, V267, P19043; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIE Y, 1993, BRIT J HAEMATOL, V84, P392, DOI 10.1111/j.1365-2141.1993.tb03092.x	68	47	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					599	608						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760301				2022-12-25	WOS:A1996VB32800017
J	Zou, XG; Xian, J; Davies, NP; Popov, AV; Bruggemann, M				Zou, XG; Xian, J; Davies, NP; Popov, AV; Bruggemann, M			Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production	FASEB JOURNAL			English	Article						locus introduction; transgenesis; expression control; human antibodies	YEAST ARTIFICIAL CHROMOSOMES; SOMATIC HYPERMUTATION; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE; REGION; HEAVY; REPERTOIRE; CONSTANT	Expression studies of multigene families, such as the immunoglobulin (Ig) loci, are difficult because of their large size and the necessity to introduce germline configured regions into an animal. Antibody diversity from Ig gene miniloci is limited by the number of variable (V) region genes and the need for distal regulatory elements to control expression, Here, we show germline transfer into mice of a 1300 kb human Ig kappa light chain locus on a yeast artificial chromosome that resulted in early DNA rearrangement and highly efficient human light chain expression, The human locus was assembled from a 300 kb authentic region using contig extension by addition of cosmid multimers to supplement the variable gene cluster. This resulted in the addition of about 100 V region genes in germline configuration from different families. In transgenic animals with Ig kappa disruption, this large human kappa locus replaced the endogenous locus, and subsequent down-regulation of Ig lambda light chain contribution Zed to a dominant expression of the rearranged human genes. Contrary to expectation, rather than providing a solely selective advantage for ensuring repertoire formation controlled by the sheer number of introduced genes, the lambda/kappa ratio in serum appears to be the result of competition for early surface Ig expression maintained in the developing B cell.	BABRAHAM INST, DEPT GENET & DEV, DEV IMMUNOL LAB, CAMBRIDGE CB2 4AT, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BRUGGEMANN M, 1991, Methods (Orlando), V2, P159, DOI 10.1016/S1046-2023(05)80216-6; BRUGGEMANN M, 1989, P NATL ACAD SCI USA, V86, P6709, DOI 10.1073/pnas.86.17.6709; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DAVIES NP, 1993, BIO-TECHNOL, V11, P911, DOI 10.1038/nbt0893-911; DAVIES NP, 1993, NUCLEIC ACIDS RES, V21, P767, DOI 10.1093/nar/21.3.767; DAVIES NP, 1992, NUCLEIC ACIDS RES, V20, P2693, DOI 10.1093/nar/20.11.2693; DAVIES NP, 1996, ANTIBODY ENG PRACTIC, P59; DAVIES NP, 1994, THESIS U CAMBRIDGE; FRIPPIAT JP, 1995, HUM MOL GENET, V4, P983; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; Guthrie C, 1991, GUIDE YEAST GENETICS; HIETER PA, 1980, CELL, V22, P197, DOI 10.1016/0092-8674(80)90168-3; Hogan B, 1994, MANIPULATING MOUSE E; JAKOBOVITS A, 1993, NATURE, V362, P255, DOI 10.1038/362255a0; KLEIN R, 1993, EUR J IMMUNOL, V23, P3248, DOI 10.1002/eji.1830231231; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; PECH M, 1985, J MOL BIOL, V183, P291, DOI 10.1016/0022-2836(85)90001-4; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; ZACHAU HG, 1993, GENE, V135, P167, DOI 10.1016/0378-1119(93)90062-8; ZOU XG, 1995, EUR J IMMUNOL, V25, P2154, DOI 10.1002/eji.1830250806	25	19	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1996	10	10					1227	1232		10.1096/fasebj.10.10.8751726	http://dx.doi.org/10.1096/fasebj.10.10.8751726			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751726				2022-12-25	WOS:A1996VD42900015
J	Reverey, H; Veit, M; Ponimaskin, E; Schmidt, MFG				Reverey, H; Veit, M; Ponimaskin, E; Schmidt, MFG			Differential fatty acid selection during biosynthetic S-acylation of a transmembrane protein (HEF) and other proteins in insect cells (Sf9) and in mammalian cells (CV1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-C-VIRUS; COA-BINDING PROTEIN; BACULOVIRUS VECTOR; GLYCOPROTEIN; FUSION; EXPRESSION; OLIGOSACCHARIDES; HEMAGGLUTININ; GENE; DNA	The transmembrane glycoprotein HEF and its acylation deficient mutant M1 were expressed in Sf9 insect cells infected with recombinant baculovirus and in CV1 mammalian cells using the vaccinia T7 system, In insect cells (Sf9), both wild type HEF and HEF(M1) are synthesized in their precursor form HEF(0), which appears as a double band in SDS gels, Digestion with glycopeptidase F and endoglycosidase H reveals that the larger 84-kDa form is modified by the attachment of unprocessed carbohydrates of the high mannose type whereas the smaller 76-kDa form is non-glycosylated. As revealed by in vitro labeling experiments with palmitic acid another modification of HEF is the attachment of a long chain fatty acid to cysteine residue Cys-652 which is located at the internal border of the cytoplasmic membrane, After labeling with [H-3]palmitic acid in both systems only HEF(WT) is acylated, whereas HEF(M1) is not, High performance liquid chromatography analysis of the fatty acids bound to HEF(WT) expressed in Sf9 insect cells reveals nearly 80% of palmitic acid. In contrast to this finding, the acylation pattern of HEF expressed in CV1 cells shows nearly the same amounts of stearic and palmitic acid (40%), Since the interconversion of the input [H-3]palmitic acid to stearic acid is even lower in CV1 cells than in insect cells, it follows that only HEF expressed in mammalian, but not in insect cells selects for stearic acid during its biosynthetic acylation, We extended our study to acylation of endogenous proteins in Sf9 cells. In finding only palmitate linked to protein we present evidence that, in contrast to mammalian cells, insect cells (Sf9) cannot transfer stearic acid to polypeptide, This finding favors the hypothesis of enzymatic acylation over non-enzymatic mechanisms of acyl transfer to protein.	FREE UNIV BERLIN, INST IMMUNOL & MOL BIOL, FACHBEREICH VET MED, D-10117 BERLIN, GERMANY	Free University of Berlin			Veit, Michael/G-6492-2010	Veit, Michael/0000-0002-7638-1829; Ponimaskin, evgeni/0000-0002-4570-5130				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; FORMANOWSKI F, 1988, VIRUS RES, V10, P177, DOI 10.1016/0168-1702(88)90014-7; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839; HERRLER G, 1979, VIROLOGY, V99, P49, DOI 10.1016/0042-6822(79)90035-7; HEWAT EA, 1984, J MOL BIOL, V175, P175, DOI 10.1016/0022-2836(84)90473-X; KITAME F, 1982, ARCH VIROL, V73, P357, DOI 10.1007/BF01318090; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAGELE A, 1983, THESIS TU MUNICH; NAKADA S, 1984, J VIROL, V50, P118, DOI 10.1128/JVI.50.1.118-124.1984; OHUCHI M, 1982, J VIROL, V42, P1076, DOI 10.1128/JVI.42.3.1076-1079.1982; PFEIFER JB, 1984, VIRUS RES, V1, P281, DOI 10.1016/0168-1702(84)90017-0; PONIMASKIN E, 1994, J GEN VIROL, V75, P1163, DOI 10.1099/0022-1317-75-5-1163; Possee RD., 1992, BACULOVIRUS EXPRESSI; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SZEPANSKI S, 1994, J GEN VIROL, V75, P1023, DOI 10.1099/0022-1317-75-5-1023; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; VEIT M, 1990, VIROLOGY, V177, P807, DOI 10.1016/0042-6822(90)90554-5; Veit M, 1996, BIOCHEM J, V318, P163, DOI 10.1042/bj3180163	27	23	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23607	23610		10.1074/jbc.271.39.23607	http://dx.doi.org/10.1074/jbc.271.39.23607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798573	hybrid			2022-12-25	WOS:A1996VJ44200002
J	Ayala, A; Parrado, J; Bougria, M; Machado, A				Ayala, A; Parrado, J; Bougria, M; Machado, A			Effect of oxidative stress, produced by cumene hydroperoxide, on the various steps of protein synthesis - Modifications of elongation factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE AMINO-ACIDS; FACTOR-II; LIPID-PEROXIDATION; RAT-LIVER; GLUTAMINE-SYNTHETASE; ADP-RIBOSYLATION; OXYGEN RADICALS; HYDROLYSIS PRODUCTS; HISTIDINE RESIDUE; DIPHTHERIA-TOXIN	We have studied the effect of oxidative stress on protein synthesis in rat liver. Cumene hydroperoxide (CH) was used as an oxidant agent, The approach used was to determine the ribosomal state of aggregation and the time for assembly and release of polypeptide chains in the process of protein synthesis in rat liver in vivo. The results suggest that the elongation step is the most sensitive to CH treatment. The measurement of both carbonyl groups content and ADP-ribosylatable elongation factor 2 (EF-2), the main protein involved in the elongation step, indicates that under CH treatment EF-2 is oxidatively modified and a lower amount of active EF-2 is present. These results are corroborated by in vitro oxidation of EF-2 and could explain for the decline in the elongation step.	UNIV SEVILLA,FAC FARM,DEPT BIOQUIM BROMATOL & TOXICOL,E-41012 SEVILLE,SPAIN	University of Sevilla			Parrado, Juan/E-6637-2010; IBIS, ENVEJECIMIENTO/O-9381-2015; Ayala, Antonio/N-7591-2019	Parrado, Juan/0000-0002-1462-408X; Ayala, Antonio/0000-0001-9711-3711				AIRHART J, 1974, BIOCHEMISTRY-US, V140, P539, DOI 10.1042/bj1400539; AYUSOPARRILLA M, 1973, J BIOL CHEM, V248, P4394; CHEN JYC, 1988, J BIOL CHEM, V263, P11692; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FENDRICK JL, 1989, P NATL ACAD SCI USA, V86, P554, DOI 10.1073/pnas.86.2.554; FERN EB, 1974, BIOCHEM J, V142, P413, DOI 10.1042/bj1420413; GIULIVI C, 1994, METHOD ENZYMOL, V233, P363; GORDILLO E, 1988, J BIOL CHEM, V263, P8053; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1986, FREE RADICAL BIO MED, P139; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HENSHAW EC, 1971, J BIOL CHEM, V246, P436; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IGLEWSKI WJ, 1991, FEBS LETT, V283, P235, DOI 10.1016/0014-5793(91)80596-U; IGLEWSKI WJ, 1994, MOL CELL BIOCHEM, V138, P131, DOI 10.1007/BF00928454; IGLEWSKI WJ, 1984, FEBS LETT, V173, P113, DOI 10.1016/0014-5793(84)81028-5; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401, DOI 10.1152/ajpcell.1993.264.6.C1401; KODAMAN PH, 1994, ENDOCRINOLOGY, V135, P27; KRAMER K, 1986, FEBS LETT, V198, P80, DOI 10.1016/0014-5793(86)81188-7; LAJTHA A, 1981, LIFE SCI, V29, P755, DOI 10.1016/0024-3205(81)90030-8; LEE H, 1984, P NATL ACAD SCI USA, V81, P2704; LENZ AG, 1989, ANAL BIOCHEM, V177, P419, DOI 10.1016/0003-2697(89)90077-8; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; MORTIMOR.GE, 1970, J BIOL CHEM, V245, P2375; MORTIMORE GE, 1972, J BIOL CHEM, V247, P2776; NILSSON A, 1995, BBA-GENE STRUCT EXPR, V1260, P200, DOI 10.1016/0167-4781(94)00198-C; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PERENTESIS JP, 1992, BIOFACTORS, V3, P173; POOT M, 1988, MECH AGEING DEV, V43, P1, DOI 10.1016/0047-6374(88)90093-0; POOT M, 1988, J CELL PHYSIOL, V137, P421, DOI 10.1002/jcp.1041370305; RATTAN SIS, 1991, MUTAT RES, V256, P115, DOI 10.1016/0921-8734(91)90005-V; Richardson A, 1983, REV BIOL RES AGING, V1, P255; RIIS B, 1989, BIOCHEM BIOPH RES CO, V159, P1141, DOI 10.1016/0006-291X(89)92228-6; RIIS B, 1989, J BIOCHEM BIOPH METH, V19, P319, DOI 10.1016/0165-022X(89)90063-8; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; SAHAKIAN JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P411, DOI 10.1006/abbi.1995.1248; SCORNIK OA, 1974, J BIOL CHEM, V249, P3876; SHIMURA J, 1985, BIOCHIM BIOPHYS ACTA, V845, P43, DOI 10.1016/0167-4889(85)90052-7; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; TAFFE BG, 1987, J BIOL CHEM, V262, P12143; VANNESS BG, 1980, J BIOL CHEM, V255, P710; VANNESS BG, 1980, J BIOL CHEM, V255, P717; WEISS RH, 1986, ARCH BIOCHEM BIOPHYS, V251, P336, DOI 10.1016/0003-9861(86)90081-0; WENDEL A, 1981, BIOCHEM PHARMACOL, V30, P2513, DOI 10.1016/0006-2952(81)90576-1	56	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23105	23110		10.1074/jbc.271.38.23105	http://dx.doi.org/10.1074/jbc.271.38.23105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798501	hybrid			2022-12-25	WOS:A1996VH76800027
J	Hartman, JL; Northup, JK				Hartman, JL; Northup, JK			Functional reconstitution in situ of 5-hydroxytryptamine(2c) (5HT(2c)) receptors with alpha(q) and inverse agonism of 5HT(2c) receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHOSPHOLIPASE-C ISOZYMES; BETA-GAMMA-SUBUNITS; GTP-BINDING PROTEIN; SF9 CELLS; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDES; INTRINSIC ACTIVITY; ADENYLATE-CYCLASE; CHOROID-PLEXUS	Membranes prepared after infection of Sf9 cells with recombinant baculovirus containing the rat 5HT(2c) receptor DNA, but not after infection with wild-type virus, expressed high affinity binding sites for I-125-lysergic acid diethylamide and [H-3]mesulergine. The receptor site density reached an optimum of 50-70 pmol/mg membrane protein at 60 h postinfection. Extraction of peripheral membrane proteins from the postnuclear membrane fraction with 6 M urea depleted GTP gamma S-binding 4-fold without decreasing 5HT(2c) receptor binding activity. Urea-extracted Sf9 membranes expressing the 5HT(2c) receptor catalyzed the activation of squid retinal alpha(q) but not bovine retinal alpha(t) or bovine alpha(o) alpha(i). Productive interaction of 5HT(2c), receptors with squid alpha(q) was enhanced by the addition of beta gamma dimers prepared from either bovine brain or bovine rod outer segment discs. While the addition of serotonin increased 5HT(2c) receptor-catalyzed GTP gamma S binding to alpha(q), the unoccupied receptor was also catalytically active. The 5HT(2c) receptor antagonists, mesulergine, mianserin, and ketanserin competitively inhibited 5HT activation of the receptor with predicted rank-order affinities; and mianserin and ketanserin markedly inhibited basal 5HT(2c) receptor activity. Interestingly, this ''inverse agonist'' efficacy did not correlate with antagonist affinity for the 5HT(2c) receptor. Baculoviral expression of the 5HT(2c) receptor and urea extraction of postnuclear Sf9 cell membranes have provided a high density of in situ, uncoupled, G-protein-linked receptor useful for reconstitution with purified G-protein subunits. This has allowed for independent manipulation of receptor and G protein chemical concentrations and has revealed that a G-protein-linked receptor can possess a significant basal catalytic activity and that antagonist compounds can act as inverse agonists of this basal activity at the level of receptor activation of G-proteins.			Hartman, JL (corresponding author), NIMH, CELL BIOL LAB, BLDG 36, BETHESDA, MD 20892 USA.			Hartman, John/0000-0003-1176-6469				BARKER EL, 1994, J BIOL CHEM, V269, P11687; BERTIN B, 1992, J BIOL CHEM, V267, P8200; CERIONE RA, 1991, METHOD ENZYMOL, V195, P329; CERIONE RA, 1991, BIOCHIM BIOPHYS ACTA, V1071, P473, DOI 10.1016/0304-4157(91)90007-J; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CONN PJ, 1986, P NATL ACAD SCI USA, V83, P4086, DOI 10.1073/pnas.83.11.4086; CONN PJ, 1986, J NEUROCHEM, V47, P1754, DOI 10.1111/j.1471-4159.1986.tb13085.x; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; Hargrave PA, 1991, CURR OPIN STRUC BIOL, V1, P575, DOI 10.1016/S0959-440X(05)80080-6; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HOYER D, 1988, TRENDS PHARMACOL SCI, V9, P89, DOI 10.1016/0165-6147(88)90174-5; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENAKIN T, 1987, TRENDS PHARMACOL SCI, V8, P423, DOI 10.1016/0165-6147(87)90229-X; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; PEROUTKA SJ, 1988, ANNU REV NEUROSCI, V11, P45, DOI 10.1146/annurev.ne.11.030188.000401; POTTINGER JDD, 1991, BIOCHEM J, V279, P323, DOI 10.1042/bj2790323; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RYBA NJ, 1993, BIOCHEM J, V292, P333, DOI 10.1042/bj2920333; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SJOERDSMA A, 1990, ANN NY ACAD SCI, V600, P1, DOI 10.1111/j.1749-6632.1990.tb16869.x; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TAYLOR P, 1990, P1; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	47	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22591	22597		10.1074/jbc.271.37.22591	http://dx.doi.org/10.1074/jbc.271.37.22591			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798428	hybrid			2022-12-25	WOS:A1996VG67200047
J	Leng, XH; Manolson, MF; Liu, Q; Forgac, M				Leng, XH; Manolson, MF; Liu, Q; Forgac, M			Site-directed mutagenesis of the 100-kDa subunit (Vph1p) of the yeast vacuolar (H+)-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE ENCODES; TRANSLOCATING ATPASE; CDNA SEQUENCE; ADENOSINE-TRIPHOSPHATASE; CHROMAFFIN GRANULES; 116-KDA POLYPEPTIDE	Vacuolar (H+) ATPases (V-ATPases) are multisubunit complexes responsible for acidification of intracellular compartments in eukaryotic cells. V-ATPases possess a subunit of approximate molecular mass 100 kDa of unknown function that is composed of an amino-terminal hydrophilic domain and a carboxyl-terminal hydrophobic domain. To test whether the 100-kDa subunit plays a role in proton transport, site-directed mutagenesis of the VPH1 gene, which is one of two genes that encodes this subunit in yeast, has been carried out in a strain lacking both endogenous genes. Ten charged and twelve polar residues located in the seven putative transmembrane helices in the COOH-terminal domain of the molecule were individually changed, and the effects on pro ton transport, ATPase activity, and assembly of the yeast V-ATPase were measured. Two mutations (R735L and Q634L) in transmembrane helix 6 and at the border of transmembrane helix 5, respectively, showed greatly reduced levels of the 100 kDa subunit in the vacuolar membrane, suggesting that these mutations affected stability of the 100-kDa subunit. Two mutations, D425N and K538A, in transmembrane helix 1 and at the border of transmembrane helix 3, respectively, showed reduced assembly of the V-ATPase, with the D425N mutation also reducing the activity of V-ATPase complexes that did assemble. Two mutations, H743A and K593A, in transmembrane helix 6 and at the border of transmembrane helix 4, respectively, have significantly greater effects on activity than on assembly, with proton transport and ATPase activity inhibited 40-60%. One mutation, E789Q, in transmembrane helix 7, virtually completely abolished proton transport and ATPase activity while having no effect on assembly. These results suggest that the 100-kDa subunit may be required for activity as well as assembly of the V-ATPase complex and that several charged residues in the last four putative transmembrane helices of this subunit may play a role in proton transport.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, BOSTON, MA 02111 USA; HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA	Tufts University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Manolson, Morris/0000-0001-8755-5460	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; [Anonymous], 1991, Methods Enzymol, V194, P1; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FENG Y, 1992, J BIOL CHEM, V267, P5817; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CK, 1990, MOL IMMUNOL, V27, P1137; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENG SB, 1994, J BIOL CHEM, V269, P17262; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SUN SZ, 1987, J BIOL CHEM, V262, P14790; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WANG SY, 1988, J BIOL CHEM, V263, P17638; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	70	108	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22487	22493		10.1074/jbc.271.37.22487	http://dx.doi.org/10.1074/jbc.271.37.22487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798414				2022-12-25	WOS:A1996VG67200033
J	Tabas, I; Marathe, S; Keesler, GA; Beatini, N; Shiratori, Y				Tabas, I; Marathe, S; Keesler, GA; Beatini, N; Shiratori, Y			Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis - Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ACYL-COENZYME-A; UNESTERIFIED CHOLESTEROL; ATHEROGENIC LIPOPROTEINS; HUMAN-MONOCYTES; LYSOPHOSPHATIDYLCHOLINE; INHIBITION; ACYLTRANSFERASE; ACCUMULATION	Macrophages in atherosclerotic lesions accumulate free cholesterol (FC) as well as cholesteryl ester and appear to have high rates of phospholipid (PL) synthesis and increased PL mass, Previous short term (i.e. less than or equal to 24 h) studies with cultured macrophages have shown that these cells respond to FC loading by up-regulating phosphatidylcholine biosynthesis, We propose that this response is adaptive by keeping the FC:PL ratio in the macrophages from reaching toxic levels. We further propose that one cause of macrophage necrosis, a prominent and important event in atherosclerosis, is an eventual decrease of this adaptive response, To explore these ideas, cultured macrophages were loaded with FC for up to 4 days and assayed for phosphatidylcholine biosynthesis, FC and PL mass, and cytotoxicity. For the first 24 h, cellular phosphatidylcholine biosynthesis and FC and PL mass increased 3-4-fold, and thus the FC:PL molar ratio was prevented from reaching very high levels; at this point, there were no overt signs of cytotoxicity. Over the next 24-48 h, however, phosphatidylcholine biosynthesis, and then phosphatidylcholine mass, began to decrease. Initially, the macrophages remained healthy and continued to accumulate FC, but eventually these macrophages, but not unloaded macrophages, became necrotic (swollen organelles and disrupted membranes), Lipoprotein dose studies indicated a close relationship between the onset of macrophage necrosis and the FC:PL ratio, To test further the causal nature of these relationships, cellular FC and PL mass were independently manipulated by using high density lipoprotein, (HDL,) to decrease cellular FC and choline depletion to decrease cellular PC. As predicted by our hypotheses, HDL, protected FC-loaded macrophages from necrosis, whereas choline depletion accelerated cytotoxic changes, These findings support the idea that the initial increase in phosphatidylcholine biosynthesis in FC-loaded macrophages is an adaptive response that prevents cholesterol-induced macrophage necrosis, We propose that an eventual failure of the PL response in foam cells may represent one cause of macrophage necrosis in advanced atherosclerotic lesions.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA	Columbia University	Tabas, I (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Shiratori, Yoshimune/I-6206-2014		NHLBI NIH HHS [HL-21006, HL-54591, HL-39703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, R01HL039703, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARIASDIAZ J, 1994, J CLIN INVEST, V94, P244, DOI 10.1172/JCI117313; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCK RC, 1951, AMA ARCH PATHOL, V51, P224; COFFEY MD, 1995, J CLIN INVEST, V96, P1866, DOI 10.1172/JCI118232; CORNELL R, 1985, J BIOL CHEM, V260, P1290; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; DAY AJ, 1969, EXP MOL PATHOL, V11, P263, DOI 10.1016/0014-4800(69)90014-8; FOWLER S, 1980, ACTA MED SCAND, P151; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEINLE H, 1987, EXP MOL PATHOL, V46, P312, DOI 10.1016/0014-4800(87)90052-9; JACKSON RL, 1976, ATHEROSCLER REV, V1, P1; JEROME WG, 1985, AM J PATHOL, V119, P210; KASHFI K, 1991, BIOCHEM BIOPH RES CO, V177, P1121, DOI 10.1016/0006-291X(91)90655-Q; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MAOR I, 1995, ARTERIOSCL THROM VAS, V15, P1378, DOI 10.1161/01.ATV.15.9.1378; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NIEWOEHNER DE, 1989, J APPL PHYSIOL, V66, P261, DOI 10.1152/jappl.1989.66.1.261; OKWU AK, 1994, J LIPID RES, V35, P644; ORTEGA A, 1986, BIOCHEM BIOPH RES CO, V139, P868, DOI 10.1016/S0006-291X(86)80258-3; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RAPP JH, 1983, J LIPID RES, V24, P1329; RENIER G, 1994, J LIPID RES, V35, P271; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; SALMON WD, 1962, ARCH PATHOL, V73, P190; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SHECHTER I, 1981, J LIPID RES, V22, P63; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SMITH CW, 1972, EXP CELL RES, V73, P394, DOI 10.1016/0014-4827(72)90063-8; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; TABAS I, 1993, J BIOL CHEM, V268, P20419; TANGIRALA RK, 1994, J LIPID RES, V35, P93; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WAHLQVIST ML, 1969, EXP MOL PATHOL, V11, P275, DOI 10.1016/0014-4800(69)90015-X; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; YAO ZM, 1990, J BIOL CHEM, V265, P4326; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; ZILVERSMIT DB, 1954, CIRCULATION, V9, P581, DOI 10.1161/01.CIR.9.4.581	62	94	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22773	22781		10.1074/jbc.271.37.22773	http://dx.doi.org/10.1074/jbc.271.37.22773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798453	hybrid			2022-12-25	WOS:A1996VG67200072
J	Bu, GJ; Rennke, S				Bu, GJ; Rennke, S			Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; 39-KDA PROTEIN; INFLUENZA HEMAGGLUTININ; HEYMANN NEPHRITIS; LIGAND-BINDING; CELLS; SYSTEM; SITES; LRP	The 39-kDa receptor-associated protein (RAP) is a receptor antagonist that inhibits ligand interactions with the receptors that belong to the low density lipoprotein receptor gene family. Our previous studies have demonstrated that RAP interacts with the low density Lipoprotein receptor-related protein (LRP) within the endoplasmic reticulum and prevents premature interaction of ligands with the receptor. To analyze whether RAP is also involved in the folding of LRP during receptor biosynthesis, we generated anchor-free, soluble minireceptors that represent each of the four putative ligand-binding domains of LRP (SLRP1, -2, -3, and -4, corresponding to the clusters with 2, 8, 10, and 11 cysteine-rich complement-type repeats, respectively). When these SLRPs were overexpressed by cell transfection, only SLRP1 was secreted. Little or no secretion was observed for SLR92, -3, and -4. However, when RAP cDNA was cotransfected with SLRP2, -3, and -4 cDNAs, each of these SLRP2 was secreted. The cellular retention of SLRPs in the absence of RAP coexpression appeared to be a result of the formation of SDS-resistant, oligomeric aggregates observed under nonreducing conditions. Such oligomers of the SLRPs likely resulted from formation of intermolecular disulfide bonds since they were reduced to monomers when analyzed under reducing conditions. The oligomers were formed not only among molecules of a given SLRP, but also between different SLRPs. The role of RAP in the process of LRP folding was shown by the reduction in aggregated SLRP oligomers upon RAP coexpression. A similar role of RAP in preventing the aggregation of newly synthesized receptor was also observed using- membrane-containing minireceptor of LRP. Coimmunoprecipitation and ligand binding studies demonstrated that RAP binds avidly to SLRP2, -3, and -4, but not to SLRP1. These results suggest that these interactions may be important for proper folding of LRP by ensuring the formation of proper intradomain, but not intermolecular or interdomain, disulfide bonds. Thus, our results strongly suggest that, in addition to the prevention of premature binding of ligands to LRP, RAP also plays an important role in receptor folding.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL)								BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	28	155	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22218	22224		10.1074/jbc.271.36.22218	http://dx.doi.org/10.1074/jbc.271.36.22218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703036	hybrid			2022-12-25	WOS:A1996VF61200078
J	Lee, HW; Smith, L; Pettit, GR; Vinitsky, A; Smith, JB				Lee, HW; Smith, L; Pettit, GR; Vinitsky, A; Smith, JB			Ubiquitination of protein kinase C-alpha and degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TUMOR PROMOTERS; DOWN-REGULATION; PERMISSIVE ACTIVATION; PHORBOL ESTERS; BRYOSTATIN-1; CELLS; INHIBITION; CALPAIN	Bryostatins and phorbol esters acutely activate and subsequently down-regulate protein kinase C (PKC) by inducing its proteolysis via an unknown pathway, Here we show that treatment of renal epithelial cells with bryostatin 1 (Bryo) produced novel PKC-alpha species, which were larger than the native protein (80 kDa). The >80 kDa PKC-alpha species contained Ubi as indicated by immunostaining and accumulated in the presence of lactacystin, a selective inhibitor of proteolysis by the proteasome. In vitro experiments with I-125-ubiquitin and membranes from Bryo-treated cells showed that PKC-alpha became ubiquitinated by a reaction that depended on ATP and a cytosolic fraction. Lactacystin or a peptidyl aldehyde, Bz-Gly-Leu-Ala-leucinal, which inhibits certain proteinase activities of the proteasome, inhibited Bryo-evoked disappearance of PKC-alpha protein from the cells. Lacta preserved Bryo-induced P-32-labeled PKC-alpha indicating that the proteasome inhibitor spared activated enzyme from down-regulation in, vivo. These findings show that Bryo induces the degradation of PKC-alpha by the ubiquitin-proteasome complex.	UNIV ALABAMA,SCH MED,DEPT PHARMACOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT PHARMACOL,BIRMINGHAM,AL 35294; ARIZONA STATE UNIV,CANC RES INST,TEMPE,AZ 85287; ARIZONA STATE UNIV,DEPT CHEM,TEMPE,AZ 85287; CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [HL44408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COSTAGNA M, 1982, J BIOL CHEM, V257, P7847; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOODE NT, 1995, J BIOL CHEM, V270, P2669, DOI 10.1074/jbc.270.6.2669; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HUWILER A, 1994, BIOCHEM PHARMACOL, V48, P689, DOI 10.1016/0006-2952(94)90046-9; ISAKOV N, 1993, J IMMUNOL, V150, P1195; JALAVA A, 1993, BIOCHEM BIOPH RES CO, V191, P472, DOI 10.1006/bbrc.1993.1242; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; LYU RM, 1991, J MEMBRANE BIOL, V124, P73, DOI 10.1007/BF01871366; MAHONEY CW, 1994, PROTEIN KINASE C, P16; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; QUEST AFG, 1994, PROTEIN KINASE C, P64; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SAKO T, 1987, CANCER RES, V47, P5445; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Singer WD, 1996, J BIOL CHEM, V271, P4504; SMITH JB, 1985, BIOCHEM BIOPH RES CO, V132, P939, DOI 10.1016/0006-291X(85)91898-4; TALLANT EA, 1987, BIOCHIM BIOPHYS ACTA, V929, P40, DOI 10.1016/0167-4889(87)90239-4; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WENDER PA, 1988, P NATL ACAD SCI USA, V85, P7197, DOI 10.1073/pnas.85.19.7197; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	32	136	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20973	20976		10.1074/jbc.271.35.20973	http://dx.doi.org/10.1074/jbc.271.35.20973			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702857	hybrid			2022-12-25	WOS:A1996VE47700001
J	Musch, MW; Goldstein, L				Musch, MW; Goldstein, L			High affinity binding of ankyrin induced by volume expansion in skate erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGER; CYTOPLASMIC DOMAIN; MEMBRANE-SKELETON; TAURINE EFFLUX; CELL-LINE; BAND 3; ASSOCIATION; PROTEIN; SPECTRIN; TRANSPORT	Volume expansion of little skate (Raja erinacea) erythrocytes increases the affinity of ankyrin binding without altering in the number of binding sites. Potassium iodide-stripped inside-out vesicles (KI-IOV) were used to assess ankyrin binding under volume expanded conditions. Under isoosmotic conditions, ankyrin binds nearly exclusively to a single class of sites (B-max 52 +/- 12 mu g/mg; K-d, 150 +/- 28 nM). KI-IOV from volume-expanded cells (either with one-half osmolarity medium or with inclusion of the permeant solute ethylene glycol) demonstrate two ankyrin-binding populations. A high affinity population occurs transiently under volume-expanded conditions. This population has a B-max of 18 +/- 7 mu g/mg and a K-d of 25 +/- 9 nM. Total binding of high and low affinity sites is 57 +/- 17 mu g/mg. This change in ankyrin affinity is reversible on volume regulatory decrease. A major target protein in the KI-IOV was identified as the skate homolog of the mammalian red cell anion exchanger band 3. Inclusion of the purified cytoplasmic domain of band 3 competes away more than 80% of the ankyrin binding. To determine whether increased ankyrin affinity is due to band 3 tetramer formation that occurs in volume expansion, cells were treated with pyridoxal 5-phosphate or 4,4'-dinitrostilbene-2,2'-disulfonic acid, two agents that increase tetramer formation under isoosmotic conditions. Both treatments altered the binding affinity with a shift toward higher affinity binding without significant alteration in the number of binding sites.	UNIV CHICAGO,DEPT MED,CTR INFLAMMATORY BOWEL DIS,CHICAGO,IL 60637; MT DESERT ISL BIOL LAB,SALSBURY COVE,ME 04672; BROWN UNIV,DEPT PHYSIOL,PROVIDENCE,RI 02912	University of Chicago; Mount Desert Island Biological Laboratory; Brown University								ALPER SL, 1988, J BIOL CHEM, V263, P17092; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BRILL SR, 1992, J EXP ZOOL, V264, P19, DOI 10.1002/jez.1402640104; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CIANCI CD, 1988, J CELL BIOCHEM, V37, P219; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; Goldstein L, 1996, KIDNEY INT, V49, P1690, DOI 10.1038/ki.1996.249; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENNINGS ML, 1985, ANNU REV PHYSIOL, V47, P519; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MULZER K, 1990, COLLOID POLYM SCI, V268, P60, DOI 10.1007/BF01410424; MUSCH MW, 1994, AM J PHYSIOL, V266, pR65, DOI 10.1152/ajpregu.1994.266.1.R65; MUSCH MW, 1994, J BIOL CHEM, V269, P19683; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SARABIA VE, 1993, J BIOL CHEM, V268, P10676; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21221	21225		10.1074/jbc.271.35.21221	http://dx.doi.org/10.1074/jbc.271.35.21221			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702894	hybrid			2022-12-25	WOS:A1996VE47700040
J	Rolland, V; LeLiepvre, X; Jump, DB; Lavau, M; Dugail, I				Rolland, V; LeLiepvre, X; Jump, DB; Lavau, M; Dugail, I			A GC-rich region containing Sp1 and Sp1-like binding sites is a crucial regulatory motif for fatty acid synthase gene promoter activity in adipocytes - Implication in the overactivity of FAS promoter in obese Zucker rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED ADIPOCYTES; RESPONSIVE REGIONS; ADIPOSE-TISSUE; TRANSCRIPTION; EXPRESSION; INSULIN; CLONING; ACTIVATION; PROTEINS; IDENTIFICATION	We have previously shown that the proximal 2-kb sequence of the fatty acid synthase (FAS) promoter transfected into rat adipocytes was highly sensitive to the cellular context, displaying an overactivity in obese (fa/fa) versus lean Zucker rat adipocytes, Using deletional analysis, we show here that FAS promoter activity mainly depends on a region from -200 to -126. This sequence exerts a strong negative effect on FAS promoter in adipocytes from lean rats but not in those from obese rats, resulting in a marked overtranscriptional activity in the latter cells, This region, fused to a heterologous promoter, the E1b TATA box, induced differential levels of gene reporter activity in lean and obese rat adipocytes, indicating it harbors fa-responsive element(s), Whatever the rat genotype, adipocyte nuclear proteins were shown to footprint the same protected sequence within the fa-responsive region, and supershift analysis demonstrated that Sp1 or Sp1-like proteins were bound to this DNA subregion, Compelling evidence that the Sp1 binding site contained in this sequence was implicated in the differential promoter activity in lean versus obese rats, was provided by the observation that mutations at this Sp1 site induced a 2.5-fold increase in FAS promoter activity in adipocytes from lean rats, whereas they had no effect in adipocytes from obese rats.	MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824	Michigan State University	Rolland, V (corresponding author), INSERM,U177,UNITE RECH PHYSIOPATHOL NUTR,15 RUE ECOLE MED,F-75006 PARIS,FRANCE.		Dugail, Isabelle/L-1567-2017	Dugail, Isabelle/0000-0003-3631-2252	NIDDK NIH HHS [R01 DK043220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; BAZIN R, 1982, J LIPID RES, V23, P839; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONFELLE F, 1992, J BIOL CHEM, V267, P20543; GUICHARD C, 1992, J LIPID RES, V33, P679; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAINAULT I, 1995, BIOCHEM BIOPH RES CO, V209, P1053, DOI 10.1006/bbrc.1995.1604; JUMP DB, 1994, J LIPID RES, V35, P1076; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V182, P631, DOI 10.1016/0006-291X(92)91779-P; MAXAM A, 1980, METHOD ENZYMOL, V152, P721; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MURATA Y, 1994, J BIOL CHEM, V269, P20674; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; ROLLAND V, 1995, J BIOL CHEM, V270, P1102, DOI 10.1074/jbc.270.3.1102; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21297	21302		10.1074/jbc.271.35.21297	http://dx.doi.org/10.1074/jbc.271.35.21297			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702907	hybrid			2022-12-25	WOS:A1996VE47700053
J	Sharma, V; Vijayan, M; Surolia, A				Sharma, V; Vijayan, M; Surolia, A			Imparting exquisite specificity to peanut agglutinin for the tumor-associated Thomsen-Friedenreich antigen by redesign of its combining site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIS-HYPOGAEA AGGLUTININ; T-ANTIGEN; DIRECTED MUTAGENESIS; LEGUME LECTINS; BINDING; RECOGNITION; PROTEIN; EXPRESSION; SEQUENCE; REVEALS	Lectins from legumes constitute one of the most thoroughly studied families of proteins, yet the absence of a rigorous framework to explain their carbohydrate binding specificities appears to have prevented a rational approach to alter their ligand binding activity. Studies reported here deal with the redesign of the recognition propensity of peanut agglutinin (PNA), an important member of the family. PNA is extensively used as a tool for recognition of the tumor-associated Thomsen-Friedenrich antigen (T-antigen; Gal beta 1-3GalNAc) on the surfaces of malignant cells and immature thymocytes. PNA also recognizes N-acetyllactosamine (LacNAc; Gal beta 1-4GlcNAc), which is present at the termini of several cell-surface glycoproteins. The crystal structure of the PNA-lactose complex revealed, in addition to the expected interactions with the residues constituting the binding site, the presence of leucine 212 at a position close enough to be in steric contact with the acetamido group on LacNAc. We report here two leucine mutants, one to asparagine (L212N) and the other to alanine (L212A), that exhibit distinct preference for T-antigen and N-acetyllactosamine, respectively. Carbohydrate binding studies reveal that mutant L212N does not recognize LacNAc at high concentrations, thus making it an exquisitely specific cell-surface marker compared with its wild-type counterpart.	INDIAN INST SCI,MOL BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore			SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; ARANGO R, 1993, FEBS LETT, V330, P133, DOI 10.1016/0014-5793(93)80258-V; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; Banerjee R, 1996, J MOL BIOL, V259, P281, DOI 10.1006/jmbi.1996.0319; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; CLAUSEN H, 1988, MOL IMMUNOL, V25, P199, DOI 10.1016/0161-5890(88)90068-5; CLING CK, 1989, BRIT J CANCER, V59, P949; GOULUTCHASSAING C, 1992, BIOCHIMIE, V74, P101, DOI 10.1016/0300-9084(92)90189-L; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; IRIMURA T, 1975, CARBOHYD RES, V39, P317, DOI 10.1016/S0008-6215(00)86141-8; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGKLIDE NC, 1995, GLYCOCONJUGATE J, V12, P567; LEINER LE, 1986, LECTINS PROPERTIES F; LOTAN R, 1975, J BIOL CHEM, V250, P8518; OKEEFE D, 1982, CLIN EXP IMMUNOL, V48, P329; PEREIRA MEA, 1976, CARBOHYD RES, V51, P107; REISNER Y, 1979, P NATL ACAD SCI USA, V76, P447, DOI 10.1073/pnas.76.1.447; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; RINDERLE SJ, 1989, J BIOL CHEM, V264, P16123; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SALUNKE DM, 1985, J BIOL CHEM, V260, P3576; Sambrook J., 2002, MOL CLONING LAB MANU; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SHARMA V, 1994, GENE, V148, P299, DOI 10.1016/0378-1119(94)90702-1; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; SWAMY MJ, 1991, CARBOHYD RES, V213, P59; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K; YOUNG NM, 1991, EUR J BIOCHEM, V196, P631, DOI 10.1111/j.1432-1033.1991.tb15859.x; ZABEL PL, 1983, EUR J NUCL MED, V8, P250, DOI 10.1007/BF00522515; ZEBDA N, 1994, J CELL BIOCHEM, V54, P161, DOI 10.1002/jcb.240540205	35	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21209	21213		10.1074/jbc.271.35.21209	http://dx.doi.org/10.1074/jbc.271.35.21209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702892	hybrid			2022-12-25	WOS:A1996VE47700038
J	Vaughan, RA; Kuhar, MJ				Vaughan, RA; Kuhar, MJ			Dopamine transporter ligand binding domains - Structural and functional properties revealed by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; COCAINE RECEPTORS; CLONING; GLYCOSYLATION; SITES; EXPRESSION; SUBSTRATE; PROGRESS; PROTEINS; COMPLEX	Dopamine transporters (DATs) are members of the Na+- and Cl--dependent neurotransmitter and amino acid transporter family predicted by hydrophobicity analysis to have 12 transmembrane-spanning helices. The structure of DAT was studied using the photoaffinity compounds [I-125]1-[2-(diphenylmethoxy)-ethyl]-4-[2-(4-azido-3- iodophenyl)ethyl]piperazine ([I-125]DEEP), a 1-(2-diphenylmethoxy)-ethyl-4-(3-phenyl propyl)piperazine (GBR analog), and [I-125]-3 beta-(p-chlorophenyl)tropane-2 beta-carboxylic acid, 4'-azido-3'-idophenylethyl ester ([I-125]RTI 82), a cocaine analog, which had been shown in a previous study to become incorporated into different regions of the DAT primary sequence. The proximity of the photolabeled binding sites to integral membrane structures was investigated by subjecting photolabeled membrane suspensions to limited proteolysis with trypsin and separately analyzing the resulting membranes and supernatants for the presence of photolabeled DAT fragments. Trypsin treatment of [I-125] DEEP-labeled membranes generated labeled 45- and 14-kDa DAT fragments that immunoprecipitated with an epitope-specific antiserum generated against amino acids 42-59 near the first putative transmembrane domain, whereas [I-125]RTI 82 was found in 32- and 16-kDa tryptic fragments that precipitated with an antiserum directed against a sequence near transmembrane domain 4 (amino acids 225-238), All of the photolabeled fragments were recovered in the protease-treated membranes, indicating that they possess integral membrane structures that prevent their release from the membrane as soluble forms. The size of the two smallest fragments in conjunction with their retention in the membrane suggests that incorporation of the photoaffinity ligands occurs in or near membrane spanning regions and delineates the maximum possible distance between the transmembrane structures, incorporated photolabel, and antibody epitopes. Carbohydrate analysis of the fragments identified sialic acids and N-linked oligosaccharides exclusively on the 45 kDa [I-125]DEEP-labeled fragment, which, based on size, would be expected to contain four consensus glycosylation sites between putative transmembrane domains 3 and 4. Photoaffinity labeling after trypsin treatment of membranes showed that the larger but not the smaller fragments retain binding capacity, as the 45- and 32-kDa fragments were capable of becoming photolabeled. Binding of photoaffinity ligands at these fragments was displaced with the same pharmacology as that of intact DATs. These results verify numerous aspects of DAT structure and topology heretofore only predicted from theoretical considerations and extend our knowledge of DAT structure function properties.	EMORY UNIV,YERKES REG PRIMATE RES CTR,DIV NEUROSCI,ATLANTA,GA 30322	Emory University	Vaughan, RA (corresponding author), NIDA,NEUROSCI BRANCH,INTRAMURAL RES PROGRAM,POB 5180,BALTIMORE,MD 21224, USA.							AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BERGER P, 1990, EUR J PHARMACOL, V176, P251, DOI 10.1016/0014-2999(90)90540-M; BERGER SP, 1991, MOL PHARMACOL, V39, P429; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; FREED C, 1995, J COMP NEUROL, V359, P340, DOI 10.1002/cne.903590211; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1992, MOL PHARMACOL, V42, P383; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; HERELD D, 1994, J BIOL CHEM, V269, P7036; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LEW R, 1991, BRAIN RES, V539, P239, DOI 10.1016/0006-8993(91)91627-D; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MAURICE T, 1991, NEUROPHARMACOLOGY, V30, P591, DOI 10.1016/0028-3908(91)90078-P; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; PATEL A, 1992, BRAIN RES, V576, P173, DOI 10.1016/0006-8993(92)90627-L; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; REITH MEA, 1992, EUR J PHARM-MOLEC PH, V227, P417, DOI 10.1016/0922-4106(92)90160-W; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SALLEE FR, 1989, FEBS LETT, V256, P219, DOI 10.1016/0014-5793(89)81752-1; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TATE CG, 1994, J BIOL CHEM, V269, P26303; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; Wang J.-B., 1993, Society for Neuroscience Abstracts, V19, P745; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	41	61	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21672	21680		10.1074/jbc.271.35.21672	http://dx.doi.org/10.1074/jbc.271.35.21672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702957	hybrid			2022-12-25	WOS:A1996VE47700103
J	Rao, GN; Runge, MS				Rao, GN; Runge, MS			Cyclic AMP inhibition of thrombin-induced growth in vascular smooth muscle cells correlates with decreased JNK1 activity and c-Jun expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; N-TERMINAL KINASE; DEPENDENT ACTIVATION; MOLECULAR-CLONING; PHOSPHORYLATION; RECEPTOR; DOMAIN; FOS; RAF-1	Thrombin is a potent modulator of vascular tone and vascular smooth muscle cell (VSMC) mitogenesis. Early studies from other laboratories demonstrated that cyclic AMP (cAMP) antagonizes the mitogenic effects of platelet-derived growth factor and epidermal growth factor by inhibiting the extracellular signal-regulated protein kinases (ERKs; p42, p44) group of mitogen-activated protein kinases (MAPKs) in several cell types. This report examines the role of ERKs and Jun N-terminal kinase 1 (JNK1) groups of mitogen-activated protein kinases in thrombin-induced DNA synthesis in VSMCs using agents such as forskolin and dibutyrylcyclic AMP that increase intracellular cAMP levels, Both agents significantly inhibited thrombin-stimulated DNA synthesis in VSMCs, These agents, however, had no effect on thrombin induction of ERKs activation and c-Fos expression, suggesting divergence of the latter two events from the growth-signaling events of thrombin that are sensitive to inhibition by cAMP. Thrombin activated JNK1 and induced c-Jun expression in VSMCs in a time-dependent manner, In contrast to ERKs and c-Fos, thrombin-induced JNK1 activation and c-Jun expression were sensitive to inhibition by forskolin, suggesting an association of these events with thrombin-stimulated growth in these cells, Thrombin also increased AP-1 activity, and this response was significantly blunted by forskolin, Together, these results demonstrate a correlation between JNK1 activation and c-Jun expression by thrombin and their association with the mitogenic signaling events of thrombin in VSMCs.			Rao, GN (corresponding author), UNIV TEXAS,MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,301 UNIV BLVD,RT 1064,GALVESTON,TX 77555, USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; CHAIKOF EL, 1995, J BIOL CHEM, V270, P7431, DOI 10.1074/jbc.270.13.7431; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIVESEY SA, 1982, J BIOL CHEM, V257, P4983; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RYSECK RP, 1991, ONCOGENE, V6, P533; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	45	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20805	20810		10.1074/jbc.271.34.20805	http://dx.doi.org/10.1074/jbc.271.34.20805			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702835	hybrid			2022-12-25	WOS:A1996VD33700087
J	Juan, TSC; McNiece, IK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Fletcher, FA				Juan, TSC; McNiece, IK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Fletcher, FA			Molecular characterization of mouse and rat CPP32 beta gene encoding a cysteine protease resembling interleukin-1 beta converting enzyme and CED-3	ONCOGENE			English	Article						cysteine protease; apoptosis, CED-3; gene structure	PROGRAMMED CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; C-ELEGANS; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; MAMMALIAN HOMOLOG; MICE DEFICIENT; APOPTOSIS; IDENTIFICATION; INDUCTION	Interleukin-1 beta converting enzyme (ICE) defines a new class of mammalian cysteine protease that shares strong homology with the Caenorhabditis elegans death gene ced-3, Both ICE and CED-3, when introduced into cultured cells, induce apoptosis, indicating that this type of cysteine protease may play an important role in the process of programmed cell death, Here, we report the cloning of a mouse and rat gene encoding a novel cysteine protease. The putative proteins encoded by these cDNAs contain the conserved sequence (QACRG) necessary for covalent linkage to the substrate as well as the three amino acids responsible for substrate binding and catalysis in ICE, Amino acid sequence analysis indicates that this rodent cysteine protease is the homolog of human CPP32 beta, Mouse CPP32 beta mRNA is highly expressed in spleen, and to a lesser degree in brain, lung, liver, and kidney, The mouse CPP32 beta genomic locus spans a region of approximately 20 kb, including seven exons and six introns, Mouse interspecific backcross mapping allowed localization of CPP32 beta to the central region of mouse chromosome 8, linked to Scvr, Lpl, Jund1 and Mlr.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Juan, TSC (corresponding author), AMGEN INC,DEPT DEV HEMATOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fichant Gwennaele A., 1992, Human Molecular Genetics, V1, P259, DOI 10.1093/hmg/1.4.259; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Green EL, 1981, GENETICS PROBABILITY, P77; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JENKINS NA, 1981, J VIROL, V43, P269; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; STEINGRIMSSON E, 1995, GENOMICS, V28, P179, DOI 10.1006/geno.1995.1129; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	36	48	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					749	755						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761296				2022-12-25	WOS:A1996VD43300010
J	Dehbi, M; Ghahremani, M; Lechner, M; Dressler, G; Pelletier, J				Dehbi, M; Ghahremani, M; Lechner, M; Dressler, G; Pelletier, J			The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1)	ONCOGENE			English	Article						Wilms' tumor; WT1; Pax-2; kidney development; cancer genetics	FACTOR-A-CHAIN; ALVEOLAR RHABDOMYOSARCOMA; PROMOTER ACTIVITY; POINT MUTATIONS; PRODUCT; REPRESSION; PROTEIN; KIDNEY; BINDING; RECOGNITION	The Wilms' tumor suppressor gene, wt1, encodes a zinc finger protein which functions as a transcriptional regulator. Expression of the wt1 gene is developmentally regulated and restricted to a small set of tissues which include the fetal urogenital system, mesothelium, and spleen. In the developing kidney, induction of neprohogenesis by the ureter is accompanied by an increase in expression levels of the Pax-2 gene, a developmentally and spatially regulated paired-box member. This is followed by an increase in wt1 expression as mesenchymal cells condense and differentiate. In this report, we demonstrate that PAX2 isoforms are capable of transactivating the wt1 promoter. Deletion mutagenesis of the wt1 promoter identified an element responsible for mediating PAX2 responsiveness, located between nucleotides -33 and -71 relative to the first wt1 transcription start site. Consistent with its identity as a PAX responsive element, multimerization of this mofit upstream of a heterologous minimal promoter enhanced reporter activity when co-transfected with a Pax-2 expression vector. Finally, we demonstrate that PAX2 can stimulate expression of the endogenous wt1 gene. These results suggest that a role for mesenchyme-to-epithelium transition in ment is to induce wt1 expression.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA	McGill University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1988, DEVELOPMENT, V104, P181; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1995, AM J PATHOL, V146, P40; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GNARRA JR, 1995, CANCER RES, V55, P4092; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOFMANN W, 1993, ONCOGENE, V8, P3123; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SHAPIRO DN, 1993, CANCER RES, V53, P5108; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TAGGE EP, 1994, J PEDIATR SURG, V29, P134, DOI 10.1016/0022-3468(94)90308-5; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	49	111	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					447	453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760285				2022-12-25	WOS:A1996VB32800001
J	Foster, JL; Higgins, GC; Jackson, FR				Foster, JL; Higgins, GC; Jackson, FR			Biochemical properties and cellular localization of the Drosophila DG1 cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITES; CATALYTIC DOMAIN; I-BETA; EXPRESSION; CLONING; SEQUENCE; MUSCLE; BRAIN; RAT; PHOSPHORYLATION	The protein encoded by the Drosophila cGMP-dependent protein kinase gene, DG1, was expressed in Sf9 cells. cGMP (10 mu M) stimulated histone H2B phosphorylation by the DG1 protein kinase 20-fold. Maximal activity was observed at 40-50 mM Mg2+. The concentrations of cGMP, cAMP, cIMP, 8-bromo-cGMP, and 8-bromo-cAMP that gave 50% activation were 0.19 +/- 0.06, 11.7 +/- 2.8, 5.3 +/- 1.5, 0.04 +/- 0.01, and 0.62 +/- 0.06 mu M, respectively. cGMP activation was cooperative with a Hill coefficient (n(H)) of 1.28 +/- 0.10, whereas activation by cAMP was not cooperative. DG1 kinase expressed in Sf9 cells was found to be a dimer with an amino-terminal dimerization domain. It also autophosphorylated in a reaction stimulated by cGMP and cAMP. Immunoadsorbed DG1 protein from fly extracts was also capable of autophosphorylation, and this assay was used to quantitate the DG1 kinase in extracts from heads and bodies of adults and whole embryos. Activity was highest in heads of either sex and male bodies, intermediate in female bodies, and lowest in embryos. These results were in accord with DG1 mRNA abundance. Tissue distribution of the DG1 kinase was investigated by immunohistochemistry. In embryos, specific immunoreactivity was observed in large cells scattered along the anterior-posterior axis at stage 13. Prominent staining of adult heads was restricted to the proximal level of the lamina cortex.	UNIV TENNESSEE,COLL MED,LEBONHEUR CHILDRENS MED CTR,DEPT BIOCHEM,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,LEBONHEUR CHILDRENS MED CTR,DEPT PEDIAT,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,LEBONHEUR CHILDRENS MED CTR,CRIPPLED CHILDREN FDN RES CTR,MEMPHIS,TN 38163; WORCESTER FDN BIOMED RES,SHREWSBURY,MA 01545	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Worcester Foundation for Biomedical Research					NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009767] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR09767] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BOERTH NJ, 1994, FEBS LETT, V342, P255, DOI 10.1016/0014-5793(94)80512-1; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; FEIL R, 1995, BIOCHEMISTRY-US, V34, P13152, DOI 10.1021/bi00040a029; FLOCKERZI V, 1978, J BIOL CHEM, V253, P3395; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FOSTER JL, 1988, J BIOL CHEM, V263, P1676; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; ITOH N, 1985, DROS INF SERVICE, V61, P89; JACKSON FR, 1990, J NEUROCHEM, V54, P1068, DOI 10.1111/j.1471-4159.1990.tb02359.x; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; JOYCE NC, 1984, MICROVASC RES, V28, P206, DOI 10.1016/0026-2862(84)90018-9; KALDERON D, 1989, J BIOL CHEM, V264, P10738; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; MACKENZIE CW, 1982, J BIOL CHEM, V257, P5589; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MERINEY SD, 1994, NATURE, V369, P336, DOI 10.1038/369336a0; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; PRYZWANSKY KB, 1995, BLOOD, V85, P222, DOI 10.1182/blood.V85.1.222.bloodjournal851222; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SMITH JA, 1993, BIOCHEMISTRY-US, V127, P51; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TEPASS U, 1994, DEVELOPMENT, V120, P1829; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WALDMANN R, 1986, EUR J BIOCHEM, V158, P203, DOI 10.1111/j.1432-1033.1986.tb09739.x; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	37	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23322	23328		10.1074/jbc.271.38.23322	http://dx.doi.org/10.1074/jbc.271.38.23322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798533	hybrid			2022-12-25	WOS:A1996VH76800059
J	Hazen, SL; Hsu, FF; Duffin, K; Heinecke, JW				Hazen, SL; Hsu, FF; Duffin, K; Heinecke, JW			Molecular chlorine generated by the myeloperoxidase hydrogen peroxide chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; HYPOCHLOROUS ACID; HUMAN-NEUTROPHILS; OXIDATIVE MODIFICATION; BIOLOGICAL-ACTIVITIES; LIPID-PEROXIDATION; SCAVENGER RECEPTOR; OXYGENATED STEROLS; MACROPHAGES; PROTEINS	Oxidation of low density lipoprotein (LDL) may be of critical importance in triggering the pathological events of atherosclerosis. Myeloperoxidase, a heme protein secreted by phagocytes, is a potent catalyst for LDL oxidation in vitro, and active enzyme is present in human atherosclerotic lesions, We have explored the possibility that reactive intermediates generated by myeloperoxidase target LDL cholesterol for oxidation, LDL exposed to the myeloperoxidase-H2O2-Cl- system at acidic pH yielded a family of chlorinated sterols, The products were identified by mass spectrometry as a novel dichlorinated sterol, cholesterol alpha-chlorohydrin (6 beta-chlorocholestane-(3 beta,5 alpha)-diol), cholesterol beta-chlorohydrin (5 alpha-chlorocholestane-(3 beta,6 beta)-diol), and a structurally related cholesterol chlorohydrin, Oxidation of LDL cholesterol by myeloperoxidase required H2O2 and Cl-, suggesting that hypochlorous acid (HOCl) was an intermediate in the reaction. However, HOCl failed to generate chlorinated sterols under chloride-free conditions. Since HOCl is in equilibrium with molecular chlorine (Cl-2) through a reaction which requires Cl- and H+, this raised the possibility that Cl-2 was the actual chlorinating intermediate. Consonant with this hypothesis, HOCl oxidized LDL cholesterol in the presence of Cl- and at acidic pH. Moreover, in the absence of Cl- and at neutral pH, Cl-2 generated the same family of chlorinated sterols as the myeloperoxidase-H2O2-Cl- system. Finally, direct addition of Cl-2 to the double bond of cholesterol accounts for dichlorinated sterol formation by myeloperoxidase, Collectively, these results indicate that Cl-2 derived from HOCl is the chlorinating intermediate in the oxidation of cholesterol by myeloperoxidase. Our observations suggest that Cl-2 generation in acidic compartments may constitute one pathway for oxidation of LDL cholesterol in the artery wall.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; MONSANTO CO,ST LOUIS,MO 63198	Washington University (WUSTL); Washington University (WUSTL); Monsanto			Hazen, Stanley L/ABD-5845-2021	Hsu, Fong-Fu/0000-0001-5368-0183	NIA NIH HHS [AG12293] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012293] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agner K., 1972, STRUCTURE FUNCTION O, P329; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ARNHOLD J, 1991, BIOMED BIOCHIM ACTA, V50, P967; BARTON DHR, 1950, J AM CHEM SOC, V72, P370, DOI 10.1021/ja01157a100; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DELAMARE PBD, 1954, J CHEM SOC, P1290, DOI 10.1039/jr9540001290; DELAMARE PBD, 1959, AROMATIC SUBSTITUTIO, P105; DOUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FRANK JS, 1989, J LIPID RES, V30, P967; HAJJAR DP, 1988, ARCH BIOCHEM BIOPHYS, V262, P375, DOI 10.1016/0003-9861(88)90201-9; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HAZEN SL, 1996, IN PRESS J CLIN INVE; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1994, CORONARY ARTERY DIS, V5, P205, DOI 10.1097/00019501-199403000-00004; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HODIS HN, 1992, ATHEROSCLEROSIS, V96, P125, DOI 10.1016/0021-9150(92)90059-P; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; HWANG PL, 1991, BIOESSAYS, V13, P583, DOI 10.1002/bies.950131108; JENSEN MS, 1973, J CELL BIOL, V56, P379, DOI 10.1083/jcb.56.2.379; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; KNOX WE, 1948, J BACTERIOL, V55, P451, DOI 10.1128/JB.55.4.451-458.1948; LEHRER RI, 1984, BLOOD, V63, P88; MAERKER G, 1988, LIPIDS, V23, P761, DOI 10.1007/BF02536218; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Orton KJP, 1927, J CHEM SOC, P986, DOI 10.1039/jr9270000986; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RASMUSSEN J, 1995, CIRCULATION S1, V92, P162; RIVETT DEA, 1950, J ORG CHEM, V15, P35; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SEPE SM, 1985, J IMMUNOL, V134, P1888; SEVANIAN A, 1994, FREE RADICAL BIO MED, V17, P397, DOI 10.1016/0891-5849(94)90166-X; SEVANIAN A, 1986, FOOD CHEM TOXICOL, V24, P1103, DOI 10.1016/0278-6915(86)90295-4; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; TURK J, 1983, BIOCHIM BIOPHYS ACTA, V751, P189, DOI 10.1016/0005-2760(83)90173-X; WEIL I, 1949, J AM CHEM SOC, V71, P1664, DOI 10.1021/ja01173a033; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WHITE GC, 1972, HDB CHLORINATION, P182; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WRIGHT SD, 1984, NATURE, V309, P359, DOI 10.1038/309359a0; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	67	189	194	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23080	23088		10.1074/jbc.271.38.23080	http://dx.doi.org/10.1074/jbc.271.38.23080			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798498	hybrid			2022-12-25	WOS:A1996VH76800024
J	Moyers, JS; Bilan, PJ; Reynet, C; Kahn, CR				Moyers, JS; Bilan, PJ; Reynet, C; Kahn, CR			Overexpression of rad inhibits glucose uptake in cultured muscle and fat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; GROWTH-FACTOR-I; PROTEIN-PHOSPHORYLATION; GUANINE-NUCLEOTIDES; 3T3-L1 ADIPOCYTES; BINDING PROTEINS; PLASMA-MEMBRANE; TRANSPORT; STIMULATION; GENE	Rad is a Ras-like GTPase that was isolated by subtraction cloning of human muscle and shown to have increased expression in some individuals with Type II diabetes, To ascertain the potential role of Rad in insulin-mediated signaling, we have overexpressed Rad in myocyte and adipocyte cell lines, Expression of Rad resulted in a 50-90% reduction in insulin-stimulated 2-deoxyglucose glucose uptake in C2C12 murine myotubes, L6 rat myotubes, and 3T3-L1 adipocytes and a 25% reduction in 3-O-methylglucose uptake in 3T3-L1 adipocytes, This occurred despite unaltered levels of glucose transporter expression, with no detectable change in Glut4 translocation and with no alteration in insulin receptor or substrate phosphorylation or phosphatidylinositol 3-kinase activity, These data indicate that Rad is a negative regulator of glucose uptake and that this effect may be due to a decrease in the intrinsic activity of the transporter molecules, rather than an effect on the translocation of Glut4.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02216; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02216	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045935, T32DK007260, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836, DK 07260, DK 45935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLTENSPERGER K, 1993, SCIENCE, V260, P1950; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHEATHAM BC, 1993, P NATL ACAD SCI USA, V90, P7366; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FARESE RV, 1993, J BIOL CHEM, V268, P19949; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; KARNIELI E, 1990, HORM RES, V33, P99, DOI 10.1159/000181491; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REIZMAN H, 1993, TRENDS CELL BIOL, V3, P273; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; SARGEANT R, 1993, J ENDOCRINOL INVEST, V16, P147, DOI 10.1007/BF03347669; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHURMANN A, 1989, FEBS LETT, V255, P259, DOI 10.1016/0014-5793(89)81102-0; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUZUKI Y, 1992, BIOCHEM BIOPH RES CO, V189, P572, DOI 10.1016/0006-291X(92)91596-I; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; YANO Y, 1993, BIOCHIM BIOPHYS ACTA, V1176, P327, DOI 10.1016/0167-4889(93)90062-T; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	43	109	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23111	23116		10.1074/jbc.271.38.23111	http://dx.doi.org/10.1074/jbc.271.38.23111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798502	hybrid			2022-12-25	WOS:A1996VH76800028
J	Saks, ME; Sampson, JR; Nowak, MW; Kearney, PC; Du, FY; Abelson, JN; Lester, HA; Dougherty, DA				Saks, ME; Sampson, JR; Nowak, MW; Kearney, PC; Du, FY; Abelson, JN; Lester, HA; Dougherty, DA			An engineered Tetrahymena tRNA(Gln) for in vivo incorporation of unnatural amino acids into proteins by nonsense suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION CHANNELS; M2 DOMAIN; RECOGNITION; ANTICODON; MUTATIONS; IDENTITY; GENES; ISOPENTENYLATION	A new tRNA, THG73, has been designed and evaluated as a vehicle for incorporating unnatural amino acids site-specifically into proteins expressed in vivo using the stop codon suppression technique, The construct is a modification of tRNA(Gln)(CUA) from Tetrahymena thermophila, which naturally recognizes the stop codon UAG. Using electrophysiological studies of mutations at several sites of the nicotinic acetylcholine receptor, it is established that THG73 represents a major improvement over previous nonsense suppressors both in terms of efficiency and fidelity of unnatural amino acid incorporation, Compared with a previous tRNA used for in vivo suppression, THG73 is as much as 100-fold less likely to be acylated by endogenous synthetases of the Xenopus oocyte. This effectively eliminates a major concern of the in vivo suppression methodology, the undesirable incorporation of natural amino acids at the suppression site. In addition, THG73 is 4-10-fold more efficient at incorporating unnatural amino acids in the oocyte system, Taken together, these two advances should greatly expand the range of applicability of the in vivo nonsense suppression methodology.	CALTECH, DIV CHEM & CHEM ENGN 16430, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034407, R01NS011756, R37NS034407] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48560] Funding Source: Medline; NINDS NIH HHS [NS34407, NS11756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; BIENZ M, 1980, NUCLEIC ACIDS RES, V8, P5169, DOI 10.1093/nar/8.22.5169; BJORK GR, 1995, PROG NUCLEIC ACID RE, V50, P263, DOI 10.1016/S0079-6603(08)60817-X; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; COULONDRE C, 1977, J MOL BIOL, V117, P525, DOI 10.1016/0022-2836(77)90056-0; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; England T E, 1980, Methods Enzymol, V65, P65; ENGLAND TE, 1978, BIOCHEMISTRY-US, V17, P2069, DOI 10.1021/bi00604a008; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GUREVITZ M, 1983, BIOCHEMISTRY-US, V22, P4000, DOI 10.1021/bi00286a002; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HATFIELD DL, 1990, CRIT REV BIOCHEM MOL, V25, P71, DOI 10.3109/10409239009090606; HAYASE Y, 1992, EMBO J, V11, P4159, DOI 10.1002/j.1460-2075.1992.tb05509.x; HIRSH, 1971, J MOL BIOL, V58, P439, DOI 10.1016/0022-2836(71)90362-7; HUDZIAK RM, 1982, CELL, V31, P137, DOI 10.1016/0092-8674(82)90413-5; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LASKI FA, 1982, P NATL ACAD SCI-BIOL, V79, P5813, DOI 10.1073/pnas.79.19.5813; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MARTIN NC, 1982, J BIOL CHEM, V257, P562; MATTAJ IW, 1987, EMBO J, V6, P2409, DOI 10.1002/j.1460-2075.1987.tb02519.x; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; MILLER JH, 1979, NONSENSE MUTATIONS T, P127; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Nowak MW, 1996, BIOPHYS J, V70, pSU253; NOWAK NW, 1996, BIOPHYS J, V70, P76; PICARD B, 1980, EUR J BIOCHEM, V109, P359, DOI 10.1111/j.1432-1033.1980.tb04802.x; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHULL C, 1994, NUCLEIC ACIDS RES, V22, P1974, DOI 10.1093/nar/22.11.1974; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; STEEGE DA, 1979, BIOL REGUL DEV, P433; YARUS M, 1982, SCIENCE, V218, P646, DOI 10.1126/science.6753149; YOUNG JF, 1983, SCIENCE, V221, P873, DOI 10.1126/science.6308765	47	95	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23169	23175		10.1074/jbc.271.38.23169	http://dx.doi.org/10.1074/jbc.271.38.23169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798511	hybrid, Green Accepted			2022-12-25	WOS:A1996VH76800037
J	Cowen, DS; Sowers, RS; Manning, DR				Cowen, DS; Sowers, RS; Manning, DR			Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine(1A) receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; MAP KINASE; SIGNAL-TRANSDUCTION; 5-HT1A RECEPTOR; CELLS; RAS; INVOLVEMENT; WORTMANNIN; SUBUNITS; PATHWAYS	A variety of receptors coupled to GTP binding regulatory proteins (G proteins) initiate signals that culminate in activation of the mitogen-activated protein kinases ERK1 and ERK2. We demonstrate here that the human 5-HT1A receptor expressed in Chinese hamster ovary cells similarly promotes activation of ERK1 and ERK2, but that the pathway used does not conform entirely to those proposed previously for G protein-coupled receptors. Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate, The implied requirement for protein kinase C, however, was negated in studies with bisindolylmaleimide and Ro-31-8220, which, although completely inhibiting activation of ERK2 by phorbol ester, had no impact on activation by 8-OH-DPAT, The anticipated inhibition by the tyrosine kinase inhibitors genistein and herbimycin A, moreover, was marginal at best, As expected for a G(i)-coupled receptor, the inhibitors of phosphatidylinositol 3-kinase wortmannin and LY294002 inhibited activation of ERK2, albeit only partly (70%), Of significance, an inhibitor of a phosphatidylcholine-specific phospholipase C, tricyclodecan-9-yl-xanthogenate (D609), caused a similar degree of inhibition, When the two types of inhibitors were combined, an almost complete inhibition was achieved, Our data suggest that phosphatidylinositol 3-kinase and phosphatidylcholine-specific phospholipase C represent components of different, but partly overlapping pathways that can account almost entirely for the activation of ERK2 by the 5-HT1A receptor.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PSYCHIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125, T32MH014654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline; NIMH NIH HHS [MH14654, MH48125] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BUSCHER D, 1995, MOL CELL BIOL, V15, P466; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COWEN DS, 1990, J BIOL CHEM, V265, P1618; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DELLACQUA M, 1993, J BIOL CHEM, V269, P5678; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; EXTON JH, 1990, J BIOL CHEM, V265, P1; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KAHAN C, 1992, J BIOL CHEM, V267, P13369; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SHUTZE S, 1992, CELL, V71, P765; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZHANG WY, 1995, J CELL PHYSIOL, V162, P348, DOI 10.1002/jcp.1041620307	32	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22297	22300		10.1074/jbc.271.37.22297	http://dx.doi.org/10.1074/jbc.271.37.22297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798386				2022-12-25	WOS:A1996VG67200005
J	Daas, PJH; Hagen, WR; Keltjens, JT; vanderDrift, C; Vogels, GD				Daas, PJH; Hagen, WR; Keltjens, JT; vanderDrift, C; Vogels, GD			Activation mechanism of Methanol:5-hydroxybenzimidazolylcobamide methyltransferase from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISSIMILATORY SULFITE REDUCTASE; DEPENDENT METHIONINE SYNTHASE; 2-MERCAPTOETHANESULFONIC ACID; METHANOL; IRON; CORRINOIDS; 5-HYDROXYBENZIMIDAZOLYLCOBAMIDE; DEHYDROGENASE; INVOLVEMENT; COMPONENT	Methanol:5-hydroxybenzimidazolylcobamide methyltransferase (MT(1)) is the first of two enzymes involved in the transmethylation reaction from methanol to 2-mercaptoethanesulfonic acid in Methanosarcina barkeri. MT(1) only binds the methyl group of methanol when the cobalt atom of its corrinoid prosthetic groups is present in the highly reduced Co(I) state. Formation of this redox state requires H-2, hydrogenase, methyltransferase activation protein, and ATP. Optical and electron paramagnetic resonance spectroscopy studies were employed to determine the oxidation states and coordinating ligands of the corrinoids of MT(1) during the activation process. Purified MT(1) contained 1.7 corrinoids per enzyme with cobalt in the fully oxidized Co(III) state. Water and N-3 of the 5-hydroxybenzimidazolyl base served as the upper and lower ligands, respectively. Reduction to the Co(II) level was accomplished by H-2 and hydrogenase. The Co(II)amide of MT(1) had the base coordinated at this stage. Subsequent addition of methyltransferase activation protein and ATP resulted in the formation of base-uncoordinated Co(II) MT(1). The activation mechanism is discussed within the context of a proposed model and compared to those described for other corrinoid-containing methyl group transferring proteins.	UNIV NIJMEGEN,FAC SCI,DEPT MICROBIOL,NL-6525 ED NIJMEGEN,NETHERLANDS; AGR UNIV WAGENINGEN,DEPT BIOCHEM,NL-6703 HA WAGENINGEN,NETHERLANDS	Radboud University Nijmegen; Wageningen University & Research			Keltjens, Jan/M-3002-2013; Hagen, Wilfred R./H-8918-2017	Hagen, Wilfred R./0000-0002-1609-6671				ARENDSEN AF, 1993, BIOCHEMISTRY-US, V32, P10323, DOI 10.1021/bi00090a007; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BARTLEY W, 1957, BIOCHEM J, V67, P291, DOI 10.1042/bj0670291; DAAS PJH, 1995, ARCH BIOCHEM BIOPHYS, V319, P244, DOI 10.1006/abbi.1995.1288; DAAS PJH, 1993, J BACTERIOL, V175, P1278, DOI 10.1128/JB.175.5.1278-1283.1993; DAAS PJH, 1996, J BIOL CHEM, V172, P22339; DIEKERT G, 1994, ANTON LEEUW INT J G, V66, P209, DOI 10.1007/BF00871640; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FRIEDRICH W, 1975, FERMENTE HORMONE VIT, V3, P46; Gianotti C., 1982, B12, V1, P393; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HOLLIGER C, 1993, J AM CHEM SOC, V115, P5651, DOI 10.1021/ja00066a034; HUTTEN TJ, 1981, J BACTERIOL, V145, P27, DOI 10.1128/JB.145.1.27-34.1981; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; JETTEN MSM, 1991, EUR J BIOCHEM, V202, P1291, DOI 10.1111/j.1432-1033.1991.tb16502.x; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; LJUNGDAHL LG, 1973, J BIOL CHEM, V12, P1802; LU WP, 1995, J BACTERIOL, V177, P2245, DOI 10.1128/jb.177.9.2245-2250.1995; MATTHEWS R G, 1990, Biofactors, V2, P147; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; Pilbrow J. R., 1982, B12, V1, P431; POL A, 1982, BIOCHEM BIOPH RES CO, V108, P731, DOI 10.1016/0006-291X(82)90890-7; POL A, 1984, BIOCHIM BIOPHYS ACTA, V797, P83, DOI 10.1016/0304-4165(84)90385-4; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; ROUVIERE PE, 1989, J BACTERIOL, V171, P4556, DOI 10.1128/jb.171.9.4556-4562.1989; VANDERMEIJDEN P, 1983, FEMS MICROBIOL LETT, V19, P247, DOI 10.1016/0378-1097(83)90069-1; VANDERMEIJDEN P, 1984, BIOCHEM BIOPH RES CO, V118, P760, DOI 10.1016/0006-291X(84)91460-8; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; VANDERMEIJDEN P, 1983, J BACTERIOL, V153, P6, DOI 10.1128/JB.153.1.6-11.1983	32	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22346	22351		10.1074/jbc.271.37.22346	http://dx.doi.org/10.1074/jbc.271.37.22346			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798395	Green Submitted, hybrid			2022-12-25	WOS:A1996VG67200014
J	Klein, ES; Pino, ME; Johnson, AT; Davies, PJA; Nagpal, S; Thacher, SM; Krasinski, G; Chandraratna, AS				Klein, ES; Pino, ME; Johnson, AT; Davies, PJA; Nagpal, S; Thacher, SM; Krasinski, G; Chandraratna, AS			Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; THYROID-HORMONE; CO-REPRESSOR; NUCLEAR RECEPTOR; BINDING-PROTEINS; EXPRESSION; LIGAND; ESTROGEN; GENE; TRANSCRIPTION	Inverse agonists are ligands that are capable of repressing basal receptor activity in the absence of an agonist. We have designed a series of C-1-substituted acetylenic retinoids that exhibit potent antagonism of retinoic acid receptor (RAR)-mediated transactivation. Comparison of these related retinoid antagonists for their ability 60 repress basal RAR transcriptional activity demonstrates that the identity of the C-1 substituent differentiates these ligands into two groups: RAR inverse agonists and neutral antagonists, We show that treatment of cultured human keratinocytes with a RAR inverse agonist, but not a RAR neutral antagonist, leads to the repression of the serum-induced differentiation marker MRP-8. While RAR-selective agonists also repress expression of MRP-8, cotreatment with a RAR inverse agonist and a RAR agonist results in a mutual repression of their individual inhibitory activities, indicating the distinct modes of action of these two disparate retinoids in modulating MRP-8 expression, Our data indicate that RARs, like beta(2)-adrenoreceptors, are sensitive to inverse agonists and that this new class of retinoids will provide insight into the molecular mechanisms of RAR function in skin and other responsive tissues.	ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT BIOL, IRVINE, CA 92715 USA; ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT CHEM, IRVINE, CA 92715 USA; UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA; UNIV TEXAS, SCH MED, DEPT MED, HOUSTON, TX 77225 USA	AbbVie; Allergan; AbbVie; Allergan; University of Texas System; University of Texas System			Nagpal, Sunil/A-8007-2009					ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BYGDEMAN M, 1994, HUM REPROD, V9, P121, DOI 10.1093/humrep/9.suppl_1.121; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COSTA T, 1992, MOL PHARMACOL, V41, P549; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; JORDAN VC, 1992, CANCER, V70, P977; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KELLY SE, 1989, J PATHOL, V159, P17, DOI 10.1002/path.1711590107; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; Standeven AM, 1996, TOXICOL APPL PHARM, V138, P169, DOI 10.1006/taap.1996.0110; THACHER SM, 1991, EXP CELL RES, V194, P238, DOI 10.1016/0014-4827(91)90360-7; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WILKINSON MM, 1988, J CELL SCI, V91, P221	34	94	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22692	22696		10.1074/jbc.271.37.22692	http://dx.doi.org/10.1074/jbc.271.37.22692			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798442	hybrid			2022-12-25	WOS:A1996VG67200061
J	Shuttleworth, TJ				Shuttleworth, TJ			Arachidonic acid activates the noncapacitative entry of Ca2+ during [Ca2+](i) oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; GTP-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; AVIAN SALT-GLAND; PHOSPHOLIPASE-C; EXOCRINE CELL; MAST-CELLS; CHOLECYSTOKININ RECEPTOR; BISCOCLAURINE ALKALOIDS; PANCREATIC ACINI	Current models for agonist-activated Ca2+ entry in nonexcitable cells focus on the capacitative mechanism where entry is activated as a downstream result of the sustained depletion of agonist-sensitive stores without any direct requirement for inositol phosphates. This mechanism has been shown to be important for the sustained Ca2+ signals seen in a variety of nonexcitable cells under conditions of maximal stimulation. In contrast, relatively little attention has been given to Ca2+ entry under more physiological levels of agonist where, for example, oscillating Ca2+ responses are common. In recent studies using cells from the exocrine avian nasal gland, we have shown that agonist-activated Ca2+ entry under these conditions demonstrates properties that are inconsistent with current versions of the capacitative model. We now report that activation of this novel noncapacitative Ca2+ entry is via a distinct signaling pathway involving an agonist-induced, phospholipase A(2)-mediated generation of arachidonic acid.	UNIV ROCHESTER,SCH MED & DENT,DEPT PHYSIOL & PHARMACOL,ROCHESTER,NY 14642	University of Rochester					NIGMS NIH HHS [GM 40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIBA S, 1992, BIOCHEM PHARMACOL, V44, P45, DOI 10.1016/0006-2952(92)90036-I; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOMALASKI JS, 1990, J LAB CLIN MED, V116, P814; CHOW SC, 1990, J BIOL CHEM, V265, P902; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIXON JF, 1984, J BIOL CHEM, V259, P4418; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELIX JP, 1992, BIOCHEMISTRY-US, V31, P11793, DOI 10.1021/bi00162a017; HASHIZUME T, 1991, BIOCHEM PHARMACOL, V41, P419, DOI 10.1016/0006-2952(91)90539-H; HILDEBRANDT JP, 1993, J MEMBRANE BIOL, V133, P183; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUNT TW, 1994, J BIOL CHEM, V269, P29565; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; LIGETI E, 1993, EUR J BIOCHEM, V216, P813, DOI 10.1111/j.1432-1033.1993.tb18202.x; MARTIN SC, 1994, FEBS LETT, V352, P32, DOI 10.1016/0014-5793(94)00913-9; MARTIN SC, 1994, PFLUG ARCH EUR J PHY, V426, P231, DOI 10.1007/BF00374776; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PEITSCH MC, 1993, TRENDS BIOCHEM SCI, V18, P292, DOI 10.1016/0968-0004(93)90038-O; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; SHUTTLEWORTH TJ, 1990, BIOCHEM J, V269, P417, DOI 10.1042/bj2690417; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; TSUNODA Y, 1993, BIOCHEM BIOPH RES CO, V194, P1194, DOI 10.1006/bbrc.1993.1949; TSUNODA Y, 1995, BIOCHEM BIOPH RES CO, V211, P648, DOI 10.1006/bbrc.1995.1861; TSUNODA Y, 1995, AM J PHYSIOL-GASTR L, V269, pG435, DOI 10.1152/ajpgi.1995.269.3.G435; WU L, 1994, CELL CALCIUM, V15, P228, DOI 10.1016/0143-4160(94)90062-0; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	40	138	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21720	21725		10.1074/jbc.271.36.21720	http://dx.doi.org/10.1074/jbc.271.36.21720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702966	hybrid			2022-12-25	WOS:A1996VF61200008
J	Turko, IV; Haik, TL; McAllisterLucas, LM; Burns, F; Francis, SH; Corbin, JD				Turko, IV; Haik, TL; McAllisterLucas, LM; Burns, F; Francis, SH; Corbin, JD			Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases - A putative NKX(n)D motif for cGMP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; DEPENDENT PROTEIN-KINASE; PREDICTED STRUCTURES; CRYSTAL-STRUCTURE; DOMAINS; CAMP; RAS; DERIVATIVES; RESOLUTION; ANALOGS	cGMP-binding phosphodiesterases contain two kinetically distinct cGMP-binding sites (a and b), and each site contains a conserved N(K/R)X(n)FX(3)DE sequence, N276A, K277A, R277R, D289A, and E290A mutants in the N(276)KX(7)FX(3)DE(290) sequence of site a (higher affinity site) of bovine cGMP-binding, cGMP-specific phosphodiesterase (cGB-PDE or PDE5A) were expressed in High Five cells and purified, The cGMP-binding affinities of three mutants [K277A (K-d approximate to 12 mu M), D289A (K-d approximate to 24 mu M) and N276A (K-d approximate to 60 mu M)] were decreased in comparison with wild-type enzyme (K-d = 1.3 mu M), which suggested an important role for Asn(276), Lys(277), and Asp(289) in cGMP binding, These residues could be presented as a putative NKX(n)D motif, and their functions were predicted based on analogy with the canonical NKXD motifin GTP-binding proteins, No marked differences in catalytic functions such as specific activity, K-m for cGMP, and IC50 for zaprinast or 3-isobutyl-1-methylxanthine were found among wild-type and mutant cGB-PDEs. This suggested that cGMP binding to site a does not influence the catalytic properties of cGB-PDE.			Turko, IV (corresponding author), VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, 221 KIRKLAND HALL, NASHVILLE, TN 37232 USA.				NIGMS NIH HHS [GM41269, GM07347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269, T32GM007347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BELTMAN J, 1995, MOL PHARMACOL, V47, P330; BENATTI L, 1991, GENE, V101, P255, DOI 10.1016/0378-1119(91)90420-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUCHIE D, 1983, EUR J BIOCHEM, V136, P571, DOI 10.1111/j.1432-1033.1983.tb07778.x; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; ERNEUX C, 1984, ADV CYCLIC NUCL PROT, V16, P107; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; Maniatis T, 1989, MOL CLONING; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; THOMAS MK, 1992, ADV SEC MESS PHOSPH, V25, P45; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	25	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22240	22244		10.1074/jbc.271.36.22240	http://dx.doi.org/10.1074/jbc.271.36.22240			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703039	hybrid			2022-12-25	WOS:A1996VF61200081
J	Anafi, M; Rosen, MK; Gish, GD; Kay, LE; Pawson, T				Anafi, M; Rosen, MK; Gish, GD; Kay, LE; Pawson, T			A potential SH3 domain-binding site in the Crk SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; C-13-LABELED PROTEINS; HIGH-AFFINITY; WW DOMAIN; SRC; PEPTIDE; IDENTIFICATION; PHOSPHATASE; SPECIFICITY; SUBSTRATE	The Src homology 2 (SH2) domain of the mammalian adaptor protein Crk-II contains a proline-rich insert, predicted to lie within an extended DE loop, which is dispensable for phosphopeptide binding, Using the yeast two-hybrid system, this region of the Crk-II SH2 domain was found to interact with a subset of SH3 domains, notably the Abl SH3 domain. Furthermore, this proline-rich insert was found to modify the efficiency with which Crk-II was phosphorylated by the p140(c-abl) tyrosine kinase, In vitro, the interaction of full length non-phosphorylated Crk-II with a glutathione S-transferase Abl SH3 domain fusion protein was very weak, However, phosphorylation of Crk-II on Tyr-221 which induces an intramolecular association with the SH2 domain, or addition of a phosphopeptide corresponding to the Crk-II Tyr-221 phosphorylation site, stimulated association of Crk-II with the Abl SH3 domain, NMR spectroscopic analysis showed that binding of the Tyr-221 phosphopeptide to the Crk SH2 domain induced a chemical shift change in Val-71, located in the proline-rich insert, indicative of a change in the structure of the proline-rich loop in response of Crk SH2 pTyr-221 interaction, These results suggest that the proline-rich insert in the Crk SH2 domain constitutes an SH3 domain-binding site that can be regulated by binding of a phosphopeptide ligand to the Crk SH2 domain.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, PROT ENGN NETWORK CTR EXCELLENCE, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT CHEM, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					ANAFI M, 1992, J BIOL CHEM, V267, P4518; ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLUBB RT, 1992, J BIOMOL NMR, V2, P203, DOI 10.1007/BF01875531; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FRIEDRICHS MS, 1994, J BIOMOL NMR, V4, P703, DOI 10.1007/BF00404279; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; ODA T, 1994, J BIOL CHEM, V269, P22925; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSUCHIE H, 1989, ONCOGENE, V4, P1281; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZONGHAN D, 1995, GENE DEV, V9, P2569	51	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21365	21374		10.1074/jbc.271.35.21365	http://dx.doi.org/10.1074/jbc.271.35.21365			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702917	hybrid			2022-12-25	WOS:A1996VE47700063
J	Chen, CG; Yin, YL; deRiel, JK; DesJarlais, RL; Raveglia, LF; Zhu, JM; LiuChen, LY				Chen, CG; Yin, YL; deRiel, JK; DesJarlais, RL; Raveglia, LF; Zhu, JM; LiuChen, LY			Determination of the amino acid residue involved in [H-13]beta-funaltrexamine covalent binding in the cloned rat mu opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; H-3 BETA-FUNALTREXAMINE; GUINEA-PIG BRAIN; OPIATE RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; IRREVERSIBLE BINDING; EXTRACELLULAR LOOP; MOLECULAR-CLONING; SELECTIVE AGONIST	We previously demonstrated that [H-3]beta-funaltrexamine ([H-3]beta-FNA) labeled the rat mu opioid receptor expressed in Chinese hamster ovary cells with high specificity, and [H-3] beta-FNA-Iabeled receptors migrated as one broad band with a mass of 80 kDa. In this study, we determined the region and then the amino acid residue of the mu receptor involved in the covalent binding of [H-3]beta-FNA. [H-3]beta-FNA-labeled receptors were solubilized and purified to similar to 10% purity by immunoaffinity chromatography with antibodies against a C-terminal domain peptide. The site of covalent bond formation was determined to be within Ala(206)-Met(243) by CNBr cleavage of partially purified labeled mu receptors and determinations of sizes of labeled receptor fragments. The amino acid residue of beta-FNA covalent incorporation was then determined by site-directed mutagenesis studies within this region. Mutation of Lys(233) to Ala, Arg, His, and Leu completely eliminated covalent binding of [H-3]beta-FNA, although these mutants bound beta-FNA with high affinity. Mutations of other amino acid residues did not affect covalent binding of [H-3]beta-FNA. These results indicate that [H-3]beta-FNA binds covalently to Lys(233). Since [H-3]beta-FNA is a rigid molecule, the information will be very useful for molecular modeling of interaction between morphinans and the mu receptor.	TEMPLE UNIV, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST MOL BIOL & CANC RES, PHILADELPHIA, PA 19140 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHYS & STRUCT CHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM SPA, DEPT CHEM, I-20021 BARANZATE, MILAN, ITALY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline; GlaxoSmithKline					NIDA NIH HHS [DA 04745, T32 DA07237] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA004745, R01DA004745, T32DA007237] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALLEN G, 1981, SEQUENCING PROTEINS, P62; BARE LA, 1994, FEBS LETT, V354, P213, DOI 10.1016/0014-5793(94)01129-X; Befort K, 1996, MOL PHARMACOL, V49, P216; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUNZOW JR, 1995, J NEUROCHEM, V64, P14; CHEN CG, 1995, J BIOL CHEM, V270, P17866, DOI 10.1074/jbc.270.30.17866; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FRANKLIN TG, 1991, BRIT J PHARMACOL, V102, P718, DOI 10.1111/j.1476-5381.1991.tb12239.x; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; GRIFFIN JF, 1986, J MED CHEM, V29, P778, DOI 10.1021/jm00155a031; Harlow E, 1988, ANTIBODIES LAB MANUA, P104; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; LIUCHEN LY, 1993, MOL PHARMACOL, V44, P749; LIUCHEN LY, 1990, MOL PHARMACOL, V37, P243; LIUCHEN LY, 1987, MOL PHARMACOL, V32, P321; LIUCHEN LY, 1991, BRAIN RES, V544, P235, DOI 10.1016/0006-8993(91)90059-5; LUTHIN GR, 1988, MOL PHARMACOL, V34, P327; MATSUI H, 1989, BIOCHEMISTRY-US, V28, P4125, DOI 10.1021/bi00435a075; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PASTERNAK GW, 1988, OPIATE RECEPTORS; PORTOGHESE PS, 1980, J MED CHEM, V23, P233, DOI 10.1021/jm00177a002; RECHT LD, 1987, EUR J PHARMACOL, V140, P209, DOI 10.1016/0014-2999(87)90807-7; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYRE LM, 1983, J MED CHEM, V26, P1229, DOI 10.1021/jm00363a005; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TAKEMORI AE, 1985, ANNU REV PHARMACOL, V25, P193; TAM SW, 1986, J PHARMACOL EXP THER, V239, P351; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WANG JB, 1994, J BIOL CHEM, V269, P25966; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; XUE JC, 1995, J BIOL CHEM, V270, P12977; XUE JC, 1994, J BIOL CHEM, V269, P30195; Zhu JM, 1996, J BIOL CHEM, V271, P1430, DOI 10.1074/jbc.271.3.1430; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	58	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21422	21429		10.1074/jbc.271.35.21422	http://dx.doi.org/10.1074/jbc.271.35.21422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702924				2022-12-25	WOS:A1996VE47700070
J	Hiasa, H; Marians, KJ				Hiasa, H; Marians, KJ			Two distinct modes of strand unlinking during theta-type DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOPOISOMERASE-IV; PBR322 DNA; IN-VITRO; DEOXYRIBONUCLEIC-ACID; LEADING-STRAND; GENE-PRODUCT; GYRASE; IDENTIFICATION; DECATENATION	DNA gyrase and topoisomerase IV (Topo IV) are type II bacterial DNA topoisomerases that show a high degree of similarity to each other yet appear to have different functions during DNA replication. We show here that the torsional stress generated during theta-type DNA replication in vitro can take the form of either positive supercoils ahead of the replication fork or catenane-like right-handed windings (precatenanes) of the two partially replicated duplexes behind the fork. Gyrase prefers to act on the former, whereas Topo IV prefers the latter. Removal of either form of positive winding can support nascent chain elongation, but only precatenane removal can support the final stages of DNA replication: processing of the late intermediate and daughter chromosome decatenation.			Hiasa, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; Champoux JJ, 1980, MECH STUDIES DNA REP, P809; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; FILUTOWICZ M, 1983, MOL GEN GENET, V191, P282, DOI 10.1007/BF00334827; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIASA H, 1994, J BIOL CHEM, V269, P32655; HIASA H, 1994, J BIOL CHEM, V269, P2093; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KIM RA, 1992, J BIOL CHEM, V267, P17178; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KORNBERG A, 1992, DNA REPLICATION, P379; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; MORRISON A, 1980, J BIOL CHEM, V255, P2211; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; PENG H, 1995, THESIS CORNELL U; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU CA, 1992, J BIOL CHEM, V267, P4030; YAMAGISHI JI, 1981, J BACTERIOL, V148, P450, DOI 10.1128/JB.148.2.450-458.1981; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	33	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21529	21535		10.1074/jbc.271.35.21529	http://dx.doi.org/10.1074/jbc.271.35.21529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702938	hybrid			2022-12-25	WOS:A1996VE47700084
J	Lau, LF; Mammen, A; Ehlers, MD; Kindler, S; Chung, WJ; Garner, CC; Huganir, RL				Lau, LF; Mammen, A; Ehlers, MD; Kindler, S; Chung, WJ; Garner, CC; Huganir, RL			Interaction of the N-methyl-D-aspartate receptor complex with a novel synapse-associated protein, SAP102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; HETEROMERIC NMDA RECEPTORS; GLUTAMATE-RECEPTOR; RAT-BRAIN; ACETYLCHOLINE-RECEPTOR; POSTSYNAPTIC PROTEIN; GUANYLATE KINASES; DROSOPHILA; PHOSPHORYLATION; SUBUNITS	Ionotropic glutamate receptors are known to cluster at high concentration on the postsynaptic membrane of excitatory synapses, but the mechanism by which this occurs is poorly understood. Studies on the neuromuscular junction and central inhibitory synapses suggest that clustering of neurotransmitter receptors requires its interaction with a cytoplasmic protein. Recently, in vitro studies have shown that members of the N-methyl-D-aspartate (NMDA) class of glutamate receptors interact with a synapse-associated protein, SAP90 (PSD-95). However, evidence for the in vivo interaction of NMDA receptors with SAPs is still lacking. In the present study, we demonstrate the specific interaction between SAP102, a novel synapse-associated protein, and the NMDA receptor complex from the rat cortical synaptic plasma membranes using co-immunoprecipitation techniques. No association was observed between SAP102 and GluR1, a member of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate class of glutamate receptors. To identify the domain on the NMDA receptor responsible for this interaction, we constructed hexahistidine fusion proteins hom different regions of the NR1a and NR2 subunits of the NMDA receptor. Immunoblot overlay experiments showed that while the C-terminal domain of the NR2 subunit displayed strong binding, the NR1a intracellular C-terminal tail did not interact with SAP102. The site of interaction was more precisely located to the last 20 amino acids of the NR2 subunit as indicated by the interaction of the synthetic peptide with SAP102. In summary, we demonstrate here for the first time an in vivo interaction between the native NMDA receptor complex and a synapse-associated protein. These results suggest that SAP102 may play an important role in NMDA receptor clustering and immobilization at excitatory synapses.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV ALABAMA,BIRMINGHAM,AL 35294	Howard Hughes Medical Institute; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham			Mammen, Andrew/AAF-2885-2021	Garner, Craig/0000-0003-1970-5417				APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BROSE N, 1993, J BIOL CHEM, V268, P22663; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Hunt CA, 1996, J NEUROSCI, V16, P1380; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Niethammer M, 1996, J NEUROSCI, V16, P2157; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WO ZGL, 1995, J BIOL CHEM, V270, P2000, DOI 10.1074/jbc.270.5.2000; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	44	157	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21622	21628		10.1074/jbc.271.35.21622	http://dx.doi.org/10.1074/jbc.271.35.21622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702950	hybrid			2022-12-25	WOS:A1996VE47700096
J	Saxena, SK; Gravell, M; Wu, YN; Mikulski, SM; Shogen, K; Ardelt, W; Youle, RJ				Saxena, SK; Gravell, M; Wu, YN; Mikulski, SM; Shogen, K; Ardelt, W; Youle, RJ			Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; III REPLICATION INVITRO; ALPHA-A-INTERFERON; CYTOTOXIC RIBONUCLEASES; SYNERGISTIC INHIBITION; MOLECULAR EVOLUTION; P-30 PROTEIN; H9 CELLS; INFECTION; SUPERFAMILY	Ribonucleases appear to have physiologic roles in host defense against cancer, viruses, and other parasites, Previously it was shown that select ribonucleases added to cells concurrently with virions blocked human immunodeficiency virus, type I (HIV-1) infection of H9 cells, We now report that a ribonuclease homologous to RNase A, named onconase, inhibits virus replication in chronically HIV-1-infected human cells without killing the virally infected cell, Examining the mechanism of this inhibition shows that onconase enters the infected cells and degrades HIV-1 RNA without degrading ribosomal RNA or the three different cellular messenger RNAs analyzed, The homologous human pancreatic RNase lacks anti-viral activity, Comparing recombinant forms of onconase and a onconase-human RNase chimera shows that the N-terminal 9 amino acids and the pyroglutamyl residue of onconase are required for full anti-viral activity. Thus extracellular ribonucleases can enter cells, metabolize select RNAs, and inhibit HIV virion production within viable replicating cells.	NINCDS, BIOCHEM SECT, SURG NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; NINCDS, LAB MOL MED & NEUROSCI, BETHESDA, MD 20892 USA; ALFACELL CORP, BLOOMFIELD, NJ 07003 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			Saxena, Shailendra K/X-4252-2019; Saxena, Shailendra K/ABK-6489-2022	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARDELT W, 1991, J BIOL CHEM, V266, P245; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BENNER SA, 1988, FEBS LETT, V233, P225, DOI 10.1016/0014-5793(88)80431-9; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; CARTER WA, 1987, LANCET, V1, P1286; CHAKRAVORTY AK, 1974, NATURE, V247, P577, DOI 10.1038/247577b0; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTSHORN KL, 1986, ANTIMICROB AGENTS CH, V30, P189, DOI 10.1128/AAC.30.1.189; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1985, LANCET, V1, P602; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; LIN JJ, 1994, BIOCHEM BIOPH RES CO, V204, P156, DOI 10.1006/bbrc.1994.2439; LORING HUBERT S., 1942, JOUR GEN PHYSIOL, V25, P497, DOI 10.1085/jgp.25.3.497; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; NATSOULIS G, 1995, P NATL ACAD SCI USA, V92, P364, DOI 10.1073/pnas.92.2.364; NEWTON DL, 1994, J BIOL CHEM, V269, P26739; PETERS GG, 1980, J VIROL, V33, P708, DOI 10.1128/JVI.33.2.708-716.1980; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; Rybak S.M., 1993, DRUG DELIV, V1, P3; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; Schroder H C, 1994, Prog Mol Subcell Biol, V14, P176; SCHRODER HC, 1989, J BIOL CHEM, V264, P5669; SEN GC, 1992, J BIOL CHEM, V267, P5017; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	42	81	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20783	20788		10.1074/jbc.271.34.20783	http://dx.doi.org/10.1074/jbc.271.34.20783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702832	hybrid			2022-12-25	WOS:A1996VD33700084
J	Katoh, M; Hirai, M; Sugimura, T; Terada, M				Katoh, M; Hirai, M; Sugimura, T; Terada, M			Cloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family	ONCOGENE			English	Article						Wnt gene family; human carcinogenesis; gastric cancer	RECEPTOR TYROSINE KINASE; TRANSGENIC MICE; MAMMARY CARCINOGENESIS; MOLECULAR-CLONING; SEQUENCE; INT-1; INT-2/FGF-3; ONCOGENE; WELL	The Wnt genes, encoding structurally-related secreted glycoproteins, are implicated in mammary carcinogenesis induced by mouse mammary tumor virus, In search of the Wnt gene(s) expressed in human gastric cancer, a WTGC1 cDNA fragment sharing 66.9% amino-acid homology with human and mouse Wnt-2 was isolated by degenerate polymerase chain reaction. The human gene corresponding to WTGC1 was designated as Wnt-13 and overlapping Wnt-13 cDNAs were cloned, Nucleotide sequence analysis indicated that the Wnt-13 gene encodes the protein of 372 amino acids, including a signal peptide, two potential N-glycosylation sites and 24 cystein residues highly conserved among members of the Wnt gene family, The Wnt-13 mRNA of 2.5 kb in size was detected in heart, brain, placenta, lung, prostate, testis, ovary, small intestine and colon of adult human and also in brain, lung and kidney of fetal human, Among various cancer cell lines, the Wnt-13 mRNA was detected in HeLa (cervical cancer), MKN28 and MKN74 (gastric cancer), The Wnt-13 gene has been mapped to human chromosome 1p13, These results suggest that the Wnt-13 gene may be involved in normal human development or differentiation as well as in human carcinogenesis.	NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; HUGUET EL, 1994, CANCER RES, V54, P2615; IOZZO RV, 1995, CANCER RES, V55, P3495; KATOH M, 1995, ONCOGENE, V10, P1447; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; NAKATANI H, 1990, JPN J CANCER RES, V81, P707, DOI 10.1111/j.1349-7006.1990.tb02631.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WOLDA SL, 1992, ONCOGENE, V7, P1941; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	23	156	163	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					873	876						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761309				2022-12-25	WOS:A1996VD43300023
J	Meyers, S; Lenny, N; Sun, WH; Hiebert, SW				Meyers, S; Lenny, N; Sun, WH; Hiebert, SW			AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia	ONCOGENE			English	Article						AML-1; translocation; leukemia; transcription	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RUNT DOMAIN; DNA-BINDING; GENE; EXPRESSION; IDENTIFICATION; CELLS; TRANSLOCATION; PROMOTER	AML-1B is targeted directly and indirectly in multiple chromosomal translocations in myeloid and B-cells. The AML-1/ETO and TEL/AML-1 fusion proteins, created by the t(8;21) and t(12;21) respectively, disrupt AML-1B-dependent transcription. Recently, two human members of the runt homology domain family of transcription factors have been identified, AML-2 and AML-3, which also regulate transcription through enhancer core motifs. If multiple factors regulate transcription through the same site, a dominant interfering protein may be required to promote leukemogenesis, rather than the inactivation of both AML1 alleles. To determine which AML family proteins are active in hematopoietic cells, we developed antisera specific to each family member for use in gel mobility shift assays. We have found that AML-1B is the major DNA binding activity in T-cell lines, while both AML-1B and AML-2 are expressed in myeloid and B-cell lines. AML-1B represents most of the active protein in the mouse thymus, whereas AML-1 and AML-2 are equally expressed in the mouse spleen. AML-3 is expressed at very low levels in a single myeloid cell line, 32D.3, and is the only core binding activity present in Buffalo rat liver cells. We demonstrate that AML-2-dependent transactivation mediated by enhancer core motifs is inhibited by the AML-1/ETO and TEL/AML-1 fusion proteins. This indicates that the t(8;21) and t(12;21) fusion proteins inhibit transcriptional activation by the AML-1 transcription factor family, and in so doing contributes to leukemogenesis.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN USA	St Jude Children's Research Hospital			Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [R01CA064140, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765, R01 CA-64140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HIBERT SW, 1996, MOL CELL BIOL, V16, P1349; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; WANG S, 1993, EMBO J, V13, P3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	38	118	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					303	312						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710369				2022-12-25	WOS:A1996VA25200009
J	Yasumoto, S; Kunimura, C; Kikuchi, K; Tahara, H; Ohji, H; Yamamoto, H; Ide, T; Utakoji, T				Yasumoto, S; Kunimura, C; Kikuchi, K; Tahara, H; Ohji, H; Yamamoto, H; Ide, T; Utakoji, T			Telomerase activity in normal human epithelial cells	ONCOGENE			English	Article						telomerase activity; normal human cells; epithelial cells	HUMAN-FIBROBLASTS; EPIDERMAL-CELLS; IMMORTAL CELLS; BURN WOUNDS; IN-VIVO; KERATINOCYTES; LYMPHOCYTES; TISSUES; RNA	Telomerase activity is found in most cancer tissues and many immortalized cell lines as well as in germ line cells but it is generally undetected in normal human somatic tissues. There is weak telomerase activity in some cell types of hematopoietic lineage in which a stem cell-like subpopulation may exist. Likewise, physiologically regenerating somatic tissues and organs such as skin, small intestine, and most other epithelia of the human body are supposed to contain similar cell lineages to maintain their renewal throughout the life span of individuals. It is therefore of interest whether telomerase activity is present in physiologically regenerating epithelial cells. Telomerase activity was detected, though very weakly, in cultured normal epidermal keratinocytes and at higher levels in a subpopulation that adhere rapidly on collagen IV-coated culture dishes. No telomerase activity was detected in a subpopulation that was less adherent on the coated dishes. The rapidly adherent subpopulation of keratinocytes was enriched in small proliferating cells with macrocolony forming potential. It was also passaged through more generations in culture, and expressed integrin beta 1 at higher levels than the less adherent subpopulation. Telomerase activity was similarly found in ectocervical keratinocytes as well as in simple endocervical epithelial cells. These findings provide the evidence of a telomerase-positive population among physiologically regenerating normal human epithelial cells. The identity of the telomerase-positive cells remains to be defined.	NISSHO COOPERAT,RES & DEV,KUSATU SHI,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOL BIOL,MINAMI KU,HIROSHIMA 734,JAPAN	Hiroshima University	Yasumoto, S (corresponding author), KANAGAWA CANC CTR,RES INST,MOL CELL BIOL LAB,ASAHI KU,54-2 NAKAO CHO,YOKOHAMA,KANAGAWA 241,JAPAN.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHADENEAU C, 1995, ONCOGENE, V11, P893; COMPTON CC, 1989, LAB INVEST, V60, P600; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GREEN H, 1988, NEWS PHYSIOL SCI, V3, P53; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HIYAMA E, 1995, NAT MED, V1, P294; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HIYAMA K, 1995, J IMMUNOL, V155, P3711; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LEVY MZ, 1992, J MOL BIOL, V225, P114; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NILSSON P, 1994, ONCOGENE, V9, P3043; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 1995, CLIN CANCER RES, V1, P1245; TSUTSUMI K, 1993, AM J PATHOL, V143, P1150; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; YASUMOTO S, 1992, TISSUE CULT RES COMM, V11, P13; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	35	252	262	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					433	439						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710384				2022-12-25	WOS:A1996VA25200024
J	vanEs, S; Virdy, KJ; Pitt, GS; Meima, M; Sands, TW; Devreotes, PN; Cotter, DA; Schaap, P				vanEs, S; Virdy, KJ; Pitt, GS; Meima, M; Sands, TW; Devreotes, PN; Cotter, DA; Schaap, P			Adenylyl cyclase G, an osmosensor controlling germination of Dictyostelium spores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; REGULATORY SUBUNIT; GENE-EXPRESSION; CAMP; DIFFERENTIATION; DISCOIDEUM; PRESPORE; SUFFICIENT; CELLS; YEAST	Dictyostelium cells express a G-protein-coupled adenylyl cyclase, ACA, during aggregation and an atypical adenylyl cyclase, ACG, in mature spores, The ACG gene was disrupted by homologous recombination. acg(-) cells developed into normal fruiting bodies with viable spores, but spore germination was no longer inhibited by high osmolarity, a fairly universal constraint for spore and seed germination, ACG activity, measured in aca(-)/ACG cells, was strongly stimulated by high osmolarity with optimal stimulation occurring at 200 milliosmolar. RdeC mutants, which display unrestrained protein kinase A (PKA) activity and a cell line, which overexpresses PKA under a prespore specific promoter, germinate very poorly, both at high and low osmolarity, These data indicate that ACG is an osmosensor controlling spore germination through activation of protein kinase A.	LEIDEN UNIV,CELL BIOL SECT,INST MOL PLANT SCI,NL-2333 AL LEIDEN,NETHERLANDS; UNIV WINDSOR,DEPT BIOL SCI,WINDSOR,ON N9B 3P4,CANADA; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Leiden University; Leiden University - Excl LUMC; University of Windsor; Johns Hopkins University			Pitt, Geoffrey/L-4927-2019; Schaap, Pauline/A-3682-2009; Schaap, Pauline/M-5355-2019	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555				ABE H, 1976, Tetrahedron Letters, V42, P3807; BURKI E, 1991, GENE, V102, P57, DOI 10.1016/0378-1119(91)90538-M; COTTER DA, 1977, CAN J MICROBIOL, V23, P1170, DOI 10.1139/m77-176; COTTER DA, 1981, FUNGAL SPORE MORPHOG, P385; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; KAHN A, 1960, PLANT PHYSIOL, V35, P1, DOI 10.1104/pp.35.1.1; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MIZUNO T, 1990, MOL MICROBIOL, V4, P1077, DOI 10.1111/j.1365-2958.1990.tb00681.x; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; SCHULKES C, 1995, FEBS LETT, V368, P381, DOI 10.1016/0014-5793(95)00676-Z; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; WELBAUM GE, 1990, PLANT PHYSIOL, V92, P1029, DOI 10.1104/pp.92.4.1029; WERNER JE, 1995, PHYSIOL PLANTARUM, V93, P659, DOI 10.1111/j.1399-3054.1995.tb05114.x	23	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23623	23625		10.1074/jbc.271.39.23623	http://dx.doi.org/10.1074/jbc.271.39.23623			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798577				2022-12-25	WOS:A1996VJ44200006
J	Kwon, J; Lee, SJ; Benveniste, EN				Kwon, J; Lee, SJ; Benveniste, EN			A 3' cis-acting element is involved in tumor necrosis factor-alpha gene expression in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROMOTER REGION; HYPERSENSITIVE SITES; ENHANCER ELEMENTS; CELL LINES; T-CELL; ACTIVATION; LIPOPOLYSACCHARIDE; TRANSCRIPTION; PROTEIN	Tumor necrosis factor-alpha (TNF-alpha) contributes to demyelinating diseases in the central nervous system. Astrocytes, the major glial cells in the CNS, do not constitutively express TNF-alpha, but the TNF-alpha gene is transcriptionally activated in response to a variety of stimuli, including TNF-alpha itself. Because of the importance of TNF-alpha in the CNS, we examined the mechanisms underlying transcriptional regulation of the TNF-alpha gene in astrocytes, In transient transfection assays, a plasmid construct containing 1.3 kilobase pairs (kb) of 5' flanking sequence of the rat TNF-alpha gene showed high basal activity that could not be further enhanced by TNF-alpha stimulation. A ''marked'' 10-kb TNF-alpha gene construct, which contains the whole TNF-beta gene with 1.2 kb of 5' flanking sequence, 1.1 kb of intergenic sequence, and the whole TNF-alpha gene with 3 kb of 3' flanking sequence, was able to respond to TNF-alpha stimulation, Analysis of a series of 5' and 3' deletion constructs of the marked TNF-alpha genes demonstrated that upstream sequence elements such as NF-kappa B are not required for TNF-alpha induction and that TNF-alpha responsive elements are located in the 3' flanking region of the TNF-alpha gene, We also found that a TNF-alpha-inducible DNase I-hypersensitive (DH) site is present in this 3' region whose deletion abolishes TNF-alpha inducibility of the marked TNF-alpha gene. Electrophoresis mobility shift assays showed that TNF-alpha-inducible nuclear proteins, consisting of p50 and p65 NF-kappa B proteins, specifically bind to two consecutive NF-kappa B binding sites within the 3' DH site, These results indicate that TNF-alpha-induced TNF-alpha gene expression in astrocytes involves p50 and p65 NF-kappa B proteins binding to downstream NF-kappa B sites and concomitant modulation of the chromatin structure.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIMH NIH HHS [MH-50421] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050421] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BENVENISTE EN, 1994, J IMMUNOL, V153, P5210; BENVENISTE EN, 1995, HUMAN CYTOKINES THEI, P195; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHUNG IY, 1992, J IMMUNOL, V149, P3894; CHUNG IY, 1990, J IMMUNOL, V144, P2999; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KUPRASH DV, 1995, ONCOGENE, V11, P97; KWON JB, 1993, GENE, V132, P227, DOI 10.1016/0378-1119(93)90200-M; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANEK RB, 1992, P NATL ACAD SCI USA, V89, P11518, DOI 10.1073/pnas.89.23.11518; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L	40	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22383	22390		10.1074/jbc.271.37.22383	http://dx.doi.org/10.1074/jbc.271.37.22383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798400	hybrid			2022-12-25	WOS:A1996VG67200019
J	Sawaya, BE; Rohr, O; Aunis, D; Schaeffer, E				Sawaya, BE; Rohr, O; Aunis, D; Schaeffer, E			Regulation of human immunodeficiency virus type 1 gene transcription by nuclear receptors in human brain cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; RETINOIC ACID RECEPTORS; CENTRAL-NERVOUS-SYSTEM; THYROID-HORMONE RECEPTOR; HUMAN TRANSFERRIN GENE; NF-KAPPA-B; PHORBOL ESTER; CO-REPRESSOR; X-RECEPTOR; EXPRESSION	Infection of cells of the central nervous system by the human immunodeficiency virus type-1 (HIV-1) leads to HIV-1-associated neuropathology. Recent studies have demonstrated the importance of long terminal repeat (LTR) binding sites in determining the pathogenicity of HIV. Here we have investigated the presence and the functional role of transcription factors that have the potential to interact, directly or indirectly, with the nuclear receptor-responsive element in the LTR of HIV-1, in different human cell lines of the brain. Cotransfection experiments showed that in oligodendroglioma TC-620 cells, the retinoic acid receptor and the retinoid X receptor activate LTR-driven transcription in the absence of ligand. Addition of all trans- or 9-cis-retinoic acid reverses this effect. In contrast, in astrocytoma, neuronal, and microglial cells, no significant effect of the retinoid acid pathway was detected. This retinoid response is mediated by distinct molecular interactions in the lymphotropic LAI and the neurotropic JR-CSF HIV-1 strains. Moreover, retinoid receptors were found to antagonize the chicken ovalbumin upstream promoter transcription factor- as well as the c-JUN-mediated LTR transactivation, Our findings demonstrate the importance of the retinoic acid signaling pathway and of cross coupling interactions in the repression of HIV-1 LTR gene expression.	INSERM,UNITE 338,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Dominique, Aunis/W-1419-2019	ROHR, Olivier/0000-0001-8992-2025				BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; CANONNEHERGAUX F, 1995, J VIROL, V69, P6634, DOI 10.1128/JVI.69.11.6634-6642.1995; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GAYNOR R, 1992, AIDS, V6, P3761; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HATCH WC, 1994, AIDS RES HUM RETROV, V10, P1597, DOI 10.1089/aid.1994.10.1597; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; MACIASZEK JW, 1994, J VIROL, V68, P6598, DOI 10.1128/JVI.68.10.6598-6604.1994; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MERRILL JE, 1988, AGENTS, V2, P77; NUOVO GJ, 1994, AM J PATHOL, V144, P659; ORCHARD K, 1993, J ACQ IMMUN DEF SYND, V6, P440; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; TURPIN JA, 1992, J IMMUNOL, V148, P2539; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; YAMAGUCHI K, 1994, AIDS, V8, P1675, DOI 10.1097/00002030-199412000-00006	38	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22895	22900		10.1074/jbc.271.37.22895	http://dx.doi.org/10.1074/jbc.271.37.22895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798469	Green Published, hybrid			2022-12-25	WOS:A1996VG67200088
J	Schulz, K; Danner, S; Bauer, P; Schroder, S; Lohse, MJ				Schulz, K; Danner, S; Bauer, P; Schroder, S; Lohse, MJ			Expression of phosducin in a phosducin-negative cell line reveals functions of a G(beta gamma)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; BETA-GAMMA-SUBUNITS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; PLECKSTRIN-HOMOLOGY DOMAIN; HETEROTRIMERIC G-PROTEINS; DEPENDENT PHOSPHORYLATION; BETA-2-ADRENERGIC RECEPTORS; ADENOSINE RECEPTORS; CYCLIC-AMP; DESENSITIZATION	Phosducin is a member of the large group of proteins that bind to G-protein beta gamma-subunits (G(beta gamma)) and whose biological functions are often unknown. Human A431 cells do not contain detectable amounts of phosducin. We generated A431 cells expressing phosducin at a level of approximate to 1 pmol/mg of cytosolic protein, which is approximate to 10% of the phosducin level in brain, cAMP accumulation in response to beta(2)-adrenergic receptor agonists was enhanced at early times in phosducin-expressing cells, but reached a lower plateau than in control cells. Permeabilization of the cells with digitonin did not change this pattern, but allowed the introduction of specific inhibitors: antibodies to phosducin abolished all differences between the two cell lines. Inhibitors of the beta-adrenergic receptor kinase abolished the differences at early time points. An almost complete loss of beta(2)-adrenergic receptor desensitization in the phosducin-expressing cells was also observed when intact cells were desensitized and receptor function was then determined in membrane preparations. Inhibition of protein kinase A accentuated the effects of phosducin, suggesting that also in vivo phosducin is regulated by this kinase. These data indicate that phosducin affects G-protein-mediated signaling in at least two ways: it dampens the overall responsiveness, and it impairs the rapid desensitization mediated by the beta-adrenergic receptor kinase.			Schulz, K (corresponding author), UNIV WURZBURG,INST PHARMACOL,VERSBACHER STR 9,D-97078 WURZBURG,GERMANY.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOHSE MJ, 1991, MOL PHARMACOL, V39, P517; LOHSE MJ, 1984, MOL PHARMACOL, V26, P1; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, N-S ARCH PHARMACOL, V345, P444; LOHSE MJ, 1990, J BIOL CHEM, V265, P3210; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MULLER S, 1995, BIOCHEM SOC T, V23, P141; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, N-S ARCH PHARMACOL, V350, P329; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REIG JA, 1990, J BIOL CHEM, V265, P5816; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WINSTEL R, 1995, N-S ARCH PHARMACOL, V351, pR139; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	43	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22546	22551		10.1074/jbc.271.37.22546	http://dx.doi.org/10.1074/jbc.271.37.22546			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798422	hybrid			2022-12-25	WOS:A1996VG67200041
J	Hosseini, G; Liu, J; deAgostini, AI				Hosseini, G; Liu, J; deAgostini, AI			Characterization and hormonal modulation of anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; AORTIC ENDOTHELIAL-CELLS; MAMMARY EPITHELIAL-CELLS; ANTITHROMBIN-III; GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; INTRACELLULAR DEGRADATION; VASCULAR-PERMEABILITY; CULTURED INVITRO; HIGH-AFFINITY	Anticoagulant heparan sulfate proteoglycans endow the vascular endothelium with antithrombotic properties, but their role outside the vascular bed is unknown. Granulosa cells form an avascular compartment in the ovarian follicle, in which a heparin-like activity has been described. At ovulation extravascular coagulation occurs around ovulatory follicles, and after expulsion of the oocyte, a fibrin clot forms in the antral cavity. Granulosa cells synthesize two major heparan sulfate proteoglycans, whose anticoagulant nature has not been investigated. The purpose of this study was to characterize anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells. Affinity purified S-35-labeled anticoagulant heparan sulfate glycosaminoglycans represent 6.5% of the total heparan sulfate synthesized, and they contain 13% 3-O-sulfated disaccharides that are markers of the antithrombin-binding site of heparin. The biological activity of granulosa cell heparan sulfate proteoglycans was demonstrated by their ability to bind antithrombin and to accelerate the formation of thrombin-antithrombin complexes. The impact of hormonal stimulation on granulosa cell anticoagulant heparan sulfate proteoglycans was studied using I-125-antithrombin binding assays. Follicle-stimulating hormone induced a redistribution of anticoagulant heparan sulfate proteoglycans from the granulosa cell layer to the culture medium, indicating that their distribution could be modulated according to the stage of follicular development. These results suggest that anticoagulant heparan sulfate might be critically located in the follicle to maintain fluidity around the oocyte until its expulsion at ovulation.	UNIV HOSP GENEVA, DEPT OBSTET & GYNAECOL, STERIL & GYNAECOL ENDOCRINOL CLIN, CH-1211 GENEVA 14, SWITZERLAND; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of Geneva; Massachusetts Institute of Technology (MIT)								ADASHI EY, 1986, ENDOCRINOLOGY, V118, P456, DOI 10.1210/endo-118-1-456; AMSTERDAM A, 1987, ENDOCR REV, V8, P309, DOI 10.1210/edrv-8-3-309; ANDRADEGORDON P, 1992, THROMB RES, V66, P475, DOI 10.1016/0049-3848(92)90302-Q; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BERRY L, 1991, AM J RESP CELL MOL, V4, P338, DOI 10.1165/ajrcmb/4.4.338; CANIPARI R, 1986, ENDOCRINOLOGY, V118, P1652, DOI 10.1210/endo-118-4-1652; CARLSON TH, 1985, BLOOD, V66, P13, DOI 10.1182/blood.V66.1.13.13; CAVENDER JL, 1988, BIOL REPROD, V39, P989, DOI 10.1095/biolreprod39.4.989; COLLIEC S, 1994, PHYTOCHEMISTRY, V35, P697, DOI 10.1016/S0031-9422(00)90590-9; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DEAGOSTINI AI, 1991, ANN NY ACAD SCI, V614, P279; DEAGOSTINI AI, 1994, J CELL BIOCHEM, V54, P174, DOI 10.1002/jcb.240540206; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; ENGLAND BG, 1974, J CLIN ENDOCR METAB, V38, P42, DOI 10.1210/jcem-38-1-42; FAULK WP, 1993, HAEMOSTASIS, V23, P194; GERDES U, 1992, J REPROD FERTIL, V95, P539, DOI 10.1530/jrf.0.0950539; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GRAUFFEL V, 1989, BIOMATERIALS, V10, P363, DOI 10.1016/0142-9612(89)90127-0; GULAMALIMAJID F, 1987, CLIN CHEM, V33, P1185; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HATTON MWC, 1988, BLOOD VESSELS, V25, P12; HELUSOVA S, 1995, GLYCOCONJUGATE J, V12, P484; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JIA XC, 1985, NEUROENDOCRINOLOGY, V41, P445, DOI 10.1159/000124216; KAMAT BR, 1995, AM J PATHOL, V146, P157; KERENTAL I, 1993, MOL CELL ENDOCRINOL, V95, pR1, DOI 10.1016/0303-7207(93)90042-I; KOBAYASHI M, 1992, GERONTOLOGY, V38, P36; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOURTEVA Y, 1995, THROMB RES, V78, P521, DOI 10.1016/0049-3848(95)00085-6; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINHARDT RJ, 1995, THROMB HAEMOSTASIS, V73, P1352; LYON M, 1990, ANAL BIOCHEM, V185, P63, DOI 10.1016/0003-2697(90)90255-8; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, EXP CELL RES, V166, P253, DOI 10.1016/0014-4827(86)90525-2; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, ANN NY ACAD SCI, V556, P81; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; MERTENS G, 1992, J BIOL CHEM, V267, P20435; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; ORLY J, 1980, CELL, V20, P817, DOI 10.1016/0092-8674(80)90328-1; PARR EL, 1974, BIOL REPROD, V11, P483, DOI 10.1095/biolreprod11.5.483; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PIEPKORN M, 1988, BIOCHEM BIOPH RES CO, V151, P327, DOI 10.1016/0006-291X(88)90597-9; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SHALGI R, 1973, FERTIL STERIL, V24, P429; SHIMADA K, 1991, JPN CIRC J, V55, P1016, DOI 10.1253/jcj.55.1016; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SKINNER MK, 1987, ENDOCRINOLOGY, V121, P1892, DOI 10.1210/endo-121-5-1892; SUCHANEK E, 1990, INT J GYNECOL OBSTET, V32, P53, DOI 10.1016/0020-7292(90)90982-Q; XU YH, 1994, J HISTOCHEM CYTOCHEM, V42, P1365, DOI 10.1177/42.10.7930519; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YANAGISHITA M, 1979, J BIOL CHEM, V254, P2355; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260; YANAGISHITA M, 1981, ENDOCRINOLOGY, V109, P1641, DOI 10.1210/endo-109-5-1641	74	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22090	22099		10.1074/jbc.271.36.22090	http://dx.doi.org/10.1074/jbc.271.36.22090			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703018	hybrid			2022-12-25	WOS:A1996VF61200060
J	Iwasaki, T; Yamada, M; Satoh, T; Konaka, S; Ren, Y; Hashimoto, K; Kohga, H; Kato, Y; Mori, M				Iwasaki, T; Yamada, M; Satoh, T; Konaka, S; Ren, Y; Hashimoto, K; Kohga, H; Kato, Y; Mori, M			Genomic organization and promoter function of the human thyrotropin-releasing hormone receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; CELL-SPECIFIC EXPRESSION; RAT PITUITARY-CELLS; TRH RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; 5'-FLANKING REGION; MOLECULAR-CLONING; DOWN-REGULATION; PROLACTIN GENE	We isolated and characterized the gene for the human thyrotropin-releasing hormone receptor, The gene spanned more than 30 kilobases and contained three exons and two introns, Intron 1 exists in the 5'-untranslated region, and intron 2 is more than 25 kilobases in length which interrupts the coding region before the beginning of the putative sixth transmembrane domain. Exon 3 encodes the rest of the coding region and the entire 3'-untranslated region. The 3'-flanking region contains four potential polyadenylation signals, and 3'-rapid amplification of cDNA ends studies showed that only a signal at 2076 base pairs downstream of the stop codon was functional in the anterior pituitary, Primer extension and anchor-polymerase chain reaction studies indicated a transcriptional start site at 344 base pairs upstream of the translational start site, The promoter region does not contain either a TATA box or a CAAT box in the appropriate location, Transient transfection study revealed significant activity of the promoter in GH4C1 cells, and the region between -338 and -933 bp from the transcriptional start site worked as a negative regulator, Knowledge of the genomic organization and the promoter region of thyrotropin-releasing hormone (TRH) receptor gene will allow further studies of possible disorders of the TRH receptor, as well as facilitate elucidation of transcriptional control of the human TRH receptor gene.	GUNMA UNIV, SCH MED, DEPT INTERNAL MED 1, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT NEUROSURG, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, BIOSIGNAL RES CTR, MAEBASHI, GUMMA 371, JAPAN	Gunma University; Gunma University; Gunma University								ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BURT DR, 1982, EXP EYE RES, V35, P173, DOI 10.1016/S0014-4835(82)80064-X; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DUTHIE SM, 1993, MOL CELL ENDOCRINOL, V95, pR11, DOI 10.1016/0303-7207(93)90043-J; DUTHIE SM, 1993, J MOL ENDOCRINOL, V11, P141, DOI 10.1677/jme.0.0110141; FAN NC, 1995, MOL CELL ENDOCRINOL, V107, pR1, DOI 10.1016/0303-7207(94)03460-B; FUKUSUMI S, 1995, REGUL PEPTIDES, V57, P115, DOI 10.1016/0167-0115(95)00026-8; GERSHENGORN MC, 1989, ANN NY ACAD SCI, V553, P191; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HINKLE PM, 1984, P NATL ACAD SCI-BIOL, V81, P6183, DOI 10.1073/pnas.81.19.6183; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; HOSODA K, 1992, J BIOL CHEM, V267, P18797; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JACKSON IMD, 1982, NEW ENGL J MED, V306, P145, DOI 10.1056/NEJM198201213060305; KAJI H, 1993, NEUROSCI LETT, V151, P81, DOI 10.1016/0304-3940(93)90051-L; KIMURA N, 1994, ENDOCRINOLOGY, V134, P432, DOI 10.1210/en.134.1.432; LECHAN RM, 1982, ENDOCRINOLOGY, V111, P55, DOI 10.1210/endo-111-1-55; LOTTI VJ, 1986, NEUROSCI LETT, V64, P173, DOI 10.1016/0304-3940(86)90095-9; MANTYH PW, 1985, J NEUROSCI, V5, P551; MONDEN T, 1995, J MOL ENDOCRINOL, V15, P73, DOI 10.1677/jme.0.0150073; MORLEY JE, 1979, LIFE SCI, V25, P1539, DOI 10.1016/0024-3205(79)90435-1; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; SCHOMBURG L, 1995, ENDOCRINOLOGY, V136, P3480, DOI 10.1210/en.136.8.3480; SEARLES RP, 1995, J BIOL CHEM, V270, P157, DOI 10.1074/jbc.270.1.157; SELLAR RE, 1993, J MOL ENDOCRINOL, V10, P199, DOI 10.1677/jme.0.0100199; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; WANG HY, 1992, MOL ENDOCRINOL, V6, P320, DOI 10.1210/me.6.3.320; WU W, 1992, NEUROSCI LETT, V142, P143, DOI 10.1016/0304-3940(92)90359-F; YAMADA M, 1993, BIOCHEM BIOPH RES CO, V195, P737, DOI 10.1006/bbrc.1993.2107; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551; YAMADA M, 1992, BIOCHEM BIOPH RES CO, V184, P367, DOI 10.1016/0006-291X(92)91202-2; YANG JP, 1993, ENDOCRINOLOGY, V133, P487, DOI 10.1210/en.133.2.487; YANG JP, 1993, MOL ENDOCRINOL, V7, P753, DOI 10.1210/me.7.6.753; ZHAO DY, 1992, ENDOCRINOLOGY, V130, P3529, DOI 10.1210/en.130.6.3529	43	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22183	22188		10.1074/jbc.271.36.22183	http://dx.doi.org/10.1074/jbc.271.36.22183			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703031	hybrid			2022-12-25	WOS:A1996VF61200073
J	Yue, CC; MullerGreven, J; Dailey, P; Lozanski, G; Anderson, V; Macintyre, S				Yue, CC; MullerGreven, J; Dailey, P; Lozanski, G; Anderson, V; Macintyre, S			Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; BETA-GLUCURONIDASE; ACTIVE-SITE; ESTERASE; SEQUENCE; EGASYN; COMPARTMENTALIZATION; ACETYLCHOLINESTERASE; INVOLVEMENT; EXPRESSION	C-reactive protein (CRP) is normally synthesized by hepatocytes at relatively low rates and is retained within the endoplasmic reticulum (ER) via interaction with two carboxylesterases (termed gp60a and gp60b), which themselves are restricted to the ER by their COOH-terminal retention signals (HIEL and HTEL), During the acute phase response, an increase in CRP synthesis is accompanied by a decrease in its ER retention as a result of a decrease in the CRP binding affinity of gp60b, Our previous data indicated that the esterase active site, the CRP binding site, and the ER retention signal are functionally distinct. In the present studies, we have identified CRP-binding peptides produced by proteolytic cleavage of gp60a. The sequence shared by two CRP-binding peptides indicated that the CRP binding site of gp60a is contained within residues 477-499, These results were confirmed by expression of cDNAs coding for gp60a and b as bacterial fusion proteins. Fusion proteins containing the complete esterase COOH terminus bound CRP, whereas those truncated at residue 477 (or the homologous site in gp60b) did not, Based on the known crystal structures of three homologous hydrolases, the putative CRP-binding site of the gp60s is located on the surface and is physically distant from the esterase active site and the COOP-terminal ER retention signal.	CASE WESTERN RESERVE UNIV, METROHLTH MED CTR, DEPT MED, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University			Anderson, Vernon/W-2673-2019		NIAMS NIH HHS [AR34313] Funding Source: Medline; NIA NIH HHS [AG2467] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034313, R23AR034313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002467] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CYGLER M, 1993, PROTEIN SCI, V2, P366; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; DUCLOS TW, 1990, J IMMUNOL, V145, P3869; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; JEWELL W, 1993, MOL IMMUNOL, V30; KORZA G, 1988, J BIOL CHEM, V263, P3486; KUSHNER I, 1993, PERSPECT BIOL MED, V36, P611; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LI H, 1990, J BIOL CHEM, V265, P14732; MACINTYRE S, 1994, J BIOL CHEM, V269, P24496; MACINTYRE SS, 1992, J CELL BIOL, V118, P253, DOI 10.1083/jcb.118.2.253; MACINTYRE SS, 1985, J BIOL CHEM, V260, P4169; Maniatis T., 1982, MOL CLONING; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; ZHEN LD, 1993, ARCH BIOCHEM BIOPHYS, V304, P402, DOI 10.1006/abbi.1993.1368	29	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22245	22250		10.1074/jbc.271.36.22245	http://dx.doi.org/10.1074/jbc.271.36.22245			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703040	hybrid			2022-12-25	WOS:A1996VF61200082
J	Aleshkov, SB; Fa, M; Karolin, J; Strandberg, L; Johansson, LBA; Wilczynska, M; Ny, T				Aleshkov, SB; Fa, M; Karolin, J; Strandberg, L; Johansson, LBA; Wilczynska, M; Ny, T			Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1 - The distance between P3 and P1' determined by donor-donor fluorescence energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTITHROMBIN-III; ESCHERICHIA-COLI; ALPHA-1-PROTEINASE INHIBITOR; PROTEOLYTIC INACTIVATION; CONFORMATIONAL-CHANGES; PROTEINASE-INHIBITORS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; LATENT FORMS; CENTER LOOP	Plasminogen activator inhibitor type 1 (PAI-1) is a fast acting inhibitor of plasminogen activators (PAs). In accordance with other serpins, PAI-1 is thought to undergo a conformational change upon reactive center cleavage. In this study we have developed methods to produce and purify reactive center cleaved wild-type PAI-1 and characterized this molecular form of PAI-1 by biochemical and biophysical methods. Incubation with Sepharose-bound trypsin caused cleavage only at the P1-P1' bond in the reactive center and resulted in 39- and 4-kDa polypeptides, strongly held together by noncovalent interactions. Circular dichroism measurements suggest that the reactive center cleavage triggers larger conformational changes than the conversion from the active to the latent form. Cleaved PAI-1 did not bind to either PAs or vitronectin but retained the heparin-binding capacity. To study the structure of cleaved PAI-1 by polarized fluorescence spectroscopy and to measure intramolecular distances, we used cysteine substitution mutants to which extrinsic fluorescence probes were attached. These studies revealed increasing orientational freedom of probes in the P3 and P1' positions upon cleavage. Distance measurements based on fluorescence energy transfer between probes in positions P3 and P1' indicate that these residues are separated by at least 68 +/- 10 Angstrom in cleaved PAI-1.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT PHYS CHEM,S-90187 UMEA,SWEDEN	Umea University; Umea University								AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DWIVEDI AM, 1991, BIOCHEM BIOPH RES CO, V175, P437, DOI 10.1016/0006-291X(91)91583-X; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Johansson LBA, 1996, J CHEM SOC FARADAY T, V92, P1563, DOI 10.1039/ft9969201563; KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042; KEILDLOUHA V, 1971, FEBS LETT, V16, P287, DOI 10.1016/0014-5793(71)80372-1; KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOBERMANN H, 1984, J MOL BIOL, V177, P731; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; Maniatis T., 1982, MOL CLONING; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SANCHO E, 1995, BIOCHEMISTRY-US, V34, P1064, DOI 10.1021/bi00003a042; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SEETHARAM R, 1992, BIOCHEMISTRY-US, V31, P9877, DOI 10.1021/bi00156a004; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STRANDBERG L, 1991, J BIOL CHEM, V266, P13852; STRANDBERG L, 1994, THROMB RES, V76, P253, DOI 10.1016/0049-3848(94)90197-X; TRISLER P, 1984, J BACTERIOL, V160, P184, DOI 10.1128/JB.160.1.184-191.1984; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	56	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21231	21238		10.1074/jbc.271.35.21231	http://dx.doi.org/10.1074/jbc.271.35.21231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702896	hybrid			2022-12-25	WOS:A1996VE47700042
J	Gliubich, F; Gazerro, M; Zanotti, G; Delbono, S; Bombieri, G; Berni, R				Gliubich, F; Gazerro, M; Zanotti, G; Delbono, S; Bombieri, G; Berni, R			Active site structural features for chemically modified forms of rhodanese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; CATALYSIS; CLONING; FLUORESCENCE; CYSTEINE-254; REFINEMENT; EXPRESSION; SEQUENCE; COVALENT; ENZYME	In the course of the reaction catalyzed by rhodanese, the enzyme cycles between two catalytic intermediates, the sulfur-free and the sulfur-substituted (persulfide-containing) forms. The crystal structure of sulfur-free rhodanese, which was prepared in solution and then crystallized, is highly similar to that of sulfur-substituted enzyme. The inactivation of sulfur-free rhodanese with a small molar excess of hydrogen peroxide relies essentially on a modification limited to the active site, consisting of the oxidation of the essential sulfhydryl to sulfenyl group (-S-OH). Upon reaction of the sulfur-free enzyme with monoiodoacetate in the crystal, the Cys-247 side chain with the bound carboxymethyl group is forced into a conformation that allows favorable interactions of the carboxylate with the four peptide NH groups that participate in hydrogen bonding interactions with the transferable sulfur atom of the persulfide group in the sulfur-substituted rhodanese. It is concluded that active site-specific chemical modifications of sulfur-free rhodanese do not lead to significant changes of the protein structure, consistent with a high degree of similarity of the structures of the sulfur-free and sulfur-substituted forms of the enzyme both in solution and iu the crystal.	UNIV PADUA,DIPARTIMENTO CHIM ORGAN,I-35131 PADUA,ITALY; CNR,BIOPOLYMER RES CTR,I-35131 PADUA,ITALY; UNIV MILAN,INST PHARMACEUT CHEM,I-20135 MILAN,ITALY; UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Parma				Berni, Rodolfo/0000-0002-1839-0479; Zanotti, Giuseppe/0000-0002-0945-6501				BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CANNELLA C, 1986, BIOCHEMISTRY-US, V25, P7319, DOI 10.1021/bi00371a012; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; CHOW SF, 1985, J BIOL CHEM, V260, P2763; DOOLEY TP, 1995, BIOCHEM BIOPH RES CO, V216, P1101, DOI 10.1006/bbrc.1995.2734; DRENTH J, 1971, BIOCHEM BIOPH RES CO, V45, P1320, DOI 10.1016/0006-291X(71)90163-X; FINAZZIAGRO A, 1972, EUR J BIOCHEM, V28, P89, DOI 10.1111/j.1432-1033.1972.tb01887.x; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ P, 1970, J BIOL CHEM, V245, P984; HOROWITZ P, 1983, BIOCHIM BIOPHYS ACTA, V747, P37, DOI 10.1016/0167-4838(83)90118-8; HOROWITZ P, 1982, BIOCHIM BIOPHYS ACTA, V702, P173, DOI 10.1016/0167-4838(82)90499-X; HOROWITZ PM, 1980, BIOCHEM BIOPH RES CO, V94, P419, DOI 10.1016/0006-291X(80)91247-4; ISLAM TA, 1994, J BIOL CHEM, V269, P7908; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHANSKI RA, 1990, J PROTEIN CHEM, V9, P369, DOI 10.1007/BF01024612; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUO GX, 1994, J BIOL CHEM, V269, P8220; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P12414; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P3423; PALLINI R, 1991, BIOCHEM BIOPH RES CO, V180, P887, DOI 10.1016/S0006-291X(05)81148-9; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RUSSELL J, 1978, J BIOL CHEM, V253, P8102; SCHLESINGER P, 1974, J BIOL CHEM, V249, P780; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TORCHINSKY YM, 1981, SULFUR PROTEINS, P48; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLINI M, 1973, J BIOL CHEM, V248, P7392; VOLINI M, 1973, J BIOL CHEM, V248, P7386; WANG SF, 1973, J BIOL CHEM, V248, P7376; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; Westley J., 1977, BIOORG CHEM, V1, P371	36	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21054	21061		10.1074/jbc.271.35.21054	http://dx.doi.org/10.1074/jbc.271.35.21054			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702871	hybrid			2022-12-25	WOS:A1996VE47700017
J	Kawamura, S; Kuwata, O; Yamada, M; Matsuda, S; Hisatomi, O; Tokunaga, F				Kawamura, S; Kuwata, O; Yamada, M; Matsuda, S; Hisatomi, O; Tokunaga, F			Photoreceptor protein s26, a cone homologue of S-modulin in frog retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; CANCER-ASSOCIATED RETINOPATHY; CYCLIC-GMP PHOSPHODIESTERASE; RHODOPSIN PHOSPHORYLATION; RECOVERIN; RODS; CDNA; FAMILY; IDENTIFICATION; GENE	A frog retinal protein named s26 is a 26-kDa protein found during purification of S-modulin in frog retina (Kawamura, S. (1992) Photochem. Photobiol. 56, 1173-1180). To identify its role in frog retina, first s26 was purified to nearly homogeneity with three chromatographical steps, Based on the partial amino acid sequences of the proteolysed fragments of s26, we isolated cDNAs that encode s26. The analysis of its amino acid sequence revealed that s26 is an S-modulin-like protein, while it shows higher homology to visinin. Visinin is a Ca2+-binding protein reported to be present in chicken cones, but its localization in the retina had been a subject in dispute, The present study showed that s26 is present in cone photoreceptors, The study also showed that s26 inhibits phosphorylation of rhodopsin after a light flash at high Ca2+ concentrations as S-modulin does. From these results, we concluded that s26 is a cone homologue of S-modulin, The result is consistent with the idea that each type of photoreceptors expresses each cell-type specific version of phototransduction proteins.	OSAKA UNIV,DEPT EARTH & SPACE SCI,GRAD SCH SCI,TOYONAKA,OSAKA 560,JAPAN; KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINJUKU KU,TOKYO 160,JAPAN	Osaka University; Keio University	Kawamura, S (corresponding author), OSAKA UNIV,DEPT BIOL,GRAD SCH SCI,MACHIKANE YAMA 1-1,TOYONAKA,OSAKA 560,JAPAN.		Kuwata, Osamu/I-3218-2016; Matsuda, Shinji/GRR-5226-2022; Matsuda, Shinji/L-4727-2013	Kuwata, Osamu/0000-0002-5226-9250; 				BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Fein A., 1982, PHOTORECEPTORS THEIR, P33; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HISATOMI O, 1991, BIOCHEM BIOPH RES CO, V174, P1125, DOI 10.1016/0006-291X(91)91537-M; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1992, PHOTOCHEM PHOTOBIOL, V56, P1173, DOI 10.1111/j.1751-1097.1992.tb09742.x; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KAWAMURA S, 1994, NEUROSCI RES, V20, P293, DOI 10.1016/0168-0102(94)90050-7; Kawamura Satoru, 1995, P105; Kimura MA, 1985, NEUTRAL THEORY MOL E; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAGNADO L, 1992, NEURON, V8, P955; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1968, VISION RES, V8, P761, DOI 10.1016/0042-6989(68)90128-4; Maniatis T., 1982, MOL CLONING; MCGINNIS JF, 1992, FEBS LETT, V302, P172, DOI 10.1016/0014-5793(92)80433-H; MILAM AH, 1993, VISUAL NEUROSCI, V10, P1, DOI 10.1017/S0952523800003175; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; NILSSON SEG, 1964, J ULTRA MOL STRUCT R, V10, P390, DOI 10.1016/S0022-5320(64)80018-6; NIR I, 1992, J HISTOCHEM CYTOCHEM, V40, P343, DOI 10.1177/40.3.1372630; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; POLANS AS, 1993, INVEST OPHTH VIS SCI, V34, P81; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; POLANS AS, 1993, METH NEUROSCI, V15, P248; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANADA K, 1995, J BIOL CHEM, V270, P15459, DOI 10.1074/jbc.270.26.15459; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKAMATSU K, 1994, BIOCHEM BIOPH RES CO, V200, P606, DOI 10.1006/bbrc.1994.1491; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; YAMAGATA K, 1990, NEURON, V2, P469	44	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21359	21364		10.1074/jbc.271.35.21359	http://dx.doi.org/10.1074/jbc.271.35.21359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702916	hybrid			2022-12-25	WOS:A1996VE47700062
J	Kimura, K; Nozaki, N; Enomoto, T; Tanaka, M; Kikuchi, A				Kimura, K; Nozaki, N; Enomoto, T; Tanaka, M; Kikuchi, A			Analysis of M phase-specific phosphorylation of DNA topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CYCLE-DEPENDENT PHOSPHORYLATION; C-TERMINAL DOMAIN; MITOTIC CHROMOSOMES; FISSION YEAST; EGG EXTRACTS; GROWTH-STATE; FORMS; CELLS; CONDENSATION	In mammalian cells, two isoforms of DNA topoisomerase II (topo II), topo II alpha and topo II beta, are phosphorylated, The phosphorylation of topo II beta changes its apparent molecular mass determined by SDS-polyacrylamide gel electrophoresis from 180 to 190 kDa in mitotic cells, whereas topo II alpha affects it only slightly (Kimura, K,, Nozaki, N,, Saijo, M,, Kikuchi, A., Ui, M,, and Enomoto, T. (1994) J, Biol, Chem, 269, 24523-24526), Here we examined the stability of the protein and the phosphate moiety of each topo II isoform, as the cells progressed from M to G(1) phase, While its protein moiety remained intact, 75% of the phosphates attached to topo II beta were removed within 4 h after release from mitotic block, On the other hand, 35% of topo II alpha protein and 52% of the attached phosphates disappeared, We verified that M phase-specific phosphorylation had no particular effect on the catalytic activities of both topo II isoforms after extensive phosphatase digestion, We also examined the binding of two isoforms to the nucleus or chromosomes, In logarithmically growing cells, both isoforms were extracted from nuclei at the same concentrations of NaCl, From the mitotic chromosomes, topo II beta was extracted at much lower concentrations of NaCl than topo II alpha.	TOHOKU UNIV,DEPT MOL & CELL BIOL,FAC PHARMACEUT SCI,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University	Kimura, K (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; KIMURA K, 1994, J BIOL CHEM, V269, P1173; KIMURA K, 1994, J BIOL CHEM, V269, P24523; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PETROV P, 1993, EXP CELL RES, V204, P73, DOI 10.1006/excr.1993.1010; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAKANO H, 1991, CANCER RES, V51, P3951; TSUTSUI K, 1993, J BIOL CHEM, V268, P19076; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	40	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21439	21445		10.1074/jbc.271.35.21439	http://dx.doi.org/10.1074/jbc.271.35.21439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702926	hybrid			2022-12-25	WOS:A1996VE47700072
J	Rooney, RD; Tuazon, PT; Meek, WE; Carroll, EJ; Hagen, JJ; Gump, EL; Monnig, CA; Lugo, T; Traugh, JA				Rooney, RD; Tuazon, PT; Meek, WE; Carroll, EJ; Hagen, JJ; Gump, EL; Monnig, CA; Lugo, T; Traugh, JA			Cleavage arrest of early frog embryos by the G protein-activated protein kinase PAK I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; XENOPUS-OOCYTES; MAP KINASE; RABBIT RETICULOCYTES; MOLECULAR-CLONING; ONCOGENE PRODUCT; MAMMALIAN-CELLS; PHOSPHORYLATION; MOS; RAS	PAK I is a member of the PAK (p21-activated protein kinase) family and is activated by Cdc42 (Jakobi, R., Chen, C.-J., Tuazon, P. T., and Traugh, J. A. (1996) J. Biol. Chem. 271, 6206-6211). To examine the effects of PAK I on cleavage arrest, subfemtomole amounts of endogenously active (58 kDa) and inactive (60 kDa) PAK I and a tryptic peptide (37 kDa) containing the active catalytic domain were injected into one blastomere of 2-cell frog embryos. Active PAK I resulted in cleavage arrest in the injected blastomere at mitotic metaphase, whereas the uninjected blastomere progressed through mid- to late cleavage. Injection of other protein kinases at similar concentrations had no effect on cleavage. Endogenous PAK I was highly active in frog oocytes, and antibody to PAK I reacted specifically with protein of 58-60 kDa. PAK I protein was decreased at 60 min post-fertilization, with little or no PAK I protein or activity detectable at 80 min post-fertilization or in 2-cell embryos. At the 4-cell stage PAK I protein increased, but the protein kinase was present primarily as an inactive form. Rac2 and Cdc42, but not Rac 1, were identified in oocytes and throughout early embryo development. Thus, PAK I appears to be a potent cytostatic protein kinase involved in maintaining cells in a non-dividing state. PAK I activity is high in oocytes and appears to be regulated by degradation/synthesis and through autophosphorylation via binding of Cdc42. PAK I may act through regulation of the stress-activated protein kinase signaling pathway and/or by direct regulation of multiple metabolic pathways.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT CHEM, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARROLL EJ, 1991, DEV GROWTH DIFFER, V33, P37; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FU XD, 1988, J BIOL CHEM, V263, P2134; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HACCARD O, 1993, MOL REPROD DEV, V36, P96, DOI 10.1002/mrd.1080360114; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hathaway G M, 1979, Methods Enzymol, V60, P495; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEIS J, 1984, J BIOL CHEM, V259, P7726; MALLER JL, 1993, MOL CELL BIOCHEM, V128, P267, DOI 10.1007/BF01076777; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MASUI Y, 1992, BIOCHEM CELL BIOL, V70, P920, DOI 10.1139/o92-138; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROONEY RD, 1992, FASEB J, V6, pA1852; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1984, J BIOL CHEM, V259, P541; TUAZON PT, 1982, EUR J BIOCHEM, V129, P205, DOI 10.1111/j.1432-1033.1982.tb07041.x; VENEMA RC, 1991, J BIOL CHEM, V266, P5298; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; YAN MH, 1994, NATURE, V372, P798; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21498	21504		10.1074/jbc.271.35.21498	http://dx.doi.org/10.1074/jbc.271.35.21498			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702934	hybrid			2022-12-25	WOS:A1996VE47700080
J	Seufferlein, T; Withers, DJ; Rozengurt, E				Seufferlein, T; Withers, DJ; Rozengurt, E			Reduced requirement of mitogen-activated protein kinase (MAPK) activity for entry into the S phase of the cell cycle in Swiss 3T3 fibroblasts stimulated by bombesin and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; GROWTH-FACTORS; TYROSINE PHOSPHORYLATION; IN-VITRO; PATHWAY; RAF; NEUROPEPTIDES; TRANSDUCTION; RECEPTOR; TRANSFORMATION	Bombesin induced a marked and persistent activation of the mitogen-activated protein kinase kinase-1 (MEK-1), p42(mapk) and p90(rsk) in Swiss 3T3 cells by a pathway that was independent of p74(raf-1) but dependent on the activity of protein kinase C. Pretreatment of the cells with a specific inhibitor of MEK-1, PD 098059, markedly reduced the early and abolished the sustained phase of bombesin-induced p42(mapk) activation. In addition, PD 098059 prevented bombesin-induced DNA synthesis and progression of the cells through the cell cycle, indicating that the mitogenic effect of bombesin is dependent on the activation of p42(mapk) However, in the presence of insulin, which neither stimulated p42(mapk) activation nor DNA synthesis on its own in Swiss 3T3 cells, bombesin potently stimulated DNA synthesis even at concentrations of PD 098059 (15 mu m) that completely abolished the mitogenic effect of bombesin alone. Furthermore, Swiss 3T3 cells stably transfected with interfering mutants of MEK-1 showed a marked decrease in the mitogenic effect of bombesin. In contrast, the combination of bombesin and insulin strongly stimulated DNA synthesis in these cells to levels comparable with that obtained in the wild type cells, Thus, our data demonstrate that insulin dramatically reduced the requirement for the mitogen-activated protein kinase pathway for reinitiation of DNA synthesis in bombesin-treated Swiss 3T3 cells and consequently indicate that the contribution of the mitogen-activated protein kinase cascade to mitogenesis depends on the combination of extracellular signals that are used to stimulate these cells.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018; Withers, Dominic J/D-7671-2014	Withers, Dominic J/0000-0002-8009-7521				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; NANBERG E, 1993, J BIOL CHEM, V268, P18187; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SETHI T, 1992, CANCER RES, V52, pS2737; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SOZERI O, 1992, ONCOGENE, V7, P2259; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21471	21477		10.1074/jbc.271.35.21471	http://dx.doi.org/10.1074/jbc.271.35.21471			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702930	hybrid			2022-12-25	WOS:A1996VE47700076
J	Stemmer, C; RichaletSecordel, P; vanBruggen, M; Kramers, K; Berden, J; Muller, S				Stemmer, C; RichaletSecordel, P; vanBruggen, M; Kramers, K; Berden, J; Muller, S			Dual reactivity of several monoclonal anti-nucleosome autoantibodies for double-stranded DNA and a short segment of histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIHISTONE ANTIBODIES; RESTRICTED ANTIBODIES; SYNTHETIC PEPTIDES; BINDING-SITES; PROTEIN; LPR/LPR; MURINE; KIDNEY; IMMUNOGENICITY	We have shown previously that four IgG monoclonal autoantibodies (mAbs) reacted in ELISA with both double-stranded (ds) DNA and peptide 83-100 of histone H3. The peptide 83-100 contains a cysteine residue at position 96 and readily dimerizes at pH 7-8. We describe here that only the 83-100 dimers, and not the 83-100 monomers, are recognized by the four antibodies and inhibit in ELISA the binding of mAbs to dsDNA. The equilibrium affinity constants (K-a) and kinetic rate constants of two of these mAbs were measured in a biosensor system. K-a values were significantly higher when these mAbs were tested with dsDNA as compared with the 83-100 dimer. Further higher K-a values were measured with mononucleosomes containing DNA and histones. It is proposed that these four mAbs are directed against a topographic determinant formed by DNA and the region 83-100 of H3 present as a dimer at the surface of nucleosome, and that they react, although significantly less well, with DNA and peptide dimer tested separately. This study provides a quantitative and kinetic basis to interaction between several antibodies and distinct antigenic structures and allows us to better understand the structural basis of apparent autoantibody cross-reactivity.	INST BIOL MOL & CELLULAIRE, UPR CNRS 9021, F-67000 STRASBOURG, FRANCE; UNIV HOSP, DIV NEPHROL, NL-6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen			Kramers, C./L-4458-2015; Muller, Sylviane/J-5319-2014					AMOURA Z, 1994, ARTHRITIS RHEUM, V37, P1684, DOI 10.1002/art.1780371118; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; ATANASSOV C, 1991, CLIN EXP IMMUNOL, V86, P124; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; BRINKMAN K, 1989, RES IMMUNOL, V140, P595, DOI 10.1016/0923-2494(89)90104-1; CHABRE H, 1995, ARTHRITIS RHEUM, V38, P1485, DOI 10.1002/art.1780381015; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DIVALERIO R, 1995, J IMMUNOL, V155, P2258; ELOUAAI F, 1994, NEPHROL DIAL TRANSPL, V9, P362; FERRARI N, 1987, CELL BIOPHYS, V10, P1; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; KARLSSON R, 1993, J IMMUNOL METHODS, V166, P75, DOI 10.1016/0022-1759(93)90330-A; KOREN E, 1995, J IMMUNOL, V154, P4857; KRAMERS C, 1994, J CLIN INVEST, V94, P568, DOI 10.1172/JCI117371; KRAMERS C, 1995, J AM SOC NEPHROL, V6, P425; LOSMAN JA, 1993, ARTHRITIS RHEUM-US, V36, P552, DOI 10.1002/art.1780360417; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MOHAN C, 1995, CLIN IMMUNOL IMMUNOP, V77, P209, DOI 10.1006/clin.1995.1146; MONESTIER M, 1990, J IMMUNOL METHODS, V127, P289, DOI 10.1016/0022-1759(90)90081-6; MULLER S, 1991, MOL IMMUNOL, V28, P763, DOI 10.1016/0161-5890(91)90119-5; NILSSON P, 1995, ANAL BIOCHEM, V224, P400, DOI 10.1006/abio.1995.1057; PASQUALI JL, 1988, EUR J IMMUNOL, V18, P1127, DOI 10.1002/eji.1830180724; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RAZ E, 1989, J IMMUNOL, V142, P3076; SAUNAL H, 1996, IMMUNOCHEMISTRY, V2; SCHMIEDEKE T, 1992, CLIN EXP IMMUNOL, V90, P453; SMEENK RJT, 1988, J IMMUNOL, V140, P3786; STEMMER C, 1995, CLIN IMMUNOL IMMUNOP, V76, P82, DOI 10.1006/clin.1995.1091; STOCKL F, 1994, CLIN NEPHROL, V41, P10; SUBIZA JL, 1989, ARTHRITIS RHEUM, V32, P406, DOI 10.1002/anr.1780320409; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAX WJM, 1995, KIDNEY INT, V48, P666, DOI 10.1038/ki.1995.336; TUAILLON N, 1992, J AUTOIMMUN, V5, P1, DOI 10.1016/S0896-8411(05)80047-2; WING MG, 1995, CLIN EXP IMMUNOL, V99, P313, DOI 10.1111/j.1365-2249.1995.tb05551.x; ZACK DJ, 1995, J IMMUNOL, V154, P1987	39	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21257	21261		10.1074/jbc.271.35.21257	http://dx.doi.org/10.1074/jbc.271.35.21257			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702900	Green Published			2022-12-25	WOS:A1996VE47700046
J	Xu, L; Murphy, J; Otero, AD				Xu, L; Murphy, J; Otero, AD			Participation of nucleoside-diphosphate kinase in muscarinic K+ channel activation does not involve GTP formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; GUANINE-NUCLEOTIDES; ATRIAL CELLS; GUINEA-PIG; MEMBRANE; BINDING; PHOSPHORYLATION; MECHANISM; AGONIST; COMPLEX	Agonist-bound muscarinic receptors open atrial K+ channels through a GTP-dependent pathway mediated by the G protein G(k). However, nucleotides other than GTP are also able to support channel activity, even in the absence of agonists. This process was proposed to be mediated by nucleoside-diphosphate (NDP) kinase, which would transfer phosphate from nucleotide triphosphates to the GDP bound to G(k), producing G(k)-GTP without the need for receptor-induced GDP-GTP exchange. We examined the effect of antibodies to NDP kinase on the ATP-supported activity of atrial muscarinic K+ channels and the corresponding GIRK1/CIR. channels expressed in HEK 293 cells. Inhibitory antibodies reduced ATP-induced channel openings, but this effect displayed an absolute requirement for agonist and was also seen with antibodies that do not inhibit the enzyme. Both types of antibodies also reduced agonist-dependent channel activity in the presence of GTP, ruling out a role for NDP kinase in GDP rephosphorylation. Channel activity was not affected by the antibodies in preparations where ATP-induced muscarinic channels are not under tight receptor control, namely pertussis toxin-treated atrial patches and membranes from cells expressing K-ACh channel subunits. Thus, participation of NDP kinase in this pathway requires activated receptors and has a function distinct from phosphate transfer between nucleotides.	UNIV VIRGINIA, SCH MED, DEPT MOL PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22908 USA	University of Virginia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048726] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48726] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; HARNILL OP, 1981, PFLUGERS ARCH, V391, P85; HEIDBUCHEL H, 1992, CIRC RES, V71, P808, DOI 10.1161/01.RES.71.4.808; HEIDBUCHEL H, 1990, PFLUG ARCH EUR J PHY, V416, P213, DOI 10.1007/BF00370246; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; KAIBARA M, 1991, J PHYSIOL-LONDON, V433, P589, DOI 10.1113/jphysiol.1991.sp018445; Khromov A, 1995, BIOPHYS J, V69, P2611, DOI 10.1016/S0006-3495(95)80132-3; KIKKAWA S, 1992, FEBS LETT, V305, P237, DOI 10.1016/0014-5793(92)80676-8; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KIMURA N, 1988, BIOCHEM BIOPH RES CO, V151, P248, DOI 10.1016/0006-291X(88)90586-4; KIMURA N, 1993, HDB EXPT PHARM, V108, P485; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KURACHI Y, 1994, TRENDS CARDIOVAS MED, V4, P64, DOI 10.1016/1050-1738(94)90011-6; LACOMBE ML, 1992, TRENDS PHARMACOL SCI, V13, P45; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; NAKAJIMA T, 1992, J GEN PHYSIOL, V99, P665, DOI 10.1085/jgp.99.5.665; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKABEKADO J, 1995, BBA-MOL CELL RES, V1267, P101, DOI 10.1016/0167-4889(95)00037-S; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; OTERO AD, 1993, MOL PHARMACOL, V44, P595; OTERO AS, 1988, SCIENCE, V242, P443, DOI 10.1126/science.3051383; OTERO AS, 1988, J MEMBRANE BIOL, V104, P253, DOI 10.1007/BF01872327; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; PHILIPSON LH, 1995, J BIOL CHEM, V270, P14604, DOI 10.1074/jbc.270.24.14604; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROBISHAW JD, 1989, ANNU REV PHYSIOL, V51, P229, DOI 10.1146/annurev.ph.51.030189.001305; RODBELL M, 1971, J BIOL CHEM, V246, P1877; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SZABO G, 1990, ANNU REV PHYSIOL, V52, P293; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Yi XB, 1996, BBA-MOL CELL RES, V1310, P334, DOI 10.1016/0167-4889(95)00164-6	39	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21120	21125		10.1074/jbc.271.35.21120	http://dx.doi.org/10.1074/jbc.271.35.21120			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702881	hybrid			2022-12-25	WOS:A1996VE47700027
J	Swartz, DA; Park, EI; Visek, WJ; Kaput, J				Swartz, DA; Park, EI; Visek, WJ; Kaput, J			The e subunit gene of murine F1F0-ATP synthase - Genomic sequence, chromosomal mapping, and diet regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; ATP SYNTHASE; FATTY-ACIDS; IDENTIFICATION; EXPRESSION; F1-ATPASE; LIVER	Genomic sequences encoding murine Lfm1, whose predicted protein sequence is 96% and 98% similar to bovine and rat F1F0-ATP synthase e subunits (respectively), have been amplified from BALB/cByJ DNA, cloned, and sequenced. The 1,1-kilobase gene has 3 introns and 4 exons, and its coding sequence differs by two nucleotides compared to the previously published BALB/cHnn Lfm1 cDNA sequence. A PstI restriction site polymorphism in intron 2 between C57BL/6J and Mus spretus was used to map this gene to Chromosome 5 near D5Mit9. Related sequences mere mapped on Chromosomes 8, 11, and 2 unlinked loci on Chromosome 2 using Southern blot analyses with the 1.1-kilobase gene as probe. Previous studies from this laboratory indicated that the Lfm1/e subunit was regulated by the level of dietary fat and carbohydrate. Northern hybridization analyses demonstrated that e subunit mRNA abundance showed statistically significant differences (p < 0.025) between hearts of BALB/c mice fed 3% and those fed 20% corn oil for 2 weeks and in liver (p < 0.05) from the same animals. Significant differences were also observed in hepatic and heart mRNA expression at different times after eating in animals subjected to a fast/refeed regimen. The implications of the high degree of sequence similarity to the e subunit for rat and bovine F1F0-ATP synthase and its regulation by diet are discussed.	UNIV ILLINOIS, COLL MED, DIV NUTR, DEPT INTERNAL MED, URBANA, IL 61801 USA; SAPIENTS INST, DEPT INTERNAL MED, MOL GENET NUTR PROGRAM, DALLAS, TX 75209 USA	University of Illinois System; University of Illinois Urbana-Champaign			Kaput, Jim/GSD-5978-2022; Kaput, Jim/AAJ-1386-2020					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AUWERX J, 1992, HORM RES, V38, P269, DOI 10.1159/000182557; Bieri JG., 1980, J NUTR, V110, P1726, DOI [10.1093/jn/110.8.1726, DOI 10.1093/JN/110.8.1726]; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; ELLIOTT TS, 1993, BIOCHEM BIOPH RES CO, V190, P167, DOI 10.1006/bbrc.1993.1026; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; HIGUTI T, 1992, BIOCHEMISTRY-US, V31, P12451, DOI 10.1021/bi00164a022; *JACKS LAB, 1996, BSS BSB BACKCR DAT B; JUMP DB, 1994, J LIPID RES, V35, P1076; KAPUT J, 1994, J NUTR, V124, pS1296, DOI 10.1093/jn/124.suppl_8.1296S; KOELLER DM, 1995, GENOMICS, V28, P508, DOI 10.1006/geno.1995.1182; LEBOEUF RC, 1994, J LIPID RES, V35, P121; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PILZ A, 1992, MAMM GENOME, V3, P633, DOI 10.1007/BF00352480; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; *SAS I INC, 1987, SAS STAT GUID PERS C, P549; SHIS H, 1994, J BIOL CHEM, V269, P9380; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7	26	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20942	20948		10.1074/jbc.271.34.20942	http://dx.doi.org/10.1074/jbc.271.34.20942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702853				2022-12-25	WOS:A1996VD33700105
J	Amundadottir, LT; Nass, SJ; Berchem, GJ; Johnson, MD; Dickson, RB				Amundadottir, LT; Nass, SJ; Berchem, GJ; Johnson, MD; Dickson, RB			Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis	ONCOGENE			English	Article						c-Myc; TGF alpha; apoptosis; mammary tumorigenesis	HUMAN-BREAST-CANCER; PROGRAMMED CELL-DEATH; DNA STRAND BREAKS; TRANSGENIC MICE; EPITHELIAL-CELLS; FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; MEDIATED APOPTOSIS; FACTOR RECEPTOR; LEUKEMIA-CELLS	We have previously shown that TGF alpha and c-Myc interact in a strong, synergistic fashion to induce mammary gland tumors in double transgenic mice. Here we show this interaction can be explained, at least in part, by a cooperative growth stimulus by the two proteins, and by TGF alpha-mediated inhibition of c-Myc-induced apoptosis, We initially compared rapidly progressing mammary tumors from double transgenic mice to long latency tumors from single transgenic mice and observed a striking difference in the occurrence of apoptosis among the three groups, Tumors exhibiting apoptosis were derived exclusively from mice that expressed the c-myc transgene in the absence of the TGF alpha transgene, indicating that TGF alpha might protect c-Myc-overexpressing cells from programmed cell death, Cell lines were derived from single and double transgenic mammary tumors to examine further the mechanism underlying the cooperative interaction between the two gene products, In accordance with our in vivo data, apoptosis was only detected when the c-myc transgene was expressed without the TGF alpha transgene, Furthermore, exogenous addition of TGF alpha inhibited apoptosis in cells overexpressing c-Myc alone, In addition, tumor-derived cells that overexpressed both TGF alpha and c-Myc exhibited faster growth rates in vitro and in vivo and were less sensitive to the inhibitory effects of TGF beta in vitro compared to cell lines expressing only one of the transgenes, Based on our findings we propose that TGF alpha acts both as a proliferative and a survival factor for c-Myc-expressing tumor cells, Our results indicate that TGF alpha and c-Myc cooperate in tumorigenesis via a dual mechanism: TGF alpha can inhibit c-Myc-induced apoptosis and both proteins provide a growth stimulus.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT CELL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DIV HEMATOL ONCOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University; Georgetown University			Berchem, Guy/C-9364-2014; Amundadottir, Laufey T/L-7656-2016	Berchem, Guy/0000-0003-0157-2257; Amundadottir, Laufey T/0000-0003-1859-8971				AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; ARTEAGA CL, 1988, CANCER RES, V48, P5023; ASKEW DS, 1991, ONCOGENE, V6, P1915; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; CATCHPOOLE DR, 1993, CANCER RES, V53, P4287; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DERYNCK R, 1987, CANCER RES, V47, P707; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GARCIA I, 1989, CANCER RES, V49, P6675; GORSCH SM, 1992, CANCER RES, V52, P6949; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAVRILESKY LJ, 1995, CANCER RES, V55, P944; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KAMESAKI S, 1993, CANCER RES, V53, P4251; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KHAZAIE K, 1991, ONCOGENE, V6, P21; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PERROTEAU I, 1986, BREAST CANCER RES TR, V7, P201, DOI 10.1007/BF01806251; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Sakamuro D, 1995, ONCOGENE, V11, P2411; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SMITH GH, 1995, AM J PATHOL, V147, P1081; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAETLE R, 1993, CANCER RES, V53, P3386; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TRAVERS MT, 1988, BRIT MED J, V296, P1621, DOI 10.1136/bmj.296.6637.1621; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WITKIEWICZ H, 1993, BIOTECHNIQUES, V14, P458; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	65	72	73	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					757	765						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761297				2022-12-25	WOS:A1996VD43300011
J	Hack, V; Gross, A; Kinscherf, R; Bockstette, M; Fiers, W; Berke, G; Droge, W				Hack, V; Gross, A; Kinscherf, R; Bockstette, M; Fiers, W; Berke, G; Droge, W			Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia	FASEB JOURNAL			English	Article						IL-6; cytokines; glutathione, role in cachexia; cysteine catabolism, role in cachexia	AMINO-ACID-CONCENTRATIONS; NECROSIS-FACTOR-ALPHA; CANCER CACHEXIA; METABOLISM; PROTEIN; TRANSPORT; GAMMA; MALNUTRITION; INFLAMMATION; SYNTHETASE	Excessive urea excretion associated with a negative nitrogen balance and massive loss of skeletal muscle mass (cachexia) is a frequent life-threatening complication in malignancies and HIV infection. As these patients have often elevated interleukin-6 (IL-6) and abnormally low cystine levels, we have now determined the intracellular levels of glutathione and other cysteine derivatives in the liver and muscle tissue of IL-6-treated or tumor-bearing C57BL/6 mice, IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis. Treatment with cysteine, conversely, caused an increase in sulfate, gluzamine/urea ratios, and glutamine/glutamate ratios and may thus be a useful therapeutic tool in clinical medicine, In contrast to the liver, muscle tissue of tumor-bearing mice showed decreased glutathione and increased sulfate levels, suggesting that the cysteine pool may be drained by an increased cysteine catabolism in this tissue, The findings indicate that tumor cachexia is triggered initially by IL-6 and is later sustained by processes driven by an abnormal cysteine metabolism in different organs.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV IMMUNOCHEM,D-69120 HEIDELBERG,GERMANY; STATE UNIV GHENT,MOL BIOL LAB,B-9000 GHENT,BELGIUM; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Helmholtz Association; German Cancer Research Center (DKFZ); Ghent University; Weizmann Institute of Science			Kinscherf, Ralf/AAV-7164-2021					AUDUS T, 1987, FEBS LETT, V221, P18; BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BRENNAN MF, 1977, CANCER RES, V37, P2359; BRENNAN MF, 1986, DIGEST DIS SCI, V31, pS77, DOI 10.1007/BF01295991; BROUCKAERT P, 1989, J EXP MED, V169, P2257, DOI 10.1084/jem.169.6.2257; BURT ME, 1983, ANN SURG, V198, P685, DOI 10.1097/00000658-198312000-00003; CAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CRUNFELD C, 1991, GASTROINTESTINAL NUT, P207; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1988, J CANCER RES CLIN, V114, P124, DOI 10.1007/BF00417824; ECK HP, 1989, J CANCER RES CLIN, V115, P571, DOI 10.1007/BF00391360; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; FEIN R, 1985, CANCER, V56, P2512, DOI 10.1002/1097-0142(19851115)56:10<2512::AID-CNCR2820561032>3.0.CO;2-9; FOX BA, 1990, J BIOL RESP MODIF, V9, P499; FRIEDMAN PJ, 1987, NUTR RES, V7, P707, DOI 10.1016/S0271-5317(87)80101-X; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hack V, 1996, J MOL MED-JMM, V74, P337, DOI 10.1007/BF00207511; HAMETT WL, 1952, SURVEY CANC LONDON; HAUSSINGER D, 1985, EUR J BIOCHEM, V152, P381, DOI 10.1111/j.1432-1033.1985.tb09208.x; HEIM ME, 1980, RECENT ADV CLIN NUTR, V1, P185; HORTIN GL, 1994, CLIN CHEM, V40, P785; HUNTER EAL, 1994, J NUTR, V124, P2319, DOI 10.1093/jn/124.12.2319; JABLONS DM, 1989, J IMMUNOL, V142, P1542; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; OLDENBURG HSA, 1993, EUR J IMMUNOL, V23, P1889, DOI 10.1002/eji.1830230824; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PISTERS PWT, 1993, CRIT REV CL LAB SCI, V30, P223, DOI 10.3109/10408369309084669; PLAITAKIS A, 1987, ANN NEUROL, V22, P575, DOI 10.1002/ana.410220503; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROTH E, 1985, SURGERY, V97, P436; SHAW JHF, 1987, SURGERY, V101, P181; SHERRY BA, 1989, FASEB J, V3, P1956, DOI 10.1096/fasebj.3.8.2721856; SHI MM, 1994, J BIOL CHEM, V269, P26512; SIEGEL JH, 1979, SURGERY, V86, P163; STRAIN AJ, 1979, INVEST CELL PATHOL, V2, P181; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; STRIEBEL JP, 1986, INFUSIONSTHERAPIE, V13, P92; SVANINGER G, 1987, J NATL CANCER I, V78, P913; TALGREN LC, 1980, ACTA MED SCAND S, V640, P1; TAYEK JA, 1992, J AM COLL NUTR, V11, P445; TESSITORE L, 1993, ARCH BIOCHEM BIOPHYS, V306, P52, DOI 10.1006/abbi.1993.1479; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TISDALE MJ, 1991, BRIT J CANCER, V63, P337, DOI 10.1038/bjc.1991.80; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; Warren S, 1932, AM J MED SCI, V184, P610, DOI 10.1097/00000441-193211000-00002; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628; WATERHOUSE C, 1968, CANCER RES, V39, P1968; ZHANG PC, 1992, CLIN CHEM, V38, P1198	53	49	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1219	1226		10.1096/fasebj.10.10.8751725	http://dx.doi.org/10.1096/fasebj.10.10.8751725			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751725				2022-12-25	WOS:A1996VD42900014
J	Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronovo, V				Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronovo, V			Isolation from a multigene family of the active human gene of the metastasis-associated multifunctional protein 37LRP/p40 at chromosome 3p21.3	ONCOGENE			English	Article						37 kD laminin receptor precursor; 3p21.3; Alu sequences; p40 ribosome-associated protein; small nuclear RNA E2 gene	AFFINITY LAMININ RECEPTOR; SMALL NUCLEOLAR RNAS; CELL LUNG-CANCER; RIBOSOMAL-PROTEIN; MESSENGER-RNA; TRANSLATIONAL CONTROL; BINDING-PROTEIN; MAMMALIAN-CELLS; CARCINOMA-CELLS; ALU RNA	The 37 kD precursor of the 67 kD laminin receptor (37LRP) is a polypeptide whose expression is consistently upregulated in aggressive carcinoma. Interestingly, the 37LRP appears to be a multifunctional protein involved in the translational machinery and has also been identified as p40 ribosome-associated protein. Although highly conserved cDNAs corresponding to this polypeptide have been isolated from several species including vertebrates, invertebrates, plants and prokaryotes, characterization of any of the corresponding active genes has never been reported. In this study, we have cloned an intron-containing fragment which permitted us to isolate the active 37LRP/p40 human gene. This gene contains seven exons and six introns. Ribonuclease protection experiments suggest multiple transcription start sites. The promoter area does not bear a TATA box but contains four Sp1 sites. The first intron is also GC rich containing five Sp1 sites. Intron 4 contains the full sequence of the small nuclear RNA E2 and two Alu sequences are found in intron 3. Fluorescent in situ hybridization localized the 37LRP/p40 active gene on chromosome 3 in the locus 3p21.3 which, interestingly, is a hot spot for genetic alterations in several cancers and particularly in small cell lung carcinoma.	IST TUMORI,MILAN,ITALY; NCI,MOL PATHOL SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Belotti, Dorina/AAA-8077-2020; sozzi, gabriella/G-8259-2011	Belotti, Dorina/0000-0002-3868-9144; sozzi, gabriella/0000-0001-9360-6914				ANTOINE M, 1992, HUM MOL GENET, V1, P565, DOI 10.1093/hmg/1.8.565; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; AXELOS M, 1993, PLANT PHYSIOL, V103, P299, DOI 10.1104/pp.103.1.299; BIGNON C, 1991, GENOMICS, V10, P481, DOI 10.1016/0888-7543(91)90336-D; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; CARRITT B, 1992, CANCER RES, V52, P1536; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CASTRONOVO V, 1989, J NATL CANCER I, V81, P781, DOI 10.1093/jnci/81.10.781; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CHEN LC, 1994, CANCER RES, V54, P3021; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIES B, 1993, GENOMICS, V15, P68, DOI 10.1006/geno.1993.1011; DAVIS SC, 1992, J BIOL CHEM, V267, P5508; DEFALCO S, 1993, GENE, V126, P227, DOI 10.1016/0378-1119(93)90371-9; ELLIS S, 1994, FASEB J, V8, pA1312; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; FAUTSCH MP, 1991, J BIOL CHEM, V266, P23288; FERNANDEZ MT, 1991, BIOCHEM BIOPH RES CO, V175, P84, DOI 10.1016/S0006-291X(05)81203-3; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HEPPELLPARTON AC, 1992, GENE CHROMOSOME CANC, V4, P228, DOI 10.1002/gcc.2870040307; HERNNDEZ MG, 1994, J BIOL CHEM, V269, P20744; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; JACKERS P, 1996, IN PRESS BIOCH BIOPH; KEPPEL E, 1991, J CELL SCI, V100, P789; KROMER WJ, 1991, J BIOL CHEM, V266, P24573; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LOPEZRIBOT JL, 1994, INFECT IMMUN, V62, P742; LUBINSKI J, 1994, CANCER RES, V54, P3710; MAKRIDES S, 1988, NUCLEIC ACIDS RES, V16, P2349, DOI 10.1093/nar/16.5.2349; MARAIA RJ, 1993, MOL CELL BIOL, V13, P4233, DOI 10.1128/MCB.13.7.4233; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MIOZZO M, 1990, GENE CHROMOSOME CANC, V2, P163, DOI 10.1002/gcc.2870020213; MOSCOW JA, 1994, CARCINOGENESIS, V15, P2769, DOI 10.1093/carcin/15.12.2769; NAG MK, 1993, P NATL ACAD SCI USA, V90, P9001, DOI 10.1073/pnas.90.19.9001; OUZOUNIS C, 1995, NUCLEIC ACIDS RES, V23, P565, DOI 10.1093/nar/23.4.565; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RABACCHI SA, 1990, DEVELOPMENT, V109, P521; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; ROSENTHAL ET, 1995, J CELL SCI, V108, P245; ROWE SM, 1995, CANCER RES, V55, P2743; RUFF EA, 1993, P NATL ACAD SCI USA, V90, P635, DOI 10.1073/pnas.90.2.635; SHIRAISHI M, 1995, ONCOGENE, V10, P1453; SINNETT D, 1992, J MOL BIOL, V226, P689, DOI 10.1016/0022-2836(92)90626-U; SIYANOVA EY, 1991, DOKL AKAD NAUK SSSR, V313, P227; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TOHGO A, 1994, FEBS LETT, V340, P133, DOI 10.1016/0014-5793(94)80188-6; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P3829, DOI 10.1093/nar/17.10.3829; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; WESTENDORF J M, 1990, Journal of Cell Biology, V111, p93A; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; ZINN AR, 1994, MOL CELL BIOL, V14, P2485, DOI 10.1128/MCB.14.4.2485	60	51	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					495	503						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760291				2022-12-25	WOS:A1996VB32800007
J	Grammer, TC; Blenis, J				Grammer, TC; Blenis, J			The serine protease inhibitors, tosylphenylalanine chloromethyl ketone and tosyllysine chloromethyl ketone, potently inhibit pp70(s6k) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; P70 S6 KINASE; INDUCED PHOSPHORYLATION; RAPAMYCIN; DISSOCIATION; SUFFICIENT; SIGNAL	pp70(s6k) is a mitogen-regulated serine/threonine kinase involved in the G(1) to S phase transition of the cell cycle. We have analyzed its regulation in several cell lines by a variety of agonists and have found that pp70(s6k) activation by all. stimuli tested is completely blocked by the serine protease inhibitors tosylphenylalanine chloromethyl ketone (TPCK) and tosyllysine chloromethyl ketone (TLCK). TPCK inhibition of the pp70(s6k) signaling pathway resembles that of the immunosuppressant rapamycin; however, we demonstrate that their methods of inhibition differ. We find that TPCK and TLCK are not general signaling inhibitors since the activation of the mitogen-activated protein kinase pathway is not abrogated. The demonstration that these protease inhibitors prevent signaling via the pp70(s6k) pathway will help in understanding the variety of physiological processes that TPCK and TLCK have been shown to effect.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; BARNA JB, 1995, INFLAMMATION, V19, P561, DOI 10.1007/BF01539136; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUMONT FJ, 1994, J IMMUNOL, V152, P992; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GRISCAVAGE JM, 1995, BIOCHEM BIOPH RES CO, V215, P721, DOI 10.1006/bbrc.1995.2523; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Rodriguez J, 1996, LIFE SCI, V58, P607, DOI 10.1016/0024-3205(95)02330-5; Yoshida A, 1996, LEUKEMIA, V10, P821	16	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23650	23652		10.1074/jbc.271.39.23650	http://dx.doi.org/10.1074/jbc.271.39.23650			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798584				2022-12-25	WOS:A1996VJ44200013
J	McArdle, CA; Willars, GB; Fowkes, RC; Nahorski, SR; Davidson, JS; ForrestOwen, W				McArdle, CA; Willars, GB; Fowkes, RC; Nahorski, SR; Davidson, JS; ForrestOwen, W			Desensitization of gonadotropin-releasing hormone action in alpha T3-1 cells due to uncoupling of inositol 1,4,5-trisphosphate generation and Ca2+ mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH-SY5Y NEUROBLASTOMA-CELLS; ANTERIOR-PITUITARY CELLS; PROTEIN KINASE-C; RAPID DESENSITIZATION; RECEPTOR; GNRH; SIGNAL; CA-2+; INTERNALIZATION; REFRACTORINESS	Gonadotropin-releasing hormone (GnRH) acts via a G-protein coupled receptor on gonadotropes to increase cytosolic Ca2+ and stimulate gonadotropin secretion, Sustained exposure causes desensitization of these effects, but the GnRH receptor has no C-terminal tail and does not undergo rapid (<5 min) desensitization. Nevertheless, pretreatment of alpha T3-1 cells with GnRH reduced the spike Ca2+ response to GnRH and decreased the GnRH effect on inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) by 30-50%. Ca2+-free medium with or without thapsigargin also decreased GnRH-stimulated Ins(1,4,5)P-3 generation, implying that attenuation of the Ca2+ response underlies the Ins(1,4,5)P-3 reduction rather than vice versa. Intracellular Ca2+ pool depletion cannot explain desensitization of the Ca2+ response because pool depletion and repletion were faster (half-times, <1 min) than the onset of and recovery from desensitization (half-times 10-20 min and 4-6 h). Moreover, 1-h GnRH pretreatment attenuated the spike Ca2+ response to GnRH but not that to ionomycin, and brief GnRH exposure in Ca2+-free medium reduced the response to ionomycin more effectively in controls than in desensitized cells, GnRH pretreatment also attenuated the Ca2+ response to PACAP38. This novel form of desensitization does not reflect uncoupling of GnRH receptors from their immediate effector system but rather a reduced efficiency of mobilization by Ins(1,4,5)P-3 of Ca2+ from an intact intracellular pool.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,LEICESTER LE1 9HN,LEICS,ENGLAND; UNIV CAPE TOWN,DEPT CHEM PATHOL,ZA-7925 CAPE TOWN,SOUTH AFRICA	University of Leicester; University of Cape Town	McArdle, CA (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,MARLBOROUGH ST,BRISTOL BS2 8HW,AVON,ENGLAND.		Fowkes, Robert/AAI-4756-2020; Fowkes, Robert/HHT-0664-2022; McArdle, Craig/AAQ-5660-2021	Fowkes, Robert/0000-0002-2222-2056; McArdle, Craig/0000-0003-4836-5351	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKERMAN SN, 1991, ENDOCRINOLOGY, V129, P475, DOI 10.1210/endo-129-1-475; ANDERSON L, 1993, J ENDOCRINOL, V136, P51, DOI 10.1677/joe.0.1360051; BARBIERI RL, 1992, TRENDS ENDOCRIN MET, V3, P30, DOI 10.1016/1043-2760(92)90089-J; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CONN PM, 1991, NEW ENGL J MED, V324, P93; CONN PM, 1995, REPROD ENDOCRINOLOGY, V1, P163; DAVIDSON J, 1991, MOL CELL ENDOCRINOL, V76, P33; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; DEKONING J, 1978, J ENDOCRINOL, V79, P311, DOI 10.1677/joe.0.0790311; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; JINNAH HA, 1986, ENDOCRINOLOGY, V118, P2599, DOI 10.1210/endo-118-6-2599; JINNAH HA, 1985, AM J PHYSIOL, V249, pE619, DOI 10.1152/ajpendo.1985.249.6.E619; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; Knobil E, 1980, Recent Prog Horm Res, V36, P53; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MCARDLE CA, 1988, ENDOCRINOLOGY, V122, P1905, DOI 10.1210/endo-122-5-1905; MCARDLE CA, 1995, ENDOCRINOLOGY, V136, P4864, DOI 10.1210/en.136.11.4864; McArdle CA, 1996, J ENDOCRINOL, V149, P155, DOI 10.1677/joe.0.1490155; MCARDLE CA, 1992, MOL CELL NEUROSCI, V3, P124, DOI 10.1016/1044-7431(92)90016-U; MCARDLE CA, 1992, ENDOCRINOLOGY, V130, P3567, DOI 10.1210/en.130.6.3567; MCARDLE CA, 1987, MOL ENDOCRINOL, V1, P420, DOI 10.1210/mend-1-6-420; MCDONOUGH PM, 1988, BIOCHEM J, V249, P135, DOI 10.1042/bj2490135; MERELLI F, 1992, ENDOCRINOLOGY, V131, P925, DOI 10.1210/en.131.2.925; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P615; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STOJILKOVIC SS, 1989, J BIOL CHEM, V264, P10939; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; WILLARS GB, 1995, MOL PHARMACOL, V47, P509; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	44	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23711	23717		10.1074/jbc.271.39.23711	http://dx.doi.org/10.1074/jbc.271.39.23711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798594	Green Published, hybrid			2022-12-25	WOS:A1996VJ44200023
J	LaPres, JJ; Hudson, LG				LaPres, JJ; Hudson, LG			Identification of a functional determinant of differentiation-dependent expression in the involucrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; TRANSCRIPTION FACTOR; BETA-GALACTOSIDASE; HUMAN KERATINOCYTE; PROMOTER; CELLS; ACTIVATION; EPIDERMIS; ELEMENT; PROLIFERATION	Involucrin is an integral component of the cornified envelope which is a characteristic feature of the differentiated keratinocyte. Involucrin expression is tightly linked to the onset of differentiation and first expressed in the immediate suprabasal layers of the epidermis. We have identified a transcriptional response element within the distal 5'-flanking region of the involucrin gene which contributes to differentiation dependent expression, Deletion of this site impairs differentiation-dependent promoter activity in transient transfection analysis, and conversely, this region imparts differentiation-dependent expression to a heterologous promoter. The identified site bears sequence similarity to several AP2-like response elements identified in keratinocyte-specific genes and binds a protein complex (keratinocyte differentiation factor, KDF-1) which is distinct from AP2 by several criteria. The migration of KDF-1 is distinct from AP2 in electrophoretic mobility shift assays, KDF-1 is antigenically unrelated to AP2 since AP2 specific antibodies do not supershift the KDF-1-DNA complex and KDF-1 is poorly competed by oligonucleotides representing consensus AP2 recognition sequences. In addition, the KDF-1 complex is not detected in nuclear extracts derived from human dermal fibroblasts or an enriched population of basal keratinocytes. These findings provide insights to the underlying basis of differentiation-dependent expression of a keratinocyte specific gene.	NORTHWESTERN UNIV, DEPT MOL PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM08061] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Bernerd Francoise, 1993, Gene Expression, V3, P187; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRENNAN JK, 1975, IN VITRO CELL DEV B, V11, P354, DOI 10.1007/BF02616371; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CARROLL JM, 1992, J CELL SCI, V103, P925; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; HU L, 1994, J BIOL CHEM, V269, P183; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Leigh I.M., 1994, KERATINOCYTE METHODS; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LOTAN R, 1993, J CELL BIOCHEM, P167; LU B, 1994, J BIOL CHEM, V269, P7443; MAGNALDO T, 1993, DNA CELL BIOL, V12, P911, DOI 10.1089/dna.1993.12.911; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; MOSER M, 1995, DEVELOPMENT, V121, P2779; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OFFORD EA, 1993, CARCINOGENESIS, V14, P2447, DOI 10.1093/carcin/14.12.2447; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STAEDEL C, 1994, J INVEST DERMATOL, V102, P768, DOI 10.1111/1523-1747.ep12377673; TAMAI K, 1994, J BIOL CHEM, V269, P493; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKE MS, 1988, AM J PATHOL, V131, P171	39	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23154	23160		10.1074/jbc.271.38.23154	http://dx.doi.org/10.1074/jbc.271.38.23154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798509	hybrid			2022-12-25	WOS:A1996VH76800035
J	Liu, L; Dudler, T; Gelb, MH				Liu, L; Dudler, T; Gelb, MH			Purification of a protein palmitoyltransferase that acts on H-Ras protein and on a C-terminal N-Ras peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ACYLATION; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TUBE FORMATION; SARCOMA-VIRUS; FARNESYL; P21RAS; ACYLTRANSFERASE; PALMITOYLATION; CYSTEINE	Mammalian H-Ras and N-Ras are GTP-binding proteins that must be post-translationally lipidated to function as molecular switches in signal transduction cascades controlling cell growth and differentiation. These proteins contain a C-terminal farnesyl-cysteine cu-methyl ester and palmitoyl groups attached to nearby cysteines. Data is presented showing that rat liver microsomes contain an enzyme that transfers the palmitoyl group from palmitoyl-coenzyme A to cysteine residues of H-Ras protein and of a synthetic peptide having the structure of the C terminus of N-Ras, This protein palmitoyltransferase (PPT) was solubilized from membranes and purified 10,500-fold to apparent homogeneity with an overall yield of 10%. On an SDS gel, PPT appears as two proteins of molecular masses of approximate to 30 and approximate to 33 kDa. If the palmitoylation sites of the N-Ras peptide (the non-farnesylated cysteine) or H-Ras protein (cysteines 181 and 184) are changed to serine, palmitoylation by PPT does not occur. Non-farnesylated H-Ras produced in bacteria as well as in vitro farnesylated bacterial H-Ras are not substrates for PPT nor is the non farnesylated, methylated N-Ras peptide, These results suggest, but do not prove, that farnesylation and possibly C-terminal methylation are prerequisites for Ras palmitoylation, PPT shows a large preference for palmitoyl-coenzyme A over myristoyl-coenzyme as the acyl donor, Values of K-m for palmitoyl-CoA and H-Ras are 4.3 +/- 1.2 and 0.8 +/- 0.3 mu M, respectively. PPT is the first protein palmitoyltransferase to be purified, and the availability of pure enzyme should contribute to our understanding of the function and regulation of Ras palmitoylation in cells.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BERGER M, 1984, J BIOL CHEM, V259, P7245; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BHARADWAJ M, 1995, J NEUROCHEM, V65, P1805; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; GRAND RJA, 1987, ONCOGENE, V1, P305; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KAJRA AK, 1986, METHOD ENZYMOL, V122, P50; KAMIYA Y, 1978, BIOCHEM BIOPH RES CO, V83, P1077, DOI 10.1016/0006-291X(78)91505-X; LIU L, 1994, METHOD ENZYMOL, V250, P189; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; SAKAGAMI Y, 1978, AGR BIOL CHEM TOKYO, V42, P1093, DOI 10.1080/00021369.1978.10863118; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHMIDT MFG, 1989, BIOCHEM SOC T, V17, P859, DOI 10.1042/bst0170859; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	43	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23269	23276		10.1074/jbc.271.38.23269	http://dx.doi.org/10.1074/jbc.271.38.23269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798525	hybrid			2022-12-25	WOS:A1996VH76800051
J	Morrow, JD; Awad, JA; Wu, AP; Zackert, WE; Daniel, VC; Roberts, LJ				Morrow, JD; Awad, JA; Wu, AP; Zackert, WE; Daniel, VC; Roberts, LJ			Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTANOIDS F2-ISOPROSTANES; HUMAN-DISEASE; RAT; NONCYCLOOXYGENASE; PROSTAGLANDINS; MECHANISM; RECEPTORS; SERIES	The isoprostanes (IsoPs) are novel bioactive prostaglandin-like compounds produced in vivo by free radical catalyzed peroxidation of arachidonyl-containing lip ids, Previously, we have identified IsoPs containing F-type and D- and E-type prostane rings that are formed by reduction and rearrangement of IsoP endoperoxide intermediates, respectively, We now explore whether thromboxane B-2 (TxB(2))-like compounds, termed B-2-isothromboxanes (B-2-IsoTxs), are formed by rearrangement of IsoP endoperoxides. Detection of these compounds was carried out using a stable isotope dilution mass spectrometric assay originally developed for quantification of cyclooxygenase-derived TxB(2). Incubations of arachidonic acid with Fe/ADP/ascorbate for 30 min in vitro generated a series of peaks representing putative B-2-IsoTx at levels of 62.4 +/- 21.0 ng/mg arachidonate. Using various chemical modification and derivatization approaches, it was determined that these compounds contained hemiacetal ring structures and two double bonds, as would be expected for B-2-IsoTx. Analysis of the compounds by electron ionization mass spectrometry yielded multiple mass spectra similar to those of TxB(2). B-2-IsoTxs are also formed esterified to phospholipids; oxidation of arachidonyl containing phosphatidylcholine in vitro followed by hydrolysis resulted in the release of large amounts of these compounds. To explore whether B-2-IsoTxs are also formed in vivo, a well characterized animal model of lipid peroxidation consisting of orogastric administration of CCl4 to rats was used, Levels of B-2-IsoTx esterified in lipids in the liver increased 41-fold from 2.5 +/- 0.5 to 102 +/- 30 ng/g of liver. In addition, circulating levels of free compounds increased from undetectable (<5 pg/ml) to 185 +/- 30 pg/ml after CCl4, a 37-fold increase. Thus, we have provided evidence that IsoTxs constitute another novel class of eicosanoids produced in vivo nonenzymatically by free radical-catalyzed lipid peroxidation. These studies thus expand our understanding of products of lipid peroxidation formed in vivo from the free radical-catalyzed peroxidation of arachidonic acid.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, P50GM015431, P01GM015431, R01GM042056] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; BURK RF, 1979, TOXICOL APPL PHARM, V50, P467, DOI 10.1016/0041-008X(79)90400-9; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HECKER M, 1989, J BIOL CHEM, V264, P141; JACKSON EK, 1989, J PHARMACOL EXP THER, V250, P9; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; PARSONS WG, 1988, J IMMUNOL, V141, P2413; RADIN NS, 1969, METHOD ENZYMOL, V14, P245; ROBERTS LJ, 1981, J BIOL CHEM, V256, P8384; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; WAUGH RJ, 1996, J AM SOC MASS SPECTR, V1, P490	21	99	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23185	23190		10.1074/jbc.271.38.23185	http://dx.doi.org/10.1074/jbc.271.38.23185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798513	hybrid			2022-12-25	WOS:A1996VH76800039
J	Spicer, AP; Augustine, ML; McDonald, JA				Spicer, AP; Augustine, ML; McDonald, JA			Molecular cloning and characterization of a putative mouse hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; SACCHAROMYCES-CEREVISIAE; STREPTOCOCCUS-PYOGENES; EXTRACELLULAR-MATRIX; NUCLEOTIDE-SEQUENCE; DEGENERATE PRIMERS; BINDING PROTEINS; MESSENGER-RNAS; GENE; LOCALIZATION	We report the isolation of a novel mouse gene which encodes a putative hyaluronan synthase. The cDNA was identified using degenerate reverse transcriptase polymerase chain reaction. Degenerate primers were designed based upon an alignment of the amino acid sequences of Streptococcus pyogenes HasA, Xenopus laevis DG42, and Rhizobium meliloti NodC. A mouse embryo cDNA library was screened with the resultant polymerase chain reaction product, and multiple cDNA clones spanning 3 kilobase pairs (kb) were isolated. The open reading frame predicted a 63-kDa protein with several transmembrane sequences, multiple consensus phosphorylation sites, and four putative hyaluronan binding motifs. The amino acid sequence displayed 55% identity to mouse HAS, 56% identity to Xenopus DG42, and 21% identity to Streptococcus HasA. Northern analysis identified transcripts of 4.8 kb and 3.2 kb, which were expressed highly in the developing mouse embryo and at lower levels in adult mouse heart, brain, spleen, lung, and skeletal muscle. Transfection experiments demonstrated that mouse Has2 could direct hyaluronan coat biosynthesis in transfected COS cells, as evidenced by a classical particle exclusion assay. These results suggest that mammalian HA synthase activity is regulated by at least two related genes. Accordingly, we propose the name Has2 for this gene.			Spicer, AP (corresponding author), MAYO CLIN SCOTTSDALE,DEPT BIOCHEM & MOL BIOL,SAMUEL C JOHNSON MED RES BLDG,SCOTTSDALE,AZ 85259, USA.							BALBAS JAM, 1993, TERATOLOGY, V48, P197, DOI 10.1002/tera.1420480303; BALDWIN HS, 1994, CIRC RES, V74, P244, DOI 10.1161/01.RES.74.2.244; BERTHEIM U, 1994, BRIT J PLAST SURG, V47, P483, DOI 10.1016/0007-1226(94)90031-0; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; BRAY BA, 1994, EXP LUNG RES, V20, P317, DOI 10.3109/01902149409064390; BROWN JJG, 1993, DEVELOPMENT, V117, P483; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; COLLINSEMERSON JM, 1990, NUCLEIC ACIDS RES, V18, P6690, DOI 10.1093/nar/18.22.6690; COPP AJ, 1988, DEV BIOL, V130, P583, DOI 10.1016/0012-1606(88)90353-3; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; EGGLI PS, 1992, NEUROSCIENCE, V48, P737, DOI 10.1016/0306-4522(92)90417-Z; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HADDON CM, 1991, DEVELOPMENT, V112, P541; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; JACOBS TW, 1985, J BACTERIOL, V162, P469, DOI 10.1128/JB.162.2.469-476.1985; KLEWES L, 1994, J CELL PHYSIOL, V160, P539, DOI 10.1002/jcp.1041600317; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON CB, 1988, BIOCHEM INT, V17, P735; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; LAURENT C, 1991, CELL TISSUE RES, V263, P201, DOI 10.1007/BF00318761; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE GM, 1993, J CELL BIOL, V123, P1899, DOI 10.1083/jcb.123.6.1899; MAIER J, 1995, BIOCHEM BIOPH RES CO, V212, P705, DOI 10.1006/bbrc.1995.2026; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARKWALD RR, 1978, DEV BIOL, V62, P292, DOI 10.1016/0012-1606(78)90218-X; Meyer K, 1934, J BIOL CHEM, V107, P629; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; NAKAMURA A, 1981, J EMBRYOL EXP MORPH, V65, P235; OREGAN M, 1994, INT J BIOL MACROMOL, V16, P283, DOI 10.1016/0141-8130(94)90056-6; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PHILIPSON LH, 1985, BIOCHEMISTRY-US, V24, P7899, DOI 10.1021/bi00348a008; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; PREHM P, 1990, BIOCHEM J, V267, P185, DOI 10.1042/bj2670185; PREHM P, 1986, ARTICULAR CARTILAGE, P81; PYTELA R, 1994, METHOD ENZYMOL, V245, P420; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; SINGH GD, 1994, ARCH ORAL BIOL, V39, P401, DOI 10.1016/0003-9969(94)90170-8; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YASUHARA O, 1994, BRAIN RES, V635, P269, DOI 10.1016/0006-8993(94)91448-6; [No title captured]	65	144	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23400	23406		10.1074/jbc.271.38.23400	http://dx.doi.org/10.1074/jbc.271.38.23400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798545	hybrid			2022-12-25	WOS:A1996VH76800071
J	Vogel, BS; Wildung, MR; Vogel, G; Croteau, R				Vogel, BS; Wildung, MR; Vogel, G; Croteau, R			Abietadiene synthase from grand fir (Abies grandis) - cDNA isolation, characterization, and bacterial expression of a bifunctional diterpene cyclase involved in resin acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; CHLOROPLAST TRANSIT PEPTIDES; SITE-DIRECTED MUTAGENESIS; SESQUITERPENE CYCLASE; GIBBERELLIN BIOSYNTHESIS; ENZYMATIC CYCLIZATION; OXIDOSQUALENE CYCLASE; 4S-LIMONENE SYNTHASE; MONOTERPENE CYCLASE; TERPENE CYCLASES	(-)-Abietic acid, the principal diterpenoid resin acid of the wound-induced oleoresin secreted by grand fir (Abies grandis), is synthesized by the cyclization of geranylgeranyl diphosphate to (-)-abieta-7(8),13(14)-diene, followed by sequential three-step oxidation of the C-18 methyl group of the olefin to a carboxyl function, The enzyme catalyzing the cyclization reaction, abietadiene synthase, was purified from stems of wounded grand fir saplings and was digested with trypsin, Amino acid sequence information from the resulting peptides allowed construction of degenerate oligonucleotide primers, which amplified a 551-base pair fragment from a wound-induced stem cDNA library, This hybridization probe was then utilized to screen the wound-induced stern cDNA library, from which three cDNA clones were isolated that were functionally expressed in Escherichia coli, thereby confirming that a single protein catalyzes the complex, multistep cyclization of geranylgeranyl diphosphate tea abietadiene, cDNA isolate Ac22.1, which yielded the highest expressed level of cyclase activity, was 2861 base pairs in length and encoded an 868-amino acid open reading frame that included a putative plastidial transit peptide, Deduced amino acid sequence comparison to other terpene cyclases revealed an amino-terminal region of the abietadiene synthase, which resembles those of enzymes that employ substrate double bond protonation to initiate the carbocationic reaction cascade, and a carboxyl-terminal region of the synthase, which resembles those of enzymes that employ ionization of the substrate allylic diphosphate ester function to initiate the cyclization reaction. This apparent fusion of segments of the two distinct terpenoid cyclase types is consistent with the novel mechanism of the bifunctional abietadiene synthase in catalyzing both protonation-initiated and ionization-initiated cyclization steps.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University; Washington State University								ABE I, 1995, LIPIDS, V30, P231, DOI 10.1007/BF02537826; ABE I, 1994, J BIOL CHEM, V269, P802; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen XY, 1995, ARCH BIOCHEM BIOPHYS, V324, P255, DOI 10.1006/abbi.1995.0038; CHENICLET C, 1987, J EXP BOT, V38, P1557, DOI 10.1093/jxb/38.9.1557; COLBY SM, 1993, J BIOL CHEM, V268, P23016; COOLBAUGH RC, 1983, BIOCH PHYSL GIBBEREL, V1, P53; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Croteau R., 1985, BIOSYNTHESIS BIODEGR, P379; DENNIS DT, 1967, J BIOL CHEM, V242, P3293; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; DUNCAN JD, 1981, PLANT PHYSIOL, V68, P1128, DOI 10.1104/pp.68.5.1128; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; FAHN A, 1979, SECRETORY TISSUES PL, P185; FUNK C, 1994, PLANT PHYSIOL, V106, P999, DOI 10.1104/pp.106.3.999; FUNK C, 1994, ARCH BIOCHEM BIOPHYS, V308, P258, DOI 10.1006/abbi.1994.1036; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIJZEN M, 1991, ARCH BIOCHEM BIOPHYS, V289, P267, DOI 10.1016/0003-9861(91)90471-T; Graebe J. E., 1980, Plant growth substances 1979 [Skoog, F. (Editor)]., P180; GRAEBE JE, 1987, ANNU REV PLANT PHYS, V38, P419, DOI 10.1146/annurev.pp.38.060187.002223; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; JOHNSON MA, 1987, ACS SYM SER, V325, P76; JOLY A, 1993, J BIOL CHEM, V268, P26983; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFEVER RE, 1994, ARCH BIOCHEM BIOPHYS, V313, P139, DOI 10.1006/abbi.1994.1370; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; LEWINSOHN E, 1993, PHYTOCHEM ANALYSIS, V4, P220, DOI 10.1002/pca.2800040506; LEWINSOHN E, 1993, PLANT PHYSIOL, V101, P1021, DOI 10.1104/pp.101.3.1021; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MURPHY PJ, 1969, ARCH BIOCHEM BIOPHYS, V133, P395, DOI 10.1016/0003-9861(69)90468-8; NEBEKER TE, 1993, BEETLE PATHOGEN INTE, P158; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; Raffa K.F., 1991, P245; RAFFA KF, 1985, ENVIRON ENTOMOL, V14, P552, DOI 10.1093/ee/14.5.552; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; SAITO T, 1995, PLANT PHYSIOL, V109, P1239, DOI 10.1104/pp.109.4.1239; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVAGE TJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P257, DOI 10.1016/0003-9861(95)90008-X; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; STEELE CL, 1995, P NATL ACAD SCI USA, V92, P4164, DOI 10.1073/pnas.92.10.4164; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TABOR S, 1991, CURRENT PROTOCOLS MO; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; West C. A., 1981, BIOSYNTHESIS ISOPREN, V1, P375; WEST CA, 1979, RECENT ADV PHYTOCHEM, V13, P163; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201; YAMADA T, 1992, DEFENSE MECHANISMS W, P147; YAMAGUCHI S, 1996, IN PRESS PLANT J	71	157	168	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23262	23268						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798524	hybrid			2022-12-25	WOS:A1996VH76800050
J	Buchbinder, JL; Fletterick, RJ				Buchbinder, JL; Fletterick, RJ			Role of the active site gate of glycogen phosphorylase in allosteric inhibition and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISUBSTRATE ANALOG N-(PHOSPHONACETYL)-L-ASPARTATE; ASPARTATE CARBAMOYLTRANSFERASE; CATALYTIC SITE; STRUCTURAL-CHANGES; ESCHERICHIA-COLI; RABBIT MUSCLE; T-STATE; ACTIVATION; GLUCOSE; ALPHA	The functional role in allosteric regulation of a flexible loop (residues 280-288) located near the active site of muscle glycogen phosphorylase was investigated. Mutations were made in residues 283-285 based on crystallographic studies that indicate that the loop functions as a gate controlling access of substrates to the active site and that these specific residues play distinct roles in mimicking the substrate and binding inhibitors when the enzyme is in an inactive conformation, Substitution of Ala or Asn for Asp-283, the putative substrate mimic, results in a 15-fold decrease in V-max, a 10-fold decrease in the S-0.5 for glucose 1-phosphate, a 10-fold increase in the K-alpha for AMP, and a 10-20-fold increase in the K-i for glucose, Substitution of Ala for Asn-284, which normally forms a hydrogen bond with the inhibitor glucose, re duces V-max 3-fold, increases the K-i for glucose 2-fold, but has little effect on AMP or glucose 1-phosphate binding or cooperativity, Substitution of Asp at 284, on the other hand, reduces V-max 10-fold, elevates the K-i for glucose 10-fold, decreases AMP cooperativity, but has little effect on the affinity of AMP or the cooperativity and binding of glucose 1-phosphate. Substitution of Leu for Phe-285, which forms aromatic stacking interactions with purine inhibitors, reduces V-max 2-fold, decreases the affinity for caffeine at least 10-fold, raises the K-alpha for AMP 3-fold, and decreases AMP cooperativity but has little effect on glucose 1-phosphate binding or cooperativity. The results of the mutagenesis studies show the importance of the 280's loop for inhibitor binding and modulation of substrate affinity and suggest a role for the loop in allosteric activation, The propagation of allosteric effects across the domain interface may depend upon specific contacts between residues of the 280's loop and the C-terminal domain.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Buchbinder, Ioseph/K-9306-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015371] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32822] Funding Source: Medline; NIGMS NIH HHS [GM15371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BROWNER MF, 1994, NAT STRUCT BIOL, V1, P327, DOI 10.1038/nsb0594-327; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11291, DOI 10.1021/bi00161a005; BUC MH, 1971, BIOCHIMIE, V53, P283, DOI 10.1016/S0300-9084(71)80094-9; BUCHBINDER JL, 1995, BIOCHEMISTRY-US, V34, P6423, DOI 10.1021/bi00019a023; CARNEY IT, 1978, ANAL BIOCHEM, V85, P321, DOI 10.1016/0003-2697(78)90309-3; Cori CF, 1936, P SOC EXP BIOL MED, V34, P702; Cori GT, 1940, J BIOL CHEM, V135, P733; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FISCHER EH, 1955, J BIOL CHEM, V216, P121; FISCHER EH, 1959, J BIOL CHEM, V234, P1698; FLETTERICK RJ, 1980, ANNU REV BIOCHEM, V49, P31, DOI 10.1146/annurev.bi.49.070180.000335; FLETTERICK RJ, 1982, ACCOUNTS CHEM RES, V15, P361, DOI 10.1021/ar00083a004; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GOLDSMITH EJ, 1987, J BIOL CHEM, V262, P1449; HELMREICH E, 1967, BIOCHEMISTRY-US, V6, P3695, DOI 10.1021/bi00864a012; HUANG CY, 1970, BIOCHEMISTRY-US, V9, P660, DOI 10.1021/bi00805a028; HUDSON JW, 1993, BIOCHIM BIOPHYS ACTA, V1164, P197, DOI 10.1016/0167-4838(93)90248-P; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P9102; KIHLMAN B, 1955, EXP CELL RES, V8, P252, DOI 10.1016/0014-4827(55)90066-5; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUONG CBH, 1992, J CHROMATOGR-BIOMED, V584, P77, DOI 10.1016/0378-4347(92)80011-E; MADSEN NB, 1976, MOL CELL BIOCHEM, V11, P35, DOI 10.1007/BF01792832; MADSEN NB, 1967, J BIOL CHEM, V242, P3301; Madsen NB, 1986, ENZYMES, V17, P365; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; MEYER F, 1970, J BIOL CHEM, V245, P6642; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MORGAN HE, 1964, J BIOL CHEM, V239, P2440; PARMEGGIANI A, 1962, BIOCHEM BIOPH RES CO, V9, P252, DOI 10.1016/0006-291X(62)90068-2; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Segel I.H., 1975, ENZYME KINETICS; SOMAN G, 1972, INDIAN J BIOCHEM BIO, V9, P304; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; SPRANG S, 1982, BIOCHEMISTRY-US, V21, P2036, DOI 10.1021/bi00538a010; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1982, BIOCHEMISTRY-US, V21, P5364, DOI 10.1021/bi00264a038; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SPRANG SR, 1992, PROTEIN SCI, V1, P1100, DOI 10.1002/pro.5560010904; Wang J. H, 1972, ENZYMES, V7, P435; WANG JH, 1970, J BIOL CHEM, V245, P3115; WITHERS SG, 1982, BIOCHEMISTRY-US, V21, P5372, DOI 10.1021/bi00264a039	53	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22305	22309		10.1074/jbc.271.37.22305	http://dx.doi.org/10.1074/jbc.271.37.22305			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798388	hybrid			2022-12-25	WOS:A1996VG67200007
J	Keller, SH; Lindstrom, J; Taylor, P				Keller, SH; Lindstrom, J; Taylor, P			Involvement of the chaperone protein calnexin and the acetylcholine receptor beta-subunit in the assembly and cell surface expression of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; BREFELDIN-A; XENOPUS OOCYTES; N-GLYCOSYLATION; LIGAND-BINDING; RETENTION; ER; IDENTIFICATION; DETERMINANTS	The nicotinic acetylcholine receptor at the neuromuscular junction is a ligand-gated ion channel assembled in the endoplasmic reticulum from four distinct glycoprotein subunits into the pentameric configuration of alpha(2) beta gamma delta. The individual homologous subunits form specific contacts at interfaces with neighboring subunits to achieve the appropriate orientation and order of each subunit in surrounding the ion channel. Assembly is thought to proceed through the formation of intermediates composed of dimers of the alpha delta and alpha gamma subunits which are eventually joined by the beta-subunit to achieve a circular structure enclosing the gated ion channel. In this study, we transfect cDNAs encoding receptor subunits in various combinations into HEK-293 cells to identify intracellular factors that influence the assembly and cell surface expression of the receptor. Our data derived from brefeldin A-treated cells indicate that intracellular association of the receptor subunits with the beta-subunit increases the pool of fully assembled receptors available for transport to the cell surface, presumably by protection from degradation, In addition, we determined that the chaperone protein calnexin is associated with the isolated alpha-, beta-, and delta-subunits of the receptor, but calnexin is not detected in association with assembled alpha delta subunit dimers. Calnexin is also detected in association with maturely folded, unassembled a-subunits, as ob served by the recognition of this complex by the monoclonal antibody mAb 35, believed to be specific for correctly folded alpha-subunits. Thus, calnexin appears to associate with the individual nascent subunits, thereby facilitating their assembly into the mature pentameric receptor.	UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT NEUROSCI,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Keller, SH (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GM 18360] Funding Source: Medline; NINDS NIH HHS [NS 09715, NS 11323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009715, R01NS011323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KELLER SH, 1995, J BIOL CHEM, V270, P4165, DOI 10.1074/jbc.270.8.4165; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KREIENKAMP HJ, 1995, NEURON, V14, P636; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MILES K, 1988, MOL NEUROBIOL, V91, P1; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67	42	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22871	22877		10.1074/jbc.271.37.22871	http://dx.doi.org/10.1074/jbc.271.37.22871			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798466				2022-12-25	WOS:A1996VG67200085
J	Ruan, J; Xie, QW; Hutchinson, N; Cho, H; Wolfe, GC; Nathan, C				Ruan, J; Xie, QW; Hutchinson, N; Cho, H; Wolfe, GC; Nathan, C			Inducible nitric oxide synthase requires both the canonical calmodulin-binding domain and additional sequences in order to bind calmodulin and produce nitric oxide in the absence of free Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MACROPHAGES; MOLECULAR-CLONING; PEPTIDE COMPLEX; IDENTIFICATION; EXPRESSION; ENZYME; PURIFICATION; FLAVOPROTEIN; RECOGNITION; SUBUNIT	All three mammalian isoforms of nitric oxide synthase (NOS) must bind calmodulin (CaM) for enzymatic activity, Only NOS2 (the inducible isoform, iNOS) does so at the low levels of free Ca2+ in resting cells and when almost all Ca2+ is chelated in cell-free preparations, To test directly whether the predicted CaM-binding region of mouse NOS2 accounts for its Ca2+ independence, we prepared chimeric NOS's in which mouse NOS2 residues 503-532 were reciprocally exchanged with the corresponding residues 725-754 of rat NOS1 (neuronal NOS). Unlike either parent, both chimeras required an intermediate level of free Ca2+ to bind CaM and generate NO. In cell lysates, the concentration of Ca2+ necessary for half-maximal activity (EC(50)) was similar to 0 for NOS2, 200-300 nM for NOS1, and 7-10 nM for the chimeras, Results were similar when the region exchanged was enlarged by 7-8 residues toward the amino terminus, In contrast, when the carboxyl-terminal half of NOS2 (residues 454-1144) was replaced with that of NOS1 (residues 675-1429), the resulting chimera resembled NOS1 (EC(50), 200-300 nM free Ca2+). Truncation analysis suggested that NOS2 residues within the sequence 484-726 were required for Ca2+-independent CaM-binding. Thus, both the canonical CaM-binding domain and additional residues within the region 484-726 are necessary for NOS2's ability to bind CaM and produce NO when Ca2+ levels approach zero.	MERCK RES LABS, DEPT IMMUNOL & INFLAMMAT, RAHWAY, NJ 07065 USA; CORNELL UNIV, COLL MED, DEPT MED, BEATRICE & SAMUEL A SEAVER LAB, NEW YORK, NY 10021 USA	Merck & Company; Cornell University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034543, R01AI034543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Anderson JT, 1996, J BIOL CHEM, V271, P6605, DOI 10.1074/jbc.271.12.6605; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LADANT D, 1988, J BIOL CHEM, V263, P2612; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHARMA RK, 1986, J BIOL CHEM, V261, P14160; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; XIE QW, 1994, J BIOL CHEM, V269, P28500; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	42	91	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22679	22686		10.1074/jbc.271.37.22679	http://dx.doi.org/10.1074/jbc.271.37.22679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798440	hybrid			2022-12-25	WOS:A1996VG67200059
J	Suzuki, T; Saga, S; Sasakawa, C				Suzuki, T; Saga, S; Sasakawa, C			Functional analysis of Shigella VirG domains essential for interaction with vinculin and actin-based motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEIN VINCULIN; F-ACTIN; INTERCELLULAR SPREAD; SURFACE PROTEIN; VIRULENCE GENE; FOCAL ADHESION; BINDING-SITE; INTRAMOLECULAR ASSOCIATION; LISTERIA-MONOCYTOGENES; UNIPOLAR LOCALIZATION	The VirG (IcsA) protein of Shigella is required for recruitment of host actin filament (F-actin) by intracellularly motile bacteria. An N-terminal 80-kDa VirG portion (alpha-domain) is exposed on the bacterial surface, while the following C-terminal 37-kDa portion (beta-core) is embedded in the outer membrane. Here, we report that the surface exposed alpha-domain of VirG possesses two distinct functional domains; one is the N-terminal two-thirds portion of the alpha-domain which is required for eliciting F-actin assembly on the bacteria in infected cells, and the other one is the rest of the C-terminal portion of the VirG alpha-domain, which is essential for the asymmetric distribution of VirG on the bacterial surface, Furthermore, we found that vinculin, an actin-binding cytoskeletal protein, accumulates on the surface of bacteria expressing VirG in infected cells, and that the distribution of vinculin coincided with the distribution of VirG and assembled F-actin. The vinculin accumulation depended on the expression of the alpha-domain VirG portion required for F-actin assembly, but the recruitment of vinculin on Shigella appeared prior to the appearance of F-actin in the infected cells. Analysis of proteins interacting with VirG using Xenopus laevis eggs extracts revealed that vinculin was a protein that bound to the alpha-domain portion. This was further confirmed using purified chicken gizzard vinculin, in that the 95-kDa vinculin head part, but not the 30-kDa tail part, directly bound to the alpha-domain portion. These results suggest a possible role for vinculin in recruitment of F-actin to the VirG moiety exposed on Shigella in infected mammalian cells.	UNIV TOKYO,INST MED SCI,DEPT BACTERIOL,MINATO KU,TOKYO 108,JAPAN; AICHI HUMAN SERV CTR,INST DEV RES,DEPT MORPHOL,KASUGAI,AICHI 48003,JAPAN	University of Tokyo								ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; dHauteville H, 1996, INFECT IMMUN, V64, P511, DOI 10.1128/IAI.64.2.511-517.1996; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKUDA I, 1995, J BACTERIOL, V177, P1719, DOI 10.1128/jb.177.7.1719-1726.1995; GEIGER B, 1984, J CELL BIOL, V99, pS83, DOI 10.1083/jcb.99.1.83s; Gerstel B, 1996, INFECT IMMUN, V64, P1929, DOI 10.1128/IAI.64.6.1929-1936.1996; GILMORE AP, 1995, NATURE, V373, P197, DOI 10.1038/373197a0; GOLDBERG MB, 1995, P NATL ACAD SCI USA, V92, P6572, DOI 10.1073/pnas.92.14.6572; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3463, DOI 10.1128/IAI.59.10.3463-3471.1991; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOEKS C, 1995, MOL MICROBIOL, V18, P413; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1996, TRENDS CELL BIOL, V6, P109, DOI 10.1016/0962-8924(96)81001-4; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; NAKATA N, 1993, MOL MICROBIOL, V9, P459, DOI 10.1111/j.1365-2958.1993.tb01707.x; PREVOST MC, 1992, INFECT IMMUN, V60, P4088; RAJAKUMAR K, 1994, J BACTERIOL, V176, P2362, DOI 10.1128/JB.176.8.2362-2373.1994; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SAGA S, 1985, EXP CELL RES, V156, P45, DOI 10.1016/0014-4827(85)90260-5; SANDLIN RC, 1995, INFECT IMMUN, V63, P229, DOI 10.1128/IAI.63.1.229-237.1995; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; SUZUKI T, 1994, MOL MICROBIOL, V11, P31, DOI 10.1111/j.1365-2958.1994.tb00287.x; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; WOOD CK, 1994, J CELL SCI, V107, P709	43	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21878	21885		10.1074/jbc.271.36.21878	http://dx.doi.org/10.1074/jbc.271.36.21878			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702989				2022-12-25	WOS:A1996VF61200031
J	Trautwein, C; Rakemann, T; Pietrangelo, A; Plumpe, J; Montosi, G; Mann, MP				Trautwein, C; Rakemann, T; Pietrangelo, A; Plumpe, J; Montosi, G; Mann, MP			C/EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER; MESSENGER-RNA; GROWTH-FACTOR; INDUCTION-PATTERNS; ALPHA-FETOPROTEIN; PROMOTER ELEMENTS; MOLECULAR-CLONING; NUCLEAR FACTOR; DNA-BINDING; C-JUN	Expression of the albumin gene in the liver is controlled by several liver-enriched transcription factors. However, the mechanisms which contribute to its regulation during pathophysiological states, such as liver regeneration, are still little understood. In the present study we found that during liver regeneration downregulation of albumin mRNA expression is transcriptionally controlled through a minimal element (nucleotide -170 to +22) of the albumin promoter and is observed mainly during the G(1) phase of the cell cycle, while high levels of albumin expression are preserved at later time points, Decreased albumin mRNA levels correlate with a dramatic increase in nuclear expression of C/EBP-beta/LAP, a protein known to bind to the D site of the albumin promoter and also to be involved in cell cycle control. In contrast, nuclear expression of other factors such as HNF-1 or C/EBP-alpha, which also have been shown to transcriptionally control albumin expression, is either unchanged or slightly decreased. We show that pre- and post-translational mechanisms are involved in the higher nuclear expression of C/EBP-beta/LAP as early as 1 h after hepatectomy, which also leads to ifs increased binding toward the D site of the albumin promoter. Finally, in vitro transcription assays with liver nuclear extracts and recombinant C/EBP-beta/LAP demonstrate that C/EBP-beta/LAP can directly down-regulate transcription mediated by the minimal element of the albumin promoter. Additionally the inhibitory role of C/EBP-beta/LAP on the albumin minimal promoter could be confirmed by transfection experiments in hepatoma cells. These results indicate that C/EBP-beta/LAP, while enhancing transcription of cell cycle-related genes and controlling G(1)/S phase checkpoint, down-regulates a major liver function, i.e. albumin synthesis, to prepare the hepatocyte for entry into the cell cycle.	HANNOVER MED SCH,DEPT GASTROENTEROL & HEPATOL,D-30625 HANNOVER,GERMANY; UNIV MODENA,DEPT INTERNAL MED,I-41100 MODENA,ITALY	Hannover Medical School; Universita di Modena e Reggio Emilia			Pietrangelo, Antonello/K-1517-2016	Pietrangelo, Antonello/0000-0002-7411-935X				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALCORN JA, 1990, HEPATOLOGY, V11, P909, DOI 10.1002/hep.1840110602; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENBAUM LE, 1995, J CLIN INVEST, V96, P1351, DOI 10.1172/JCI118170; GRISHAM JW, 1962, CANCER RES, V22, P842; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KREN BT, 1994, HEPATOLOGY, V19, P1214, DOI 10.1002/hep.1840190520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEUTZKOWENZ E, 1994, GENE DEV, V8, P2781; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PANDURO A, 1986, BIOCHEMISTRY-US, V25, P1414, DOI 10.1021/bi00354a034; PANDURO A, 1987, GENE DEV, V1, P1172, DOI 10.1101/gad.1.10.1172; PIETRANGELO A, 1994, P NATL ACAD SCI USA, V91, P182, DOI 10.1073/pnas.91.1.182; PIETRANGELO A, 1995, J CLIN INVEST, V95, P1824, DOI 10.1172/JCI117861; PIETRANGELO A, 1992, J CLIN INVEST, V89, P1755, DOI 10.1172/JCI115778; PIETRANGELO A, 1994, HEPATOLOGY, V19, P714, DOI 10.1002/hep.1840190325; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TRAUTWEIN C, 1992, BIOCHEM BIOPH RES CO, V182, P617, DOI 10.1016/0006-291X(92)91777-N; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	54	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22262	22270		10.1074/jbc.271.36.22262	http://dx.doi.org/10.1074/jbc.271.36.22262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703043	hybrid			2022-12-25	WOS:A1996VF61200085
J	Ahn, BC; Grossman, L				Ahn, BC; Grossman, L			RNA polymerase signals UvrAB landing sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI UVRAB; LAMBDA-PL-PROMOTER; DNA-REPAIR; TRANSCRIPTION FACTOR; DAMAGED DNA; SACCHAROMYCES-CEREVISIAE; ENZYMATIC-PROPERTIES; SUPERCOILED DOMAINS; (A)BC EXCINUCLEASE	Transcription when coupled to nucleotide excision repair specifies the location in active genes where preferential DNA repair is to take place, During DNA damage-induced recruitment of RNA polymerase (RNAP), there is a physical association of the beta subunit of Escherichia coli RNAP and the UvrA component of the repair apparatus (G. C, Lin and L, Grossman, submitted for publication). This molecular affinity is reflected in the ability of the RNAP to increase, in a promoter-dependent manner, DNA supercoiling by the UvrAB complex. In the presence of the RNAP, the UvrAB complex is able to bind to promoter regions and to translocate in a 5' to 3' direction along the non-transcribed strand. As a consequence of this helicase-catalyzed translocation, preferential incision of DNA damaged sites occurs downstream on the transcribed strand. Because of the helicase directionality, the initial binding of the UvrAB complex to the transcribed strand would inevitably lead to its collision with the RNAP. These results imply that the RNAP-induced DNA structure in the vicinity of the transcription start site signals a landing or entry site for the UvrAB complex on DNA.	JOHNS HOPKINS UNIV,DEPT BIOCHEM,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022846, R37GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GILADI H, 1992, J MOL BIOL, V224, P937, DOI 10.1016/0022-2836(92)90461-R; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OH EY, 1987, THESIS J HOPKINS U B; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18322; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1994, BIOCHEMISTRY-US, V33, P9881, DOI 10.1021/bi00199a009; WANG JT, 1993, J BIOL CHEM, V268, P5323; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	59	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21453	21461		10.1074/jbc.271.35.21453	http://dx.doi.org/10.1074/jbc.271.35.21453			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702928	hybrid			2022-12-25	WOS:A1996VE47700074
J	Kershaw, MH; Darcy, PK; Hulett, MD; Hogarth, PM; Trapani, JA; Smyth, MJ				Kershaw, MH; Darcy, PK; Hulett, MD; Hogarth, PM; Trapani, JA; Smyth, MJ			Redirected cytotoxic effector function - Requirements for expression of chimeric single chain high affinity immunoglobulin E receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; ZETA-CHAIN; MOLECULAR-CLONING; GAMMA-SUBUNIT; ALPHA-SUBUNIT; ETA-CHAIN; SEQUENCE REQUIREMENTS; TRANSFECTED CELLS	The aim of this study was to construct a single chain chimeric Fc epsilon RI alpha receptor capable of effector function in leukocytes, including cytotoxic lymphocytes. To determine the most effective single chain Fc epsilon RI alpha receptor with respect to IgE binding and signaling function, a variety of chimeric gene constructs were transiently transfected into COS-7 cells. The most effective chimera consisted of four parts including: wild-type or mutated extracellular domains (Trp(130) --> Ala(130), W130A) of Fc epsilon RI alpha, membrane proximal and transmembrane regions of Fc gamma RIIa, and intracellular CD3 zeta (epsilon(IIa)IIa zeta). Scatchard analysis indicated that these Fc epsilon RI alpha chimeric receptor bound ligand with an affinity of 0.9 to 2.2 x 10(9) M(-1). Ligand binding capacity was dramatically reduced with the deletion of 11 membrane proximal amino acids of Fc epsilon RI alpha; however, function was restored by substitution with the equivalent region of Fc gamma RIIa, suggesting a crucial requirement for a ''spacer'' segment between the transmembrane and extracellular ligand binding domain. Chimeras that bound IgE effectively also mediated phagocytosis. Chimeric receptors that contained transmembrane zeta were expressed as multimers and consequently did not bind IgE effectively; however, cotransfection of these chimeras with gamma-chain largely reconstituted IgE-mediated phagocytosis. The mouse cytotoxic T lymphocyte cell line, CTLLR8 was stably transfected with epsilon(IIa)IIa zeta, and cloned transfectants were demonstrated to lyse target cells in an anti-Fc epsilon RI alpha or IgE antibody-dependent manlier. Therefore, functional single chain chimeric Fe epsilon RI alpha receptors were expressed in the absence or presence of associated zeta or gamma molecules and were used to redirect killer lymphocytes to target cells.	AUSTIN HOSP,HELEN SCHUTT LAB,HEIDELBERG,VIC 3084,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Kershaw, MH (corresponding author), AUSTIN HOSP,CELLULAR CYTOTOX LAB,HEIDELBERG,VIC 3084,AUSTRALIA.		Hulett, Mark D/C-4160-2012; Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Hulett, Mark/0000-0003-2072-5968; Kershaw, Michael/0000-0002-2697-487X; Trapani, Joseph/0000-0003-0983-1532; Hogarth, Mark/0000-0002-0360-7890; Darcy, Phillip/0000-0002-5303-9561				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BROCKER T, 1995, J EXP MED, V181, P1653, DOI 10.1084/jem.181.5.1653; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CAPRA JD, 1989, J BIOL CHEM, V264, P12745; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HOLOWKA D, 1985, BIOCHEMISTRY-US, V24, P6260, DOI 10.1021/bi00343a033; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3475, DOI 10.1021/bi00283a026; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1995, ADV IMMUNOL, V57, P1; HUTCHINSON MJ, 1995, EUR J IMMUNOL, V25, P481, DOI 10.1002/eji.1830250226; HWU P, 1993, J EXP MED, V178, P361, DOI 10.1084/jem.178.1.361; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISAACS JD, 1992, J IMMUNOL, V148, P3062; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LICHTENHELD MG, 1995, J IMMUNOL, V154, P2153; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MORITZ D, 1994, P NATL ACAD SCI USA, V91, P4318, DOI 10.1073/pnas.91.10.4318; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PALLADINO MA, 1983, CANCER RES, V43, P572; PARK JG, 1995, P NATL ACAD SCI USA, V92, P7381, DOI 10.1073/pnas.92.16.7381; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROBERTS MR, 1994, BLOOD, V84, P2878; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SNOW PM, 1983, J BIOL CHEM, V258, P4675; STANCOVSKI I, 1993, J IMMUNOL, V151, P6577; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TRAN AC, 1995, J IMMUNOL, V155, P1000; TUIJNMAN WB, 1992, BLOOD, V79, P1651; VIVIER E, 1991, J IMMUNOL, V147, P4263; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	52	13	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21214	21220		10.1074/jbc.271.35.21214	http://dx.doi.org/10.1074/jbc.271.35.21214			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702893	hybrid			2022-12-25	WOS:A1996VE47700039
J	Viglietto, G; Romano, A; Maglione, D; Rambaldi, M; Paoletti, I; Lago, CT; Califano, D; Monaco, C; Mineo, A; Santelli, G; Manzo, G; Botti, G; Chiappetta, G; Persico, MG				Viglietto, G; Romano, A; Maglione, D; Rambaldi, M; Paoletti, I; Lago, CT; Califano, D; Monaco, C; Mineo, A; Santelli, G; Manzo, G; Botti, G; Chiappetta, G; Persico, MG			Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor	ONCOGENE			English	Article						VEGF; PlGF; angiogenesis; germ cell tumors; vascular count	HUMAN COLON-CANCER; PERMEABILITY FACTOR; TYROSINE KINASE; STROMA GENERATION; BREAST-CARCINOMA; MESSENGER-RNAS; UP-REGULATION; FACTOR PIGF; IN-VIVO; ANGIOGENESIS	Neoangiogenesis is a prerequisite for tumor growth and metastasis. In germ cell cancer patients with the disease limited to the testicle (stage A), tumor-associated neovascularization is predictive of metastatic disease (stage B). To investigate the molecular mechanisms underlying neovascularization in human germ cell tumors (GCTs), we analysed the expression of two angiogenic growth factors, vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF), and of their receptors (FLT-1) and Flk-1/KDR) in a panel of testicular tumors. In this study we show a marked increase in VEGF expression in 36/44 (81.8%) primary testicular-derived GCTs, as compared to normal testis, that significantly correlates with a high density of intratumor microvessels (r = 0.72461, P < 0.001; n = 24). As determined by RT-PCR and/or Western blot, the predominant VEGF isoforms expressed in GCTs are the VEGF(121) and VEGF(165) which are more efficiently secreted by the cells, and thus more active in eliciting angiogenesis. Conversely, in the case of PIGF, only a weak correlation with the vascular density of tumors is observed (r = 0.26599, P < 0.05; n = 24). Northern blot analysis also revealed significant up-regulation of VEGF/ PIGF receptors in highly vascularized germ cell tumors, compared to normal testes. These findings suggest that VEGF may act in a paracrine manner to induce neovascularization, oedema extravasation and cyst formation in human germ cell tumors. The correlation between VEGF expression and the vascular density of tumors, suggest that the evaluation of VEGF expression may be of help in predicting patients at risk for metastatic diseases. Finally, we demonstrate that VEGF up-regulation may occur at the RNA level since no gene amplification is observed; conversely, in in vitro models such as the embryonal stem cell line NTERA-2 and the choriocarcinoma JEG-3 cell line, VEGF (but not PIGF) mRNA expression is regulated by hypoxic stress.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Viglietto, G (corresponding author), FDN SENATORE PASCALE,IST NAZL TUMORI,VIA M SEMMOLA,I-80131 NAPLES,ITALY.		Califano, Daniela/Y-6313-2018; Viglietto, Giuseppe/AAC-2852-2019	Califano, Daniela/0000-0001-6945-3209; Viglietto, Giuseppe/0000-0003-2327-7515; Botti, Gerardo/0000-0002-6287-733X				ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1993, CANCER RES, V53, P4727; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jacobsen GK., 1989, ATLAS GERM CELL TUMO; KATO Y, 1991, ENDOCRINOLOGY, V128, P401, DOI 10.1210/endo-128-1-401; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OLIVAREZ D, 1994, CANCER RES, V54, P2800; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Sambrook J., 2002, MOL CLONING LAB MANU; SAMOTO K, 1995, CANCER RES, V55, P1189; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIGEGRIST W, 1994, CANCER RES, V54, P2604; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tisher E, 1991, J BIOL CHEM, V266, P11947; Toi M, 1995, CLIN CANCER RES, V1, P961; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	49	105	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					577	587						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760299				2022-12-25	WOS:A1996VB32800015
